{ "date": "2026-08-25", "generatedAt": "2026-08-25T07:30:54.078Z", "sourceLastUpdated": "2026-08-22", "total": 1628, "records": [ { "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0480-3564-01)", "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3564-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "company_name": "Teva Pharmaceuticals USA, Inc.", "contact_info": "800-545-8800", "availability": "Available", "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "status": "Current", "dosage_form": "Capsule" }, { "discontinued_date": "10/17/2025", "update_type": "New", "initial_posting_date": "10/17/2025", "package_ndc": "0006-3074-02", "generic_name": "Elbasvir; Grazoprevir Tablet", "contact_info": "800-672-6372", "related_info": "To be discontinued December 1, 2025", "openfda": { "application_number": [ "NDA208261" ], "brand_name": [ "ZEPATIER" ], "generic_name": [ "ELBASVIR AND GRAZOPREVIR" ], "manufacturer_name": [ "Merck Sharp & Dohme LLC" ], "product_ndc": [ "0006-3074" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ELBASVIR", "GRAZOPREVIR ANHYDROUS" ], "rxcui": [ "1734636", "1734642" ], "spl_id": [ "227ae348-5f6f-44d8-a6dc-103e63d28102" ], "spl_set_id": [ "164dc02a-9180-426a-b8b5-04ab39d2bbd4" ], "package_ndc": [ "0006-3074-01", "0006-3074-02" ], "nui": [ "N0000191256", "N0000190113", "N0000182638", "N0000182639", "N0000190114" ], "pharm_class_epc": [ "Hepatitis C Virus NS5A Inhibitor [EPC]", "Hepatitis C Virus NS3/4A Protease Inhibitor [EPC]" ], "pharm_class_moa": [ "Breast Cancer Resistance Protein Inhibitors [MoA]", "HCV NS3/4A Protease Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]" ], "unii": [ "632L571YDK", "8YE81R1X1J" ] }, "update_date": "10/17/2025", "therapeutic_category": [ "Antiviral" ], "dosage_form": "Tablet", "presentation": "Zepatier, Tablet, 50 mg; 100 mg (NDC 0006-3074-02)", "company_name": "Merck Sharp & Dohme LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-799-05", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA064150" ], "brand_name": [ "RIFAMPIN" ], "generic_name": [ "RIFAMPIN" ], "manufacturer_name": [ "EPIC PHARMA, LLC" ], "product_ndc": [ "42806-799", "42806-801" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RIFAMPIN" ], "rxcui": [ "198201", "198202" ], "spl_id": [ "a4ac02e8-68ac-4e79-8ca5-0939dd002c87" ], "spl_set_id": [ "0391f1e1-70d4-4b15-8b58-055bb6a385b8" ], "package_ndc": [ "42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05" ], "nui": [ "N0000175500", "M0019113" ], "pharm_class_epc": [ "Rifamycin Antibacterial [EPC]" ], "pharm_class_cs": [ "Rifamycins [CS]" ], "unii": [ "VJT6J7R4TR" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 42806-799-05)", "company_name": "Epic Pharma, LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "03/02/2026", "update_type": "New", "initial_posting_date": "03/02/2026", "package_ndc": "0093-7766-24", "generic_name": "Everolimus Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA210050" ], "brand_name": [ "EVEROLIMUS" ], "generic_name": [ "EVEROLIMUS" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0093-7766", "0093-7767", "0093-7768", "0093-7769" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "EVEROLIMUS" ], "rxcui": [ "845507", "845515", "998189", "1119400" ], "spl_id": [ "0f7ea770-928b-43b2-8971-849d1d12bbc8" ], "spl_set_id": [ "e3bca36b-29ed-4a2b-a1be-a57b6af805f6" ], "package_ndc": [ "0093-7766-19", "0093-7766-24", "0093-7767-19", "0093-7767-24", "0093-7768-19", "0093-7768-24", "0093-7769-19", "0093-7769-24" ], "nui": [ "N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550" ], "pharm_class_epc": [ "Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]" ], "pharm_class_moa": [ "Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]" ], "pharm_class_pe": [ "Decreased Immunologic Activity [PE]" ], "unii": [ "9HW64Q8G6G" ] }, "update_date": "03/02/2026", "therapeutic_category": [ "Transplant" ], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 2.5 mg (NDC 0093-7766-24)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "presentation": "Marcaine, Injection, Marcaine 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1559-10)", "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1559-10", "generic_name": "Bupivacaine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "status": "Current", "dosage_form": "Injection" }, { "update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "25021-820-10", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-625-1618", "availability": "Unavailable", "related_info": "Estimated recovery: November 2026", "openfda": { "application_number": [ "ANDA201835" ], "brand_name": [ "METHYLPREDNISOLONE ACETATE" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-820", "25021-821" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1358610", "1358617" ], "spl_id": [ "f73618f0-0723-4d8b-8a8d-b9081acb44f9" ], "spl_set_id": [ "f98314ea-a4e4-4f78-987b-3e9b45a08bb4" ], "package_ndc": [ "25021-820-05", "25021-820-10", "25021-821-05" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-10)", "company_name": "Sagent Pharmaceuticals", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3178-03", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA089644" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3178", "0409-1209", "0409-3177", "0409-3181", "0409-3182", "0409-3183", "0409-0007", "0409-0147" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE", "EPINEPHRINE" ], "rxcui": [ "1010688", "1010745", "1010751", "1010759", "1867996", "1867998" ], "spl_id": [ "68a37af1-d237-4836-af13-1eec28245f8b" ], "spl_set_id": [ "2f94f711-14c4-48ec-c5a3-c5ec4b8e8729" ], "package_ndc": [ "0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10" ], "nui": [ "N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647" ], "pharm_class_moa": [ "Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]" ], "pharm_class_epc": [ "alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]" ], "pharm_class_cs": [ "Catecholamines [CS]" ], "unii": [ "YKH834O4BH", "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 500 mg/50 mL (1%; 1:100,000) (NDC 0409-3178-03)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-495-07", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE MPF" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-495", "63323-492", "63323-491", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428", "0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17", "4dd52202-8eef-4136-92dd-ada573b7cf74" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31", "63323-492-41", "63323-492-16", "63323-492-43", "63323-492-36", "63323-492-45", "63323-492-26", "63323-485-41", "63323-485-26", "63323-486-41", "63323-486-26", "63323-482-41", "63323-482-26", "63323-495-41", "63323-495-26" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-07)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "63323-824-74", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA209448" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-824" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481" ], "spl_id": [ "0591ab74-99a6-40ee-af96-80bc2ef423dc" ], "spl_set_id": [ "3b8f2692-4371-4f1a-95af-b41842131fdd" ], "package_ndc": [ "63323-824-24", "63323-824-74", "63323-824-25", "63323-824-75", "63323-824-26", "63323-824-76" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-74)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5166-32", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "PHENOBARBITAL" ], "generic_name": [ "PHENOBARBITAL" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "0603-5166", "0603-5165", "0603-5167", "0603-5168" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "PHENOBARBITAL" ], "rxcui": [ "198086", "199164", "199167", "199168" ], "spl_id": [ "f8c5136e-e35c-4425-8d49-b7f92c827b42" ], "spl_set_id": [ "069b92ce-0061-4724-8c25-08d8596770a2" ], "package_ndc": [ "0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32" ], "unii": [ "YQE403BP4D" ] }, "update_date": "10/31/2025", "therapeutic_category": [ "Analgesia/Addiction", "Neurology", "Other" ], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-32)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1077-02", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA020255" ], "brand_name": [ "DOBUTAMINE HYDROCHLORIDE IN DEXTROSE" ], "generic_name": [ "DOBUTAMINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-1077", "0338-1073", "0338-1075" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOBUTAMINE HYDROCHLORIDE" ], "rxcui": [ "309985", "309986", "309987" ], "spl_id": [ "34c787c1-46f7-4264-951d-c88a34dca533" ], "spl_set_id": [ "6b17b98b-e06d-42ed-925f-69aa2699dead" ], "package_ndc": [ "0338-1073-02", "0338-1075-02", "0338-1077-02" ], "unii": [ "0WR771DJXV" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Cardiovascular", "Pediatric", "Renal" ], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/100 mL (NDC 0338-1077-02)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "0338-0004-03", "generic_name": "Sterile Water Irrigant", "contact_info": "888-229-0001", "availability": "Limited Availability", "related_info": "Estimated recovery: August 2026", "openfda": { "application_number": [ "NDA017428" ], "brand_name": [ "STERILE WATER" ], "generic_name": [ "WATER" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0004", "0338-0003" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "IRRIGATION" ], "substance_name": [ "WATER" ], "rxcui": [ "150985" ], "spl_id": [ "97390588-b679-4caa-b7f3-3d2e11074d0e" ], "spl_set_id": [ "ef3e79c5-3f58-4b36-a296-64b7d9a651c1" ], "package_ndc": [ "0338-0003-44", "0338-0003-46", "0338-0003-47", "0338-0004-02", "0338-0004-03", "0338-0004-04", "0338-0004-05" ], "unii": [ "059QF0KO0R" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Irrigant", "presentation": "Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-03)", "company_name": "Baxter Healthcare", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-083-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": { "application_number": [ "ANDA214134" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "57664-083", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "560b4c9e-9cce-4717-e063-6294a90a58c9" ], "spl_set_id": [ "da3148af-f9b6-4725-adae-3595b4c7dc4b" ], "package_ndc": [ "57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 57664-083-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7923-37", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Available", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA016367" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "ICU Medical, Inc." ], "product_ndc": [ "0990-7923", "0990-7922", "0990-7930" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621" ], "spl_id": [ "06e4d957-1a56-4adb-a42b-fe0773b2fa97" ], "spl_set_id": [ "8b25b7e0-703e-4b43-a4eb-52863511602d" ], "package_ndc": [ "0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-37)", "company_name": "Otsuka ICU Medical LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0370-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": { "application_number": [ "ANDA202827" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0054-0370", "0054-0660", "0054-0371", "0054-0372", "0054-0373", "0054-0374", "0054-0375" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "ccd9e87c-bd03-4fe0-8129-41c1ced49c8d" ], "spl_set_id": [ "6740a621-9bec-4178-a4fc-a3fc89f34e0a" ], "package_ndc": [ "0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0054-0370-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7923-13", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Available", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA016367" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "ICU Medical, Inc." ], "product_ndc": [ "0990-7923", "0990-7922", "0990-7930" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621" ], "spl_id": [ "06e4d957-1a56-4adb-a42b-fe0773b2fa97" ], "spl_set_id": [ "8b25b7e0-703e-4b43-a4eb-52863511602d" ], "package_ndc": [ "0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-13)", "company_name": "Otsuka ICU Medical LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "43547-410-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-931-9829", "availability": "Unavailable", "related_info": "Not available. Long-term backorder for all NDCs. No estimated release date at this time.", "openfda": { "application_number": [ "ANDA205823" ], "brand_name": [ "QUINAPRIL" ], "generic_name": [ "QUINAPRIL" ], "manufacturer_name": [ "Solco Healthcare US, LLC" ], "product_ndc": [ "43547-410", "43547-411", "43547-412", "43547-413" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE" ], "rxcui": [ "312748", "312749", "312750", "314203" ], "spl_id": [ "b8f1731a-cbac-4f64-a8d4-320b80b335e1" ], "spl_set_id": [ "cd46691d-5593-4a9f-a937-999c6803e312" ], "package_ndc": [ "43547-410-09", "43547-411-09", "43547-412-09", "43547-413-09" ], "unii": [ "33067B3N2M" ] }, "update_date": "06/29/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 5 mg (NDC 43547-410-09)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "47781-179-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": { "application_number": [ "ANDA207388" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 20 MG,CLL" ], "manufacturer_name": [ "Alvogen Inc." ], "product_ndc": [ "47781-179", "47781-174", "47781-175", "47781-176", "47781-177", "47781-178", "47781-180" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "0374f0f7-9297-810c-38b3-623a72709a7d" ], "spl_set_id": [ "c907301d-e24d-9609-5529-fed14f94549f" ], "package_ndc": [ "47781-174-30", "47781-174-05", "47781-174-01", "47781-175-30", "47781-175-05", "47781-175-01", "47781-176-30", "47781-176-05", "47781-176-01", "47781-177-30", "47781-177-05", "47781-177-01", "47781-178-30", "47781-178-05", "47781-178-01", "47781-179-30", "47781-179-05", "47781-179-01", "47781-180-30", "47781-180-05", "47781-180-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 20mg (NDC 47781-179-01)", "company_name": "Alvogen", "status": "Current" }, { "discontinued_date": "07/07/2026", "update_type": "New", "initial_posting_date": "07/07/2026", "package_ndc": "0378-9651-50", "generic_name": "Travoprost Ophthalmic Solution", "contact_info": "877-446-3679", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA205050" ], "brand_name": [ "TRAVOPROST OPHTHALMIC SOLUTION, 0.004%" ], "generic_name": [ "TRAVOPROST OPHTHALMIC SOLUTION, 0.004%" ], "manufacturer_name": [ "Mylan Pharmaceuticals Inc." ], "product_ndc": [ "0378-9651" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "OPHTHALMIC" ], "substance_name": [ "TRAVOPROST" ], "rxcui": [ "284008" ], "spl_id": [ "d78c5705-68ac-4363-b9ae-5facc60e2b79" ], "spl_set_id": [ "00dc284f-fd96-423b-bb8f-b90ee13439bf" ], "package_ndc": [ "0378-9651-32", "0378-9651-50" ], "nui": [ "N0000175454", "M0017805" ], "pharm_class_epc": [ "Prostaglandin Analog [EPC]" ], "pharm_class_cs": [ "Prostaglandins [CS]" ], "unii": [ "WJ68R08KX9" ] }, "update_date": "07/07/2026", "therapeutic_category": [ "Ophthalmology" ], "dosage_form": "Ophthalmic Solution", "presentation": "Travoprost, Ophthalmic Solution, 0.004%, 5 mL (NDC 0378-9651-50)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1178-30", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA021171" ], "brand_name": [ "DEMEROL" ], "generic_name": [ "MEPERIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1178", "0409-1181", "0409-1176", "0409-1179", "0409-1180", "0409-1362", "0409-1418" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "MEPERIDINE HYDROCHLORIDE" ], "rxcui": [ "860792", "861463", "861473", "861493", "861494", "861522", "861529", "861617", "1242106", "1242503", "2539186", "2539188", "2539191", "2539192" ], "spl_id": [ "b6935f73-7b93-496d-871b-de6f9b379649" ], "spl_set_id": [ "b31d1308-28c3-43f4-e0a6-2f3ed76b8975" ], "package_ndc": [ "0409-1181-30", "0409-1176-03", "0409-1176-30", "0409-1178-03", "0409-1178-30", "0409-1179-03", "0409-1179-30", "0409-1180-59", "0409-1180-69", "0409-1362-11", "0409-1362-01", "0409-1418-11", "0409-1418-01" ], "unii": [ "N8E7F7Q170" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Demerol, Injection, 50 mg/1 mL (NDC 0409-1178-30)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-03", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA016673" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0017", "0338-0023" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618" ], "spl_id": [ "9c644eb4-5844-415a-8c01-4459d98af222" ], "spl_set_id": [ "3bb406a9-f5cb-403a-b1bb-5c4facbea3d5" ], "package_ndc": [ "0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-03)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-024-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Available", "openfda": { "application_number": [ "ANDA202830" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE" ], "manufacturer_name": [ "Amneal Pharmaceuticals LLC" ], "product_ndc": [ "65162-024", "65162-023", "65162-025", "65162-026", "65162-027", "65162-028" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850" ], "spl_id": [ "ba9f3370-3096-4d8c-9571-e28faf54291f" ], "spl_set_id": [ "c11cb3b6-3dff-477b-a249-b4c3118edc5f" ], "package_ndc": [ "65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 65162-024-09)", "company_name": "Amneal Pharmaceuticals", "status": "Current" }, { "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 1,000 mg/250mL (400 mg/mL) (NDC 0409-3724-32)", "update_type": "Revised", "initial_posting_date": "11/06/2017", "package_ndc": "0409-3724-32", "generic_name": "Dobutamine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular", "Pediatric", "Renal" ], "status": "Current", "dosage_form": "Injection" }, { "update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "72078-035-02", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "NDA020630" ], "brand_name": [ "ULTIVA" ], "generic_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "manufacturer_name": [ "Mylan Institutional LLC" ], "product_ndc": [ "72078-035", "72078-034", "72078-036" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "rxcui": [ "1729578", "1729581", "1729584", "1729586", "1729710", "1729712" ], "spl_id": [ "f41b6542-9305-43e7-bbbc-52c7ee2cb0dc" ], "spl_set_id": [ "8b4c8696-e23e-4c51-a4d2-babab5bd945a" ], "package_ndc": [ "72078-034-00", "72078-034-01", "72078-035-00", "72078-035-02", "72078-036-00", "72078-036-05" ], "unii": [ "5V444H5WIC" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ultiva, Injection, 2 mg (NDC 72078-035-02)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "0143-9506-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional product will be made available as it is released.", "openfda": { "application_number": [ "ANDA202354" ], "brand_name": [ "ETOMIDATE" ], "generic_name": [ "ETOMIDATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9506", "0143-9507" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008" ], "spl_id": [ "98560882-bfdf-404e-ab8b-3ee2a6875830" ], "spl_set_id": [ "75bf0494-7cb9-4e8a-8edd-af62f035d236" ], "package_ndc": [ "0143-9506-01", "0143-9506-10", "0143-9507-01", "0143-9507-10" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 0143-9506-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "70069-753-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": { "application_number": [ "ANDA217792" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-753", "70069-752" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404" ], "spl_id": [ "2b24af95-6f20-4945-bf8c-742f1d6f2721" ], "spl_set_id": [ "bcaab86f-20f0-4482-8d73-e29b36dced58" ], "package_ndc": [ "70069-752-25", "70069-752-10", "70069-752-01", "70069-753-25", "70069-753-01", "70069-753-10" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-01)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "0143-9519-10", "generic_name": "Methotrexate Sodium Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA089340" ], "brand_name": [ "METHOTREXATE" ], "generic_name": [ "METHOTREXATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9519", "0143-9518", "0143-9517", "0143-9516" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS" ], "substance_name": [ "METHOTREXATE" ], "rxcui": [ "1655959", "1655960", "1655967", "1655968" ], "spl_id": [ "3046ff78-3565-46d1-a88b-283e5ff6e7c3" ], "spl_set_id": [ "3989d30d-56e5-4e8d-9379-c30fecc894f2" ], "package_ndc": [ "0143-9519-10", "0143-9518-01", "0143-9517-01", "0143-9516-01" ], "nui": [ "N0000175584", "N0000000111" ], "pharm_class_epc": [ "Folate Analog Metabolic Inhibitor [EPC]" ], "pharm_class_moa": [ "Folic Acid Metabolism Inhibitors [MoA]" ], "unii": [ "YL5FZ2Y5U1" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Rheumatology", "Oncology" ], "dosage_form": "Injection", "presentation": "Methotrexate, Preservative Free, Injection, 25 mg/1 mL (NDC 0143-9519-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-482-27", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-482", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428", "0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17", "4dd52202-8eef-4136-92dd-ada573b7cf74" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31", "63323-492-41", "63323-492-16", "63323-492-43", "63323-492-36", "63323-492-45", "63323-492-26", "63323-485-41", "63323-485-26", "63323-486-41", "63323-486-26", "63323-482-41", "63323-482-26", "63323-495-41", "63323-495-26" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-088-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": { "application_number": [ "NDA216117" ], "brand_name": [ "RELEXXII" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Vertical Pharmaceuticals, LLC" ], "product_ndc": [ "68025-088", "68025-089", "68025-095", "68025-096", "68025-097", "68025-084", "68025-098" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505" ], "spl_id": [ "86f477e9-07fc-466b-913e-1a4434c91df4" ], "spl_set_id": [ "22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d" ], "package_ndc": [ "68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current" }, { "discontinued_date": "02/27/2026", "update_type": "New", "initial_posting_date": "02/27/2026", "package_ndc": "50458-290-04", "generic_name": "Itraconazole Capsule", "contact_info": "800-JANSSEN (1-800-526-7736)", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA020083" ], "brand_name": [ "SPORANOX" ], "generic_name": [ "ITRACONAZOLE" ], "manufacturer_name": [ "Janssen Pharmaceuticals, Inc." ], "product_ndc": [ "50458-290" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ITRACONAZOLE" ], "rxcui": [ "311204", "833164" ], "spl_id": [ "a79c080b-711a-4a15-af92-ff0c60cbfdf1" ], "spl_set_id": [ "a4d555fa-787c-40fb-bb7d-b0d4f7318fd0" ], "package_ndc": [ "50458-290-01", "50458-290-04", "50458-290-28" ], "nui": [ "N0000175487", "M0002083", "N0000182141", "N0000185503", "N0000190113" ], "pharm_class_epc": [ "Azole Antifungal [EPC]" ], "pharm_class_cs": [ "Azoles [CS]" ], "pharm_class_moa": [ "Cytochrome P450 3A4 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]" ], "unii": [ "304NUG5GF4" ] }, "update_date": "02/27/2026", "therapeutic_category": [ "Anti-Infective", "Other" ], "dosage_form": "Capsule", "presentation": "Sporanox, Capsule, 100 mg (NDC 50458-290-04)", "company_name": "Janssen Pharmaceuticals", "status": "To Be Discontinued" }, { "update_type": "New", "initial_posting_date": "02/20/2018", "package_ndc": "31722-275-34", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "732-529-0430, customerservice@camberpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA217821" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Camber Pharmaceuticals, Inc." ], "product_ndc": [ "31722-275", "31722-276", "31722-277" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1724786", "1724787", "1724880", "1724884", "1725078", "1725082" ], "spl_id": [ "4ea16f8e-77de-3ba7-e063-6394a90a5667" ], "spl_set_id": [ "0e552e3a-cf52-4d74-9381-6cc1b29b4c90" ], "package_ndc": [ "31722-275-10", "31722-275-31", "31722-275-32", "31722-275-30", "31722-275-33", "31722-275-34", "31722-275-35", "31722-276-10", "31722-276-31", "31722-276-32", "31722-276-30", "31722-276-33", "31722-276-34", "31722-277-10", "31722-277-31", "31722-277-32", "31722-277-30", "31722-277-33", "31722-277-34" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "07/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-34)", "company_name": "Aspiro Pharma Limited", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0644-03", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA018931" ], "brand_name": [ "TRAVASOL" ], "generic_name": [ "LEUCINE, PHENYLALANINE, LYSINE HYDROCHLORIDE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, TYROSINE, SERINE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0644" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LEUCINE", "PHENYLALANINE", "LYSINE HYDROCHLORIDE", "METHIONINE", "ISOLEUCINE", "VALINE", "HISTIDINE", "THREONINE", "TRYPTOPHAN", "ALANINE", "GLYCINE", "ARGININE", "PROLINE", "TYROSINE", "SERINE" ], "rxcui": [ "801644", "801648" ], "spl_id": [ "e0279078-016d-48fd-8de1-c894422b33ff" ], "spl_set_id": [ "8543b5be-0f43-4891-9e56-d7c39fe839b5" ], "package_ndc": [ "0338-0644-03", "0338-0644-04", "0338-0644-06" ], "nui": [ "N0000175780", "M0000922" ], "pharm_class_epc": [ "Amino Acid [EPC]" ], "pharm_class_cs": [ "Amino Acids [CS]" ], "unii": [ "GMW67QNF9C", "47E5O17Y3R", "JNJ23Q2COM", "AE28F7PNPL", "04Y7590D77", "HG18B9YRS7", "4QD397987E", "2ZD004190S", "8DUH1N11BX", "OF5P57N2ZX", "TE7660XO1C", "94ZLA3W45F", "9DLQ4CIU6V", "42HK56048U", "452VLY9402" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-03)", "company_name": "Baxter Healthcare", "shortage_reason": "Shortage of an inactive ingredient component", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/26/2023", "package_ndc": "60793-701-10", "generic_name": "Penicillin G Benzathine Injection", "related_info_link": "https://www.fda.gov/media/190713/download", "contact_info": "800-533-4535", "availability": "Limited Availability", "related_info": "Next Delivery: Fourth Quarter 2026 Estimated Recovery: 4Q 2027; Manufacturing delay", "openfda": { "application_number": [ "NDA050141" ], "brand_name": [ "BICILLIN L-A" ], "generic_name": [ "PENICILLIN G BENZATHINE" ], "manufacturer_name": [ "Pfizer Laboratories Div Pfizer Inc" ], "product_ndc": [ "60793-701", "60793-700", "60793-702" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "PENICILLIN G BENZATHINE" ], "rxcui": [ "731564", "731566", "731567", "731568", "731570", "731571" ], "spl_id": [ "526e051e-d0fc-4f5d-886a-d61947aa8a7f" ], "spl_set_id": [ "012d46f1-d0a0-4676-a879-cd320297ab16" ], "package_ndc": [ "60793-700-01", "60793-700-10", "60793-701-02", "60793-701-10", "60793-702-04", "60793-702-10" ], "unii": [ "RIT82F58GK" ] }, "update_date": "08/12/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Bicillin L-A, Injection, 1200000 [iU]/2 mL (NDC 60793-701-10)", "company_name": "Pfizer Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1283-37", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA200403" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1283", "0409-1312", "0409-4264", "0409-1805", "0409-2552", "0409-3356", "0409-2540", "0409-3365", "0409-1304" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897756", "897757", "1433251", "1724383", "1724644", "2675350", "897653", "897753", "897758", "1724276" ], "spl_id": [ "766e302a-2d03-4d93-b237-2348b57ee517", "a3ebafac-648e-47b1-a6f5-1e3bff1e3e08" ], "spl_set_id": [ "f9ca2ef5-46d8-475a-a26e-f7c8becd6db7", "e9c9ef18-7dfc-4322-b2fc-29b934c30f8b" ], "package_ndc": [ "0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01", "0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 0409-1283-37)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0480-3570-01)", "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3570-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "company_name": "Teva Pharmaceuticals USA, Inc.", "contact_info": "800-545-8800", "availability": "Available", "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "status": "Current", "dosage_form": "Capsule" }, { "discontinued_date": "01/09/2026", "update_type": "New", "initial_posting_date": "01/09/2026", "package_ndc": "63323-469-01", "generic_name": "Haloperidol Decanoate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA074893" ], "brand_name": [ "HALOPERIDOL DECANOATE" ], "generic_name": [ "HALOPERIDOL DECANOATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-469", "63323-471" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "HALOPERIDOL DECANOATE" ], "rxcui": [ "859867", "859871", "1719803", "1719862" ], "spl_id": [ "86dff2aa-2ab3-42fc-989e-619b13ace573" ], "spl_set_id": [ "ca9896e0-fb2e-46a4-8700-20d144c14764" ], "package_ndc": [ "63323-469-01", "63323-469-05", "63323-471-01", "63323-471-05" ], "unii": [ "AC20PJ4101" ] }, "update_date": "01/09/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Injection", "presentation": "Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 63323-469-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "12/03/2021", "package_ndc": "0409-3977-03", "generic_name": "Sterile Water Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA018802" ], "brand_name": [ "BACTERIOSTATIC WATER" ], "generic_name": [ "BACTERIOSTATIC WATER" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3977", "0409-1093" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "WATER" ], "spl_id": [ "dfac2c43-36b4-4fc0-a22d-f70c4aad5f97" ], "spl_set_id": [ "87d6e9dc-fe3b-4593-ac9a-d7493d1959c7" ], "package_ndc": [ "0409-3977-01", "0409-3977-03", "0409-1093-14", "0409-1093-04" ], "unii": [ "059QF0KO0R" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Injection", "presentation": "Bacteriostatic Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 0409-3977-03)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0415-07", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA017512" ], "brand_name": [ "DIANEAL PD-2 WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0415", "0941-0411", "0941-0413", "0941-0409", "0941-0457", "0941-0459", "0941-0426", "0941-0427", "0941-0429", "0941-0424", "0941-0430", "0941-0433", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0415-07)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6039-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "NDA018565" ], "brand_name": [ "INFUMORPH 200" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6039", "0641-6040" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRATHECAL" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "892652", "1731522", "1731998", "1731999" ], "spl_id": [ "b1c060cb-5c5b-495f-90b5-044e04f2a3f2" ], "spl_set_id": [ "db9ac9e3-d761-4a99-9f34-4946ebe8f255" ], "package_ndc": [ "0641-6039-01", "0641-6040-01" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0781-3465-95", "generic_name": "Fondaparinux Sodium Injection", "contact_info": "609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.", "openfda": { "application_number": [ "ANDA206812" ], "brand_name": [ "FONDAPARINUX SODIUM" ], "generic_name": [ "FONDAPARINUX SODIUM" ], "manufacturer_name": [ "Sandoz Inc." ], "product_ndc": [ "0781-3465", "0781-3443", "0781-3454", "0781-3476" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "FONDAPARINUX SODIUM" ], "rxcui": [ "861356", "861360", "861363", "861365" ], "spl_id": [ "3d5a4b69-462b-7e51-e063-6294a90a0721" ], "spl_set_id": [ "baa50757-a927-4d56-a933-5d7798fe6ab0" ], "package_ndc": [ "0781-3443-94", "0781-3443-12", "0781-3443-95", "0781-3454-94", "0781-3454-12", "0781-3454-95", "0781-3465-94", "0781-3465-12", "0781-3465-95", "0781-3476-94", "0781-3476-12", "0781-3476-95" ], "unii": [ "X0Q6N9USOZ" ] }, "update_date": "09/29/2025", "therapeutic_category": [ "Hematology" ], "dosage_form": "Injection", "presentation": "Fondaparinux Sodium, Injection, 7.5 mg/.6 mL (NDC 0781-3465-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "05/03/2018", "package_ndc": "0409-1985-30", "generic_name": "Lorazepam Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: September 2026", "openfda": { "application_number": [ "ANDA074243" ], "brand_name": [ "LORAZEPAM" ], "generic_name": [ "LORAZEPAM" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1985", "0409-1539" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "LORAZEPAM" ], "rxcui": [ "763028", "763029" ], "spl_id": [ "0280cc35-0696-4091-a000-2314f292feb2" ], "spl_set_id": [ "20140b19-846b-425f-b191-670e17809945" ], "package_ndc": [ "0409-1539-03", "0409-1539-31", "0409-1985-03", "0409-1985-30" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "O26FZP769L" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 2 mg/1 mL Syringes (NDC 0409-1985-30)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-5212-23", "generic_name": "Hydrochlorothiazide; Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Accuretic, Tablet, 12.5 mg; 20 mg (NDC 0071-5212-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "12/27/2023", "package_ndc": "45567-0060-2", "generic_name": "Technetium TC-99M Pyrophosphate Kit Injection", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA019039" ], "brand_name": [ "KIT FOR THE PREPARATION OF TECHNETIUM TC99M PYROPHOSPHATE" ], "generic_name": [ "TECHNETIUM TC99M PYROPHOSPHATE" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "45567-0060" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "TECHNETIUM TC-99M PYROPHOSPHATE" ], "spl_id": [ "3010b45e-eed1-a5d0-e063-6294a90a40cf" ], "spl_set_id": [ "1f0cbd23-2fb3-43b7-b8af-7de246151149" ], "package_ndc": [ "45567-0060-1", "45567-0060-2" ], "nui": [ "N0000177914", "N0000000205" ], "pharm_class_epc": [ "Radioactive Diagnostic Agent [EPC]" ], "pharm_class_moa": [ "Radiopharmaceutical Activity [MoA]" ], "unii": [ "5L76I61H2B" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Medical Imaging" ], "dosage_form": "Injection", "presentation": "CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-2)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "54288-166-01", "generic_name": "Carboplatin Injection", "contact_info": "Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270", "availability": "Limited Availability", "related_info": "Estimated recovery: end of June 2026; Distributed by BPI Labs, LLC", "openfda": { "application_number": [ "ANDA207324" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "BPI Labs LLC" ], "product_ndc": [ "54288-166", "54288-165", "54288-167", "54288-164" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "c0a7463c-d90f-4060-a54e-6a4888e8af0e" ], "spl_set_id": [ "5484d2f0-0cc2-4bba-8f26-c7f6539a9606" ], "package_ndc": [ "54288-165-01", "54288-166-01", "54288-167-01", "54288-164-01" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450mg/45mL (NDC 54288-166-01)", "company_name": "Gland Pharma Limited", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2859-01", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA075757" ], "brand_name": [ "OMEPRAZOLE" ], "generic_name": [ "OMEPRAZOLE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-2859", "0781-2868" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OMEPRAZOLE" ], "rxcui": [ "198051", "199119" ], "spl_id": [ "b182f298-e28f-434b-b6f1-ecfac29d495e" ], "spl_set_id": [ "516170d4-4913-4577-a2d2-f5c52d1e79c6" ], "package_ndc": [ "0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31" ], "nui": [ "N0000175525", "N0000000147", "N0000182140" ], "pharm_class_epc": [ "Proton Pump Inhibitor [EPC]" ], "pharm_class_moa": [ "Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]" ], "unii": [ "KG60484QX9" ] }, "update_date": "10/09/2025", "therapeutic_category": [ "Gastroenterology" ], "presentation": "Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-01)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "71288-205-03", "generic_name": "Furosemide Injection", "contact_info": "844-824-8426", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA217501" ], "brand_name": [ "HYDRALAZINE HYDROCHLORIDE" ], "generic_name": [ "HYDRALAZINE HYDROCHLORIDE" ], "manufacturer_name": [ "Meitheal Pharmaceuticals Inc." ], "product_ndc": [ "71288-205" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "HYDRALAZINE HYDROCHLORIDE" ], "rxcui": [ "966571" ], "spl_id": [ "2926d221-0ca5-4379-ac53-773051ec5c79" ], "spl_set_id": [ "f3c806a4-b971-421c-bcb9-9979c6d7aaec" ], "package_ndc": [ "71288-205-01", "71288-205-02" ], "unii": [ "FD171B778Y" ] }, "update_date": "04/23/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/mL, 2 mL (NDC 71288-205-03)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "64850-504-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": { "application_number": [ "ANDA211352" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Elite Laboratories, Inc." ], "product_ndc": [ "64850-504", "64850-500", "64850-501", "64850-502", "64850-503", "64850-505", "64850-506" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "a41cf8e5-cb1b-488c-96b3-3bef8283d6c4" ], "spl_set_id": [ "e677690f-790f-4626-ad78-097cdb6ea540" ], "package_ndc": [ "64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 64850-504-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1312-36", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA200403" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1312", "0409-1283", "0409-4264", "0409-1805", "0409-2552", "0409-3356", "0409-2540", "0409-3365", "0409-1304" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897756", "897757", "1433251", "1724383", "1724644", "2675350", "897653", "897753", "897758", "1724276" ], "spl_id": [ "766e302a-2d03-4d93-b237-2348b57ee517", "a3ebafac-648e-47b1-a6f5-1e3bff1e3e08" ], "spl_set_id": [ "f9ca2ef5-46d8-475a-a26e-f7c8becd6db7", "e9c9ef18-7dfc-4322-b2fc-29b934c30f8b" ], "package_ndc": [ "0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01", "0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-1312-36)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/13/2017", "package_ndc": "83301-0081-2", "generic_name": "Bumetanide Injection", "contact_info": "800-673-9839", "availability": "Available", "openfda": { "application_number": [ "ANDA219116" ], "brand_name": [ "BUMETANIDE" ], "generic_name": [ "BUMETANIDE" ], "manufacturer_name": [ "Mullan Pharmaceutical Inc." ], "product_ndc": [ "83301-0081", "83301-0080" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "BUMETANIDE" ], "rxcui": [ "282486", "1727569" ], "spl_id": [ "4c241a3e-649b-4414-e063-6294a90a3a32" ], "spl_set_id": [ "b7cd724b-817b-4b45-8133-1ebf505867e7" ], "package_ndc": [ "83301-0080-1", "83301-0080-2", "83301-0081-1", "83301-0081-2" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "0Y2S3XUQ5H" ] }, "update_date": "08/11/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, 2.5 mg/10 mL (0.25 mg/mL) (NDC 83301-0081-2)", "company_name": "Mullan Pharmaceutical Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-150-05", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA076517" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "61703-150", "61703-360", "61703-262", "61703-600" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "5aa72c15-8033-4559-b257-373371b18958" ], "spl_set_id": [ "47677091-fd20-49af-933c-c9dd2be21de9" ], "package_ndc": [ "61703-360-18", "61703-150-05", "61703-262-05", "61703-600-05" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-150-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "09/11/2025", "update_type": "New", "initial_posting_date": "09/11/2025", "package_ndc": "0054-0390-41", "generic_name": "Oxycodone Hydrochloride Oral Solution", "contact_info": "800-631-2174", "related_info": "Hikma has permanently discontinued (NDC 0054-0390-41) for the 15 mL bottle configuration. Hikma will continue to distribute Oxycodone Hydrochloride Oral Solution 5 mg/5 mL in the 500 mL bottle (NDC 0054-0390-63).", "openfda": { "application_number": [ "ANDA204037" ], "brand_name": [ "OXYCODONE HYDROCHLORIDE" ], "generic_name": [ "OXYCODONE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmceuticals USA Inc." ], "product_ndc": [ "0054-0390" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OXYCODONE HYDROCHLORIDE" ], "rxcui": [ "1049604" ], "spl_id": [ "47e856d4-de7d-49aa-8671-d1b4a35bad4d" ], "spl_set_id": [ "d8e87c66-f872-4e1d-9ade-ef11490af63b" ], "package_ndc": [ "0054-0390-41", "0054-0390-63" ], "unii": [ "C1ENJ2TE6C" ] }, "update_date": "09/11/2025", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Oral Solution", "presentation": "Oxycodone Hydrochloride, Oral Solution, 5 mg/5 mL (NDC 0054-0390-41)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "0228-2855-11", "generic_name": "Guanfacine Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA200881" ], "brand_name": [ "GUANFACINE" ], "generic_name": [ "GUANFACINE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0228-2855", "0228-2850", "0228-2851", "0228-2853" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "GUANFACINE HYDROCHLORIDE" ], "rxcui": [ "862006", "862013", "862019", "862025" ], "spl_id": [ "00143252-2b74-4b11-86ed-9b864635f129" ], "spl_set_id": [ "3a171942-37af-430d-8b9d-bb678ca2be4b" ], "package_ndc": [ "0228-2850-11", "0228-2851-11", "0228-2853-11", "0228-2855-11" ], "unii": [ "PML56A160O" ] }, "update_date": "11/13/2025", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Guanfacine Hydrochloride, Tablet, Extended Release, 4 mg (NDC 0228-2855-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "10/10/2025", "update_type": "New", "initial_posting_date": "10/10/2025", "package_ndc": "0781-3518-76", "generic_name": "Pemetrexed Disodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA214657" ], "brand_name": [ "PEMETREXED" ], "generic_name": [ "PEMETREXED DISODIUM" ], "manufacturer_name": [ "Sandoz Inc." ], "product_ndc": [ "0781-3518", "0781-3519", "0781-3520" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "PEMETREXED DISODIUM" ], "rxcui": [ "2602363", "2602365", "2602366" ], "spl_id": [ "764ab64b-c642-4314-83a9-efee79fe83a3" ], "spl_set_id": [ "7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3" ], "package_ndc": [ "0781-3518-76", "0781-3519-90", "0781-3520-91" ], "unii": [ "2PKU919BA9" ] }, "update_date": "10/10/2025", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Pemetrexed Disodium, Injection, 100 mg/4 mL (NDC 0781-3518-76)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "72516-016-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "855-257-0292", "availability": "Unavailable", "related_info": "Estimated availability April 2027", "openfda": { "application_number": [ "ANDA210293" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Oryza Pharmaceuticals Inc." ], "product_ndc": [ "72516-016", "72516-015", "72516-014", "72516-013", "72516-012", "72516-011" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "1009145" ], "spl_id": [ "5734011d-5044-b490-e063-6394a90a3174" ], "spl_set_id": [ "acd27181-a3f3-4c38-85d8-029a4a82e7c2" ], "package_ndc": [ "72516-016-01", "72516-015-01", "72516-014-01", "72516-013-01", "72516-012-01", "72516-011-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 72516-016-01)", "company_name": "Oryza Pharmaceuticals Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-339-18", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: February 2027; Estimated Recovery: March 2027", "openfda": { "application_number": [ "ANDA076517" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "61703-339" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "0ddf4411-7138-412a-908a-fadf22bdfb79" ], "spl_set_id": [ "c3ae9880-44bb-4f4e-93d8-8a5e21708a30" ], "package_ndc": [ "61703-339-18", "61703-339-22", "61703-339-50", "61703-339-56" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-339-18)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "05/15/2026", "update_type": "New", "initial_posting_date": "05/15/2026", "package_ndc": "0574-0521-76", "generic_name": "Activated Charcoal Oral Suspension", "contact_info": "866-634-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "M023" ], "brand_name": [ "ACTIDOSE AQUA" ], "generic_name": [ "ACTIVATED CHARCOAL" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-0521" ], "product_type": [ "HUMAN OTC DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ACTIVATED CHARCOAL" ], "rxcui": [ "309150", "1251411" ], "spl_id": [ "bd250d66-b8ea-4cab-a8f2-d2913a157fc5" ], "spl_set_id": [ "c85dc235-3f42-4361-9bd2-1aaff798ad75" ], "package_ndc": [ "0574-0521-25", "0574-0521-74", "0574-0521-76" ], "unii": [ "2P3VWU3H10" ] }, "update_date": "05/15/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Oral Suspension", "presentation": "Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-76)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "67457-422-54", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA040803" ], "brand_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "generic_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "manufacturer_name": [ "Mylan Institutional LLC" ], "product_ndc": [ "67457-422", "67457-423", "67457-421", "67457-420" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE" ], "substance_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "rxcui": [ "309696", "1116927", "1812194" ], "spl_id": [ "dd5c82b6-a194-462c-9626-34a9b410cfea" ], "spl_set_id": [ "dff598e8-e662-411f-978d-4ba3fb8ef7db" ], "package_ndc": [ "67457-423-00", "67457-423-12", "67457-422-00", "67457-422-54", "67457-421-00", "67457-421-30", "67457-420-00", "67457-420-10" ], "unii": [ "AI9376Y64P" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-422-54)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "55150-226-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA206206" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-226", "55150-225" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "1bb59a7e-d219-466c-abae-8a0680af9b8c" ], "spl_set_id": [ "116385ea-69fc-4f44-b463-6210291032df" ], "package_ndc": [ "55150-225-05", "55150-226-10" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 55150-226-10)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "0409-1323-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 100 mg/5mL (2%,20 mg/1 mL) Syringes (NDC 0409-1323-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "12/22/2025", "update_type": "New", "initial_posting_date": "12/22/2025", "package_ndc": "0002-8870-27", "generic_name": "Mirikizumab-mrkz Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-1442-11) will remain.", "openfda": { "application_number": [ "BLA761279" ], "brand_name": [ "OMVOH" ], "generic_name": [ "MIRIKIZUMAB-MRKZ" ], "manufacturer_name": [ "Eli Lilly and Company" ], "product_ndc": [ "0002-8870", "0002-7575", "0002-8011", "0002-7717", "0002-7722", "0002-3116", "0002-1442" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "MIRIKIZUMAB" ], "rxcui": [ "2668391", "2668398", "2668405", "2668410", "2680728", "2680732", "2703047", "2703048", "2703049", "2703050", "2703051", "2703052", "2703053", "2703054" ], "spl_id": [ "3553ca93-cbe0-4286-b806-a423598eb42a" ], "spl_set_id": [ "472cbe04-263e-433d-9a0f-58c1b50b715a" ], "package_ndc": [ "0002-7575-01", "0002-8011-01", "0002-8011-27", "0002-8011-61", "0002-8870-01", "0002-8870-27", "0002-7717-11", "0002-7717-61", "0002-3116-01", "0002-7722-11", "0002-1442-01", "0002-3116-11", "0002-3116-61", "0002-1442-11" ], "nui": [ "N0000192799", "N0000192798" ], "pharm_class_epc": [ "Interleukin-23 Antagonist [EPC]" ], "pharm_class_moa": [ "Interleukin-23 Antagonists [MoA]" ], "unii": [ "Z7HVY03PHP" ] }, "update_date": "12/22/2025", "therapeutic_category": [ "Gastroenterology", "Other" ], "dosage_form": "Injection", "presentation": "Omvoh, Injection, 100 mg/1 mL (NDC 0002-8870-27)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "63323-162-02", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release September 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "ANDA075784" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-162", "63323-161" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "2b1c6066-d9e0-40a0-ade5-776fc35a3626", "55ed7afb-db66-4b28-939b-db45b55bf058", "ab476c4c-2c72-47b1-bf42-7a89703b0dd4" ], "spl_set_id": [ "ccf905ca-e164-4779-9485-2d139c821bad", "950b7295-3f68-4027-ac2b-2f7d0f5f8ef9", "d1920335-8e45-4960-b6e9-e6f1f9e6820c" ], "package_ndc": [ "63323-161-41", "63323-161-16", "63323-162-43", "63323-162-16", "63323-162-45", "63323-162-26", "63323-161-21", "63323-161-12", "63323-162-23", "63323-162-12", "63323-162-25", "63323-162-14", "63323-161-00", "63323-161-01", "63323-162-11", "63323-162-51", "63323-162-00", "63323-162-01", "63323-162-03", "63323-162-02" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-02)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1159-02", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA070583" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1725078", "1725082", "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1867594", "1867596" ], "spl_id": [ "fb58e702-b0da-4fa9-91f2-4580b2305950", "6e442bfd-d3da-4913-8585-ce3485644364" ], "spl_set_id": [ "bb44c7e1-d911-4788-908f-09b7b271969b", "02a845c3-4521-4926-e397-25ab536e7cf6" ], "package_ndc": [ "0409-1159-09", "0409-1159-10", "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17" ], "unii": [ "7TQO7W3VT8", "30Q7KI53AK" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0338-9545-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA208083" ], "brand_name": [ "CLINDAMYCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "0338-9545", "0338-9549", "0338-9553" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "309335", "309336", "309339" ], "spl_id": [ "b0a47c5e-911b-4b12-a0d1-a4425f173eec" ], "spl_set_id": [ "44fa506b-90ac-42de-831b-5f3f1a500fc0" ], "package_ndc": [ "0338-9545-50", "0338-9545-24", "0338-9549-50", "0338-9549-24", "0338-9553-50", "0338-9553-24" ], "unii": [ "EH6D7113I8" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-6082-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA083312" ], "brand_name": [ "PHENERGAN" ], "generic_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6082", "0641-6083" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "rxcui": [ "992460", "992462", "992858", "992876" ], "spl_id": [ "a64f0625-8d56-4994-8908-13614ca7b09f" ], "spl_set_id": [ "6f7e47cc-f823-4336-8107-f980e3049617" ], "package_ndc": [ "0641-6082-01", "0641-6082-25", "0641-6083-01", "0641-6083-25" ], "unii": [ "R61ZEH7I1I" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy" ], "dosage_form": "Injection", "presentation": "Phenergan, Injection, 25 mg/1 mL (NDC 0641-6082-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "02/27/2026", "update_type": "New", "initial_posting_date": "02/27/2026", "package_ndc": "50458-290-01", "generic_name": "Itraconazole Capsule", "contact_info": "800-JANSSEN (1-800-526-7736)", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA020083" ], "brand_name": [ "SPORANOX" ], "generic_name": [ "ITRACONAZOLE" ], "manufacturer_name": [ "Janssen Pharmaceuticals, Inc." ], "product_ndc": [ "50458-290" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ITRACONAZOLE" ], "rxcui": [ "311204", "833164" ], "spl_id": [ "a79c080b-711a-4a15-af92-ff0c60cbfdf1" ], "spl_set_id": [ "a4d555fa-787c-40fb-bb7d-b0d4f7318fd0" ], "package_ndc": [ "50458-290-01", "50458-290-04", "50458-290-28" ], "nui": [ "N0000175487", "M0002083", "N0000182141", "N0000185503", "N0000190113" ], "pharm_class_epc": [ "Azole Antifungal [EPC]" ], "pharm_class_cs": [ "Azoles [CS]" ], "pharm_class_moa": [ "Cytochrome P450 3A4 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]" ], "unii": [ "304NUG5GF4" ] }, "update_date": "02/27/2026", "therapeutic_category": [ "Anti-Infective", "Other" ], "dosage_form": "Capsule", "presentation": "Sporanox, Capsule, 100 mg (NDC 50458-290-01)", "company_name": "Janssen Pharmaceuticals", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6126-25", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA205758" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6126", "0641-6127", "0641-6125" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "1731993", "1732006", "1732011" ], "spl_id": [ "fb513d10-94f4-45f5-8b30-fa82ef83e4e2" ], "spl_set_id": [ "6023606c-150c-40c5-9175-598efe2a56c3" ], "package_ndc": [ "0641-6126-01", "0641-6126-25", "0641-6127-01", "0641-6127-25", "0641-6125-01", "0641-6125-25" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "presentation": "Lidocaine Hydrochloride Preservative Free In Plastic Container, Injection, 50 mg/5mL (1%, 10 mg/1 mL) Syringes (NDC 0409-9137-05)", "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-9137-05", "generic_name": "Lidocaine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "status": "Current", "dosage_form": "Injection" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-2253-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "related_info": "Historical NDC: 0409-1582-29", "openfda": { "application_number": [ "NDA016964" ], "brand_name": [ "MARCAINE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-2253", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1746", "0409-1749", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "RETROBULBAR" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614" ], "spl_id": [ "7040888c-2cde-4408-af99-d249985f8444" ], "spl_set_id": [ "67578b56-7540-487e-1fba-481255620e78" ], "package_ndc": [ "0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Marcaine, Injection, Marcaine 225 mg/30 mL (7.5 mg/mL) (NDC 0409-2253-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "16729-137-16", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": { "application_number": [ "ANDA077147" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Accord Healthcare Inc." ], "product_ndc": [ "16729-137", "16729-136", "16729-138" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "0e1e7f41-f78b-27cf-e063-6394a90a1ae0" ], "spl_set_id": [ "ebc11109-e7bf-452d-b675-4b3236d54164" ], "package_ndc": [ "16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 16729-137-16)", "company_name": "Accord Healthcare Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "43547-412-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-931-9829", "availability": "Unavailable", "related_info": "Not available. Long-term backorder for all NDCs. No estimated release date at this time.", "openfda": { "application_number": [ "ANDA205823" ], "brand_name": [ "QUINAPRIL" ], "generic_name": [ "QUINAPRIL" ], "manufacturer_name": [ "Solco Healthcare US, LLC" ], "product_ndc": [ "43547-412", "43547-410", "43547-411", "43547-413" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE" ], "rxcui": [ "312748", "312749", "312750", "314203" ], "spl_id": [ "b8f1731a-cbac-4f64-a8d4-320b80b335e1" ], "spl_set_id": [ "cd46691d-5593-4a9f-a937-999c6803e312" ], "package_ndc": [ "43547-410-09", "43547-411-09", "43547-412-09", "43547-413-09" ], "unii": [ "33067B3N2M" ] }, "update_date": "06/29/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 20 mg (NDC 43547-412-09)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-162-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release August 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "ANDA075784" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-162", "63323-161" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "2b1c6066-d9e0-40a0-ade5-776fc35a3626", "55ed7afb-db66-4b28-939b-db45b55bf058", "ab476c4c-2c72-47b1-bf42-7a89703b0dd4" ], "spl_set_id": [ "ccf905ca-e164-4779-9485-2d139c821bad", "950b7295-3f68-4027-ac2b-2f7d0f5f8ef9", "d1920335-8e45-4960-b6e9-e6f1f9e6820c" ], "package_ndc": [ "63323-161-41", "63323-161-16", "63323-162-43", "63323-162-16", "63323-162-45", "63323-162-26", "63323-161-21", "63323-161-12", "63323-162-23", "63323-162-12", "63323-162-25", "63323-162-14", "63323-161-00", "63323-161-01", "63323-162-11", "63323-162-51", "63323-162-00", "63323-162-01", "63323-162-03", "63323-162-02" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 63323-162-01)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "discontinued_date": "04/14/2026", "update_type": "New", "initial_posting_date": "04/14/2026", "package_ndc": "58914-301-80", "generic_name": "Nitroglycerin Ointment", "contact_info": "800-678-1605", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA021359" ], "brand_name": [ "RECTIV" ], "generic_name": [ "NITROGLYCERIN" ], "manufacturer_name": [ "Allergan, Inc." ], "product_ndc": [ "58914-301" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RECTAL" ], "substance_name": [ "NITROGLYCERIN" ], "rxcui": [ "1114466", "1114470" ], "spl_id": [ "a2f0ef5a-c3b6-4330-9b33-131369431ddd" ], "spl_set_id": [ "603aa9ed-54c4-4a35-ade4-690fa44850e4" ], "package_ndc": [ "58914-301-80", "58914-301-85" ], "nui": [ "N0000175415", "M0014874", "N0000009909" ], "pharm_class_epc": [ "Nitrate Vasodilator [EPC]" ], "pharm_class_cs": [ "Nitrates [CS]" ], "pharm_class_pe": [ "Vasodilation [PE]" ], "unii": [ "G59M7S0WS3" ] }, "update_date": "04/14/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Ointment", "presentation": "Rectiv, Ointment, 0.4% (NDC 58914-301-80)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "76329-3390-1", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-423-4136", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": { "application_number": [ "ANDA083173" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "International Medication Systems, Limited" ], "product_ndc": [ "76329-3390" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1012068" ], "spl_id": [ "3d910bb6-792f-41f3-8b28-b33bcbec5ccb" ], "spl_set_id": [ "5d3e9984-cef9-46f2-a6c9-3be8b26f45b3" ], "package_ndc": [ "76329-3390-1" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 76329-3390-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0413-06", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA017512" ], "brand_name": [ "DIANEAL PD-2 WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0413", "0941-0411", "0941-0415", "0941-0409", "0941-0457", "0941-0459", "0941-0426", "0941-0427", "0941-0429", "0941-0424", "0941-0430", "0941-0433", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0413-06)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-154-05", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": { "application_number": [ "ANDA075468" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Advagen Pharma Ltd" ], "product_ndc": [ "72888-154", "72888-497", "72888-152", "72888-153" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529", "204892" ], "spl_id": [ "5510f17b-a980-f412-e063-6394a90ae1c4" ], "spl_set_id": [ "30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec" ], "package_ndc": [ "72888-497-01", "72888-497-02", "72888-497-03", "72888-497-04", "72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 72888-154-05)", "company_name": "Rubicon Research Private Limited", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0222-23", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Accuretic, Tablet, 10 mg/12.5 mg (NDC 0071-0222-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-492-37", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE MPF" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487", "63323-493", "63323-496" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029", "1737636", "1737637", "1737640", "1737641", "1737763", "1737764" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428", "0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33", "fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17", "4dd52202-8eef-4136-92dd-ada573b7cf74", "d5e0d06f-ba1e-44d4-aa89-39d6c146dc23" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31", "63323-492-41", "63323-492-16", "63323-492-43", "63323-492-36", "63323-492-45", "63323-492-26", "63323-485-41", "63323-485-26", "63323-486-41", "63323-486-26", "63323-482-41", "63323-482-26", "63323-495-41", "63323-495-26", "63323-492-08", "63323-492-97", "63323-493-03", "63323-493-97", "63323-493-01", "63323-493-91", "63323-496-03", "63323-496-97" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "0781-3220-95", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-525-8747", "availability": "Available", "openfda": { "application_number": [ "ANDA079195" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-3220" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "eaf32464-7950-434a-e053-2a95a90aa2dc" ], "spl_set_id": [ "cb28d869-6510-4402-9462-f6bb25fa0fa8" ], "package_ndc": [ "0781-3220-70", "0781-3220-92", "0781-3220-75", "0781-3220-95" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-95)", "company_name": "Sandoz Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/13/2023", "package_ndc": "0703-3671-01", "generic_name": "Methotrexate Sodium Injection", "contact_info": "800-545-8800", "availability": "Unavailable", "related_info": "Estimated recovery: October 2026", "openfda": { "application_number": [ "ANDA040843" ], "brand_name": [ "METHOTREXATE" ], "generic_name": [ "METHOTREXATE" ], "manufacturer_name": [ "Teva Parenteral Medicines, Inc." ], "product_ndc": [ "0703-3671", "0703-3675", "0703-3678" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS" ], "substance_name": [ "METHOTREXATE SODIUM" ], "rxcui": [ "1655956", "1655959", "1655960" ], "spl_id": [ "e81074cc-12b4-4ac9-a5bb-749188989b2c" ], "spl_set_id": [ "346ec9ce-dc98-4a55-b55e-d3af11f2d703" ], "package_ndc": [ "0703-3671-01", "0703-3675-01", "0703-3678-01" ], "unii": [ "3IG1E710ZN" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Rheumatology", "Oncology" ], "dosage_form": "Injection", "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "55150-297-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA210321" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-297", "55150-209", "55150-296" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "309710", "1718906", "1718909" ], "spl_id": [ "a1eab62d-fcef-4b83-9266-3c5f7a05927b" ], "spl_set_id": [ "8c162541-986b-4b30-866c-b2631ba2c975" ], "package_ndc": [ "55150-209-02", "55150-296-10", "55150-297-10" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-297-10)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-116-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": { "application_number": [ "NDA208510" ], "brand_name": [ "VYVANSE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "59417-116", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-117", "59417-118", "59417-119", "59417-120" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469" ], "spl_id": [ "81d087b6-4cb4-466a-9693-679edeb062e2" ], "spl_set_id": [ "704e4378-ca83-445c-8b45-3cfa51c1ecad" ], "package_ndc": [ "59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 20 mg (NDC 59417-116-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current" }, { "discontinued_date": "06/17/2026", "update_type": "New", "initial_posting_date": "06/17/2026", "package_ndc": "61958-0601-1", "generic_name": "Emtricitabine Capsule", "contact_info": "800-445-3235", "related_info": "Product expected to be available until March 2027", "openfda": { "application_number": [ "NDA021500" ], "brand_name": [ "EMTRIVA" ], "generic_name": [ "EMTRICITABINE" ], "manufacturer_name": [ "Gilead Sciences, Inc." ], "product_ndc": [ "61958-0601", "61958-0602" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "EMTRICITABINE" ], "rxcui": [ "403875", "404587", "597291", "616148" ], "spl_id": [ "13ed3577-67a4-4828-b886-f35206f149a6" ], "spl_set_id": [ "d6599395-3944-44f9-97f2-e0424c6b6a1f" ], "package_ndc": [ "61958-0601-1", "61958-0602-1" ], "nui": [ "N0000175462", "M0015066", "N0000009947" ], "pharm_class_epc": [ "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]" ], "pharm_class_cs": [ "Nucleosides [CS]" ], "pharm_class_moa": [ "Nucleoside Reverse Transcriptase Inhibitors [MoA]" ], "unii": [ "G70B4ETF4S" ] }, "update_date": "06/17/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Capsule", "presentation": "Emtriva, Capsule, 200 mg (NDC 61958-0601-1)", "company_name": "Gilead Sciences, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "09/09/2025", "update_type": "New", "initial_posting_date": "09/09/2025", "package_ndc": "0409-0144-11", "generic_name": "Azithromycin Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "09/09/2025", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Azithromycin, Injection, 500 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-0144-11)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "61703-350-10", "generic_name": "Methotrexate Sodium Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA011719" ], "brand_name": [ "METHOTREXATE" ], "generic_name": [ "METHOTREXATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "61703-350", "61703-408" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "METHOTREXATE SODIUM" ], "rxcui": [ "1655956", "1946772" ], "spl_id": [ "95b8b8da-da4e-4bba-9038-3cf65f3d5c1a", "37b3e76b-ac3d-4f93-adf1-91f52f676b8a" ], "spl_set_id": [ "0d63ba29-b692-41b4-87e8-351265c8273f", "0e30eaef-5a09-4104-8a11-c32933eadeab" ], "package_ndc": [ "61703-350-37", "61703-350-38", "61703-408-41", "61703-350-09", "61703-350-10", "61703-408-25" ], "unii": [ "3IG1E710ZN" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology", "Oncology" ], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "49230-209-94", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "update_date": "03/10/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 49230-209-94)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-164-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA215330" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Rhodes Pharmaceuticals LLC" ], "product_ndc": [ "42858-164", "42858-161", "42858-162", "42858-163", "42858-165", "42858-166", "42858-167" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "0002e227-1109-4ecc-a8c5-4b4f11fac3cc" ], "spl_set_id": [ "d918b40d-a461-41bc-b6c0-83dc76c28e32" ], "package_ndc": [ "42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/24/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 42858-164-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/21/2023", "package_ndc": "25021-115-02", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "866-625-1618", "availability": "Limited Availability", "related_info": "Selling through remaining short-dated inventory (Dec 2026), API not available, Exiting product line", "openfda": { "application_number": [ "ANDA090108" ], "brand_name": [ "CLINDAMYCIN" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-115" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "1737244", "1737578", "1737581" ], "spl_id": [ "4662502b-ce7c-4278-854d-cf8632ac9b83" ], "spl_set_id": [ "7a6967b3-5563-4bed-9eee-d400f800e799" ], "package_ndc": [ "25021-115-02", "25021-115-04", "25021-115-06" ], "unii": [ "EH6D7113I8" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02)", "company_name": "Sagent Pharmaceuticals", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4664-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": { "application_number": [ "ANDA215802" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Lannett Company, Inc." ], "product_ndc": [ "0527-4664", "0527-4661", "0527-4662", "0527-4663", "0527-4665", "0527-4666", "0527-4667" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "cb49954d-0f9d-4471-bc86-0c926473c00b" ], "spl_set_id": [ "2cedb4c2-1e40-4bc4-b9f4-127150c4afbd" ], "package_ndc": [ "0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0527-4664-37)", "company_name": "Lannett Company, Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/08/2019", "package_ndc": "70069-025-10", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": { "application_number": [ "ANDA211036" ], "brand_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "generic_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-025" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "rxcui": [ "309696" ], "spl_id": [ "0fefe630-0e29-4d04-a083-eb3036f48100" ], "spl_set_id": [ "5a1b0266-90c8-4176-a6b0-c4204d3c604e" ], "package_ndc": [ "70069-025-10" ], "unii": [ "AI9376Y64P" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 70069-025-10)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-061-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": { "application_number": [ "ANDA207636" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-061", "70069-062", "70069-063", "70069-064", "70069-065", "70069-066", "70069-067" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483" ], "spl_id": [ "79b226f0-c08a-4f84-bf2b-ae5c60e01d67" ], "spl_set_id": [ "ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64" ], "package_ndc": [ "70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10" ], "unii": [ "V910P86109" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-10)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-117-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Unavailable", "related_info": "Estimated recovery: October 2026", "openfda": { "application_number": [ "ANDA215771" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Granules Pharmaceuticals Inc." ], "product_ndc": [ "70010-117", "70010-111", "70010-112", "70010-113", "70010-114", "70010-115", "70010-116" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "56c7c921-e560-c5ad-e063-6294a90a4c81" ], "spl_set_id": [ "b0b4eccc-34c7-483d-966f-82d588358e1b" ], "package_ndc": [ "70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 70010-117-01)", "company_name": "Granules Pharmaceuticals Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-484-60", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA076803" ], "brand_name": [ "QUINAPRIL" ], "generic_name": [ "QUINAPRIL" ], "manufacturer_name": [ "Chartwell RX, LLC" ], "product_ndc": [ "62135-484", "62135-485", "62135-486", "62135-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE" ], "rxcui": [ "312748", "312749", "312750", "314203" ], "spl_id": [ "09cd5cb9-4fdf-f133-e063-6294a90af691" ], "spl_set_id": [ "dbc43dbd-94aa-40e2-a9ea-766110cc8687" ], "package_ndc": [ "62135-484-60", "62135-485-90", "62135-486-90", "62135-487-90" ], "unii": [ "33067B3N2M" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 5 mg (NDC 62135-484-60)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-104-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": { "application_number": [ "NDA021977" ], "brand_name": [ "VYVANSE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "59417-104", "59417-101", "59417-102", "59417-103", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469" ], "spl_id": [ "81d087b6-4cb4-466a-9693-679edeb062e2" ], "spl_set_id": [ "704e4378-ca83-445c-8b45-3cfa51c1ecad" ], "package_ndc": [ "59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 40 mg (NDC 59417-104-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/08/2019", "package_ndc": "76045-0210-10", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "update_date": "08/04/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-0210-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-606-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": { "application_number": [ "ANDA216266" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE CAPSULES" ], "manufacturer_name": [ "Solco Healthcare US,LLC" ], "product_ndc": [ "43547-606", "43547-602", "43547-603", "43547-604", "43547-605", "43547-607", "43547-608" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "d6435613-e052-4b4f-8bf7-4acb7458d8df" ], "spl_set_id": [ "68b10d9f-ca3e-493d-a309-45f1d7e08061" ], "package_ndc": [ "43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/29/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 43547-606-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7923-20", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Available", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA016367" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "ICU Medical, Inc." ], "product_ndc": [ "0990-7923", "0990-7922", "0990-7930" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621" ], "spl_id": [ "06e4d957-1a56-4adb-a42b-fe0773b2fa97" ], "spl_set_id": [ "8b25b7e0-703e-4b43-a4eb-52863511602d" ], "package_ndc": [ "0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-20)", "company_name": "Otsuka ICU Medical LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-7299-25", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA018893" ], "brand_name": [ "SODIUM ACETATE" ], "generic_name": [ "SODIUM ACETATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-7299" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM ACETATE ANHYDROUS" ], "rxcui": [ "1859490" ], "spl_id": [ "013001c4-5584-4d8c-8bf6-917d2a919aa4", "10c75a24-9542-431a-84f8-44611bc916df" ], "spl_set_id": [ "ce9a7469-c4ba-4f60-8f7a-47ef0974316e", "c91ede49-c7cc-47b7-0f93-e6841dd5916a" ], "package_ndc": [ "0409-7299-45", "0409-7299-25", "0409-7299-83", "0409-7299-73" ], "unii": [ "NVG71ZZ7P0" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition" ], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5112-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Available", "openfda": { "application_number": [ "ANDA211840" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "SpecGx LLC" ], "product_ndc": [ "0406-5112", "0406-5111", "0406-5113", "0406-5114", "0406-5115", "0406-5116", "0406-5117" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "b4be564a-404d-4ca1-bac0-ec9cf40fef93" ], "spl_set_id": [ "806a1c15-0842-4787-b2ad-09a21fd96b37" ], "package_ndc": [ "0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0406-5112-01)", "company_name": "SpecGx LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-667-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA076374" ], "brand_name": [ "QUINAPRIL AND HYDROCHLOROTHIAZIDE" ], "generic_name": [ "QUINAPRIL AND HYDROCHLOROTHIAZIDE" ], "manufacturer_name": [ "Chartwell RX, LLC" ], "product_ndc": [ "62135-667", "62135-668", "62135-669" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE", "HYDROCHLOROTHIAZIDE" ], "rxcui": [ "310796", "310797", "310809" ], "spl_id": [ "0c3f4504-d57e-aa79-e063-6294a90ad5b8" ], "spl_set_id": [ "2eae533f-d0af-47e8-a1f2-94bc8cc89b5a" ], "package_ndc": [ "62135-667-90", "62135-668-90", "62135-669-90" ], "nui": [ "N0000175359", "N0000175419", "M0471776" ], "pharm_class_pe": [ "Increased Diuresis [PE]" ], "pharm_class_epc": [ "Thiazide Diuretic [EPC]" ], "pharm_class_cs": [ "Thiazides [CS]" ], "unii": [ "0J48LPH2TH", "33067B3N2M" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 62135-667-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1181-30", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA021171" ], "brand_name": [ "DEMEROL" ], "generic_name": [ "MEPERIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1181", "0409-1176", "0409-1178", "0409-1179", "0409-1180", "0409-1362", "0409-1418" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "MEPERIDINE HYDROCHLORIDE" ], "rxcui": [ "860792", "861463", "861473", "861493", "861494", "861522", "861529", "861617", "1242106", "1242503", "2539186", "2539188", "2539191", "2539192" ], "spl_id": [ "b6935f73-7b93-496d-871b-de6f9b379649" ], "spl_set_id": [ "b31d1308-28c3-43f4-e0a6-2f3ed76b8975" ], "package_ndc": [ "0409-1181-30", "0409-1176-03", "0409-1176-30", "0409-1178-03", "0409-1178-30", "0409-1179-03", "0409-1179-30", "0409-1180-59", "0409-1180-69", "0409-1362-11", "0409-1362-01", "0409-1418-11", "0409-1418-01" ], "unii": [ "N8E7F7Q170" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Demerol, Injection, 50 mg/1 mL (NDC 0409-1181-30)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "0641-0367-25", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA087702" ], "brand_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "generic_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-0367", "0641-6145", "0641-6146" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "rxcui": [ "309696", "1116927", "1812194" ], "spl_id": [ "02bf3273-f0c8-448c-9f74-eb009fee9299" ], "spl_set_id": [ "0277cc0a-2fd4-4605-a310-b613be84ee26" ], "package_ndc": [ "0641-0367-21", "0641-0367-25", "0641-6145-01", "0641-6145-25", "0641-6146-01", "0641-6146-10", "0641-6146-25" ], "unii": [ "AI9376Y64P" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 0641-0367-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "64850-500-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": { "application_number": [ "ANDA211352" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Elite Laboratories, Inc." ], "product_ndc": [ "64850-500", "64850-501", "64850-502", "64850-503", "64850-504", "64850-505", "64850-506" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "a41cf8e5-cb1b-488c-96b3-3bef8283d6c4" ], "spl_set_id": [ "e677690f-790f-4626-ad78-097cdb6ea540" ], "package_ndc": [ "64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 64850-500-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-2344-01", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA074086" ], "brand_name": [ "DOBUTAMINE" ], "generic_name": [ "DOBUTAMINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-2344" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOBUTAMINE HYDROCHLORIDE" ], "rxcui": [ "1812168" ], "spl_id": [ "e71e9520-871b-479d-9652-1857fceca863", "f6a67673-07a7-44e4-b05c-1f7e63326f79" ], "spl_set_id": [ "dc537761-d5f4-488d-24ab-b2bcd2b17b7a", "89becb0c-da60-4f43-0a98-29ff7a9eca58" ], "package_ndc": [ "0409-2344-01", "0409-2344-62", "0409-2344-02", "0409-2344-68", "0409-2344-88" ], "unii": [ "0WR771DJXV" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular", "Pediatric", "Renal" ], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/24/2017", "package_ndc": "51754-5001-5", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "828-758-5474 ext. 154", "availability": "Available", "openfda": { "application_number": [ "ANDA211091" ], "brand_name": [ "SODIUM BICARBONATE" ], "generic_name": [ "SODIUM BICARBONATE" ], "manufacturer_name": [ "Exela Pharma Sciences, LLC" ], "product_ndc": [ "51754-5001", "51754-5011", "51754-5002", "51754-5012" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM BICARBONATE" ], "rxcui": [ "807284", "1868486", "1923484", "2198792" ], "spl_id": [ "4da0ba66-756d-4b4d-8018-81ca16578ef1" ], "spl_set_id": [ "e9698a4f-1a95-4f28-a945-e8009d1d6dd4" ], "package_ndc": [ "51754-5001-5", "51754-5001-4", "51754-5011-4", "51754-5002-5", "51754-5012-4" ], "unii": [ "8MDF5V39QO" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5001-5)", "company_name": "Exela Pharma Sciences, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4739-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Available", "openfda": { "application_number": [ "ANDA216944" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Apotex Corp." ], "product_ndc": [ "60505-4739", "60505-4740", "60505-4741", "60505-4742", "60505-4743", "60505-4744", "60505-4745" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "2eec36cd-6063-fea0-d6dd-b7a5c8df186b" ], "spl_set_id": [ "ecad4442-a644-18e3-6ff2-fdbac45eec47" ], "package_ndc": [ "60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 60505-4739-1)", "company_name": "Apotex Corp.", "status": "Current" }, { "discontinued_date": "10/16/2025", "update_type": "New", "initial_posting_date": "10/16/2025", "package_ndc": "0049-3190-01", "generic_name": "Voriconazole Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA021267" ], "brand_name": [ "VFEND" ], "generic_name": [ "VORICONAZOLE" ], "manufacturer_name": [ "Roerig" ], "product_ndc": [ "0049-3190", "0049-3170", "0049-3180", "0049-3160" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "VORICONAZOLE" ], "rxcui": [ "351209", "352220", "349434", "349435", "352218", "352219", "465355", "546624" ], "spl_id": [ "8b24199e-0319-4538-a971-19d5ac52fd35", "cf9f1b2e-eeb4-48bb-9f1a-c2b8d94dfbea" ], "spl_set_id": [ "dac26bcd-7a59-401f-9f66-a0649767cece", "ce3ef5cf-3087-4d92-9d94-9eb8287228db" ], "package_ndc": [ "0049-3190-01", "0049-3170-30", "0049-3180-30", "0049-3190-28", "0049-3160-44" ], "nui": [ "N0000175487", "M0002083", "N0000182141", "N0000182140", "N0000185504" ], "pharm_class_epc": [ "Azole Antifungal [EPC]" ], "pharm_class_cs": [ "Azoles [CS]" ], "pharm_class_moa": [ "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]" ], "unii": [ "JFU09I87TR" ] }, "update_date": "10/16/2025", "therapeutic_category": [ "Antiviral" ], "dosage_form": "Injection", "presentation": "Vfend, Injection, 10 mg/1 mL (NDC 0049-3190-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "64253-400-91", "generic_name": "Atropine Sulfate Injection", "contact_info": "630-682-4600", "availability": "Available", "openfda": { "application_number": [ "ANDA214970" ], "brand_name": [ "ATROPINE SULFATE" ], "generic_name": [ "ATROPINE SULFATE INJECTION" ], "manufacturer_name": [ "Medefil, Inc." ], "product_ndc": [ "64253-400" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ATROPINE SULFATE" ], "rxcui": [ "1190546" ], "spl_id": [ "46a6a31f-46ab-a437-e063-6394a90a4ad0" ], "spl_set_id": [ "fbfdf718-befe-ad22-e053-6294a90a3715" ], "package_ndc": [ "64253-400-30", "64253-400-91" ], "unii": [ "03J5ZE7KA5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 64253-400-91)", "company_name": "Medefil, Inc.", "status": "Current" }, { "discontinued_date": "01/12/2026", "update_type": "New", "initial_posting_date": "01/12/2026", "package_ndc": "0378-4615-01", "generic_name": "Doxylamine Succinate and Pyridoxine Hydrochloride Tablet, Delayed Release", "contact_info": "800-796-9526", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "01/12/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Tablet", "presentation": "Doxylamine Succinate and Pyridoxine Hydrochloride, Tablet, Delayed Release, 10 mg; 10 mg (NDC 0378-4615-01)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-454-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA204223" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-454", "63323-452", "63323-455", "63323-458", "63323-451" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "1731993", "1732006", "1732011", "1732136", "2003714" ], "spl_id": [ "dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc" ], "spl_set_id": [ "582f42e5-444e-4246-af8c-e7e28097c69a" ], "package_ndc": [ "63323-452-00", "63323-452-01", "63323-454-00", "63323-454-01", "63323-455-00", "63323-455-01", "63323-458-00", "63323-458-01", "63323-451-00", "63323-451-01" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "06/30/2026", "update_type": "New", "initial_posting_date": "06/30/2026", "package_ndc": "65219-281-07", "generic_name": "Gadobutrol Injection", "contact_info": "888-386-1300", "related_info": "Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA", "openfda": { "application_number": [ "ANDA215061" ], "brand_name": [ "GADOBUTROL" ], "generic_name": [ "GADOBUTROL" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-281" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GADOBUTROL" ], "spl_id": [ "490c8c3e-3195-40af-8f34-40d8df2719c3" ], "spl_set_id": [ "007696d0-4b62-4937-9640-4ad619504df4" ], "package_ndc": [ "65219-281-00", "65219-281-02", "65219-281-03", "65219-281-07", "65219-281-08", "65219-281-10", "65219-281-05", "65219-281-15" ], "nui": [ "N0000183362", "N0000175862" ], "pharm_class_epc": [ "Gadolinium-based Contrast Agent [EPC]" ], "pharm_class_moa": [ "Magnetic Resonance Contrast Activity [MoA]" ], "unii": [ "1BJ477IO2L" ] }, "update_date": "06/30/2026", "therapeutic_category": [ "Medical Imaging" ], "dosage_form": "Injection", "presentation": "Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-07)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1755-50", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA016964" ], "brand_name": [ "MARCAINE WITH EPINEPHRINE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1755", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1746", "0409-1749", "0409-1752", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614" ], "spl_id": [ "7040888c-2cde-4408-af99-d249985f8444" ], "spl_set_id": [ "67578b56-7540-487e-1fba-481255620e78" ], "package_ndc": [ "0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2596-03", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA075293" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-2596", "0409-2587" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "311700", "311702" ], "spl_id": [ "6c075a2d-b68b-41a7-aa0c-bcf9894e3f76" ], "spl_set_id": [ "affecd4d-1f78-4bbe-5a8d-86849bbdc520" ], "package_ndc": [ "0409-2587-04", "0409-2587-05", "0409-2596-13", "0409-2596-03", "0409-2596-15", "0409-2596-05" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 25 mg/5 mL (5 mg/mL) (NDC 0409-2596-03)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-4900-14", "generic_name": "Sodium Bicarbonate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 10 mEq/10 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-4900-14)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "25021-820-05", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-625-1618", "availability": "Unavailable", "related_info": "Estimated recovery: November 2026", "openfda": { "application_number": [ "ANDA201835" ], "brand_name": [ "METHYLPREDNISOLONE ACETATE" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-820", "25021-821" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1358610", "1358617" ], "spl_id": [ "f73618f0-0723-4d8b-8a8d-b9081acb44f9" ], "spl_set_id": [ "f98314ea-a4e4-4f78-987b-3e9b45a08bb4" ], "package_ndc": [ "25021-820-05", "25021-820-10", "25021-821-05" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 25021-820-05)", "company_name": "Sagent Pharmaceuticals", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0264-7520-10", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "NDA019626" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-7520", "0264-7510" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE, UNSPECIFIED FORM" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795610", "1795612" ], "spl_id": [ "c9f87749-8dd5-41fd-b393-f63d45fd00ef" ], "spl_set_id": [ "085614c7-ada4-4e2c-87c0-c9bc2f18365a" ], "package_ndc": [ "0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20" ], "unii": [ "IY9XDZ35W2" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-10)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "discontinued_date": "01/20/2026", "update_type": "New", "initial_posting_date": "01/20/2026", "package_ndc": "49702-260-55", "generic_name": "Maraviroc Solution", "contact_info": "877-844-8872", "related_info": "The anticipated date that GSK will cease distribution of the product is approximately August 1, 2026.", "openfda": { "application_number": [ "NDA208984" ], "brand_name": [ "SELZENTRY" ], "generic_name": [ "MARAVIROC" ], "manufacturer_name": [ "ViiV Healthcare Company" ], "product_ndc": [ "49702-260", "49702-223", "49702-224" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "rxcui": [ "728223", "728225", "729201", "729203", "1857921", "1857925" ], "spl_id": [ "bd98c45d-446e-4023-882c-9c36d612f5a5" ], "spl_set_id": [ "46f30ac5-c96b-429e-976d-8c5ee1c0761b" ], "package_ndc": [ "49702-223-18", "49702-224-18", "49702-260-55" ], "nui": [ "N0000175572", "N0000175445" ], "pharm_class_epc": [ "CCR5 Co-receptor Antagonist [EPC]" ], "pharm_class_moa": [ "Chemokine Co-receptor 5 Antagonists [MoA]" ], "unii": [ "MD6P741W8A" ] }, "update_date": "01/20/2026", "therapeutic_category": [ "Antiviral" ], "dosage_form": "Solution", "presentation": "Selzentry, Solution, 20 mg/mL Oral Solution Kit | 230 mL Oral Solution per Bottle | 1 Bottle per Carton (NDC 49702-260-55)", "company_name": "ViiV Healthcare Company", "status": "To Be Discontinued" }, { "discontinued_date": "01/06/2026", "update_type": "New", "initial_posting_date": "01/06/2026", "package_ndc": "49884-119-91", "generic_name": "Everolimus Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "01/06/2026", "therapeutic_category": [ "Transplant" ], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 2.5 mg (NDC 49884-119-91)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0378-5814-77", "generic_name": "Valsartan Tablet", "contact_info": "800-796-9526", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA090866" ], "brand_name": [ "VALSARTAN" ], "generic_name": [ "VALSARTAN" ], "manufacturer_name": [ "Mylan Pharmaceuticals Inc." ], "product_ndc": [ "0378-5814", "0378-5807", "0378-5813", "0378-5815" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "VALSARTAN" ], "rxcui": [ "349199", "349200", "349201", "349483" ], "spl_id": [ "a5384d58-48c7-494a-a8a8-c296b316bd91" ], "spl_set_id": [ "73e01dc6-7dd4-421a-a4f6-137e75f69f9a" ], "package_ndc": [ "0378-5807-93", "0378-5813-77", "0378-5814-77", "0378-5815-77" ], "nui": [ "N0000000070", "N0000175561" ], "pharm_class_moa": [ "Angiotensin 2 Receptor Antagonists [MoA]" ], "pharm_class_epc": [ "Angiotensin 2 Receptor Blocker [EPC]" ], "unii": [ "80M03YXJ7I" ] }, "update_date": "11/19/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Valsartan, Tablet, 160 mg (NDC 0378-5814-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-097-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": { "application_number": [ "NDA216117" ], "brand_name": [ "RELEXXII" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Vertical Pharmaceuticals, LLC" ], "product_ndc": [ "68025-097", "68025-088", "68025-089", "68025-095", "68025-096", "68025-084", "68025-098" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505" ], "spl_id": [ "86f477e9-07fc-466b-913e-1a4434c91df4" ], "spl_set_id": [ "22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d" ], "package_ndc": [ "68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current" }, { "discontinued_date": "12/03/2025", "update_type": "New", "initial_posting_date": "12/03/2025", "package_ndc": "0409-7101-67", "generic_name": "Sodium Chloride 0.9% Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA019465" ], "brand_name": [ "SODIUM CHLORIDE" ], "generic_name": [ "SODIUM CHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-7101", "0409-7132" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM CHLORIDE" ], "rxcui": [ "1807547", "1807631", "1807632", "1807633" ], "spl_id": [ "147cbba6-2ead-49c4-bce7-4e9c65b303c9" ], "spl_set_id": [ "a2a964f7-c3ec-4dfb-e3a0-6d8136a80397" ], "package_ndc": [ "0409-7101-68", "0409-7101-66", "0409-7101-69", "0409-7101-67", "0409-7101-04", "0409-7101-02", "0409-7132-68", "0409-7132-66", "0409-7132-69", "0409-7132-67", "0409-7132-04", "0409-7132-02" ], "unii": [ "451W47IQ8X" ] }, "update_date": "12/03/2025", "therapeutic_category": [ "Gastroenterology", "Other", "Renal" ], "dosage_form": "Injection", "presentation": "Sodium Chloride 0.9%, Injection, 100 mL ADD-Vantage® Flexible Container (NDC 0409-7101-67)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "23155-600-41", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "855-228-9470", "availability": "Limited Availability", "related_info": "Estimated recovery: 8/25/2026", "openfda": { "application_number": [ "ANDA090696" ], "brand_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc." ], "product_ndc": [ "23155-600" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "1666798" ], "spl_id": [ "4962482c-a9a7-4aa2-9663-da251cd150dc" ], "spl_set_id": [ "8b690f5c-2923-4c34-a8f7-11af5f546b62" ], "package_ndc": [ "23155-600-31", "23155-600-41" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 23155-600-41)", "company_name": "Avet Pharmaceuticals, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7922-02", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Available", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA016367" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "ICU Medical, Inc." ], "product_ndc": [ "0990-7922", "0990-7923", "0990-7930" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621" ], "spl_id": [ "06e4d957-1a56-4adb-a42b-fe0773b2fa97" ], "spl_set_id": [ "8b25b7e0-703e-4b43-a4eb-52863511602d" ], "package_ndc": [ "0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-02)", "company_name": "Otsuka ICU Medical LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "62037-726-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: September 2026", "openfda": { "application_number": [ "ANDA076772" ], "brand_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "62037-726", "62037-725", "62037-734", "62037-727" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210" ], "spl_id": [ "24aa9277-3773-489d-8459-f9215140c53f" ], "spl_set_id": [ "85ef422d-af27-4126-9841-6892af1871d6" ], "package_ndc": [ "62037-725-01", "62037-734-01", "62037-726-01", "62037-727-01" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62037-726-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6027-25", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Additional lots will be available August 2026 timeframe. Product will be made available as it is released.", "openfda": { "application_number": [ "NDA019101" ], "brand_name": [ "FENTANYL CITRATE" ], "generic_name": [ "FENTANYL CITRATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6027", "0641-6024", "0641-6025", "0641-6028", "0641-6026", "0641-6029", "0641-6030", "0641-6247", "0641-6248", "0641-6249" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FENTANYL CITRATE" ], "rxcui": [ "1735003", "1735007", "1735008", "1735013", "2168270", "2474269", "2629337" ], "spl_id": [ "546a047c-1faf-4751-9e48-079e4c35b6fa" ], "spl_set_id": [ "ce5db1c2-feb1-4ad2-847a-d02e865bd47e" ], "package_ndc": [ "0641-6024-01", "0641-6024-10", "0641-6027-01", "0641-6027-25", "0641-6025-01", "0641-6025-10", "0641-6028-01", "0641-6028-10", "0641-6028-25", "0641-6026-01", "0641-6026-05", "0641-6029-01", "0641-6029-25", "0641-6030-01", "0641-6247-01", "0641-6247-25", "0641-6248-01", "0641-6248-10", "0641-6249-01", "0641-6249-10" ], "unii": [ "MUN5LYG46H" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6027-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/31/2018", "package_ndc": "65219-572-10", "generic_name": "Bumetanide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA216434" ], "brand_name": [ "BUMETANIDE" ], "generic_name": [ "BUMETANIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-572", "65219-570" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "BUMETANIDE" ], "rxcui": [ "282486", "1727569" ], "spl_id": [ "aaff61c4-203b-4905-9138-0f98959ad013" ], "spl_set_id": [ "a007f3aa-3977-4be3-a9a2-db3d458bca58" ], "package_ndc": [ "65219-570-01", "65219-570-04", "65219-572-01", "65219-572-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "0Y2S3XUQ5H" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 65219-572-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "70121-1573-5", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-525-7270", "availability": "Available", "openfda": { "application_number": [ "ANDA210043" ], "brand_name": [ "METHYLPREDNISOLONE ACETATE" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Amneal Pharmaceuticals LLC" ], "product_ndc": [ "70121-1573", "70121-1574" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1743779", "1743855" ], "spl_id": [ "af4215ff-94ca-44f8-8506-3024e738cd13" ], "spl_set_id": [ "d944240d-2c19-46ba-ad4f-3fbee7b8629c" ], "package_ndc": [ "70121-1573-1", "70121-1573-5", "70121-1574-1", "70121-1574-5" ], "unii": [ "43502P7F0P" ] }, "update_date": "06/17/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-5)", "company_name": "Amneal Pharmaceuticals", "status": "Current" }, { "discontinued_date": "03/27/2026", "update_type": "New", "initial_posting_date": "03/27/2026", "package_ndc": "72607-100-00", "generic_name": "Tazemetostat Hydrobromide Tablet", "contact_info": "(855)-463-5127", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": { "application_number": [ "NDA211723" ], "brand_name": [ "TAZVERIK" ], "generic_name": [ "TAZEMETOSTAT" ], "manufacturer_name": [ "Epizyme, Inc." ], "product_ndc": [ "72607-100" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "TAZEMETOSTAT HYDROBROMIDE" ], "rxcui": [ "2274384", "2274390" ], "spl_id": [ "c4bd8d8a-22c1-4911-a9b4-7368582d8e5d" ], "spl_set_id": [ "7db07b5f-4e22-467c-9c0a-f830b08dbb1d" ], "package_ndc": [ "72607-100-00" ], "unii": [ "6P89T5M073" ] }, "update_date": "03/27/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Tablet", "presentation": "Tazverik, Tablet, 200 mg (NDC 72607-100-00)", "company_name": "Epizyme, Inc. (An Ipsen Company)", "status": "To Be Discontinued" }, { "discontinued_date": "12/22/2025", "update_type": "New", "initial_posting_date": "12/22/2025", "package_ndc": "0832-0273-11", "generic_name": "Morphine Sulfate Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA210610" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Upsher-Smith Laboratories, LLC" ], "product_ndc": [ "0832-0273", "0832-0274" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "892582", "892672" ], "spl_id": [ "46a682fc-0430-5a66-e063-6294a90a6179" ], "spl_set_id": [ "5ceb3205-2f8d-4ba3-9f27-dc328bab4fa1" ], "package_ndc": [ "0832-0273-11", "0832-0274-11" ], "unii": [ "X3P646A2J0" ] }, "update_date": "12/22/2025", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Tablet", "presentation": "Morphine Sulfate, Tablet, 15 mg (NDC 0832-0273-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued" }, { "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 250 mg/250mL (100 mg/mL) (NDC 0409-2346-32)", "update_type": "Revised", "initial_posting_date": "11/06/2017", "package_ndc": "0409-2346-32", "generic_name": "Dobutamine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular", "Pediatric", "Renal" ], "status": "Current", "dosage_form": "Injection" }, { "discontinued_date": "04/08/2026", "update_type": "New", "initial_posting_date": "04/08/2026", "package_ndc": "0006-3066-03", "generic_name": "Aprepitant Oral Powder for Suspension", "contact_info": "800-672-6372", "related_info": "To be discontinued in approximately early-September 2026.", "openfda": { "application_number": [ "NDA207865" ], "brand_name": [ "EMEND" ], "generic_name": [ "APREPITANT" ], "manufacturer_name": [ "Merck Sharp & Dohme LLC" ], "product_ndc": [ "0006-3066", "0006-0461", "0006-0462", "0006-3862", "0006-0464" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "APREPITANT" ], "rxcui": [ "403810", "403811", "404465", "404466", "644088", "644278", "754508", "754509", "1729308", "1729311" ], "spl_id": [ "428f7828-6d1c-438b-a17d-b4af0700c740" ], "spl_set_id": [ "696f9e80-9cae-403b-de9e-078343ce4713" ], "package_ndc": [ "0006-0461-02", "0006-0461-01", "0006-0461-06", "0006-0461-12", "0006-0462-01", "0006-0462-06", "0006-3862-03", "0006-3862-13", "0006-0464-01", "0006-0464-10", "0006-0464-05", "0006-3066-01", "0006-3066-03" ], "nui": [ "N0000010262", "N0000175786", "N0000182141", "N0000185507", "N0000185506" ], "pharm_class_moa": [ "Neurokinin 1 Antagonists [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 3A4 Inducers [MoA]" ], "pharm_class_epc": [ "Substance P/Neurokinin-1 Receptor Antagonist [EPC]" ], "unii": [ "1NF15YR6UY" ] }, "update_date": "04/08/2026", "therapeutic_category": [ "Gastroenterology" ], "presentation": "Emend, Oral Powder for Suspension, 125 mg (NDC 0006-3066-03)", "company_name": "Merck Sharp & Dohme LLC", "status": "To Be Discontinued" }, { "discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0781-3443-95", "generic_name": "Fondaparinux Sodium Injection", "contact_info": "609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.", "openfda": { "application_number": [ "ANDA206812" ], "brand_name": [ "FONDAPARINUX SODIUM" ], "generic_name": [ "FONDAPARINUX SODIUM" ], "manufacturer_name": [ "Sandoz Inc." ], "product_ndc": [ "0781-3443", "0781-3454", "0781-3465", "0781-3476" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "FONDAPARINUX SODIUM" ], "rxcui": [ "861356", "861360", "861363", "861365" ], "spl_id": [ "3d5a4b69-462b-7e51-e063-6294a90a0721" ], "spl_set_id": [ "baa50757-a927-4d56-a933-5d7798fe6ab0" ], "package_ndc": [ "0781-3443-94", "0781-3443-12", "0781-3443-95", "0781-3454-94", "0781-3454-12", "0781-3454-95", "0781-3465-94", "0781-3465-12", "0781-3465-95", "0781-3476-94", "0781-3476-12", "0781-3476-95" ], "unii": [ "X0Q6N9USOZ" ] }, "update_date": "09/29/2025", "therapeutic_category": [ "Hematology" ], "dosage_form": "Injection", "presentation": "Fondaparinux Sodium, Injection, 2.5 mg/.5 mL (NDC 0781-3443-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1159-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA070583" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1725078", "1725082", "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1867594", "1867596" ], "spl_id": [ "fb58e702-b0da-4fa9-91f2-4580b2305950", "6e442bfd-d3da-4913-8585-ce3485644364" ], "spl_set_id": [ "bb44c7e1-d911-4788-908f-09b7b271969b", "02a845c3-4521-4926-e397-25ab536e7cf6" ], "package_ndc": [ "0409-1159-09", "0409-1159-10", "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17" ], "unii": [ "7TQO7W3VT8", "30Q7KI53AK" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 0.25%; 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1159-10)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "63323-411-25", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA075154" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-411", "63323-412" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "311700", "311702" ], "spl_id": [ "9814447b-a93e-42ad-b57e-5db0a5b7f552" ], "spl_set_id": [ "a91ce254-14a3-4cbf-8ab8-5da252aa3fdc" ], "package_ndc": [ "63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-25)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "16729-295-12", "generic_name": "Carboplatin Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; NDC is non-exempt", "openfda": { "application_number": [ "ANDA206775" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Accord Healthcare, Inc." ], "product_ndc": [ "16729-295" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "35cf6068-f31a-211b-e063-6294a90a6b53" ], "spl_set_id": [ "48aa7ef3-9f44-2a08-e054-00144ff88e88" ], "package_ndc": [ "16729-295-31", "16729-295-33", "16729-295-34", "16729-295-12", "16729-295-38" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-12)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2020", "package_ndc": "16729-484-45", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": { "application_number": [ "ANDA212868" ], "brand_name": [ "ATROPINE SULFATE" ], "generic_name": [ "ATROPINE SULFATE" ], "manufacturer_name": [ "Accord Healthcare, Inc.," ], "product_ndc": [ "16729-484", "16729-483" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ATROPINE SULFATE" ], "rxcui": [ "1190546", "1190551", "1190552" ], "spl_id": [ "4082a1cf-1e1b-6f40-e063-6294a90aec06" ], "spl_set_id": [ "c82cb295-ffce-47d6-97ad-a8aa723f4e4f" ], "package_ndc": [ "16729-483-03", "16729-483-31", "16729-484-90", "16729-484-31", "16729-484-45", "16729-484-03" ], "unii": [ "03J5ZE7KA5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 0.1 mg/1 mL (NDC 16729-484-45)", "company_name": "Accord Healthcare Inc.", "status": "Current" }, { "discontinued_date": "09/11/2025", "update_type": "New", "initial_posting_date": "09/11/2025", "package_ndc": "0409-0181-25", "generic_name": "Gemcitabine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA200795" ], "brand_name": [ "GEMCITABINE" ], "generic_name": [ "GEMCITABINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-0181", "0409-0183", "0409-0182" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GEMCITABINE HYDROCHLORIDE" ], "rxcui": [ "1720960", "1720975", "1720977" ], "spl_id": [ "3a284abb-8c57-47dc-a138-5a6e6ab92b05", "c0f06508-36d7-4325-a425-707d254d185b" ], "spl_set_id": [ "dc02a23b-3ff9-4441-aa91-8e9e629a7315", "e18ed1cb-7dd0-4001-bfda-17d1f4587fb8" ], "package_ndc": [ "0409-0181-01", "0409-0183-01", "0409-0182-01", "0409-0181-25", "0409-0182-25", "0409-0183-25" ], "unii": [ "U347PV74IL" ] }, "update_date": "09/11/2025", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Gemcitabine Hydrochloride, Injection, 1 g/26.3 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0181-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "discontinued_date": "12/01/2025", "update_type": "New", "initial_posting_date": "12/01/2025", "package_ndc": "59212-001-02", "generic_name": "Phenoxybenzamine Hydrochloride Capsule", "contact_info": "847-283-7921", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/01/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Capsule", "presentation": "Dibenzyline, Capsule, 10 mg (NDC 59212-001-02)", "company_name": "Advanz Pharma (US) Corp.", "status": "To Be Discontinued" }, { "discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4491-08", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": { "application_number": [ "NDA211280" ], "brand_name": [ "REYVOW" ], "generic_name": [ "LASMIDITAN" ], "manufacturer_name": [ "Eli Lilly and Company" ], "product_ndc": [ "0002-4491", "0002-4312" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LASMIDITAN" ], "rxcui": [ "2256937", "2256943", "2256945", "2256947" ], "spl_id": [ "29f467c6-0365-4831-b4ce-9a0eefaf5896" ], "spl_set_id": [ "aea3358c-ff41-4490-9e6d-c7bf7b3de13f" ], "package_ndc": [ "0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62" ], "unii": [ "760I9WM792" ] }, "update_date": "11/03/2025", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 100 mg (NDC 0002-4491-08)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "11/03/2023", "package_ndc": "76204-025-96", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or customerservice@omniviumpharma.com", "availability": "Limited Availability", "related_info": "No longer manufactured, some supplies still available in supply chain. Distributed by Ritedose Pharmaceuticals, LLC (855) 806 3300", "update_date": "07/17/2026", "therapeutic_category": [ "Pulmonary/Allergy" ], "dosage_form": "Concentrate", "presentation": "Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 76204-025-96)", "company_name": "Ailex Pharmaceuticals", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "66794-229-41", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-414-1901", "availability": "Limited Availability", "related_info": "On allocation", "openfda": { "application_number": [ "ANDA210437" ], "brand_name": [ "ROCURONIUM" ], "generic_name": [ "ROCURONIUM" ], "manufacturer_name": [ "Piramal Critical Care Inc" ], "product_ndc": [ "66794-229", "66794-228" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "3f9e12e4-d3c5-fba6-e063-6294a90a7fd6" ], "spl_set_id": [ "98255b70-51f9-8d16-e053-2995a90a8f97" ], "package_ndc": [ "66794-229-02", "66794-229-41", "66794-228-02", "66794-228-41" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 66794-229-41)", "company_name": "Piramal Critical Care Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "07/23/2026", "update_type": "New", "initial_posting_date": "07/23/2026", "package_ndc": "0574-7045-12", "generic_name": "Belladonna and Opium Suppository", "contact_info": "(800) 775-2054", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "BELLADONNA AND OPIUM" ], "generic_name": [ "ATROPA BELLADONNA AND OPIUM" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-7045", "0574-7040" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RECTAL" ], "substance_name": [ "ATROPA BELLADONNA", "OPIUM" ], "rxcui": [ "312104", "312107" ], "spl_id": [ "7b45a1d7-c3a5-4434-a848-45638cedd6e1" ], "spl_set_id": [ "8301e76b-134a-43d2-a7dc-c600ccf2695c" ], "package_ndc": [ "0574-7040-12", "0574-7040-04", "0574-7045-12", "0574-7045-04" ], "unii": [ "37M3MZ001L", "WQZ3G9PF0H" ] }, "update_date": "07/23/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Suppository", "presentation": "Belladonna and Opium, Suppository, 16.2 mg; 30 mg (NDC 0574-7045-12)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-355-90", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-90)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued" }, { "discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0378-0005-85", "generic_name": "Everolimus Tablet", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/03/2025", "therapeutic_category": [ "Transplant" ], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 2 mg (NDC 0378-0005-85)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "76045-004-11", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release August 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "NDA204223" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Fresenius Kabi, USA LLC" ], "product_ndc": [ "76045-004", "76045-005", "76045-006", "76045-007", "76045-008" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "894912", "894914", "998212", "998213", "1442790" ], "spl_id": [ "286bce70-23cd-4d5b-989b-230d6cdd5a91" ], "spl_set_id": [ "1f53de80-efc8-4930-b3e3-fba0d026af05" ], "package_ndc": [ "76045-004-01", "76045-004-11", "76045-005-01", "76045-005-11", "76045-006-01", "76045-006-11", "76045-007-01", "76045-007-11", "76045-008-01", "76045-008-11" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "02/10/2026", "update_type": "New", "initial_posting_date": "02/10/2026", "package_ndc": "0071-0737-20", "generic_name": "Gemfibrozil Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": { "application_number": [ "NDA018422" ], "brand_name": [ "LOPID" ], "generic_name": [ "GEMFIBROZIL" ], "manufacturer_name": [ "Parke-Davis Div of Pfizer Inc" ], "product_ndc": [ "0071-0737" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "GEMFIBROZIL" ], "rxcui": [ "205751", "310459" ], "spl_id": [ "c2888455-2200-497a-8e5a-10515dcb4f66" ], "spl_set_id": [ "c48855b7-215e-453b-b3b1-a0f9dee7221f" ], "package_ndc": [ "0071-0737-20", "0071-0737-30" ], "nui": [ "N0000175596", "N0000175375", "M0543661" ], "pharm_class_epc": [ "Peroxisome Proliferator Receptor alpha Agonist [EPC]" ], "pharm_class_moa": [ "Peroxisome Proliferator-activated Receptor alpha Agonists [MoA]" ], "pharm_class_cs": [ "Fibric Acids [CS]" ], "unii": [ "Q8X02027X3" ] }, "update_date": "02/10/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Tablet", "presentation": "Lopid, Tablet, 600 mg (NDC 0071-0737-20)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "50742-447-45", "generic_name": "Carboplatin Injection", "contact_info": "866-321-5031", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "02/20/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450 mg/45 mL (NDC 50742-447-45)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued" }, { "discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-356-90", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-90)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9046-01", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA071170" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-9046", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9045", "0409-9042" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596" ], "spl_id": [ "6e442bfd-d3da-4913-8585-ce3485644364" ], "spl_set_id": [ "02a845c3-4521-4926-e397-25ab536e7cf6" ], "package_ndc": [ "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "03/24/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "0074-7098-06", "generic_name": "Pilocarpine Hydrochloride Ophthalmic Solution", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA214028" ], "brand_name": [ "VUITY" ], "generic_name": [ "PILOCARPINE HYDROCHLORIDE" ], "manufacturer_name": [ "AbbVie Inc." ], "product_ndc": [ "0074-7098" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "OPHTHALMIC" ], "substance_name": [ "PILOCARPINE HYDROCHLORIDE" ], "rxcui": [ "2584552", "2584557" ], "spl_id": [ "ed4cf150-c4b6-4d26-9326-e3a3490de489" ], "spl_set_id": [ "8d806897-8a2a-4518-8c68-0ec3b778de50" ], "package_ndc": [ "0074-7098-02", "0074-7098-01", "0074-7098-03", "0074-7098-04", "0074-7098-05", "0074-7098-06" ], "unii": [ "0WW6D218XJ" ] }, "update_date": "03/24/2026", "therapeutic_category": [ "Ophthalmology" ], "dosage_form": "Ophthalmic Solution", "presentation": "Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-06)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-191-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": { "application_number": [ "ANDA209799" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "SUNRISE PHARMACEUTICAL, INC." ], "product_ndc": [ "11534-191", "11534-190", "11534-192", "11534-193", "11534-194", "11534-195", "11534-196" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "60dcfbf6-d07a-4010-ae77-8a9ae4529828" ], "spl_set_id": [ "ac102599-3a5b-4154-899e-6ff262be7ff7" ], "package_ndc": [ "11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/16/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 11534-191-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current" }, { "discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2868-10", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA075757" ], "brand_name": [ "OMEPRAZOLE" ], "generic_name": [ "OMEPRAZOLE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-2868", "0781-2859" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OMEPRAZOLE" ], "rxcui": [ "198051", "199119" ], "spl_id": [ "b182f298-e28f-434b-b6f1-ecfac29d495e" ], "spl_set_id": [ "516170d4-4913-4577-a2d2-f5c52d1e79c6" ], "package_ndc": [ "0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31" ], "nui": [ "N0000175525", "N0000000147", "N0000182140" ], "pharm_class_epc": [ "Proton Pump Inhibitor [EPC]" ], "pharm_class_moa": [ "Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]" ], "unii": [ "KG60484QX9" ] }, "update_date": "10/09/2025", "therapeutic_category": [ "Gastroenterology" ], "presentation": "Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-10)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0777-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA040422" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0555-0777", "0555-0971", "0555-0775", "0555-0972", "0555-0776", "0555-0973", "0555-0974" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "88468f3d-7d03-4cee-aabf-3abc8c9b5e38" ], "spl_set_id": [ "cffbbb15-d776-41ae-a8a6-687f2c07bfa4" ], "package_ndc": [ "0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0555-0777-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "11/14/2025", "update_type": "New", "initial_posting_date": "11/14/2025", "package_ndc": "0409-5093-11", "generic_name": "Ceftazidime Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA064032" ], "brand_name": [ "TAZICEF" ], "generic_name": [ "CEFTAZIDIME" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-5093", "0409-5092" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CEFTAZIDIME" ], "rxcui": [ "1659283", "1659287", "1659292", "1659294" ], "spl_id": [ "71a753fc-ae3d-4d94-bc72-a3a51a5bdd9a" ], "spl_set_id": [ "9b73979c-c95a-4433-0a9d-f9cea3cb557f" ], "package_ndc": [ "0409-5092-11", "0409-5092-16", "0409-5093-14", "0409-5093-11" ], "unii": [ "9M416Z9QNR" ] }, "update_date": "11/14/2025", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Tazicef, Injection, 2 g (NDC 0409-5093-11)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "discontinued_date": "11/14/2025", "update_type": "New", "initial_posting_date": "11/14/2025", "package_ndc": "0703-4094-01", "generic_name": "Palonosetron Hydrochloride Injection", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA090713" ], "brand_name": [ "PALONOSETRON HYDROCHLORIDE" ], "generic_name": [ "PALONOSETRON HYDROCHLORIDE" ], "manufacturer_name": [ "Teva Parenteral Medicines, Inc." ], "product_ndc": [ "0703-4094" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "PALONOSETRON HYDROCHLORIDE" ], "rxcui": [ "1728055" ], "spl_id": [ "124fd0ad-cda6-4a00-9355-c4809c039c74" ], "spl_set_id": [ "911783eb-91a8-4ef4-bd6f-809211e207d6" ], "package_ndc": [ "0703-4094-01" ], "unii": [ "23310D4I19" ] }, "update_date": "11/14/2025", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "Palonosetron Hydrochloride, Injection, .25 mg/5 mL (NDC 0703-4094-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-460-37", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesaler for inventory", "openfda": { "application_number": [ "NDA018304" ], "brand_name": [ "SENSORCAINE MPF" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-460", "63323-465", "63323-467", "63323-464", "63323-466", "63323-462" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "RETROBULBAR" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1012391", "1012396", "1012404", "1012421", "1012455", "1012457", "1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177" ], "spl_id": [ "2b1a1f80-cb29-4ac1-9e72-20225ed45715" ], "spl_set_id": [ "eb6d8fee-def4-4c96-9972-695e8cea8ea8" ], "package_ndc": [ "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "11/21/2025", "update_type": "New", "initial_posting_date": "11/21/2025", "package_ndc": "62037-720-10", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA075604" ], "brand_name": [ "POTASSIUM CHLORIDE" ], "generic_name": [ "POTASSIUM CHLORIDE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "62037-720", "62037-710" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "POTASSIUM CHLORIDE" ], "rxcui": [ "1801294", "1801298" ], "spl_id": [ "01fbdb24-0987-40f6-a920-f36349f6ba61" ], "spl_set_id": [ "db002ae3-f54c-40a4-9cb4-e5681bf426e3" ], "package_ndc": [ "62037-710-01", "62037-720-01", "62037-720-05", "62037-720-10" ], "unii": [ "660YQ98I10" ] }, "update_date": "11/21/2025", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology" ], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/31/2026", "package_ndc": "0054-3294-50", "generic_name": "Furosemide Oral Solution", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": { "application_number": [ "ANDA070434" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0054-3294", "0054-4297", "0054-8297", "0054-4299", "0054-8299", "0054-4301", "0054-8301", "0054-3298" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "197730", "197731", "197732", "310429", "313988" ], "spl_id": [ "bc62ddda-7639-4090-99f0-7dd4d13518f3" ], "spl_set_id": [ "9e493331-dddd-496e-abf8-61747fb67aba" ], "package_ndc": [ "0054-4297-31", "0054-4297-25", "0054-8297-25", "0054-4299-31", "0054-4299-25", "0054-8299-25", "0054-4301-29", "0054-4301-25", "0054-8301-25", "0054-3298-63", "0054-3294-50", "0054-3294-46" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Oral Solution", "presentation": "Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-50)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an inactive ingredient component", "status": "Current" }, { "discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "46163-212-92", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "openfda": { "application_number": [ "NDA020171" ], "brand_name": [ "DELFLEX" ], "generic_name": [ "DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE" ], "manufacturer_name": [ "Fresenius Medical Care de Mexico, S.A. de C.V." ], "product_ndc": [ "46163-212", "46163-209", "46163-206" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "spl_id": [ "579dba0f-f820-8f9a-e063-6294a90a76b0" ], "spl_set_id": [ "a98facd6-9daa-4d37-8209-63a0599dbfaa" ], "package_ndc": [ "46163-209-92", "46163-209-94", "46163-209-95", "46163-212-95", "46163-212-92", "46163-212-94", "46163-206-92", "46163-206-94", "46163-206-95" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "03/10/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2L, 5/cs (NDC 46163-212-92)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued" }, { "discontinued_date": "01/08/2026", "update_type": "New", "initial_posting_date": "01/08/2026", "package_ndc": "0006-3516-59", "generic_name": "Imipenem and Cilastatin Injection", "contact_info": "800-672-6372", "related_info": "To be discontinued in approximately Q4 2026.", "openfda": { "application_number": [ "NDA050587" ], "brand_name": [ "PRIMAXIN IV" ], "generic_name": [ "IMIPENEM AND CILASTATIN SODIUM" ], "manufacturer_name": [ "Merck Sharp & Dohme LLC" ], "product_ndc": [ "0006-3516", "0006-3514", "0006-3551", "0006-3552" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "IMIPENEM", "CILASTATIN SODIUM" ], "rxcui": [ "1726204", "1726207", "1726214", "1726216" ], "spl_id": [ "34854f9b-7be0-4bfb-8cd2-40baf206fb80" ], "spl_set_id": [ "f41d8abd-7792-4918-1b93-bd83ea01955e" ], "package_ndc": [ "0006-3514-58", "0006-3516-59", "0006-3551-58", "0006-3552-59" ], "unii": [ "71OTZ9ZE0A", "5428WXZ74M" ] }, "update_date": "01/08/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Primaxin, Injection, 500mg (NDC 0006-3516-59)", "company_name": "Merck Sharp & Dohme Corp.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "0093-0832-01", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA074569" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0093-0832", "0093-3212", "0093-3213" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "d6abe4e3-7699-4ead-95f4-739a961b23ad" ], "spl_set_id": [ "8069b1a0-7c06-4252-b44e-e2eef065d9b8" ], "package_ndc": [ "0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 0093-0832-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "04/28/2023", "update_type": "New", "initial_posting_date": "04/28/2023", "change_date": "04/28/2023", "package_ndc": "0069-4370-71", "generic_name": "Prazosin Hydrochloride Capsule", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023", "update_date": "04/28/2023", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Capsule", "presentation": "Minipress, Capsule, 2 mg (NDC 0069-4370-71)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-152-05", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": { "application_number": [ "ANDA075468" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Advagen Pharma Ltd" ], "product_ndc": [ "72888-152", "72888-497", "72888-153", "72888-154" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529", "204892" ], "spl_id": [ "5510f17b-a980-f412-e063-6394a90ae1c4" ], "spl_set_id": [ "30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec" ], "package_ndc": [ "72888-497-01", "72888-497-02", "72888-497-03", "72888-497-04", "72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 72888-152-05)", "company_name": "Rubicon Research Private Limited", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-35", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-286", "63323-285", "63323-287", "63323-288" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091" ], "spl_id": [ "324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cb6583ff-cde4-4280-aa5b-0bea2b844792", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c" ], "spl_set_id": [ "dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "cb6583ff-cde4-4280-aa5b-0bea2b844792", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6" ], "package_ndc": [ "63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-51", "63323-286-55", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-35)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "06/12/2026", "package_ndc": "0143-9531-01", "generic_name": "Ifosfamide Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA076619" ], "brand_name": [ "IFOSFAMIDE" ], "generic_name": [ "IFOSFAMIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9531", "0143-9530" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "IFOSFAMIDE" ], "rxcui": [ "1791597", "1791599" ], "spl_id": [ "517c3bf6-41f5-4199-a17e-1f46b120cb1e" ], "spl_set_id": [ "c90ab05f-8fe5-437e-a1c0-8b11ef63291e" ], "package_ndc": [ "0143-9531-01", "0143-9530-01" ], "nui": [ "N0000000236", "N0000175558" ], "pharm_class_moa": [ "Alkylating Activity [MoA]" ], "pharm_class_epc": [ "Alkylating Drug [EPC]" ], "unii": [ "UM20QQM95Y" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Oncology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9531-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-671-66", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD; Marketed by Sagent Pharmaceuticals", "openfda": { "application_number": [ "ANDA206166" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-671", "25021-652" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734347", "1734355", "1734479", "1734481" ], "spl_id": [ "41f4446a-ca6e-465e-9a79-8c4f99eb1ac3", "22d83514-0f7b-4671-ae6a-7ca47449c184" ], "spl_set_id": [ "8c5c762f-d266-4b1a-809e-f11bfc89bc2d", "9572b3de-684c-4028-a577-5aa69ba6b02d" ], "package_ndc": [ "25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87", "25021-671-66", "25021-671-67" ], "unii": [ "V910P86109" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-66)", "company_name": "InfoRLife SA", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-604-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": { "application_number": [ "ANDA216266" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE CAPSULES" ], "manufacturer_name": [ "Solco Healthcare US,LLC" ], "product_ndc": [ "43547-604", "43547-602", "43547-603", "43547-605", "43547-606", "43547-607", "43547-608" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "d6435613-e052-4b4f-8bf7-4acb7458d8df" ], "spl_set_id": [ "68b10d9f-ca3e-493d-a309-45f1d7e08061" ], "package_ndc": [ "43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/29/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 43547-604-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0551-18", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA020179" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "0338-0551" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795609", "1795616" ], "spl_id": [ "1abb6ba4-fa29-4807-8623-3bd98ac11440" ], "spl_set_id": [ "7de48bdb-9a05-4f2a-bbff-dcfeb284ca6e" ], "package_ndc": [ "0338-0551-11", "0338-0551-18" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-18)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/03/2016", "package_ndc": "0641-6261-01", "generic_name": "Sodium Acetate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA216920" ], "brand_name": [ "SODIUM ACETATE" ], "generic_name": [ "SODIUM ACETATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6261" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM ACETATE ANHYDROUS" ], "rxcui": [ "1859490" ], "spl_id": [ "3493d4c1-4f73-44e8-94bc-7b55fe4fd436" ], "spl_set_id": [ "8a338072-6f1e-460c-b9ec-59cef4f3f597" ], "package_ndc": [ "0641-6261-01" ], "unii": [ "NVG71ZZ7P0" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition" ], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 0641-6261-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/17/2015", "package_ndc": "0143-9931-25", "generic_name": "Cefotaxime Sodium Powder, for Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA065072" ], "brand_name": [ "CEFOTAXIME" ], "generic_name": [ "CEFOTAXIME" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9931", "0143-9933", "0143-9930" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CEFOTAXIME SODIUM" ], "rxcui": [ "309068", "1656313", "1656318" ], "spl_id": [ "7e0897ec-2275-4438-9cc5-4c951e52ad97" ], "spl_set_id": [ "ed23b6bc-32c7-4c50-a53d-313ae78e5623" ], "package_ndc": [ "0143-9931-01", "0143-9931-25", "0143-9933-01", "0143-9933-25", "0143-9930-01", "0143-9930-10" ], "unii": [ "258J72S7TZ" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anti-Infective", "Pediatric" ], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 0143-9931-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-799-60", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Available", "openfda": { "application_number": [ "ANDA064150" ], "brand_name": [ "RIFAMPIN" ], "generic_name": [ "RIFAMPIN" ], "manufacturer_name": [ "EPIC PHARMA, LLC" ], "product_ndc": [ "42806-799", "42806-801" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RIFAMPIN" ], "rxcui": [ "198201", "198202" ], "spl_id": [ "a4ac02e8-68ac-4e79-8ca5-0939dd002c87" ], "spl_set_id": [ "0391f1e1-70d4-4b15-8b58-055bb6a385b8" ], "package_ndc": [ "42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05" ], "nui": [ "N0000175500", "M0019113" ], "pharm_class_epc": [ "Rifamycin Antibacterial [EPC]" ], "pharm_class_cs": [ "Rifamycins [CS]" ], "unii": [ "VJT6J7R4TR" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 42806-799-60)", "company_name": "Epic Pharma, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0013-05", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": { "application_number": [ "NDA009866" ], "brand_name": [ "SOLU-CORTEF" ], "generic_name": [ "HYDROCORTISONE SODIUM SUCCINATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0013", "0009-0825", "0009-0011", "0009-0016", "0009-0005" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "HYDROCORTISONE SODIUM SUCCINATE" ], "rxcui": [ "105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596" ], "spl_id": [ "8512044a-4a54-4634-bb97-9e20126adc61" ], "spl_set_id": [ "65eefd58-b166-4d71-ade6-45c8fdf86922" ], "package_ndc": [ "0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01" ], "unii": [ "50LQB69S1Z" ] }, "update_date": "02/24/2026", "therapeutic_category": [ "Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "68180-558-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-587-4617", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA077690" ], "brand_name": [ "QUINAPRIL" ], "generic_name": [ "QUINAPRIL" ], "manufacturer_name": [ "Lupin Pharmaceuticals, Inc." ], "product_ndc": [ "68180-558", "68180-556", "68180-557", "68180-554", "68180-559" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE" ], "rxcui": [ "312748", "312749", "312750", "314203" ], "spl_id": [ "a9598a21-6f99-4c86-ace6-b5638da2bec8" ], "spl_set_id": [ "8ded0773-3aec-4e89-9836-d22a5a84abf0" ], "package_ndc": [ "68180-556-09", "68180-557-09", "68180-557-03", "68180-558-09", "68180-558-03", "68180-554-09", "68180-554-03", "68180-559-03", "68180-559-09" ], "unii": [ "33067B3N2M" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 20 mg (NDC 68180-558-09)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/25/2017", "package_ndc": "0338-0411-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA018461" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE AND DEXTROSE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0411", "0338-0409" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1737723", "1737742", "1737744" ], "spl_id": [ "9e9121a0-25dd-46ba-a2b7-6f71fc3ff9cd" ], "spl_set_id": [ "f21512ea-c7c3-4766-b976-b2c0b5616bf0" ], "package_ndc": [ "0338-0409-03", "0338-0409-02", "0338-0411-02" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Dextrose, Injection, 8 mg/1 mL (NDC 0338-0411-02)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0527-0763-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-834-0530", "availability": "Available", "openfda": { "application_number": [ "ANDA215565" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Lannett Company, LLC" ], "product_ndc": [ "0527-0763", "0527-0760", "0527-0761", "0527-0762", "0527-0764", "0527-0765", "0527-0766" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "391d7c4a-47df-41ce-b1ba-3c4758adf87f" ], "spl_set_id": [ "f92497b5-baea-4760-b615-45a0b6184402" ], "package_ndc": [ "0527-0760-37", "0527-0761-37", "0527-0762-37", "0527-0763-37", "0527-0764-37", "0527-0765-37", "0527-0766-37" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0527-0763-37)", "company_name": "Lannett Company, Inc.", "status": "Current" }, { "update_type": "New", "initial_posting_date": "01/01/2012", "package_ndc": "70069-481-10", "generic_name": "Atropine Sulfate Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": { "application_number": [ "ANDA215005" ], "brand_name": [ "ATROPINE SULFATE" ], "generic_name": [ "ATROPINE SULFATE MONOHYDRATE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-481" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ENDOTRACHEAL", "INTRAMEDULLARY", "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "ATROPINE SULFATE" ], "rxcui": [ "1190776" ], "spl_id": [ "125328fe-c82b-42fd-bb3b-ba3f6c125ced" ], "spl_set_id": [ "84ba1689-3030-48d5-9cce-70b5a24a4033" ], "package_ndc": [ "70069-481-01", "70069-481-10" ], "unii": [ "03J5ZE7KA5" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-481-10)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "discontinued_date": "02/27/2026", "update_type": "New", "initial_posting_date": "02/27/2026", "package_ndc": "53746-468-19", "generic_name": "Clindamycin Palmitate Hydrochloride Injection", "contact_info": "866-525-7270", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA203513" ], "brand_name": [ "CLINDAMYCIN PALMITATE HYDROCHLORIDE (PEDIATRIC)" ], "generic_name": [ "CLINDAMYCIN PALMITATE HYDROCHLORIDE" ], "manufacturer_name": [ "Amneal Pharmaceuticals of New York LLC" ], "product_ndc": [ "53746-468" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLINDAMYCIN PALMITATE HYDROCHLORIDE" ], "rxcui": [ "562266" ], "spl_id": [ "bacc9e9f-6a9f-4a68-b2ec-131ed86205ec" ], "spl_set_id": [ "faf67eb8-1fd7-4b2c-a55b-24ba664c0dce" ], "package_ndc": [ "53746-468-19" ], "unii": [ "VN9A8JM7M7" ] }, "update_date": "02/27/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Clindamycin Palmitate Hydrochloride, Injection, 75 mg/5 mL (NDC 53746-468-19)", "company_name": "Amneal Pharmaceuticals", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "01/26/2024", "package_ndc": "70726-0306-1", "generic_name": "Riluzole Oral Suspension", "related_info_link": "https://www.fda.gov/media/185612/download?attachment", "contact_info": "610-937-6172", "availability": "Available", "openfda": { "brand_name": [ "TEGLUTIK" ], "generic_name": [ "RILUZOLE" ], "manufacturer_name": [ "EDW PHARMA" ], "product_ndc": [ "70726-0306" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RILUZOLE" ], "rxcui": [ "2058147", "2675565" ], "spl_id": [ "4746bb53-bb35-7aa0-e063-6394a90a647b" ], "spl_set_id": [ "1a3aeb59-d589-8d12-e063-6394a90a0a3a" ], "package_ndc": [ "70726-0306-1" ], "nui": [ "N0000175740", "M0483511" ], "pharm_class_epc": [ "Benzothiazole [EPC]" ], "pharm_class_cs": [ "Benzothiazoles [CS]" ], "unii": [ "7LJ087RS6F" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Oral Suspension", "presentation": "Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0306-1)", "company_name": "EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "57844-105-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA040422" ], "brand_name": [ "ADDERALL" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "57844-105", "57844-117", "57844-110", "57844-112", "57844-115", "57844-120", "57844-130" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147" ], "spl_id": [ "79af1dc6-c7cf-41b1-a750-e9b47c2187ff" ], "spl_set_id": [ "f22635fe-821d-4cde-aa12-419f8b53db81" ], "package_ndc": [ "57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 57844-105-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-162-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA078450" ], "brand_name": [ "QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE" ], "generic_name": [ "QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE" ], "manufacturer_name": [ "Aurobindo Pharma Limited" ], "product_ndc": [ "65862-162", "65862-161", "65862-163" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE", "HYDROCHLOROTHIAZIDE" ], "rxcui": [ "310796", "310797", "310809" ], "spl_id": [ "5842ecc2-874a-481b-8997-afa9d862dc5d" ], "spl_set_id": [ "50a58159-9572-4445-9859-b392632597da" ], "package_ndc": [ "65862-161-90", "65862-162-30", "65862-162-90", "65862-163-90" ], "nui": [ "N0000175359", "N0000175419", "M0471776" ], "pharm_class_pe": [ "Increased Diuresis [PE]" ], "pharm_class_epc": [ "Thiazide Diuretic [EPC]" ], "pharm_class_cs": [ "Thiazides [CS]" ], "unii": [ "0J48LPH2TH", "33067B3N2M" ] }, "update_date": "06/02/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 65862-162-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0143-9144-03", "generic_name": "Liraglutide Injection", "contact_info": "800-631-2174", "availability": "Available", "openfda": { "application_number": [ "ANDA215503" ], "brand_name": [ "LIRAGLUTIDE" ], "generic_name": [ "LIRAGLUTIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9144" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "LIRAGLUTIDE" ], "rxcui": [ "897122" ], "spl_id": [ "4e2acb7a-d32d-49d3-b59b-39332b5809f3" ], "spl_set_id": [ "2100ec49-57b2-4330-ab5f-057ce9b7e4d0" ], "package_ndc": [ "0143-9144-01", "0143-9144-03", "0143-9144-02" ], "nui": [ "N0000178480", "M0160181", "N0000020058" ], "pharm_class_epc": [ "GLP-1 Receptor Agonist [EPC]" ], "pharm_class_cs": [ "Glucagon-Like Peptide 1 [CS]" ], "pharm_class_moa": [ "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]" ], "unii": [ "839I73S42A" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-03)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "43066-557-12", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "ANDA208532" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "43066-557", "43066-555" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909" ], "spl_id": [ "d0910ea1-c3e1-44f8-b8b5-1f39ffd43290" ], "spl_set_id": [ "aea9a3ad-c244-42be-9cd3-5df83fe2b522" ], "package_ndc": [ "43066-555-24", "43066-557-12" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 43066-557-12)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "63323-426-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA078651" ], "brand_name": [ "ROCURONIUM" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-426" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "d6e2ff8d-838d-4c27-8e73-230548b09d63", "3f4d5e11-2c14-4406-8954-04dba2fc65ff" ], "spl_set_id": [ "f1933332-1ae0-4dc1-be4c-694849e6c9f9", "fb9524b2-c353-4747-8954-7ca2529eabb2" ], "package_ndc": [ "63323-426-02", "63323-426-05", "63323-426-01", "63323-426-10", "63323-426-12", "63323-426-15" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0990-4178-03", "generic_name": "Amino Acid Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Unavailable", "related_info": "Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA019398" ], "brand_name": [ "AMINOSYN-PF" ], "generic_name": [ "ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, AND TYROSINE" ], "manufacturer_name": [ "ICU Medical Inc." ], "product_ndc": [ "0990-4178" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "THREONINE", "TRYPTOPHAN", "VALINE", "ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "PROLINE", "SERINE", "TAURINE", "TYROSINE" ], "rxcui": [ "831426", "831430" ], "spl_id": [ "33d8e12a-620f-41d0-bdca-3a18fc0c20cb" ], "spl_set_id": [ "2d212e10-7e08-4aeb-b63f-dcc927897769" ], "package_ndc": [ "0990-4178-03" ], "nui": [ "N0000175780", "M0000922" ], "pharm_class_epc": [ "Amino Acid [EPC]" ], "pharm_class_cs": [ "Amino Acids [CS]" ], "unii": [ "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "2ZD004190S", "8DUH1N11BX", "HG18B9YRS7", "OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "9DLQ4CIU6V", "452VLY9402", "1EQV5MLY3D", "42HK56048U" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "Aminosyn-PF 7%, Injection, 0.07 (NDC 0990-4178-03)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-285", "63323-286", "63323-287", "63323-288" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091" ], "spl_id": [ "324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c" ], "spl_set_id": [ "dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6" ], "package_ndc": [ "63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "07/23/2026", "update_type": "New", "initial_posting_date": "07/23/2026", "package_ndc": "0574-7224-06", "generic_name": "Hydromorphone Hydrochloride Suppository", "contact_info": "(800) 775-2054", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-7224" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RECTAL" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897749" ], "spl_id": [ "8c369b50-cf2a-4e30-a31c-ccf5f49ab920" ], "spl_set_id": [ "1bfbba46-1979-4797-a29e-d67718131686" ], "package_ndc": [ "0574-7224-06" ], "unii": [ "L960UP2KRW" ] }, "update_date": "07/23/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Suppository", "presentation": "Hydromorphone Hydrochloride, Suppository, 3 mg (NDC 0574-7224-06)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "06/28/2022", "package_ndc": "63323-724-05", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: September 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "ANDA206223" ], "brand_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "generic_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-724", "63323-723", "63323-725" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "rxcui": [ "1729578", "1729584", "1729710" ], "spl_id": [ "2f27e51f-2b55-47ee-bd4a-001b71c60622" ], "spl_set_id": [ "d2374b84-81c9-44f9-a4a9-1071281b2531" ], "package_ndc": [ "63323-723-01", "63323-723-03", "63323-724-01", "63323-724-05", "63323-725-01", "63323-725-10" ], "unii": [ "5V444H5WIC" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-724-05)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6859-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA202835" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE" ], "manufacturer_name": [ "Mylan Pharmaceuticals Inc." ], "product_ndc": [ "0378-6859", "0378-6854", "0378-6855", "0378-6856", "0378-6857", "0378-6858", "0378-6860" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "6e77cd71-95ae-4fa8-830b-ab62b714e4b9" ], "spl_set_id": [ "efbde0f6-b848-4664-b741-c6c630e66108" ], "package_ndc": [ "0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0378-6859-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1638-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA021038" ], "brand_name": [ "PRECEDEX" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1638", "0409-1660", "0409-1434", "0409-1596", "0409-7838", "0409-7853", "0409-7875" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892" ], "spl_id": [ "3c5274fd-6597-4b88-babc-92e4e16c6329" ], "spl_set_id": [ "548a88c0-afda-427e-75ac-5af0cfa2224c" ], "package_ndc": [ "0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Precedex, Injection, 200 mcg/2 mL (100 mcg/mL) (NDC 0409-1638-02)", "company_name": "Pfizer Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-288-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-288", "63323-286", "63323-287", "63323-285" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484" ], "spl_id": [ "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c", "75465ceb-e894-487d-aa80-671fa0841fce" ], "spl_set_id": [ "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6", "56dfabf7-f7a8-4601-b17a-cb16fb995b0f" ], "package_ndc": [ "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95", "63323-288-25", "63323-288-27" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 10 mg/1 mL (NDC 63323-288-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-7875-12", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA021038" ], "brand_name": [ "PRECEDEX" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-7875", "0409-1660", "0409-1638", "0409-1434", "0409-1596", "0409-7838", "0409-7853" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892" ], "spl_id": [ "3c5274fd-6597-4b88-babc-92e4e16c6329" ], "spl_set_id": [ "548a88c0-afda-427e-75ac-5af0cfa2224c" ], "package_ndc": [ "0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Precedex, Injection, 1000 mcg/250 mL (NDC 0409-7875-12)", "company_name": "Pfizer Inc.", "status": "Current" }, { "discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0025-0325-01", "generic_name": "Adalimumab-afzb Injection", "contact_info": "800-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "BLA761118" ], "brand_name": [ "ABRILADA" ], "generic_name": [ "ADALIMUMAB-AFZB" ], "manufacturer_name": [ "Pfizer Laboratories Div Pfizer Inc" ], "product_ndc": [ "0025-0325", "0025-0328", "0025-0333", "0025-0347", "0025-0319" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "rxcui": [ "797544", "2668064", "2668071", "2668074", "2668078", "2668095", "2668096", "2668105", "2668106", "2668109", "2668113" ], "spl_id": [ "0989d777-c225-46a6-854e-01bdf4f19679" ], "spl_set_id": [ "5ef1c7cf-466f-495e-8d13-82e2ddfa7a4f" ], "package_ndc": [ "0025-0325-01", "0025-0325-02", "0025-0318-01", "0069-1111-01", "0025-0328-01", "0025-0328-02", "0025-0317-01", "0025-0333-02", "0025-0329-01", "0025-0347-02", "0025-0331-01", "0025-0319-01" ] }, "update_date": "10/09/2025", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Abrilada, Injection, Kit (NDC 0025-0325-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "06/14/2018", "package_ndc": "65282-1605-1", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "978-657-0889 ext. 5231", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA208017" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "manufacturer_name": [ "Spectra Medical Devices, LLC" ], "product_ndc": [ "65282-1605" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "rxcui": [ "1737566" ], "spl_id": [ "447bfde4-fff3-32a6-e063-6394a90a667e" ], "spl_set_id": [ "e8ba012a-08a9-4f67-9f88-3284377e80be" ], "package_ndc": [ "65282-1605-1" ], "unii": [ "EC2CNF7XFP" ] }, "update_date": "05/15/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 65282-1605-1)", "company_name": "Spectra Medical Devices, LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "12/13/2017", "package_ndc": "72205-102-07", "generic_name": "Bumetanide Injection", "contact_info": "855-668-2369; customerservice@novadozpharma.com", "availability": "Available", "related_info": "Distributed by: Novadoz Pharmaceuticals LLC", "openfda": { "application_number": [ "ANDA215364" ], "brand_name": [ "BUMETANIDE" ], "generic_name": [ "BUMETANIDE" ], "manufacturer_name": [ "Novadoz Pharmaceuticals LLC" ], "product_ndc": [ "72205-102", "72205-101" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "BUMETANIDE" ], "rxcui": [ "282486", "1727569" ], "spl_id": [ "387edfd4-be85-41cd-8a6d-14e6a022b5a9" ], "spl_set_id": [ "387edfd4-be85-41cd-8a6d-14e6a022b5a9" ], "package_ndc": [ "72205-101-01", "72205-101-07", "72205-102-01", "72205-102-07" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "0Y2S3XUQ5H" ] }, "update_date": "08/21/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-102-07)", "company_name": "MSN Laboratories Private Limited", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "50458-587-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET", "availability": "Available", "openfda": { "application_number": [ "NDA021121" ], "brand_name": [ "CONCERTA" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Janssen Pharmaceuticals, Inc." ], "product_ndc": [ "50458-587", "50458-585", "50458-588", "50458-586" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091157", "1091170", "1091172", "1091185", "1091187", "1091210", "1091212" ], "spl_id": [ "64d7c1e1-e7ed-4d74-a44d-13b4da64af9a" ], "spl_set_id": [ "1a88218c-5b18-4220-8f56-526de1a276cd" ], "package_ndc": [ "50458-585-01", "50458-588-01", "50458-586-01", "50458-587-01" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/19/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01)", "company_name": "Janssen Pharmaceuticals", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "62135-737-30", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "845-268-5000 Ext. 510", "availability": "Available", "openfda": { "application_number": [ "ANDA072369" ], "brand_name": [ "FLURAZEPAM HYDROCHLORIDE" ], "generic_name": [ "FLURAZEPAM HYDROCHLORIDE" ], "manufacturer_name": [ "Chartwell RX, LLC" ], "product_ndc": [ "62135-737", "62135-736" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "FLURAZEPAM HYDROCHLORIDE" ], "rxcui": [ "1298088", "1298091" ], "spl_id": [ "25893c92-c8f1-567a-e063-6294a90a00d4" ], "spl_set_id": [ "8f476891-1346-4e8c-ac1b-f8cbdc64f5a1" ], "package_ndc": [ "62135-736-30", "62135-736-90", "62135-737-30", "62135-737-90" ], "unii": [ "756RDM536M" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Neurology", "Other" ], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-30)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current" }, { "discontinued_date": "10/21/2025", "update_type": "New", "initial_posting_date": "10/21/2025", "package_ndc": "0591-5590-01", "generic_name": "Tranylcypromine Sulfate Tablet", "contact_info": "800-545-8800", "related_info": "Supply is expected to be depleted by 12/31/2025.", "openfda": { "application_number": [ "NDA012342" ], "brand_name": [ "TRANYLCYPROMINE SULFATE" ], "generic_name": [ "TRANYLCYPROMINE SULFATE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0591-5590" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "TRANYLCYPROMINE SULFATE" ], "rxcui": [ "313447" ], "spl_id": [ "e42c8b23-863e-4370-a3b1-b71526b12ee5" ], "spl_set_id": [ "6a0b609b-0625-4c26-91a1-59ee3ece3ddf" ], "package_ndc": [ "0591-5590-01" ], "unii": [ "7ZAT6ES870" ] }, "update_date": "10/21/2025", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Parnate, Tablet, 10 mg (NDC 0591-5590-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "59651-724-05", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": { "application_number": [ "ANDA075150" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Aurobindo Pharma Limited" ], "product_ndc": [ "59651-724", "59651-722", "59651-723" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "b1582eb7-af35-45d5-a52e-0e380d08527d" ], "spl_set_id": [ "b1582eb7-af35-45d5-a52e-0e380d08527d" ], "package_ndc": [ "59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "06/02/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 59651-724-05)", "company_name": "Aurobindo Pharma USA", "status": "Current" }, { "discontinued_date": "06/04/2026", "update_type": "New", "initial_posting_date": "06/04/2026", "package_ndc": "0169-4314-30", "generic_name": "Semaglutide Tablet", "contact_info": "833-493-4689", "related_info": "Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.", "update_date": "06/04/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Tablet", "presentation": "Rybelsus, Tablet, 14 mg (NDC 0169-4314-30)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4312-08", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": { "application_number": [ "NDA211280" ], "brand_name": [ "REYVOW" ], "generic_name": [ "LASMIDITAN" ], "manufacturer_name": [ "Eli Lilly and Company" ], "product_ndc": [ "0002-4312", "0002-4491" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LASMIDITAN" ], "rxcui": [ "2256937", "2256943", "2256945", "2256947" ], "spl_id": [ "29f467c6-0365-4831-b4ce-9a0eefaf5896" ], "spl_set_id": [ "aea3358c-ff41-4490-9e6d-c7bf7b3de13f" ], "package_ndc": [ "0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62" ], "unii": [ "760I9WM792" ] }, "update_date": "11/03/2025", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 50 mg (NDC 0002-4312-08)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-65", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-285", "63323-286", "63323-287", "63323-288" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091" ], "spl_id": [ "324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c" ], "spl_set_id": [ "dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6" ], "package_ndc": [ "63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-65)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "47781-564-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": { "application_number": [ "ANDA214547" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Alvogen Inc." ], "product_ndc": [ "47781-564", "47781-562", "47781-563", "47781-565", "47781-566", "47781-567", "47781-568" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "db02ec6b-f17f-ab22-b671-e1ddb90e017c" ], "spl_set_id": [ "7f2dd6ee-3363-c87c-9693-ed838942556c" ], "package_ndc": [ "47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 47781-564-01)", "company_name": "Alvogen", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "76329-3302-1", "generic_name": "Dextrose Monohydrate 50% Injection", "contact_info": "800-423-4136", "availability": "Available", "openfda": { "application_number": [ "ANDA203451" ], "brand_name": [ "DEXTROSE MONOHYDRATE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "International Medication Systems, Limited" ], "product_ndc": [ "76329-3302" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "727517" ], "spl_id": [ "45b366a9-6c0c-4643-9951-4ff880b29c83" ], "spl_set_id": [ "fcc7ac79-cd70-4f03-a4de-f051f9ca1f7d" ], "package_ndc": [ "76329-3302-1" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 76329-3302-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/01/2017", "package_ndc": "0409-5555-02", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA202981" ], "brand_name": [ "SODIUM BICARBONATE" ], "generic_name": [ "SODIUM BICARBONATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-5555" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM BICARBONATE" ], "rxcui": [ "1868469" ], "spl_id": [ "e3a44e63-8594-40b6-a3fa-d135b3149661", "bcb3a2dc-1a3f-4ac7-8ea2-426f0771c246" ], "spl_set_id": [ "0c24b592-4bc8-456f-acac-9c9525844a06", "ea9f4498-0d43-4043-8dd1-f22537841c21" ], "package_ndc": [ "0409-5555-11", "0409-5555-01", "0409-5555-12", "0409-5555-02" ], "unii": [ "8MDF5V39QO" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-02)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "06/30/2026", "update_type": "New", "initial_posting_date": "06/30/2026", "package_ndc": "0143-9378-01", "generic_name": "Daptomycin Injection", "contact_info": "609-395-8625 ext. 203", "related_info": "Discontinuation of the manufacture of the drug; Marketed by Hikma Pharmaceuticals USA, Inc.", "update_date": "06/30/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Daptomycin, Injection, 500 mg/10 mL (NDC 0143-9378-01)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0487-6105-01", "generic_name": "Sterile Water Injection", "contact_info": "800-443-4313", "availability": "Limited Availability", "related_info": "Small amount of inventory available with 12/31/2026 dating", "openfda": { "application_number": [ "ANDA211222" ], "brand_name": [ "STERILE WATER" ], "generic_name": [ "STERILE WATER" ], "manufacturer_name": [ "Nephron Pharmaceuticals Corporation" ], "product_ndc": [ "0487-6105" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "WATER" ], "spl_id": [ "39ada97d-53b0-5144-e063-6294a90a91ba" ], "spl_set_id": [ "bc04a883-babc-87a6-e053-2995a90a3dfd" ], "package_ndc": [ "0487-6105-01" ], "unii": [ "059QF0KO0R" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0487-6105-01)", "company_name": "Nephron Pharmaceuticals Corporation", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "05/15/2026", "update_type": "New", "initial_posting_date": "05/15/2026", "package_ndc": "0574-0521-74", "generic_name": "Activated Charcoal Oral Suspension", "contact_info": "866-634-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "M023" ], "brand_name": [ "ACTIDOSE AQUA" ], "generic_name": [ "ACTIVATED CHARCOAL" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-0521" ], "product_type": [ "HUMAN OTC DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ACTIVATED CHARCOAL" ], "rxcui": [ "309150", "1251411" ], "spl_id": [ "bd250d66-b8ea-4cab-a8f2-d2913a157fc5" ], "spl_set_id": [ "c85dc235-3f42-4361-9bd2-1aaff798ad75" ], "package_ndc": [ "0574-0521-25", "0574-0521-74", "0574-0521-76" ], "unii": [ "2P3VWU3H10" ] }, "update_date": "05/15/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Oral Suspension", "presentation": "Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-74)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-6637-14", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA202494" ], "brand_name": [ "SODIUM BICARBONATE" ], "generic_name": [ "SODIUM BICARBONATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-6637", "0409-4916" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM BICARBONATE" ], "rxcui": [ "727995", "792582" ], "spl_id": [ "f79ec8cb-b6a3-4ffb-bccf-d39f59d65621" ], "spl_set_id": [ "ea20a5eb-641e-48cd-bcfa-74c04c45dfda" ], "package_ndc": [ "0409-4916-24", "0409-4916-14", "0409-6637-24", "0409-6637-14" ], "unii": [ "8MDF5V39QO" ] }, "update_date": "11/07/2025", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-6637-14)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "discontinued_date": "07/24/2026", "update_type": "New", "initial_posting_date": "07/24/2026", "package_ndc": "0074-0522-60", "generic_name": "Lopinavir and Ritonavir Tablet", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/24/2026", "therapeutic_category": [ "Antiviral" ], "dosage_form": "Tablet", "presentation": "Kaletra, Tablet, 100 mg; 25 mg (NDC 0074-0522-60)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3177-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA089635" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3177", "0409-1209", "0409-3178", "0409-3181", "0409-3182", "0409-3183", "0409-0007", "0409-0147" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE", "EPINEPHRINE" ], "rxcui": [ "1010688", "1010745", "1010751", "1010759", "1867996", "1867998" ], "spl_id": [ "68a37af1-d237-4836-af13-1eec28245f8b" ], "spl_set_id": [ "2f94f711-14c4-48ec-c5a3-c5ec4b8e8729" ], "package_ndc": [ "0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10" ], "nui": [ "N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647" ], "pharm_class_moa": [ "Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]" ], "pharm_class_epc": [ "alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]" ], "pharm_class_cs": [ "Catecholamines [CS]" ], "unii": [ "YKH834O4BH", "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 2.5 g/50 mL (0.5%; 1:200,000) (NDC 0409-3177-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "05/08/2026", "update_type": "New", "initial_posting_date": "05/08/2026", "package_ndc": "69489-721-30", "generic_name": "Sulconazole Nitrate Solution", "contact_info": "480-434-6670", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA018738" ], "brand_name": [ "EXELDERM" ], "generic_name": [ "SULCONAZOLE NITRATE" ], "manufacturer_name": [ "Journey Medical Corporation" ], "product_ndc": [ "69489-721" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "TOPICAL" ], "substance_name": [ "SULCONAZOLE NITRATE" ], "rxcui": [ "208118", "313125" ], "spl_id": [ "53b92932-d626-2d66-e063-6294a90a8f6a" ], "spl_set_id": [ "5b73e83e-8d3c-4d96-b4f6-9f854430add8" ], "package_ndc": [ "69489-721-30", "69489-721-05" ], "unii": [ "1T89100D5U" ] }, "update_date": "05/08/2026", "therapeutic_category": [ "Dermatology" ], "dosage_form": "Solution", "presentation": "Exelderm, Solution, 1.0% 30 mL (NDC 69489-721-30)", "company_name": "Journey Medical Corporation", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "44567-603-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "WG Critical Care 888-493-0861", "availability": "Available", "related_info": "Marketed by WG Critical Care", "openfda": { "application_number": [ "NDA206628" ], "brand_name": [ "DEXMEDETOMIDINE IN DEXTROSE" ], "generic_name": [ "DEXMEDETOMIDINE" ], "manufacturer_name": [ "WG Critical Care, LLC" ], "product_ndc": [ "44567-603", "44567-600", "44567-601", "44567-602" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909", "1788947" ], "spl_id": [ "42a0bb50-be84-4c46-abfd-fd44c6f10087" ], "spl_set_id": [ "0d2710f2-ee47-4114-ab5c-8dca74cdcb8d" ], "package_ndc": [ "44567-600-04", "44567-601-04", "44567-602-24", "44567-603-24" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-603-24)", "company_name": "HQ Specialty Pharma", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "05/03/2022", "package_ndc": "17478-050-01", "generic_name": "Sufentanil Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Not currently manufactured", "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "83634-653-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "Avenacy, LLC: 877-283-6229", "availability": "Available", "related_info": "Distributed by Avenacy, LLC", "openfda": { "application_number": [ "ANDA219535" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Avenacy, LLC" ], "product_ndc": [ "83634-653", "83634-651" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1737562", "1737566", "1737568" ], "spl_id": [ "8fb1dd7b-f349-4a64-96c1-bd72bf748f3b" ], "spl_set_id": [ "46480253-29b9-4d7f-98ed-10377929026b" ], "package_ndc": [ "83634-653-41", "83634-653-02", "83634-653-42", "83634-653-05", "83634-653-43", "83634-653-30", "83634-651-41", "83634-651-10", "83634-651-42", "83634-651-20", "83634-651-43", "83634-651-50" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/2 mL (NDC 83634-653-02)", "company_name": "Anthea Pharma", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "63323-185-10", "generic_name": "Sterile Water Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release August 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "ANDA088400" ], "brand_name": [ "STERILE WATER" ], "generic_name": [ "WATER" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-185" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "WATER" ], "spl_id": [ "42c6c812-706a-425b-b8cb-931006e40484" ], "spl_set_id": [ "e71c6c83-d518-496c-b2ab-efd5987e4783" ], "package_ndc": [ "63323-185-07", "63323-185-10", "63323-185-09", "63323-185-50", "63323-185-08", "63323-185-20", "63323-185-04", "63323-185-05" ], "unii": [ "059QF0KO0R" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Injection", "presentation": "Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-012-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 12.5 mg/.4 mL (NDC 82497-012-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "55150-221-10", "generic_name": "Etomidate Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA206126" ], "brand_name": [ "ETOMIDATE" ], "generic_name": [ "ETOMIDATE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-221", "55150-222" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008" ], "spl_id": [ "278b160e-cdc4-451e-9405-cb001f443680" ], "spl_set_id": [ "0820f15a-046b-4185-a2b3-2e4051ee3d82" ], "package_ndc": [ "55150-221-10", "55150-222-20" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 20 mg/10 mL (NDC 55150-221-10)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "04/09/2026", "update_type": "New", "initial_posting_date": "04/09/2026", "package_ndc": "0069-4061-01", "generic_name": "Azithromycin Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA050711" ], "brand_name": [ "ZITHROMAX" ], "generic_name": [ "AZITHROMYCIN DIHYDRATE" ], "manufacturer_name": [ "Pfizer Laboratories Div Pfizer Inc" ], "product_ndc": [ "0069-4061", "0069-3060", "0069-3070", "0069-3110", "0069-3120", "0069-3130", "0069-3140" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "AZITHROMYCIN DIHYDRATE" ], "rxcui": [ "105260", "141963", "211307", "212446", "226827", "248656", "308459", "308460", "749780", "749783", "750149", "750157" ], "spl_id": [ "1c5f0fcc-88ce-47e9-a128-b7326b7a5a02" ], "spl_set_id": [ "db52b91e-79f7-4cc1-9564-f2eee8e31c45" ], "package_ndc": [ "0069-3060-30", "0069-3060-75", "0069-3060-86", "0069-3070-30", "0069-3070-75", "0069-3110-19", "0069-3120-19", "0069-3130-19", "0069-3140-19", "0069-4061-01", "0069-4061-75", "0069-4061-89" ], "unii": [ "5FD1131I7S" ] }, "update_date": "04/09/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Tablet", "presentation": "Zithromax, Tablet, 250 mg (NDC 0069-4061-01)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3182-03", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: May 2027; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA089646" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3182", "0409-1209", "0409-3177", "0409-3178", "0409-3181", "0409-3183", "0409-0007", "0409-0147" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE", "EPINEPHRINE" ], "rxcui": [ "1010688", "1010745", "1010751", "1010759", "1867996", "1867998" ], "spl_id": [ "68a37af1-d237-4836-af13-1eec28245f8b" ], "spl_set_id": [ "2f94f711-14c4-48ec-c5a3-c5ec4b8e8729" ], "package_ndc": [ "0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10" ], "nui": [ "N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647" ], "pharm_class_moa": [ "Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]" ], "pharm_class_epc": [ "alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]" ], "pharm_class_cs": [ "Catecholamines [CS]" ], "unii": [ "YKH834O4BH", "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 1 g/50 mL (2%; 1:100,000) (NDC 0409-3182-03)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "55150-168-30", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA203895" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-168", "55150-167", "55150-169", "55150-170", "55150-171", "55150-172", "55150-249", "55150-250" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082" ], "spl_id": [ "39649703-e633-4a20-ba71-0c04dbf8ff2a" ], "spl_set_id": [ "ffecf450-1f01-4721-8e10-251385852612" ], "package_ndc": [ "55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-168-30)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-087-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": { "application_number": [ "ANDA214134" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "57664-087", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-088" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "560b4c9e-9cce-4717-e063-6294a90a58c9" ], "spl_set_id": [ "da3148af-f9b6-4725-adae-3595b4c7dc4b" ], "package_ndc": [ "57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 57664-087-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current" }, { "discontinued_date": "05/06/2026", "update_type": "New", "initial_posting_date": "05/06/2026", "package_ndc": "0409-1103-01", "generic_name": "Cisatracurium Besylate Injection", "contact_info": "844-646-4398", "related_info": "Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA203236" ], "brand_name": [ "CISATRACURIUM BESYLATE" ], "generic_name": [ "CISATRACURIUM BESYLATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1103", "0409-1098", "0409-1208" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CISATRACURIUM BESYLATE" ], "rxcui": [ "199211", "199212", "1730194" ], "spl_id": [ "7b64e51a-1a55-4949-ac7c-b0a21cbd6ec9" ], "spl_set_id": [ "67908e20-044d-454d-9c51-bf106e817bd0" ], "package_ndc": [ "0409-1098-12", "0409-1098-02", "0409-1103-11", "0409-1103-01", "0409-1208-11", "0409-1208-01" ], "unii": [ "80YS8O1MBS" ] }, "update_date": "05/06/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Cisatracurium Besylate, Injection, 200 mg/20ml (10 mg/mL) Single Dose Vial (NDC 0409-1103-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-353-90", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-90)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "11/01/2017", "package_ndc": "0409-4264-01", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA200403" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4264", "0409-1283", "0409-1312", "0409-1805" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897756", "897757", "1433251", "1724383", "1724644", "2675350" ], "spl_id": [ "766e302a-2d03-4d93-b237-2348b57ee517" ], "spl_set_id": [ "f9ca2ef5-46d8-475a-a26e-f7c8becd6db7" ], "package_ndc": [ "0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 0.5 mg/0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-4264-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9042-01", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA071165" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-9042", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596" ], "spl_id": [ "6e442bfd-d3da-4913-8585-ce3485644364" ], "spl_set_id": [ "02a845c3-4521-4926-e397-25ab536e7cf6" ], "package_ndc": [ "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8893-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Available", "openfda": { "application_number": [ "ANDA040440" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "SpecGx LLC" ], "product_ndc": [ "0406-8893", "0406-8891", "0406-8884", "0406-8892", "0406-8885", "0406-8894" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "1009145" ], "spl_id": [ "0d3fb5ba-ff79-4862-bc1d-45b8343e115b" ], "spl_set_id": [ "72ddd1c9-ddbd-4c95-acd9-003189a353a3" ], "package_ndc": [ "0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0406-8893-01)", "company_name": "SpecGx LLC", "status": "Current" }, { "discontinued_date": "04/15/2026", "update_type": "New", "initial_posting_date": "04/15/2026", "package_ndc": "0093-5031-56", "generic_name": "Tiagabine Hydrochloride Tablet", "contact_info": "888-838-2872", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA020646" ], "brand_name": [ "TIAGABINE HYDROCHLORIDE" ], "generic_name": [ "TIAGABINE HYDROCHLORIDE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0093-5031", "0093-5030", "0093-8072", "0093-8076" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "TIAGABINE HYDROCHLORIDE" ], "rxcui": [ "1299903", "1299909", "1299911", "1299917" ], "spl_id": [ "2a8d7987-54ae-45d7-8224-361dac37e0a4" ], "spl_set_id": [ "953ef3cc-e3cb-480f-b9ea-256520fd62b8" ], "package_ndc": [ "0093-5030-56", "0093-5031-56", "0093-8072-56", "0093-8076-56" ], "unii": [ "DQH6T6D8OY" ] }, "update_date": "04/15/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Tiagabine Hydrochloride, Tablet, 4mg 30 count (NDC 0093-5031-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "03/26/2026", "update_type": "New", "initial_posting_date": "03/26/2026", "package_ndc": "39822-0350-2", "generic_name": "Lincomycin Hydrochloride Injection", "contact_info": "866-390-4411", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA201746" ], "brand_name": [ "LINCOMYCIN" ], "generic_name": [ "LINCOMYCIN HYDROCHLORIDE" ], "manufacturer_name": [ "XGen Pharmaceuticals DJB, Inc." ], "product_ndc": [ "39822-0350", "39822-0353" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCONJUNCTIVAL" ], "substance_name": [ "LINCOMYCIN HYDROCHLORIDE" ], "rxcui": [ "239212" ], "spl_id": [ "df369d62-f1a4-1a53-e053-2995a90abbf9" ], "spl_set_id": [ "61f4851d-d919-400d-912a-05eb9dca11d4" ], "package_ndc": [ "39822-0350-1", "39822-0350-2", "39822-0353-6" ], "unii": [ "M6T05Z2B68" ] }, "update_date": "03/26/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Lincomycin Hydrochloride, Injection, 600 mg/2 mL vial x 10 count (NDC 39822-0350-2)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-466-31", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA070553", "NDA018304" ], "brand_name": [ "SENSORCAINE MPF" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-466", "63323-464", "63323-462", "63323-465", "63323-467", "63323-460" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRACAUDAL", "PERINEURAL", "INFILTRATION" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457" ], "spl_id": [ "b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715" ], "spl_set_id": [ "e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8" ], "package_ndc": [ "63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31" ], "unii": [ "7TQO7W3VT8", "30Q7KI53AK" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-31)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "70121-1574-5", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-525-7270", "availability": "Available", "openfda": { "application_number": [ "ANDA210043" ], "brand_name": [ "METHYLPREDNISOLONE ACETATE" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Amneal Pharmaceuticals LLC" ], "product_ndc": [ "70121-1574", "70121-1573" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1743779", "1743855" ], "spl_id": [ "af4215ff-94ca-44f8-8506-3024e738cd13" ], "spl_set_id": [ "d944240d-2c19-46ba-ad4f-3fbee7b8629c" ], "package_ndc": [ "70121-1573-1", "70121-1573-5", "70121-1574-1", "70121-1574-5" ], "unii": [ "43502P7F0P" ] }, "update_date": "06/17/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-5)", "company_name": "Amneal Pharmaceuticals", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "71288-203-11", "generic_name": "Furosemide Injection", "contact_info": "844-824-8426", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA212803" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Meitheal Pharmaceuticals Inc." ], "product_ndc": [ "71288-203" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "b06d36f6-507c-4b04-b79d-d6370a30a551", "53a09c30-7295-4337-89a4-93d3748d6ea3" ], "spl_set_id": [ "a2e3c748-28ce-4c50-a182-721912919840", "3aadaca7-3661-4bfe-87f8-6368e4ab6536" ], "package_ndc": [ "71288-203-02", "71288-203-03", "71288-203-04", "71288-203-05", "71288-203-10", "71288-203-11", "71288-203-91", "71288-203-92", "71288-203-93", "71288-203-94" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "04/23/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-11)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current" }, { "discontinued_date": "09/09/2025", "update_type": "New", "initial_posting_date": "09/09/2025", "package_ndc": "0409-6531-01", "generic_name": "Vancomycin Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA062912" ], "brand_name": [ "VANCOMYCIN HYDROCHLORIDE" ], "generic_name": [ "VANCOMYCIN HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-6531", "0409-6533", "0409-4332", "0409-3515" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "VANCOMYCIN HYDROCHLORIDE" ], "rxcui": [ "1807513", "1807516", "1807518", "2049890" ], "spl_id": [ "10032a19-0373-4c42-b785-f3d915614e30" ], "spl_set_id": [ "f2901045-904f-47bd-74a1-c561facd7f25" ], "package_ndc": [ "0409-6531-12", "0409-6531-02", "0409-6533-11", "0409-6533-01", "0409-6533-21", "0409-4332-11", "0409-4332-01", "0409-3515-11", "0409-3515-01" ], "unii": [ "71WO621TJD" ] }, "update_date": "09/09/2025", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Vancomycin Hydrochloride, Injection, 750 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-6531-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0264-1510-31", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "NDA016730" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-1510" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795609", "1795616", "1795618" ], "spl_id": [ "638a41c3-0f07-4d1a-bb4e-1bab16e61266" ], "spl_set_id": [ "60b6d7c3-0164-46c9-aa38-b5aa1c31a5d5" ], "package_ndc": [ "0264-1510-36", "0264-1510-31", "0264-1510-32" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-31)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "update_type": "New", "initial_posting_date": "02/20/2018", "package_ndc": "31722-277-34", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "732-529-0430, customerservice@camberpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA217821" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Camber Pharmaceuticals, Inc." ], "product_ndc": [ "31722-277", "31722-275", "31722-276" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "RETROBULBAR" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1724786", "1724787", "1724880", "1724884", "1725078", "1725082" ], "spl_id": [ "4ea16f8e-77de-3ba7-e063-6394a90a5667" ], "spl_set_id": [ "0e552e3a-cf52-4d74-9381-6cc1b29b4c90" ], "package_ndc": [ "31722-275-10", "31722-275-31", "31722-275-32", "31722-275-30", "31722-275-33", "31722-275-34", "31722-275-35", "31722-276-10", "31722-276-31", "31722-276-32", "31722-276-30", "31722-276-33", "31722-276-34", "31722-277-10", "31722-277-31", "31722-277-32", "31722-277-30", "31722-277-33", "31722-277-34" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "07/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-34)", "company_name": "Aspiro Pharma Limited", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-027-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Available", "openfda": { "application_number": [ "ANDA202830" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE" ], "manufacturer_name": [ "Amneal Pharmaceuticals LLC" ], "product_ndc": [ "65162-027", "65162-023", "65162-024", "65162-025", "65162-026", "65162-028" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850" ], "spl_id": [ "ba9f3370-3096-4d8c-9571-e28faf54291f" ], "spl_set_id": [ "c11cb3b6-3dff-477b-a249-b4c3118edc5f" ], "package_ndc": [ "65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 65162-027-09)", "company_name": "Amneal Pharmaceuticals", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-468-37", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release August 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "ANDA070966" ], "brand_name": [ "SENSORCAINE MPF" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-468", "63323-472", "63323-463", "63323-461" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1867594", "1867596", "1867618", "1867620", "1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810" ], "spl_id": [ "b671015d-f620-4930-a890-5e27a40ae42f", "cc1f6507-eb3e-4398-a1d3-0c56a2099e6b" ], "spl_set_id": [ "b671015d-f620-4930-a890-5e27a40ae42f", "bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb" ], "package_ndc": [ "63323-468-08", "63323-468-38", "63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17" ], "unii": [ "7TQO7W3VT8", "30Q7KI53AK" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "47335-993-01", "generic_name": "Metronidazole Injection", "contact_info": "Distributed by Sun Pharma", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA212435" ], "brand_name": [ "METRONIDAZOLE" ], "generic_name": [ "METRONIDAZOLE" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "47335-993" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "METRONIDAZOLE" ], "rxcui": [ "311683" ], "spl_id": [ "53cfb044-6f56-f028-e063-6394a90a53f2" ], "spl_set_id": [ "7187779a-1f4c-4607-af53-4119e324aad5" ], "package_ndc": [ "47335-993-01" ], "nui": [ "N0000175435", "M0014907" ], "pharm_class_epc": [ "Nitroimidazole Antimicrobial [EPC]" ], "pharm_class_cs": [ "Nitroimidazoles [CS]" ], "unii": [ "140QMO216E" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Metronidazole In Plastic Container, Injection, 500 mg/100 mL (NDC 47335-993-01)", "company_name": "Gland Pharma Limited", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "01/09/2026", "update_type": "New", "initial_posting_date": "01/09/2026", "package_ndc": "63323-469-05", "generic_name": "Haloperidol Decanoate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA074893" ], "brand_name": [ "HALOPERIDOL DECANOATE" ], "generic_name": [ "HALOPERIDOL DECANOATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-469", "63323-471" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "HALOPERIDOL DECANOATE" ], "rxcui": [ "859867", "859871", "1719803", "1719862" ], "spl_id": [ "86dff2aa-2ab3-42fc-989e-619b13ace573" ], "spl_set_id": [ "ca9896e0-fb2e-46a4-8700-20d144c14764" ], "package_ndc": [ "63323-469-01", "63323-469-05", "63323-471-01", "63323-471-05" ], "unii": [ "AC20PJ4101" ] }, "update_date": "01/09/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Injection", "presentation": "Haloperidol Decanoate, Injection, 50 mg/1 mL (NDC 63323-469-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-464-37", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA070552", "NDA018304" ], "brand_name": [ "SENSORCAINE MPF" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-464", "63323-466", "63323-462", "63323-465", "63323-467", "63323-460" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457" ], "spl_id": [ "b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715" ], "spl_set_id": [ "e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8" ], "package_ndc": [ "63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31" ], "unii": [ "7TQO7W3VT8", "30Q7KI53AK" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/11/2024", "package_ndc": "0990-7120-07", "generic_name": "Dextrose Monohydrate 70% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Available", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA019893" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "ICU Medical Inc." ], "product_ndc": [ "0990-7120" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "237656" ], "spl_id": [ "90d9a0b7-d5a5-4897-90ae-47679f28dac8" ], "spl_set_id": [ "cdf35d11-fbc8-4f8e-85a8-33220312c0b4" ], "package_ndc": [ "0990-7120-07" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7120-07)", "company_name": "Otsuka ICU Medical LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1162-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA070584" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1162", "0409-1159", "0409-1160", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596" ], "spl_id": [ "6e442bfd-d3da-4913-8585-ce3485644364" ], "spl_set_id": [ "02a845c3-4521-4926-e397-25ab536e7cf6" ], "package_ndc": [ "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-1162-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "72205-133-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA218306" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Novadoz Pharmaceuticals LLC" ], "product_ndc": [ "72205-133", "72205-132", "72205-134", "72205-135", "72205-136", "72205-137" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811" ], "spl_set_id": [ "a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811" ], "package_ndc": [ "72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 72205-133-91)", "company_name": "Novadoz Pharmaceuticals LLC", "status": "Current" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0429-53", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA020163" ], "brand_name": [ "DIANEAL PD-2 WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0429", "0941-0411", "0941-0413", "0941-0415", "0941-0409", "0941-0457", "0941-0459", "0941-0426", "0941-0427", "0941-0424", "0941-0430", "0941-0433", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0429-53)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1896-20", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA202515" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1896", "0409-2022" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "1731537", "1731545" ], "spl_id": [ "6f2d5741-5543-4bea-8d1d-7e4889b634a0" ], "spl_set_id": [ "ee8057d1-ed12-4e18-9efa-d83504abf612" ], "package_ndc": [ "0409-1896-20", "0409-2022-01" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "07/23/2026", "update_type": "New", "initial_posting_date": "07/23/2026", "package_ndc": "0574-7090-12", "generic_name": "Hydrocortisone Acetate Suppository", "contact_info": "(800) 775-2054", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "HYDROCORTISONE ACETATE" ], "generic_name": [ "HYDROCORTISONE ACETATE" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-7090", "0574-7093" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RECTAL" ], "substance_name": [ "HYDROCORTISONE ACETATE" ], "rxcui": [ "1291082", "1291085" ], "spl_id": [ "5ae35aec-6ba9-48b8-8b5f-c1b5accb9e1c" ], "spl_set_id": [ "2fdb9940-6da8-49b0-a236-9817943f7a4b" ], "package_ndc": [ "0574-7090-12", "0574-7093-12" ], "unii": [ "3X7931PO74" ] }, "update_date": "07/23/2026", "therapeutic_category": [ "Analgesia/Addiction", "Other" ], "dosage_form": "Suppository", "presentation": "Hydrocortisone Acetate, Suppository, 25 mg (NDC 0574-7090-12)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "55150-172-30", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA203895" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-172", "55150-167", "55150-168", "55150-169", "55150-170", "55150-171", "55150-249", "55150-250" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "RETROBULBAR" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082" ], "spl_id": [ "39649703-e633-4a20-ba71-0c04dbf8ff2a" ], "spl_set_id": [ "ffecf450-1f01-4721-8e10-251385852612" ], "package_ndc": [ "55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-172-30)", "company_name": "Eugia US LLC", "status": "Current" }, { "presentation": "Heparin Sodium, Injection, 2,000 Units/1,000 mL (2 Units/mL) (NDC 0409-7620-59)", "update_type": "Reverified", "initial_posting_date": "11/14/2017", "package_ndc": "0409-7620-59", "generic_name": "Heparin Sodium Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "08/07/2026", "therapeutic_category": [ "Hematology" ], "status": "Current", "dosage_form": "Injection" }, { "update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-339-22", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA076517" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "61703-339" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "0ddf4411-7138-412a-908a-fadf22bdfb79" ], "spl_set_id": [ "c3ae9880-44bb-4f4e-93d8-8a5e21708a30" ], "package_ndc": [ "61703-339-18", "61703-339-22", "61703-339-50", "61703-339-56" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) (NDC 61703-339-22)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "12/08/2025", "update_type": "New", "initial_posting_date": "12/08/2025", "package_ndc": "0781-9408-95", "generic_name": "Ampicillin Sodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of private label only", "openfda": { "application_number": [ "ANDA061395" ], "brand_name": [ "AMPICILLIN" ], "generic_name": [ "AMPICILLIN SODIUM" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-9408", "0781-9401", "0781-9402", "0781-9407", "0781-9404" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "AMPICILLIN SODIUM" ], "rxcui": [ "308207", "1721473", "1721474", "1721475", "1721476" ], "spl_id": [ "a3ddae6c-ac4c-425f-82b0-eb388d92bc0e" ], "spl_set_id": [ "b371e1a5-1fef-4df2-8940-c4fc02b9e2f0" ], "package_ndc": [ "0781-9401-78", "0781-9401-95", "0781-9402-78", "0781-9402-95", "0781-9407-78", "0781-9407-95", "0781-9404-85", "0781-9404-95", "0781-9408-80", "0781-9408-95" ], "unii": [ "JFN36L5S8K" ] }, "update_date": "12/08/2025", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Ampicillin Sodium, Injection, 2 g (NDC 0781-9408-95)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "42023-187-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-828-9393", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; Please check wholesalers for inventory", "openfda": { "application_number": [ "ANDA208266" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "42023-187", "42023-146", "42023-186" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "309710", "1718906", "1718909" ], "spl_id": [ "54174211-6684-4fb9-a605-be12b94e2948" ], "spl_set_id": [ "1ee59985-4c1d-48f7-b8f9-5584c2d55e08" ], "package_ndc": [ "42023-146-25", "42023-186-20", "42023-187-10" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-187-10)", "company_name": "Par Health, USA LLC", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "03/13/2026", "update_type": "New", "initial_posting_date": "03/13/2026", "package_ndc": "65219-284-12", "generic_name": "Plerixafor Injection", "contact_info": "888-391-6300 www.fresenius-kabi.com", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA022311" ], "brand_name": [ "PLERIXAFOR" ], "generic_name": [ "PLERIXAFOR" ], "manufacturer_name": [ "Fresenius Kabi Usa, LLC" ], "product_ndc": [ "65219-284" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "PLERIXAFOR" ], "rxcui": [ "828700" ], "spl_id": [ "ba468eca-fb47-497b-8aed-a1576249ea6a" ], "spl_set_id": [ "5d670cb4-163e-498c-b5fa-c193ea9d55c0" ], "package_ndc": [ "65219-284-12" ], "nui": [ "N0000178326", "N0000178324" ], "pharm_class_epc": [ "Hematopoietic Stem Cell Mobilizer [EPC]" ], "pharm_class_pe": [ "Increased Hematopoietic Stem Cell Mobilization [PE]" ], "unii": [ "S915P5499N" ] }, "update_date": "03/13/2026", "therapeutic_category": [ "Hematology" ], "dosage_form": "Injection", "presentation": "Plerixafor, Injection, 24 mg per 1.2 mL (20 mg per mL) (NDC 65219-284-12)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4713-32", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA080408" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4276", "0409-4275" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763" ], "spl_id": [ "05d1a200-9d75-4e48-b14a-5069d4ab816f" ], "spl_set_id": [ "3b2dd84e-cee8-4e58-d494-395a65a353a0" ], "package_ndc": [ "0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/2 mL (1%; 10 mg/mL) (NDC 0409-4713-32)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0502-03", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "ANDA020512" ], "brand_name": [ "CLINISOL" ], "generic_name": [ "LYSINE, LEUCINE, PHENYLALANINE, VALINE, HISTIDINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, TYROSINE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0502" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LYSINE ACETATE", "LEUCINE", "PHENYLALANINE", "VALINE", "HISTIDINE", "ISOLEUCINE", "METHIONINE", "THREONINE", "TRYPTOPHAN", "ALANINE", "ARGININE", "GLYCINE", "PROLINE", "GLUTAMIC ACID", "SERINE", "ASPARTIC ACID", "TYROSINE" ], "rxcui": [ "800584", "800588" ], "spl_id": [ "85da84a9-36a7-4d9b-bc6b-d0a58941b5c9" ], "spl_set_id": [ "65ffc962-7538-41ea-9afb-4af5fbce4c5b" ], "package_ndc": [ "0338-0502-03", "0338-0502-06" ], "nui": [ "N0000175780", "M0000922" ], "pharm_class_epc": [ "Amino Acid [EPC]" ], "pharm_class_cs": [ "Amino Acids [CS]" ], "unii": [ "TTL6G7LIWZ", "GMW67QNF9C", "47E5O17Y3R", "HG18B9YRS7", "4QD397987E", "04Y7590D77", "AE28F7PNPL", "2ZD004190S", "8DUH1N11BX", "OF5P57N2ZX", "94ZLA3W45F", "TE7660XO1C", "9DLQ4CIU6V", "3KX376GY7L", "452VLY9402", "30KYC7MIAI", "42HK56048U" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-03)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "67457-902-10", "generic_name": "Etomidate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA201044" ], "brand_name": [ "ETOMIDATE" ], "generic_name": [ "ETOMIDATE" ], "manufacturer_name": [ "Mylan Institutional LLC" ], "product_ndc": [ "67457-902", "67457-903" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008" ], "spl_id": [ "25fc0aef-d4b3-4b33-897c-81cc7cdae470" ], "spl_set_id": [ "461e34d1-b862-4a02-9727-548c907aac48" ], "package_ndc": [ "67457-902-00", "67457-902-10", "67457-903-00", "67457-903-20" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 67457-902-10)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0415-06", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA017512" ], "brand_name": [ "DIANEAL PD-2 WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0415", "0941-0411", "0941-0413", "0941-0409", "0941-0457", "0941-0459", "0941-0426", "0941-0427", "0941-0429", "0941-0424", "0941-0430", "0941-0433", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0415-06)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6003-25", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA018140" ], "brand_name": [ "ATIVAN" ], "generic_name": [ "LORAZEPAM" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6003", "0641-6002", "0641-6001", "0641-6000" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "LORAZEPAM" ], "rxcui": [ "206819", "206820", "238100", "238101", "1665188", "1665190", "1665326", "1665327" ], "spl_id": [ "209b0091-c890-4f69-a693-d0594c2606fe" ], "spl_set_id": [ "5fc0e987-61c9-40c4-b0d5-fcea07c8733e" ], "package_ndc": [ "0641-6003-01", "0641-6003-25", "0641-6002-01", "0641-6002-10", "0641-6001-01", "0641-6001-25", "0641-6000-01", "0641-6000-10" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "O26FZP769L" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Injection", "presentation": "Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0009-4073-04", "generic_name": "Clindamycin Phosphate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA050441" ], "brand_name": [ "CLEOCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-4073", "0009-3051", "0009-5095" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "1737244", "1737245", "1737578", "1737579", "1737581", "1737582" ], "spl_id": [ "8d0dac99-6ec9-4648-8ae1-0cc2894d56cf" ], "spl_set_id": [ "a0a2eff7-b7de-42fe-8e5a-0cfbed38bb4b" ], "package_ndc": [ "0009-3051-01", "0009-3051-02", "0009-4073-03", "0009-4073-04", "0009-5095-05", "0009-5095-06" ], "unii": [ "EH6D7113I8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL) (NDC 0009-4073-04)", "company_name": "Pfizer Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2868-31", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA075757" ], "brand_name": [ "OMEPRAZOLE" ], "generic_name": [ "OMEPRAZOLE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-2868", "0781-2859" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OMEPRAZOLE" ], "rxcui": [ "198051", "199119" ], "spl_id": [ "b182f298-e28f-434b-b6f1-ecfac29d495e" ], "spl_set_id": [ "516170d4-4913-4577-a2d2-f5c52d1e79c6" ], "package_ndc": [ "0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31" ], "nui": [ "N0000175525", "N0000000147", "N0000182140" ], "pharm_class_epc": [ "Proton Pump Inhibitor [EPC]" ], "pharm_class_moa": [ "Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]" ], "unii": [ "KG60484QX9" ] }, "update_date": "10/09/2025", "therapeutic_category": [ "Gastroenterology" ], "presentation": "Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-31)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "01/01/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "55513-800-60", "generic_name": "Ivabradine Hydrochloride Tablet", "contact_info": "1-800-772-6436", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": { "application_number": [ "NDA206143" ], "brand_name": [ "CORLANOR" ], "generic_name": [ "IVABRADINE" ], "manufacturer_name": [ "Amgen Inc" ], "product_ndc": [ "55513-800", "55513-810", "55513-813" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "IVABRADINE HYDROCHLORIDE" ], "rxcui": [ "1649485", "1649491", "1649493", "1649495", "2168592", "2168596" ], "spl_id": [ "8ab000cd-0258-489a-b1bb-4cc1ca359d6c" ], "spl_set_id": [ "92018a65-38f6-45f7-91d4-a34921b81d0d" ], "package_ndc": [ "55513-800-60", "55513-800-99", "55513-810-60", "55513-813-01", "55513-813-28" ], "unii": [ "TP19837BZK" ] }, "update_date": "03/24/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Corlanor, Tablet, eq. 5 mg base (NDC 55513-800-60)", "company_name": "Amgen Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "60505-6282-3", "generic_name": "Carboplatin Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Carboplatin%20Injection&st=d", "contact_info": "Apotex Inc.: 800-706-5575", "availability": "Unavailable", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA077861" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Apotex Corp." ], "product_ndc": [ "60505-6282" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "0e68e276-b0df-4f03-e063-6394a90a22b9" ], "spl_set_id": [ "1c275825-0275-4c73-b650-e4c1519f13b8" ], "package_ndc": [ "60505-6282-1", "60505-6282-3", "60505-6282-6", "60505-6282-7" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)", "company_name": "Teyro Labs", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "16729-500-08", "generic_name": "Furosemide Injection", "contact_info": "866-941-7875", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; NDC is non-exempt", "openfda": { "application_number": [ "ANDA070017" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Accord Healthcare, Inc." ], "product_ndc": [ "16729-500", "16729-501", "16729-502" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "1cfab300-d796-6a68-e063-6394a90a73f9" ], "spl_set_id": [ "f6f64972-714c-4ee9-8a5e-9ffcab41a73b" ], "package_ndc": [ "16729-500-30", "16729-500-08", "16729-501-64", "16729-501-43", "16729-502-03", "16729-502-43" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 16729-500-08)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "54288-165-01", "generic_name": "Carboplatin Injection", "contact_info": "Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270", "availability": "Limited Availability", "related_info": "Estimated recovery: end of August 2026; Distributed by BPI Labs, LLC", "openfda": { "application_number": [ "ANDA207324" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "BPI Labs LLC" ], "product_ndc": [ "54288-165", "54288-166", "54288-167", "54288-164" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "c0a7463c-d90f-4060-a54e-6a4888e8af0e" ], "spl_set_id": [ "5484d2f0-0cc2-4bba-8f26-c7f6539a9606" ], "package_ndc": [ "54288-165-01", "54288-166-01", "54288-167-01", "54288-164-01" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 150mg/15mL (NDC 54288-165-01)", "company_name": "Gland Pharma Limited", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1180-69", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Demerol, Injection, 100 mg/1 mL (NDC 0409-1180-69)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "06/08/2026", "update_type": "New", "initial_posting_date": "06/08/2026", "package_ndc": "0069-0197-30", "generic_name": "Dacomitinib Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA211288" ], "brand_name": [ "VIZIMPRO" ], "generic_name": [ "DACOMITINIB" ], "manufacturer_name": [ "Pfizer Laboratories Div Pfizer Inc" ], "product_ndc": [ "0069-0197", "0069-1198", "0069-2299" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DACOMITINIB" ], "rxcui": [ "2058915", "2058922", "2058924", "2058926", "2058930", "2058932" ], "spl_id": [ "3ffd0da1-5601-4ecc-a8fb-f484693cb4c5" ], "spl_set_id": [ "4ab27d2f-e385-4e9c-b324-fa69c10b855a" ], "package_ndc": [ "0069-0197-30", "0069-1198-30", "0069-2299-30" ], "unii": [ "5092U85G58" ] }, "update_date": "06/08/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Tablet", "presentation": "Vizimpro, Tablet, 15 mg (NDC 0069-0197-30)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5168-32", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "PHENOBARBITAL" ], "generic_name": [ "PHENOBARBITAL" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "0603-5168", "0603-5165", "0603-5166", "0603-5167" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "PHENOBARBITAL" ], "rxcui": [ "198086", "199164", "199167", "199168" ], "spl_id": [ "f8c5136e-e35c-4425-8d49-b7f92c827b42" ], "spl_set_id": [ "069b92ce-0061-4724-8c25-08d8596770a2" ], "package_ndc": [ "0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32" ], "unii": [ "YQE403BP4D" ] }, "update_date": "10/31/2025", "therapeutic_category": [ "Analgesia/Addiction", "Neurology", "Other" ], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-32)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "03/26/2018", "package_ndc": "25021-700-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "866-625-1618", "availability": "Limited Availability", "related_info": "Estimated recovery: late September 2026", "openfda": { "application_number": [ "ANDA204216" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-700", "25021-701" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "cb23332a-48fa-458b-93ab-c4eef189a051" ], "spl_set_id": [ "62591551-a644-4b2c-a0de-982e906fabc3" ], "package_ndc": [ "25021-700-01", "25021-701-01", "25021-701-02" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)", "company_name": "Sagent Pharmaceuticals", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-339-56", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA076517" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "61703-339" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "0ddf4411-7138-412a-908a-fadf22bdfb79" ], "spl_set_id": [ "c3ae9880-44bb-4f4e-93d8-8a5e21708a30" ], "package_ndc": [ "61703-339-18", "61703-339-22", "61703-339-50", "61703-339-56" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-339-56)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "55150-323-25", "generic_name": "Furosemide Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA212174" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-323", "55150-322", "55150-324" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "9bb2ffa4-0891-4197-a970-90b178bbfad9" ], "spl_set_id": [ "421aa6d5-623b-4dc2-abd5-bb9e7765bf37" ], "package_ndc": [ "55150-322-01", "55150-322-25", "55150-323-01", "55150-323-25", "55150-324-01", "55150-324-25" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 40 mg/4 mL (NDC 55150-323-25)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0499-06", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA020849" ], "brand_name": [ "PROSOL" ], "generic_name": [ "VALINE, LYSINE, HISTIDINE, ISOLEUCINE, LEUCINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID AND TYROSINE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0499" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "VALINE", "LYSINE ACETATE", "HISTIDINE", "ISOLEUCINE", "LEUCINE", "PHENYLALANINE", "THREONINE", "METHIONINE", "TRYPTOPHAN", "ALANINE", "GLYCINE", "ARGININE", "PROLINE", "GLUTAMIC ACID", "SERINE", "ASPARTIC ACID", "TYROSINE" ], "rxcui": [ "801133", "801136" ], "spl_id": [ "c00d3085-f7b6-4e78-aafc-dca7f757158b" ], "spl_set_id": [ "cc2ace81-5881-43f1-ba94-41b674adc2fc" ], "package_ndc": [ "0338-0499-06" ], "nui": [ "N0000175780", "M0000922" ], "pharm_class_epc": [ "Amino Acid [EPC]" ], "pharm_class_cs": [ "Amino Acids [CS]" ], "unii": [ "HG18B9YRS7", "TTL6G7LIWZ", "4QD397987E", "04Y7590D77", "GMW67QNF9C", "47E5O17Y3R", "2ZD004190S", "AE28F7PNPL", "8DUH1N11BX", "OF5P57N2ZX", "TE7660XO1C", "94ZLA3W45F", "9DLQ4CIU6V", "3KX376GY7L", "452VLY9402", "30KYC7MIAI", "42HK56048U" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, Injection, 2.76 g/100 mL; 1.96 g/100 mL; 600 mg/100 mL; 1.02 g/100 mL; 2.06 g/100 mL; 1.18 g/100 mL; 1.08 g/100 mL; 1.08 g/100 mL; 1.35 g/100 mL; 760 mg/100 mL; 1 g/100 mL; 1.34 g/100 mL; 1.02 g/100 mL; 980 mg/100 mL; 320 mg/100 mL; 50 mg/100 mL; 1.44 g/100 mL (NDC 0338-0499-06)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "62175-310-37", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "844-834-0530", "availability": "Available", "openfda": { "application_number": [ "ANDA091695" ], "brand_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Lannett Company, Inc." ], "product_ndc": [ "62175-310", "62175-311", "62175-312", "62175-313" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "2001564", "2001565", "2001566", "2001568" ], "spl_id": [ "8b133cd2-e3c6-4742-b402-2393b56ffc93" ], "spl_set_id": [ "3d1f5aff-5d39-496c-b5ed-7f3c70ec641c" ], "package_ndc": [ "62175-310-37", "62175-311-37", "62175-312-37", "62175-313-37" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62175-310-37)", "company_name": "Lannett Company, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/12/2021", "package_ndc": "0053-6871-00", "generic_name": "Desmopressin Acetate Spray", "contact_info": "888-337-7464", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/01/2026", "therapeutic_category": [ "Hematology" ], "dosage_form": "Spray", "presentation": "Stimate, Spray, 1.5 mg/1 mL (NDC 0053-6871-00)", "company_name": "Ferring", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-4911-34", "generic_name": "Atropine Sulfate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Atropine+Sulfate+Injection&st=d&tab=tabs-2", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "06/08/2026", "update_type": "New", "initial_posting_date": "06/08/2026", "package_ndc": "0088-2160-30", "generic_name": "Leflunomide Tablet", "contact_info": "800-981-2491", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA020905" ], "brand_name": [ "ARAVA" ], "generic_name": [ "LEFLUNOMIDE" ], "manufacturer_name": [ "sanofi-aventis U.S. LLC" ], "product_ndc": [ "0088-2160", "0088-2161", "0088-2162" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LEFLUNOMIDE" ], "rxcui": [ "205284", "205285", "205286", "213377", "213379", "213380" ], "spl_id": [ "765327c7-cb5b-4637-84da-4fd9a024ad96" ], "spl_set_id": [ "320f63f2-fac3-4aee-aff8-85724e00ef52" ], "package_ndc": [ "0088-2160-30", "0088-2161-30", "0088-2162-33" ], "nui": [ "N0000175713" ], "pharm_class_epc": [ "Antirheumatic Agent [EPC]" ], "unii": [ "G162GK9U4W" ] }, "update_date": "06/08/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Tablet", "presentation": "Arava, Tablet, 10 mg (NDC 0088-2160-30)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued" }, { "discontinued_date": "06/30/2026", "update_type": "New", "initial_posting_date": "06/30/2026", "package_ndc": "0781-3423-94", "generic_name": "Caspofungin Acetate Injection", "contact_info": "Sandoz: 800-525-8747", "related_info": "Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA200833" ], "brand_name": [ "CASPOFUNGIN ACETATE" ], "generic_name": [ "CASPOFUNGIN ACETATE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-3423", "0781-3421" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CASPOFUNGIN ACETATE" ], "rxcui": [ "828539", "828755" ], "spl_id": [ "d70d52c0-6601-f632-e053-2995a90a9291" ], "spl_set_id": [ "722facc6-d4ea-4975-b83e-3ae63df69ed2" ], "package_ndc": [ "0781-3421-01", "0781-3421-94", "0781-3423-01", "0781-3423-94" ], "unii": [ "VUW370O5QE" ] }, "update_date": "06/30/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 0781-3423-94)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-2066-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA040078" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-2066" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1737761" ], "spl_id": [ "c3ff0219-b020-4dd0-aa08-0784b215d479" ], "spl_set_id": [ "9c18eaf1-4a0b-4916-70b2-88a827494711" ], "package_ndc": [ "0409-2066-10", "0409-2066-05" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 100 mg/5 mL (2%; 20 mg/mL) (NDC 0409-2066-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "76045-210-10", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA203129" ], "brand_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "generic_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "76045-210" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE" ], "substance_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "rxcui": [ "1812095" ], "spl_id": [ "9af24370-ee9f-4005-b1e9-96eef58fbde5" ], "spl_set_id": [ "ce25183b-cd67-4997-8de9-df59b750883b" ], "package_ndc": [ "76045-210-00", "76045-210-10" ], "unii": [ "AI9376Y64P" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 76045-210-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2020", "package_ndc": "76329-3340-1", "generic_name": "Atropine Sulfate Injection", "contact_info": "800-423-4136", "availability": "Available", "openfda": { "application_number": [ "ANDA212461" ], "brand_name": [ "ATROPINE SULFATE" ], "generic_name": [ "ATROPINE SULFATE" ], "manufacturer_name": [ "International Medication Systems, Limited" ], "product_ndc": [ "76329-3340" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ATROPINE SULFATE" ], "rxcui": [ "1190546" ], "spl_id": [ "697aa53c-f31f-463a-a752-d2faaad354db" ], "spl_set_id": [ "b72d0a82-6163-460f-965a-12f6da47370a" ], "package_ndc": [ "76329-3340-1" ], "unii": [ "03J5ZE7KA5" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .1 mg/1 mL (NDC 76329-3340-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "status": "Current" }, { "discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4902-34", "generic_name": "Dextrose Monohydrate 50% Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 50%, Injection, 50% Dextrose Injection 0.5 g/mL; ABBOJECT® Glass Syringe (NDC 0409-4902-34)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0409-4887-50", "generic_name": "Sterile Water Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA018801" ], "brand_name": [ "STERILE WATER" ], "generic_name": [ "WATER" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4887" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "WATER" ], "spl_id": [ "055437a7-5be5-414a-a97a-946e2730fe12" ], "spl_set_id": [ "2b9ea23a-f9e9-48a8-25b7-519e3bbd6828" ], "package_ndc": [ "0409-4887-25", "0409-4887-99", "0409-4887-31", "0409-4887-05", "0409-4887-17", "0409-4887-10", "0409-4887-32", "0409-4887-34", "0409-4887-23", "0409-4887-20", "0409-4887-24", "0409-4887-50" ], "unii": [ "059QF0KO0R" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-50)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-103-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": { "application_number": [ "NDA021977" ], "brand_name": [ "VYVANSE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "59417-103", "59417-101", "59417-102", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469" ], "spl_id": [ "81d087b6-4cb4-466a-9693-679edeb062e2" ], "spl_set_id": [ "704e4378-ca83-445c-8b45-3cfa51c1ecad" ], "package_ndc": [ "59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 30 mg (NDC 59417-103-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "63323-671-00", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-00)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "change_date": "01/02/2025", "package_ndc": "0409-1283-31", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA200403" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1283", "0409-1312", "0409-4264", "0409-1805", "0409-2552", "0409-3356", "0409-2540", "0409-3365", "0409-1304" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897756", "897757", "1433251", "1724383", "1724644", "2675350", "897653", "897753", "897758", "1724276" ], "spl_id": [ "766e302a-2d03-4d93-b237-2348b57ee517", "a3ebafac-648e-47b1-a6f5-1e3bff1e3e08" ], "spl_set_id": [ "f9ca2ef5-46d8-475a-a26e-f7c8becd6db7", "e9c9ef18-7dfc-4322-b2fc-29b934c30f8b" ], "package_ndc": [ "0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01", "0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 1 mg/1 mL Syringes (NDC 0409-1283-31)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/21/2023", "package_ndc": "25021-115-06", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "866-625-1618", "availability": "Limited Availability", "related_info": "Selling through remaining short-dated inventory (Dec 2026), API not available, Exiting product line", "openfda": { "application_number": [ "ANDA090108" ], "brand_name": [ "CLINDAMYCIN" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-115" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "1737244", "1737578", "1737581" ], "spl_id": [ "4662502b-ce7c-4278-854d-cf8632ac9b83" ], "spl_set_id": [ "7a6967b3-5563-4bed-9eee-d400f800e799" ], "package_ndc": [ "25021-115-02", "25021-115-04", "25021-115-06" ], "unii": [ "EH6D7113I8" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06)", "company_name": "Sagent Pharmaceuticals", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-710-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": { "application_number": [ "ANDA205327" ], "brand_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Trigen Laboratories, LLC" ], "product_ndc": [ "13811-710", "13811-709", "13811-706", "13811-707", "13811-708" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210", "1995461" ], "spl_id": [ "0944cf70-d59a-483b-9698-e96ef955a65a" ], "spl_set_id": [ "c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f" ], "package_ndc": [ "13811-709-10", "13811-706-10", "13811-707-10", "13811-708-10", "13811-710-10", "13811-710-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8884-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Available", "openfda": { "application_number": [ "ANDA040440" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "SpecGx LLC" ], "product_ndc": [ "0406-8884", "0406-8891", "0406-8892", "0406-8885", "0406-8893", "0406-8894" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "1009145" ], "spl_id": [ "0d3fb5ba-ff79-4862-bc1d-45b8343e115b" ], "spl_set_id": [ "72ddd1c9-ddbd-4c95-acd9-003189a353a3" ], "package_ndc": [ "0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0406-8884-01)", "company_name": "SpecGx LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/17/2021", "package_ndc": "63323-351-20", "generic_name": "Rifampin Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release August 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "ANDA091181" ], "brand_name": [ "RIFAMPIN" ], "generic_name": [ "RIFAMPIN" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-351" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "RIFAMPIN" ], "rxcui": [ "312821" ], "spl_id": [ "60eb9c46-3c34-455b-a740-c03884565072" ], "spl_set_id": [ "a1f9f1e2-dfc0-4d31-a13b-b656d897b791" ], "package_ndc": [ "63323-351-20" ], "nui": [ "N0000175500", "M0019113" ], "pharm_class_epc": [ "Rifamycin Antibacterial [EPC]" ], "pharm_class_cs": [ "Rifamycins [CS]" ], "unii": [ "VJT6J7R4TR" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Rifampin, Injection, 600 mg (NDC 63323-351-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-493-97", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE MPF" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-493", "63323-492", "63323-496" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "rxcui": [ "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737636", "1737637", "1737640", "1737641", "1737763", "1737764" ], "spl_id": [ "fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df" ], "spl_set_id": [ "d5e0d06f-ba1e-44d4-aa89-39d6c146dc23" ], "package_ndc": [ "63323-492-08", "63323-492-97", "63323-493-03", "63323-493-97", "63323-493-01", "63323-493-91", "63323-496-03", "63323-496-97" ], "unii": [ "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-97)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "61269-605-10", "generic_name": "Clonazepam Tablet", "contact_info": "orders@h2-pharma.com", "availability": "Available", "related_info": "Marketed by H2-Pharma", "openfda": { "application_number": [ "NDA017533" ], "brand_name": [ "KLONOPIN" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "H2-Pharma, LLC" ], "product_ndc": [ "61269-605", "61269-610", "61269-620" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529", "206157", "206159", "206160" ], "spl_id": [ "63cfdab9-fb3d-4c2b-bf88-8ba841dba839" ], "spl_set_id": [ "cfa0d79a-843c-4b88-95a1-e9511d649ca1" ], "package_ndc": [ "61269-605-10", "61269-610-10", "61269-620-10" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Klonopin, Tablet, .5 mg (NDC 61269-605-10)", "company_name": "Cheplapharm Arzneimittel GmbH", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "62332-600-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "908-393-9604", "availability": "Available", "openfda": { "application_number": [ "ANDA214456" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Alembic Pharmaceuticals Inc." ], "product_ndc": [ "62332-600", "62332-599", "62332-601" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "9030f496-5021-4454-ac16-dbb376315608" ], "spl_set_id": [ "419cf756-3c96-4bb8-ae96-6aea5a5f3afd" ], "package_ndc": [ "62332-599-01", "62332-599-25", "62332-600-01", "62332-600-25", "62332-601-02", "62332-601-25" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "05/15/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 62332-600-25)", "company_name": "Alembic Pharmaceuticals", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "16729-137-00", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": { "application_number": [ "ANDA077147" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Accord Healthcare Inc." ], "product_ndc": [ "16729-137", "16729-136", "16729-138" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "0e1e7f41-f78b-27cf-e063-6394a90a1ae0" ], "spl_set_id": [ "ebc11109-e7bf-452d-b675-4b3236d54164" ], "package_ndc": [ "16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 16729-137-00)", "company_name": "Accord Healthcare Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3073-22", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: September 2026; Estimated Recovery: December 2026", "openfda": { "application_number": [ "NDA011757" ], "brand_name": [ "DEPO-MEDROL" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-3073", "0009-3475" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE", "INTRA-ARTICULAR" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1743779", "1743781", "1743855", "1743856" ], "spl_id": [ "e4917f75-3e1c-4f3c-803d-d9ec65df06c7", "742fcec7-8db3-4cc6-b276-42587a993810" ], "spl_set_id": [ "bf1b104d-85cb-414d-a366-78068c82c883", "9a7b3837-e038-48bf-97e9-78ad463760dc" ], "package_ndc": [ "0009-3073-22", "0009-3073-23", "0009-3475-22", "0009-3475-23", "0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-22)", "company_name": "Pfizer Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "63481-627-70", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/03/2025", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 2.5 mg (NDC 63481-627-70)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-671-87", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Available", "related_info": "Marketed by Sagent Pharmaceuticals", "openfda": { "application_number": [ "ANDA206166" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-671", "25021-652" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734347", "1734355", "1734479", "1734481" ], "spl_id": [ "41f4446a-ca6e-465e-9a79-8c4f99eb1ac3", "22d83514-0f7b-4671-ae6a-7ca47449c184" ], "spl_set_id": [ "8c5c762f-d266-4b1a-809e-f11bfc89bc2d", "9572b3de-684c-4028-a577-5aa69ba6b02d" ], "package_ndc": [ "25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87", "25021-671-66", "25021-671-67" ], "unii": [ "V910P86109" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-87)", "company_name": "InfoRLife SA", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "72516-014-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "855-257-0292", "availability": "Unavailable", "related_info": "Estimated availability April 2027", "openfda": { "application_number": [ "ANDA210293" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Oryza Pharmaceuticals Inc." ], "product_ndc": [ "72516-014", "72516-016", "72516-015", "72516-013", "72516-012", "72516-011" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "1009145" ], "spl_id": [ "5734011d-5044-b490-e063-6394a90a3174" ], "spl_set_id": [ "acd27181-a3f3-4c38-85d8-029a4a82e7c2" ], "package_ndc": [ "72516-016-01", "72516-015-01", "72516-014-01", "72516-013-01", "72516-012-01", "72516-011-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 72516-014-01)", "company_name": "Oryza Pharmaceuticals Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "59651-722-01", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": { "application_number": [ "ANDA075150" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Aurobindo Pharma Limited" ], "product_ndc": [ "59651-722", "59651-723", "59651-724" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "b1582eb7-af35-45d5-a52e-0e380d08527d" ], "spl_set_id": [ "b1582eb7-af35-45d5-a52e-0e380d08527d" ], "package_ndc": [ "59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "06/02/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 59651-722-01)", "company_name": "Aurobindo Pharma USA", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "76045-104-10", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA203242" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "76045-104", "76045-105", "76045-107", "76045-209" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860113", "860114", "860115" ], "spl_id": [ "0dab642d-7fcf-4301-8ac9-10e64a040c6b" ], "spl_set_id": [ "3d88cbe6-5230-47aa-80af-0c41283d1f00" ], "package_ndc": [ "76045-104-10", "76045-105-20", "76045-107-10", "76045-209-00", "76045-209-10" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 76045-104-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "67457-423-12", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA040803" ], "brand_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "generic_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "manufacturer_name": [ "Mylan Institutional LLC" ], "product_ndc": [ "67457-423", "67457-422", "67457-421", "67457-420" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE" ], "substance_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "rxcui": [ "309696", "1116927", "1812194" ], "spl_id": [ "dd5c82b6-a194-462c-9626-34a9b410cfea" ], "spl_set_id": [ "dff598e8-e662-411f-978d-4ba3fb8ef7db" ], "package_ndc": [ "67457-423-00", "67457-423-12", "67457-422-00", "67457-422-54", "67457-421-00", "67457-421-30", "67457-420-00", "67457-420-10" ], "unii": [ "AI9376Y64P" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-423-12)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1892-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 8 mg/1 mL Syringes (NDC 0409-1892-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0338-0023-02", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA016694" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0023", "0338-0017" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618" ], "spl_id": [ "9c644eb4-5844-415a-8c01-4459d98af222" ], "spl_set_id": [ "3bb406a9-f5cb-403a-b1bb-5c4facbea3d5" ], "package_ndc": [ "0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-02)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "65219-632-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": { "application_number": [ "ANDA212808" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "FRESENIUS KABI USA, LLC" ], "product_ndc": [ "65219-632" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734347", "1734355" ], "spl_id": [ "7203f32f-2e48-4924-b882-d4f3863ae952" ], "spl_set_id": [ "da4a7675-97bf-4d2a-9fdc-c1b4b2999126" ], "package_ndc": [ "65219-632-02", "65219-632-10", "65219-632-04", "65219-632-20" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 65219-632-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-163-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA215330" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Rhodes Pharmaceuticals LLC" ], "product_ndc": [ "42858-163", "42858-161", "42858-162", "42858-164", "42858-165", "42858-166", "42858-167" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "0002e227-1109-4ecc-a8c5-4b4f11fac3cc" ], "spl_set_id": [ "d918b40d-a461-41bc-b6c0-83dc76c28e32" ], "package_ndc": [ "42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/24/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 42858-163-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "discontinued_date": "06/05/2026", "update_type": "New", "initial_posting_date": "06/05/2026", "package_ndc": "71225-126-05", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-461-7449", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "06/05/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-05)", "company_name": "Slayback Pharma", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "06/12/2026", "package_ndc": "63323-142-10", "generic_name": "Ifosfamide Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release August 2026", "openfda": { "application_number": [ "ANDA076078" ], "brand_name": [ "IFOSFAMIDE" ], "generic_name": [ "IFOSFAMIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-142" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "IFOSFAMIDE" ], "rxcui": [ "1791593" ], "spl_id": [ "8f166a04-4395-4ea1-8eda-98274f1bfec3" ], "spl_set_id": [ "a311a947-7b78-4226-bfe0-f4aa0be20e27" ], "package_ndc": [ "63323-142-10" ], "nui": [ "N0000000236", "N0000175558" ], "pharm_class_moa": [ "Alkylating Activity [MoA]" ], "pharm_class_epc": [ "Alkylating Drug [EPC]" ], "unii": [ "UM20QQM95Y" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Oncology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Ifosfamide, Injection, 1 g (NDC 63323-142-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4928-34", "generic_name": "Calcium Chloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": [ "Cardiovascular", "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Calcium Chloride, Injection, 100 mg/1 mL (NDC 0409-4928-34)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5165-21", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "PHENOBARBITAL" ], "generic_name": [ "PHENOBARBITAL" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "0603-5165", "0603-5166", "0603-5167", "0603-5168" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "PHENOBARBITAL" ], "rxcui": [ "198086", "199164", "199167", "199168" ], "spl_id": [ "f8c5136e-e35c-4425-8d49-b7f92c827b42" ], "spl_set_id": [ "069b92ce-0061-4724-8c25-08d8596770a2" ], "package_ndc": [ "0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32" ], "unii": [ "YQE403BP4D" ] }, "update_date": "10/31/2025", "therapeutic_category": [ "Analgesia/Addiction", "Neurology", "Other" ], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-21)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "06/08/2026", "update_type": "New", "initial_posting_date": "06/08/2026", "package_ndc": "0955-1737-30", "generic_name": "Leflunomide Tablet", "contact_info": "800-981-2491", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "06/08/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Tablet", "presentation": "Leflunomide, Tablet, 20 mg (NDC 0955-1737-30)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0781-3493-95", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "See Related Information section below for customer service information", "availability": "Available", "related_info": "Marketed by Sandoz Inc.; Customer service: 800-525-8747", "openfda": { "application_number": [ "ANDA209065" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE" ], "manufacturer_name": [ "Sandoz Inc." ], "product_ndc": [ "0781-3493", "0781-3494", "0781-3495" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718900", "1718906", "1718909" ], "spl_id": [ "fdf227d9-008e-60f8-e053-6294a90af5c4" ], "spl_set_id": [ "809e8f77-390f-4cc8-8c8a-4f67a249c9df" ], "package_ndc": [ "0781-3493-95", "0781-3494-95", "0781-3495-95" ], "unii": [ "1018WH7F9I" ] }, "update_date": "07/30/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 80 mcg/20 mL (NDC 0781-3493-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-799-30", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA064150" ], "brand_name": [ "RIFAMPIN" ], "generic_name": [ "RIFAMPIN" ], "manufacturer_name": [ "EPIC PHARMA, LLC" ], "product_ndc": [ "42806-799", "42806-801" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RIFAMPIN" ], "rxcui": [ "198201", "198202" ], "spl_id": [ "a4ac02e8-68ac-4e79-8ca5-0939dd002c87" ], "spl_set_id": [ "0391f1e1-70d4-4b15-8b58-055bb6a385b8" ], "package_ndc": [ "42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05" ], "nui": [ "N0000175500", "M0019113" ], "pharm_class_epc": [ "Rifamycin Antibacterial [EPC]" ], "pharm_class_cs": [ "Rifamycins [CS]" ], "unii": [ "VJT6J7R4TR" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 42806-799-30)", "company_name": "Epic Pharma, LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/25/2017", "package_ndc": "0264-9594-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "NDA019830" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE AND DEXTROSE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS AND DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-9594", "0264-9598" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS", "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1737723", "1737742", "1737744" ], "spl_id": [ "9e352802-107c-4f90-babe-4f69c7dc892e" ], "spl_set_id": [ "7dff29d9-522d-40eb-a9d9-42377912d640" ], "package_ndc": [ "0264-9598-20", "0264-9594-20", "0264-9594-10" ], "unii": [ "EC2CNF7XFP", "LX22YL083G" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-10)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "discontinued_date": "09/11/2025", "update_type": "New", "initial_posting_date": "09/11/2025", "package_ndc": "0409-0183-25", "generic_name": "Gemcitabine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA200795" ], "brand_name": [ "GEMCITABINE" ], "generic_name": [ "GEMCITABINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-0183", "0409-0181", "0409-0182" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GEMCITABINE HYDROCHLORIDE" ], "rxcui": [ "1720960", "1720975", "1720977" ], "spl_id": [ "3a284abb-8c57-47dc-a138-5a6e6ab92b05", "c0f06508-36d7-4325-a425-707d254d185b" ], "spl_set_id": [ "dc02a23b-3ff9-4441-aa91-8e9e629a7315", "e18ed1cb-7dd0-4001-bfda-17d1f4587fb8" ], "package_ndc": [ "0409-0181-01", "0409-0183-01", "0409-0182-01", "0409-0181-25", "0409-0182-25", "0409-0183-25" ], "unii": [ "U347PV74IL" ] }, "update_date": "09/11/2025", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Gemcitabine Hydrochloride, Injection, 200 mg/5.26 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0183-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "01/31/2018", "package_ndc": "25021-321-10", "generic_name": "Bumetanide Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": { "application_number": [ "ANDA074441" ], "brand_name": [ "BUMETANIDE" ], "generic_name": [ "BUMETANIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-321" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "BUMETANIDE" ], "rxcui": [ "282486", "1727569" ], "spl_id": [ "88a191ea-bf0d-4c27-a33c-91a126ff1aba" ], "spl_set_id": [ "c38a404d-a919-4a2c-9fbb-d0655dee9516" ], "package_ndc": [ "25021-321-04", "25021-321-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "0Y2S3XUQ5H" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-10)", "company_name": "Sagent Pharmaceuticals", "status": "Current" }, { "discontinued_date": "11/17/2025", "update_type": "New", "initial_posting_date": "11/17/2025", "package_ndc": "78206-170-01", "generic_name": "Montelukast Sodium Tablet, Chewable", "contact_info": "844-674-3200", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA020830" ], "brand_name": [ "SINGULAIR" ], "generic_name": [ "MONTELUKAST SODIUM" ], "manufacturer_name": [ "Organon LLC" ], "product_ndc": [ "78206-170", "78206-171", "78206-173", "78206-172" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "MONTELUKAST SODIUM" ], "rxcui": [ "153892", "153893", "200224", "242438", "261367", "311759", "351246", "404406" ], "spl_id": [ "57a12189-3bb3-4a5d-b5fe-fc57db87c134" ], "spl_set_id": [ "482dcc92-b47f-4ea6-854a-f5ac2aea7842" ], "package_ndc": [ "78206-171-01", "78206-170-01", "78206-173-01", "78206-172-01", "78206-172-02" ], "unii": [ "U1O3J18SFL" ] }, "update_date": "11/17/2025", "therapeutic_category": [ "Pulmonary/Allergy" ], "dosage_form": "Tablet, Chewable", "presentation": "Singulair, Tablet, Chewable, 4 mg (NDC 78206-170-01)", "company_name": "Organon", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "11/01/2017", "package_ndc": "0641-6254-01", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Product temporarily on backorder. Additional lots will be available in the August 2026 timeframe.", "openfda": { "application_number": [ "NDA217812" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6254" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897745" ], "spl_id": [ "ba25ec4f-3b81-4960-bf74-6a1e4c6be45c" ], "spl_set_id": [ "c729424e-e483-4bf8-b86c-ce56636dcffa" ], "package_ndc": [ "0641-6254-01" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-6254-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0009-3051-02", "generic_name": "Clindamycin Phosphate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA050441" ], "brand_name": [ "CLEOCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-3051", "0009-4073", "0009-5095" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "1737244", "1737245", "1737578", "1737579", "1737581", "1737582" ], "spl_id": [ "8d0dac99-6ec9-4648-8ae1-0cc2894d56cf" ], "spl_set_id": [ "a0a2eff7-b7de-42fe-8e5a-0cfbed38bb4b" ], "package_ndc": [ "0009-3051-01", "0009-3051-02", "0009-4073-03", "0009-4073-04", "0009-5095-05", "0009-5095-06" ], "unii": [ "EH6D7113I8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL) (NDC 0009-3051-02)", "company_name": "Pfizer Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "11/21/2025", "update_type": "New", "initial_posting_date": "11/21/2025", "package_ndc": "62037-720-05", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA075604" ], "brand_name": [ "POTASSIUM CHLORIDE" ], "generic_name": [ "POTASSIUM CHLORIDE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "62037-720", "62037-710" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "POTASSIUM CHLORIDE" ], "rxcui": [ "1801294", "1801298" ], "spl_id": [ "01fbdb24-0987-40f6-a920-f36349f6ba61" ], "spl_set_id": [ "db002ae3-f54c-40a4-9cb4-e5681bf426e3" ], "package_ndc": [ "62037-710-01", "62037-720-01", "62037-720-05", "62037-720-10" ], "unii": [ "660YQ98I10" ] }, "update_date": "11/21/2025", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology" ], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "10/24/2025", "update_type": "New", "initial_posting_date": "10/24/2025", "package_ndc": "0002-8235-05", "generic_name": "Insulin Lispro-aabc Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "BLA761109" ], "brand_name": [ "LYUMJEV TEMPO PEN" ], "generic_name": [ "INSULIN LISPRO-AABC" ], "manufacturer_name": [ "Eli Lilly and Company" ], "product_ndc": [ "0002-8235", "0002-7728", "0002-7726", "0002-8207", "0002-8351", "0002-8228" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "INSULIN LISPRO" ], "rxcui": [ "2380231", "2380236", "2380248", "2380250", "2380254", "2380256", "2380259", "2380260", "2380265", "2380266", "2380267", "2380268" ], "spl_id": [ "965b6bd6-37d4-451e-8c41-4df16df442d1" ], "spl_set_id": [ "c5a056e2-b568-4ca6-9ed8-79c010942d00" ], "package_ndc": [ "0002-7728-01", "0002-7728-99", "0002-7726-01", "0002-7726-05", "0002-8207-01", "0002-8207-05", "0002-8207-61", "0002-8351-01", "0002-8351-05", "0002-8235-01", "0002-8235-05", "0002-8235-99", "0002-8228-01", "0002-8228-27" ], "nui": [ "N0000004931", "N0000175453" ], "pharm_class_cs": [ "Insulin [Chemical/Ingredient]" ], "pharm_class_epc": [ "Insulin Analog [EPC]" ], "unii": [ "GFX7QIS1II" ] }, "update_date": "10/24/2025", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Lyumjev, Injection, U-100 Tempo Pen (NDC 0002-8235-05)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "11/04/2024", "package_ndc": "0591-2888-30", "generic_name": "Hydroxocobalamin Injection", "contact_info": "800-545-8800", "availability": "Unavailable", "related_info": "Estimated recovery: September 2026", "openfda": { "application_number": [ "ANDA085998" ], "brand_name": [ "HYDROXOCOBALAMIN" ], "generic_name": [ "HYDROXOCOBALAMIN" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0591-2888" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "HYDROXOCOBALAMIN ACETATE" ], "rxcui": [ "317106" ], "spl_id": [ "c47477bf-6413-4699-ab77-c5441a9d1557" ], "spl_set_id": [ "a3087a39-f218-4f16-a1e7-17c39bb2eb69" ], "package_ndc": [ "0591-2888-30" ], "unii": [ "S535M27N3Q" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Injection", "presentation": "Hydroxocobalamin, Injection, 1000 MCG/ML, 30 ML Multi-Dose Vial (NDC 0591-2888-30)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "05/05/2026", "update_type": "New", "initial_posting_date": "05/05/2026", "package_ndc": "71288-725-32", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-824-8426", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/05/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6127-25", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA205758" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6127", "0641-6126", "0641-6125" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "1731993", "1732006", "1732011" ], "spl_id": [ "fb513d10-94f4-45f5-8b30-fa82ef83e4e2" ], "spl_set_id": [ "6023606c-150c-40c5-9175-598efe2a56c3" ], "package_ndc": [ "0641-6126-01", "0641-6126-25", "0641-6127-01", "0641-6127-25", "0641-6125-01", "0641-6125-25" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/26/2018", "package_ndc": "0409-3795-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA074802" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3795", "0409-3793", "0409-3796" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "4beb8ebd-934e-4181-8374-01be0bb80680" ], "spl_set_id": [ "8accbb78-fc64-45d5-69b0-35c23a1d2a2e" ], "package_ndc": [ "0409-3793-19", "0409-3793-01", "0409-3793-25", "0409-3795-19", "0409-3795-01", "0409-3795-25", "0409-3796-19", "0409-3796-01", "0409-3796-25" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0409-3795-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0338-3814-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Limited Availability", "related_info": "Estimated recovery: October 2026", "openfda": { "application_number": [ "ANDA208084" ], "brand_name": [ "CLINDAMYCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "0338-3814", "0338-3410", "0338-3612" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "309335", "309336", "309339" ], "spl_id": [ "c8906ab2-37d2-4fde-9784-0442bf7b9565" ], "spl_set_id": [ "78832ac6-04c5-45e0-ae4d-f56d7920dda9" ], "package_ndc": [ "0338-3410-50", "0338-3410-24", "0338-3612-50", "0338-3612-24", "0338-3814-50", "0338-3814-24" ], "unii": [ "EH6D7113I8" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-620-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA202725" ], "brand_name": [ "QUINAPRIL" ], "generic_name": [ "QUINAPRIL HYDROCHLORIDE" ], "manufacturer_name": [ "Aurobindo Pharma Limited" ], "product_ndc": [ "65862-620", "65862-617", "65862-618", "65862-619" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE" ], "rxcui": [ "312748", "312749", "312750", "314203" ], "spl_id": [ "5263abd5-ce46-4918-9bb0-9632861bcbc9" ], "spl_set_id": [ "93e6e668-5306-4f26-81d8-cbc3a7a5e787" ], "package_ndc": [ "65862-617-30", "65862-617-90", "65862-617-99", "65862-617-55", "65862-617-10", "65862-617-78", "65862-618-30", "65862-618-90", "65862-618-99", "65862-618-55", "65862-618-10", "65862-618-78", "65862-619-30", "65862-619-90", "65862-619-99", "65862-619-19", "65862-619-10", "65862-619-78", "65862-620-30", "65862-620-90", "65862-620-99", "65862-620-39", "65862-620-10", "65862-620-78" ], "unii": [ "33067B3N2M" ] }, "update_date": "06/02/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 40 mg (NDC 65862-620-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-0040-10", "generic_name": "Ketamine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ketamine Hydrochloride, Injection, 500 mg/5mL (100 mg/mL); Multiple Dose Glass Fliptop Vial Novaplus (NDC 0409-0040-10)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0776-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA040422" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0555-0776", "0555-0971", "0555-0775", "0555-0972", "0555-0777", "0555-0973", "0555-0974" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "88468f3d-7d03-4cee-aabf-3abc8c9b5e38" ], "spl_set_id": [ "cffbbb15-d776-41ae-a8a6-687f2c07bfa4" ], "package_ndc": [ "0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 0555-0776-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1163-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA070597" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1163", "0409-1159", "0409-1160", "0409-1162", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596" ], "spl_id": [ "6e442bfd-d3da-4913-8585-ce3485644364" ], "spl_set_id": [ "02a845c3-4521-4926-e397-25ab536e7cf6" ], "package_ndc": [ "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-1163-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "discontinued_date": "10/10/2025", "update_type": "New", "initial_posting_date": "10/10/2025", "package_ndc": "0781-3519-90", "generic_name": "Pemetrexed Disodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA214657" ], "brand_name": [ "PEMETREXED" ], "generic_name": [ "PEMETREXED DISODIUM" ], "manufacturer_name": [ "Sandoz Inc." ], "product_ndc": [ "0781-3519", "0781-3518", "0781-3520" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "PEMETREXED DISODIUM" ], "rxcui": [ "2602363", "2602365", "2602366" ], "spl_id": [ "764ab64b-c642-4314-83a9-efee79fe83a3" ], "spl_set_id": [ "7ac04ab7-7f8c-46ce-ab56-a7a08cd02ab3" ], "package_ndc": [ "0781-3518-76", "0781-3519-90", "0781-3520-91" ], "unii": [ "2PKU919BA9" ] }, "update_date": "10/10/2025", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Pemetrexed Disodium, Injection, 500 mg/20 mL (NDC 0781-3519-90)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-563-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "04/29/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 100 mg (NDC 49884-563-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "02/08/2019", "package_ndc": "63323-516-10", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA040572" ], "brand_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "generic_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-516", "63323-506" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "rxcui": [ "309696", "1812079" ], "spl_id": [ "2ce90eb7-067d-4f1c-9184-c250e387e533" ], "spl_set_id": [ "cca2c160-9188-48e8-9505-49a52388dcb7" ], "package_ndc": [ "63323-506-00", "63323-506-01", "63323-506-03", "63323-506-13", "63323-516-01", "63323-516-10" ], "unii": [ "AI9376Y64P" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 63323-516-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2020", "package_ndc": "16729-483-03", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA212868" ], "brand_name": [ "ATROPINE SULFATE" ], "generic_name": [ "ATROPINE SULFATE" ], "manufacturer_name": [ "Accord Healthcare, Inc.," ], "product_ndc": [ "16729-483", "16729-484" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ATROPINE SULFATE" ], "rxcui": [ "1190546", "1190551", "1190552" ], "spl_id": [ "4082a1cf-1e1b-6f40-e063-6294a90aec06" ], "spl_set_id": [ "c82cb295-ffce-47d6-97ad-a8aa723f4e4f" ], "package_ndc": [ "16729-483-03", "16729-483-31", "16729-484-90", "16729-484-31", "16729-484-45", "16729-484-03" ], "unii": [ "03J5ZE7KA5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .05 mg/1 mL (NDC 16729-483-03)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0973-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA040422" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0555-0973", "0555-0971", "0555-0775", "0555-0972", "0555-0776", "0555-0777", "0555-0974" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "88468f3d-7d03-4cee-aabf-3abc8c9b5e38" ], "spl_set_id": [ "cffbbb15-d776-41ae-a8a6-687f2c07bfa4" ], "package_ndc": [ "0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0555-0973-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6858-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA202835" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE" ], "manufacturer_name": [ "Mylan Pharmaceuticals Inc." ], "product_ndc": [ "0378-6858", "0378-6854", "0378-6855", "0378-6856", "0378-6857", "0378-6859", "0378-6860" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "6e77cd71-95ae-4fa8-830b-ab62b714e4b9" ], "spl_set_id": [ "efbde0f6-b848-4664-b741-c6c630e66108" ], "package_ndc": [ "0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0378-6858-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "67457-421-30", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA040803" ], "brand_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "generic_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "manufacturer_name": [ "Mylan Institutional LLC" ], "product_ndc": [ "67457-421", "67457-423", "67457-422", "67457-420" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE" ], "substance_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "rxcui": [ "309696", "1116927", "1812194" ], "spl_id": [ "dd5c82b6-a194-462c-9626-34a9b410cfea" ], "spl_set_id": [ "dff598e8-e662-411f-978d-4ba3fb8ef7db" ], "package_ndc": [ "67457-423-00", "67457-423-12", "67457-422-00", "67457-422-54", "67457-421-00", "67457-421-30", "67457-420-00", "67457-420-10" ], "unii": [ "AI9376Y64P" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 67457-421-30)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/22/2020", "package_ndc": "43066-015-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Limited Availability", "related_info": "Check wholesalers for inventory; Marketed by Baxter", "openfda": { "application_number": [ "ANDA212808" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "43066-015", "43066-019", "43066-023", "43066-027" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734084", "1734207", "1734475", "1734483" ], "spl_id": [ "a8d08579-825f-40d9-b1e3-e47b73765ae6" ], "spl_set_id": [ "781d4b7f-7556-4695-8d48-7772d7a0d8e9" ], "package_ndc": [ "43066-015-01", "43066-015-10", "43066-019-01", "43066-019-10", "43066-023-01", "43066-023-10", "43066-027-01", "43066-027-10" ], "unii": [ "V910P86109" ] }, "update_date": "06/10/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 43066-015-10)", "company_name": "Caplin Steriles, Ltd.", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "07/24/2026", "update_type": "New", "initial_posting_date": "07/24/2026", "package_ndc": "0074-3008-60", "generic_name": "Lopinavir and Ritonavir Tablet", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA021906" ], "brand_name": [ "KALETRA" ], "generic_name": [ "LOPINAVIR AND RITONAVIR" ], "manufacturer_name": [ "AbbVie Inc." ], "product_ndc": [ "0074-3008", "0074-3956", "0074-4014" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LOPINAVIR", "RITONAVIR" ], "rxcui": [ "311369", "597730", "746645", "847741", "847745", "847749" ], "spl_id": [ "36abdfba-ddc2-43ae-9173-903d66a23b23" ], "spl_set_id": [ "8290add3-4449-4e58-6c97-8fe1eec972e3" ], "package_ndc": [ "0074-3956-46", "0074-4014-12", "0074-3008-60" ], "nui": [ "N0000000246", "N0000175889", "N0000185503", "N0000190114", "N0000190107", "N0000191001", "N0000182137", "N0000185607", "N0000190118", "N0000190113", "N0000182141", "N0000191266", "N0000185507", "N0000187064", "N0000190117" ], "pharm_class_moa": [ "HIV Protease Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 2C19 Inducers [MoA]", "Cytochrome P450 3A Inducers [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "UDP Glucuronosyltransferases Inducers [MoA]" ], "pharm_class_epc": [ "Protease Inhibitor [EPC]", "Cytochrome P450 3A Inhibitor [EPC]" ], "unii": [ "2494G1JF75", "O3J8G9O825" ] }, "update_date": "07/24/2026", "therapeutic_category": [ "Antiviral" ], "dosage_form": "Tablet", "presentation": "Kaletra, Tablet, 100 mg; 25 mg (NDC 0074-3008-60)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "12/10/2025", "update_type": "New", "initial_posting_date": "12/10/2025", "package_ndc": "58468-0126-1", "generic_name": "Doxercalciferol Injection", "contact_info": "800-633-1610", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/10/2025", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Hectorol, Injection, 2 mcg/mL injection 50 single-dose vials (NDC 58468-0126-1)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-23", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-285", "63323-286", "63323-287", "63323-288" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091" ], "spl_id": [ "324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c" ], "spl_set_id": [ "dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6" ], "package_ndc": [ "63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-23)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "47781-562-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": { "application_number": [ "ANDA214547" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Alvogen Inc." ], "product_ndc": [ "47781-562", "47781-563", "47781-564", "47781-565", "47781-566", "47781-567", "47781-568" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "db02ec6b-f17f-ab22-b671-e1ddb90e017c" ], "spl_set_id": [ "7f2dd6ee-3363-c87c-9693-ed838942556c" ], "package_ndc": [ "47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 47781-562-01)", "company_name": "Alvogen", "status": "Current" }, { "discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4312-62", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": { "application_number": [ "NDA211280" ], "brand_name": [ "REYVOW" ], "generic_name": [ "LASMIDITAN" ], "manufacturer_name": [ "Eli Lilly and Company" ], "product_ndc": [ "0002-4312", "0002-4491" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LASMIDITAN" ], "rxcui": [ "2256937", "2256943", "2256945", "2256947" ], "spl_id": [ "29f467c6-0365-4831-b4ce-9a0eefaf5896" ], "spl_set_id": [ "aea3358c-ff41-4490-9e6d-c7bf7b3de13f" ], "package_ndc": [ "0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62" ], "unii": [ "760I9WM792" ] }, "update_date": "11/03/2025", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 50 mg (NDC 0002-4312-62)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued" }, { "discontinued_date": "06/01/2026", "update_type": "New", "initial_posting_date": "06/01/2026", "package_ndc": "0009-0902-18", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA050441" ], "brand_name": [ "CLEOCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0902", "0009-0870", "0009-0775", "0009-0728", "0009-3124", "0009-3447", "0009-3381", "0009-3375", "0009-3382", "0009-6582" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "205964", "309335", "309336", "309339", "685574", "685576", "685578", "706461", "1737244", "1737245", "1737578", "1737579", "1737581", "1737582" ], "spl_id": [ "fa11e62e-4625-4e9c-8676-f318b1cb890f" ], "spl_set_id": [ "05a75685-0af5-407c-ac57-e380c882b49d" ], "package_ndc": [ "0009-0870-21", "0009-0870-26", "0009-0775-20", "0009-0775-26", "0009-0902-11", "0009-0902-18", "0009-0728-05", "0009-0728-09", "0009-3124-01", "0009-3124-03", "0009-3447-01", "0009-3447-03", "0009-3381-01", "0009-3381-02", "0009-3375-01", "0009-3375-02", "0009-3382-01", "0009-3382-02", "0009-6582-02", "0009-6582-01" ], "unii": [ "EH6D7113I8" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial (NDC 0009-0902-18)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-485-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA076803" ], "brand_name": [ "QUINAPRIL" ], "generic_name": [ "QUINAPRIL" ], "manufacturer_name": [ "Chartwell RX, LLC" ], "product_ndc": [ "62135-485", "62135-484", "62135-486", "62135-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE" ], "rxcui": [ "312748", "312749", "312750", "314203" ], "spl_id": [ "09cd5cb9-4fdf-f133-e063-6294a90af691" ], "spl_set_id": [ "dbc43dbd-94aa-40e2-a9ea-766110cc8687" ], "package_ndc": [ "62135-484-60", "62135-485-90", "62135-486-90", "62135-487-90" ], "unii": [ "33067B3N2M" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 10 mg (NDC 62135-485-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-486-17", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-486", "63323-492", "63323-491", "63323-495", "63323-485", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428", "0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17", "4dd52202-8eef-4136-92dd-ada573b7cf74" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31", "63323-492-41", "63323-492-16", "63323-492-43", "63323-492-36", "63323-492-45", "63323-492-26", "63323-485-41", "63323-485-26", "63323-486-41", "63323-486-26", "63323-482-41", "63323-482-26", "63323-495-41", "63323-495-26" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0990-7938-19", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Unavailable", "related_info": "Product discontinued. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA018080" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "ICU Medical, Inc." ], "product_ndc": [ "0990-7938" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477" ], "spl_id": [ "19e8876b-0d2f-4524-85c9-9c8d682ab2c8" ], "spl_set_id": [ "cb578dba-094c-4787-951d-763d12fd06e1" ], "package_ndc": [ "0990-7938-19" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7938-19)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/26/2024", "package_ndc": "70726-0304-1", "generic_name": "Riluzole Oral Suspension", "related_info_link": "https://www.fda.gov/media/185611/download?attachment", "contact_info": "610-937-6172", "availability": "Available", "openfda": { "brand_name": [ "TEGLUTIK" ], "generic_name": [ "RILUZOLE" ], "manufacturer_name": [ "EDW PHARMA, INC" ], "product_ndc": [ "70726-0304" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RILUZOLE" ], "rxcui": [ "2058147", "2675565" ], "spl_id": [ "4746bd79-5116-423c-e063-6394a90a17e1" ], "spl_set_id": [ "0f2b5cfc-a23d-699a-e063-6394a90a67d1" ], "package_ndc": [ "70726-0304-1" ], "nui": [ "N0000175740", "M0483511" ], "pharm_class_epc": [ "Benzothiazole [EPC]" ], "pharm_class_cs": [ "Benzothiazoles [CS]" ], "unii": [ "7LJ087RS6F" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Oral Suspension", "presentation": "Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0304-1)", "company_name": "EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4276-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA088299" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4276", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4275" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763" ], "spl_id": [ "05d1a200-9d75-4e48-b14a-5069d4ab816f" ], "spl_set_id": [ "3b2dd84e-cee8-4e58-d494-395a65a353a0" ], "package_ndc": [ "0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 500 mg/50 mL (1%; 10 mg/mL) (NDC 0409-4276-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/25/2017", "package_ndc": "0338-0409-03", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA018461" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE AND DEXTROSE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0409", "0338-0411" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1737723", "1737742", "1737744" ], "spl_id": [ "9e9121a0-25dd-46ba-a2b7-6f71fc3ff9cd" ], "spl_set_id": [ "f21512ea-c7c3-4766-b976-b2c0b5616bf0" ], "package_ndc": [ "0338-0409-03", "0338-0409-02", "0338-0411-02" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Dextrose, Injection, 4 mg/1 mL (NDC 0338-0409-03)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-154-30", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": { "application_number": [ "ANDA075468" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Advagen Pharma Ltd" ], "product_ndc": [ "72888-154", "72888-497", "72888-152", "72888-153" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529", "204892" ], "spl_id": [ "5510f17b-a980-f412-e063-6394a90ae1c4" ], "spl_set_id": [ "30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec" ], "package_ndc": [ "72888-497-01", "72888-497-02", "72888-497-03", "72888-497-04", "72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 72888-154-30)", "company_name": "Rubicon Research Private Limited", "status": "Current" }, { "discontinued_date": "03/19/2026", "update_type": "New", "initial_posting_date": "03/19/2026", "package_ndc": "64764-805-10", "generic_name": "Ramelteon Tablet", "contact_info": "877-825-3327", "related_info": "Product is expected to be available through February 2027.", "openfda": { "application_number": [ "NDA021782" ], "brand_name": [ "ROZEREM" ], "generic_name": [ "RAMELTEON" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "64764-805" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RAMELTEON" ], "rxcui": [ "577348", "603162" ], "spl_id": [ "2021e7fb-108a-4783-9a37-8bc05bf28b28" ], "spl_set_id": [ "9de82310-70e8-47b9-b1fc-6c6848b99455" ], "package_ndc": [ "64764-805-30", "64764-805-10", "64764-805-22" ], "nui": [ "N0000175743", "N0000000250" ], "pharm_class_epc": [ "Melatonin Receptor Agonist [EPC]" ], "pharm_class_moa": [ "Melatonin Receptor Agonists [MoA]" ], "unii": [ "901AS54I69" ] }, "update_date": "03/19/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Rozerem, Tablet, 8 mg (NDC 64764-805-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-165-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA203082" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-165", "55150-161", "55150-162", "55150-163", "55150-164" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1737562", "1737566", "1737568", "1737757", "1737761" ], "spl_id": [ "bab2ea79-0aed-4f48-8b4e-f864f8b82fb8", "d95a0a28-804f-44d2-aa31-01df376a3154" ], "spl_set_id": [ "9916b09d-a116-469d-92d5-60e50ea9782b", "89701fac-7536-4f16-87fb-f4cc121e74ee" ], "package_ndc": [ "55150-161-09", "55150-162-09", "55150-163-00", "55150-163-24", "55150-164-09", "55150-165-09", "55150-161-02", "55150-162-05", "55150-163-30", "55150-163-25", "55150-164-02", "55150-165-05" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 55150-165-05)", "company_name": "Eugia US LLC", "status": "Current" }, { "discontinued_date": "08/27/2025", "update_type": "New", "initial_posting_date": "08/27/2025", "package_ndc": "0409-2344-88", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA074086" ], "brand_name": [ "DOBUTAMINE" ], "generic_name": [ "DOBUTAMINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-2344" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOBUTAMINE HYDROCHLORIDE" ], "rxcui": [ "1812168" ], "spl_id": [ "e71e9520-871b-479d-9652-1857fceca863", "f6a67673-07a7-44e4-b05c-1f7e63326f79" ], "spl_set_id": [ "dc537761-d5f4-488d-24ab-b2bcd2b17b7a", "89becb0c-da60-4f43-0a98-29ff7a9eca58" ], "package_ndc": [ "0409-2344-01", "0409-2344-62", "0409-2344-02", "0409-2344-68", "0409-2344-88" ], "unii": [ "0WR771DJXV" ] }, "update_date": "08/27/2025", "therapeutic_category": [ "Cardiovascular", "Pediatric", "Renal" ], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride, Injection, 12.5 mg/1 mL (NDC 0409-2344-88)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "55150-201-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA205612" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-201", "55150-195", "55150-196", "55150-197", "55150-198", "55150-199", "55150-200" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483" ], "spl_id": [ "1e5f1368-058a-492c-b4b7-d9329a7745e2" ], "spl_set_id": [ "3763b7b6-da49-4658-b93d-28f5da24d09e" ], "package_ndc": [ "55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20" ], "unii": [ "V910P86109" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-201-20)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-048-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA214484" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "57664-048", "57664-047", "57664-046", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "560b4c9e-9cce-4717-e063-6294a90a58c9" ], "spl_set_id": [ "da3148af-f9b6-4725-adae-3595b4c7dc4b" ], "package_ndc": [ "57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 57664-048-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "05/14/2026", "update_type": "New", "initial_posting_date": "05/14/2026", "package_ndc": "0480-7250-46", "generic_name": "Liraglutide Injection", "contact_info": "888-838-2872", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA214568" ], "brand_name": [ "LIRAGLUTIDE" ], "generic_name": [ "LIRAGLUTIDE" ], "manufacturer_name": [ "Teva Pharmaceuticals, Inc." ], "product_ndc": [ "0480-7250" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "LIRAGLUTIDE" ], "rxcui": [ "2735350" ], "spl_id": [ "4df44cd9-cb11-46b6-ba6c-88ff963ec414" ], "spl_set_id": [ "625ac780-70a9-41e4-a892-bcba0f803f1c" ], "package_ndc": [ "0480-7250-46" ], "nui": [ "N0000178480", "M0160181", "N0000020058" ], "pharm_class_epc": [ "GLP-1 Receptor Agonist [EPC]" ], "pharm_class_cs": [ "Glucagon-Like Peptide 1 [CS]" ], "pharm_class_moa": [ "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]" ], "unii": [ "839I73S42A" ] }, "update_date": "05/14/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0480-7250-46)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "10122-100-10", "generic_name": "Deferiprone Tablet", "contact_info": "888-466-6505", "related_info": "Discontinuation of the manufacture of the drug.", "update_date": "11/07/2025", "therapeutic_category": [ "Hematology" ], "dosage_form": "Tablet", "presentation": "Ferriprox, Tablet, 500 mg (NDC 10122-100-10)", "company_name": "Chiesi USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "0781-3220-92", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-525-8747", "availability": "Available", "openfda": { "application_number": [ "ANDA079195" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-3220" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "eaf32464-7950-434a-e053-2a95a90aa2dc" ], "spl_set_id": [ "cb28d869-6510-4402-9462-f6bb25fa0fa8" ], "package_ndc": [ "0781-3220-70", "0781-3220-92", "0781-3220-75", "0781-3220-95" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0781-3220-92)", "company_name": "Sandoz Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "47781-565-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": { "application_number": [ "ANDA214547" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Alvogen Inc." ], "product_ndc": [ "47781-565", "47781-562", "47781-563", "47781-564", "47781-566", "47781-567", "47781-568" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "db02ec6b-f17f-ab22-b671-e1ddb90e017c" ], "spl_set_id": [ "7f2dd6ee-3363-c87c-9693-ed838942556c" ], "package_ndc": [ "47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 47781-565-01)", "company_name": "Alvogen", "status": "Current" }, { "discontinued_date": "06/15/2026", "update_type": "New", "initial_posting_date": "06/15/2026", "package_ndc": "69238-1248-3", "generic_name": "Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release", "contact_info": "866-525-7270", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA208328" ], "brand_name": [ "MEMANTINE AND DONEPEZIL HYDROCHLORIDES EXTENDED-RELEASE" ], "generic_name": [ "MEMANTINE AND DONEPEZIL" ], "manufacturer_name": [ "Amneal Pharmaceuticals NY LLC" ], "product_ndc": [ "69238-1248", "69238-1247", "69238-1552", "69238-1553" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "MEMANTINE HYDROCHLORIDE", "DONEPEZIL HYDROCHLORIDE" ], "rxcui": [ "1599803", "1599805", "1805420", "1805425" ], "spl_id": [ "acd577e1-312c-4d5a-85b5-bc50ef9de545" ], "spl_set_id": [ "2335950c-be3b-4248-ad04-e9763aee47d2" ], "package_ndc": [ "69238-1248-3", "69238-1248-9", "69238-1247-3", "69238-1247-9", "69238-1552-3", "69238-1552-9", "69238-1553-3", "69238-1553-9" ], "unii": [ "3O2T2PJ89D", "JY0WD0UA60" ] }, "update_date": "06/15/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Capsule, Extended Release", "presentation": "Donepezil Hydrochloride; Memantine Hydrochloride, Capsule, Extended Release, 10 mg; 14 mg (NDC 69238-1248-3)", "company_name": "Amneal Pharmaceuticals", "status": "To Be Discontinued" }, { "discontinued_date": "01/13/2026", "update_type": "New", "initial_posting_date": "01/13/2026", "package_ndc": "61314-454-36", "generic_name": "Adalimumab-adaz Injection", "contact_info": "800-525-8747", "related_info": "Equivalent Sandoz format is available.", "update_date": "01/13/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-36)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-602-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": { "application_number": [ "ANDA216266" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE CAPSULES" ], "manufacturer_name": [ "Solco Healthcare US,LLC" ], "product_ndc": [ "43547-602", "43547-603", "43547-604", "43547-605", "43547-606", "43547-607", "43547-608" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "d6435613-e052-4b4f-8bf7-4acb7458d8df" ], "spl_set_id": [ "68b10d9f-ca3e-493d-a309-45f1d7e08061" ], "package_ndc": [ "43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/29/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 43547-602-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-084-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": { "application_number": [ "ANDA214134" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "57664-084", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-085", "57664-086", "57664-087", "57664-088" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "560b4c9e-9cce-4717-e063-6294a90a58c9" ], "spl_set_id": [ "da3148af-f9b6-4725-adae-3595b4c7dc4b" ], "package_ndc": [ "57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 20 mg (NDC 57664-084-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "63323-824-76", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA209448" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-824" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481" ], "spl_id": [ "0591ab74-99a6-40ee-af96-80bc2ef423dc" ], "spl_set_id": [ "3b8f2692-4371-4f1a-95af-b41842131fdd" ], "package_ndc": [ "63323-824-24", "63323-824-74", "63323-824-25", "63323-824-75", "63323-824-26", "63323-824-76" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-76)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "05/05/2026", "update_type": "New", "initial_posting_date": "05/05/2026", "package_ndc": "71288-723-52", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-824-8426", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA216039" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Meitheal Pharmaceuticals Inc" ], "product_ndc": [ "71288-723", "71288-726" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404" ], "spl_id": [ "0949c302-51ce-4fc9-8b99-1df94e693718" ], "spl_set_id": [ "fe340f98-a0f3-446e-b281-47fd91c1e537" ], "package_ndc": [ "71288-723-52", "71288-726-52" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "05/05/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "0338-1055-48", "generic_name": "Metronidazole Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA018657" ], "brand_name": [ "METRONIDAZOLE" ], "generic_name": [ "METRONIDAZOLE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-1055" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "METRONIDAZOLE" ], "rxcui": [ "311683" ], "spl_id": [ "7841a410-43a9-4c79-acee-b831b42da8a8" ], "spl_set_id": [ "d2112f37-5080-4a19-bcc3-6386b49abe1d" ], "package_ndc": [ "0338-1055-48" ], "nui": [ "N0000175435", "M0014907" ], "pharm_class_epc": [ "Nitroimidazole Antimicrobial [EPC]" ], "pharm_class_cs": [ "Nitroimidazoles [CS]" ], "unii": [ "140QMO216E" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Flagyl I.v. Rtu In Plastic Container, Injection, 500 mg/100 mL (NDC 0338-1055-48)", "company_name": "Baxter Healthcare", "status": "Current" }, { "discontinued_date": "07/27/2026", "update_type": "New", "initial_posting_date": "07/27/2026", "package_ndc": "0173-0715-22", "generic_name": "Fluticasone Propionate and Salmeterol Xinafoate Aerosol, Metered", "contact_info": "888-825-5249", "related_info": "The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product will still be available.", "openfda": { "application_number": [ "NDA021254" ], "brand_name": [ "ADVAIR HFA" ], "generic_name": [ "FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE" ], "manufacturer_name": [ "GlaxoSmithKline LLC" ], "product_ndc": [ "0173-0715", "0173-0716", "0173-0717" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RESPIRATORY (INHALATION)" ], "substance_name": [ "FLUTICASONE PROPIONATE", "SALMETEROL XINAFOATE" ], "rxcui": [ "896231", "896235", "896236", "896237", "896239", "896243", "896244", "896245", "896267", "896271", "896272", "896273" ], "spl_id": [ "bea52e57-aa75-4dce-8cfb-a163bbc22be2" ], "spl_set_id": [ "dfaca6f9-3277-47b2-319d-1377917cb54c" ], "package_ndc": [ "0173-0715-20", "0173-0715-22", "0173-0716-20", "0173-0716-22", "0173-0717-20", "0173-0717-22" ], "unii": [ "O2GMZ0LF5W", "6EW8Q962A5" ] }, "update_date": "07/27/2026", "therapeutic_category": [ "Pulmonary/Allergy" ], "presentation": "Advair HFA, Aerosol, Metered, 45 ug; 21 ug (NDC 0173-0715-22)", "company_name": "GlaxoSmithKline", "status": "To Be Discontinued" }, { "update_type": "New", "initial_posting_date": "02/20/2018", "package_ndc": "31722-276-34", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "732-529-0430, customerservice@camberpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA217821" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Camber Pharmaceuticals, Inc." ], "product_ndc": [ "31722-276", "31722-275", "31722-277" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1724786", "1724787", "1724880", "1724884", "1725078", "1725082" ], "spl_id": [ "4ea16f8e-77de-3ba7-e063-6394a90a5667" ], "spl_set_id": [ "0e552e3a-cf52-4d74-9381-6cc1b29b4c90" ], "package_ndc": [ "31722-275-10", "31722-275-31", "31722-275-32", "31722-275-30", "31722-275-33", "31722-275-34", "31722-275-35", "31722-276-10", "31722-276-31", "31722-276-32", "31722-276-30", "31722-276-33", "31722-276-34", "31722-277-10", "31722-277-31", "31722-277-32", "31722-277-30", "31722-277-33", "31722-277-34" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "07/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-34)", "company_name": "Aspiro Pharma Limited", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "50458-588-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET", "availability": "Available", "openfda": { "application_number": [ "NDA021121" ], "brand_name": [ "CONCERTA" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Janssen Pharmaceuticals, Inc." ], "product_ndc": [ "50458-588", "50458-585", "50458-586", "50458-587" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091157", "1091170", "1091172", "1091185", "1091187", "1091210", "1091212" ], "spl_id": [ "64d7c1e1-e7ed-4d74-a44d-13b4da64af9a" ], "spl_set_id": [ "1a88218c-5b18-4220-8f56-526de1a276cd" ], "package_ndc": [ "50458-585-01", "50458-588-01", "50458-586-01", "50458-587-01" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/19/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01)", "company_name": "Janssen Pharmaceuticals", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0371-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": { "application_number": [ "ANDA202827" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0054-0371", "0054-0660", "0054-0370", "0054-0372", "0054-0373", "0054-0374", "0054-0375" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "ccd9e87c-bd03-4fe0-8129-41c1ced49c8d" ], "spl_set_id": [ "6740a621-9bec-4178-a4fc-a3fc89f34e0a" ], "package_ndc": [ "0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0054-0371-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1660-50", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA021038" ], "brand_name": [ "PRECEDEX" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1660", "0409-1638", "0409-1434", "0409-1596", "0409-7838", "0409-7853", "0409-7875" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892" ], "spl_id": [ "3c5274fd-6597-4b88-babc-92e4e16c6329" ], "spl_set_id": [ "548a88c0-afda-427e-75ac-5af0cfa2224c" ], "package_ndc": [ "0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1660-50)", "company_name": "Pfizer Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-5534-14", "generic_name": "Sodium Bicarbonate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 5 mEq/10 mL (4.2%, 0.5 mEq/mL) Syringes (NDC 0409-5534-14)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-015-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 15 mg/.4 mL (NDC 82497-015-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-483-27", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-483", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-482", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "06/04/2026", "update_type": "New", "initial_posting_date": "06/04/2026", "package_ndc": "0169-4307-30", "generic_name": "Semaglutide Tablet", "contact_info": "833-493-4689", "related_info": "Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.", "update_date": "06/04/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Tablet", "presentation": "Rybelsus, Tablet, 7 mg (NDC 0169-4307-30)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-086-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": { "application_number": [ "ANDA214134" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "57664-086", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-087", "57664-088" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "560b4c9e-9cce-4717-e063-6294a90a58c9" ], "spl_set_id": [ "da3148af-f9b6-4725-adae-3595b4c7dc4b" ], "package_ndc": [ "57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 57664-086-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-025-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Available", "openfda": { "application_number": [ "ANDA202830" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE" ], "manufacturer_name": [ "Amneal Pharmaceuticals LLC" ], "product_ndc": [ "65162-025", "65162-023", "65162-024", "65162-026", "65162-027", "65162-028" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850" ], "spl_id": [ "ba9f3370-3096-4d8c-9571-e28faf54291f" ], "spl_set_id": [ "c11cb3b6-3dff-477b-a249-b4c3118edc5f" ], "package_ndc": [ "65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 65162-025-09)", "company_name": "Amneal Pharmaceuticals", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "43598-975-58", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "Distributed by DRL", "availability": "Available", "related_info": "Distributed by DRL", "openfda": { "application_number": [ "ANDA209307" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Dr.Reddy's Laboratories Inc" ], "product_ndc": [ "43598-975", "43598-976" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909" ], "spl_id": [ "5785a11f-7784-4ae0-8029-f50b782eaf4a" ], "spl_set_id": [ "d174c19d-56f1-4ef4-087c-23c26db8e40b" ], "package_ndc": [ "43598-976-11", "43598-976-58", "43598-975-11", "43598-975-58" ], "unii": [ "1018WH7F9I" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-975-58)", "company_name": "Gland Pharma Limited", "status": "Current" }, { "discontinued_date": "12/29/2025", "update_type": "New", "initial_posting_date": "12/29/2025", "package_ndc": "69238-2391-1", "generic_name": "Sodium Oxybate Solution", "contact_info": "800-525-7270", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/29/2025", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Solution", "presentation": "Sodium Oxybate, Solution, .5 g/1 mL (NDC 69238-2391-1)", "company_name": "Amneal Pharmaceuticals", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "57664-606-88", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "Currently not marketed", "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "10147-0570-1", "generic_name": "Etravirine Tablet", "contact_info": "800-526-7736", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA022187" ], "brand_name": [ "ETRAVIRINE" ], "generic_name": [ "ETRAVIRINE" ], "manufacturer_name": [ "Patriot Pharmaceuticals" ], "product_ndc": [ "10147-0570", "10147-0571" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ETRAVIRINE" ], "rxcui": [ "754761", "1052658" ], "spl_id": [ "31cddc7a-0154-c49a-e063-6394a90a1a49" ], "spl_set_id": [ "50ca19cb-0f43-4d7b-8c9e-8b3aaded0546" ], "package_ndc": [ "10147-0570-1", "10147-0571-1" ], "nui": [ "N0000175463", "N0000175460", "N0000009948", "N0000190118", "N0000185504", "N0000182140", "N0000185503" ], "pharm_class_epc": [ "Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]" ], "pharm_class_moa": [ "Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Cytochrome P450 3A Inducers [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]" ], "unii": [ "0C50HW4FO1" ] }, "update_date": "04/28/2026", "therapeutic_category": [ "Antiviral" ], "dosage_form": "Tablet", "presentation": "Etravirine, Tablet, 100 mg (NDC 10147-0570-1)", "company_name": "Janssen Research and Development", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "63323-178-76", "generic_name": "Sterile Water Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA209689" ], "brand_name": [ "STERILE WATER" ], "generic_name": [ "WATER" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-178" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "WATER" ], "spl_id": [ "d40f0ff2-4abf-4030-b4e1-2b85ad7448a0" ], "spl_set_id": [ "b45e9f1d-9c48-4b46-8541-d846b89540df" ], "package_ndc": [ "63323-178-76" ], "unii": [ "059QF0KO0R" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1000 mL/1000 mL (NDC 63323-178-76)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6044-25", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Lots are being manufactured to meet demand", "openfda": { "application_number": [ "NDA018140" ], "brand_name": [ "LORAZEPAM" ], "generic_name": [ "LORAZEPAM" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6044", "0641-6046", "0641-6045", "0641-6047" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "LORAZEPAM" ], "rxcui": [ "238100", "238101", "1665188", "1665326" ], "spl_id": [ "7c73dbc6-2623-4443-9b05-97dec7a0be2e" ], "spl_set_id": [ "e9b54e42-04cf-4c62-90e1-36f7b31a4e81" ], "package_ndc": [ "0641-6044-01", "0641-6044-25", "0641-6046-01", "0641-6046-10", "0641-6045-01", "0641-6045-25", "0641-6047-01", "0641-6047-10" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "O26FZP769L" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0660-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": { "application_number": [ "ANDA202827" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0054-0660", "0054-0370", "0054-0371", "0054-0372", "0054-0373", "0054-0374", "0054-0375" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "ccd9e87c-bd03-4fe0-8129-41c1ced49c8d" ], "spl_set_id": [ "6740a621-9bec-4178-a4fc-a3fc89f34e0a" ], "package_ndc": [ "0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25" ], "unii": [ "SJT761GEGS" ] }, "update_date": "05/12/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0054-0660-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1174-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA021038" ], "brand_name": [ "PRECEDEX" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1174", "0409-1454", "0409-3301", "0409-2815" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892" ], "spl_id": [ "e1705533-5a85-441f-a95b-3cb88c47e482" ], "spl_set_id": [ "4419162d-81d4-49bd-96de-1729440bdb74" ], "package_ndc": [ "0409-1454-01", "0409-1454-20", "0409-3301-01", "0409-3301-10", "0409-1174-01", "0409-1174-10", "0409-2815-01" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1174-10)", "company_name": "Pfizer Inc.", "status": "Current" }, { "discontinued_date": "07/23/2026", "update_type": "New", "initial_posting_date": "07/23/2026", "package_ndc": "63459-390-08", "generic_name": "Bendamustine Hydrochloride Injection, Solution", "contact_info": "(610) 344-0200", "related_info": "A business decision has been made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA022249" ], "brand_name": [ "TREANDA" ], "generic_name": [ "BENDAMUSTINE HYDROCHLORIDE" ], "manufacturer_name": [ "Cephalon, LLC" ], "product_ndc": [ "63459-390", "63459-395", "63459-396", "63459-391" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "BENDAMUSTINE HYDROCHLORIDE" ], "rxcui": [ "1805001", "1805004", "1805007", "1805009", "1805011", "1805012", "1805015", "1805016" ], "spl_id": [ "77ae475d-2d59-4fe2-8de7-833b6fc9d51a" ], "spl_set_id": [ "39d53698-57fa-7c99-fc5b-f52a55684826" ], "package_ndc": [ "63459-395-02", "63459-396-02", "63459-390-08", "63459-391-20" ], "unii": [ "981Y8SX18M" ] }, "update_date": "07/23/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Treanda, Injection, Solution, 25 mg/5 mL, 1 vial, Single-Dose in 1 carton (NDC 63459-390-08)", "company_name": "Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceutical Industries, Ltd.)", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0274-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA011757" ], "brand_name": [ "DEPO-MEDROL" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0274", "0009-0280", "0009-0306" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1358510", "1358512", "1358610", "1358612", "1358617", "1358619" ], "spl_id": [ "267dd735-f800-4735-ba1c-d39d00f0cee5" ], "spl_set_id": [ "823b0010-2b57-4e76-b5ac-4a8c2963438f" ], "package_ndc": [ "0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 20 mg/1 mL (NDC 0009-0274-01)", "company_name": "Pfizer Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "63323-808-11", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA212086" ], "brand_name": [ "FENTANYL CITRATE" ], "generic_name": [ "FENTANYL CITRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-808", "63323-810" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FENTANYL CITRATE" ], "rxcui": [ "2474267", "2474269" ], "spl_id": [ "a47a3a31-e293-49d5-b6bc-950303525a64" ], "spl_set_id": [ "0c10e465-4117-48ba-a454-23ccb7a3fcc7" ], "package_ndc": [ "63323-808-01", "63323-808-11", "63323-810-00", "63323-810-20" ], "unii": [ "MUN5LYG46H" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 63323-808-11)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "04/15/2026", "update_type": "New", "initial_posting_date": "04/15/2026", "package_ndc": "0093-5030-56", "generic_name": "Tiagabine Hydrochloride Tablet", "contact_info": "888-838-2872", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA020646" ], "brand_name": [ "TIAGABINE HYDROCHLORIDE" ], "generic_name": [ "TIAGABINE HYDROCHLORIDE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0093-5030", "0093-5031", "0093-8072", "0093-8076" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "TIAGABINE HYDROCHLORIDE" ], "rxcui": [ "1299903", "1299909", "1299911", "1299917" ], "spl_id": [ "2a8d7987-54ae-45d7-8224-361dac37e0a4" ], "spl_set_id": [ "953ef3cc-e3cb-480f-b9ea-256520fd62b8" ], "package_ndc": [ "0093-5030-56", "0093-5031-56", "0093-8072-56", "0093-8076-56" ], "unii": [ "DQH6T6D8OY" ] }, "update_date": "04/15/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Tiagabine Hydrochloride, Tablet, 2mg 30 count (NDC 0093-5030-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1418-01", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Demerol, Injection, 50 mg/1 mL (NDC 0409-1418-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-709-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": { "application_number": [ "ANDA205327" ], "brand_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Trigen Laboratories, LLC" ], "product_ndc": [ "13811-709", "13811-706", "13811-707", "13811-708", "13811-710" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210", "1995461" ], "spl_id": [ "0944cf70-d59a-483b-9698-e96ef955a65a" ], "spl_set_id": [ "c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f" ], "package_ndc": [ "13811-709-10", "13811-706-10", "13811-707-10", "13811-708-10", "13811-710-10", "13811-710-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/05/2022", "package_ndc": "65219-445-10", "generic_name": "Etomidate Injection", "contact_info": "800-551-7176", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Fresenius Kabi", "openfda": { "application_number": [ "ANDA215028" ], "brand_name": [ "ETOMIDATE" ], "generic_name": [ "ETOMIDATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-445", "65219-447" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008" ], "spl_id": [ "446487f1-002e-41d3-846a-67570e797171", "30488a7e-ea9e-4a27-95a9-a07149c50282" ], "spl_set_id": [ "f38fad46-f2dd-4692-a2a9-a13d0a717bf8", "d07efb9e-5264-461d-96d8-e11fa71c5751" ], "package_ndc": [ "65219-445-12", "65219-445-22", "65219-445-01", "65219-445-10", "65219-447-02", "65219-447-20" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "06/16/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2mg/1 mL (NDC 65219-445-10)", "company_name": "Caplin Steriles, Ltd.", "status": "Current" }, { "discontinued_date": "03/26/2026", "update_type": "New", "initial_posting_date": "03/26/2026", "package_ndc": "53746-468-19", "generic_name": "Clindamycin Palmitate Hydrochloride Injection", "contact_info": "866-525-7270", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA203513" ], "brand_name": [ "CLINDAMYCIN PALMITATE HYDROCHLORIDE (PEDIATRIC)" ], "generic_name": [ "CLINDAMYCIN PALMITATE HYDROCHLORIDE" ], "manufacturer_name": [ "Amneal Pharmaceuticals of New York LLC" ], "product_ndc": [ "53746-468" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLINDAMYCIN PALMITATE HYDROCHLORIDE" ], "rxcui": [ "562266" ], "spl_id": [ "bacc9e9f-6a9f-4a68-b2ec-131ed86205ec" ], "spl_set_id": [ "faf67eb8-1fd7-4b2c-a55b-24ba664c0dce" ], "package_ndc": [ "53746-468-19" ], "unii": [ "VN9A8JM7M7" ] }, "update_date": "03/26/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Clindamycin Palmitate Hydrochloride, Injection, 75 mg/5 mL (NDC 53746-468-19)", "company_name": "Amneal Pharmaceuticals", "status": "To Be Discontinued" }, { "discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2868-92", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA075757" ], "brand_name": [ "OMEPRAZOLE" ], "generic_name": [ "OMEPRAZOLE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-2868", "0781-2859" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OMEPRAZOLE" ], "rxcui": [ "198051", "199119" ], "spl_id": [ "b182f298-e28f-434b-b6f1-ecfac29d495e" ], "spl_set_id": [ "516170d4-4913-4577-a2d2-f5c52d1e79c6" ], "package_ndc": [ "0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31" ], "nui": [ "N0000175525", "N0000000147", "N0000182140" ], "pharm_class_epc": [ "Proton Pump Inhibitor [EPC]" ], "pharm_class_moa": [ "Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]" ], "unii": [ "KG60484QX9" ] }, "update_date": "10/09/2025", "therapeutic_category": [ "Gastroenterology" ], "presentation": "Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-92)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-561-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA201791" ], "brand_name": [ "LAMOTRIGINE EXTENDED RELEASE" ], "generic_name": [ "LAMOTRIGINE EXTENDED RELEASE" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "49884-561", "49884-562", "49884-563", "49884-564", "49884-604", "49884-605" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LAMOTRIGINE" ], "rxcui": [ "850087", "850091", "900156", "900164", "1098608", "1146690" ], "spl_id": [ "9c5e0c2a-800e-47e9-a26b-582b98a05957" ], "spl_set_id": [ "fb59c76a-9b6f-40ea-ac3a-58c3195c4377" ], "package_ndc": [ "49884-561-11", "49884-561-01", "49884-561-05", "49884-562-11", "49884-562-01", "49884-562-05", "49884-563-11", "49884-563-01", "49884-563-05", "49884-564-11", "49884-564-01", "49884-564-05", "49884-604-11", "49884-604-01", "49884-604-05", "49884-605-11", "49884-605-01", "49884-605-05" ], "nui": [ "N0000175753", "N0000008486", "N0000175751", "N0000187061", "N0000000191" ], "pharm_class_epc": [ "Anti-epileptic Agent [EPC]", "Mood Stabilizer [EPC]" ], "pharm_class_pe": [ "Decreased Central Nervous System Disorganized Electrical Activity [PE]" ], "pharm_class_moa": [ "Organic Cation Transporter 2 Inhibitors [MoA]", "Dihydrofolate Reductase Inhibitors [MoA]" ], "unii": [ "U3H27498KS" ] }, "update_date": "04/29/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 25 mg (NDC 49884-561-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-360-18", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: February 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA076517" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "61703-360", "61703-150", "61703-262", "61703-600" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "5aa72c15-8033-4559-b257-373371b18958" ], "spl_set_id": [ "47677091-fd20-49af-933c-c9dd2be21de9" ], "package_ndc": [ "61703-360-18", "61703-150-05", "61703-262-05", "61703-600-05" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) (NDC 61703-360-18)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-353-05", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-05)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6001-25", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Lots are being manufactured to meet demand", "openfda": { "application_number": [ "NDA018140" ], "brand_name": [ "ATIVAN" ], "generic_name": [ "LORAZEPAM" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6001", "0641-6003", "0641-6002", "0641-6000" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "LORAZEPAM" ], "rxcui": [ "206819", "206820", "238100", "238101", "1665188", "1665190", "1665326", "1665327" ], "spl_id": [ "209b0091-c890-4f69-a693-d0594c2606fe" ], "spl_set_id": [ "5fc0e987-61c9-40c4-b0d5-fcea07c8733e" ], "package_ndc": [ "0641-6003-01", "0641-6003-25", "0641-6002-01", "0641-6002-10", "0641-6001-01", "0641-6001-25", "0641-6000-01", "0641-6000-10" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "O26FZP769L" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Injection", "presentation": "Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "42806-343-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(718) 276-8600 ext. 3", "availability": "Available", "openfda": { "application_number": [ "ANDA040444" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Epic Pharma, LLC" ], "product_ndc": [ "42806-343", "42806-339", "42806-341", "42806-344", "42806-345" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961" ], "spl_id": [ "f11301e2-3b5d-468d-b44c-45839e7e5dfb" ], "spl_set_id": [ "1757e132-061d-4773-89ed-fdc77f69008f" ], "package_ndc": [ "42806-339-01", "42806-341-01", "42806-343-01", "42806-344-01", "42806-345-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 42806-343-01)", "company_name": "Epic Pharma, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1746-10", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA016964" ], "brand_name": [ "MARCAINE WITH EPINEPHRINE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1746", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1749", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614" ], "spl_id": [ "7040888c-2cde-4408-af99-d249985f8444" ], "spl_set_id": [ "67578b56-7540-487e-1fba-481255620e78" ], "package_ndc": [ "0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "63323-412-02", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA075154" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-412", "63323-411" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "311700", "311702" ], "spl_id": [ "9814447b-a93e-42ad-b57e-5db0a5b7f552" ], "spl_set_id": [ "a91ce254-14a3-4cbf-8ab8-5da252aa3fdc" ], "package_ndc": [ "63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0185-2098-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-525-8747", "availability": "Available", "openfda": { "application_number": [ "ANDA040439" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0185-2098", "0185-0831", "0185-0842", "0185-0853", "0185-0864", "0185-2099" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577961" ], "spl_id": [ "9a21fb59-a99c-4c63-91e8-4b5d72fbd9cd" ], "spl_set_id": [ "288dafc4-fe6e-4891-832f-511022c87445" ], "package_ndc": [ "0185-0831-01", "0185-0842-01", "0185-0853-01", "0185-0864-01", "0185-2099-01", "0185-2098-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0185-2098-01)", "company_name": "Sandoz Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1160-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA070590" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1160", "0409-1159", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596" ], "spl_id": [ "6e442bfd-d3da-4913-8585-ce3485644364" ], "spl_set_id": [ "02a845c3-4521-4926-e397-25ab536e7cf6" ], "package_ndc": [ "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "discontinued_date": "12/08/2025", "update_type": "New", "initial_posting_date": "12/08/2025", "package_ndc": "0781-9412-92", "generic_name": "Ampicillin Sodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of private label only", "openfda": { "application_number": [ "ANDA062738" ], "brand_name": [ "AMPICILLIN" ], "generic_name": [ "AMPICILLIN SODIUM" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-9412", "0781-9413" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "AMPICILLIN SODIUM" ], "rxcui": [ "1721475", "1721476" ], "spl_id": [ "f1afd007-8e8c-40e2-b353-8def35a0ce8b" ], "spl_set_id": [ "f77db491-31c4-4a7c-a114-0f3244c97090" ], "package_ndc": [ "0781-9412-15", "0781-9412-92", "0781-9413-15", "0781-9413-92" ], "unii": [ "JFN36L5S8K" ] }, "update_date": "12/08/2025", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Ampicillin Sodium, Injection, 1 g (NDC 0781-9412-92)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "08/15/2023", "package_ndc": "64850-506-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": { "application_number": [ "ANDA211352" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Elite Laboratories, Inc." ], "product_ndc": [ "64850-506", "64850-500", "64850-501", "64850-502", "64850-503", "64850-504", "64850-505" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "a41cf8e5-cb1b-488c-96b3-3bef8283d6c4" ], "spl_set_id": [ "e677690f-790f-4626-ad78-097cdb6ea540" ], "package_ndc": [ "64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 64850-506-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current" }, { "discontinued_date": "08/13/2026", "update_type": "New", "initial_posting_date": "08/13/2026", "package_ndc": "0228-2551-06", "generic_name": "Diclofenac Sodium Tablet, Delayed Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA074514" ], "brand_name": [ "DICLOFENAC SODIUM" ], "generic_name": [ "DICLOFENAC SODIUM" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0228-2551", "0228-2550" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DICLOFENAC SODIUM" ], "rxcui": [ "855906", "855926" ], "spl_id": [ "a1fbc994-b8a6-4759-be76-1cfd98275ca6" ], "spl_set_id": [ "a57b897e-0cbe-4ac3-969f-b00357a0cfa8" ], "package_ndc": [ "0228-2550-06", "0228-2550-11", "0228-2550-96", "0228-2551-06", "0228-2551-11", "0228-2551-96" ], "unii": [ "QTG126297Q" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Musculoskeletal", "Rheumatology" ], "dosage_form": "Tablet", "presentation": "Diclofenac Sodium, Tablet, Delayed Release, 75 mg (NDC 0228-2551-06)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "10/24/2025", "update_type": "New", "initial_posting_date": "10/24/2025", "package_ndc": "67457-893-08", "generic_name": "Busulfan Injection", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug.", "update_date": "10/24/2025", "therapeutic_category": [ "Hematology" ], "dosage_form": "Injection", "presentation": "Busulfan, Injection, 6 mg/1 mL (NDC 67457-893-08)", "company_name": "Mylan Institutional, a Viatris Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1134-05", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1134-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "06/30/2026", "update_type": "New", "initial_posting_date": "06/30/2026", "package_ndc": "65219-084-15", "generic_name": "Gadoterate Meglumine Injection", "contact_info": "888-386-1800", "related_info": "Marketed by Fresenius Kabi, USA; Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA215304" ], "brand_name": [ "GADOTERATE MEGLUMINE" ], "generic_name": [ "GADOTERATE MEGLUMINE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-084", "65219-080", "65219-082", "65219-086" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GADOTERATE MEGLUMINE" ], "spl_id": [ "f05922b7-99d4-48c7-972a-7966bbbbc3b4" ], "spl_set_id": [ "e0655aac-9508-4141-94f5-fcca6af1c41d" ], "package_ndc": [ "65219-080-01", "65219-080-05", "65219-082-01", "65219-082-10", "65219-084-01", "65219-084-15", "65219-086-01", "65219-086-20" ], "unii": [ "L0ND3981AG" ] }, "update_date": "06/30/2026", "therapeutic_category": [ "Medical Imaging" ], "dosage_form": "Injection", "presentation": "Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-084-15)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "55150-167-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA203895" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-167", "55150-168", "55150-169", "55150-170", "55150-171", "55150-172", "55150-249", "55150-250" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082" ], "spl_id": [ "39649703-e633-4a20-ba71-0c04dbf8ff2a" ], "spl_set_id": [ "ffecf450-1f01-4721-8e10-251385852612" ], "package_ndc": [ "55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-167-10)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3475-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA011757" ], "brand_name": [ "DEPO-MEDROL" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-3475", "0009-3073" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1743779", "1743781", "1743855", "1743856" ], "spl_id": [ "742fcec7-8db3-4cc6-b276-42587a993810" ], "spl_set_id": [ "9a7b3837-e038-48bf-97e9-78ad463760dc" ], "package_ndc": [ "0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-01)", "company_name": "Pfizer Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-089-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": { "application_number": [ "NDA216117" ], "brand_name": [ "RELEXXII" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Vertical Pharmaceuticals, LLC" ], "product_ndc": [ "68025-089", "68025-088", "68025-095", "68025-096", "68025-097", "68025-084", "68025-098" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505" ], "spl_id": [ "86f477e9-07fc-466b-913e-1a4434c91df4" ], "spl_set_id": [ "22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d" ], "package_ndc": [ "68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1005-02", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA019615" ], "brand_name": [ "DOPAMINE HYDROCHLORIDE AND DEXTROSE" ], "generic_name": [ "DOPAMINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-1005", "0338-1007", "0338-1009" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOPAMINE HYDROCHLORIDE" ], "rxcui": [ "1292887", "1743869", "1743871", "1743877", "1743879" ], "spl_id": [ "edc9a091-4cb5-4ec7-b6f9-44d2d588bab9" ], "spl_set_id": [ "cb97d4a0-89ed-407c-a763-209386b6f75c" ], "package_ndc": [ "0338-1005-02", "0338-1005-03", "0338-1007-02", "0338-1007-03", "0338-1009-02" ], "unii": [ "7L3E358N9L" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-02)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/17/2015", "package_ndc": "0143-9933-25", "generic_name": "Cefotaxime Sodium Powder, for Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA065072" ], "brand_name": [ "CEFOTAXIME" ], "generic_name": [ "CEFOTAXIME" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9933", "0143-9931", "0143-9930" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CEFOTAXIME SODIUM" ], "rxcui": [ "309068", "1656313", "1656318" ], "spl_id": [ "7e0897ec-2275-4438-9cc5-4c951e52ad97" ], "spl_set_id": [ "ed23b6bc-32c7-4c50-a53d-313ae78e5623" ], "package_ndc": [ "0143-9931-01", "0143-9931-25", "0143-9933-01", "0143-9933-25", "0143-9930-01", "0143-9930-10" ], "unii": [ "258J72S7TZ" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anti-Infective", "Pediatric" ], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 0143-9933-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-354-01", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-01)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued" }, { "discontinued_date": "04/07/2026", "update_type": "New", "initial_posting_date": "04/07/2026", "package_ndc": "61958-1701-1", "generic_name": "Idelalisib Tablet", "contact_info": "800-445-3235", "related_info": "Discontinuation in the manufacturing of the drug", "openfda": { "application_number": [ "NDA205858" ], "brand_name": [ "ZYDELIG" ], "generic_name": [ "IDELALISIB" ], "manufacturer_name": [ "Gilead Sciences, Inc." ], "product_ndc": [ "61958-1701", "61958-1702" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "IDELALISIB" ], "rxcui": [ "1544465", "1544471", "1544473", "1544475" ], "spl_id": [ "ca3e7112-6dfe-403f-af6f-a0051e77d125" ], "spl_set_id": [ "efbdafa9-d18c-4e85-b4a2-1e620fc74e50" ], "package_ndc": [ "61958-1701-1", "61958-1702-1" ], "nui": [ "N0000175605", "N0000175082", "N0000190114" ], "pharm_class_epc": [ "Kinase Inhibitor [EPC]" ], "pharm_class_moa": [ "Kinase Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]" ], "unii": [ "YG57I8T5M0" ] }, "update_date": "04/07/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Tablet", "presentation": "Zydelig, Tablet, 100 mg (NDC 61958-1701-1)", "company_name": "Gilead Sciences, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0413-07", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA017512" ], "brand_name": [ "DIANEAL PD-2 WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0413", "0941-0411", "0941-0415", "0941-0409", "0941-0457", "0941-0459", "0941-0426", "0941-0427", "0941-0429", "0941-0424", "0941-0430", "0941-0433", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0413-07)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-3814-12", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA073509" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3814", "0409-3815" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRATHECAL", "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "1728783", "1728800" ], "spl_id": [ "0a2ba20b-448f-4412-9899-b82040ebfa7d" ], "spl_set_id": [ "1d181906-f3ec-4222-1883-e61577a3122e" ], "package_ndc": [ "0409-3814-11", "0409-3814-12", "0409-3815-11", "0409-3815-12" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5165-32", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "PHENOBARBITAL" ], "generic_name": [ "PHENOBARBITAL" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "0603-5165", "0603-5166", "0603-5167", "0603-5168" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "PHENOBARBITAL" ], "rxcui": [ "198086", "199164", "199167", "199168" ], "spl_id": [ "f8c5136e-e35c-4425-8d49-b7f92c827b42" ], "spl_set_id": [ "069b92ce-0061-4724-8c25-08d8596770a2" ], "package_ndc": [ "0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32" ], "unii": [ "YQE403BP4D" ] }, "update_date": "10/31/2025", "therapeutic_category": [ "Analgesia/Addiction", "Neurology", "Other" ], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 16.2 mg (NDC 0603-5165-32)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-3112-23", "generic_name": "Hydrochlorothiazide; Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Accuretic, Tablet, 12.5 mg; 10 mg (NDC 0071-3112-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "67457-251-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA202881" ], "brand_name": [ "DEXMEDETOMIDINE" ], "generic_name": [ "DEXMEDETOMIDINE" ], "manufacturer_name": [ "Mylan Institutional LLC" ], "product_ndc": [ "67457-251" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "309710" ], "spl_id": [ "afa561b9-9d6c-47b3-87e6-8d049597a0ed" ], "spl_set_id": [ "ebdfe2e8-30ca-4f18-935a-41bcbbce4937" ], "package_ndc": [ "67457-251-00", "67457-251-02" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 67457-251-02)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "55150-195-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA205612" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-195", "55150-196", "55150-197", "55150-198", "55150-199", "55150-200", "55150-201" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483" ], "spl_id": [ "1e5f1368-058a-492c-b4b7-d9329a7745e2" ], "spl_set_id": [ "3763b7b6-da49-4658-b93d-28f5da24d09e" ], "package_ndc": [ "55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20" ], "unii": [ "V910P86109" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-195-20)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0480-3667-22", "generic_name": "Liraglutide Injection", "contact_info": "833-493-4689", "availability": "Available", "related_info": "Distributed by Teva", "openfda": { "application_number": [ "NDA022341" ], "brand_name": [ "LIRAGLUTIDE" ], "generic_name": [ "LIRAGLUTIDE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0480-3667" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "LIRAGLUTIDE" ], "rxcui": [ "897122" ], "spl_id": [ "57c9f463-a1b8-4efa-8982-40175cf6cf4f" ], "spl_set_id": [ "14bf9812-14ee-46ce-93b1-686e4906cbbc" ], "package_ndc": [ "0480-3667-19", "0480-3667-22", "0480-3667-20" ], "nui": [ "N0000178480", "M0160181", "N0000020058" ], "pharm_class_epc": [ "GLP-1 Receptor Agonist [EPC]" ], "pharm_class_cs": [ "Glucagon-Like Peptide 1 [CS]" ], "pharm_class_moa": [ "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]" ], "unii": [ "839I73S42A" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-22)", "company_name": "Novo Nordisk, Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/08/2019", "package_ndc": "76045-212-10", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Limited Availability", "related_info": "4 month expiry available on request. Next release not available at this time.", "openfda": { "application_number": [ "ANDA209192" ], "brand_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "generic_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "76045-212", "76045-109" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "rxcui": [ "2099700" ], "spl_id": [ "6fd9ed0e-dddc-4e73-9442-49da54685f7b" ], "spl_set_id": [ "4dd55929-fe0a-4884-ae0d-6f9435920eb7" ], "package_ndc": [ "76045-109-01", "76045-109-10", "76045-212-00", "76045-212-10" ], "unii": [ "AI9376Y64P" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-212-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "06/28/2022", "package_ndc": "0143-9391-10", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA210594" ], "brand_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "generic_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9391", "0143-9392", "0143-9393" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "rxcui": [ "1729578", "1729584", "1729710" ], "spl_id": [ "5c5e498b-d829-4f78-bcca-466631014767" ], "spl_set_id": [ "9d289052-1eb6-4ba2-a3ca-d2e542a052ae" ], "package_ndc": [ "0143-9391-01", "0143-9391-10", "0143-9392-01", "0143-9392-10", "0143-9393-01", "0143-9393-10" ], "unii": [ "5V444H5WIC" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 1 mg per vial (NDC 0143-9391-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "66794-160-02", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-414-1901", "availability": "Limited Availability", "related_info": "On allocation", "openfda": { "application_number": [ "ANDA204393" ], "brand_name": [ "MITIGO" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Piramal Critical Care, Inc." ], "product_ndc": [ "66794-160", "66794-162" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRATHECAL" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "1731522", "1731998", "2055307", "2055311" ], "spl_id": [ "495a6a51-d35d-2b96-e063-6394a90ac5f3" ], "spl_set_id": [ "728f3d83-9a63-0c1f-e053-2a91aa0ac7db" ], "package_ndc": [ "66794-160-02", "66794-162-02" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02)", "company_name": "Piramal Critical Care Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-196-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": { "application_number": [ "ANDA209799" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "SUNRISE PHARMACEUTICAL, INC." ], "product_ndc": [ "11534-196", "11534-190", "11534-191", "11534-192", "11534-193", "11534-194", "11534-195" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "60dcfbf6-d07a-4010-ae77-8a9ae4529828" ], "spl_set_id": [ "ac102599-3a5b-4154-899e-6ff262be7ff7" ], "package_ndc": [ "11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/16/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 11534-196-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-153-30", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": { "application_number": [ "ANDA075468" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Advagen Pharma Ltd" ], "product_ndc": [ "72888-153", "72888-497", "72888-152", "72888-154" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529", "204892" ], "spl_id": [ "5510f17b-a980-f412-e063-6394a90ae1c4" ], "spl_set_id": [ "30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec" ], "package_ndc": [ "72888-497-01", "72888-497-02", "72888-497-03", "72888-497-04", "72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 72888-153-30)", "company_name": "Rubicon Research Private Limited", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0517-1001-25", "generic_name": "Atropine Sulfate Injection", "contact_info": "800-645-1706", "availability": "Available", "openfda": { "application_number": [ "ANDA216120" ], "brand_name": [ "ATROPINE SULFATE" ], "generic_name": [ "ATROPINE SULFATE" ], "manufacturer_name": [ "American Regent, Inc." ], "product_ndc": [ "0517-1001", "0517-1004" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ATROPINE SULFATE" ], "rxcui": [ "1190795", "1666781" ], "spl_id": [ "1c500ed9-94a9-472c-bfb7-50e1fcfc31fb" ], "spl_set_id": [ "6fee1727-52b7-4f73-ab45-ef47d6a1c5bb" ], "package_ndc": [ "0517-1004-01", "0517-1004-25", "0517-1001-01", "0517-1001-25" ], "unii": [ "03J5ZE7KA5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 1 mg/1 mL (NDC 0517-1001-25)", "company_name": "American Regent, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "06/13/2018", "package_ndc": "55150-254-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA207182" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-254", "55150-251", "55150-252", "55150-255", "55150-253", "55150-256" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671" ], "spl_id": [ "ccc38d8a-43fd-44c0-985e-32af9ed956ab", "0b1f03c2-db2f-4f90-acc0-d73abd731bf6" ], "spl_set_id": [ "ccc38d8a-43fd-44c0-985e-32af9ed956ab", "ef782e5e-e2d7-465a-99c6-b12611f3158c" ], "package_ndc": [ "55150-251-24", "55150-252-24", "55150-254-24", "55150-255-24", "55150-251-10", "55150-252-20", "55150-253-50", "55150-254-10", "55150-255-20", "55150-256-50" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-254-10)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "25021-115-04", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "866-625-1618", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA090108" ], "brand_name": [ "CLINDAMYCIN" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-115" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "1737244", "1737578", "1737581" ], "spl_id": [ "4662502b-ce7c-4278-854d-cf8632ac9b83" ], "spl_set_id": [ "7a6967b3-5563-4bed-9eee-d400f800e799" ], "package_ndc": [ "25021-115-02", "25021-115-04", "25021-115-06" ], "unii": [ "EH6D7113I8" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04)", "company_name": "Sagent Pharmaceuticals", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9630-05", "generic_name": "Atropine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA021146" ], "brand_name": [ "ATROPINE SULFATE" ], "generic_name": [ "ATROPINE SULFATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-9630", "0409-1630", "0409-4910", "0409-4911" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ATROPINE SULFATE" ], "rxcui": [ "1190546", "1190551", "1190552" ], "spl_id": [ "3f33c683-46fb-40db-af0d-9211bc29d2a7" ], "spl_set_id": [ "ad8916e7-206e-409e-2582-30d072845dd4" ], "package_ndc": [ "0409-1630-15", "0409-1630-10", "0409-9630-15", "0409-9630-05", "0409-4910-11", "0409-4910-34", "0409-4911-11", "0409-4911-34" ], "unii": [ "03J5ZE7KA5" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 0.25 mg/5 mL (0.05 mg/mL) Syringes (NDC 0409-9630-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1890-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA202515" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1890", "0409-1891", "0409-1892", "0409-1893", "0409-1894" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "894912", "998212", "998213", "1729197", "1731995", "1732014" ], "spl_id": [ "56671cfe-7548-442e-a2b5-ffebebf65ade" ], "spl_set_id": [ "be420e8b-bcb0-49b5-bb4d-1df8b9959809" ], "package_ndc": [ "0409-1890-03", "0409-1890-01", "0409-1890-13", "0409-1890-23", "0409-1891-03", "0409-1891-01", "0409-1891-13", "0409-1891-23", "0409-1892-03", "0409-1892-01", "0409-1892-13", "0409-1892-23", "0409-1893-03", "0409-1893-01", "0409-1893-13", "0409-1893-23", "0409-1894-03", "0409-1894-01" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "36000-283-25", "generic_name": "Furosemide Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "ANDA202747" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "36000-283", "36000-063", "36000-064", "36000-065", "36000-282", "36000-284" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "b4c1ae97-0f6c-4ae1-858a-4e0ab8f1ce53" ], "spl_set_id": [ "c71371a7-75c5-45b8-b762-8d782d4c71bc" ], "package_ndc": [ "36000-063-05", "36000-064-05", "36000-065-05", "36000-282-25", "36000-283-25", "36000-284-25" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 36000-283-25)", "company_name": "Baxter Healthcare", "status": "Current" }, { "discontinued_date": "10/07/2025", "update_type": "New", "initial_posting_date": "10/07/2025", "package_ndc": "61958-1401-1", "generic_name": "Cobicistat Tablet", "contact_info": "800-445-3235", "related_info": "Gilead plans to sell through the end of February 2026. Discontinuation of the manufacture of the drug due to business reasons.", "openfda": { "application_number": [ "NDA203094" ], "brand_name": [ "TYBOST" ], "generic_name": [ "COBICISTAT" ], "manufacturer_name": [ "Gilead Sciences, Inc." ], "product_ndc": [ "61958-1401", "61958-1402" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "COBICISTAT" ], "rxcui": [ "1551993", "1551999", "2719618", "2719620" ], "spl_id": [ "169d8571-3b28-4b3b-8def-18316f1297f3" ], "spl_set_id": [ "3784c35c-e87f-410c-900b-8fd6313c6010" ], "package_ndc": [ "61958-1401-1", "61958-1402-1" ], "nui": [ "N0000190114", "N0000191001", "N0000185503", "N0000182137", "N0000190107", "N0000190108", "N0000190113", "N0000191423" ], "pharm_class_moa": [ "Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]" ], "pharm_class_epc": [ "Cytochrome P450 3A Inhibitor [EPC]" ], "unii": [ "LW2E03M5PG" ] }, "update_date": "10/07/2025", "therapeutic_category": [ "Antiviral" ], "dosage_form": "Tablet", "presentation": "Tybost, Tablet, 150 mg (NDC 61958-1401-1)", "company_name": "Gilead Sciences, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "01/28/2026", "update_type": "New", "initial_posting_date": "01/28/2026", "package_ndc": "0023-6118-03", "generic_name": "Podofilox Topical Gel", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA020529" ], "brand_name": [ "CONDYLOX" ], "generic_name": [ "PODOFILOX" ], "manufacturer_name": [ "Allergan, Inc." ], "product_ndc": [ "0023-6118" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "TOPICAL" ], "substance_name": [ "PODOFILOX" ], "rxcui": [ "312466", "351750" ], "spl_id": [ "9f2892be-8330-4fd1-930e-b4d204df4e03" ], "spl_set_id": [ "032e4bcb-b1ed-4029-b2a6-e92f3bf5cc37" ], "package_ndc": [ "0023-6118-03" ], "nui": [ "N0000008732" ], "pharm_class_pe": [ "Decreased Mitosis [PE]" ], "unii": [ "L36H50F353" ] }, "update_date": "01/28/2026", "therapeutic_category": [ "Dermatology", "Other" ], "dosage_form": "Topical Gel", "presentation": "Condylox , Topical Gel, 0.5% (NDC 0023-6118-03)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-491-57", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE MPF" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-491", "63323-492", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 5 mg/1 mL (NDC 63323-491-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "16729-136-16", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": { "application_number": [ "ANDA077147" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Accord Healthcare Inc." ], "product_ndc": [ "16729-136", "16729-137", "16729-138" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "0e1e7f41-f78b-27cf-e063-6394a90a1ae0" ], "spl_set_id": [ "ebc11109-e7bf-452d-b675-4b3236d54164" ], "package_ndc": [ "16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 16729-136-16)", "company_name": "Accord Healthcare Inc.", "status": "Current" }, { "discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5167-32", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "PHENOBARBITAL" ], "generic_name": [ "PHENOBARBITAL" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "0603-5167", "0603-5165", "0603-5166", "0603-5168" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "PHENOBARBITAL" ], "rxcui": [ "198086", "199164", "199167", "199168" ], "spl_id": [ "f8c5136e-e35c-4425-8d49-b7f92c827b42" ], "spl_set_id": [ "069b92ce-0061-4724-8c25-08d8596770a2" ], "package_ndc": [ "0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32" ], "unii": [ "YQE403BP4D" ] }, "update_date": "10/31/2025", "therapeutic_category": [ "Analgesia/Addiction", "Neurology", "Other" ], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-32)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "10/16/2025", "update_type": "New", "initial_posting_date": "10/16/2025", "package_ndc": "0002-7623-01", "generic_name": "Pemetrexed Disodium Injection", "contact_info": "800-545-5979", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA021462" ], "brand_name": [ "ALIMTA" ], "generic_name": [ "PEMETREXED DISODIUM" ], "manufacturer_name": [ "Eli Lilly and Company" ], "product_ndc": [ "0002-7623", "0002-7640" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "PEMETREXED DISODIUM HEPTAHYDRATE" ], "rxcui": [ "1728072", "1728075", "1728077", "1728079" ], "spl_id": [ "3af0bc84-13d6-46aa-a4c0-c62410b73bc6" ], "spl_set_id": [ "f5a860f3-37ec-429c-ae04-9c88d7c55c08" ], "package_ndc": [ "0002-7640-01", "0002-7623-01" ], "unii": [ "9T47E4OM16" ] }, "update_date": "10/16/2025", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Alimta, Injection, 500 mg/20 mL (NDC 0002-7623-01)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued" }, { "discontinued_date": "06/30/2026", "update_type": "New", "initial_posting_date": "06/30/2026", "package_ndc": "65219-281-10", "generic_name": "Gadobutrol Injection", "contact_info": "888-386-1300", "related_info": "Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA", "openfda": { "application_number": [ "ANDA215061" ], "brand_name": [ "GADOBUTROL" ], "generic_name": [ "GADOBUTROL" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-281" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GADOBUTROL" ], "spl_id": [ "490c8c3e-3195-40af-8f34-40d8df2719c3" ], "spl_set_id": [ "007696d0-4b62-4937-9640-4ad619504df4" ], "package_ndc": [ "65219-281-00", "65219-281-02", "65219-281-03", "65219-281-07", "65219-281-08", "65219-281-10", "65219-281-05", "65219-281-15" ], "nui": [ "N0000183362", "N0000175862" ], "pharm_class_epc": [ "Gadolinium-based Contrast Agent [EPC]" ], "pharm_class_moa": [ "Magnetic Resonance Contrast Activity [MoA]" ], "unii": [ "1BJ477IO2L" ] }, "update_date": "06/30/2026", "therapeutic_category": [ "Medical Imaging" ], "dosage_form": "Injection", "presentation": "Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-10)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "To Be Discontinued" }, { "discontinued_date": "06/30/2026", "update_type": "New", "initial_posting_date": "06/30/2026", "package_ndc": "57884-3151-1", "generic_name": "Daptomycin Injection", "contact_info": "609-395-8625 ext. 203", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "06/30/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Daptomycin, Injection, 500 mg/10 mL (NDC 57884-3151-1)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/17/2021", "package_ndc": "0068-0597-01", "generic_name": "Rifampin Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Rifampin%20Injection&st=d", "contact_info": "800-633-1610", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA050627" ], "brand_name": [ "RIFADIN IV" ], "generic_name": [ "RIFAMPIN" ], "manufacturer_name": [ "Sanofi-Aventis U.S. LLC" ], "product_ndc": [ "0068-0597" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "RIFAMPIN" ], "rxcui": [ "207436", "312821" ], "spl_id": [ "82e2bbb1-cc73-4fbd-8d85-610634876355" ], "spl_set_id": [ "036ab68e-5085-4edc-bd83-784b43d64eab" ], "package_ndc": [ "0068-0597-01" ], "nui": [ "N0000175500", "M0019113" ], "pharm_class_epc": [ "Rifamycin Antibacterial [EPC]" ], "pharm_class_cs": [ "Rifamycins [CS]" ], "unii": [ "VJT6J7R4TR" ] }, "update_date": "06/22/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Rifadin, Injection, 600 mg (NDC 0068-0597-01)", "company_name": "Sanofi-Aventis U.S. LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "55150-163-30", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA203082" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-163", "55150-161", "55150-162", "55150-164", "55150-165" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1737562", "1737566", "1737568", "1737757", "1737761" ], "spl_id": [ "bab2ea79-0aed-4f48-8b4e-f864f8b82fb8", "d95a0a28-804f-44d2-aa31-01df376a3154" ], "spl_set_id": [ "9916b09d-a116-469d-92d5-60e50ea9782b", "89701fac-7536-4f16-87fb-f4cc121e74ee" ], "package_ndc": [ "55150-161-09", "55150-162-09", "55150-163-00", "55150-163-24", "55150-164-09", "55150-165-09", "55150-161-02", "55150-162-05", "55150-163-30", "55150-163-25", "55150-164-02", "55150-165-05" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-163-30)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/08/2019", "package_ndc": "76045-0212-10", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Limited Availability", "related_info": "4 month expiry available on request. Next release not available at this time.", "update_date": "08/04/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 76045-0212-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "01/30/2026", "update_type": "New", "initial_posting_date": "01/30/2026", "package_ndc": "57664-656-88", "generic_name": "Pindolol Tablet", "contact_info": "800-818-4555", "related_info": "Discontinuation of the manufacture of the drug; Expiry date of last distributed batch October 2026", "openfda": { "application_number": [ "ANDA074063" ], "brand_name": [ "PINDOLOL" ], "generic_name": [ "PINDOLOL" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "57664-656", "57664-655" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "PINDOLOL" ], "rxcui": [ "198104", "198105" ], "spl_id": [ "4d3c89dd-e947-5f23-e063-6294a90aeb1f" ], "spl_set_id": [ "b331a73f-bf7b-4442-8901-36d016530279" ], "package_ndc": [ "57664-656-88", "57664-655-88" ], "nui": [ "N0000000161", "N0000175556" ], "pharm_class_moa": [ "Adrenergic beta-Antagonists [MoA]" ], "pharm_class_epc": [ "beta-Adrenergic Blocker [EPC]" ], "unii": [ "BJ4HF6IU1D" ] }, "update_date": "01/30/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Pindolol, Tablet, 10 mg (NDC 57664-656-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "12/22/2020", "package_ndc": "43066-019-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Baxter", "openfda": { "application_number": [ "ANDA212808" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "43066-019", "43066-015", "43066-023", "43066-027" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734084", "1734207", "1734475", "1734483" ], "spl_id": [ "a8d08579-825f-40d9-b1e3-e47b73765ae6" ], "spl_set_id": [ "781d4b7f-7556-4695-8d48-7772d7a0d8e9" ], "package_ndc": [ "43066-015-01", "43066-015-10", "43066-019-01", "43066-019-10", "43066-023-01", "43066-023-10", "43066-027-01", "43066-027-10" ], "unii": [ "V910P86109" ] }, "update_date": "06/10/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-019-10)", "company_name": "Caplin Steriles, Ltd.", "status": "Current" }, { "discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4904-34", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 1%, USP (For Cardiac Use Only) 50 mg/5 mL (10 mg/mL) LifeShield™ ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4904-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7922-03", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Available", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA016367" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "ICU Medical, Inc." ], "product_ndc": [ "0990-7922", "0990-7923", "0990-7930" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621" ], "spl_id": [ "06e4d957-1a56-4adb-a42b-fe0773b2fa97" ], "spl_set_id": [ "8b25b7e0-703e-4b43-a4eb-52863511602d" ], "package_ndc": [ "0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-03)", "company_name": "Otsuka ICU Medical LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "0338-0004-04", "generic_name": "Sterile Water Irrigant", "contact_info": "888-229-0001", "availability": "Limited Availability", "related_info": "Estimated recovery: September 2026", "openfda": { "application_number": [ "NDA017428" ], "brand_name": [ "STERILE WATER" ], "generic_name": [ "WATER" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0004", "0338-0003" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "IRRIGATION" ], "substance_name": [ "WATER" ], "rxcui": [ "150985" ], "spl_id": [ "97390588-b679-4caa-b7f3-3d2e11074d0e" ], "spl_set_id": [ "ef3e79c5-3f58-4b36-a296-64b7d9a651c1" ], "package_ndc": [ "0338-0003-44", "0338-0003-46", "0338-0003-47", "0338-0004-02", "0338-0004-03", "0338-0004-04", "0338-0004-05" ], "unii": [ "059QF0KO0R" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Irrigant", "presentation": "Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-04)", "company_name": "Baxter Healthcare", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-707-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": { "application_number": [ "ANDA205327" ], "brand_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Trigen Laboratories, LLC" ], "product_ndc": [ "13811-707", "13811-709", "13811-706", "13811-708", "13811-710" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210", "1995461" ], "spl_id": [ "0944cf70-d59a-483b-9698-e96ef955a65a" ], "spl_set_id": [ "c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f" ], "package_ndc": [ "13811-709-10", "13811-706-10", "13811-707-10", "13811-708-10", "13811-710-10", "13811-710-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "09/24/2019", "package_ndc": "48102-053-05", "generic_name": "Echothiophate Iodide Ophthalmic Solution", "contact_info": "516-277-1449", "availability": "Available", "related_info": "Available through limited distribution by Walgreens Specialty Pharmacy.", "openfda": { "application_number": [ "NDA011963" ], "brand_name": [ "PHOSPHOLINE IODIDE" ], "generic_name": [ "ECHOTHIOPHATE IODIDE FOR OPHTHALMIC SOLUTION" ], "manufacturer_name": [ "Fera Pharmaceuticals, LLC" ], "product_ndc": [ "48102-053" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "OPHTHALMIC" ], "rxcui": [ "205739", "310049" ], "spl_id": [ "66abcfcf-b16e-4181-b1db-96bfba0ab95e" ], "spl_set_id": [ "8afc8951-db76-4f27-8752-7c0d6aa47244" ], "package_ndc": [ "48102-053-05", "48102-054-05", "48102-055-05" ] }, "update_date": "08/10/2026", "therapeutic_category": [ "Ophthalmology" ], "dosage_form": "Ophthalmic Solution", "presentation": "Phospholine Iodide, Ophthalmic Solution, 0.125% (NDC 48102-053-05)", "company_name": "Fera Pharmaceuticals", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0409-4887-10", "generic_name": "Sterile Water Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA018801" ], "brand_name": [ "STERILE WATER" ], "generic_name": [ "WATER" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4887" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "WATER" ], "spl_id": [ "055437a7-5be5-414a-a97a-946e2730fe12" ], "spl_set_id": [ "2b9ea23a-f9e9-48a8-25b7-519e3bbd6828" ], "package_ndc": [ "0409-4887-25", "0409-4887-99", "0409-4887-31", "0409-4887-05", "0409-4887-17", "0409-4887-10", "0409-4887-32", "0409-4887-34", "0409-4887-23", "0409-4887-20", "0409-4887-24", "0409-4887-50" ], "unii": [ "059QF0KO0R" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-486-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA076803" ], "brand_name": [ "QUINAPRIL" ], "generic_name": [ "QUINAPRIL" ], "manufacturer_name": [ "Chartwell RX, LLC" ], "product_ndc": [ "62135-486", "62135-484", "62135-485", "62135-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE" ], "rxcui": [ "312748", "312749", "312750", "314203" ], "spl_id": [ "09cd5cb9-4fdf-f133-e063-6294a90af691" ], "spl_set_id": [ "dbc43dbd-94aa-40e2-a9ea-766110cc8687" ], "package_ndc": [ "62135-484-60", "62135-485-90", "62135-486-90", "62135-487-90" ], "unii": [ "33067B3N2M" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 20 mg (NDC 62135-486-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-2634-05", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA078591" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-2634" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "1724338", "1724340", "1724341" ], "spl_id": [ "50886ad5-eeca-4fe7-beb0-01305f92c65d" ], "spl_set_id": [ "3832ede8-d3fc-455d-ecab-3b77be5869f5" ], "package_ndc": [ "0409-2634-10", "0409-2634-01", "0409-2634-25", "0409-2634-05", "0409-2634-50" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-2634-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/10/2020", "package_ndc": "70121-1388-8", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "866-525-7270", "availability": "Available", "related_info": "Inventory available 4 to 5 month as per current demand. Next supply: week of 06/29/2026", "openfda": { "application_number": [ "ANDA207551" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Amneal Pharmaceuticals LLC" ], "product_ndc": [ "70121-1388", "70121-1389" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909" ], "spl_id": [ "af193b53-1488-401f-8f06-cc193297c4a8" ], "spl_set_id": [ "eb1ba463-ab42-4f49-9ebe-3ad5af108326" ], "package_ndc": [ "70121-1388-1", "70121-1388-8", "70121-1389-1", "70121-1389-7" ], "unii": [ "1018WH7F9I" ] }, "update_date": "06/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1388-8)", "company_name": "Amneal Pharmaceuticals", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "65219-632-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": { "application_number": [ "ANDA212808" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "FRESENIUS KABI USA, LLC" ], "product_ndc": [ "65219-632" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734347", "1734355" ], "spl_id": [ "7203f32f-2e48-4924-b882-d4f3863ae952" ], "spl_set_id": [ "da4a7675-97bf-4d2a-9fdc-c1b4b2999126" ], "package_ndc": [ "65219-632-02", "65219-632-10", "65219-632-04", "65219-632-20" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 65219-632-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-161-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Available", "openfda": { "application_number": [ "ANDA215330" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Rhodes Pharmaceuticals LLC" ], "product_ndc": [ "42858-161", "42858-162", "42858-163", "42858-164", "42858-165", "42858-166", "42858-167" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "0002e227-1109-4ecc-a8c5-4b4f11fac3cc" ], "spl_set_id": [ "d918b40d-a461-41bc-b6c0-83dc76c28e32" ], "package_ndc": [ "42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/24/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 42858-161-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0264-7520-20", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "NDA019626" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-7520", "0264-7510" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE, UNSPECIFIED FORM" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795610", "1795612" ], "spl_id": [ "c9f87749-8dd5-41fd-b393-f63d45fd00ef" ], "spl_set_id": [ "085614c7-ada4-4e2c-87c0-c9bc2f18365a" ], "package_ndc": [ "0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20" ], "unii": [ "IY9XDZ35W2" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-20)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "12/22/2021", "package_ndc": "68180-659-06", "generic_name": "Rifampin Capsule", "contact_info": "866-587-4617", "availability": "Available", "openfda": { "application_number": [ "ANDA090034" ], "brand_name": [ "RIFAMPIN" ], "generic_name": [ "RIFAMPIN" ], "manufacturer_name": [ "Lupin Pharmaceuticals, Inc." ], "product_ndc": [ "68180-659", "68180-658" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RIFAMPIN" ], "rxcui": [ "198201", "198202" ], "spl_id": [ "5ed1edac-e11e-4f87-b390-e770a69a9b37" ], "spl_set_id": [ "b56004f0-f23d-47f6-80c7-39884fccbccc" ], "package_ndc": [ "68180-658-06", "68180-658-01", "68180-659-06", "68180-659-07", "68180-659-01" ], "nui": [ "N0000175500", "M0019113" ], "pharm_class_epc": [ "Rifamycin Antibacterial [EPC]" ], "pharm_class_cs": [ "Rifamycins [CS]" ], "unii": [ "VJT6J7R4TR" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 68180-659-06)", "company_name": "Lupin Pharmaceuticals, Inc.", "status": "Current" }, { "discontinued_date": "03/19/2026", "update_type": "New", "initial_posting_date": "03/19/2026", "package_ndc": "64764-805-30", "generic_name": "Ramelteon Tablet", "contact_info": "877-825-3327", "related_info": "Product is expected to be available through June 2027.", "openfda": { "application_number": [ "NDA021782" ], "brand_name": [ "ROZEREM" ], "generic_name": [ "RAMELTEON" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "64764-805" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RAMELTEON" ], "rxcui": [ "577348", "603162" ], "spl_id": [ "2021e7fb-108a-4783-9a37-8bc05bf28b28" ], "spl_set_id": [ "9de82310-70e8-47b9-b1fc-6c6848b99455" ], "package_ndc": [ "64764-805-30", "64764-805-10", "64764-805-22" ], "nui": [ "N0000175743", "N0000000250" ], "pharm_class_epc": [ "Melatonin Receptor Agonist [EPC]" ], "pharm_class_moa": [ "Melatonin Receptor Agonists [MoA]" ], "unii": [ "901AS54I69" ] }, "update_date": "03/19/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Rozerem, Tablet, 8 mg (NDC 64764-805-30)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "05/07/2026", "update_type": "New", "initial_posting_date": "05/07/2026", "package_ndc": "63323-574-86", "generic_name": "Icatibant Acetate Injection", "contact_info": "847-550-2300", "related_info": "Discontinuation of the manufacturer of the drug", "openfda": { "application_number": [ "ANDA208317" ], "brand_name": [ "ICATIBANT" ], "generic_name": [ "ICATIBANT" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-574" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "ICATIBANT ACETATE" ], "rxcui": [ "1148141" ], "spl_id": [ "d1c9afa7-c4ac-4739-85f1-2ae82440210c" ], "spl_set_id": [ "52c12c15-c00b-4efc-952d-1425c907706a" ], "package_ndc": [ "63323-574-01", "63323-574-86", "63323-574-93" ], "unii": [ "325O8467XK" ] }, "update_date": "05/07/2026", "therapeutic_category": [ "Hematology" ], "dosage_form": "Injection", "presentation": "Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-86)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-3301-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA021038" ], "brand_name": [ "PRECEDEX" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3301", "0409-1454", "0409-1174", "0409-2815" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892" ], "spl_id": [ "e1705533-5a85-441f-a95b-3cb88c47e482" ], "spl_set_id": [ "4419162d-81d4-49bd-96de-1729440bdb74" ], "package_ndc": [ "0409-1454-01", "0409-1454-20", "0409-3301-01", "0409-3301-10", "0409-1174-01", "0409-1174-10", "0409-2815-01" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-3301-10)", "company_name": "Pfizer Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2016", "package_ndc": "63323-032-00", "generic_name": "Sodium Acetate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA206687" ], "brand_name": [ "SODIUM ACETATE" ], "generic_name": [ "SODIUM ACETATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-032" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM ACETATE" ], "rxcui": [ "312965" ], "spl_id": [ "37c19fc5-c1ce-4ea0-9cba-4cdf32112091" ], "spl_set_id": [ "d7fabf08-d4e0-4bb5-8416-2e8ffe27c04b" ], "package_ndc": [ "63323-032-04", "63323-032-00" ], "unii": [ "4550K0SC9B" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Total Parenteral Nutrition" ], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 4 meq/100 mL (NDC 63323-032-00)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-119-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": { "application_number": [ "NDA208510" ], "brand_name": [ "VYVANSE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "59417-119", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-120" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469" ], "spl_id": [ "81d087b6-4cb4-466a-9693-679edeb062e2" ], "spl_set_id": [ "704e4378-ca83-445c-8b45-3cfa51c1ecad" ], "package_ndc": [ "59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 50 mg (NDC 59417-119-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7922-61", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Available", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA016367" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "ICU Medical, Inc." ], "product_ndc": [ "0990-7922", "0990-7923", "0990-7930" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621" ], "spl_id": [ "06e4d957-1a56-4adb-a42b-fe0773b2fa97" ], "spl_set_id": [ "8b25b7e0-703e-4b43-a4eb-52863511602d" ], "package_ndc": [ "0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-61)", "company_name": "Otsuka ICU Medical LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-652-87", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Available", "related_info": "Marketed by Sagent Pharmaceuticals", "openfda": { "application_number": [ "ANDA206166" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-652", "25021-671" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734347", "1734355", "1734479", "1734481" ], "spl_id": [ "41f4446a-ca6e-465e-9a79-8c4f99eb1ac3" ], "spl_set_id": [ "8c5c762f-d266-4b1a-809e-f11bfc89bc2d" ], "package_ndc": [ "25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87" ], "unii": [ "V910P86109" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-87)", "company_name": "InfoRLife SA", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "0409-3189-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA205656" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3189", "0409-7037" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "c96726ef-f1fa-4ebb-ba33-3479c3902a8e" ], "spl_set_id": [ "c96726ef-f1fa-4ebb-ba33-3479c3902a8e" ], "package_ndc": [ "0409-3189-05", "0409-3189-10", "0409-7037-01", "0409-7037-10" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-3189-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "06/06/2018", "package_ndc": "0641-6043-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA075772" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6043", "0641-6042", "0641-6041" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "25d6c438-45d2-4162-91c2-b5caa0f86bf3" ], "spl_set_id": [ "0c2c75c9-ed7b-46a8-9543-429bf2d8f090" ], "package_ndc": [ "0641-6043-01", "0641-6043-25", "0641-6042-01", "0641-6042-25", "0641-6041-01", "0641-6041-25" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6043-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8894-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA040440" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "SpecGx LLC" ], "product_ndc": [ "0406-8894", "0406-8891", "0406-8884", "0406-8892", "0406-8885", "0406-8893" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "1009145" ], "spl_id": [ "0d3fb5ba-ff79-4862-bc1d-45b8343e115b" ], "spl_set_id": [ "72ddd1c9-ddbd-4c95-acd9-003189a353a3" ], "package_ndc": [ "0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0406-8894-01)", "company_name": "SpecGx LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0409-4887-99", "generic_name": "Sterile Water Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA018801" ], "brand_name": [ "STERILE WATER" ], "generic_name": [ "WATER" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4887" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "WATER" ], "spl_id": [ "055437a7-5be5-414a-a97a-946e2730fe12" ], "spl_set_id": [ "2b9ea23a-f9e9-48a8-25b7-519e3bbd6828" ], "package_ndc": [ "0409-4887-25", "0409-4887-99", "0409-4887-31", "0409-4887-05", "0409-4887-17", "0409-4887-10", "0409-4887-32", "0409-4887-34", "0409-4887-23", "0409-4887-20", "0409-4887-24", "0409-4887-50" ], "unii": [ "059QF0KO0R" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-99)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "05/30/2025", "package_ndc": "0641-6054-25", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA080445" ], "brand_name": [ "MEPERIDINE HYDROCHLORIDE" ], "generic_name": [ "MEPERIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6054", "0641-6053", "0641-6052" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "MEPERIDINE HYDROCHLORIDE" ], "rxcui": [ "861476", "1665685", "1665697" ], "spl_id": [ "9566d54d-7343-4695-94ff-8b5f2d384c81" ], "spl_set_id": [ "e0e998da-f056-4fce-be8e-ed60cf3b461b" ], "package_ndc": [ "0641-6053-01", "0641-6053-25", "0641-6054-01", "0641-6054-25", "0641-6052-01", "0641-6052-25" ], "unii": [ "N8E7F7Q170" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Meperidine Hydrochloride, Injection, 100 mg/1 mL (NDC 0641-6054-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 500 mg/250mL (200 mg/mL) (NDC 0409-2347-32)", "update_type": "Revised", "initial_posting_date": "11/06/2017", "package_ndc": "0409-2347-32", "generic_name": "Dobutamine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular", "Pediatric", "Renal" ], "status": "Current", "dosage_form": "Injection" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-288-21", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-288", "63323-286", "63323-287", "63323-285" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484" ], "spl_id": [ "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c", "75465ceb-e894-487d-aa80-671fa0841fce" ], "spl_set_id": [ "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6", "56dfabf7-f7a8-4601-b17a-cb16fb995b0f" ], "package_ndc": [ "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95", "63323-288-25", "63323-288-27" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 10 mg/1 mL (NDC 63323-288-21)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "05/05/2026", "update_type": "New", "initial_posting_date": "05/05/2026", "package_ndc": "71288-726-52", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-824-8426", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA216039" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Meitheal Pharmaceuticals Inc" ], "product_ndc": [ "71288-726", "71288-723" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404" ], "spl_id": [ "0949c302-51ce-4fc9-8b99-1df94e693718" ], "spl_set_id": [ "fe340f98-a0f3-446e-b281-47fd91c1e537" ], "package_ndc": [ "71288-723-52", "71288-726-52" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "05/05/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-106-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": { "application_number": [ "NDA021977" ], "brand_name": [ "VYVANSE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "59417-106", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469" ], "spl_id": [ "81d087b6-4cb4-466a-9693-679edeb062e2" ], "spl_set_id": [ "704e4378-ca83-445c-8b45-3cfa51c1ecad" ], "package_ndc": [ "59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 60 mg (NDC 59417-106-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "16729-501-43", "generic_name": "Furosemide Injection", "contact_info": "866-941-7875", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; NDC is non-exempt", "openfda": { "application_number": [ "ANDA070017" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Accord Healthcare, Inc." ], "product_ndc": [ "16729-501", "16729-500", "16729-502" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "1cfab300-d796-6a68-e063-6394a90a73f9" ], "spl_set_id": [ "f6f64972-714c-4ee9-8a5e-9ffcab41a73b" ], "package_ndc": [ "16729-500-30", "16729-500-08", "16729-501-64", "16729-501-43", "16729-502-03", "16729-502-43" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 16729-501-43)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "discontinued_date": "02/19/2026", "update_type": "New", "initial_posting_date": "02/19/2026", "package_ndc": "0591-5544-01", "generic_name": "Allopurinol Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA018877" ], "brand_name": [ "ALLOPURINOL" ], "generic_name": [ "ALLOPURINOL" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0591-5544", "0591-5543" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ALLOPURINOL" ], "rxcui": [ "197319", "197320" ], "spl_id": [ "f7e04d88-1d9b-47e6-a9ad-deb08af3c098" ], "spl_set_id": [ "a80fe56f-8d03-423f-8e2a-7ec8c9e5045b" ], "package_ndc": [ "0591-5543-01", "0591-5543-10", "0591-5544-01", "0591-5544-05" ], "nui": [ "N0000175698", "N0000000206" ], "pharm_class_epc": [ "Xanthine Oxidase Inhibitor [EPC]" ], "pharm_class_moa": [ "Xanthine Oxidase Inhibitors [MoA]" ], "unii": [ "63CZ7GJN5I" ] }, "update_date": "02/19/2026", "therapeutic_category": [ "Oncology", "Renal", "Rheumatology" ], "dosage_form": "Tablet", "presentation": "Allopurinol, Tablet, 300 mg (NDC 0591-5544-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0003-3641-11", "generic_name": "Atazanavir Sulfate; Cobicistat Tablet", "contact_info": "800-332-2056", "related_info": "The global Cease Manufacture date for EVOTAZ® currently is estimated to begin April 2026.", "openfda": { "application_number": [ "NDA206353" ], "brand_name": [ "EVOTAZ" ], "generic_name": [ "ATAZANAVIR AND COBICISTAT" ], "manufacturer_name": [ "E.R. Squibb & Sons, L.L.C." ], "product_ndc": [ "0003-3641" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ATAZANAVIR SULFATE", "COBICISTAT" ], "rxcui": [ "1601654", "1601660" ], "spl_id": [ "fa642c67-5a9e-4136-a141-64e1236f6a0f" ], "spl_set_id": [ "83db29d7-5d85-49d6-8cb6-740473365cf8" ], "package_ndc": [ "0003-3641-11" ], "nui": [ "N0000190114", "N0000191001", "N0000185503", "N0000182137", "N0000190107", "N0000190108", "N0000190113", "N0000191423" ], "pharm_class_moa": [ "Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]" ], "pharm_class_epc": [ "Cytochrome P450 3A Inhibitor [EPC]" ], "unii": [ "4MT4VIE29P", "LW2E03M5PG" ] }, "update_date": "11/03/2025", "therapeutic_category": [ "Antiviral" ], "dosage_form": "Tablet", "presentation": "Evotaz, Tablet, 300 mg; 150 mg (NDC 0003-3641-11)", "company_name": "Bristol Myers Squibb Co.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/31/2026", "package_ndc": "0054-3294-46", "generic_name": "Furosemide Oral Solution", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": { "application_number": [ "ANDA070434" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0054-3294", "0054-4297", "0054-8297", "0054-4299", "0054-8299", "0054-4301", "0054-8301", "0054-3298" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "197730", "197731", "197732", "310429", "313988" ], "spl_id": [ "bc62ddda-7639-4090-99f0-7dd4d13518f3" ], "spl_set_id": [ "9e493331-dddd-496e-abf8-61747fb67aba" ], "package_ndc": [ "0054-4297-31", "0054-4297-25", "0054-8297-25", "0054-4299-31", "0054-4299-25", "0054-8299-25", "0054-4301-29", "0054-4301-25", "0054-8301-25", "0054-3298-63", "0054-3294-50", "0054-3294-46" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Oral Solution", "presentation": "Furosemide, Oral Solution, 10 mg/1 mL (NDC 0054-3294-46)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an inactive ingredient component", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1165-02", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA070585" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1165", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-9043", "0409-9046", "0409-9045", "0409-9042" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "RETROBULBAR" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596" ], "spl_id": [ "6e442bfd-d3da-4913-8585-ce3485644364" ], "spl_set_id": [ "02a845c3-4521-4926-e397-25ab536e7cf6" ], "package_ndc": [ "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 225 mg/30 mL (7.5 mg/mL) (NDC 0409-1165-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-6637-14", "generic_name": "Sodium Bicarbonate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA202494" ], "brand_name": [ "SODIUM BICARBONATE" ], "generic_name": [ "SODIUM BICARBONATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-6637", "0409-4916" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM BICARBONATE" ], "rxcui": [ "727995", "792582" ], "spl_id": [ "f79ec8cb-b6a3-4ffb-bccf-d39f59d65621" ], "spl_set_id": [ "ea20a5eb-641e-48cd-bcfa-74c04c45dfda" ], "package_ndc": [ "0409-4916-24", "0409-4916-14", "0409-6637-24", "0409-6637-14" ], "unii": [ "8MDF5V39QO" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) Syringes (NDC 0409-6637-14)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4713-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA080408" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4276", "0409-4275" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763" ], "spl_id": [ "05d1a200-9d75-4e48-b14a-5069d4ab816f" ], "spl_set_id": [ "3b2dd84e-cee8-4e58-d494-395a65a353a0" ], "package_ndc": [ "0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free, Injection, 50 mg/5 mL (1%; 10 mg/mL) (NDC 0409-4713-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "discontinued_date": "08/13/2026", "update_type": "New", "initial_posting_date": "08/13/2026", "package_ndc": "0228-2550-06", "generic_name": "Diclofenac Sodium Tablet, Delayed Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA074514" ], "brand_name": [ "DICLOFENAC SODIUM" ], "generic_name": [ "DICLOFENAC SODIUM" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0228-2550", "0228-2551" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DICLOFENAC SODIUM" ], "rxcui": [ "855906", "855926" ], "spl_id": [ "a1fbc994-b8a6-4759-be76-1cfd98275ca6" ], "spl_set_id": [ "a57b897e-0cbe-4ac3-969f-b00357a0cfa8" ], "package_ndc": [ "0228-2550-06", "0228-2550-11", "0228-2550-96", "0228-2551-06", "0228-2551-11", "0228-2551-96" ], "unii": [ "QTG126297Q" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Musculoskeletal", "Rheumatology" ], "dosage_form": "Tablet", "presentation": "Diclofenac Sodium, Tablet, Delayed Release, 50 mg (NDC 0228-2550-06)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "New", "initial_posting_date": "09/27/2021", "change_date": "07/31/2026", "package_ndc": "82667-800-01", "generic_name": "Triamcinolone Acetonide Injection", "contact_info": "(615) 733-4734", "openfda": { "application_number": [ "NDA022048" ], "brand_name": [ "TRIESENCE" ], "generic_name": [ "TRIAMCINOLONE ACETONIDE" ], "manufacturer_name": [ "Harrow Eye, LLC" ], "product_ndc": [ "82667-800" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "OPHTHALMIC" ], "substance_name": [ "TRIAMCINOLONE ACETONIDE" ], "rxcui": [ "1086259", "1792144" ], "spl_id": [ "5386eec5-c123-04b8-e063-6294a90a2952" ], "spl_set_id": [ "2267978c-72ad-9229-e063-6394a90a09d0" ], "package_ndc": [ "82667-800-01" ], "nui": [ "N0000175576", "N0000175450" ], "pharm_class_epc": [ "Corticosteroid [EPC]" ], "pharm_class_moa": [ "Corticosteroid Hormone Receptor Agonists [MoA]" ], "unii": [ "F446C597KA" ] }, "update_date": "07/31/2026", "therapeutic_category": [ "Ophthalmology" ], "dosage_form": "Injection", "presentation": "Triesence, Injection, 40 mg/1 mL (NDC 82667-800-01)", "company_name": "Harrow Eye, LLC", "status": "Resolved" }, { "update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "55150-313-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA211930" ], "brand_name": [ "METHYLPREDNISOLONE ACETATE" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-313", "55150-314" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1358610", "1358617" ], "spl_id": [ "25c5133c-ee17-4be0-88a3-d0231e38f5a0" ], "spl_set_id": [ "a0cbcdb5-f657-49f7-8f86-cc5959d69db0" ], "package_ndc": [ "55150-313-25", "55150-313-01", "55150-314-25", "55150-314-01" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 55150-313-01)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0378-0006-85", "generic_name": "Everolimus Tablet", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/03/2025", "therapeutic_category": [ "Transplant" ], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 3 mg (NDC 0378-0006-85)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "0990-7139-36", "generic_name": "Sterile Water Irrigant", "related_info_link": "https://www.fda.gov/media/182619/download?attachment", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Unavailable", "related_info": "Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-36)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "11/14/2025", "update_type": "New", "initial_posting_date": "11/14/2025", "package_ndc": "0169-7703-21", "generic_name": "Somatropin Injection", "contact_info": "833-493-4689", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "BLA021148" ], "brand_name": [ "NORDITROPIN" ], "generic_name": [ "SOMATROPIN" ], "manufacturer_name": [ "Novo Nordisk" ], "product_ndc": [ "0169-7703", "0169-7704", "0169-7705", "0169-7708" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "SOMATROPIN" ], "rxcui": [ "847243", "847245", "847247", "847348", "849850", "849851", "1736262", "1736329" ], "spl_id": [ "b67c2419-4feb-4ce1-b97e-88760a8e1aee" ], "spl_set_id": [ "1058e17c-9261-459c-a3e6-fae38d196c14" ], "package_ndc": [ "0169-7704-21", "0169-7704-92", "0169-7705-21", "0169-7705-92", "0169-7708-21", "0169-7708-92", "0169-7703-11", "0169-7703-91", "0169-7703-21", "0169-7703-92" ], "nui": [ "N0000175606", "M0028842" ], "pharm_class_epc": [ "Recombinant Human Growth Hormone [EPC]" ], "pharm_class_cs": [ "Human Growth Hormone [CS]" ], "unii": [ "NQX9KB6PCL" ] }, "update_date": "11/14/2025", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Norditropin, Injection, 30 mg/3 mL (NDC 0169-7703-21)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-052-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA214484" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "57664-052", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "560b4c9e-9cce-4717-e063-6294a90a58c9" ], "spl_set_id": [ "da3148af-f9b6-4725-adae-3595b4c7dc4b" ], "package_ndc": [ "57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 57664-052-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3183-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA089651" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3183", "0409-1209", "0409-3177", "0409-3178", "0409-3181", "0409-3182", "0409-0007", "0409-0147" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE", "EPINEPHRINE" ], "rxcui": [ "1010688", "1010745", "1010751", "1010759", "1867996", "1867998" ], "spl_id": [ "68a37af1-d237-4836-af13-1eec28245f8b" ], "spl_set_id": [ "2f94f711-14c4-48ec-c5a3-c5ec4b8e8729" ], "package_ndc": [ "0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10" ], "nui": [ "N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647" ], "pharm_class_moa": [ "Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]" ], "pharm_class_epc": [ "alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]" ], "pharm_class_cs": [ "Catecholamines [CS]" ], "unii": [ "YKH834O4BH", "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:200,000) (NDC 0409-3183-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "70069-753-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": { "application_number": [ "ANDA217792" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-753", "70069-752" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404" ], "spl_id": [ "2b24af95-6f20-4945-bf8c-742f1d6f2721" ], "spl_set_id": [ "bcaab86f-20f0-4482-8d73-e29b36dced58" ], "package_ndc": [ "70069-752-25", "70069-752-10", "70069-752-01", "70069-753-25", "70069-753-01", "70069-753-10" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-10)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "44567-611-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-493-0861", "availability": "Available", "related_info": "Please check wholesalers and distributors for inventory.", "openfda": { "application_number": [ "NDA211844" ], "brand_name": [ "MIDAZOLAM IN SODIUM CHLORIDE" ], "generic_name": [ "MIDAZOLAM" ], "manufacturer_name": [ "WG Critical Care, LLC." ], "product_ndc": [ "44567-611", "44567-610" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM" ], "rxcui": [ "2541170", "2541171" ], "spl_id": [ "6cea9d5b-d0a6-4f93-b45e-2d615f6c4337" ], "spl_set_id": [ "f051776f-94c5-4e34-80ed-f45b9c36881e" ], "package_ndc": [ "44567-610-01", "44567-610-10", "44567-611-01", "44567-611-10" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "R60L0SM5BC" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-611-10)", "company_name": "WG Critical Care", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-193-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": { "application_number": [ "ANDA209799" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "SUNRISE PHARMACEUTICAL, INC." ], "product_ndc": [ "11534-193", "11534-190", "11534-191", "11534-192", "11534-194", "11534-195", "11534-196" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "60dcfbf6-d07a-4010-ae77-8a9ae4529828" ], "spl_set_id": [ "ac102599-3a5b-4154-899e-6ff262be7ff7" ], "package_ndc": [ "11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/16/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 11534-193-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "70069-752-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": { "application_number": [ "ANDA217792" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-752", "70069-753" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404" ], "spl_id": [ "2b24af95-6f20-4945-bf8c-742f1d6f2721" ], "spl_set_id": [ "bcaab86f-20f0-4482-8d73-e29b36dced58" ], "package_ndc": [ "70069-752-25", "70069-752-10", "70069-752-01", "70069-753-25", "70069-753-01", "70069-753-10" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-01)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "discontinued_date": "01/27/2026", "update_type": "New", "initial_posting_date": "01/27/2026", "package_ndc": "63323-970-02", "generic_name": "Benztropine Mesylate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA090233" ], "brand_name": [ "BENZTROPINE MESYLATE" ], "generic_name": [ "BENZTROPINE MESYLATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-970" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "BENZTROPINE MESYLATE" ], "rxcui": [ "885205" ], "spl_id": [ "11222231-55b1-48ee-a8f8-3385f1a2eb36" ], "spl_set_id": [ "b03bd28e-3b44-41e4-9a7e-28b9d7975245" ], "package_ndc": [ "63323-970-02" ], "unii": [ "WMJ8TL7510" ] }, "update_date": "01/27/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Injection", "presentation": "Benztropine Mesylate, Injection, 1 mg/1 mL (NDC 63323-970-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-165-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA215330" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Rhodes Pharmaceuticals LLC" ], "product_ndc": [ "42858-165", "42858-161", "42858-162", "42858-163", "42858-164", "42858-166", "42858-167" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "0002e227-1109-4ecc-a8c5-4b4f11fac3cc" ], "spl_set_id": [ "d918b40d-a461-41bc-b6c0-83dc76c28e32" ], "package_ndc": [ "42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/24/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 42858-165-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "67457-903-20", "generic_name": "Etomidate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA201044" ], "brand_name": [ "ETOMIDATE" ], "generic_name": [ "ETOMIDATE" ], "manufacturer_name": [ "Mylan Institutional LLC" ], "product_ndc": [ "67457-903", "67457-902" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008" ], "spl_id": [ "25fc0aef-d4b3-4b33-897c-81cc7cdae470" ], "spl_set_id": [ "461e34d1-b862-4a02-9727-548c907aac48" ], "package_ndc": [ "67457-902-00", "67457-902-10", "67457-903-00", "67457-903-20" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 67457-903-20)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current" }, { "presentation": "Marcaine, Injection, Marcaine 75 mg/30 mL (2.5 mg/mL) (NDC 0409-1559-30)", "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1559-30", "generic_name": "Bupivacaine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "status": "Current", "dosage_form": "Injection" }, { "update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6125-25", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA205758" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6125", "0641-6126", "0641-6127" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "1731993", "1732006", "1732011" ], "spl_id": [ "fb513d10-94f4-45f5-8b30-fa82ef83e4e2" ], "spl_set_id": [ "6023606c-150c-40c5-9175-598efe2a56c3" ], "package_ndc": [ "0641-6126-01", "0641-6126-25", "0641-6127-01", "0641-6127-25", "0641-6125-01", "0641-6125-25" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6025-10", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Inventory available in vial presentations.", "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6025-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/25/2022", "package_ndc": "0487-9901-30", "generic_name": "Albuterol Sulfate Solution", "contact_info": "800-443-4313", "availability": "Available", "openfda": { "application_number": [ "ANDA075664" ], "brand_name": [ "ALBUTEROL SULFATE" ], "generic_name": [ "ALBUTEROL SULFATE" ], "manufacturer_name": [ "Nephron Pharmaceuticals Corporation" ], "product_ndc": [ "0487-9901" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RESPIRATORY (INHALATION)" ], "substance_name": [ "ALBUTEROL SULFATE" ], "rxcui": [ "245314" ], "spl_id": [ "30dbae21-c906-0624-e063-6394a90a299c" ], "spl_set_id": [ "ecc00500-58b8-491f-80df-dc6c89a08cae" ], "package_ndc": [ "0487-9901-30", "0487-9901-02" ], "unii": [ "021SEF3731" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Pulmonary/Allergy", "Pediatric" ], "dosage_form": "Solution", "presentation": "Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 0487-9901-30)", "company_name": "Nephron Pharmaceuticals Corporation", "status": "Current" }, { "discontinued_date": "06/01/2026", "update_type": "New", "initial_posting_date": "06/01/2026", "package_ndc": "0009-0775-26", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA050441" ], "brand_name": [ "CLEOCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0775", "0009-0870", "0009-0902", "0009-0728", "0009-3124", "0009-3447", "0009-3381", "0009-3375", "0009-3382", "0009-6582" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "205964", "309335", "309336", "309339", "685574", "685576", "685578", "706461", "1737244", "1737245", "1737578", "1737579", "1737581", "1737582" ], "spl_id": [ "fa11e62e-4625-4e9c-8676-f318b1cb890f" ], "spl_set_id": [ "05a75685-0af5-407c-ac57-e380c882b49d" ], "package_ndc": [ "0009-0870-21", "0009-0870-26", "0009-0775-20", "0009-0775-26", "0009-0902-11", "0009-0902-18", "0009-0728-05", "0009-0728-09", "0009-3124-01", "0009-3124-03", "0009-3447-01", "0009-3447-03", "0009-3381-01", "0009-3381-02", "0009-3375-01", "0009-3375-02", "0009-3382-01", "0009-3382-02", "0009-6582-02", "0009-6582-01" ], "unii": [ "EH6D7113I8" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial (NDC 0009-0775-26)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "10/29/2025", "update_type": "New", "initial_posting_date": "10/29/2025", "package_ndc": "63323-850-74", "generic_name": "Moxifloxacin Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA205572" ], "brand_name": [ "MOXIFLOXACIN" ], "generic_name": [ "MOXIFLOXACIN HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-850" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "MOXIFLOXACIN HYDROCHLORIDE" ], "rxcui": [ "351156" ], "spl_id": [ "4070f637-059f-4e3d-8cf3-e5256a46ff3e" ], "spl_set_id": [ "a4e28b09-714b-46e7-b4e6-0163cad78fc5" ], "package_ndc": [ "63323-850-74", "63323-850-04" ], "unii": [ "C53598599T" ] }, "update_date": "10/29/2025", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Moxifloxacin, Injection, 400mg per 250mL (NDC 63323-850-74)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "62332-601-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "908-393-9604", "availability": "Available", "openfda": { "application_number": [ "ANDA214456" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Alembic Pharmaceuticals Inc." ], "product_ndc": [ "62332-601", "62332-599", "62332-600" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "9030f496-5021-4454-ac16-dbb376315608" ], "spl_set_id": [ "419cf756-3c96-4bb8-ae96-6aea5a5f3afd" ], "package_ndc": [ "62332-599-01", "62332-599-25", "62332-600-01", "62332-600-25", "62332-601-02", "62332-601-25" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "05/15/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 62332-601-25)", "company_name": "Alembic Pharmaceuticals", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0703-4246-01", "generic_name": "Carboplatin Injection", "contact_info": "800-545-8800", "availability": "Unavailable", "related_info": "Estimated recovery: September 2026", "openfda": { "application_number": [ "ANDA077269" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Teva Parenteral Medicines, Inc." ], "product_ndc": [ "0703-4246", "0703-4244", "0703-4248", "0703-4239" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df", "b943761e-6a46-45a0-bdb4-1fec1e101f8c" ], "spl_set_id": [ "f330f5a2-2cad-402f-bcbb-26245a753276", "e176b6ef-2ff6-498b-a9d8-7a634d147f37" ], "package_ndc": [ "0703-4244-01", "0703-4246-01", "0703-4248-01", "0703-4239-01", "0703-4244-81", "0703-4246-81", "0703-4248-81", "0703-4239-81" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4246-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-618-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA202725" ], "brand_name": [ "QUINAPRIL" ], "generic_name": [ "QUINAPRIL HYDROCHLORIDE" ], "manufacturer_name": [ "Aurobindo Pharma Limited" ], "product_ndc": [ "65862-618", "65862-617", "65862-619", "65862-620" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE" ], "rxcui": [ "312748", "312749", "312750", "314203" ], "spl_id": [ "5263abd5-ce46-4918-9bb0-9632861bcbc9" ], "spl_set_id": [ "93e6e668-5306-4f26-81d8-cbc3a7a5e787" ], "package_ndc": [ "65862-617-30", "65862-617-90", "65862-617-99", "65862-617-55", "65862-617-10", "65862-617-78", "65862-618-30", "65862-618-90", "65862-618-99", "65862-618-55", "65862-618-10", "65862-618-78", "65862-619-30", "65862-619-90", "65862-619-99", "65862-619-19", "65862-619-10", "65862-619-78", "65862-620-30", "65862-620-90", "65862-620-99", "65862-620-39", "65862-620-10", "65862-620-78" ], "unii": [ "33067B3N2M" ] }, "update_date": "06/02/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "06/12/2026", "package_ndc": "0143-9530-01", "generic_name": "Ifosfamide Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA076619" ], "brand_name": [ "IFOSFAMIDE" ], "generic_name": [ "IFOSFAMIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9530", "0143-9531" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "IFOSFAMIDE" ], "rxcui": [ "1791597", "1791599" ], "spl_id": [ "517c3bf6-41f5-4199-a17e-1f46b120cb1e" ], "spl_set_id": [ "c90ab05f-8fe5-437e-a1c0-8b11ef63291e" ], "package_ndc": [ "0143-9531-01", "0143-9530-01" ], "nui": [ "N0000000236", "N0000175558" ], "pharm_class_moa": [ "Alkylating Activity [MoA]" ], "pharm_class_epc": [ "Alkylating Drug [EPC]" ], "unii": [ "UM20QQM95Y" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Oncology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Ifosfamide, Injection, 50 mg/1 mL (NDC 0143-9530-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0338-3410-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "ANDA208084" ], "brand_name": [ "CLINDAMYCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "0338-3410", "0338-3612", "0338-3814" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "309335", "309336", "309339" ], "spl_id": [ "c8906ab2-37d2-4fde-9784-0442bf7b9565" ], "spl_set_id": [ "78832ac6-04c5-45e0-ae4d-f56d7920dda9" ], "package_ndc": [ "0338-3410-50", "0338-3410-24", "0338-3612-50", "0338-3612-24", "0338-3814-50", "0338-3814-24" ], "unii": [ "EH6D7113I8" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1746-30", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA016964" ], "brand_name": [ "MARCAINE WITH EPINEPHRINE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1746", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1749", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614" ], "spl_id": [ "7040888c-2cde-4408-af99-d249985f8444" ], "spl_set_id": [ "67578b56-7540-487e-1fba-481255620e78" ], "package_ndc": [ "0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/13/2023", "package_ndc": "0703-3678-01", "generic_name": "Methotrexate Sodium Injection", "contact_info": "800-545-8800", "availability": "Unavailable", "related_info": "Estimated recovery: October 2026", "openfda": { "application_number": [ "ANDA040843" ], "brand_name": [ "METHOTREXATE" ], "generic_name": [ "METHOTREXATE" ], "manufacturer_name": [ "Teva Parenteral Medicines, Inc." ], "product_ndc": [ "0703-3678", "0703-3671", "0703-3675" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS" ], "substance_name": [ "METHOTREXATE SODIUM" ], "rxcui": [ "1655956", "1655959", "1655960" ], "spl_id": [ "e81074cc-12b4-4ac9-a5bb-749188989b2c" ], "spl_set_id": [ "346ec9ce-dc98-4a55-b55e-d3af11f2d703" ], "package_ndc": [ "0703-3671-01", "0703-3675-01", "0703-3678-01" ], "unii": [ "3IG1E710ZN" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Rheumatology", "Oncology" ], "dosage_form": "Injection", "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "55150-324-25", "generic_name": "Furosemide Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA212174" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-324", "55150-322", "55150-323" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "9bb2ffa4-0891-4197-a970-90b178bbfad9" ], "spl_set_id": [ "421aa6d5-623b-4dc2-abd5-bb9e7765bf37" ], "package_ndc": [ "55150-322-01", "55150-322-25", "55150-323-01", "55150-323-25", "55150-324-01", "55150-324-25" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 100 mg/10 mL (NDC 55150-324-25)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "73293-0002-2", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "+82-2-854-4700 or via email intbiz@huons.com", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA212822" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Huons Co., Ltd." ], "product_ndc": [ "73293-0002" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBARACHNOID" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1724784" ], "spl_id": [ "2e641a0d-4d42-e7cd-e063-6394a90a47d4" ], "spl_set_id": [ "2dc693df-3218-4a90-b3f7-21e80966a851" ], "package_ndc": [ "73293-0002-1", "73293-0002-2" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "07/30/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 73293-0002-2)", "company_name": "Huons Co., Ltd", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "07/23/2026", "update_type": "New", "initial_posting_date": "07/23/2026", "package_ndc": "0574-7112-12", "generic_name": "Morphine Sulfate Suppository", "contact_info": "(800) 775-2054", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-7112", "0574-7110", "0574-7114", "0574-7116" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RECTAL" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "892516", "892603", "892678", "894807" ], "spl_id": [ "fa18ac09-a625-47aa-8cde-7051dc4d0c49" ], "spl_set_id": [ "649d731b-962a-45df-b043-7e0781e8a530" ], "package_ndc": [ "0574-7110-12", "0574-7112-12", "0574-7114-12", "0574-7116-12" ], "unii": [ "X3P646A2J0" ] }, "update_date": "07/23/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Suppository", "presentation": "Morphine Sulfate, Suppository, 10 mg (NDC 0574-7112-12)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "discontinued_date": "09/11/2025", "update_type": "New", "initial_posting_date": "09/11/2025", "package_ndc": "0409-0182-25", "generic_name": "Gemcitabine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA200795" ], "brand_name": [ "GEMCITABINE" ], "generic_name": [ "GEMCITABINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-0182", "0409-0181", "0409-0183" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GEMCITABINE HYDROCHLORIDE" ], "rxcui": [ "1720960", "1720975", "1720977" ], "spl_id": [ "3a284abb-8c57-47dc-a138-5a6e6ab92b05", "c0f06508-36d7-4325-a425-707d254d185b" ], "spl_set_id": [ "dc02a23b-3ff9-4441-aa91-8e9e629a7315", "e18ed1cb-7dd0-4001-bfda-17d1f4587fb8" ], "package_ndc": [ "0409-0181-01", "0409-0183-01", "0409-0182-01", "0409-0181-25", "0409-0182-25", "0409-0183-25" ], "unii": [ "U347PV74IL" ] }, "update_date": "09/11/2025", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Gemcitabine Hydrochloride, Injection, 2 g/52.6 mL (38 mg/mL), sterile solution in a single-dose glass vial NovaPlus (NDC 0409-0182-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0426-53", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA020163" ], "brand_name": [ "DIANEAL PD-2 WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0426", "0941-0411", "0941-0413", "0941-0415", "0941-0409", "0941-0457", "0941-0459", "0941-0427", "0941-0429", "0941-0424", "0941-0430", "0941-0433", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0426-53)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "discontinued_date": "12/04/2025", "update_type": "New", "initial_posting_date": "12/04/2025", "package_ndc": "0093-7352-01", "generic_name": "Calcitriol Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug", "openfda": { "application_number": [ "ANDA075765" ], "brand_name": [ "CALCITRIOL" ], "generic_name": [ "CALCITRIOL" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0093-7352", "0093-7353" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CALCITRIOL" ], "rxcui": [ "308867", "308868" ], "spl_id": [ "9e6df585-e3d1-4a89-bc02-8e4b223578c4" ], "spl_set_id": [ "ec93b667-aad2-4e3a-adc6-952f070a0c0a" ], "package_ndc": [ "0093-7352-01", "0093-7353-01" ], "nui": [ "M0004229", "N0000175908" ], "pharm_class_cs": [ "Cholecalciferol [CS]" ], "pharm_class_epc": [ "Vitamin D3 Analog [EPC]" ], "unii": [ "FXC9231JVH" ] }, "update_date": "12/04/2025", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Capsule", "presentation": "Calcitriol, Capsule, .25 ug (NDC 0093-7352-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "06/16/2022", "package_ndc": "42023-240-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "800-828-9393", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "08/18/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 42023-240-01)", "company_name": "Par Health, USA LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "09/11/2025", "update_type": "New", "initial_posting_date": "09/11/2025", "package_ndc": "0472-1030-16", "generic_name": "Homatropine Methylbromide and Hydrocodone Bitartrate Syrup", "contact_info": "800-545-8800", "openfda": { "application_number": [ "ANDA088017" ], "brand_name": [ "HYDROMET" ], "generic_name": [ "HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0472-1030" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "HYDROCODONE BITARTRATE", "HOMATROPINE METHYLBROMIDE" ], "rxcui": [ "992668", "992675" ], "spl_id": [ "7937f983-1f1c-475b-ab10-76a582d1bedd" ], "spl_set_id": [ "a324c912-a3ef-4296-b9a8-b0fec687eb06" ], "package_ndc": [ "0472-1030-16" ], "unii": [ "NO70W886KK", "68JRS2HC1C" ] }, "update_date": "09/11/2025", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Syrup", "presentation": "Hydromet, Syrup, 1.5 mg/5 mL; 5 mg/5 mL (NDC 0472-1030-16)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0429-52", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA020163" ], "brand_name": [ "DIANEAL PD-2 WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0429", "0941-0411", "0941-0413", "0941-0415", "0941-0409", "0941-0457", "0941-0459", "0941-0426", "0941-0427", "0941-0424", "0941-0430", "0941-0433", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0429-52)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "discontinued_date": "01/13/2026", "update_type": "New", "initial_posting_date": "01/13/2026", "package_ndc": "61314-473-64", "generic_name": "Adalimumab-adaz Injection", "contact_info": "800-525-8747", "related_info": "Equivalent Sandoz format is available.", "update_date": "01/13/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Hyrimoz, Injection, 40 mg/.4 mL (NDC 61314-473-64)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "57844-117-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA040422" ], "brand_name": [ "ADDERALL" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "57844-117", "57844-105", "57844-110", "57844-112", "57844-115", "57844-120", "57844-130" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147" ], "spl_id": [ "79af1dc6-c7cf-41b1-a750-e9b47c2187ff" ], "spl_set_id": [ "f22635fe-821d-4cde-aa12-419f8b53db81" ], "package_ndc": [ "57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 57844-117-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0433-51", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA020183" ], "brand_name": [ "DIANEAL LOW CALCIUM WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0433", "0941-0411", "0941-0413", "0941-0415", "0941-0409", "0941-0457", "0941-0459", "0941-0426", "0941-0427", "0941-0429", "0941-0424", "0941-0430", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0433-51)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/17/2015", "package_ndc": "0143-9935-01", "generic_name": "Cefotaxime Sodium Powder, for Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA065071" ], "brand_name": [ "CEFOTAXIME" ], "generic_name": [ "CEFOTAXIME" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9935" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CEFOTAXIME SODIUM" ], "rxcui": [ "309065" ], "spl_id": [ "e25af43f-54cb-4526-a8a5-6bef0a7939c7" ], "spl_set_id": [ "ef1a6dc6-bc3d-4f09-8f92-7ff328f56561" ], "package_ndc": [ "0143-9935-01" ], "unii": [ "258J72S7TZ" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anti-Infective", "Pediatric" ], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 10 g (NDC 0143-9935-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "76045-211-20", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA203460" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "76045-211", "76045-001", "76045-002", "76045-003" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "998211", "1551393", "1551395" ], "spl_id": [ "ec9c9aee-b95f-4645-bf17-df7f1e3967d3" ], "spl_set_id": [ "1cc9ba6e-fa1b-405e-9de8-720c567b2a73" ], "package_ndc": [ "76045-211-00", "76045-211-20", "76045-001-00", "76045-001-20", "76045-002-00", "76045-002-10", "76045-003-00", "76045-003-20" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2 mL (NDC 76045-211-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "change_date": "01/02/2025", "package_ndc": "0409-1312-30", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA200403" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1312", "0409-1283", "0409-4264", "0409-1805", "0409-2552", "0409-3356", "0409-2540", "0409-3365", "0409-1304" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897756", "897757", "1433251", "1724383", "1724644", "2675350", "897653", "897753", "897758", "1724276" ], "spl_id": [ "766e302a-2d03-4d93-b237-2348b57ee517", "a3ebafac-648e-47b1-a6f5-1e3bff1e3e08" ], "spl_set_id": [ "f9ca2ef5-46d8-475a-a26e-f7c8becd6db7", "e9c9ef18-7dfc-4322-b2fc-29b934c30f8b" ], "package_ndc": [ "0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01", "0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL Syringes (NDC 0409-1312-30)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "discontinued_date": "12/19/2025", "update_type": "New", "initial_posting_date": "12/19/2025", "package_ndc": "54092-171-12", "generic_name": "Carbamazepine Capsule, Extended Release", "contact_info": "855-268-1825", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA020712" ], "brand_name": [ "CARBATROL" ], "generic_name": [ "CARBAMAZEPINE" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "54092-171", "54092-172", "54092-173" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CARBAMAZEPINE" ], "rxcui": [ "200131", "200133", "308977", "313931", "388311", "404742" ], "spl_id": [ "39171a32-c78d-4130-be53-638e19cf2261" ], "spl_set_id": [ "bc03e499-5bac-4293-bff4-6864153a624d" ], "package_ndc": [ "54092-171-12", "54092-172-12", "54092-173-12" ], "nui": [ "N0000008486", "N0000175751", "N0000185506", "N0000191266", "N0000187064", "N0000185507", "N0000185607" ], "pharm_class_pe": [ "Decreased Central Nervous System Disorganized Electrical Activity [PE]" ], "pharm_class_epc": [ "Mood Stabilizer [EPC]" ], "pharm_class_moa": [ "Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2C19 Inducers [MoA]" ], "unii": [ "33CM23913M" ] }, "update_date": "12/19/2025", "therapeutic_category": [ "Neurology" ], "dosage_form": "Capsule, Extended Release", "presentation": "Carbatrol, Capsule, Extended Release, 100 mg (NDC 54092-171-12)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "03/24/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "0074-7098-03", "generic_name": "Pilocarpine Hydrochloride Ophthalmic Solution", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA214028" ], "brand_name": [ "VUITY" ], "generic_name": [ "PILOCARPINE HYDROCHLORIDE" ], "manufacturer_name": [ "AbbVie Inc." ], "product_ndc": [ "0074-7098" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "OPHTHALMIC" ], "substance_name": [ "PILOCARPINE HYDROCHLORIDE" ], "rxcui": [ "2584552", "2584557" ], "spl_id": [ "ed4cf150-c4b6-4d26-9326-e3a3490de489" ], "spl_set_id": [ "8d806897-8a2a-4518-8c68-0ec3b778de50" ], "package_ndc": [ "0074-7098-02", "0074-7098-01", "0074-7098-03", "0074-7098-04", "0074-7098-05", "0074-7098-06" ], "unii": [ "0WW6D218XJ" ] }, "update_date": "03/24/2026", "therapeutic_category": [ "Ophthalmology" ], "dosage_form": "Ophthalmic Solution", "presentation": "Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-03)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "11/04/2024", "package_ndc": "50633-310-11", "generic_name": "Hydroxocobalamin Injection", "related_info_link": "https://www.fda.gov/media/185400/download", "contact_info": "1 877 377 3784", "availability": "Limited Availability", "related_info": "Cyanokit is available to order. To address the drug shortage, BTG International Inc (a SERB Pharmaceuticals company) coordinated with the U.S. Food and Drug Administration (FDA) to make the following impacted batches available to U.S. patients during this period of shortage.", "openfda": { "application_number": [ "NDA022041" ], "brand_name": [ "CYANOKIT" ], "generic_name": [ "HYDROXOCOBALAMIN" ], "manufacturer_name": [ "BTG INTERNATIONAL INC." ], "product_ndc": [ "50633-310" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "HYDROXOCOBALAMIN" ], "rxcui": [ "700496", "700499" ], "spl_id": [ "9955075c-c059-4b63-b387-e98ef13e60dc" ], "spl_set_id": [ "d56fcc8d-bd64-46ab-b0c0-2124bd745a6b" ], "package_ndc": [ "50633-310-11" ], "nui": [ "N0000175429" ], "pharm_class_epc": [ "Antidote [EPC]" ], "unii": [ "Q40X8H422O" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Injection", "presentation": "Cyanokit, Injection, 5 g/250mL (NDC 50633-310-11)", "company_name": "BTG International Inc.", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "06/01/2026", "update_type": "New", "initial_posting_date": "06/01/2026", "package_ndc": "0009-4073-04", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA050441" ], "brand_name": [ "CLEOCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-4073", "0009-3051", "0009-5095" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "1737244", "1737245", "1737578", "1737579", "1737581", "1737582" ], "spl_id": [ "8d0dac99-6ec9-4648-8ae1-0cc2894d56cf" ], "spl_set_id": [ "a0a2eff7-b7de-42fe-8e5a-0cfbed38bb4b" ], "package_ndc": [ "0009-3051-01", "0009-3051-02", "0009-4073-03", "0009-4073-04", "0009-5095-05", "0009-5095-06" ], "unii": [ "EH6D7113I8" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, 600 mg/4 mL (150 mg/mL); 4 mL Vial NovaPlus (NDC 0009-4073-04)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "70121-1389-7", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "866-525-7270", "availability": "Available", "openfda": { "application_number": [ "ANDA207551" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Amneal Pharmaceuticals LLC" ], "product_ndc": [ "70121-1389", "70121-1388" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909" ], "spl_id": [ "af193b53-1488-401f-8f06-cc193297c4a8" ], "spl_set_id": [ "eb1ba463-ab42-4f49-9ebe-3ad5af108326" ], "package_ndc": [ "70121-1388-1", "70121-1388-8", "70121-1389-1", "70121-1389-7" ], "unii": [ "1018WH7F9I" ] }, "update_date": "06/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 70121-1389-7)", "company_name": "Amneal Pharmaceuticals", "status": "Current" }, { "discontinued_date": "10/27/2025", "update_type": "New", "initial_posting_date": "10/27/2025", "package_ndc": "0310-6627-02", "generic_name": "Pramlintide Acetate Injection", "contact_info": "800-236-9933", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": { "application_number": [ "NDA021332" ], "brand_name": [ "SYMLINPEN" ], "generic_name": [ "PRAMLINTIDE ACETATE" ], "manufacturer_name": [ "AstraZeneca Pharmaceuticals LP" ], "product_ndc": [ "0310-6627", "0310-6615" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "PRAMLINTIDE ACETATE" ], "rxcui": [ "861042", "861043", "861044", "861045" ], "spl_id": [ "a84753f1-6ac5-4a47-a382-29972938ccaa" ], "spl_set_id": [ "4aea30ff-eb0d-45c1-b114-3127966328ff" ], "package_ndc": [ "0310-6615-02", "0310-6627-02" ], "unii": [ "726I6TE06G" ] }, "update_date": "10/27/2025", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "SymlinPen® 120 , Injection, 1000 ug/1 mL (NDC 0310-6627-02)", "company_name": "AstraZeneca AB", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4662-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": { "application_number": [ "ANDA215802" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Lannett Company, Inc." ], "product_ndc": [ "0527-4662", "0527-4661", "0527-4663", "0527-4664", "0527-4665", "0527-4666", "0527-4667" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "cb49954d-0f9d-4471-bc86-0c926473c00b" ], "spl_set_id": [ "2cedb4c2-1e40-4bc4-b9f4-127150c4afbd" ], "package_ndc": [ "0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0527-4662-37)", "company_name": "Lannett Company, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "65219-464-50", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA207449" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "FRESENIUS KABI USA, LLC" ], "product_ndc": [ "65219-464", "65219-456", "65219-458", "65219-460", "65219-462" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795607", "1795609", "1795610", "1795612", "1795616" ], "spl_id": [ "efc3b0c9-518a-47db-bb3e-ebdfd4646e9b" ], "spl_set_id": [ "576a22d8-5f2f-497e-80ad-1842ca74bb53" ], "package_ndc": [ "65219-456-05", "65219-456-60", "65219-464-05", "65219-464-50", "65219-458-05", "65219-458-30", "65219-460-05", "65219-460-20", "65219-462-05", "65219-462-10" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-464-50)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-63", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-286", "63323-285", "63323-287", "63323-288" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091" ], "spl_id": [ "324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cb6583ff-cde4-4280-aa5b-0bea2b844792", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c" ], "spl_set_id": [ "dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "cb6583ff-cde4-4280-aa5b-0bea2b844792", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6" ], "package_ndc": [ "63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-51", "63323-286-55", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-63)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "03/26/2026", "update_type": "New", "initial_posting_date": "03/26/2026", "package_ndc": "39822-0355-6", "generic_name": "Lincomycin Hydrochloride Injection", "contact_info": "866-390-4411", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "03/26/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Lincomycin Hydrochloride, Injection, 3 grams/10 mL vial x 10 count (NDC 39822-0355-6)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-2815-01", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA021038" ], "brand_name": [ "PRECEDEX" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-2815", "0409-1454", "0409-3301", "0409-1174" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892" ], "spl_id": [ "e1705533-5a85-441f-a95b-3cb88c47e482" ], "spl_set_id": [ "4419162d-81d4-49bd-96de-1729440bdb74" ], "package_ndc": [ "0409-1454-01", "0409-1454-20", "0409-3301-01", "0409-3301-10", "0409-1174-01", "0409-1174-10", "0409-2815-01" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Precedex, Injection, 1000 mcg/250 mL Glass Bottle NovaPlus (NDC 0409-2815-01)", "company_name": "Pfizer Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/27/2023", "package_ndc": "72888-153-01", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": { "application_number": [ "ANDA075468" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Advagen Pharma Ltd" ], "product_ndc": [ "72888-153", "72888-497", "72888-152", "72888-154" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529", "204892" ], "spl_id": [ "5510f17b-a980-f412-e063-6394a90ae1c4" ], "spl_set_id": [ "30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec" ], "package_ndc": [ "72888-497-01", "72888-497-02", "72888-497-03", "72888-497-04", "72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 72888-153-01)", "company_name": "Rubicon Research Private Limited", "status": "Current" }, { "discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-356-05", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-05)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "76045-105-20", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA203242" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "76045-105", "76045-104", "76045-107", "76045-209" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860113", "860114", "860115" ], "spl_id": [ "0dab642d-7fcf-4301-8ac9-10e64a040c6b" ], "spl_set_id": [ "3d88cbe6-5230-47aa-80af-0c41283d1f00" ], "package_ndc": [ "76045-104-10", "76045-105-20", "76045-107-10", "76045-209-00", "76045-209-10" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 60 mg/2 mL (NDC 76045-105-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0781-3288-09", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-525-8747", "availability": "Available", "openfda": { "application_number": [ "ANDA201692" ], "brand_name": [ "CLINDAMYCIN IN 5 PERCENT DEXTROSE" ], "generic_name": [ "CLINDAMYCIN IN 5 PERCENT DEXTROSE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-3288", "0781-3289", "0781-3290" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN" ], "rxcui": [ "309335", "309336", "309339" ], "spl_id": [ "b553b8ab-ef4d-40ae-a5fb-a6242f2ad30a" ], "spl_set_id": [ "231d95a6-5e5f-4a45-a92b-d3d16ef0a7ca" ], "package_ndc": [ "0781-3288-91", "0781-3288-09", "0781-3289-91", "0781-3289-09", "0781-3290-91", "0781-3290-09" ], "nui": [ "N0000009982", "N0000175443", "M0515779", "N0000175731" ], "pharm_class_pe": [ "Decreased Sebaceous Gland Activity [PE]", "Neuromuscular Blockade [PE]" ], "pharm_class_epc": [ "Lincosamide Antibacterial [EPC]" ], "pharm_class_cs": [ "Lincosamides [CS]" ], "unii": [ "3U02EL437C" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09)", "company_name": "Sandoz Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-801-30", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Available", "openfda": { "application_number": [ "ANDA064150" ], "brand_name": [ "RIFAMPIN" ], "generic_name": [ "RIFAMPIN" ], "manufacturer_name": [ "EPIC PHARMA, LLC" ], "product_ndc": [ "42806-801", "42806-799" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RIFAMPIN" ], "rxcui": [ "198201", "198202" ], "spl_id": [ "a4ac02e8-68ac-4e79-8ca5-0939dd002c87" ], "spl_set_id": [ "0391f1e1-70d4-4b15-8b58-055bb6a385b8" ], "package_ndc": [ "42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05" ], "nui": [ "N0000175500", "M0019113" ], "pharm_class_epc": [ "Rifamycin Antibacterial [EPC]" ], "pharm_class_cs": [ "Rifamycins [CS]" ], "unii": [ "VJT6J7R4TR" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 150 mg (NDC 42806-801-30)", "company_name": "Epic Pharma, LLC", "status": "Current" }, { "discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4312-61", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": { "application_number": [ "NDA211280" ], "brand_name": [ "REYVOW" ], "generic_name": [ "LASMIDITAN" ], "manufacturer_name": [ "Eli Lilly and Company" ], "product_ndc": [ "0002-4312", "0002-4491" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LASMIDITAN" ], "rxcui": [ "2256937", "2256943", "2256945", "2256947" ], "spl_id": [ "29f467c6-0365-4831-b4ce-9a0eefaf5896" ], "spl_set_id": [ "aea3358c-ff41-4490-9e6d-c7bf7b3de13f" ], "package_ndc": [ "0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62" ], "unii": [ "760I9WM792" ] }, "update_date": "11/03/2025", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 50 mg (NDC 0002-4312-61)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued" }, { "discontinued_date": "07/02/2026", "update_type": "New", "initial_posting_date": "07/02/2026", "package_ndc": "0781-6172-86", "generic_name": "Desflurane Liquid for Inhalation", "contact_info": "Sandoz: 800-525-8747", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sandoz, Inc.", "openfda": { "application_number": [ "ANDA208234" ], "brand_name": [ "DESFLURANE" ], "generic_name": [ "DESFLURANE" ], "manufacturer_name": [ "Sandoz Inc." ], "product_ndc": [ "0781-6172" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RESPIRATORY (INHALATION)" ], "substance_name": [ "DESFLURANE" ], "rxcui": [ "562366" ], "spl_id": [ "ecf9968e-58b0-4792-e053-2995a90aef25" ], "spl_set_id": [ "21ba0e18-3dbc-4feb-a3a4-f6470c00910a" ], "package_ndc": [ "0781-6172-22", "0781-6172-86" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "CRS35BZ94Q" ] }, "update_date": "07/02/2026", "therapeutic_category": [ "Anesthesia" ], "presentation": "Desflurane, Liquid for Inhalation, 240 mL/240 mL (NDC 0781-6172-86)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued" }, { "discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "50742-430-01", "generic_name": "Decitabine Injection", "contact_info": "866-321-5031", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "02/20/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Decitabine, Injection, 50 mg (NDC 50742-430-01)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued" }, { "discontinued_date": "04/22/2026", "update_type": "New", "initial_posting_date": "04/22/2026", "package_ndc": "0069-0187-21", "generic_name": "Palbociclib Capsule", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacturing of the capsule presentation. 75 mg Tablet \nNDC 0069-0284-03 will continue to be manufactured.", "openfda": { "application_number": [ "NDA207103" ], "brand_name": [ "IBRANCE" ], "generic_name": [ "PALBOCICLIB" ], "manufacturer_name": [ "Pfizer Laboratories Div Pfizer Inc" ], "product_ndc": [ "0069-0187", "0069-0188", "0069-0189" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "PALBOCICLIB" ], "rxcui": [ "1601380", "1601386", "1601388", "1601390", "1601392", "1601394" ], "spl_id": [ "7dcc9b87-0aa4-4a00-aced-96be3553e8ac" ], "spl_set_id": [ "e0e6412f-50b4-4fd4-9364-62818d121a07" ], "package_ndc": [ "0069-0187-21", "0069-0188-21", "0069-0189-21" ], "nui": [ "N0000175605", "N0000175082", "N0000190114" ], "pharm_class_epc": [ "Kinase Inhibitor [EPC]" ], "pharm_class_moa": [ "Kinase Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]" ], "unii": [ "G9ZF61LE7G" ] }, "update_date": "04/22/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Capsule", "presentation": "Ibrance, Capsule, 75 mg (NDC 0069-0187-21)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4277-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA088327" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4277", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4276", "0409-4275" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763" ], "spl_id": [ "05d1a200-9d75-4e48-b14a-5069d4ab816f" ], "spl_set_id": [ "3b2dd84e-cee8-4e58-d494-395a65a353a0" ], "package_ndc": [ "0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 400 mg/20 mL (2%; 20 mg/mL) (NDC 0409-4277-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/08/2019", "package_ndc": "63323-165-30", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "3 & 7 month expiry available on request. Check wholesalers for inventory.", "openfda": { "application_number": [ "ANDA084916" ], "brand_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "generic_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-165" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "rxcui": [ "1116927", "1812194" ], "spl_id": [ "1815f54a-5637-45bc-a582-3e62350935ba", "9dd90418-e564-4bc5-9077-506a1c2c1bce" ], "spl_set_id": [ "2b626a48-c7aa-4443-9164-a08ff069ccd1", "4fedef4f-ec96-4f36-b2f0-01e243e3b89e" ], "package_ndc": [ "63323-165-11", "63323-165-51", "63323-165-13", "63323-165-53", "63323-165-02", "63323-165-01", "63323-165-03", "63323-165-05", "63323-165-30", "63323-165-16", "63323-165-26" ], "unii": [ "AI9376Y64P" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-30)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-064-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": { "application_number": [ "ANDA207636" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-064", "70069-061", "70069-062", "70069-063", "70069-065", "70069-066", "70069-067" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483" ], "spl_id": [ "79b226f0-c08a-4f84-bf2b-ae5c60e01d67" ], "spl_set_id": [ "ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64" ], "package_ndc": [ "70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10" ], "unii": [ "V910P86109" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-10)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "83634-653-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "Avenacy, LLC: 877-283-6229", "availability": "Available", "related_info": "Distributed by Avenacy, LLC", "openfda": { "application_number": [ "ANDA219535" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Avenacy, LLC" ], "product_ndc": [ "83634-653", "83634-651" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1737562", "1737566", "1737568" ], "spl_id": [ "8fb1dd7b-f349-4a64-96c1-bd72bf748f3b" ], "spl_set_id": [ "46480253-29b9-4d7f-98ed-10377929026b" ], "package_ndc": [ "83634-653-41", "83634-653-02", "83634-653-42", "83634-653-05", "83634-653-43", "83634-653-30", "83634-651-41", "83634-651-10", "83634-651-42", "83634-651-20", "83634-651-43", "83634-651-50" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydochloride, Injection, 50 mg/5 mL (NDC 83634-653-05)", "company_name": "Anthea Pharma", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "70069-021-25", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": { "application_number": [ "ANDA207442" ], "brand_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "generic_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-021" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "rxcui": [ "1812079" ], "spl_id": [ "73618326-ff56-4a30-9d6d-6b019b61c2cd" ], "spl_set_id": [ "799028e2-c0e4-494f-89ff-1b786babc34a" ], "package_ndc": [ "70069-021-01", "70069-021-25" ], "unii": [ "AI9376Y64P" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 70069-021-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "42023-146-25", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-828-9393", "availability": "Available", "related_info": "Please check wholesalers for inventory", "openfda": { "application_number": [ "ANDA203972" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "42023-146", "42023-186", "42023-187" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "309710", "1718906", "1718909" ], "spl_id": [ "54174211-6684-4fb9-a605-be12b94e2948" ], "spl_set_id": [ "1ee59985-4c1d-48f7-b8f9-5584c2d55e08" ], "package_ndc": [ "42023-146-25", "42023-186-20", "42023-187-10" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 42023-146-25)", "company_name": "Par Health, USA LLC", "status": "Current" }, { "discontinued_date": "09/19/2025", "update_type": "New", "initial_posting_date": "09/19/2025", "package_ndc": "0228-2837-11", "generic_name": "Pilocarpine Hydrochloride Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": { "application_number": [ "NDA020237" ], "brand_name": [ "PILOCARPINE HYDROCHLORIDE" ], "generic_name": [ "PILOCARPINE HYDROCHLORIDE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0228-2837", "0228-2801" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "PILOCARPINE HYDROCHLORIDE" ], "rxcui": [ "1000913", "1001004" ], "spl_id": [ "7db72b88-d664-4f26-901c-46c901b20d80" ], "spl_set_id": [ "610022b7-7dc9-405a-a580-104657f43bdf" ], "package_ndc": [ "0228-2801-11", "0228-2837-11" ], "unii": [ "0WW6D218XJ" ] }, "update_date": "09/19/2025", "therapeutic_category": [ "Other" ], "dosage_form": "Tablet", "presentation": "Salagen, Tablet, 7.5 mg (NDC 0228-2837-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-496-97", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE MPF" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-496", "63323-492", "63323-493" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "rxcui": [ "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737636", "1737637", "1737640", "1737641", "1737763", "1737764" ], "spl_id": [ "fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df" ], "spl_set_id": [ "d5e0d06f-ba1e-44d4-aa89-39d6c146dc23" ], "package_ndc": [ "63323-492-08", "63323-492-97", "63323-493-03", "63323-493-97", "63323-493-01", "63323-493-91", "63323-496-03", "63323-496-97" ], "unii": [ "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-496-97)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0781-3494-95", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "See Related Information section below for customer service information", "availability": "Available", "related_info": "Marketed by Sandoz Inc.; Customer service: 800-525-8747", "openfda": { "application_number": [ "ANDA209065" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE" ], "manufacturer_name": [ "Sandoz Inc." ], "product_ndc": [ "0781-3494", "0781-3493", "0781-3495" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718900", "1718906", "1718909" ], "spl_id": [ "fdf227d9-008e-60f8-e053-6294a90af5c4" ], "spl_set_id": [ "809e8f77-390f-4cc8-8c8a-4f67a249c9df" ], "package_ndc": [ "0781-3493-95", "0781-3494-95", "0781-3495-95" ], "unii": [ "1018WH7F9I" ] }, "update_date": "07/30/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (NDC 0781-3494-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "55150-199-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: end-August 2026. Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA205612" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-199", "55150-195", "55150-196", "55150-197", "55150-198", "55150-200", "55150-201" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483" ], "spl_id": [ "1e5f1368-058a-492c-b4b7-d9329a7745e2" ], "spl_set_id": [ "3763b7b6-da49-4658-b93d-28f5da24d09e" ], "package_ndc": [ "55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20" ], "unii": [ "V910P86109" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-199-20)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-492-31", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE MPF" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487", "63323-493", "63323-496" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029", "1737636", "1737637", "1737640", "1737641", "1737763", "1737764" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428", "0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33", "fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17", "4dd52202-8eef-4136-92dd-ada573b7cf74", "d5e0d06f-ba1e-44d4-aa89-39d6c146dc23" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31", "63323-492-41", "63323-492-16", "63323-492-43", "63323-492-36", "63323-492-45", "63323-492-26", "63323-485-41", "63323-485-26", "63323-486-41", "63323-486-26", "63323-482-41", "63323-482-26", "63323-495-41", "63323-495-26", "63323-492-08", "63323-492-97", "63323-493-03", "63323-493-97", "63323-493-01", "63323-493-91", "63323-496-03", "63323-496-97" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-31)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2021", "package_ndc": "71288-505-03", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-824-8426", "availability": "Available", "openfda": { "application_number": [ "ANDA204843" ], "brand_name": [ "DEXMEDETOMIDINE" ], "generic_name": [ "DEXMEDETOMIDINE" ], "manufacturer_name": [ "Meitheal Pharmaceuticals Inc." ], "product_ndc": [ "71288-505" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "309710" ], "spl_id": [ "aa312d38-51c9-4615-a1ad-7dd639394b0f" ], "spl_set_id": [ "8fa36783-b94d-4084-8c41-40ee64192074" ], "package_ndc": [ "71288-505-02", "71288-505-03" ], "unii": [ "1018WH7F9I" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 71288-505-03)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current" }, { "discontinued_date": "08/13/2026", "update_type": "New", "initial_posting_date": "08/13/2026", "package_ndc": "0228-2550-11", "generic_name": "Diclofenac Sodium Tablet, Delayed Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA074514" ], "brand_name": [ "DICLOFENAC SODIUM" ], "generic_name": [ "DICLOFENAC SODIUM" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0228-2550", "0228-2551" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DICLOFENAC SODIUM" ], "rxcui": [ "855906", "855926" ], "spl_id": [ "a1fbc994-b8a6-4759-be76-1cfd98275ca6" ], "spl_set_id": [ "a57b897e-0cbe-4ac3-969f-b00357a0cfa8" ], "package_ndc": [ "0228-2550-06", "0228-2550-11", "0228-2550-96", "0228-2551-06", "0228-2551-11", "0228-2551-96" ], "unii": [ "QTG126297Q" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Musculoskeletal", "Rheumatology" ], "dosage_form": "Tablet", "presentation": "Diclofenac Sodium, Tablet, Delayed Release, 50 mg (NDC 0228-2550-11)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "New", "initial_posting_date": "02/03/2016", "package_ndc": "70069-048-20", "generic_name": "Sodium Acetate Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": { "application_number": [ "ANDA219826" ], "brand_name": [ "SODIUM ACETATE ANHYDROUS" ], "generic_name": [ "SODIUM ACETATE ANHYDROUS" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-048", "70069-047" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM ACETATE ANHYDROUS" ], "rxcui": [ "237371" ], "spl_id": [ "1aae3237-9555-442b-b962-619d23f7e00a" ], "spl_set_id": [ "93edebd6-ef7f-483a-80b6-bfaf34ea5ded" ], "package_ndc": [ "70069-047-25", "70069-048-20" ], "unii": [ "NVG71ZZ7P0" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition" ], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-048-20)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6045-25", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA018140" ], "brand_name": [ "LORAZEPAM" ], "generic_name": [ "LORAZEPAM" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6045", "0641-6044", "0641-6046", "0641-6047" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "LORAZEPAM" ], "rxcui": [ "238100", "238101", "1665188", "1665326" ], "spl_id": [ "7c73dbc6-2623-4443-9b05-97dec7a0be2e" ], "spl_set_id": [ "e9b54e42-04cf-4c62-90e1-36f7b31a4e81" ], "package_ndc": [ "0641-6044-01", "0641-6044-25", "0641-6046-01", "0641-6046-10", "0641-6045-01", "0641-6045-25", "0641-6047-01", "0641-6047-10" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "O26FZP769L" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "12/10/2025", "update_type": "New", "initial_posting_date": "12/10/2025", "package_ndc": "58468-0127-1", "generic_name": "Doxercalciferol Injection", "contact_info": "800-633-1610", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/10/2025", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Hectorol, Injection, 4 mcg/2 mL injection 50 multiple-dose vials (NDC 58468-0127-1)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "12/27/2023", "package_ndc": "45567-0060-1", "generic_name": "Technetium TC-99M Pyrophosphate Kit Injection", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA019039" ], "brand_name": [ "KIT FOR THE PREPARATION OF TECHNETIUM TC99M PYROPHOSPHATE" ], "generic_name": [ "TECHNETIUM TC99M PYROPHOSPHATE" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "45567-0060" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "TECHNETIUM TC-99M PYROPHOSPHATE" ], "spl_id": [ "3010b45e-eed1-a5d0-e063-6294a90a40cf" ], "spl_set_id": [ "1f0cbd23-2fb3-43b7-b8af-7de246151149" ], "package_ndc": [ "45567-0060-1", "45567-0060-2" ], "nui": [ "N0000177914", "N0000000205" ], "pharm_class_epc": [ "Radioactive Diagnostic Agent [EPC]" ], "pharm_class_moa": [ "Radiopharmaceutical Activity [MoA]" ], "unii": [ "5L76I61H2B" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Medical Imaging" ], "dosage_form": "Injection", "presentation": "CIS-PYRO, Injection, 12 mg/10 mL (NDC 45567-0060-1)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-017-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 17.5 mg/.4 mL (NDC 82497-017-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued" }, { "discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "50742-463-16", "generic_name": "Docetaxel Injection", "contact_info": "866-321-5031", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "02/20/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Docetaxel, Injection, 10 mg/1 mL (NDC 50742-463-16)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-4596-20", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA021038" ], "brand_name": [ "PRECEDEX" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4596", "0409-0155" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718907", "1718909", "1718910" ], "spl_id": [ "b62d8928-1ce3-488e-a89f-d7085c5510a7" ], "spl_set_id": [ "92b7ddaa-e45a-4b64-a802-bb5df8771dd6" ], "package_ndc": [ "0409-4596-01", "0409-4596-20", "0409-0155-01", "0409-0155-02" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-4596-20)", "company_name": "Pfizer Inc.", "status": "Current" }, { "update_type": "New", "initial_posting_date": "01/01/2012", "package_ndc": "70069-631-25", "generic_name": "Atropine Sulfate Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": { "application_number": [ "ANDA215969" ], "brand_name": [ "ATROPINE SULFATE" ], "generic_name": [ "ATROPINE SULFATE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-631", "70069-641" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ATROPINE SULFATE" ], "rxcui": [ "1190795", "1666781" ], "spl_id": [ "7a8a5552-fe21-4d36-8396-b7c99f41b4c4" ], "spl_set_id": [ "a6fac578-c7bc-4b3c-a454-7889cc819118" ], "package_ndc": [ "70069-631-01", "70069-631-25", "70069-641-01", "70069-641-25" ], "unii": [ "03J5ZE7KA5" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .4 mg/1 mL (NDC 70069-631-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "13107-073-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 or CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability: October 2026", "openfda": { "application_number": [ "ANDA202424" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Aurolife Pharma, LLC" ], "product_ndc": [ "13107-073", "13107-068", "13107-069", "13107-070", "13107-071", "13107-072", "13107-074" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "5962d880-9f18-4a57-8c95-ca0ec1e86f44" ], "spl_set_id": [ "a582d57f-d191-4ca5-b105-585b2d8a0e3e" ], "package_ndc": [ "13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "07/21/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 13107-073-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-11", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA016673" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0017", "0338-0023" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618" ], "spl_id": [ "9c644eb4-5844-415a-8c01-4459d98af222" ], "spl_set_id": [ "3bb406a9-f5cb-403a-b1bb-5c4facbea3d5" ], "package_ndc": [ "0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-11)", "company_name": "Baxter Healthcare", "status": "Current" }, { "discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "45802-580-46", "generic_name": "Scopolamine Transdermal System", "contact_info": "866-634-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA078830" ], "brand_name": [ "SCOPOLAMINE TRANSDERMAL SYSTEM" ], "generic_name": [ "SCOPOLAMINE TRANSDERMAL SYSTEM" ], "manufacturer_name": [ "Padagis Israel Pharmaceuticals Ltd" ], "product_ndc": [ "45802-580" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "TRANSDERMAL" ], "substance_name": [ "SCOPOLAMINE" ], "rxcui": [ "226552" ], "spl_id": [ "d334a21d-7546-477f-a66a-f95b2cf523ce" ], "spl_set_id": [ "cb93bfad-3e37-4a27-92f6-f21703ae7bdf" ], "package_ndc": [ "45802-580-84", "45802-580-46", "45802-580-62", "45802-580-01" ], "nui": [ "N0000175574", "N0000175370" ], "pharm_class_epc": [ "Anticholinergic [EPC]" ], "pharm_class_moa": [ "Cholinergic Antagonists [MoA]" ], "unii": [ "DL48G20X8X" ] }, "update_date": "11/03/2025", "therapeutic_category": [ "Gastroenterology", "Neurology", "Other" ], "dosage_form": "Transdermal System", "presentation": "Scopolamine, Transdermal System, 1 mg (NDC 45802-580-46)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6857-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA202835" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE" ], "manufacturer_name": [ "Mylan Pharmaceuticals Inc." ], "product_ndc": [ "0378-6857", "0378-6854", "0378-6855", "0378-6856", "0378-6858", "0378-6859", "0378-6860" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "6e77cd71-95ae-4fa8-830b-ab62b714e4b9" ], "spl_set_id": [ "efbde0f6-b848-4664-b741-c6c630e66108" ], "package_ndc": [ "0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0378-6857-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0990-7930-03", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Available", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA018080" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "ICU Medical, Inc." ], "product_ndc": [ "0990-7930", "0990-7923", "0990-7922" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621" ], "spl_id": [ "06e4d957-1a56-4adb-a42b-fe0773b2fa97" ], "spl_set_id": [ "8b25b7e0-703e-4b43-a4eb-52863511602d" ], "package_ndc": [ "0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-03)", "company_name": "Otsuka ICU Medical LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "42806-344-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(718) 276-8600 ext. 3", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA040444" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Epic Pharma, LLC" ], "product_ndc": [ "42806-344", "42806-339", "42806-341", "42806-343", "42806-345" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961" ], "spl_id": [ "f11301e2-3b5d-468d-b44c-45839e7e5dfb" ], "spl_set_id": [ "1757e132-061d-4773-89ed-fdc77f69008f" ], "package_ndc": [ "42806-339-01", "42806-341-01", "42806-343-01", "42806-344-01", "42806-345-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 42806-344-01)", "company_name": "Epic Pharma, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "discontinued_date": "07/24/2026", "update_type": "New", "initial_posting_date": "07/24/2026", "package_ndc": "0074-2340-30", "generic_name": "Ritonavir Tablet", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA022417" ], "brand_name": [ "NORVIR" ], "generic_name": [ "RITONAVIR" ], "manufacturer_name": [ "AbbVie Inc." ], "product_ndc": [ "0074-2340", "0074-3333", "0074-1940", "0074-3399" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RITONAVIR" ], "rxcui": [ "152971", "199249", "900575", "900577", "1926066", "1926069" ], "spl_id": [ "08f28b14-eabc-4a9a-b066-d8eda837e9e4" ], "spl_set_id": [ "2849298e-de6e-47bb-8194-56e075b33fc3" ], "package_ndc": [ "0074-3333-30", "0074-1940-63", "0074-3399-30", "0074-2340-30" ], "nui": [ "N0000000246", "N0000191001", "N0000175889", "N0000190114", "N0000182137", "N0000185607", "N0000190118", "N0000185503", "N0000190113", "N0000182141", "N0000191266", "N0000185507", "N0000187064", "N0000190117" ], "pharm_class_moa": [ "HIV Protease Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 2C19 Inducers [MoA]", "Cytochrome P450 3A Inducers [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "UDP Glucuronosyltransferases Inducers [MoA]" ], "pharm_class_epc": [ "Cytochrome P450 3A Inhibitor [EPC]", "Protease Inhibitor [EPC]" ], "unii": [ "O3J8G9O825" ] }, "update_date": "07/24/2026", "therapeutic_category": [ "Antiviral" ], "dosage_form": "Tablet", "presentation": "Norvir, Tablet, 100 mg (NDC 0074-2340-30)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-556-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA218604" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Elite Laboratories, Inc." ], "product_ndc": [ "64850-556", "64850-550", "64850-551", "64850-552", "64850-553", "64850-554", "64850-555" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "2d33f701-8067-4a48-98cc-4e7dacaf3cc4" ], "spl_set_id": [ "0e024b69-567c-4b40-9c3e-a2daec34256c" ], "package_ndc": [ "64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 64850-556-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1075-02", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA020255" ], "brand_name": [ "DOBUTAMINE HYDROCHLORIDE IN DEXTROSE" ], "generic_name": [ "DOBUTAMINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-1075", "0338-1073", "0338-1077" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOBUTAMINE HYDROCHLORIDE" ], "rxcui": [ "309985", "309986", "309987" ], "spl_id": [ "34c787c1-46f7-4264-951d-c88a34dca533" ], "spl_set_id": [ "6b17b98b-e06d-42ed-925f-69aa2699dead" ], "package_ndc": [ "0338-1073-02", "0338-1075-02", "0338-1077-02" ], "unii": [ "0WR771DJXV" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Cardiovascular", "Pediatric", "Renal" ], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 200 mg/100 mL (NDC 0338-1075-02)", "company_name": "Baxter Healthcare", "status": "Current" }, { "discontinued_date": "12/03/2025", "update_type": "New", "initial_posting_date": "12/03/2025", "package_ndc": "0409-7101-66", "generic_name": "Sodium Chloride 0.9% Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA019465" ], "brand_name": [ "SODIUM CHLORIDE" ], "generic_name": [ "SODIUM CHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-7101", "0409-7132" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM CHLORIDE" ], "rxcui": [ "1807547", "1807631", "1807632", "1807633" ], "spl_id": [ "147cbba6-2ead-49c4-bce7-4e9c65b303c9" ], "spl_set_id": [ "a2a964f7-c3ec-4dfb-e3a0-6d8136a80397" ], "package_ndc": [ "0409-7101-68", "0409-7101-66", "0409-7101-69", "0409-7101-67", "0409-7101-04", "0409-7101-02", "0409-7132-68", "0409-7132-66", "0409-7132-69", "0409-7132-67", "0409-7132-04", "0409-7132-02" ], "unii": [ "451W47IQ8X" ] }, "update_date": "12/03/2025", "therapeutic_category": [ "Gastroenterology", "Other", "Renal" ], "dosage_form": "Injection", "presentation": "Sodium Chloride 0.9%, Injection, 50 mL ADD-Vantage® Flexible Container (NDC 0409-7101-66)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "47781-566-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": { "application_number": [ "ANDA214547" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Alvogen Inc." ], "product_ndc": [ "47781-566", "47781-562", "47781-563", "47781-564", "47781-565", "47781-567", "47781-568" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "db02ec6b-f17f-ab22-b671-e1ddb90e017c" ], "spl_set_id": [ "7f2dd6ee-3363-c87c-9693-ed838942556c" ], "package_ndc": [ "47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 47781-566-01)", "company_name": "Alvogen", "status": "Current" }, { "discontinued_date": "08/13/2026", "update_type": "New", "initial_posting_date": "08/13/2026", "package_ndc": "0228-2551-96", "generic_name": "Diclofenac Sodium Tablet, Delayed Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA074514" ], "brand_name": [ "DICLOFENAC SODIUM" ], "generic_name": [ "DICLOFENAC SODIUM" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0228-2551", "0228-2550" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DICLOFENAC SODIUM" ], "rxcui": [ "855906", "855926" ], "spl_id": [ "a1fbc994-b8a6-4759-be76-1cfd98275ca6" ], "spl_set_id": [ "a57b897e-0cbe-4ac3-969f-b00357a0cfa8" ], "package_ndc": [ "0228-2550-06", "0228-2550-11", "0228-2550-96", "0228-2551-06", "0228-2551-11", "0228-2551-96" ], "unii": [ "QTG126297Q" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Musculoskeletal", "Rheumatology" ], "dosage_form": "Tablet", "presentation": "Diclofenac Sodium, Tablet, Delayed Release, 75 mg (NDC 0228-2551-96)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7922-55", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Available", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA016367" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "ICU Medical, Inc." ], "product_ndc": [ "0990-7922", "0990-7923", "0990-7930" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621" ], "spl_id": [ "06e4d957-1a56-4adb-a42b-fe0773b2fa97" ], "spl_set_id": [ "8b25b7e0-703e-4b43-a4eb-52863511602d" ], "package_ndc": [ "0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-55)", "company_name": "Otsuka ICU Medical LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-286", "63323-285", "63323-287", "63323-288" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091" ], "spl_id": [ "324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cb6583ff-cde4-4280-aa5b-0bea2b844792", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c" ], "spl_set_id": [ "dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "cb6583ff-cde4-4280-aa5b-0bea2b844792", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6" ], "package_ndc": [ "63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-51", "63323-286-55", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "72205-137-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA218306" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Novadoz Pharmaceuticals LLC" ], "product_ndc": [ "72205-137", "72205-132", "72205-133", "72205-134", "72205-135", "72205-136" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811" ], "spl_set_id": [ "a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811" ], "package_ndc": [ "72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 72205-137-91)", "company_name": "Novadoz Pharmaceuticals LLC", "status": "Current" }, { "update_type": "New", "initial_posting_date": "08/27/2025", "package_ndc": "0409-7809-24", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA018826" ], "brand_name": [ "DOPAMINE HYDROCHLORIDE IN DEXTROSE" ], "generic_name": [ "DOPAMINE HYDROCHLORIDE IN DEXTROSE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-7809", "0409-7810", "0409-0042", "0409-1858" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOPAMINE HYDROCHLORIDE" ], "rxcui": [ "1292887", "1743877", "1743879" ], "spl_id": [ "188ce800-ff3a-4b22-9a95-2273c3bc99ae" ], "spl_set_id": [ "08f23f6e-150d-45ea-098e-f2edf64c21a1" ], "package_ndc": [ "0409-7809-11", "0409-7809-22", "0409-7809-31", "0409-7809-24", "0409-7810-11", "0409-7810-22", "0409-0042-01", "0409-0042-12", "0409-1858-01", "0409-1858-12" ], "unii": [ "7L3E358N9L" ] }, "update_date": "08/27/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride in Dextrose 5% in plastic container, Injection, 800 mg/500 mL (1,600 mcg/mL) (NDC 0409-7809-24)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "64253-020-30", "generic_name": "Sterile Water Injection", "contact_info": "630-682-4600", "availability": "Available", "openfda": { "application_number": [ "ANDA211188" ], "brand_name": [ "STERILE WATER" ], "generic_name": [ "STERILE WATER FOR INJECTION" ], "manufacturer_name": [ "Medefil, Inc." ], "product_ndc": [ "64253-020" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "WATER" ], "spl_id": [ "2b39b41d-419a-dab8-e063-6394a90a319a" ], "spl_set_id": [ "99e99a50-82d5-aff6-e053-2a95a90a8c56" ], "package_ndc": [ "64253-020-21", "64253-020-23", "64253-020-30", "64253-020-35", "64253-020-52", "64253-020-25", "64253-020-91" ], "unii": [ "059QF0KO0R" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 10 mL/10 mL (NDC 64253-020-30)", "company_name": "Medefil, Inc.", "status": "Current" }, { "discontinued_date": "07/24/2026", "update_type": "New", "initial_posting_date": "07/24/2026", "package_ndc": "0074-6799-22", "generic_name": "Lopinavir and Ritonavir Tablet", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "07/24/2026", "therapeutic_category": [ "Antiviral" ], "dosage_form": "Tablet", "presentation": "Kaletra, Tablet, 200 mg; 50 mg (NDC 0074-6799-22)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "42806-339-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(718) 276-8600 ext. 3", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA040444" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Epic Pharma, LLC" ], "product_ndc": [ "42806-339", "42806-341", "42806-343", "42806-344", "42806-345" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961" ], "spl_id": [ "f11301e2-3b5d-468d-b44c-45839e7e5dfb" ], "spl_set_id": [ "1757e132-061d-4773-89ed-fdc77f69008f" ], "package_ndc": [ "42806-339-01", "42806-341-01", "42806-343-01", "42806-344-01", "42806-345-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 42806-339-01)", "company_name": "Epic Pharma, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "36000-284-25", "generic_name": "Furosemide Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "ANDA202747" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "36000-284", "36000-063", "36000-064", "36000-065", "36000-282", "36000-283" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "b4c1ae97-0f6c-4ae1-858a-4e0ab8f1ce53" ], "spl_set_id": [ "c71371a7-75c5-45b8-b762-8d782d4c71bc" ], "package_ndc": [ "36000-063-05", "36000-064-05", "36000-065-05", "36000-282-25", "36000-283-25", "36000-284-25" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 36000-284-25)", "company_name": "Baxter Healthcare", "status": "Current" }, { "discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0378-5815-77", "generic_name": "Valsartan Tablet", "contact_info": "800-796-9526", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA090866" ], "brand_name": [ "VALSARTAN" ], "generic_name": [ "VALSARTAN" ], "manufacturer_name": [ "Mylan Pharmaceuticals Inc." ], "product_ndc": [ "0378-5815", "0378-5807", "0378-5813", "0378-5814" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "VALSARTAN" ], "rxcui": [ "349199", "349200", "349201", "349483" ], "spl_id": [ "a5384d58-48c7-494a-a8a8-c296b316bd91" ], "spl_set_id": [ "73e01dc6-7dd4-421a-a4f6-137e75f69f9a" ], "package_ndc": [ "0378-5807-93", "0378-5813-77", "0378-5814-77", "0378-5815-77" ], "nui": [ "N0000000070", "N0000175561" ], "pharm_class_moa": [ "Angiotensin 2 Receptor Antagonists [MoA]" ], "pharm_class_epc": [ "Angiotensin 2 Receptor Blocker [EPC]" ], "unii": [ "80M03YXJ7I" ] }, "update_date": "11/19/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Valsartan, Tablet, 320 mg (NDC 0378-5815-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "12/06/2018", "package_ndc": "76329-1912-1", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-423-4136", "availability": "Available", "openfda": { "application_number": [ "ANDA202861" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "International Medication Systems, Limited" ], "product_ndc": [ "76329-1912" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "spl_id": [ "99799101-d92b-485b-93ec-f2b5a2e5ca26" ], "spl_set_id": [ "1034467f-d436-4b87-a902-c7e8885daa8a" ], "package_ndc": [ "76329-1912-0", "76329-1912-1" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "status": "Current" }, { "discontinued_date": "06/30/2026", "update_type": "New", "initial_posting_date": "06/30/2026", "package_ndc": "65219-086-20", "generic_name": "Gadoterate Meglumine Injection", "contact_info": "888-386-1800", "related_info": "Marketed by Fresenius Kabi, USA; Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA215304" ], "brand_name": [ "GADOTERATE MEGLUMINE" ], "generic_name": [ "GADOTERATE MEGLUMINE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-086", "65219-080", "65219-082", "65219-084" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GADOTERATE MEGLUMINE" ], "spl_id": [ "f05922b7-99d4-48c7-972a-7966bbbbc3b4" ], "spl_set_id": [ "e0655aac-9508-4141-94f5-fcca6af1c41d" ], "package_ndc": [ "65219-080-01", "65219-080-05", "65219-082-01", "65219-082-10", "65219-084-01", "65219-084-15", "65219-086-01", "65219-086-20" ], "unii": [ "L0ND3981AG" ] }, "update_date": "06/30/2026", "therapeutic_category": [ "Medical Imaging" ], "dosage_form": "Injection", "presentation": "Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-086-20)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1165-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA070585" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1165", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-9043", "0409-9046", "0409-9045", "0409-9042" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "RETROBULBAR" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596" ], "spl_id": [ "6e442bfd-d3da-4913-8585-ce3485644364" ], "spl_set_id": [ "02a845c3-4521-4926-e397-25ab536e7cf6" ], "package_ndc": [ "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Marcaine, Injection, Marcaine 75 mg/10 mL (7.5 mg/mL) (NDC 0409-1165-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "0409-0152-24", "generic_name": "Metronidazole Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Limited Availability", "related_info": "Labeler: Hospira Inc.", "openfda": { "application_number": [ "ANDA206191" ], "brand_name": [ "METRONIDAZOLE" ], "generic_name": [ "METRONIDAZOLE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-0152" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "METRONIDAZOLE" ], "rxcui": [ "311683" ], "spl_id": [ "1489f8a8-873f-465f-ac91-980848a8d4a2" ], "spl_set_id": [ "49360d6f-c8b3-420e-af75-154cf7b05255" ], "package_ndc": [ "0409-0152-01", "0409-0152-24" ], "nui": [ "N0000175435", "M0014907" ], "pharm_class_epc": [ "Nitroimidazole Antimicrobial [EPC]" ], "pharm_class_cs": [ "Nitroimidazoles [CS]" ], "unii": [ "140QMO216E" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Metronidazole in Flexible Container, Injection, 500 mg/100 mL (NDC 0409-0152-24)", "company_name": "InfoRLife SA", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0185-0853-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-525-8747", "availability": "Available", "openfda": { "application_number": [ "ANDA040439" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0185-0853", "0185-0831", "0185-0842", "0185-0864", "0185-2099", "0185-2098" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577961" ], "spl_id": [ "9a21fb59-a99c-4c63-91e8-4b5d72fbd9cd" ], "spl_set_id": [ "288dafc4-fe6e-4891-832f-511022c87445" ], "package_ndc": [ "0185-0831-01", "0185-0842-01", "0185-0853-01", "0185-0864-01", "0185-2099-01", "0185-2098-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0185-0853-01)", "company_name": "Sandoz Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-5820-01", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA018132" ], "brand_name": [ "DOPAMINE HYDROCHLORIDE" ], "generic_name": [ "DOPAMINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-5820", "0409-9104" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOPAMINE HYDROCHLORIDE" ], "rxcui": [ "1743938", "1743941" ], "spl_id": [ "7a125e39-1ecb-4c76-931a-efc9b5921d1c" ], "spl_set_id": [ "1f306ad2-3606-4525-5a8a-ce78f426c1a2" ], "package_ndc": [ "0409-5820-11", "0409-5820-01", "0409-9104-21", "0409-9104-20" ], "unii": [ "7L3E358N9L" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride, Injection, 200 mg/5mL (40 mg/1 mL) (NDC 0409-5820-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "0990-6139-03", "generic_name": "Sterile Water Irrigant", "related_info_link": "https://www.fda.gov/media/182619/download?attachment", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Unavailable", "related_info": "Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-03)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-096-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": { "application_number": [ "NDA216117" ], "brand_name": [ "RELEXXII" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Vertical Pharmaceuticals, LLC" ], "product_ndc": [ "68025-096", "68025-088", "68025-089", "68025-095", "68025-097", "68025-084", "68025-098" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505" ], "spl_id": [ "86f477e9-07fc-466b-913e-1a4434c91df4" ], "spl_set_id": [ "22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d" ], "package_ndc": [ "68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-483-57", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-483", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-482", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .01 mg/1 mL; 20 mg/1 mL (NDC 63323-483-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/13/2017", "package_ndc": "83301-0080-2", "generic_name": "Bumetanide Injection", "contact_info": "800-673-9839", "availability": "Available", "openfda": { "application_number": [ "ANDA219116" ], "brand_name": [ "BUMETANIDE" ], "generic_name": [ "BUMETANIDE" ], "manufacturer_name": [ "Mullan Pharmaceutical Inc." ], "product_ndc": [ "83301-0080", "83301-0081" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "BUMETANIDE" ], "rxcui": [ "282486", "1727569" ], "spl_id": [ "4c241a3e-649b-4414-e063-6294a90a3a32" ], "spl_set_id": [ "b7cd724b-817b-4b45-8133-1ebf505867e7" ], "package_ndc": [ "83301-0080-1", "83301-0080-2", "83301-0081-1", "83301-0081-2" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "0Y2S3XUQ5H" ] }, "update_date": "08/11/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, 1 mg/4 mL (0.25 mg/mL) (NDC 83301-0080-2)", "company_name": "Mullan Pharmaceutical Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "63323-122-50", "generic_name": "Methotrexate Sodium Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesaler for inventory", "openfda": { "application_number": [ "ANDA040266" ], "brand_name": [ "METHOTREXATE" ], "generic_name": [ "METHOTREXATE SODIUM" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-122" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS" ], "substance_name": [ "METHOTREXATE SODIUM" ], "rxcui": [ "311625" ], "spl_id": [ "3d21237a-ef53-4592-bf06-0c739696203d" ], "spl_set_id": [ "ec476b11-0b3c-4139-b1eb-a3daa76bc271" ], "package_ndc": [ "63323-122-50" ], "unii": [ "3IG1E710ZN" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Rheumatology", "Oncology" ], "dosage_form": "Injection", "presentation": "Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0143-9254-25", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA207707" ], "brand_name": [ "DOPAMINE HYDROCHLORIDE" ], "generic_name": [ "DOPAMINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9254", "0143-9252", "0143-9253", "0143-9255" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOPAMINE HYDROCHLORIDE" ], "rxcui": [ "1743938", "1743941", "1743950", "1743953" ], "spl_id": [ "67349236-e8e3-45ec-a76d-2a0a150d8d59" ], "spl_set_id": [ "0e499952-46c7-4172-8c70-186312e240a3" ], "package_ndc": [ "0143-9252-01", "0143-9252-25", "0143-9253-01", "0143-9253-25", "0143-9254-01", "0143-9254-25", "0143-9255-01", "0143-9255-25" ], "unii": [ "7L3E358N9L" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9254-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4933-01", "generic_name": "Epinephrine Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": [ "Cardiovascular", "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "05/03/2022", "package_ndc": "17478-050-05", "generic_name": "Sufentanil Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Not currently manufactured", "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-05)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "62037-725-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: September 2026", "openfda": { "application_number": [ "ANDA076772" ], "brand_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "62037-725", "62037-734", "62037-726", "62037-727" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210" ], "spl_id": [ "24aa9277-3773-489d-8459-f9215140c53f" ], "spl_set_id": [ "85ef422d-af27-4126-9841-6892af1871d6" ], "package_ndc": [ "62037-725-01", "62037-734-01", "62037-726-01", "62037-727-01" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 62037-725-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9094-22", "generic_name": "Fentanyl Citrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA019115" ], "brand_name": [ "FENTANYL CITRATE" ], "generic_name": [ "FENTANYL CITRATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-9094", "0409-9093" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FENTANYL CITRATE" ], "rxcui": [ "1735003", "1735004", "1735006", "1735007", "1735008", "1735013" ], "spl_id": [ "e4eaad6d-c21e-42fd-8fd9-f0b769966d61" ], "spl_set_id": [ "bfa8018a-4cbc-434b-e09e-782872b0340a" ], "package_ndc": [ "0409-9093-41", "0409-9093-36", "0409-9093-31", "0409-9093-38", "0409-9094-12", "0409-9094-22", "0409-9094-18", "0409-9094-25", "0409-9094-17", "0409-9094-28", "0409-9094-16", "0409-9094-31", "0409-9094-41", "0409-9094-61" ], "unii": [ "MUN5LYG46H" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 100 mcg/2 mL (50 ug/1 mL) (NDC 0409-9094-22)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "New", "initial_posting_date": "02/20/2018", "package_ndc": "31722-277-32", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "732-529-0430, customerservice@camberpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA217821" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Camber Pharmaceuticals, Inc." ], "product_ndc": [ "31722-277", "31722-275", "31722-276" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "RETROBULBAR" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1724786", "1724787", "1724880", "1724884", "1725078", "1725082" ], "spl_id": [ "4ea16f8e-77de-3ba7-e063-6394a90a5667" ], "spl_set_id": [ "0e552e3a-cf52-4d74-9381-6cc1b29b4c90" ], "package_ndc": [ "31722-275-10", "31722-275-31", "31722-275-32", "31722-275-30", "31722-275-33", "31722-275-34", "31722-275-35", "31722-276-10", "31722-276-31", "31722-276-32", "31722-276-30", "31722-276-33", "31722-276-34", "31722-277-10", "31722-277-31", "31722-277-32", "31722-277-30", "31722-277-33", "31722-277-34" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "07/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 31722-277-32)", "company_name": "Aspiro Pharma Limited", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "57664-607-88", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "Currently not marketed", "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "72572-160-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Distributed by Civica", "openfda": { "application_number": [ "ANDA202354" ], "brand_name": [ "ETOMIDATE" ], "generic_name": [ "ETOMIDATE" ], "manufacturer_name": [ "Civica, Inc." ], "product_ndc": [ "72572-160", "72572-161" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008" ], "spl_id": [ "380f0c88-03f8-4cfa-8823-4766c2f7700c" ], "spl_set_id": [ "98002094-f065-4b5f-963f-2c34b5241316" ], "package_ndc": [ "72572-160-01", "72572-160-10", "72572-161-01", "72572-161-10" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 72572-160-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "0409-6695-01", "generic_name": "Etomidate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA018227" ], "brand_name": [ "AMIDATE" ], "generic_name": [ "ETOMIDATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-6695" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008", "1654009", "1654011" ], "spl_id": [ "3f83ed21-1b60-486c-8c70-1d5aa7553404" ], "spl_set_id": [ "b7ed5bf8-ba75-44dc-8f81-96b4ad5766be" ], "package_ndc": [ "0409-6695-11", "0409-6695-01", "0409-6695-12", "0409-6695-02" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Amidate, Injection, 2 mg/1 mL (NDC 0409-6695-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "discontinued_date": "04/15/2026", "update_type": "New", "initial_posting_date": "04/15/2026", "package_ndc": "0093-8076-56", "generic_name": "Tiagabine Hydrochloride Tablet", "contact_info": "888-838-2872", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA020646" ], "brand_name": [ "TIAGABINE HYDROCHLORIDE" ], "generic_name": [ "TIAGABINE HYDROCHLORIDE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0093-8076", "0093-5030", "0093-5031", "0093-8072" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "TIAGABINE HYDROCHLORIDE" ], "rxcui": [ "1299903", "1299909", "1299911", "1299917" ], "spl_id": [ "2a8d7987-54ae-45d7-8224-361dac37e0a4" ], "spl_set_id": [ "953ef3cc-e3cb-480f-b9ea-256520fd62b8" ], "package_ndc": [ "0093-5030-56", "0093-5031-56", "0093-8072-56", "0093-8076-56" ], "unii": [ "DQH6T6D8OY" ] }, "update_date": "04/15/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Tiagabine Hydrochloride, Tablet, 16mg 30 count (NDC 0093-8076-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0172-5240-60", "generic_name": "Anagrelide Hydrochloride Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "11/19/2025", "therapeutic_category": [ "Hematology" ], "dosage_form": "Capsule", "presentation": "Anagrelide Hydrochloride, Capsule, 1 mg (NDC 0172-5240-60)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "07/27/2026", "update_type": "New", "initial_posting_date": "07/27/2026", "package_ndc": "0173-0716-22", "generic_name": "Fluticasone Propionate and Salmeterol Xinafoate Aerosol, Metered", "contact_info": "888-825-5249", "related_info": "The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product will still be available.", "openfda": { "application_number": [ "NDA021254" ], "brand_name": [ "ADVAIR HFA" ], "generic_name": [ "FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE" ], "manufacturer_name": [ "GlaxoSmithKline LLC" ], "product_ndc": [ "0173-0716", "0173-0715", "0173-0717" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RESPIRATORY (INHALATION)" ], "substance_name": [ "FLUTICASONE PROPIONATE", "SALMETEROL XINAFOATE" ], "rxcui": [ "896231", "896235", "896236", "896237", "896239", "896243", "896244", "896245", "896267", "896271", "896272", "896273" ], "spl_id": [ "bea52e57-aa75-4dce-8cfb-a163bbc22be2" ], "spl_set_id": [ "dfaca6f9-3277-47b2-319d-1377917cb54c" ], "package_ndc": [ "0173-0715-20", "0173-0715-22", "0173-0716-20", "0173-0716-22", "0173-0717-20", "0173-0717-22" ], "unii": [ "O2GMZ0LF5W", "6EW8Q962A5" ] }, "update_date": "07/27/2026", "therapeutic_category": [ "Pulmonary/Allergy" ], "presentation": "Advair HFA, Aerosol, Metered, 115 ug; 21 ug (NDC 0173-0716-22)", "company_name": "GlaxoSmithKline", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1159-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA070583" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1725078", "1725082", "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1867594", "1867596" ], "spl_id": [ "fb58e702-b0da-4fa9-91f2-4580b2305950", "6e442bfd-d3da-4913-8585-ce3485644364" ], "spl_set_id": [ "bb44c7e1-d911-4788-908f-09b7b271969b", "02a845c3-4521-4926-e397-25ab536e7cf6" ], "package_ndc": [ "0409-1159-09", "0409-1159-10", "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17" ], "unii": [ "7TQO7W3VT8", "30Q7KI53AK" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-1159-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0280-02", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA011757" ], "brand_name": [ "DEPO-MEDROL" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0280", "0009-0274", "0009-0306" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1358510", "1358512", "1358610", "1358612", "1358617", "1358619" ], "spl_id": [ "267dd735-f800-4735-ba1c-d39d00f0cee5" ], "spl_set_id": [ "823b0010-2b57-4e76-b5ac-4a8c2963438f" ], "package_ndc": [ "0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-02)", "company_name": "Pfizer Inc.", "status": "Current" }, { "discontinued_date": "01/06/2026", "update_type": "New", "initial_posting_date": "01/06/2026", "package_ndc": "49884-128-91", "generic_name": "Everolimus Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "01/06/2026", "therapeutic_category": [ "Transplant" ], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 10 mg (NDC 49884-128-91)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "06/06/2018", "package_ndc": "0641-6041-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA075772" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6041", "0641-6043", "0641-6042" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "25d6c438-45d2-4162-91c2-b5caa0f86bf3" ], "spl_set_id": [ "0c2c75c9-ed7b-46a8-9543-429bf2d8f090" ], "package_ndc": [ "0641-6043-01", "0641-6043-25", "0641-6042-01", "0641-6042-25", "0641-6041-01", "0641-6041-25" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0641-6041-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0424-51", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA020183" ], "brand_name": [ "DIANEAL LOW CALCIUM WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0424", "0941-0411", "0941-0413", "0941-0415", "0941-0409", "0941-0457", "0941-0459", "0941-0426", "0941-0427", "0941-0429", "0941-0430", "0941-0433", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0424-51)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "68180-556-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-587-4617", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "08/18/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 5 mg (NDC 68180-556-09)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-562-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "04/29/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 50 mg (NDC 49884-562-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0009-0902-18", "generic_name": "Clindamycin Phosphate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d", "contact_info": "800-533-4535", "availability": "Available", "openfda": { "application_number": [ "NDA050441" ], "brand_name": [ "CLEOCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0902", "0009-0870", "0009-0775", "0009-0728", "0009-3124", "0009-3447", "0009-3381", "0009-3375", "0009-3382", "0009-6582" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "205964", "309335", "309336", "309339", "685574", "685576", "685578", "706461", "1737244", "1737245", "1737578", "1737579", "1737581", "1737582" ], "spl_id": [ "fa11e62e-4625-4e9c-8676-f318b1cb890f" ], "spl_set_id": [ "05a75685-0af5-407c-ac57-e380c882b49d" ], "package_ndc": [ "0009-0870-21", "0009-0870-26", "0009-0775-20", "0009-0775-26", "0009-0902-11", "0009-0902-18", "0009-0728-05", "0009-0728-09", "0009-3124-01", "0009-3124-03", "0009-3447-01", "0009-3447-03", "0009-3381-01", "0009-3381-02", "0009-3375-01", "0009-3375-02", "0009-3382-01", "0009-3382-02", "0009-6582-02", "0009-6582-01" ], "unii": [ "EH6D7113I8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18)", "company_name": "Pfizer Inc.", "status": "Current" }, { "discontinued_date": "07/23/2026", "update_type": "New", "initial_posting_date": "07/23/2026", "package_ndc": "0574-0601-15", "generic_name": "Podophyllum Resin Topical Tincture", "contact_info": "(800) 775-2054", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "PODOCON 25" ], "generic_name": [ "PODOPHYLLUM RESIN" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-0601" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "TOPICAL" ], "substance_name": [ "PODOPHYLLUM RESIN" ], "spl_id": [ "e2ac9612-bded-4eea-a664-f941416583fa" ], "spl_set_id": [ "de96dc6e-e6d1-4383-9ce1-4d06bac08e00" ], "package_ndc": [ "0574-0601-15" ], "unii": [ "16902YVY2B" ] }, "update_date": "07/23/2026", "therapeutic_category": [ "Dermatology" ], "presentation": "Podocon 25, Topical Tincture, 1 mg/4 mL (NDC 0574-0601-15)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "discontinued_date": "04/01/2026", "update_type": "New", "initial_posting_date": "04/01/2026", "package_ndc": "60429-005-12", "generic_name": "Icosapent Ethyl Capsule", "contact_info": "800-706-5575", "related_info": "Discontinuation of the manufacture of the drug", "openfda": {}, "update_date": "04/01/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Capsule", "presentation": "Icosapent Ethyl, Capsule, 1 g (NDC 60429-005-12)", "company_name": "Apotex Corp.", "status": "To Be Discontinued" }, { "discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0591-0347-01", "generic_name": "Hydrochlorothiazide Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA020504" ], "brand_name": [ "HYDROCHLOROTHIAZIDE" ], "generic_name": [ "HYDROCHLOROTHIAZIDE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0591-0347" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "HYDROCHLOROTHIAZIDE" ], "rxcui": [ "199903" ], "spl_id": [ "b062bc7e-af92-4648-aed1-e02568313e21" ], "spl_set_id": [ "a3eb7294-f913-434b-896c-da028bfebc73" ], "package_ndc": [ "0591-0347-01", "0591-0347-05" ], "nui": [ "N0000175359", "N0000175419", "M0471776" ], "pharm_class_pe": [ "Increased Diuresis [PE]" ], "pharm_class_epc": [ "Thiazide Diuretic [EPC]" ], "pharm_class_cs": [ "Thiazides [CS]" ], "unii": [ "0J48LPH2TH" ] }, "update_date": "11/19/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Capsule", "presentation": "Microzide, Capsule, 12.5 mg (NDC 0591-0347-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/25/2022", "package_ndc": "76204-027-01", "generic_name": "Albuterol Sulfate Solution", "contact_info": "803-806-3300", "availability": "Available", "openfda": { "application_number": [ "ANDA218386" ], "brand_name": [ "ALBUTEROL SULFATE INHALATION SOLUTION, 0.5%" ], "generic_name": [ "ALBUTEROL SULFATE" ], "manufacturer_name": [ "Ritedose Pharmaceuticals, LLC" ], "product_ndc": [ "76204-027" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RESPIRATORY (INHALATION)" ], "substance_name": [ "ALBUTEROL SULFATE" ], "rxcui": [ "245314" ], "spl_id": [ "4e7f86ab-55bc-c123-e063-6394a90abd8d" ], "spl_set_id": [ "fdb4ac5a-bf0d-4896-89f7-1828c081b79e" ], "package_ndc": [ "76204-027-11", "76204-027-01" ], "unii": [ "021SEF3731" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Pediatric", "Pulmonary/Allergy" ], "dosage_form": "Solution", "presentation": "Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 76204-027-01)", "company_name": "Ritedose Pharmaceuticals, LLC", "status": "Current" }, { "discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2859-31", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA075757" ], "brand_name": [ "OMEPRAZOLE" ], "generic_name": [ "OMEPRAZOLE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-2859", "0781-2868" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OMEPRAZOLE" ], "rxcui": [ "198051", "199119" ], "spl_id": [ "b182f298-e28f-434b-b6f1-ecfac29d495e" ], "spl_set_id": [ "516170d4-4913-4577-a2d2-f5c52d1e79c6" ], "package_ndc": [ "0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31" ], "nui": [ "N0000175525", "N0000000147", "N0000182140" ], "pharm_class_epc": [ "Proton Pump Inhibitor [EPC]" ], "pharm_class_moa": [ "Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]" ], "unii": [ "KG60484QX9" ] }, "update_date": "10/09/2025", "therapeutic_category": [ "Gastroenterology" ], "presentation": "Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-31)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "57844-110-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA040422" ], "brand_name": [ "ADDERALL" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "57844-110", "57844-105", "57844-117", "57844-112", "57844-115", "57844-120", "57844-130" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147" ], "spl_id": [ "79af1dc6-c7cf-41b1-a750-e9b47c2187ff" ], "spl_set_id": [ "f22635fe-821d-4cde-aa12-419f8b53db81" ], "package_ndc": [ "57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 57844-110-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-462-31", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA018304" ], "brand_name": [ "SENSORCAINE MPF" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-462", "63323-464", "63323-466", "63323-465", "63323-467", "63323-460" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457" ], "spl_id": [ "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715" ], "spl_set_id": [ "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8" ], "package_ndc": [ "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0641-6056-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA075243" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6056", "0641-6057", "0641-6059", "0641-6061", "0641-6063", "0641-6060" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "311700", "311702" ], "spl_id": [ "559c03fb-24ea-4b7b-8afd-e33cb3a2340a" ], "spl_set_id": [ "575d8bf0-7af7-427c-a231-966e2a5e070d" ], "package_ndc": [ "0641-6057-01", "0641-6057-10", "0641-6057-25", "0641-6059-01", "0641-6059-10", "0641-6056-01", "0641-6056-10", "0641-6061-01", "0641-6061-10", "0641-6061-25", "0641-6063-01", "0641-6063-10", "0641-6063-25", "0641-6060-01", "0641-6060-10" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6056-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "23155-473-42", "generic_name": "Furosemide Injection", "contact_info": "855-228-9470", "availability": "Unavailable", "related_info": "Estimated recovery: late October 2026; Manufacturing delay", "openfda": { "application_number": [ "ANDA203428" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc." ], "product_ndc": [ "23155-473" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "c14acada-333e-43bb-b1cf-81d569e3e918" ], "spl_set_id": [ "1b9117d5-0dd9-4577-a1fd-bb0aaf7e68ec" ], "package_ndc": [ "23155-473-31", "23155-473-41", "23155-473-32", "23155-473-42", "23155-473-43", "23155-473-33", "23155-473-44", "23155-473-45" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-42)", "company_name": "Avet Pharmaceuticals, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1304-31", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA200403" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1304", "0409-2552", "0409-3356", "0409-2540", "0409-3365", "0409-1283", "0409-1312" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897653", "897753", "897756", "897757", "897758", "1724276", "1724383", "1724644" ], "spl_id": [ "a3ebafac-648e-47b1-a6f5-1e3bff1e3e08" ], "spl_set_id": [ "e9c9ef18-7dfc-4322-b2fc-29b934c30f8b" ], "package_ndc": [ "0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 4 mg/1 mL Syringes (NDC 0409-1304-31)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-467-57", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA018304" ], "brand_name": [ "SENSORCAINE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-467", "63323-465", "63323-460", "63323-464", "63323-466", "63323-462" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012391", "1012396", "1012404", "1012421", "1012455", "1012457", "1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177" ], "spl_id": [ "2b1a1f80-cb29-4ac1-9e72-20225ed45715" ], "spl_set_id": [ "eb6d8fee-def4-4c96-9972-695e8cea8ea8" ], "package_ndc": [ "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-467-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "03/23/2026", "update_type": "New", "initial_posting_date": "03/23/2026", "package_ndc": "39822-3050-2", "generic_name": "Pentamidine Isethionate Injection", "contact_info": "866-390-4411", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA206982" ], "brand_name": [ "PENTAMIDINE ISETHIONATE" ], "generic_name": [ "PENTAMIDINE ISETHIONATE" ], "manufacturer_name": [ "XGen Pharmaceuticals DJB, Inc." ], "product_ndc": [ "39822-3050" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "PENTAMIDINE ISETHIONATE" ], "rxcui": [ "861601" ], "spl_id": [ "0fcb7bdf-013e-a77c-e063-6394a90ad20f" ], "spl_set_id": [ "860c799c-5199-4f0c-b21b-9910273474d9" ], "package_ndc": [ "39822-3050-2" ], "unii": [ "V2P3K60DA2" ] }, "update_date": "03/23/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Pentamidine Isethionate, Injection, 300 mg/3 mL (NDC 39822-3050-2)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "04/07/2026", "update_type": "New", "initial_posting_date": "04/07/2026", "package_ndc": "61958-1702-1", "generic_name": "Idelalisib Tablet", "contact_info": "800-445-3235", "related_info": "Discontinuation in the manufacturing of the drug", "openfda": { "application_number": [ "NDA205858" ], "brand_name": [ "ZYDELIG" ], "generic_name": [ "IDELALISIB" ], "manufacturer_name": [ "Gilead Sciences, Inc." ], "product_ndc": [ "61958-1702", "61958-1701" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "IDELALISIB" ], "rxcui": [ "1544465", "1544471", "1544473", "1544475" ], "spl_id": [ "ca3e7112-6dfe-403f-af6f-a0051e77d125" ], "spl_set_id": [ "efbdafa9-d18c-4e85-b4a2-1e620fc74e50" ], "package_ndc": [ "61958-1701-1", "61958-1702-1" ], "nui": [ "N0000175605", "N0000175082", "N0000190114" ], "pharm_class_epc": [ "Kinase Inhibitor [EPC]" ], "pharm_class_moa": [ "Kinase Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]" ], "unii": [ "YG57I8T5M0" ] }, "update_date": "04/07/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Tablet", "presentation": "Zydelig, Tablet, 150 mg (NDC 61958-1702-1)", "company_name": "Gilead Sciences, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0411-07", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA017512" ], "brand_name": [ "DIANEAL PD-2 WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0411", "0941-0413", "0941-0415", "0941-0409", "0941-0457", "0941-0459", "0941-0426", "0941-0427", "0941-0429", "0941-0424", "0941-0430", "0941-0433", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0411-07)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-354-05", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-05)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued" }, { "discontinued_date": "06/30/2026", "update_type": "New", "initial_posting_date": "06/30/2026", "package_ndc": "65219-080-05", "generic_name": "Gadoterate Meglumine Injection", "contact_info": "888-386-1800", "related_info": "Marketed by Fresenius Kabi, USA; Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA215304" ], "brand_name": [ "GADOTERATE MEGLUMINE" ], "generic_name": [ "GADOTERATE MEGLUMINE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-080", "65219-082", "65219-084", "65219-086" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GADOTERATE MEGLUMINE" ], "spl_id": [ "f05922b7-99d4-48c7-972a-7966bbbbc3b4" ], "spl_set_id": [ "e0655aac-9508-4141-94f5-fcca6af1c41d" ], "package_ndc": [ "65219-080-01", "65219-080-05", "65219-082-01", "65219-082-10", "65219-084-01", "65219-084-15", "65219-086-01", "65219-086-20" ], "unii": [ "L0ND3981AG" ] }, "update_date": "06/30/2026", "therapeutic_category": [ "Medical Imaging" ], "dosage_form": "Injection", "presentation": "Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-080-05)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "06/06/2018", "package_ndc": "0338-0069-10", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: January 2027", "openfda": { "application_number": [ "ANDA209900" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0069", "0338-0072", "0338-0076" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "2da4dd8a-1b18-481d-b733-9c031d9ea7e3" ], "spl_set_id": [ "4b58836d-9d58-4539-9691-9e11c505ef2a" ], "package_ndc": [ "0338-0069-10", "0338-0072-25", "0338-0076-10" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0338-0069-10)", "company_name": "Baxter Healthcare", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "55150-170-30", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA203895" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-170", "55150-167", "55150-168", "55150-169", "55150-171", "55150-172", "55150-249", "55150-250" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRACAUDAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082" ], "spl_id": [ "39649703-e633-4a20-ba71-0c04dbf8ff2a" ], "spl_set_id": [ "ffecf450-1f01-4721-8e10-251385852612" ], "package_ndc": [ "55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-170-30)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2023", "package_ndc": "63323-604-01", "generic_name": "Propranolol Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA075826" ], "brand_name": [ "PROPRANOLOL" ], "generic_name": [ "PROPRANOLOL HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-604" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "PROPRANOLOL HYDROCHLORIDE" ], "rxcui": [ "856443" ], "spl_id": [ "505851c4-b18c-4cd7-805c-4e923cc1fa7e" ], "spl_set_id": [ "f14ea537-dd5c-4c78-9037-9a85e9e610ef" ], "package_ndc": [ "63323-604-01" ], "unii": [ "F8A3652H1V" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-604-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "09/26/2025", "update_type": "New", "initial_posting_date": "09/26/2025", "package_ndc": "25021-230-05", "generic_name": "Irinotecan Hydrochloride Injection", "contact_info": "Company Contact: 609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals", "openfda": { "application_number": [ "ANDA090675" ], "brand_name": [ "IRINOTECAN HYDROCHLORIDE" ], "generic_name": [ "IRINOTECAN HYDROCHLORIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-230" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "IRINOTECAN HYDROCHLORIDE" ], "rxcui": [ "1726319", "1726324" ], "spl_id": [ "beff4b0b-e884-4134-ba9e-290020a94add" ], "spl_set_id": [ "caab50e6-0dad-4ddd-9a6c-96cc2b87aee7" ], "package_ndc": [ "25021-230-02", "25021-230-05" ], "unii": [ "042LAQ1IIS" ] }, "update_date": "09/26/2025", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 25021-230-05)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0703-4239-01", "generic_name": "Carboplatin Injection", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: December 2028", "openfda": { "application_number": [ "ANDA077269" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Teva Parenteral Medicines, Inc." ], "product_ndc": [ "0703-4239", "0703-4244", "0703-4246", "0703-4248" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df", "b943761e-6a46-45a0-bdb4-1fec1e101f8c" ], "spl_set_id": [ "f330f5a2-2cad-402f-bcbb-26245a753276", "e176b6ef-2ff6-498b-a9d8-7a634d147f37" ], "package_ndc": [ "0703-4244-01", "0703-4246-01", "0703-4248-01", "0703-4239-01", "0703-4244-81", "0703-4246-81", "0703-4248-81", "0703-4239-81" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4239-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "09/30/2025", "update_type": "New", "initial_posting_date": "09/30/2025", "package_ndc": "0004-0801-85", "generic_name": "Oseltamivir Phosphate Capsule", "contact_info": "800-551-2231", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "09/30/2025", "therapeutic_category": [ "Antiviral" ], "dosage_form": "Capsule", "presentation": "Tamiflu, Capsule, 45 mg (NDC 0004-0801-85)", "company_name": "Genentech, Inc", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "11/01/2017", "package_ndc": "0703-0110-03", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA078591" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Teva Parenteral Medicines, Inc." ], "product_ndc": [ "0703-0110", "0703-0113", "0703-0018" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "1724338", "1724340", "1724341" ], "spl_id": [ "540b835a-db66-417c-8507-0c1ed05c95bf" ], "spl_set_id": [ "f0b78db9-a38c-41bb-8233-5e93f7f18c5c" ], "package_ndc": [ "0703-0110-01", "0703-0110-03", "0703-0113-01", "0703-0113-03", "0703-0018-01" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0110-03)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "50742-448-60", "generic_name": "Carboplatin Injection", "contact_info": "866-321-5031", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "02/20/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/60 mL (NDC 50742-448-60)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-062-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": { "application_number": [ "ANDA207636" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-062", "70069-061", "70069-063", "70069-064", "70069-065", "70069-066", "70069-067" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483" ], "spl_id": [ "79b226f0-c08a-4f84-bf2b-ae5c60e01d67" ], "spl_set_id": [ "ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64" ], "package_ndc": [ "70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10" ], "unii": [ "V910P86109" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-10)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0169-4060-12", "generic_name": "Liraglutide Injection", "contact_info": "833-493-4689", "availability": "Limited Availability", "related_info": "Estimated shortage duration TBD", "openfda": { "application_number": [ "NDA022341" ], "brand_name": [ "VICTOZA" ], "generic_name": [ "LIRAGLUTIDE" ], "manufacturer_name": [ "Novo Nordisk" ], "product_ndc": [ "0169-4060" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "LIRAGLUTIDE" ], "rxcui": [ "897122", "897126" ], "spl_id": [ "0d10d10e-0fe0-47ee-b9da-628e34907e98" ], "spl_set_id": [ "5a9ef4ea-c76a-4d34-a604-27c5b505f5a4" ], "package_ndc": [ "0169-4060-13", "0169-4060-12", "0169-4060-90", "0169-4060-97", "0169-4060-98", "0169-4060-99" ], "nui": [ "N0000178480", "M0160181", "N0000020058" ], "pharm_class_epc": [ "GLP-1 Receptor Agonist [EPC]" ], "pharm_class_cs": [ "Glucagon-Like Peptide 1 [CS]" ], "pharm_class_moa": [ "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]" ], "unii": [ "839I73S42A" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-12)", "company_name": "Novo Nordisk, Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "65219-456-60", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholealers for inventory", "openfda": { "application_number": [ "ANDA207449" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "FRESENIUS KABI USA, LLC" ], "product_ndc": [ "65219-456", "65219-464", "65219-458", "65219-460", "65219-462" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795607", "1795609", "1795610", "1795612", "1795616" ], "spl_id": [ "efc3b0c9-518a-47db-bb3e-ebdfd4646e9b" ], "spl_set_id": [ "576a22d8-5f2f-497e-80ad-1842ca74bb53" ], "package_ndc": [ "65219-456-05", "65219-456-60", "65219-464-05", "65219-464-50", "65219-458-05", "65219-458-30", "65219-460-05", "65219-460-20", "65219-462-05", "65219-462-10" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-456-60)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "55150-196-99", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA205612" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-196", "55150-195", "55150-197", "55150-198", "55150-199", "55150-200", "55150-201" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483" ], "spl_id": [ "1e5f1368-058a-492c-b4b7-d9329a7745e2" ], "spl_set_id": [ "3763b7b6-da49-4658-b93d-28f5da24d09e" ], "package_ndc": [ "55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20" ], "unii": [ "V910P86109" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 55150-196-99)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/18/2023", "package_ndc": "71288-563-85", "generic_name": "Liraglutide Injection", "contact_info": "844-824-8426", "availability": "Limited Availability", "related_info": "Estimated recovery: July 2026", "openfda": { "application_number": [ "ANDA218115" ], "brand_name": [ "LIRAGLUTIDE" ], "generic_name": [ "LIRAGLUTIDE" ], "manufacturer_name": [ "Meitheal Pharmaceuticals Inc." ], "product_ndc": [ "71288-563" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "LIRAGLUTIDE" ], "rxcui": [ "897122" ], "spl_id": [ "a0bb0116-f90a-490b-9ca9-5bcd6210c763" ], "spl_set_id": [ "0efc3a89-211a-4496-baab-e8265e07de2b" ], "package_ndc": [ "71288-563-84", "71288-563-85" ], "nui": [ "N0000178480", "M0160181", "N0000020058" ], "pharm_class_epc": [ "GLP-1 Receptor Agonist [EPC]" ], "pharm_class_cs": [ "Glucagon-Like Peptide 1 [CS]" ], "pharm_class_moa": [ "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]" ], "unii": [ "839I73S42A" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-85)", "company_name": "Meitheal Pharmaceuticals, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "83634-653-30", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "Avenacy, LLC: 877-283-6229", "availability": "Available", "related_info": "Distributed by Avenacy, LLC", "openfda": { "application_number": [ "ANDA219535" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Avenacy, LLC" ], "product_ndc": [ "83634-653", "83634-651" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1737562", "1737566", "1737568" ], "spl_id": [ "8fb1dd7b-f349-4a64-96c1-bd72bf748f3b" ], "spl_set_id": [ "46480253-29b9-4d7f-98ed-10377929026b" ], "package_ndc": [ "83634-653-41", "83634-653-02", "83634-653-42", "83634-653-05", "83634-653-43", "83634-653-30", "83634-651-41", "83634-651-10", "83634-651-42", "83634-651-20", "83634-651-43", "83634-651-50" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 300 mg/30 mL (NDC 83634-653-30)", "company_name": "Anthea Pharma", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "54288-167-01", "generic_name": "Carboplatin Injection", "contact_info": "Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270", "availability": "Limited Availability", "related_info": "Distributed by BPI Labs, LLC", "openfda": { "application_number": [ "ANDA207324" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "BPI Labs LLC" ], "product_ndc": [ "54288-167", "54288-165", "54288-166", "54288-164" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "c0a7463c-d90f-4060-a54e-6a4888e8af0e" ], "spl_set_id": [ "5484d2f0-0cc2-4bba-8f26-c7f6539a9606" ], "package_ndc": [ "54288-165-01", "54288-166-01", "54288-167-01", "54288-164-01" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/65 mL (NDC 54288-167-01)", "company_name": "Gland Pharma Limited", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0223-23", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Accuretic, Tablet, 25 mg/20 mg (NDC 0071-0223-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-111-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Unavailable", "related_info": "Estimated recovery: October 2026", "openfda": { "application_number": [ "ANDA215771" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Granules Pharmaceuticals Inc." ], "product_ndc": [ "70010-111", "70010-112", "70010-113", "70010-114", "70010-115", "70010-116", "70010-117" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "56c7c921-e560-c5ad-e063-6294a90a4c81" ], "spl_set_id": [ "b0b4eccc-34c7-483d-966f-82d588358e1b" ], "package_ndc": [ "70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 70010-111-01)", "company_name": "Granules Pharmaceuticals Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "55150-304-25", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA210966" ], "brand_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "generic_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-304" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "rxcui": [ "1812079" ], "spl_id": [ "5d97a8a3-fd79-4fd1-8a0f-c8cf95d40964" ], "spl_set_id": [ "29947f67-7868-40af-8ad2-a61f7149b44c" ], "package_ndc": [ "55150-304-01", "55150-304-25" ], "unii": [ "AI9376Y64P" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 55150-304-25)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6251-10", "generic_name": "Atropine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Available", "openfda": { "application_number": [ "ANDA213561" ], "brand_name": [ "ATROPINE SULFATE" ], "generic_name": [ "ATROPINE SULFATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6251" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ENDOTRACHEAL", "INTRAMEDULLARY", "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "ATROPINE SULFATE" ], "rxcui": [ "1190776" ], "spl_id": [ "f5ca4281-8c89-4efc-80b1-2fbcf61c7c55" ], "spl_set_id": [ "4c15d3cc-7888-4c82-b3f8-a5d93c5523df" ], "package_ndc": [ "0641-6251-10" ], "unii": [ "03J5ZE7KA5" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 0.4 mg/1 mL (NDC 0641-6251-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "06/06/2018", "package_ndc": "72266-119-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.", "openfda": { "application_number": [ "ANDA204216" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "FOSUN PHARMA USA INC" ], "product_ndc": [ "72266-119", "72266-234", "72266-118" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "4dc7a413-f46f-2537-e063-6294a90a9b8c" ], "spl_set_id": [ "1aae6a4d-0909-4672-aa26-e3f2d8c4d413" ], "package_ndc": [ "72266-234-01", "72266-234-25", "72266-118-01", "72266-118-25", "72266-119-01", "72266-119-25" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-119-25)", "company_name": "Gland Pharma Limited", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4277-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA088327" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4277", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4276", "0409-4275" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763" ], "spl_id": [ "05d1a200-9d75-4e48-b14a-5069d4ab816f" ], "spl_set_id": [ "3b2dd84e-cee8-4e58-d494-395a65a353a0" ], "package_ndc": [ "0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 1,000 mg/50 mL (2%; 20 mg/mL) (NDC 0409-4277-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-339-50", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA076517" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "61703-339" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "0ddf4411-7138-412a-908a-fadf22bdfb79" ], "spl_set_id": [ "c3ae9880-44bb-4f4e-93d8-8a5e21708a30" ], "package_ndc": [ "61703-339-18", "61703-339-22", "61703-339-50", "61703-339-56" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-339-50)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "06/28/2022", "package_ndc": "0143-9393-10", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA210594" ], "brand_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "generic_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9393", "0143-9391", "0143-9392" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "rxcui": [ "1729578", "1729584", "1729710" ], "spl_id": [ "5c5e498b-d829-4f78-bcca-466631014767" ], "spl_set_id": [ "9d289052-1eb6-4ba2-a3ca-d2e542a052ae" ], "package_ndc": [ "0143-9391-01", "0143-9391-10", "0143-9392-01", "0143-9392-10", "0143-9393-01", "0143-9393-10" ], "unii": [ "5V444H5WIC" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 5 mg per vial (NDC 0143-9393-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "06/13/2018", "package_ndc": "55150-255-20", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: mid-August 2026. Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA207182" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-255", "55150-251", "55150-252", "55150-254", "55150-253", "55150-256" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671" ], "spl_id": [ "ccc38d8a-43fd-44c0-985e-32af9ed956ab", "0b1f03c2-db2f-4f90-acc0-d73abd731bf6" ], "spl_set_id": [ "ccc38d8a-43fd-44c0-985e-32af9ed956ab", "ef782e5e-e2d7-465a-99c6-b12611f3158c" ], "package_ndc": [ "55150-251-24", "55150-252-24", "55150-254-24", "55150-255-24", "55150-251-10", "55150-252-20", "55150-253-50", "55150-254-10", "55150-255-20", "55150-256-50" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-255-20)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "55150-296-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA210321" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-296", "55150-209", "55150-297" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "309710", "1718906", "1718909" ], "spl_id": [ "a1eab62d-fcef-4b83-9266-3c5f7a05927b" ], "spl_set_id": [ "8c162541-986b-4b30-866c-b2631ba2c975" ], "package_ndc": [ "55150-209-02", "55150-296-10", "55150-297-10" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 55150-296-10)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/17/2021", "package_ndc": "67457-445-60", "generic_name": "Rifampin Injection", "contact_info": "800-796-9526", "availability": "Unavailable", "related_info": "Estimated recovery: Q4 2026", "openfda": { "application_number": [ "ANDA065421" ], "brand_name": [ "RIFAMPIN" ], "generic_name": [ "RIFAMPIN" ], "manufacturer_name": [ "Mylan Institutional LLC" ], "product_ndc": [ "67457-445" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "RIFAMPIN" ], "rxcui": [ "312821" ], "spl_id": [ "2e65f8eb-0189-46db-9458-98ef7f67a156" ], "spl_set_id": [ "8be91604-d7cd-4f2b-997d-e3364e4092e5" ], "package_ndc": [ "67457-445-60" ], "nui": [ "N0000175500", "M0019113" ], "pharm_class_epc": [ "Rifamycin Antibacterial [EPC]" ], "pharm_class_cs": [ "Rifamycins [CS]" ], "unii": [ "VJT6J7R4TR" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Rifampin, Injection, 600 mg (NDC 67457-445-60)", "company_name": "Mylan Institutional, a Viatris Company", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "06/13/2018", "package_ndc": "55150-251-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: end-August 2026. Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA207182" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-251", "55150-252", "55150-254", "55150-255", "55150-253", "55150-256" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671" ], "spl_id": [ "ccc38d8a-43fd-44c0-985e-32af9ed956ab", "0b1f03c2-db2f-4f90-acc0-d73abd731bf6" ], "spl_set_id": [ "ccc38d8a-43fd-44c0-985e-32af9ed956ab", "ef782e5e-e2d7-465a-99c6-b12611f3158c" ], "package_ndc": [ "55150-251-24", "55150-252-24", "55150-254-24", "55150-255-24", "55150-251-10", "55150-252-20", "55150-253-50", "55150-254-10", "55150-255-20", "55150-256-50" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-251-10)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4275-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA088325" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4275", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4276" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763" ], "spl_id": [ "05d1a200-9d75-4e48-b14a-5069d4ab816f" ], "spl_set_id": [ "3b2dd84e-cee8-4e58-d494-395a65a353a0" ], "package_ndc": [ "0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4275-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0644-04", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA018931" ], "brand_name": [ "TRAVASOL" ], "generic_name": [ "LEUCINE, PHENYLALANINE, LYSINE HYDROCHLORIDE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, TYROSINE, SERINE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0644" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LEUCINE", "PHENYLALANINE", "LYSINE HYDROCHLORIDE", "METHIONINE", "ISOLEUCINE", "VALINE", "HISTIDINE", "THREONINE", "TRYPTOPHAN", "ALANINE", "GLYCINE", "ARGININE", "PROLINE", "TYROSINE", "SERINE" ], "rxcui": [ "801644", "801648" ], "spl_id": [ "e0279078-016d-48fd-8de1-c894422b33ff" ], "spl_set_id": [ "8543b5be-0f43-4891-9e56-d7c39fe839b5" ], "package_ndc": [ "0338-0644-03", "0338-0644-04", "0338-0644-06" ], "nui": [ "N0000175780", "M0000922" ], "pharm_class_epc": [ "Amino Acid [EPC]" ], "pharm_class_cs": [ "Amino Acids [CS]" ], "unii": [ "GMW67QNF9C", "47E5O17Y3R", "JNJ23Q2COM", "AE28F7PNPL", "04Y7590D77", "HG18B9YRS7", "4QD397987E", "2ZD004190S", "8DUH1N11BX", "OF5P57N2ZX", "TE7660XO1C", "94ZLA3W45F", "9DLQ4CIU6V", "42HK56048U", "452VLY9402" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-04)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "63323-426-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA078651" ], "brand_name": [ "ROCURONIUM" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-426" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "d6e2ff8d-838d-4c27-8e73-230548b09d63", "3f4d5e11-2c14-4406-8954-04dba2fc65ff" ], "spl_set_id": [ "f1933332-1ae0-4dc1-be4c-694849e6c9f9", "fb9524b2-c353-4747-8954-7ca2529eabb2" ], "package_ndc": [ "63323-426-02", "63323-426-05", "63323-426-01", "63323-426-10", "63323-426-12", "63323-426-15" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 63323-426-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-201-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release August 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "ANDA088586" ], "brand_name": [ "LIDOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-201", "63323-202" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1737757" ], "spl_id": [ "d19c26f4-1214-40f7-9680-43c885613306" ], "spl_set_id": [ "cddb2b22-fce3-8967-6e54-dca3df5ac4b3" ], "package_ndc": [ "63323-201-01", "63323-201-02", "63323-201-03", "63323-201-10", "63323-202-01", "63323-202-02" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 10 mg/1 mL (NDC 63323-201-02)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0264-7520-00", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "NDA019626" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-7520", "0264-7510" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE, UNSPECIFIED FORM" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795610", "1795612" ], "spl_id": [ "c9f87749-8dd5-41fd-b393-f63d45fd00ef" ], "spl_set_id": [ "085614c7-ada4-4e2c-87c0-c9bc2f18365a" ], "package_ndc": [ "0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20" ], "unii": [ "IY9XDZ35W2" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 10%, Injection, 10 g/100 mL (NDC 0264-7520-00)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "67457-228-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA079199" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Mylan Institutional LLC" ], "product_ndc": [ "67457-228" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "b65fbcab-781e-4706-a60b-a8eb4aeae0c1" ], "spl_set_id": [ "f58803b0-f173-4997-b2f8-0f415b94dacf" ], "package_ndc": [ "67457-228-00", "67457-228-05", "67457-228-99", "67457-228-10" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-10)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "55150-161-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA203082" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-161", "55150-162", "55150-163", "55150-164", "55150-165" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1737562", "1737566", "1737568", "1737757", "1737761" ], "spl_id": [ "bab2ea79-0aed-4f48-8b4e-f864f8b82fb8", "d95a0a28-804f-44d2-aa31-01df376a3154" ], "spl_set_id": [ "9916b09d-a116-469d-92d5-60e50ea9782b", "89701fac-7536-4f16-87fb-f4cc121e74ee" ], "package_ndc": [ "55150-161-09", "55150-162-09", "55150-163-00", "55150-163-24", "55150-164-09", "55150-165-09", "55150-161-02", "55150-162-05", "55150-163-30", "55150-163-25", "55150-164-02", "55150-165-05" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-161-02)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "New", "initial_posting_date": "04/10/2020", "package_ndc": "70069-758-04", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": { "application_number": [ "ANDA218112" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-758", "70069-759" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1788947" ], "spl_id": [ "6a1a2c33-1467-4eb0-adc6-6e21771fbf6b" ], "spl_set_id": [ "649e777b-9b30-4f1e-9fb9-6bba57580976" ], "package_ndc": [ "70069-758-04", "70069-759-04" ], "unii": [ "1018WH7F9I" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-758-04)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "12/13/2017", "package_ndc": "72205-101-07", "generic_name": "Bumetanide Injection", "contact_info": "855-668-2369; customerservice@novadozpharma.com", "availability": "Available", "related_info": "Distributed by: Novadoz Pharmaceuticals LLC", "openfda": { "application_number": [ "ANDA215364" ], "brand_name": [ "BUMETANIDE" ], "generic_name": [ "BUMETANIDE" ], "manufacturer_name": [ "Novadoz Pharmaceuticals LLC" ], "product_ndc": [ "72205-101", "72205-102" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "BUMETANIDE" ], "rxcui": [ "282486", "1727569" ], "spl_id": [ "387edfd4-be85-41cd-8a6d-14e6a022b5a9" ], "spl_set_id": [ "387edfd4-be85-41cd-8a6d-14e6a022b5a9" ], "package_ndc": [ "72205-101-01", "72205-101-07", "72205-102-01", "72205-102-07" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "0Y2S3XUQ5H" ] }, "update_date": "08/21/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, 0.25 mg/1 mL (NDC 72205-101-07)", "company_name": "MSN Laboratories Private Limited", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "61703-408-41", "generic_name": "Methotrexate Sodium Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA011719" ], "brand_name": [ "METHOTREXATE" ], "generic_name": [ "METHOTREXATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "61703-408", "61703-350" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "METHOTREXATE SODIUM" ], "rxcui": [ "1655956", "1946772" ], "spl_id": [ "95b8b8da-da4e-4bba-9038-3cf65f3d5c1a", "37b3e76b-ac3d-4f93-adf1-91f52f676b8a" ], "spl_set_id": [ "0d63ba29-b692-41b4-87e8-351265c8273f", "0e30eaef-5a09-4104-8a11-c32933eadeab" ], "package_ndc": [ "61703-350-37", "61703-350-38", "61703-408-41", "61703-350-09", "61703-350-10", "61703-408-25" ], "unii": [ "3IG1E710ZN" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology", "Oncology" ], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-41)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-192-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": { "application_number": [ "ANDA209799" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "SUNRISE PHARMACEUTICAL, INC." ], "product_ndc": [ "11534-192", "11534-190", "11534-191", "11534-193", "11534-194", "11534-195", "11534-196" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "60dcfbf6-d07a-4010-ae77-8a9ae4529828" ], "spl_set_id": [ "ac102599-3a5b-4154-899e-6ff262be7ff7" ], "package_ndc": [ "11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/16/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 11534-192-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "0264-2101-10", "generic_name": "Sterile Water Irrigant", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "NDA016734" ], "brand_name": [ "STERILE WATER" ], "generic_name": [ "WATER" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-2101" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "IRRIGATION" ], "substance_name": [ "WATER" ], "rxcui": [ "150985" ], "spl_id": [ "969bdf41-6565-42fb-8ac1-8661a928cc22" ], "spl_set_id": [ "f4284eb6-e553-46d4-90d8-efc80a90a480" ], "package_ndc": [ "0264-2101-00", "0264-2101-10", "0264-2101-50", "0264-2101-70" ], "unii": [ "059QF0KO0R" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-10)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "16729-277-30", "generic_name": "Methotrexate Sodium Injection", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": { "application_number": [ "ANDA040716" ], "brand_name": [ "METHOTREXATE" ], "generic_name": [ "METHOTREXATE" ], "manufacturer_name": [ "Accord Healthcare, Inc." ], "product_ndc": [ "16729-277" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS" ], "substance_name": [ "METHOTREXATE" ], "rxcui": [ "1655956", "1655959", "1655960" ], "spl_id": [ "2bae3cfe-7aa0-c14c-e063-6294a90a19f4" ], "spl_set_id": [ "dd035a9f-cd40-4314-b9d8-2294b8a924e2" ], "package_ndc": [ "16729-277-30", "16729-277-03", "16729-277-35" ], "nui": [ "N0000175584", "N0000000111" ], "pharm_class_epc": [ "Folate Analog Metabolic Inhibitor [EPC]" ], "pharm_class_moa": [ "Folic Acid Metabolism Inhibitors [MoA]" ], "unii": [ "YL5FZ2Y5U1" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Rheumatology", "Oncology" ], "dosage_form": "Injection", "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30)", "company_name": "Accord Healthcare Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/21/2023", "package_ndc": "0338-9549-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA208083" ], "brand_name": [ "CLINDAMYCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "0338-9549", "0338-9545", "0338-9553" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "309335", "309336", "309339" ], "spl_id": [ "b0a47c5e-911b-4b12-a0d1-a4425f173eec" ], "spl_set_id": [ "44fa506b-90ac-42de-831b-5f3f1a500fc0" ], "package_ndc": [ "0338-9545-50", "0338-9545-24", "0338-9549-50", "0338-9549-24", "0338-9553-50", "0338-9553-24" ], "unii": [ "EH6D7113I8" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-61", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-285", "63323-286", "63323-287", "63323-288" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091" ], "spl_id": [ "324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c" ], "spl_set_id": [ "dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6" ], "package_ndc": [ "63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-61)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5113-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Available", "openfda": { "application_number": [ "ANDA211840" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "SpecGx LLC" ], "product_ndc": [ "0406-5113", "0406-5111", "0406-5112", "0406-5114", "0406-5115", "0406-5116", "0406-5117" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "b4be564a-404d-4ca1-bac0-ec9cf40fef93" ], "spl_set_id": [ "806a1c15-0842-4787-b2ad-09a21fd96b37" ], "package_ndc": [ "0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0406-5113-01)", "company_name": "SpecGx LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/11/2024", "package_ndc": "0338-0719-06", "generic_name": "Dextrose Monohydrate 70% Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: September 2026", "openfda": { "application_number": [ "NDA020047" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0719" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "237656" ], "spl_id": [ "fa107ac2-32b9-452f-b26c-0a5df79e31ab" ], "spl_set_id": [ "0332f34a-7038-47cc-ba59-d55cad6b73ca" ], "package_ndc": [ "0338-0719-06" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0338-0719-06)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "12/18/2020", "package_ndc": "63323-771-39", "generic_name": "Azacitidine Injection", "contact_info": "1-888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA207518" ], "brand_name": [ "AZACITIDINE" ], "generic_name": [ "AZACITIDINE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-771" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "AZACITIDINE" ], "rxcui": [ "485246" ], "spl_id": [ "4becda8d-8042-4cf1-bef3-c0ec3c23eebe" ], "spl_set_id": [ "3b594aba-e798-4105-b801-0b0d970747c1" ], "package_ndc": [ "63323-771-39" ], "nui": [ "N0000000233", "N0000175595" ], "pharm_class_moa": [ "Nucleic Acid Synthesis Inhibitors [MoA]" ], "pharm_class_epc": [ "Nucleoside Metabolic Inhibitor [EPC]" ], "unii": [ "M801H13NRU" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg/30 mL (NDC 63323-771-39)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "47781-568-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": { "application_number": [ "ANDA214547" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Alvogen Inc." ], "product_ndc": [ "47781-568", "47781-562", "47781-563", "47781-564", "47781-565", "47781-566", "47781-567" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "db02ec6b-f17f-ab22-b671-e1ddb90e017c" ], "spl_set_id": [ "7f2dd6ee-3363-c87c-9693-ed838942556c" ], "package_ndc": [ "47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 47781-568-01)", "company_name": "Alvogen", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "16729-138-00", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": { "application_number": [ "ANDA077147" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Accord Healthcare Inc." ], "product_ndc": [ "16729-138", "16729-136", "16729-137" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "0e1e7f41-f78b-27cf-e063-6394a90a1ae0" ], "spl_set_id": [ "ebc11109-e7bf-452d-b675-4b3236d54164" ], "package_ndc": [ "16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 16729-138-00)", "company_name": "Accord Healthcare Inc.", "status": "Current" }, { "discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4916-14", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 75 mg/1 mL (NDC 0409-4916-14)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4740-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Limited Availability", "related_info": "Estimated recovery: 10/20/26", "openfda": { "application_number": [ "ANDA216944" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Apotex Corp." ], "product_ndc": [ "60505-4740", "60505-4739", "60505-4741", "60505-4742", "60505-4743", "60505-4744", "60505-4745" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "2eec36cd-6063-fea0-d6dd-b7a5c8df186b" ], "spl_set_id": [ "ecad4442-a644-18e3-6ff2-fdbac45eec47" ], "package_ndc": [ "60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 60505-4740-1)", "company_name": "Apotex Corp.", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1073-02", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA020255" ], "brand_name": [ "DOBUTAMINE HYDROCHLORIDE IN DEXTROSE" ], "generic_name": [ "DOBUTAMINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-1073", "0338-1075", "0338-1077" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOBUTAMINE HYDROCHLORIDE" ], "rxcui": [ "309985", "309986", "309987" ], "spl_id": [ "34c787c1-46f7-4264-951d-c88a34dca533" ], "spl_set_id": [ "6b17b98b-e06d-42ed-925f-69aa2699dead" ], "package_ndc": [ "0338-1073-02", "0338-1075-02", "0338-1077-02" ], "unii": [ "0WR771DJXV" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Cardiovascular", "Pediatric", "Renal" ], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 100 mg/100 mL (NDC 0338-1073-02)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-063-25", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": { "application_number": [ "ANDA207636" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-063", "70069-061", "70069-062", "70069-064", "70069-065", "70069-066", "70069-067" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483" ], "spl_id": [ "79b226f0-c08a-4f84-bf2b-ae5c60e01d67" ], "spl_set_id": [ "ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64" ], "package_ndc": [ "70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10" ], "unii": [ "V910P86109" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-063-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4745-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Available", "openfda": { "application_number": [ "ANDA216944" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Apotex Corp." ], "product_ndc": [ "60505-4745", "60505-4739", "60505-4740", "60505-4741", "60505-4742", "60505-4743", "60505-4744" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "2eec36cd-6063-fea0-d6dd-b7a5c8df186b" ], "spl_set_id": [ "ecad4442-a644-18e3-6ff2-fdbac45eec47" ], "package_ndc": [ "60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 60505-4745-1)", "company_name": "Apotex Corp.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-152-00", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": { "application_number": [ "ANDA075468" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Advagen Pharma Ltd" ], "product_ndc": [ "72888-152", "72888-497", "72888-153", "72888-154" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529", "204892" ], "spl_id": [ "5510f17b-a980-f412-e063-6394a90ae1c4" ], "spl_set_id": [ "30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec" ], "package_ndc": [ "72888-497-01", "72888-497-02", "72888-497-03", "72888-497-04", "72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 72888-152-00)", "company_name": "Rubicon Research Private Limited", "status": "Current" }, { "discontinued_date": "04/09/2026", "update_type": "New", "initial_posting_date": "04/09/2026", "package_ndc": "0069-3070-30", "generic_name": "Azithromycin Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA050784" ], "brand_name": [ "ZITHROMAX" ], "generic_name": [ "AZITHROMYCIN DIHYDRATE" ], "manufacturer_name": [ "Pfizer Laboratories Div Pfizer Inc" ], "product_ndc": [ "0069-3070", "0069-3060", "0069-3110", "0069-3120", "0069-3130", "0069-3140", "0069-4061" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "AZITHROMYCIN DIHYDRATE" ], "rxcui": [ "105260", "141963", "211307", "212446", "226827", "248656", "308459", "308460", "749780", "749783", "750149", "750157" ], "spl_id": [ "1c5f0fcc-88ce-47e9-a128-b7326b7a5a02" ], "spl_set_id": [ "db52b91e-79f7-4cc1-9564-f2eee8e31c45" ], "package_ndc": [ "0069-3060-30", "0069-3060-75", "0069-3060-86", "0069-3070-30", "0069-3070-75", "0069-3110-19", "0069-3120-19", "0069-3130-19", "0069-3140-19", "0069-4061-01", "0069-4061-75", "0069-4061-89" ], "unii": [ "5FD1131I7S" ] }, "update_date": "04/09/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Tablet", "presentation": "Zithromax, Tablet, 500 mg (NDC 0069-3070-30)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0480-3566-01)", "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3566-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "company_name": "Teva Pharmaceuticals USA, Inc.", "contact_info": "800-545-8800", "availability": "Available", "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "status": "Current", "dosage_form": "Capsule" }, { "discontinued_date": "07/30/2026", "update_type": "New", "initial_posting_date": "07/30/2026", "package_ndc": "0591-4575-60", "generic_name": "Doxycycline Hyclate Tablet, Delayed Release", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA090134" ], "brand_name": [ "DOXYCYCLINE HYCLATE" ], "generic_name": [ "DOXYCYCLINE HYCLATE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0591-4575", "0591-4550" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DOXYCYCLINE HYCLATE" ], "rxcui": [ "1423080", "1653433" ], "spl_id": [ "304ae0bb-5f05-4389-8952-5a99391b8047" ], "spl_set_id": [ "c2b08332-3256-4658-965a-ede3d973a388" ], "package_ndc": [ "0591-4550-22", "0591-4575-60" ], "unii": [ "19XTS3T51U" ] }, "update_date": "07/30/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Tablet", "presentation": "Doxycycline Hyclate, Tablet, Delayed Release, 200 mg (NDC 0591-4575-60)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-3299-05", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA018893" ], "brand_name": [ "SODIUM ACETATE" ], "generic_name": [ "SODIUM ACETATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3299" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM ACETATE ANHYDROUS" ], "rxcui": [ "237371" ], "spl_id": [ "4e6137c2-6b7c-4882-985c-03b591b6c046", "b7a713f4-3c97-484b-b182-2824e1e944bb" ], "spl_set_id": [ "abc41ed1-9512-4bea-9295-1a9ca134b6c2", "c3be2468-45e8-4ecc-a30b-e966743a563f" ], "package_ndc": [ "0409-3299-15", "0409-3299-05", "0409-3299-16", "0409-3299-06", "0409-3299-45", "0409-3299-25", "0409-3299-46", "0409-3299-26" ], "unii": [ "NVG71ZZ7P0" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition" ], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-022-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 22.5 mg/.4 mL (NDC 82497-022-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3178-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA089644" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3178", "0409-1209", "0409-3177", "0409-3181", "0409-3182", "0409-3183", "0409-0007", "0409-0147" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE", "EPINEPHRINE" ], "rxcui": [ "1010688", "1010745", "1010751", "1010759", "1867996", "1867998" ], "spl_id": [ "68a37af1-d237-4836-af13-1eec28245f8b" ], "spl_set_id": [ "2f94f711-14c4-48ec-c5a3-c5ec4b8e8729" ], "package_ndc": [ "0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10" ], "nui": [ "N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647" ], "pharm_class_moa": [ "Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]" ], "pharm_class_epc": [ "alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]" ], "pharm_class_cs": [ "Catecholamines [CS]" ], "unii": [ "YKH834O4BH", "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 200 mg/20 mL (1%; 1:100,000) (NDC 0409-3178-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "02/10/2026", "update_type": "New", "initial_posting_date": "02/10/2026", "package_ndc": "65649-311-12", "generic_name": "Chlorothiazide Oral Suspension", "contact_info": "800-321-4576", "openfda": { "application_number": [ "NDA011870" ], "brand_name": [ "DIURIL" ], "generic_name": [ "CHLOROTHIAZIDE" ], "manufacturer_name": [ "Salix Pharmaceuticals, Inc" ], "product_ndc": [ "65649-311" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CHLOROTHIAZIDE" ], "rxcui": [ "213439", "309198" ], "spl_id": [ "e311f727-9882-4c42-bd5b-e8e38ee54466" ], "spl_set_id": [ "bd936e35-1af8-42da-bcc0-f22489d68574" ], "package_ndc": [ "65649-311-12" ], "nui": [ "N0000175359", "N0000175419", "M0471776" ], "pharm_class_pe": [ "Increased Diuresis [PE]" ], "pharm_class_epc": [ "Thiazide Diuretic [EPC]" ], "pharm_class_cs": [ "Thiazides [CS]" ], "unii": [ "77W477J15H" ] }, "update_date": "02/10/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Oral Suspension", "presentation": "Diuril, Oral Suspension, 250 mg/5mL (NDC 65649-311-12)", "company_name": "Salix Pharmaceuticals, a division of Bausch Health US, LLC", "status": "To Be Discontinued" }, { "discontinued_date": "01/12/2026", "update_type": "New", "initial_posting_date": "01/12/2026", "package_ndc": "63323-413-10", "generic_name": "Neostigmine Methylsulfate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA203629" ], "brand_name": [ "NEOSTIGMINE METHYLSULFATE" ], "generic_name": [ "NEOSTIGMINE METHYLSULFATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-413", "63323-415" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "NEOSTIGMINE METHYLSULFATE" ], "rxcui": [ "311935", "311936" ], "spl_id": [ "3abc0611-0e8c-49f9-9678-e4b2fda3d8ed", "1efedce1-b2c3-4652-a289-6ea596b039e2" ], "spl_set_id": [ "6448229c-e650-47ba-bb00-cba3604502c5", "d0e11e4c-41c3-4874-b567-579db655fba3" ], "package_ndc": [ "63323-413-01", "63323-413-10", "63323-415-01", "63323-415-10", "63323-413-36", "63323-415-36" ], "unii": [ "98IMH7M386" ] }, "update_date": "01/12/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Neostigmine Methylsulfate, Injection, .5 mg/1 mL (NDC 63323-413-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "discontinued_date": "05/15/2026", "update_type": "New", "initial_posting_date": "05/15/2026", "package_ndc": "0574-0521-25", "generic_name": "Activated Charcoal Oral Suspension", "contact_info": "866-634-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "M023" ], "brand_name": [ "ACTIDOSE AQUA" ], "generic_name": [ "ACTIVATED CHARCOAL" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-0521" ], "product_type": [ "HUMAN OTC DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ACTIVATED CHARCOAL" ], "rxcui": [ "309150", "1251411" ], "spl_id": [ "bd250d66-b8ea-4cab-a8f2-d2913a157fc5" ], "spl_set_id": [ "c85dc235-3f42-4361-9bd2-1aaff798ad75" ], "package_ndc": [ "0574-0521-25", "0574-0521-74", "0574-0521-76" ], "unii": [ "2P3VWU3H10" ] }, "update_date": "05/15/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Oral Suspension", "presentation": "Actidose Aqua, Oral Suspension, 208 mg/1 mL (NDC 0574-0521-25)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "71288-723-52", "generic_name": "Bupivacaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-824-8426", "availability": "Limited Availability", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "openfda": { "application_number": [ "ANDA216039" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Meitheal Pharmaceuticals Inc" ], "product_ndc": [ "71288-723", "71288-726" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404" ], "spl_id": [ "0949c302-51ce-4fc9-8b99-1df94e693718" ], "spl_set_id": [ "fe340f98-a0f3-446e-b281-47fd91c1e537" ], "package_ndc": [ "71288-723-52", "71288-726-52" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "05/05/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-723-52)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-354-90", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-90)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7923-23", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Available", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA016367" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "ICU Medical, Inc." ], "product_ndc": [ "0990-7923", "0990-7922", "0990-7930" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621" ], "spl_id": [ "06e4d957-1a56-4adb-a42b-fe0773b2fa97" ], "spl_set_id": [ "8b25b7e0-703e-4b43-a4eb-52863511602d" ], "package_ndc": [ "0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-23)", "company_name": "Otsuka ICU Medical LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-466-17", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA070553", "NDA018304" ], "brand_name": [ "SENSORCAINE MPF" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-466", "63323-464", "63323-462", "63323-465", "63323-467", "63323-460" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRACAUDAL", "PERINEURAL", "INFILTRATION" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457" ], "spl_id": [ "b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715" ], "spl_set_id": [ "e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8" ], "package_ndc": [ "63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31" ], "unii": [ "7TQO7W3VT8", "30Q7KI53AK" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-098-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": { "application_number": [ "NDA216117" ], "brand_name": [ "RELEXXII" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Vertical Pharmaceuticals, LLC" ], "product_ndc": [ "68025-098", "68025-088", "68025-089", "68025-095", "68025-096", "68025-097", "68025-084" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505" ], "spl_id": [ "86f477e9-07fc-466b-913e-1a4434c91df4" ], "spl_set_id": [ "22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d" ], "package_ndc": [ "68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current" }, { "discontinued_date": "03/02/2026", "update_type": "New", "initial_posting_date": "03/02/2026", "package_ndc": "0093-7769-24", "generic_name": "Everolimus Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA210050" ], "brand_name": [ "EVEROLIMUS" ], "generic_name": [ "EVEROLIMUS" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0093-7769", "0093-7766", "0093-7767", "0093-7768" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "EVEROLIMUS" ], "rxcui": [ "845507", "845515", "998189", "1119400" ], "spl_id": [ "0f7ea770-928b-43b2-8971-849d1d12bbc8" ], "spl_set_id": [ "e3bca36b-29ed-4a2b-a1be-a57b6af805f6" ], "package_ndc": [ "0093-7766-19", "0093-7766-24", "0093-7767-19", "0093-7767-24", "0093-7768-19", "0093-7768-24", "0093-7769-19", "0093-7769-24" ], "nui": [ "N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550" ], "pharm_class_epc": [ "Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]" ], "pharm_class_moa": [ "Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]" ], "pharm_class_pe": [ "Decreased Immunologic Activity [PE]" ], "unii": [ "9HW64Q8G6G" ] }, "update_date": "03/02/2026", "therapeutic_category": [ "Transplant" ], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 10 mg (NDC 0093-7769-24)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "05/04/2021", "package_ndc": "59137-570-01", "generic_name": "Triamcinolone Hexacetonide Injection", "related_info_link": "https://www.fda.gov/media/192735/download?attachment", "contact_info": "1-855-336-3322 Option 9", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "brand_name": [ "HEXATRIONE 2%" ], "generic_name": [ "TRIAMCINOLONE HEXACETONIDE" ], "manufacturer_name": [ "Medexus Pharma, Inc." ], "product_ndc": [ "59137-570" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR" ], "substance_name": [ "TRIAMCINOLONE HEXACETONIDE" ], "rxcui": [ "2539176", "2539181" ], "spl_id": [ "5128fd5b-e866-907e-e063-6394a90ac4c9" ], "spl_set_id": [ "bc07ae9f-8a74-6bc8-e053-2995a90afc0d" ], "package_ndc": [ "59137-570-01" ], "unii": [ "I7GT1U99Y9" ] }, "update_date": "05/27/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Hexatrione, Injection, 40 mg/2 mL (NDC 59137-570-01)", "company_name": "Medexus", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0280-51", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA011757" ], "brand_name": [ "DEPO-MEDROL" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0280", "0009-0274", "0009-0306" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1358510", "1358512", "1358610", "1358612", "1358617", "1358619" ], "spl_id": [ "267dd735-f800-4735-ba1c-d39d00f0cee5" ], "spl_set_id": [ "823b0010-2b57-4e76-b5ac-4a8c2963438f" ], "package_ndc": [ "0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-51)", "company_name": "Pfizer Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-2344-02", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA074086" ], "brand_name": [ "DOBUTAMINE" ], "generic_name": [ "DOBUTAMINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-2344" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOBUTAMINE HYDROCHLORIDE" ], "rxcui": [ "1812168" ], "spl_id": [ "e71e9520-871b-479d-9652-1857fceca863", "f6a67673-07a7-44e4-b05c-1f7e63326f79" ], "spl_set_id": [ "dc537761-d5f4-488d-24ab-b2bcd2b17b7a", "89becb0c-da60-4f43-0a98-29ff7a9eca58" ], "package_ndc": [ "0409-2344-01", "0409-2344-62", "0409-2344-02", "0409-2344-68", "0409-2344-88" ], "unii": [ "0WR771DJXV" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular", "Pediatric", "Renal" ], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-463-57", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesaler for inventory", "openfda": { "application_number": [ "ANDA070968" ], "brand_name": [ "SENSORCAINE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-463", "63323-472", "63323-461", "63323-468" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810", "1867594", "1867596", "1867618", "1867620" ], "spl_id": [ "cc1f6507-eb3e-4398-a1d3-0c56a2099e6b" ], "spl_set_id": [ "bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb" ], "package_ndc": [ "63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "63323-412-25", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release September 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "ANDA075154" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-412", "63323-411" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "311700", "311702" ], "spl_id": [ "9814447b-a93e-42ad-b57e-5db0a5b7f552" ], "spl_set_id": [ "a91ce254-14a3-4cbf-8ab8-5da252aa3fdc" ], "package_ndc": [ "63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-25)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/31/2026", "package_ndc": "0054-3298-63", "generic_name": "Furosemide Oral Solution", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": { "application_number": [ "ANDA070433" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0054-3298", "0054-4297", "0054-8297", "0054-4299", "0054-8299", "0054-4301", "0054-8301", "0054-3294" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "197730", "197731", "197732", "310429", "313988" ], "spl_id": [ "bc62ddda-7639-4090-99f0-7dd4d13518f3" ], "spl_set_id": [ "9e493331-dddd-496e-abf8-61747fb67aba" ], "package_ndc": [ "0054-4297-31", "0054-4297-25", "0054-8297-25", "0054-4299-31", "0054-4299-25", "0054-8299-25", "0054-4301-29", "0054-4301-25", "0054-8301-25", "0054-3298-63", "0054-3294-50", "0054-3294-46" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Oral Solution", "presentation": "Furosemide, Oral Solution, 40 mg/5 mL (NDC 0054-3298-63)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an inactive ingredient component", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "72266-263-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-217-8103", "availability": "Available", "related_info": "Distributed by Fosun Pharma USA Inc.", "openfda": { "application_number": [ "ANDA091487" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fosun Pharma USA Inc." ], "product_ndc": [ "72266-263", "72266-264" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1724880", "1725078" ], "spl_id": [ "55904ca6-a5ad-76ce-e063-6294a90ac5e0" ], "spl_set_id": [ "3a996abe-0bb9-4590-e063-6394a90a0b60" ], "package_ndc": [ "72266-263-10", "72266-264-10" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride PRESERVATIVE FREE, Injection, 2.5 mg/1 mL (NDC 72266-263-10)", "company_name": "ONESOURCE SPECIALTY PTE LTD", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "44567-610-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-493-0861", "availability": "Available", "related_info": "Please check wholesalers and distributors for inventory.", "openfda": { "application_number": [ "NDA211844" ], "brand_name": [ "MIDAZOLAM IN SODIUM CHLORIDE" ], "generic_name": [ "MIDAZOLAM" ], "manufacturer_name": [ "WG Critical Care, LLC." ], "product_ndc": [ "44567-610", "44567-611" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM" ], "rxcui": [ "2541170", "2541171" ], "spl_id": [ "6cea9d5b-d0a6-4f93-b45e-2d615f6c4337" ], "spl_set_id": [ "f051776f-94c5-4e34-80ed-f45b9c36881e" ], "package_ndc": [ "44567-610-01", "44567-610-10", "44567-611-01", "44567-611-10" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "R60L0SM5BC" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam In 0.9% Sodium Chloride, Injection, 1 mg/1 mL (NDC 44567-610-10)", "company_name": "WG Critical Care", "status": "Current" }, { "discontinued_date": "06/17/2026", "update_type": "New", "initial_posting_date": "06/17/2026", "package_ndc": "61958-0602-1", "generic_name": "Emtricitabine Oral Solution", "contact_info": "800-445-3235", "related_info": "Product expected to be available until March 2027", "openfda": { "application_number": [ "NDA021896" ], "brand_name": [ "EMTRIVA" ], "generic_name": [ "EMTRICITABINE" ], "manufacturer_name": [ "Gilead Sciences, Inc." ], "product_ndc": [ "61958-0602", "61958-0601" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "EMTRICITABINE" ], "rxcui": [ "403875", "404587", "597291", "616148" ], "spl_id": [ "13ed3577-67a4-4828-b886-f35206f149a6" ], "spl_set_id": [ "d6599395-3944-44f9-97f2-e0424c6b6a1f" ], "package_ndc": [ "61958-0601-1", "61958-0602-1" ], "nui": [ "N0000175462", "M0015066", "N0000009947" ], "pharm_class_epc": [ "Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]" ], "pharm_class_cs": [ "Nucleosides [CS]" ], "pharm_class_moa": [ "Nucleoside Reverse Transcriptase Inhibitors [MoA]" ], "unii": [ "G70B4ETF4S" ] }, "update_date": "06/17/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Oral Solution", "presentation": "Emtriva, Oral Solution, 10 mg/1 mL (NDC 61958-0602-1)", "company_name": "Gilead Sciences, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "60951-701-70", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA040330" ], "brand_name": [ "ENDOCET" ], "generic_name": [ "OXYCODONE AND ACETAMINOPHEN" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "60951-701", "60951-602", "60951-700", "60951-712" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OXYCODONE HYDROCHLORIDE", "ACETAMINOPHEN" ], "rxcui": [ "1049214", "1049216", "1049221", "1049223", "1049225", "1049227", "1049635", "1487288" ], "spl_id": [ "a8475489-982f-4080-9565-7948155d9abb" ], "spl_set_id": [ "944d3e60-7eee-11de-a413-0002a5d5c51b" ], "package_ndc": [ "60951-602-70", "60951-602-85", "60951-700-70", "60951-712-70", "60951-701-70" ], "unii": [ "C1ENJ2TE6C", "362O9ITL9D" ] }, "update_date": "11/03/2025", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 2.5 mg (NDC 60951-701-70)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2587-05", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA075293" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-2587", "0409-2596" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "311700", "311702" ], "spl_id": [ "6c075a2d-b68b-41a7-aa0c-bcf9894e3f76" ], "spl_set_id": [ "affecd4d-1f78-4bbe-5a8d-86849bbdc520" ], "package_ndc": [ "0409-2587-04", "0409-2587-05", "0409-2596-13", "0409-2596-03", "0409-2596-15", "0409-2596-05" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-2587-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0013-06", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": { "application_number": [ "NDA009866" ], "brand_name": [ "SOLU-CORTEF" ], "generic_name": [ "HYDROCORTISONE SODIUM SUCCINATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0013", "0009-0825", "0009-0011", "0009-0016", "0009-0005" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "HYDROCORTISONE SODIUM SUCCINATE" ], "rxcui": [ "105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596" ], "spl_id": [ "8512044a-4a54-4634-bb97-9e20126adc61" ], "spl_set_id": [ "65eefd58-b166-4d71-ade6-45c8fdf86922" ], "package_ndc": [ "0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01" ], "unii": [ "50LQB69S1Z" ] }, "update_date": "02/24/2026", "therapeutic_category": [ "Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 250 mg/vial (NDC 0009-0013-06)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1160-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA070590" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1160", "0409-1159", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596" ], "spl_id": [ "6e442bfd-d3da-4913-8585-ce3485644364" ], "spl_set_id": [ "02a845c3-4521-4926-e397-25ab536e7cf6" ], "package_ndc": [ "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Marcaine, Injection, Marcaine 125 mg/50 mL (2.5 mg/mL) (NDC 0409-1160-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "0641-6059-01", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA075243" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6059", "0641-6057", "0641-6056", "0641-6061", "0641-6063", "0641-6060" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "311700", "311702" ], "spl_id": [ "559c03fb-24ea-4b7b-8afd-e33cb3a2340a" ], "spl_set_id": [ "575d8bf0-7af7-427c-a231-966e2a5e070d" ], "package_ndc": [ "0641-6057-01", "0641-6057-10", "0641-6057-25", "0641-6059-01", "0641-6059-10", "0641-6056-01", "0641-6056-10", "0641-6061-01", "0641-6061-10", "0641-6061-25", "0641-6063-01", "0641-6063-10", "0641-6063-25", "0641-6060-01", "0641-6060-10" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6059-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "08/10/2026", "update_type": "New", "initial_posting_date": "08/10/2026", "package_ndc": "0093-9364-01", "generic_name": "Glyburide Tablet", "contact_info": "800-633-1610", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA017532" ], "brand_name": [ "GLYBURIDE" ], "generic_name": [ "GLYBURIDE" ], "manufacturer_name": [ "TEVA Pharmaceuticals USA Inc" ], "product_ndc": [ "0093-9364", "0093-9477", "0093-9433" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "GLYBURIDE" ], "rxcui": [ "197737", "310534", "310537" ], "spl_id": [ "84b83205-8813-494e-933e-a70697393744" ], "spl_set_id": [ "50d16f1d-c814-4411-8749-62561321ecce" ], "package_ndc": [ "0093-9477-53", "0093-9433-01", "0093-9433-05", "0093-9364-01", "0093-9364-05", "0093-9364-10" ], "nui": [ "N0000175608", "M0020795" ], "pharm_class_epc": [ "Sulfonylurea [EPC]" ], "pharm_class_cs": [ "Sulfonylurea Compounds [CS]" ], "unii": [ "SX6K58TVWC" ] }, "update_date": "08/10/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Tablet", "presentation": "Diabeta, Tablet, 5 mg (NDC 0093-9364-01)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "63323-671-50", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-50)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "65219-065-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA078651" ], "brand_name": [ "ROCURONIUM" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-065" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "68f8f5e7-46a8-47f9-a622-6339df1a3d1b" ], "spl_set_id": [ "209a654d-f92d-4242-bfef-2dcc90a30d3f" ], "package_ndc": [ "65219-065-02", "65219-065-05" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-065-05)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "76045-107-10", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA203242" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "76045-107", "76045-104", "76045-105", "76045-209" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860113", "860114", "860115" ], "spl_id": [ "0dab642d-7fcf-4301-8ac9-10e64a040c6b" ], "spl_set_id": [ "3d88cbe6-5230-47aa-80af-0c41283d1f00" ], "package_ndc": [ "76045-104-10", "76045-105-20", "76045-107-10", "76045-209-00", "76045-209-10" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 76045-107-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0781-3289-09", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-525-8747", "availability": "Available", "openfda": { "application_number": [ "ANDA201692" ], "brand_name": [ "CLINDAMYCIN IN 5 PERCENT DEXTROSE" ], "generic_name": [ "CLINDAMYCIN IN 5 PERCENT DEXTROSE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-3289", "0781-3288", "0781-3290" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN" ], "rxcui": [ "309335", "309336", "309339" ], "spl_id": [ "b553b8ab-ef4d-40ae-a5fb-a6242f2ad30a" ], "spl_set_id": [ "231d95a6-5e5f-4a45-a92b-d3d16ef0a7ca" ], "package_ndc": [ "0781-3288-91", "0781-3288-09", "0781-3289-91", "0781-3289-09", "0781-3290-91", "0781-3290-09" ], "nui": [ "N0000009982", "N0000175443", "M0515779", "N0000175731" ], "pharm_class_pe": [ "Decreased Sebaceous Gland Activity [PE]", "Neuromuscular Blockade [PE]" ], "pharm_class_epc": [ "Lincosamide Antibacterial [EPC]" ], "pharm_class_cs": [ "Lincosamides [CS]" ], "unii": [ "3U02EL437C" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09)", "company_name": "Sandoz Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-0929-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA083312" ], "brand_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "generic_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-0929", "0641-0928" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "rxcui": [ "992460", "992858" ], "spl_id": [ "9f14d3f5-ad01-44b5-a2b7-16ed5f501f87" ], "spl_set_id": [ "4bf3912c-8339-401e-9711-dad6acf15f11" ], "package_ndc": [ "0641-0928-21", "0641-0928-25", "0641-0929-21", "0641-0929-25" ], "unii": [ "R61ZEH7I1I" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy" ], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-0929-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "01/06/2026", "update_type": "New", "initial_posting_date": "01/06/2026", "package_ndc": "49884-125-91", "generic_name": "Everolimus Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "01/06/2026", "therapeutic_category": [ "Transplant" ], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 5 mg (NDC 49884-125-91)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "0093-3212-01", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated supply: August 2026", "openfda": { "application_number": [ "ANDA074569" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0093-3212", "0093-0832", "0093-3213" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "d6abe4e3-7699-4ead-95f4-739a961b23ad" ], "spl_set_id": [ "8069b1a0-7c06-4252-b44e-e2eef065d9b8" ], "package_ndc": [ "0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 0093-3212-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "10/07/2025", "update_type": "New", "initial_posting_date": "10/07/2025", "package_ndc": "0074-9036-30", "generic_name": "Paricalcitol Capsule", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA021606" ], "brand_name": [ "ZEMPLAR" ], "generic_name": [ "PARICALCITOL" ], "manufacturer_name": [ "AbbVie Inc." ], "product_ndc": [ "0074-9036", "0074-4314", "0074-4317", "0074-9037" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "PARICALCITOL" ], "rxcui": [ "577315", "577317", "606854", "606859" ], "spl_id": [ "61ef39c0-0c32-4b82-962e-8ebdd55ce427" ], "spl_set_id": [ "1b27c026-2d60-47b4-2a9c-ded1818f21b5" ], "package_ndc": [ "0074-4314-30", "0074-4317-30", "0074-4317-73", "0074-9036-30", "0074-9037-30" ], "nui": [ "M0007651", "N0000175907", "N0000175849" ], "pharm_class_cs": [ "Ergocalciferols [CS]" ], "pharm_class_epc": [ "Vitamin D2 Analog [EPC]", "Vitamin D Analog [EPC]" ], "unii": [ "6702D36OG5" ] }, "update_date": "10/07/2025", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Capsule", "presentation": "Zemplar, Capsule, 1 ug (NDC 0074-9036-30)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "57844-130-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA040422" ], "brand_name": [ "ADDERALL" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "57844-130", "57844-105", "57844-117", "57844-110", "57844-112", "57844-115", "57844-120" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147" ], "spl_id": [ "79af1dc6-c7cf-41b1-a750-e9b47c2187ff" ], "spl_set_id": [ "f22635fe-821d-4cde-aa12-419f8b53db81" ], "package_ndc": [ "57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 57844-130-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "02/19/2026", "update_type": "New", "initial_posting_date": "02/19/2026", "package_ndc": "0591-5544-05", "generic_name": "Allopurinol Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA018877" ], "brand_name": [ "ALLOPURINOL" ], "generic_name": [ "ALLOPURINOL" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0591-5544", "0591-5543" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ALLOPURINOL" ], "rxcui": [ "197319", "197320" ], "spl_id": [ "f7e04d88-1d9b-47e6-a9ad-deb08af3c098" ], "spl_set_id": [ "a80fe56f-8d03-423f-8e2a-7ec8c9e5045b" ], "package_ndc": [ "0591-5543-01", "0591-5543-10", "0591-5544-01", "0591-5544-05" ], "nui": [ "N0000175698", "N0000000206" ], "pharm_class_epc": [ "Xanthine Oxidase Inhibitor [EPC]" ], "pharm_class_moa": [ "Xanthine Oxidase Inhibitors [MoA]" ], "unii": [ "63CZ7GJN5I" ] }, "update_date": "02/19/2026", "therapeutic_category": [ "Oncology", "Renal", "Rheumatology" ], "dosage_form": "Tablet", "presentation": "Allopurinol, Tablet, 300 mg (NDC 0591-5544-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "09/19/2025", "update_type": "New", "initial_posting_date": "09/19/2025", "package_ndc": "69516-005-30", "generic_name": "Obeticholic Acid Tablet", "contact_info": "1-844-782-4278", "related_info": "Business decision. Products will not be available after November 14, 2025.", "update_date": "09/19/2025", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Tablet", "presentation": "Ocaliva, Tablet, 5 mg (NDC 69516-005-30)", "company_name": "Intercept Pharmaceuticals", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6028-25", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.", "openfda": { "application_number": [ "NDA019101" ], "brand_name": [ "FENTANYL CITRATE" ], "generic_name": [ "FENTANYL CITRATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6028", "0641-6024", "0641-6027", "0641-6025", "0641-6026", "0641-6029", "0641-6030", "0641-6247", "0641-6248", "0641-6249" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FENTANYL CITRATE" ], "rxcui": [ "1735003", "1735007", "1735008", "1735013", "2168270", "2474269", "2629337" ], "spl_id": [ "546a047c-1faf-4751-9e48-079e4c35b6fa" ], "spl_set_id": [ "ce5db1c2-feb1-4ad2-847a-d02e865bd47e" ], "package_ndc": [ "0641-6024-01", "0641-6024-10", "0641-6027-01", "0641-6027-25", "0641-6025-01", "0641-6025-10", "0641-6028-01", "0641-6028-10", "0641-6028-25", "0641-6026-01", "0641-6026-05", "0641-6029-01", "0641-6029-25", "0641-6030-01", "0641-6247-01", "0641-6247-25", "0641-6248-01", "0641-6248-10", "0641-6249-01", "0641-6249-10" ], "unii": [ "MUN5LYG46H" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6028-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/03/2023", "package_ndc": "42571-132-52", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "(908) 484-7410", "availability": "Available", "openfda": { "application_number": [ "ANDA202745" ], "brand_name": [ "CROMOLYN SODIUM" ], "generic_name": [ "CROMOLYN SODIUM" ], "manufacturer_name": [ "Micro Labs Limited" ], "product_ndc": [ "42571-132" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CROMOLYN SODIUM" ], "rxcui": [ "831261" ], "spl_id": [ "22ffea9c-cd39-22dd-e063-6394a90aae4b" ], "spl_set_id": [ "93f80edb-3b38-423e-8cd6-5b5cb4393ec2" ], "package_ndc": [ "42571-132-21", "42571-132-52" ], "unii": [ "Q2WXR1I0PK" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Pulmonary/Allergy" ], "dosage_form": "Concentrate", "presentation": "Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 42571-132-52)", "company_name": "Micro Labs LTD", "status": "Current" }, { "discontinued_date": "04/28/2023", "update_type": "New", "initial_posting_date": "04/28/2023", "change_date": "04/28/2023", "package_ndc": "0069-4380-71", "generic_name": "Prazosin Hydrochloride Capsule", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug. Supply expected to exhaust in September 2023", "update_date": "04/28/2023", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Capsule", "presentation": "Minipress, Capsule, 5 mg (NDC 0069-4380-71)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "76045-009-11", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release September 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "NDA019034" ], "brand_name": [ "DILAUDID" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "76045-009", "76045-010", "76045-121" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897756", "897757", "1433251", "1872265", "1872269", "1872752", "2277368", "2277370" ], "spl_id": [ "97bfcafb-2037-47dc-a0ae-f7b8007c47df" ], "spl_set_id": [ "9eebd88a-5632-460f-b7b6-26c8a180540d" ], "package_ndc": [ "76045-009-96", "76045-009-06", "76045-009-01", "76045-009-11", "76045-010-01", "76045-010-11", "76045-121-01", "76045-121-11" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-11)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "12/19/2025", "update_type": "New", "initial_posting_date": "12/19/2025", "package_ndc": "54092-172-12", "generic_name": "Carbamazepine Capsule, Extended Release", "contact_info": "855-268-1825", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA020712" ], "brand_name": [ "CARBATROL" ], "generic_name": [ "CARBAMAZEPINE" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "54092-172", "54092-171", "54092-173" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CARBAMAZEPINE" ], "rxcui": [ "200131", "200133", "308977", "313931", "388311", "404742" ], "spl_id": [ "39171a32-c78d-4130-be53-638e19cf2261" ], "spl_set_id": [ "bc03e499-5bac-4293-bff4-6864153a624d" ], "package_ndc": [ "54092-171-12", "54092-172-12", "54092-173-12" ], "nui": [ "N0000008486", "N0000175751", "N0000185506", "N0000191266", "N0000187064", "N0000185507", "N0000185607" ], "pharm_class_pe": [ "Decreased Central Nervous System Disorganized Electrical Activity [PE]" ], "pharm_class_epc": [ "Mood Stabilizer [EPC]" ], "pharm_class_moa": [ "Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2C19 Inducers [MoA]" ], "unii": [ "33CM23913M" ] }, "update_date": "12/19/2025", "therapeutic_category": [ "Neurology" ], "dosage_form": "Capsule, Extended Release", "presentation": "Carbatrol, Capsule, Extended Release, 200 mg (NDC 54092-172-12)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "10/20/2025", "update_type": "New", "initial_posting_date": "10/20/2025", "package_ndc": "0781-3317-80", "generic_name": "Oxaliplatin Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA078817" ], "brand_name": [ "OXALIPLATIN" ], "generic_name": [ "OXALIPLATIN" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-3317", "0781-3315" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "OXALIPLATIN" ], "rxcui": [ "1736776", "1736781" ], "spl_id": [ "f3766495-fce3-461c-8c95-e890f5e3383f" ], "spl_set_id": [ "ab162009-6f84-4d56-ab56-5e84409ec814" ], "package_ndc": [ "0781-3315-70", "0781-3317-80" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "04ZR38536J" ] }, "update_date": "10/20/2025", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Oxaliplatin, Injection, 5 mg/1 mL (NDC 0781-3317-80)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "04/08/2026", "update_type": "New", "initial_posting_date": "04/08/2026", "package_ndc": "63323-972-10", "generic_name": "Fosaprepitant Dimeglumine Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA206197" ], "brand_name": [ "FOSAPREPITANT" ], "generic_name": [ "FOSAPREPITANT" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-972" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "FOSAPREPITANT DIMEGLUMINE" ], "rxcui": [ "1731077" ], "spl_id": [ "864bb02f-d50d-4ae2-ad9c-82bb1e9aed2c" ], "spl_set_id": [ "ffee61d1-c1c6-4224-871c-ab7ff6cd01e5" ], "package_ndc": [ "63323-972-10" ], "unii": [ "D35FM8T64X" ] }, "update_date": "04/08/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "Fosaprepitant Dimeglumine, Injection, 150 mg/5 mL (NDC 63323-972-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/12/2021", "package_ndc": "55566-2500-0", "generic_name": "Desmopressin Acetate Spray", "contact_info": "888-337-7464", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/01/2026", "therapeutic_category": [ "Hematology" ], "dosage_form": "Spray", "presentation": "Ddavp, Spray, .1 ug/1 mL (NDC 55566-2500-0)", "company_name": "Ferring", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-0527-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 5 mg (NDC 0071-0527-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "06/12/2026", "package_ndc": "0338-3993-01", "generic_name": "Ifosfamide Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: October 2026", "openfda": { "application_number": [ "NDA019763" ], "brand_name": [ "IFEX" ], "generic_name": [ "IFOSFAMIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-3993", "0338-3991" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "IFOSFAMIDE" ], "rxcui": [ "1791588", "1791591", "1791593", "1791595" ], "spl_id": [ "56f50d8e-7c87-4119-a7dc-bfd77fa3dcec" ], "spl_set_id": [ "b7241707-7538-4d1a-91e7-3a25a91e0b9a" ], "package_ndc": [ "0338-3991-01", "0338-3993-01" ], "nui": [ "N0000000236", "N0000175558" ], "pharm_class_moa": [ "Alkylating Activity [MoA]" ], "pharm_class_epc": [ "Alkylating Drug [EPC]" ], "unii": [ "UM20QQM95Y" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Oncology", "Pediatric" ], "dosage_form": "Injection", "presentation": "IFEX, Injection, 3 g/60 mL (NDC 0338-3993-01)", "company_name": "Baxter Healthcare", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0703-4248-01", "generic_name": "Carboplatin Injection", "contact_info": "800-545-8800", "availability": "Unavailable", "related_info": "Estimated recovery: February 2027", "openfda": { "application_number": [ "ANDA077269" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Teva Parenteral Medicines, Inc." ], "product_ndc": [ "0703-4248", "0703-4244", "0703-4246", "0703-4239" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df", "b943761e-6a46-45a0-bdb4-1fec1e101f8c" ], "spl_set_id": [ "f330f5a2-2cad-402f-bcbb-26245a753276", "e176b6ef-2ff6-498b-a9d8-7a634d147f37" ], "package_ndc": [ "0703-4244-01", "0703-4246-01", "0703-4248-01", "0703-4239-01", "0703-4244-81", "0703-4246-81", "0703-4248-81", "0703-4239-81" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4248-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "12/02/2025", "update_type": "New", "initial_posting_date": "12/02/2025", "package_ndc": "0085-4331-01", "generic_name": "Posaconazole Injection", "contact_info": "800-672-6372", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA205596" ], "brand_name": [ "NOXAFIL" ], "generic_name": [ "POSACONAZOLE" ], "manufacturer_name": [ "Merck Sharp & Dohme LLC" ], "product_ndc": [ "0085-4331", "0085-1328", "0085-4324", "0085-2224" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "POSACONAZOLE" ], "rxcui": [ "665019", "665022", "1482908", "1482912", "1492043", "1492047", "2558603", "2558607" ], "spl_id": [ "56740f7d-3b29-4786-b5c7-eea6c0f14400" ], "spl_set_id": [ "b073b082-7b57-4423-8c06-4fd4263d6f84" ], "package_ndc": [ "0085-1328-01", "0085-4324-02", "0085-4331-01", "0085-2224-01", "0085-2224-02" ], "nui": [ "N0000175487", "M0002083" ], "pharm_class_epc": [ "Azole Antifungal [EPC]" ], "pharm_class_cs": [ "Azoles [CS]" ], "unii": [ "6TK1G07BHZ" ] }, "update_date": "12/02/2025", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Noxafil, Injection, 18 mg/1 mL (NDC 0085-4331-01)", "company_name": "Merck Sharp & Dohme Corp.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/25/2017", "package_ndc": "0264-9598-20", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "NDA019830" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE AND DEXTROSE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS AND DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-9598", "0264-9594" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS", "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1737723", "1737742", "1737744" ], "spl_id": [ "9e352802-107c-4f90-babe-4f69c7dc892e" ], "spl_set_id": [ "7dff29d9-522d-40eb-a9d9-42377912d640" ], "package_ndc": [ "0264-9598-20", "0264-9594-20", "0264-9594-10" ], "unii": [ "EC2CNF7XFP", "LX22YL083G" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .8 g/100 mL (NDC 0264-9598-20)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/13/2022", "package_ndc": "0409-4902-34", "generic_name": "Dextrose Monohydrate 50% Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dextrose%20Monohydrate%2050per%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/01/2017", "package_ndc": "0409-5555-01", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: April 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA202981" ], "brand_name": [ "SODIUM BICARBONATE" ], "generic_name": [ "SODIUM BICARBONATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-5555" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM BICARBONATE" ], "rxcui": [ "1868469" ], "spl_id": [ "e3a44e63-8594-40b6-a3fa-d135b3149661", "bcb3a2dc-1a3f-4ac7-8ea2-426f0771c246" ], "spl_set_id": [ "0c24b592-4bc8-456f-acac-9c9525844a06", "ea9f4498-0d43-4043-8dd1-f22537841c21" ], "package_ndc": [ "0409-5555-11", "0409-5555-01", "0409-5555-12", "0409-5555-02" ], "unii": [ "8MDF5V39QO" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "0009-0104-04", "generic_name": "Lincomycin Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA050317" ], "brand_name": [ "LINCOCIN" ], "generic_name": [ "LINCOMYCIN HYDROCHLORIDE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0104", "0009-0555", "0009-0107" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCONJUNCTIVAL" ], "substance_name": [ "LINCOMYCIN HYDROCHLORIDE" ], "rxcui": [ "102787", "239212" ], "spl_id": [ "7e2f3780-88ee-4971-a4ab-3d6cd972c42c" ], "spl_set_id": [ "c01906fa-2c73-4c13-9765-2fd06628d263" ], "package_ndc": [ "0009-0555-01", "0009-0104-04", "0009-0107-04" ], "unii": [ "M6T05Z2B68" ] }, "update_date": "02/25/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Lincocin, Injection, 2 mL multiple dose vial (NDC 0009-0104-04)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "65219-458-30", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-386-1300", "availability": "Limited Availability", "related_info": "Next release September 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "ANDA207449" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "FRESENIUS KABI USA, LLC" ], "product_ndc": [ "65219-458", "65219-456", "65219-464", "65219-460", "65219-462" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795607", "1795609", "1795610", "1795612", "1795616" ], "spl_id": [ "efc3b0c9-518a-47db-bb3e-ebdfd4646e9b" ], "spl_set_id": [ "576a22d8-5f2f-497e-80ad-1842ca74bb53" ], "package_ndc": [ "65219-456-05", "65219-456-60", "65219-464-05", "65219-464-50", "65219-458-05", "65219-458-30", "65219-460-05", "65219-460-20", "65219-462-05", "65219-462-10" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-458-30)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-067-25", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": { "application_number": [ "ANDA207636" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-067", "70069-061", "70069-062", "70069-063", "70069-064", "70069-065", "70069-066" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483" ], "spl_id": [ "79b226f0-c08a-4f84-bf2b-ae5c60e01d67" ], "spl_set_id": [ "ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64" ], "package_ndc": [ "70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10" ], "unii": [ "V910P86109" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "discontinued_date": "10/24/2025", "update_type": "New", "initial_posting_date": "10/24/2025", "package_ndc": "0002-8214-05", "generic_name": "Insulin Glargine Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "10/24/2025", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Basaglar, Injection, U-100 Tempo Pen (NDC 0002-8214-05)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued" }, { "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 0527-1505-37)", "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0527-1505-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "company_name": "Lannett Company, Inc.", "contact_info": "844-834-0530", "availability": "Available", "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "status": "Current", "dosage_form": "Tablet" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "39822-4200-2", "generic_name": "Rocuronium Bromide Injection", "contact_info": "866-390-4411", "availability": "Available", "related_info": "Tamarang is the application holder and X-Gen is the distributor/labeler", "openfda": { "application_number": [ "ANDA091115" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "XGen Pharmaceuticals DJB, Inc." ], "product_ndc": [ "39822-4200" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "eedcfb07-4e23-3152-e053-2995a90a6e6a" ], "spl_set_id": [ "b73f192c-2912-4ec3-9b4f-05a58d9b35ba" ], "package_ndc": [ "39822-4200-1", "39822-4200-2", "39822-4200-5", "39822-4200-6" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 39822-4200-2)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "Current" }, { "discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-605-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA201791" ], "brand_name": [ "LAMOTRIGINE EXTENDED RELEASE" ], "generic_name": [ "LAMOTRIGINE EXTENDED RELEASE" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "49884-605", "49884-561", "49884-562", "49884-563", "49884-564", "49884-604" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LAMOTRIGINE" ], "rxcui": [ "850087", "850091", "900156", "900164", "1098608", "1146690" ], "spl_id": [ "9c5e0c2a-800e-47e9-a26b-582b98a05957" ], "spl_set_id": [ "fb59c76a-9b6f-40ea-ac3a-58c3195c4377" ], "package_ndc": [ "49884-561-11", "49884-561-01", "49884-561-05", "49884-562-11", "49884-562-01", "49884-562-05", "49884-563-11", "49884-563-01", "49884-563-05", "49884-564-11", "49884-564-01", "49884-564-05", "49884-604-11", "49884-604-01", "49884-604-05", "49884-605-11", "49884-605-01", "49884-605-05" ], "nui": [ "N0000175753", "N0000008486", "N0000175751", "N0000187061", "N0000000191" ], "pharm_class_epc": [ "Anti-epileptic Agent [EPC]", "Mood Stabilizer [EPC]" ], "pharm_class_pe": [ "Decreased Central Nervous System Disorganized Electrical Activity [PE]" ], "pharm_class_moa": [ "Organic Cation Transporter 2 Inhibitors [MoA]", "Dihydrofolate Reductase Inhibitors [MoA]" ], "unii": [ "U3H27498KS" ] }, "update_date": "04/29/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 300 mg (NDC 49884-605-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "63323-165-01", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA084916" ], "brand_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "generic_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-165" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "rxcui": [ "1116927", "1812194" ], "spl_id": [ "1815f54a-5637-45bc-a582-3e62350935ba", "9dd90418-e564-4bc5-9077-506a1c2c1bce" ], "spl_set_id": [ "2b626a48-c7aa-4443-9164-a08ff069ccd1", "4fedef4f-ec96-4f36-b2f0-01e243e3b89e" ], "package_ndc": [ "63323-165-11", "63323-165-51", "63323-165-13", "63323-165-53", "63323-165-02", "63323-165-01", "63323-165-03", "63323-165-05", "63323-165-30", "63323-165-16", "63323-165-26" ], "unii": [ "AI9376Y64P" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "01/01/2012", "package_ndc": "16729-525-08", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: September 2026", "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-525-08)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0775-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA040422" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0555-0775", "0555-0971", "0555-0972", "0555-0776", "0555-0777", "0555-0973", "0555-0974" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "88468f3d-7d03-4cee-aabf-3abc8c9b5e38" ], "spl_set_id": [ "cffbbb15-d776-41ae-a8a6-687f2c07bfa4" ], "package_ndc": [ "0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0555-0775-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "52536-126-08", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "877-495-6856", "availability": "Available", "related_info": "Distributed by Wilshire Pharmaceuticals, Inc.", "openfda": { "application_number": [ "ANDA212791" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Wilshire Pharmaceuticals, Inc." ], "product_ndc": [ "52536-126", "52536-125" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909" ], "spl_id": [ "f550d2ba-49ac-4a3b-95db-692b468af479" ], "spl_set_id": [ "f550d2ba-49ac-4a3b-95db-692b468af479" ], "package_ndc": [ "52536-125-01", "52536-125-10", "52536-126-01", "52536-126-08" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 52536-126-08)", "company_name": "Azurity Pharmaceuticals, Inc", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/18/2020", "package_ndc": "71288-115-30", "generic_name": "Azacitidine Injection", "contact_info": "844-824-8426", "availability": "Available", "openfda": { "application_number": [ "ANDA212128" ], "brand_name": [ "AZACITIDINE" ], "generic_name": [ "AZACITIDINE" ], "manufacturer_name": [ "Meitheal Pharmaceuticals Inc." ], "product_ndc": [ "71288-115" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "AZACITIDINE" ], "rxcui": [ "485246" ], "spl_id": [ "bad343f5-0c12-47de-93e7-9b2af3670b7c" ], "spl_set_id": [ "97b0917a-03fa-4cc4-91cf-1bed57a988c9" ], "package_ndc": [ "71288-115-30" ], "nui": [ "N0000000233", "N0000175595" ], "pharm_class_moa": [ "Nucleic Acid Synthesis Inhibitors [MoA]" ], "pharm_class_epc": [ "Nucleoside Metabolic Inhibitor [EPC]" ], "unii": [ "M801H13NRU" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg/30 mL (NDC 71288-115-30)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "83634-651-50", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "Avenacy, LLC: 877-283-6229", "availability": "Available", "related_info": "Distributed by Avenacy, LLC", "openfda": { "application_number": [ "ANDA219535" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Avenacy, LLC" ], "product_ndc": [ "83634-651", "83634-653" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1737562", "1737566", "1737568" ], "spl_id": [ "8fb1dd7b-f349-4a64-96c1-bd72bf748f3b" ], "spl_set_id": [ "46480253-29b9-4d7f-98ed-10377929026b" ], "package_ndc": [ "83634-653-41", "83634-653-02", "83634-653-42", "83634-653-05", "83634-653-43", "83634-653-30", "83634-651-41", "83634-651-10", "83634-651-42", "83634-651-20", "83634-651-43", "83634-651-50" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 500 mg/50 mL (NDC 83634-651-50)", "company_name": "Anthea Pharma", "status": "Current" }, { "discontinued_date": "04/21/2026", "update_type": "New", "initial_posting_date": "04/21/2026", "package_ndc": "16729-239-93", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "866-941-7875, option 2", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA204023" ], "brand_name": [ "DEXMEDETOMIDINE" ], "generic_name": [ "DEXMEDETOMIDINE" ], "manufacturer_name": [ "Accord Healthcare Inc." ], "product_ndc": [ "16729-239" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "309710" ], "spl_id": [ "2de0daf8-b7a3-1dca-e063-6394a90a4d0a" ], "spl_set_id": [ "2b9881f0-4a66-660f-e054-00144ff88e88" ], "package_ndc": [ "16729-239-30", "16729-239-93" ], "unii": [ "1018WH7F9I" ] }, "update_date": "04/21/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)", "company_name": "Accord Healthcare Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "03/25/2020", "change_date": "08/06/2026", "package_ndc": "0088-2102-24", "generic_name": "Rifapentine Tablet, Film Coated", "contact_info": "800-633-1610 Option 7", "resolved_note": "Available", "openfda": { "application_number": [ "NDA021024" ], "brand_name": [ "PRIFTIN" ], "generic_name": [ "RIFAPENTINE" ], "manufacturer_name": [ "sanofi-aventis U.S. LLC" ], "product_ndc": [ "0088-2102" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RIFAPENTINE" ], "rxcui": [ "242671", "261101" ], "spl_id": [ "83c11919-ca6d-49f5-8f9f-7b8405fcbaec" ], "spl_set_id": [ "3a64fb70-b85e-43d9-8bcd-7e893f568ae1" ], "package_ndc": [ "0088-2102-01", "0088-2102-24" ], "nui": [ "N0000175501", "M0019113" ], "pharm_class_epc": [ "Rifamycin Antimycobacterial [EPC]" ], "pharm_class_cs": [ "Rifamycins [CS]" ], "unii": [ "XJM390A33U" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Tablet", "presentation": "Priftin, Tablet, Film Coated, 150 mg (NDC 0088-2102-24)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "Resolved" }, { "discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4491-61", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": { "application_number": [ "NDA211280" ], "brand_name": [ "REYVOW" ], "generic_name": [ "LASMIDITAN" ], "manufacturer_name": [ "Eli Lilly and Company" ], "product_ndc": [ "0002-4491", "0002-4312" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LASMIDITAN" ], "rxcui": [ "2256937", "2256943", "2256945", "2256947" ], "spl_id": [ "29f467c6-0365-4831-b4ce-9a0eefaf5896" ], "spl_set_id": [ "aea3358c-ff41-4490-9e6d-c7bf7b3de13f" ], "package_ndc": [ "0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62" ], "unii": [ "760I9WM792" ] }, "update_date": "11/03/2025", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 100 mg (NDC 0002-4491-61)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "70121-1388-1", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "877-835-5472", "availability": "Available", "openfda": { "application_number": [ "ANDA207551" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Amneal Pharmaceuticals LLC" ], "product_ndc": [ "70121-1388", "70121-1389" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909" ], "spl_id": [ "af193b53-1488-401f-8f06-cc193297c4a8" ], "spl_set_id": [ "eb1ba463-ab42-4f49-9ebe-3ad5af108326" ], "package_ndc": [ "70121-1388-1", "70121-1388-8", "70121-1389-1", "70121-1389-7" ], "unii": [ "1018WH7F9I" ] }, "update_date": "06/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 50 mL (NDC 70121-1388-1)", "company_name": "Amneal Pharmaceuticals", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0641-6262-01", "generic_name": "Sodium Acetate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA216920" ], "brand_name": [ "SODIUM ACETATE" ], "generic_name": [ "SODIUM ACETATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6262", "0641-6263" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM ACETATE ANHYDROUS" ], "rxcui": [ "237371" ], "spl_id": [ "777b7564-f07b-401a-a042-0cd512ae3b25" ], "spl_set_id": [ "7ee23a1c-bc99-4ff6-b2e7-d2aa42744553" ], "package_ndc": [ "0641-6262-01", "0641-6263-01", "0641-6263-10" ], "unii": [ "NVG71ZZ7P0" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition" ], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 0641-6262-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "06/13/2018", "package_ndc": "0143-9575-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA080407" ], "brand_name": [ "LIDOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9575", "0143-9579", "0143-9578", "0143-9577", "0143-9576", "0143-9172", "0143-9173" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671" ], "spl_id": [ "e9b92d4d-8944-4235-8d77-3218f82f00a9" ], "spl_set_id": [ "5523fdfe-69fd-49a5-b51f-73e2223d49a9" ], "package_ndc": [ "0143-9579-01", "0143-9579-25", "0143-9578-01", "0143-9578-10", "0143-9577-01", "0143-9577-10", "0143-9576-01", "0143-9576-25", "0143-9575-01", "0143-9575-10", "0143-9172-01", "0143-9172-10", "0143-9173-01", "0143-9173-10" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 0143-9575-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0781-3495-95", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "See Related Information section below for customer service information", "availability": "Available", "related_info": "Marketed by Sandoz Inc.; Customer service: 800-525-8747", "openfda": { "application_number": [ "ANDA209065" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE" ], "manufacturer_name": [ "Sandoz Inc." ], "product_ndc": [ "0781-3495", "0781-3493", "0781-3494" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718900", "1718906", "1718909" ], "spl_id": [ "fdf227d9-008e-60f8-e053-6294a90af5c4" ], "spl_set_id": [ "809e8f77-390f-4cc8-8c8a-4f67a249c9df" ], "package_ndc": [ "0781-3493-95", "0781-3494-95", "0781-3495-95" ], "unii": [ "1018WH7F9I" ] }, "update_date": "07/30/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (NDC 0781-3495-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "43066-013-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "ANDA091115" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "43066-013", "43066-007" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "9e0317de-2d78-4fd8-8926-4c7b476f3ed4" ], "spl_set_id": [ "31e15c3f-aefa-4379-b684-7707744fe40d" ], "package_ndc": [ "43066-007-10", "43066-013-10" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 43066-013-10)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5111-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Available", "openfda": { "application_number": [ "ANDA211840" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "SpecGx LLC" ], "product_ndc": [ "0406-5111", "0406-5112", "0406-5113", "0406-5114", "0406-5115", "0406-5116", "0406-5117" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "b4be564a-404d-4ca1-bac0-ec9cf40fef93" ], "spl_set_id": [ "806a1c15-0842-4787-b2ad-09a21fd96b37" ], "package_ndc": [ "0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0406-5111-01)", "company_name": "SpecGx LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "25021-311-04", "generic_name": "Furosemide Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Furosemide%20Injection&st=d", "contact_info": "866-625-1618", "availability": "Unavailable", "related_info": "Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product", "openfda": { "application_number": [ "ANDA213902" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-311" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "222ce48f-2856-4be2-b16f-6fca38c0dceb" ], "spl_set_id": [ "d63c1277-dd7e-4d21-9e80-68143f55e2dc" ], "package_ndc": [ "25021-311-02", "25021-311-04", "25021-311-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)", "company_name": "Gland Pharma Limited", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "09/09/2025", "update_type": "New", "initial_posting_date": "09/09/2025", "package_ndc": "0409-6535-01", "generic_name": "Vancomycin Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "09/09/2025", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Vancomycin Hydrochloride, Injection, 1 g Single Dose ADD-Vantage® Glass Vial (NDC 0409-6535-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6000-10", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA018140" ], "brand_name": [ "ATIVAN" ], "generic_name": [ "LORAZEPAM" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6000", "0641-6003", "0641-6002", "0641-6001" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "LORAZEPAM" ], "rxcui": [ "206819", "206820", "238100", "238101", "1665188", "1665190", "1665326", "1665327" ], "spl_id": [ "209b0091-c890-4f69-a693-d0594c2606fe" ], "spl_set_id": [ "5fc0e987-61c9-40c4-b0d5-fcea07c8733e" ], "package_ndc": [ "0641-6003-01", "0641-6003-25", "0641-6002-01", "0641-6002-10", "0641-6001-01", "0641-6001-25", "0641-6000-01", "0641-6000-10" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "O26FZP769L" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Injection", "presentation": "Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-487-37", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE MPF" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-487", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "04/06/2026", "update_type": "New", "initial_posting_date": "04/06/2026", "package_ndc": "64380-844-06", "generic_name": "Ursodiol Capsule", "contact_info": "877-244-9825", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA210344" ], "brand_name": [ "URSODIOL" ], "generic_name": [ "URSODIOL" ], "manufacturer_name": [ "Strides Pharma Science Limited" ], "product_ndc": [ "64380-844" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "URSODIOL" ], "rxcui": [ "858747" ], "spl_id": [ "20f4357a-edf9-4326-804f-9c72aae8e113" ], "spl_set_id": [ "9a6c1928-2d52-4d9a-8e83-f71892a7e98d" ], "package_ndc": [ "64380-844-06", "64380-844-07", "64380-844-04" ], "nui": [ "N0000175802", "M0002475" ], "pharm_class_epc": [ "Bile Acid [EPC]" ], "pharm_class_cs": [ "Bile Acids and Salts [CS]" ], "unii": [ "724L30Y2QR" ] }, "update_date": "04/06/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Capsule", "presentation": "Ursodiol, Capsule, 300 mg (NDC 64380-844-06)", "company_name": "Strides Pharma Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4276-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA088299" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4276", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4275" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763" ], "spl_id": [ "05d1a200-9d75-4e48-b14a-5069d4ab816f" ], "spl_set_id": [ "3b2dd84e-cee8-4e58-d494-395a65a353a0" ], "package_ndc": [ "0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride In Plastic Container, Injection, 200 mg/20 mL (1%; 10 mg/mL) (NDC 0409-4276-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "47781-176-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": { "application_number": [ "ANDA207388" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 10 MG,CLL" ], "manufacturer_name": [ "Alvogen Inc." ], "product_ndc": [ "47781-176", "47781-174", "47781-175", "47781-177", "47781-178", "47781-179", "47781-180" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "0374f0f7-9297-810c-38b3-623a72709a7d" ], "spl_set_id": [ "c907301d-e24d-9609-5529-fed14f94549f" ], "package_ndc": [ "47781-174-30", "47781-174-05", "47781-174-01", "47781-175-30", "47781-175-05", "47781-175-01", "47781-176-30", "47781-176-05", "47781-176-01", "47781-177-30", "47781-177-05", "47781-177-01", "47781-178-30", "47781-178-05", "47781-178-01", "47781-179-30", "47781-179-05", "47781-179-01", "47781-180-30", "47781-180-05", "47781-180-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 10mg (NDC 47781-176-01)", "company_name": "Alvogen", "status": "Current" }, { "discontinued_date": "05/08/2026", "update_type": "New", "initial_posting_date": "05/08/2026", "package_ndc": "72143-321-30", "generic_name": "Sulconazole Nitrate Solution", "contact_info": "480-434-6670", "related_info": "Discontinuation of the manufacture of the drug. Manufactured for JG Pharma", "openfda": { "application_number": [ "NDA018738" ], "brand_name": [ "SULCONAZOLE NITRATE" ], "generic_name": [ "SULCONAZOLE NITRATE" ], "manufacturer_name": [ "JG Pharma Inc." ], "product_ndc": [ "72143-321" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "TOPICAL" ], "substance_name": [ "SULCONAZOLE NITRATE" ], "rxcui": [ "313125" ], "spl_id": [ "53b9389f-e8ec-e494-e063-6394a90a48bc" ], "spl_set_id": [ "cf6f4340-940c-4a61-b675-456e3297d810" ], "package_ndc": [ "72143-321-30" ], "unii": [ "1T89100D5U" ] }, "update_date": "05/08/2026", "therapeutic_category": [ "Dermatology" ], "dosage_form": "Solution", "presentation": "Sulconazole Nitrate, Solution, 30 mL (NDC 72143-321-30)", "company_name": "Journey Medical Corporation", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-026-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Available", "openfda": { "application_number": [ "ANDA202830" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE" ], "manufacturer_name": [ "Amneal Pharmaceuticals LLC" ], "product_ndc": [ "65162-026", "65162-023", "65162-024", "65162-025", "65162-027", "65162-028" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850" ], "spl_id": [ "ba9f3370-3096-4d8c-9571-e28faf54291f" ], "spl_set_id": [ "c11cb3b6-3dff-477b-a249-b4c3118edc5f" ], "package_ndc": [ "65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 65162-026-09)", "company_name": "Amneal Pharmaceuticals", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-31", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA016673" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0017", "0338-0023" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618" ], "spl_id": [ "9c644eb4-5844-415a-8c01-4459d98af222" ], "spl_set_id": [ "3bb406a9-f5cb-403a-b1bb-5c4facbea3d5" ], "package_ndc": [ "0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-31)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/18/2020", "package_ndc": "43598-305-62", "generic_name": "Azacitidine Injection", "contact_info": "866-732-3952", "availability": "Available", "related_info": "Available to existing customers", "openfda": { "application_number": [ "ANDA201537" ], "brand_name": [ "AZACITIDINE" ], "generic_name": [ "AZACITIDINE" ], "manufacturer_name": [ "Dr. Reddy's Laboratories Inc." ], "product_ndc": [ "43598-305" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "AZACITIDINE" ], "rxcui": [ "485246" ], "spl_id": [ "35e92030-ae2f-04b2-c3de-69f8c8da6b82" ], "spl_set_id": [ "71d8d758-86c9-b571-aed1-719654fd4b82" ], "package_ndc": [ "43598-305-62" ], "nui": [ "N0000000233", "N0000175595" ], "pharm_class_moa": [ "Nucleic Acid Synthesis Inhibitors [MoA]" ], "pharm_class_epc": [ "Nucleoside Metabolic Inhibitor [EPC]" ], "unii": [ "M801H13NRU" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg (NDC 43598-305-62)", "company_name": "Dr. Reddy's Laboratories, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0143-9144-02", "generic_name": "Liraglutide Injection", "contact_info": "800-631-2174", "availability": "Available", "openfda": { "application_number": [ "ANDA215503" ], "brand_name": [ "LIRAGLUTIDE" ], "generic_name": [ "LIRAGLUTIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9144" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "LIRAGLUTIDE" ], "rxcui": [ "897122" ], "spl_id": [ "4e2acb7a-d32d-49d3-b59b-39332b5809f3" ], "spl_set_id": [ "2100ec49-57b2-4330-ab5f-057ce9b7e4d0" ], "package_ndc": [ "0143-9144-01", "0143-9144-03", "0143-9144-02" ], "nui": [ "N0000178480", "M0160181", "N0000020058" ], "pharm_class_epc": [ "GLP-1 Receptor Agonist [EPC]" ], "pharm_class_cs": [ "Glucagon-Like Peptide 1 [CS]" ], "pharm_class_moa": [ "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]" ], "unii": [ "839I73S42A" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0143-9144-02)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "72266-146-10", "generic_name": "Etomidate Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.", "openfda": { "application_number": [ "ANDA209058" ], "brand_name": [ "ETOMIDATE" ], "generic_name": [ "ETOMIDATE INJECTION" ], "manufacturer_name": [ "Fosun Pharma USA Inc" ], "product_ndc": [ "72266-146", "72266-147" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008" ], "spl_id": [ "2b365133-b609-3285-e063-6394a90a69a6" ], "spl_set_id": [ "8b6c54d8-3f3f-4290-841c-976bea01086f" ], "package_ndc": [ "72266-146-01", "72266-146-10", "72266-147-01", "72266-147-10" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 72266-146-10)", "company_name": "Gland Pharma Limited", "status": "Current" }, { "discontinued_date": "07/07/2026", "update_type": "New", "initial_posting_date": "07/07/2026", "package_ndc": "0378-9651-32", "generic_name": "Travoprost Ophthalmic Solution", "contact_info": "877-446-3679", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA205050" ], "brand_name": [ "TRAVOPROST OPHTHALMIC SOLUTION, 0.004%" ], "generic_name": [ "TRAVOPROST OPHTHALMIC SOLUTION, 0.004%" ], "manufacturer_name": [ "Mylan Pharmaceuticals Inc." ], "product_ndc": [ "0378-9651" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "OPHTHALMIC" ], "substance_name": [ "TRAVOPROST" ], "rxcui": [ "284008" ], "spl_id": [ "d78c5705-68ac-4363-b9ae-5facc60e2b79" ], "spl_set_id": [ "00dc284f-fd96-423b-bb8f-b90ee13439bf" ], "package_ndc": [ "0378-9651-32", "0378-9651-50" ], "nui": [ "N0000175454", "M0017805" ], "pharm_class_epc": [ "Prostaglandin Analog [EPC]" ], "pharm_class_cs": [ "Prostaglandins [CS]" ], "unii": [ "WJ68R08KX9" ] }, "update_date": "07/07/2026", "therapeutic_category": [ "Ophthalmology" ], "dosage_form": "Ophthalmic Solution", "presentation": "Travoprost, Ophthalmic Solution, 0.004%, 2.5 mL (NDC 0378-9651-32)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "72205-132-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA218306" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Novadoz Pharmaceuticals LLC" ], "product_ndc": [ "72205-132", "72205-133", "72205-134", "72205-135", "72205-136", "72205-137" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811" ], "spl_set_id": [ "a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811" ], "package_ndc": [ "72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 10 mg (NDC 72205-132-91)", "company_name": "Novadoz Pharmaceuticals LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1005-03", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA019615" ], "brand_name": [ "DOPAMINE HYDROCHLORIDE AND DEXTROSE" ], "generic_name": [ "DOPAMINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-1005", "0338-1007", "0338-1009" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOPAMINE HYDROCHLORIDE" ], "rxcui": [ "1292887", "1743869", "1743871", "1743877", "1743879" ], "spl_id": [ "edc9a091-4cb5-4ec7-b6f9-44d2d588bab9" ], "spl_set_id": [ "cb97d4a0-89ed-407c-a763-209386b6f75c" ], "package_ndc": [ "0338-1005-02", "0338-1005-03", "0338-1007-02", "0338-1007-03", "0338-1009-02" ], "unii": [ "7L3E358N9L" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 80 mg/100 mL (NDC 0338-1005-03)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-7299-73", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA018893" ], "brand_name": [ "SODIUM ACETATE" ], "generic_name": [ "SODIUM ACETATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-7299" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM ACETATE ANHYDROUS" ], "rxcui": [ "1859490" ], "spl_id": [ "013001c4-5584-4d8c-8bf6-917d2a919aa4", "10c75a24-9542-431a-84f8-44611bc916df" ], "spl_set_id": [ "ce9a7469-c4ba-4f60-8f7a-47ef0974316e", "c91ede49-c7cc-47b7-0f93-e6841dd5916a" ], "package_ndc": [ "0409-7299-45", "0409-7299-25", "0409-7299-83", "0409-7299-73" ], "unii": [ "NVG71ZZ7P0" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition" ], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 40 mEq/20 mL (2 mEq/mL) (NDC 0409-7299-73)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6860-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA202835" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE" ], "manufacturer_name": [ "Mylan Pharmaceuticals Inc." ], "product_ndc": [ "0378-6860", "0378-6854", "0378-6855", "0378-6856", "0378-6857", "0378-6858", "0378-6859" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "6e77cd71-95ae-4fa8-830b-ab62b714e4b9" ], "spl_set_id": [ "efbde0f6-b848-4664-b741-c6c630e66108" ], "package_ndc": [ "0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0378-6860-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "62135-737-90", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "845-268-5000 Ext. 510", "availability": "Available", "openfda": { "application_number": [ "ANDA072369" ], "brand_name": [ "FLURAZEPAM HYDROCHLORIDE" ], "generic_name": [ "FLURAZEPAM HYDROCHLORIDE" ], "manufacturer_name": [ "Chartwell RX, LLC" ], "product_ndc": [ "62135-737", "62135-736" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "FLURAZEPAM HYDROCHLORIDE" ], "rxcui": [ "1298088", "1298091" ], "spl_id": [ "25893c92-c8f1-567a-e063-6294a90a00d4" ], "spl_set_id": [ "8f476891-1346-4e8c-ac1b-f8cbdc64f5a1" ], "package_ndc": [ "62135-736-30", "62135-736-90", "62135-737-30", "62135-737-90" ], "unii": [ "756RDM536M" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Neurology", "Other" ], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 30 mg (NDC 62135-737-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/03/2025", "package_ndc": "0574-4022-35", "generic_name": "Bacitracin Ophthalmic Ointment", "contact_info": "866-634-9120", "availability": "Unavailable", "related_info": "Shortage is estimated for 24 months", "update_date": "06/01/2026", "therapeutic_category": [ "Anti-Infective", "Ophthalmology" ], "dosage_form": "Ophthalmic Ointment", "presentation": "Bacitracin, Ophthalmic Ointment, 3.5 g (NDC 0574-4022-35)", "company_name": "Padagis US LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-085-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": { "application_number": [ "ANDA214134" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "57664-085", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-086", "57664-087", "57664-088" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "560b4c9e-9cce-4717-e063-6294a90a58c9" ], "spl_set_id": [ "da3148af-f9b6-4725-adae-3595b4c7dc4b" ], "package_ndc": [ "57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 57664-085-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current" }, { "discontinued_date": "01/12/2026", "update_type": "New", "initial_posting_date": "01/12/2026", "package_ndc": "0378-0167-02", "generic_name": "Doxycycline Hyclate Tablet", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "01/12/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Tablet", "presentation": "Doxycycline Hyclate, Tablet, 100 mg (NDC 0378-0167-02)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "07/12/2022", "package_ndc": "0703-4636-01", "generic_name": "Streptozocin Powder, For Solution", "contact_info": "800-545-8800", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "08/17/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Powder, For Solution", "presentation": "Zanosar, Powder, For Solution, 100 mg/1 mL (NDC 0703-4636-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "63323-411-12", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release August 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "ANDA075154" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-411", "63323-412" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "311700", "311702" ], "spl_id": [ "9814447b-a93e-42ad-b57e-5db0a5b7f552" ], "spl_set_id": [ "a91ce254-14a3-4cbf-8ab8-5da252aa3fdc" ], "package_ndc": [ "63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-12)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-852-25", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA019034" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-852", "63323-851", "63323-853", "63323-854" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897653", "897753", "1724276", "1724338", "1724340", "1724341" ], "spl_id": [ "9e8522c6-595c-46f9-bb25-272aa4683e0f" ], "spl_set_id": [ "e034eb96-03e0-46e1-8b92-5e1f94555e7b" ], "package_ndc": [ "63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-852-25)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-600-05", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA077059" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "61703-600", "61703-360", "61703-150", "61703-262" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "5aa72c15-8033-4559-b257-373371b18958" ], "spl_set_id": [ "47677091-fd20-49af-933c-c9dd2be21de9" ], "package_ndc": [ "61703-360-18", "61703-150-05", "61703-262-05", "61703-600-05" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) (NDC 61703-600-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3073-03", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: September 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA011757" ], "brand_name": [ "DEPO-MEDROL" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-3073", "0009-3475" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE", "INTRA-ARTICULAR" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1743779", "1743781", "1743855", "1743856" ], "spl_id": [ "e4917f75-3e1c-4f3c-803d-d9ec65df06c7", "742fcec7-8db3-4cc6-b276-42587a993810" ], "spl_set_id": [ "bf1b104d-85cb-414d-a366-78068c82c883", "9a7b3837-e038-48bf-97e9-78ad463760dc" ], "package_ndc": [ "0009-3073-22", "0009-3073-23", "0009-3475-22", "0009-3475-23", "0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-03)", "company_name": "Pfizer Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "57844-112-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Unavailable", "related_info": "Estimated recovery: October 2026", "openfda": { "application_number": [ "ANDA040422" ], "brand_name": [ "ADDERALL" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "57844-112", "57844-105", "57844-117", "57844-110", "57844-115", "57844-120", "57844-130" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147" ], "spl_id": [ "79af1dc6-c7cf-41b1-a750-e9b47c2187ff" ], "spl_set_id": [ "f22635fe-821d-4cde-aa12-419f8b53db81" ], "package_ndc": [ "57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 57844-112-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "60505-6282-7", "generic_name": "Carboplatin Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Carboplatin%20Injection&st=d", "contact_info": "Apotex Inc.: 800-706-5575", "availability": "Unavailable", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA077861" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Apotex Corp." ], "product_ndc": [ "60505-6282" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "0e68e276-b0df-4f03-e063-6394a90a22b9" ], "spl_set_id": [ "1c275825-0275-4c73-b650-e4c1519f13b8" ], "package_ndc": [ "60505-6282-1", "60505-6282-3", "60505-6282-6", "60505-6282-7" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)", "company_name": "Teyro Labs", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-107-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": { "application_number": [ "NDA021977" ], "brand_name": [ "VYVANSE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "59417-107", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469" ], "spl_id": [ "81d087b6-4cb4-466a-9693-679edeb062e2" ], "spl_set_id": [ "704e4378-ca83-445c-8b45-3cfa51c1ecad" ], "package_ndc": [ "59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 70 mg (NDC 59417-107-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-02", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA018667" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-6102" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "e598e8a6-c854-48f5-a412-fb6a6783774a", "981d5143-60cd-4987-9b47-dec24c10de42" ], "spl_set_id": [ "aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7" ], "package_ndc": [ "0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "55150-249-50", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA207183" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-249", "55150-167", "55150-168", "55150-169", "55150-170", "55150-171", "55150-172", "55150-250" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082" ], "spl_id": [ "39649703-e633-4a20-ba71-0c04dbf8ff2a" ], "spl_set_id": [ "ffecf450-1f01-4721-8e10-251385852612" ], "package_ndc": [ "55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 55150-249-50)", "company_name": "Eugia US LLC", "status": "Current" }, { "discontinued_date": "12/08/2025", "update_type": "New", "initial_posting_date": "12/08/2025", "package_ndc": "0781-9404-95", "generic_name": "Ampicillin Sodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of private label only", "openfda": { "application_number": [ "ANDA061395" ], "brand_name": [ "AMPICILLIN" ], "generic_name": [ "AMPICILLIN SODIUM" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-9404", "0781-9401", "0781-9402", "0781-9407", "0781-9408" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "AMPICILLIN SODIUM" ], "rxcui": [ "308207", "1721473", "1721474", "1721475", "1721476" ], "spl_id": [ "a3ddae6c-ac4c-425f-82b0-eb388d92bc0e" ], "spl_set_id": [ "b371e1a5-1fef-4df2-8940-c4fc02b9e2f0" ], "package_ndc": [ "0781-9401-78", "0781-9401-95", "0781-9402-78", "0781-9402-95", "0781-9407-78", "0781-9407-95", "0781-9404-85", "0781-9404-95", "0781-9408-80", "0781-9408-95" ], "unii": [ "JFN36L5S8K" ] }, "update_date": "12/08/2025", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Ampicillin Sodium, Injection, 1 g (NDC 0781-9404-95)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9094-25", "generic_name": "Fentanyl Citrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA019115" ], "brand_name": [ "FENTANYL CITRATE" ], "generic_name": [ "FENTANYL CITRATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-9094", "0409-9093" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FENTANYL CITRATE" ], "rxcui": [ "1735003", "1735004", "1735006", "1735007", "1735008", "1735013" ], "spl_id": [ "e4eaad6d-c21e-42fd-8fd9-f0b769966d61" ], "spl_set_id": [ "bfa8018a-4cbc-434b-e09e-782872b0340a" ], "package_ndc": [ "0409-9093-41", "0409-9093-36", "0409-9093-31", "0409-9093-38", "0409-9094-12", "0409-9094-22", "0409-9094-18", "0409-9094-25", "0409-9094-17", "0409-9094-28", "0409-9094-16", "0409-9094-31", "0409-9094-41", "0409-9094-61" ], "unii": [ "MUN5LYG46H" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 250 mcg/5 mL (50 ug/1 mL) (NDC 0409-9094-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "presentation": "Marcaine, Injection, Marcaine 150 mg/30 mL (5 mg/mL) (NDC 0409-1560-29)", "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1560-29", "generic_name": "Bupivacaine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "status": "Current", "dosage_form": "Injection" }, { "update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "61703-350-38", "generic_name": "Methotrexate Sodium Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA011719" ], "brand_name": [ "METHOTREXATE" ], "generic_name": [ "METHOTREXATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "61703-350", "61703-408" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "METHOTREXATE SODIUM" ], "rxcui": [ "1655956", "1946772" ], "spl_id": [ "95b8b8da-da4e-4bba-9038-3cf65f3d5c1a", "37b3e76b-ac3d-4f93-adf1-91f52f676b8a" ], "spl_set_id": [ "0d63ba29-b692-41b4-87e8-351265c8273f", "0e30eaef-5a09-4104-8a11-c32933eadeab" ], "package_ndc": [ "61703-350-37", "61703-350-38", "61703-408-41", "61703-350-09", "61703-350-10", "61703-408-25" ], "unii": [ "3IG1E710ZN" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology", "Oncology" ], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/14/2017", "package_ndc": "63323-519-77", "generic_name": "Heparin Sodium Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA212441" ], "brand_name": [ "HEPARIN SODIUM" ], "generic_name": [ "HEPARIN SODIUM" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-519" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "HEPARIN SODIUM" ], "rxcui": [ "1658690", "1658692" ], "spl_id": [ "3bbbe74a-1246-41a6-9fc3-ca0230529b40" ], "spl_set_id": [ "25b0ba06-3274-4a3f-8c39-42d13764ecdf" ], "package_ndc": [ "63323-519-02", "63323-519-77", "63323-519-01", "63323-519-10" ], "unii": [ "ZZ45AB24CA" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Hematology" ], "dosage_form": "Injection", "presentation": "Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-77)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9042-17", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA071165" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-9042", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596" ], "spl_id": [ "6e442bfd-d3da-4913-8585-ce3485644364" ], "spl_set_id": [ "02a845c3-4521-4926-e397-25ab536e7cf6" ], "package_ndc": [ "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-084-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": { "application_number": [ "NDA216117" ], "brand_name": [ "RELEXXII" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Vertical Pharmaceuticals, LLC" ], "product_ndc": [ "68025-084", "68025-088", "68025-089", "68025-095", "68025-096", "68025-097", "68025-098" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505" ], "spl_id": [ "86f477e9-07fc-466b-913e-1a4434c91df4" ], "spl_set_id": [ "22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d" ], "package_ndc": [ "68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current" }, { "discontinued_date": "07/27/2026", "update_type": "New", "initial_posting_date": "07/27/2026", "package_ndc": "0173-0717-22", "generic_name": "Fluticasone Propionate and Salmeterol Xinafoate Aerosol, Metered", "contact_info": "888-825-5249", "related_info": "The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product will still be available.", "openfda": { "application_number": [ "NDA021254" ], "brand_name": [ "ADVAIR HFA" ], "generic_name": [ "FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE" ], "manufacturer_name": [ "GlaxoSmithKline LLC" ], "product_ndc": [ "0173-0717", "0173-0715", "0173-0716" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RESPIRATORY (INHALATION)" ], "substance_name": [ "FLUTICASONE PROPIONATE", "SALMETEROL XINAFOATE" ], "rxcui": [ "896231", "896235", "896236", "896237", "896239", "896243", "896244", "896245", "896267", "896271", "896272", "896273" ], "spl_id": [ "bea52e57-aa75-4dce-8cfb-a163bbc22be2" ], "spl_set_id": [ "dfaca6f9-3277-47b2-319d-1377917cb54c" ], "package_ndc": [ "0173-0715-20", "0173-0715-22", "0173-0716-20", "0173-0716-22", "0173-0717-20", "0173-0717-22" ], "unii": [ "O2GMZ0LF5W", "6EW8Q962A5" ] }, "update_date": "07/27/2026", "therapeutic_category": [ "Pulmonary/Allergy" ], "presentation": "Advair HFA, Aerosol, Metered, 230 ug; 21 ug (NDC 0173-0717-22)", "company_name": "GlaxoSmithKline", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "70069-752-25", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": { "application_number": [ "ANDA217792" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-752", "70069-753" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404" ], "spl_id": [ "2b24af95-6f20-4945-bf8c-742f1d6f2721" ], "spl_set_id": [ "bcaab86f-20f0-4482-8d73-e29b36dced58" ], "package_ndc": [ "70069-752-25", "70069-752-10", "70069-752-01", "70069-753-25", "70069-753-01", "70069-753-10" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "70121-1573-1", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-525-7270", "availability": "Limited Availability", "related_info": "On backorder. Estimated recovery: late July", "openfda": { "application_number": [ "ANDA210043" ], "brand_name": [ "METHYLPREDNISOLONE ACETATE" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Amneal Pharmaceuticals LLC" ], "product_ndc": [ "70121-1573", "70121-1574" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1743779", "1743855" ], "spl_id": [ "af4215ff-94ca-44f8-8506-3024e738cd13" ], "spl_set_id": [ "d944240d-2c19-46ba-ad4f-3fbee7b8629c" ], "package_ndc": [ "70121-1573-1", "70121-1573-5", "70121-1574-1", "70121-1574-5" ], "unii": [ "43502P7F0P" ] }, "update_date": "06/17/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 40 mg/1 mL (NDC 70121-1573-1)", "company_name": "Amneal Pharmaceuticals", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "69097-004-67", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-247-5287", "resolved_note": "Available", "openfda": { "application_number": [ "ANDA214050" ], "brand_name": [ "HYDROCORTISONE SODIUM SUCCINATE" ], "generic_name": [ "HYDROCORTISONE SODIUM SUCCINATE" ], "manufacturer_name": [ "Cipla USA Inc." ], "product_ndc": [ "69097-004" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "HYDROCORTISONE SODIUM SUCCINATE" ], "rxcui": [ "238755" ], "spl_id": [ "44159bea-88a1-49ac-a51e-1c27dc89d9ff" ], "spl_set_id": [ "451d6d04-b7d9-47d9-ba71-43cc5b9b3054" ], "package_ndc": [ "69097-004-67" ], "unii": [ "50LQB69S1Z" ] }, "update_date": "02/24/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Pulmonary/Allergy", "Renal", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Hydrocortisone Sodium Succinate, Injection, 100 mg/ Vial (NDC 69097-004-67)", "company_name": "Cipla Limited", "status": "Resolved" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "60505-6282-6", "generic_name": "Carboplatin Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Carboplatin%20Injection&st=d", "contact_info": "Apotex Inc.: 800-706-5575", "availability": "Unavailable", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA077861" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Apotex Corp." ], "product_ndc": [ "60505-6282" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "0e68e276-b0df-4f03-e063-6394a90a22b9" ], "spl_set_id": [ "1c275825-0275-4c73-b650-e4c1519f13b8" ], "package_ndc": [ "60505-6282-1", "60505-6282-3", "60505-6282-6", "60505-6282-7" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)", "company_name": "Teyro Labs", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-700-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": { "application_number": [ "NDA216117" ], "brand_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Trigen Laboratories, LLC" ], "product_ndc": [ "13811-700", "13811-711" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "2605796", "2605798" ], "spl_id": [ "ba649db4-df0d-4587-8370-3f866e66e54b" ], "spl_set_id": [ "dd8d7b6e-c23d-4e16-bb53-959e9127ebc6" ], "package_ndc": [ "13811-711-30", "13811-700-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "05/21/2026", "update_type": "New", "initial_posting_date": "05/21/2026", "package_ndc": "65219-080-05", "generic_name": "Gadoterate Meglumine Injection", "contact_info": "Marketed by Fresenius Kabi, USA; Customer service: 888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA215304" ], "brand_name": [ "GADOTERATE MEGLUMINE" ], "generic_name": [ "GADOTERATE MEGLUMINE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-080", "65219-082", "65219-084", "65219-086" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GADOTERATE MEGLUMINE" ], "spl_id": [ "f05922b7-99d4-48c7-972a-7966bbbbc3b4" ], "spl_set_id": [ "e0655aac-9508-4141-94f5-fcca6af1c41d" ], "package_ndc": [ "65219-080-01", "65219-080-05", "65219-082-01", "65219-082-10", "65219-084-01", "65219-084-15", "65219-086-01", "65219-086-20" ], "unii": [ "L0ND3981AG" ] }, "update_date": "05/21/2026", "therapeutic_category": [ "Medical Imaging" ], "dosage_form": "Injection", "presentation": "Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-080-05)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-1130-03", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "ANDA075880" ], "brand_name": [ "PREMASOL - SULFITE-FREE (AMINO ACID)" ], "generic_name": [ "LEUCINE, LYSINE, ISOLEUCINE, VALINE, HISTIDINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, TYROSINE, N-ACETYL-TYROSINE, ARGININE, PROLINE, ALANINE, GLUTAMIC ACIDE, SERINE, GLYCINE, ASPARTIC ACID, TAURINE, CYSTEINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "0338-1130", "0338-1131" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LEUCINE", "LYSINE ACETATE", "ISOLEUCINE", "VALINE", "HISTIDINE", "PHENYLALANINE", "THREONINE", "METHIONINE", "TRYPTOPHAN", "TYROSINE", "ARGININE", "PROLINE", "ALANINE", "GLUTAMIC ACID", "SERINE", "GLYCINE", "ASPARTIC ACID", "TAURINE", "CYSTEINE HYDROCHLORIDE" ], "rxcui": [ "801395", "801398", "801403", "801405" ], "spl_id": [ "c874a813-b145-4f7f-833e-97d6c4dd727c" ], "spl_set_id": [ "9afdcc3e-0d06-47f4-86ca-40da48b2b02b" ], "package_ndc": [ "0338-1130-03", "0338-1130-04", "0338-1130-06", "0338-1131-03" ], "nui": [ "N0000175780", "M0000922" ], "pharm_class_epc": [ "Amino Acid [EPC]" ], "pharm_class_cs": [ "Amino Acids [CS]" ], "unii": [ "GMW67QNF9C", "TTL6G7LIWZ", "04Y7590D77", "HG18B9YRS7", "4QD397987E", "47E5O17Y3R", "2ZD004190S", "AE28F7PNPL", "8DUH1N11BX", "42HK56048U", "94ZLA3W45F", "9DLQ4CIU6V", "OF5P57N2ZX", "3KX376GY7L", "452VLY9402", "TE7660XO1C", "30KYC7MIAI", "1EQV5MLY3D", "ZT934N0X4W" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-03)", "company_name": "Baxter Healthcare", "status": "Current" }, { "discontinued_date": "04/22/2026", "update_type": "New", "initial_posting_date": "04/22/2026", "package_ndc": "0069-0188-21", "generic_name": "Palbociclib Capsule", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacturing of the capsule presentation. 100 mg Tablet NDC 0069-0486-03 will continue to be manufactured.", "openfda": { "application_number": [ "NDA207103" ], "brand_name": [ "IBRANCE" ], "generic_name": [ "PALBOCICLIB" ], "manufacturer_name": [ "Pfizer Laboratories Div Pfizer Inc" ], "product_ndc": [ "0069-0188", "0069-0187", "0069-0189" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "PALBOCICLIB" ], "rxcui": [ "1601380", "1601386", "1601388", "1601390", "1601392", "1601394" ], "spl_id": [ "7dcc9b87-0aa4-4a00-aced-96be3553e8ac" ], "spl_set_id": [ "e0e6412f-50b4-4fd4-9364-62818d121a07" ], "package_ndc": [ "0069-0187-21", "0069-0188-21", "0069-0189-21" ], "nui": [ "N0000175605", "N0000175082", "N0000190114" ], "pharm_class_epc": [ "Kinase Inhibitor [EPC]" ], "pharm_class_moa": [ "Kinase Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]" ], "unii": [ "G9ZF61LE7G" ] }, "update_date": "04/22/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Capsule", "presentation": "Ibrance, Capsule, 100 mg (NDC 0069-0188-21)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-202-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release August 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "ANDA088586" ], "brand_name": [ "LIDOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-202", "63323-201" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1737757" ], "spl_id": [ "d19c26f4-1214-40f7-9680-43c885613306" ], "spl_set_id": [ "cddb2b22-fce3-8967-6e54-dca3df5ac4b3" ], "package_ndc": [ "63323-201-01", "63323-201-02", "63323-201-03", "63323-201-10", "63323-202-01", "63323-202-02" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/1 mL (NDC 63323-202-02)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "0093-3213-01", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA074569" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0093-3213", "0093-0832", "0093-3212" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "d6abe4e3-7699-4ead-95f4-739a961b23ad" ], "spl_set_id": [ "8069b1a0-7c06-4252-b44e-e2eef065d9b8" ], "package_ndc": [ "0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 0093-3213-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-487-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA076803" ], "brand_name": [ "QUINAPRIL" ], "generic_name": [ "QUINAPRIL" ], "manufacturer_name": [ "Chartwell RX, LLC" ], "product_ndc": [ "62135-487", "62135-484", "62135-485", "62135-486" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE" ], "rxcui": [ "312748", "312749", "312750", "314203" ], "spl_id": [ "09cd5cb9-4fdf-f133-e063-6294a90af691" ], "spl_set_id": [ "dbc43dbd-94aa-40e2-a9ea-766110cc8687" ], "package_ndc": [ "62135-484-60", "62135-485-90", "62135-486-90", "62135-487-90" ], "unii": [ "33067B3N2M" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 40 mg (NDC 62135-487-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-112-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Unavailable", "related_info": "Estimated recovery: October 2026", "openfda": { "application_number": [ "ANDA215771" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Granules Pharmaceuticals Inc." ], "product_ndc": [ "70010-112", "70010-111", "70010-113", "70010-114", "70010-115", "70010-116", "70010-117" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "56c7c921-e560-c5ad-e063-6294a90a4c81" ], "spl_set_id": [ "b0b4eccc-34c7-483d-966f-82d588358e1b" ], "package_ndc": [ "70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 70010-112-01)", "company_name": "Granules Pharmaceuticals Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0990-4179-05", "generic_name": "Amino Acid Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Unavailable", "related_info": "Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA019492" ], "brand_name": [ "AMINOSYN-PF" ], "generic_name": [ "ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, GLYCINE, HISTIDINE, PROLINE, SERINE, TAURINE, AND TYROSINE" ], "manufacturer_name": [ "ICU Medical Inc." ], "product_ndc": [ "0990-4179" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "THREONINE", "TRYPTOPHAN", "VALINE", "ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "GLYCINE", "HISTIDINE", "PROLINE", "SERINE", "TAURINE", "TYROSINE" ], "rxcui": [ "800341", "800345" ], "spl_id": [ "549fb8fe-b1b4-4b40-b078-2511913c2d43" ], "spl_set_id": [ "46e74ce4-cd7e-437f-bf54-ca9b98eb2663" ], "package_ndc": [ "0990-4179-05" ], "nui": [ "N0000175780", "M0000922" ], "pharm_class_epc": [ "Amino Acid [EPC]" ], "pharm_class_cs": [ "Amino Acids [CS]" ], "unii": [ "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "2ZD004190S", "8DUH1N11BX", "HG18B9YRS7", "OF5P57N2ZX", "94ZLA3W45F", "30KYC7MIAI", "3KX376GY7L", "TE7660XO1C", "4QD397987E", "9DLQ4CIU6V", "452VLY9402", "1EQV5MLY3D", "42HK56048U" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "Aminosyn-PF 10%, Injection, 0.1 (NDC 0990-4179-05)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2308-02", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA075857" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-2308", "0409-2305", "0409-0001" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "1666800", "1666814", "1666823", "1666798" ], "spl_id": [ "2f69c5b1-6505-42dc-8bb3-edbd9b6c0781", "8954486a-8512-4831-8178-0b49f1efb73e" ], "spl_set_id": [ "b95415fa-17c2-42ab-a6b0-e628d01c94ed", "1abda8b8-48a8-4995-af86-39220d1aa240" ], "package_ndc": [ "0409-2305-55", "0409-2305-50", "0409-2308-69", "0409-2308-49", "0409-2308-70", "0409-2308-50", "0409-2305-16", "0409-2305-17", "0409-2305-04", "0409-2305-05", "0409-2308-21", "0409-2308-01", "0409-2308-22", "0409-2308-02", "0409-0001-01", "0409-0001-25" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride Preservative Free, Injection, 10 mg/2 mL (5 mg/mL) (NDC 0409-2308-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/01/2017", "package_ndc": "0703-0018-01", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA078591" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Teva Parenteral Medicines, Inc." ], "product_ndc": [ "0703-0018", "0703-0110", "0703-0113" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "1724338", "1724340", "1724341" ], "spl_id": [ "540b835a-db66-417c-8507-0c1ed05c95bf" ], "spl_set_id": [ "f0b78db9-a38c-41bb-8233-5e93f7f18c5c" ], "package_ndc": [ "0703-0110-01", "0703-0110-03", "0703-0113-01", "0703-0113-03", "0703-0018-01" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0018-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "01/12/2026", "update_type": "New", "initial_posting_date": "01/12/2026", "package_ndc": "63323-358-10", "generic_name": "Caspofungin Acetate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA206110" ], "brand_name": [ "CASPOFUNGIN ACETATE" ], "generic_name": [ "CASPOFUNGIN ACETATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-358", "63323-356" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CASPOFUNGIN ACETATE" ], "rxcui": [ "828539", "828755" ], "spl_id": [ "7cdf103b-418f-42a8-bd1b-ebfd8027124a" ], "spl_set_id": [ "e76d8d83-3691-451c-a32c-d91448c54d16" ], "package_ndc": [ "63323-356-01", "63323-356-10", "63323-358-01", "63323-358-10" ], "unii": [ "VUW370O5QE" ] }, "update_date": "01/12/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 63323-358-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "66794-162-02", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-414-1901", "availability": "Available", "openfda": { "application_number": [ "ANDA204393" ], "brand_name": [ "MITIGO" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Piramal Critical Care, Inc." ], "product_ndc": [ "66794-162", "66794-160" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRATHECAL" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "1731522", "1731998", "2055307", "2055311" ], "spl_id": [ "495a6a51-d35d-2b96-e063-6394a90ac5f3" ], "spl_set_id": [ "728f3d83-9a63-0c1f-e053-2a91aa0ac7db" ], "package_ndc": [ "66794-160-02", "66794-162-02" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02)", "company_name": "Piramal Critical Care Inc.", "status": "Current" }, { "discontinued_date": "07/30/2026", "update_type": "New", "initial_posting_date": "07/30/2026", "package_ndc": "63323-578-05", "generic_name": "Glycopyrrolate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA209328" ], "brand_name": [ "GLYCOPYRROLATE" ], "generic_name": [ "GLYCOPYRROLATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-578" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "GLYCOPYRROLATE" ], "rxcui": [ "238212", "1731582", "1731590" ], "spl_id": [ "779dc924-ecc3-41cc-8cf9-a7354db4f763", "d528572e-598b-4c0e-b280-b083c73c017f" ], "spl_set_id": [ "54458620-d888-4df6-ae4b-78c3dfed3423", "ccafb5c2-86dd-4bb2-883a-c13e3171227c" ], "package_ndc": [ "63323-578-03", "63323-578-01", "63323-578-04", "63323-578-02", "63323-578-07", "63323-578-05", "63323-578-18", "63323-578-20", "63323-578-41", "63323-578-11", "63323-578-42", "63323-578-12" ], "unii": [ "V92SO9WP2I" ] }, "update_date": "07/30/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Glycopyrrolate, Injection, 1 mg per 5 mL (NDC 63323-578-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "83831-142-50", "generic_name": "Carboplatin Injection", "contact_info": "877-595-7337; customerservice@avyxa.com", "availability": "Available", "openfda": { "application_number": [ "NDA219921" ], "brand_name": [ "KYXATA" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Avyxa Pharma, LLC" ], "product_ndc": [ "83831-142", "83831-140", "83831-141" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195", "2721602" ], "spl_id": [ "5c711945-70be-42f4-b153-e1459dd9929c" ], "spl_set_id": [ "f91c48da-68d1-4aa7-89b8-d84a3e8b629b" ], "package_ndc": [ "83831-140-02", "83831-141-08", "83831-142-50" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Kyxata, Injection, 500 mg/50 mL (10 mg/mL) (NDC 83831-142-50)", "company_name": "Avyxa Pharma, LLC", "status": "Current" }, { "discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-353-01", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-01)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/26/2018", "package_ndc": "25021-701-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": { "application_number": [ "ANDA204216" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-701", "25021-700" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "cb23332a-48fa-458b-93ab-c4eef189a051" ], "spl_set_id": [ "62591551-a644-4b2c-a0de-982e906fabc3" ], "package_ndc": [ "25021-700-01", "25021-701-01", "25021-701-02" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)", "company_name": "Sagent Pharmaceuticals", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0264-4500-05", "generic_name": "Amino Acid Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "ANDA091112" ], "brand_name": [ "PLENAMINE" ], "generic_name": [ "LYSINE ACETATE, LEUCINE, PHENYLALANINE, VALINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, HISTIDINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, AND TYROSINE" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-4500" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LYSINE ACETATE", "LEUCINE", "PHENYLALANINE", "VALINE", "ISOLEUCINE", "METHIONINE", "THREONINE", "TRYPTOPHAN", "ALANINE", "ARGININE", "GLYCINE", "HISTIDINE", "PROLINE", "GLUTAMIC ACID", "SERINE", "ASPARTIC ACID", "TYROSINE" ], "rxcui": [ "800584", "1601982" ], "spl_id": [ "905f7c55-bf0d-4150-90ef-e8f1a5455bc1" ], "spl_set_id": [ "a3244d1a-45b0-4e4c-bd96-f0632d761a1f" ], "package_ndc": [ "0264-4500-00", "0264-4500-05" ], "nui": [ "N0000175780", "M0000922" ], "pharm_class_epc": [ "Amino Acid [EPC]" ], "pharm_class_cs": [ "Amino Acids [CS]" ], "unii": [ "TTL6G7LIWZ", "GMW67QNF9C", "47E5O17Y3R", "HG18B9YRS7", "04Y7590D77", "AE28F7PNPL", "2ZD004190S", "8DUH1N11BX", "OF5P57N2ZX", "94ZLA3W45F", "TE7660XO1C", "4QD397987E", "9DLQ4CIU6V", "3KX376GY7L", "452VLY9402", "30KYC7MIAI", "42HK56048U" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "Plenamine, Injection, 0.15 (NDC 0264-4500-05)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1891-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA202515" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1891", "0409-1890", "0409-1892", "0409-1893", "0409-1894" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "894912", "998212", "998213", "1729197", "1731995", "1732014" ], "spl_id": [ "56671cfe-7548-442e-a2b5-ffebebf65ade" ], "spl_set_id": [ "be420e8b-bcb0-49b5-bb4d-1df8b9959809" ], "package_ndc": [ "0409-1890-03", "0409-1890-01", "0409-1890-13", "0409-1890-23", "0409-1891-03", "0409-1891-01", "0409-1891-13", "0409-1891-23", "0409-1892-03", "0409-1892-01", "0409-1892-13", "0409-1892-23", "0409-1893-03", "0409-1893-01", "0409-1893-13", "0409-1893-23", "0409-1894-03", "0409-1894-01" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "06/12/2026", "package_ndc": "10019-925-01", "generic_name": "Ifosfamide Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: September 2026", "openfda": { "application_number": [ "NDA019763" ], "brand_name": [ "IFOSFAMIDE" ], "generic_name": [ "IFOSFAMIDE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "10019-925", "10019-926" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "IFOSFAMIDE" ], "rxcui": [ "1791588", "1791593" ], "spl_id": [ "d505027a-76e6-49f1-8ed1-3eeffe9a958b" ], "spl_set_id": [ "91e433a9-6800-43a6-ac13-a49a04a5aecd" ], "package_ndc": [ "10019-925-82", "10019-925-01", "10019-926-16", "10019-926-02" ], "nui": [ "N0000000236", "N0000175558" ], "pharm_class_moa": [ "Alkylating Activity [MoA]" ], "pharm_class_epc": [ "Alkylating Drug [EPC]" ], "unii": [ "UM20QQM95Y" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Oncology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Ifosfamide, Injection, 1 g/20 mL (NDC 10019-925-01)", "company_name": "Baxter Healthcare", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "72572-074-24", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-525-8747", "availability": "Available", "related_info": "Civica Label", "openfda": { "application_number": [ "ANDA201692" ], "brand_name": [ "CLINDAMYCIN IN 5 PERCENT DEXTROSE" ], "generic_name": [ "CLINDAMYCIN IN 5 PERCENT DEXTROSE" ], "manufacturer_name": [ "Civica, Inc." ], "product_ndc": [ "72572-074", "72572-076" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN" ], "rxcui": [ "309335", "309336" ], "spl_id": [ "4711c157-19a5-4886-b468-8739876e67be" ], "spl_set_id": [ "80217bd6-2bc4-401c-9345-22532b36a24f" ], "package_ndc": [ "72572-074-01", "72572-074-24", "72572-076-01", "72572-076-24" ], "nui": [ "N0000009982", "N0000175443", "M0515779", "N0000175731" ], "pharm_class_pe": [ "Decreased Sebaceous Gland Activity [PE]", "Neuromuscular Blockade [PE]" ], "pharm_class_epc": [ "Lincosamide Antibacterial [EPC]" ], "pharm_class_cs": [ "Lincosamides [CS]" ], "unii": [ "3U02EL437C" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24)", "company_name": "Sandoz Inc.", "status": "Current" }, { "discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-356-30", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-30)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued" }, { "discontinued_date": "06/08/2026", "update_type": "New", "initial_posting_date": "06/08/2026", "package_ndc": "0088-2162-33", "generic_name": "Leflunomide Tablet", "contact_info": "800-981-2491", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA020905" ], "brand_name": [ "ARAVA" ], "generic_name": [ "LEFLUNOMIDE" ], "manufacturer_name": [ "sanofi-aventis U.S. LLC" ], "product_ndc": [ "0088-2162", "0088-2160", "0088-2161" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LEFLUNOMIDE" ], "rxcui": [ "205284", "205285", "205286", "213377", "213379", "213380" ], "spl_id": [ "765327c7-cb5b-4637-84da-4fd9a024ad96" ], "spl_set_id": [ "320f63f2-fac3-4aee-aff8-85724e00ef52" ], "package_ndc": [ "0088-2160-30", "0088-2161-30", "0088-2162-33" ], "nui": [ "N0000175713" ], "pharm_class_epc": [ "Antirheumatic Agent [EPC]" ], "unii": [ "G162GK9U4W" ] }, "update_date": "06/08/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Tablet", "presentation": "Arava, Tablet, 100 mg (NDC 0088-2162-33)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "61269-610-10", "generic_name": "Clonazepam Tablet", "contact_info": "orders@h2-pharma.com", "availability": "Available", "related_info": "Marketed by H2-Pharma", "openfda": { "application_number": [ "NDA017533" ], "brand_name": [ "KLONOPIN" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "H2-Pharma, LLC" ], "product_ndc": [ "61269-610", "61269-605", "61269-620" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529", "206157", "206159", "206160" ], "spl_id": [ "63cfdab9-fb3d-4c2b-bf88-8ba841dba839" ], "spl_set_id": [ "cfa0d79a-843c-4b88-95a1-e9511d649ca1" ], "package_ndc": [ "61269-605-10", "61269-610-10", "61269-620-10" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Klonopin, Tablet, 1 mg (NDC 61269-610-10)", "company_name": "Cheplapharm Arzneimittel GmbH", "status": "Current" }, { "discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5166-21", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "PHENOBARBITAL" ], "generic_name": [ "PHENOBARBITAL" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "0603-5166", "0603-5165", "0603-5167", "0603-5168" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "PHENOBARBITAL" ], "rxcui": [ "198086", "199164", "199167", "199168" ], "spl_id": [ "f8c5136e-e35c-4425-8d49-b7f92c827b42" ], "spl_set_id": [ "069b92ce-0061-4724-8c25-08d8596770a2" ], "package_ndc": [ "0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32" ], "unii": [ "YQE403BP4D" ] }, "update_date": "10/31/2025", "therapeutic_category": [ "Analgesia/Addiction", "Neurology", "Other" ], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 32.4 mg (NDC 0603-5166-21)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "02/24/2026", "update_type": "New", "initial_posting_date": "02/24/2026", "package_ndc": "50742-401-02", "generic_name": "Irinotecan Hydrochloride Injection", "contact_info": "866-321-5031", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA206935" ], "brand_name": [ "IRINOTECAN HYDROCHLORIDE" ], "generic_name": [ "IRINOTECAN HYDROCHLORIDE" ], "manufacturer_name": [ "Ingenus Pharmaceuticals, LLC" ], "product_ndc": [ "50742-401", "50742-402" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "IRINOTECAN HYDROCHLORIDE" ], "rxcui": [ "1726319", "1726324" ], "spl_id": [ "b3cfa0f6-fbdc-4f19-9dac-beaf398603d8" ], "spl_set_id": [ "d04f2471-3085-4fc8-a657-bb3918d48e6e" ], "package_ndc": [ "50742-401-02", "50742-402-05" ], "unii": [ "042LAQ1IIS" ] }, "update_date": "02/24/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 50742-401-02)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-407-10", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": { "application_number": [ "ANDA077856" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Solco Healthcare LLC" ], "product_ndc": [ "43547-407", "43547-406", "43547-408" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "dc17b9d4-2890-4f6c-8476-daa39d0cbc9c" ], "spl_set_id": [ "4acbb7a9-4db5-4497-b8db-9f358b3f6fb4" ], "package_ndc": [ "43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "07/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 43547-407-10)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-287-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-287", "63323-286", "63323-288", "63323-285" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484" ], "spl_id": [ "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9" ], "spl_set_id": [ "23d2d448-a744-4877-9f2d-7e57c198da89" ], "package_ndc": [ "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-088-88", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "800-818-4555", "availability": "Available", "openfda": { "application_number": [ "ANDA214134" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "57664-088", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "560b4c9e-9cce-4717-e063-6294a90a58c9" ], "spl_set_id": [ "da3148af-f9b6-4725-adae-3595b4c7dc4b" ], "package_ndc": [ "57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 60 mg (NDC 57664-088-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-10", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA016673" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0017", "0338-0023" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618" ], "spl_id": [ "9c644eb4-5844-415a-8c01-4459d98af222" ], "spl_set_id": [ "3bb406a9-f5cb-403a-b1bb-5c4facbea3d5" ], "package_ndc": [ "0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-10)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-23", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-286", "63323-285", "63323-287", "63323-288" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091" ], "spl_id": [ "324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cb6583ff-cde4-4280-aa5b-0bea2b844792", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c" ], "spl_set_id": [ "dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "cb6583ff-cde4-4280-aa5b-0bea2b844792", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6" ], "package_ndc": [ "63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-51", "63323-286-55", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-23)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4661-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": { "application_number": [ "ANDA215802" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Lannett Company, Inc." ], "product_ndc": [ "0527-4661", "0527-4662", "0527-4663", "0527-4664", "0527-4665", "0527-4666", "0527-4667" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "cb49954d-0f9d-4471-bc86-0c926473c00b" ], "spl_set_id": [ "2cedb4c2-1e40-4bc4-b9f4-127150c4afbd" ], "package_ndc": [ "0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0527-4661-37)", "company_name": "Lannett Company, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-18", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA016673" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0017", "0338-0023" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618" ], "spl_id": [ "9c644eb4-5844-415a-8c01-4459d98af222" ], "spl_set_id": [ "3bb406a9-f5cb-403a-b1bb-5c4facbea3d5" ], "package_ndc": [ "0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-18)", "company_name": "Baxter Healthcare", "status": "Current" }, { "discontinued_date": "04/28/2023", "update_type": "New", "initial_posting_date": "04/28/2023", "change_date": "04/28/2023", "package_ndc": "0069-4310-71", "generic_name": "Prazosin Hydrochloride Capsule", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug. Supply expected to exhaust in August 2023", "update_date": "04/28/2023", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Capsule", "presentation": "Minipress, Capsule, 1 mg (NDC 0069-4310-71)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-028-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Available", "openfda": { "application_number": [ "ANDA202830" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE" ], "manufacturer_name": [ "Amneal Pharmaceuticals LLC" ], "product_ndc": [ "65162-028", "65162-023", "65162-024", "65162-025", "65162-026", "65162-027" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850" ], "spl_id": [ "ba9f3370-3096-4d8c-9571-e28faf54291f" ], "spl_set_id": [ "c11cb3b6-3dff-477b-a249-b4c3118edc5f" ], "package_ndc": [ "65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 65162-028-09)", "company_name": "Amneal Pharmaceuticals", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "59651-722-99", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": { "application_number": [ "ANDA075150" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Aurobindo Pharma Limited" ], "product_ndc": [ "59651-722", "59651-723", "59651-724" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "b1582eb7-af35-45d5-a52e-0e380d08527d" ], "spl_set_id": [ "b1582eb7-af35-45d5-a52e-0e380d08527d" ], "package_ndc": [ "59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "06/02/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 59651-722-99)", "company_name": "Aurobindo Pharma USA", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "72078-034-01", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "NDA020630" ], "brand_name": [ "ULTIVA" ], "generic_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "manufacturer_name": [ "Mylan Institutional LLC" ], "product_ndc": [ "72078-034", "72078-035", "72078-036" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "rxcui": [ "1729578", "1729581", "1729584", "1729586", "1729710", "1729712" ], "spl_id": [ "f41b6542-9305-43e7-bbbc-52c7ee2cb0dc" ], "spl_set_id": [ "8b4c8696-e23e-4c51-a4d2-babab5bd945a" ], "package_ndc": [ "72078-034-00", "72078-034-01", "72078-035-00", "72078-035-02", "72078-036-00", "72078-036-05" ], "unii": [ "5V444H5WIC" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "06/13/2018", "package_ndc": "0143-9595-25", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA084625" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9595", "0143-9594" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1737566", "1737761" ], "spl_id": [ "a7da0a25-5efb-48fa-9063-f7c0423f820f" ], "spl_set_id": [ "1631e5ca-03d0-4d3b-91e3-2dc14f4eb0e1" ], "package_ndc": [ "0143-9595-01", "0143-9595-25", "0143-9594-01", "0143-9594-25" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Preservative Free, Injection, 10 mg/1 mL (NDC 0143-9595-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "0641-6145-25", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional product will be made available as it is released.", "openfda": { "application_number": [ "ANDA084282" ], "brand_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "generic_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6145", "0641-0367", "0641-6146" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE" ], "substance_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "rxcui": [ "309696", "1116927", "1812194" ], "spl_id": [ "02bf3273-f0c8-448c-9f74-eb009fee9299" ], "spl_set_id": [ "0277cc0a-2fd4-4605-a310-b613be84ee26" ], "package_ndc": [ "0641-0367-21", "0641-0367-25", "0641-6145-01", "0641-6145-25", "0641-6146-01", "0641-6146-10", "0641-6146-25" ], "unii": [ "AI9376Y64P" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6145-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "66794-228-41", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-414-1901", "availability": "Limited Availability", "related_info": "On allocation", "openfda": { "application_number": [ "ANDA210437" ], "brand_name": [ "ROCURONIUM" ], "generic_name": [ "ROCURONIUM" ], "manufacturer_name": [ "Piramal Critical Care Inc" ], "product_ndc": [ "66794-228", "66794-229" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "3f9e12e4-d3c5-fba6-e063-6294a90a7fd6" ], "spl_set_id": [ "98255b70-51f9-8d16-e053-2995a90a8f97" ], "package_ndc": [ "66794-229-02", "66794-229-41", "66794-228-02", "66794-228-41" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 66794-228-41)", "company_name": "Piramal Critical Care Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "01/11/2024", "package_ndc": "42858-167-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA215330" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Rhodes Pharmaceuticals LLC" ], "product_ndc": [ "42858-167", "42858-161", "42858-162", "42858-163", "42858-164", "42858-165", "42858-166" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "0002e227-1109-4ecc-a8c5-4b4f11fac3cc" ], "spl_set_id": [ "d918b40d-a461-41bc-b6c0-83dc76c28e32" ], "package_ndc": [ "42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/24/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 42858-167-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "discontinued_date": "06/05/2026", "update_type": "New", "initial_posting_date": "06/05/2026", "package_ndc": "71225-126-06", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-461-7449", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "06/05/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 71225-126-06)", "company_name": "Slayback Pharma", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "0409-1403-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA205656" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1403", "0409-5160" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "f01f9986-43f9-40e8-9506-11bfe78f9242" ], "spl_set_id": [ "f01f9986-43f9-40e8-9506-11bfe78f9242" ], "package_ndc": [ "0409-1403-05", "0409-1403-10", "0409-5160-01", "0409-5160-10" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (10 mg/mL) (NDC 0409-1403-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-201-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA088586" ], "brand_name": [ "LIDOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-201", "63323-202" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1737757" ], "spl_id": [ "d19c26f4-1214-40f7-9680-43c885613306" ], "spl_set_id": [ "cddb2b22-fce3-8967-6e54-dca3df5ac4b3" ], "package_ndc": [ "63323-201-01", "63323-201-02", "63323-201-03", "63323-201-10", "63323-202-01", "63323-202-02" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-201-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "16729-432-93", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-432-93)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "New", "initial_posting_date": "01/01/2012", "package_ndc": "70069-641-25", "generic_name": "Atropine Sulfate Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": { "application_number": [ "ANDA215969" ], "brand_name": [ "ATROPINE SULFATE" ], "generic_name": [ "ATROPINE SULFATE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-641", "70069-631" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ATROPINE SULFATE" ], "rxcui": [ "1190795", "1666781" ], "spl_id": [ "7a8a5552-fe21-4d36-8396-b7c99f41b4c4" ], "spl_set_id": [ "a6fac578-c7bc-4b3c-a454-7889cc819118" ], "package_ndc": [ "70069-631-01", "70069-631-25", "70069-641-01", "70069-641-25" ], "unii": [ "03J5ZE7KA5" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 1 mg/1 mL (NDC 70069-641-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "72205-134-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA218306" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Novadoz Pharmaceuticals LLC" ], "product_ndc": [ "72205-134", "72205-132", "72205-133", "72205-135", "72205-136", "72205-137" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811" ], "spl_set_id": [ "a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811" ], "package_ndc": [ "72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 30 mg (NDC 72205-134-91)", "company_name": "Novadoz Pharmaceuticals LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "63323-421-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA201072" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-421" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "309710" ], "spl_id": [ "56e0af34-aeb5-4b37-8c61-2e90b2c8ca6c" ], "spl_set_id": [ "c1b8eb58-596b-481d-beb6-ba9d2237abf4" ], "package_ndc": [ "63323-421-01", "63323-421-02" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 63323-421-02)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/22/2020", "package_ndc": "43066-023-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Limited Availability", "related_info": "Limited supply; Check wholesalers for inventory; Marketed by Baxter", "openfda": { "application_number": [ "ANDA212808" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "43066-023", "43066-015", "43066-019", "43066-027" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734084", "1734207", "1734475", "1734483" ], "spl_id": [ "a8d08579-825f-40d9-b1e3-e47b73765ae6" ], "spl_set_id": [ "781d4b7f-7556-4695-8d48-7772d7a0d8e9" ], "package_ndc": [ "43066-015-01", "43066-015-10", "43066-019-01", "43066-019-10", "43066-023-01", "43066-023-10", "43066-027-01", "43066-027-10" ], "unii": [ "V910P86109" ] }, "update_date": "06/10/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 43066-023-10)", "company_name": "Caplin Steriles, Ltd.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0169-4060-13", "generic_name": "Liraglutide Injection", "contact_info": "833-493-4689", "availability": "Limited Availability", "related_info": "Estimated shortage duration TBD", "openfda": { "application_number": [ "NDA022341" ], "brand_name": [ "VICTOZA" ], "generic_name": [ "LIRAGLUTIDE" ], "manufacturer_name": [ "Novo Nordisk" ], "product_ndc": [ "0169-4060" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "LIRAGLUTIDE" ], "rxcui": [ "897122", "897126" ], "spl_id": [ "0d10d10e-0fe0-47ee-b9da-628e34907e98" ], "spl_set_id": [ "5a9ef4ea-c76a-4d34-a604-27c5b505f5a4" ], "package_ndc": [ "0169-4060-13", "0169-4060-12", "0169-4060-90", "0169-4060-97", "0169-4060-98", "0169-4060-99" ], "nui": [ "N0000178480", "M0160181", "N0000020058" ], "pharm_class_epc": [ "GLP-1 Receptor Agonist [EPC]" ], "pharm_class_cs": [ "Glucagon-Like Peptide 1 [CS]" ], "pharm_class_moa": [ "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]" ], "unii": [ "839I73S42A" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Victoza, Injection, 6 mg/1 mL (NDC 0169-4060-13)", "company_name": "Novo Nordisk, Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "65219-462-10", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release August 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "ANDA207449" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "FRESENIUS KABI USA, LLC" ], "product_ndc": [ "65219-462", "65219-456", "65219-464", "65219-458", "65219-460" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795607", "1795609", "1795610", "1795612", "1795616" ], "spl_id": [ "efc3b0c9-518a-47db-bb3e-ebdfd4646e9b" ], "spl_set_id": [ "576a22d8-5f2f-497e-80ad-1842ca74bb53" ], "package_ndc": [ "65219-456-05", "65219-456-60", "65219-464-05", "65219-464-50", "65219-458-05", "65219-458-30", "65219-460-05", "65219-460-20", "65219-462-05", "65219-462-10" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-462-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "05/08/2026", "update_type": "New", "initial_posting_date": "05/08/2026", "package_ndc": "69489-721-05", "generic_name": "Sulconazole Nitrate Solution", "contact_info": "480-434-6670", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA018738" ], "brand_name": [ "EXELDERM" ], "generic_name": [ "SULCONAZOLE NITRATE" ], "manufacturer_name": [ "Journey Medical Corporation" ], "product_ndc": [ "69489-721" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "TOPICAL" ], "substance_name": [ "SULCONAZOLE NITRATE" ], "rxcui": [ "208118", "313125" ], "spl_id": [ "53b92932-d626-2d66-e063-6294a90a8f6a" ], "spl_set_id": [ "5b73e83e-8d3c-4d96-b4f6-9f854430add8" ], "package_ndc": [ "69489-721-30", "69489-721-05" ], "unii": [ "1T89100D5U" ] }, "update_date": "05/08/2026", "therapeutic_category": [ "Dermatology" ], "dosage_form": "Solution", "presentation": "Exelderm, Solution, 1.0% 5 mL (NDC 69489-721-05)", "company_name": "Journey Medical Corporation", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "50458-585-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET", "availability": "Available", "openfda": { "application_number": [ "NDA021121" ], "brand_name": [ "CONCERTA" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Janssen Pharmaceuticals, Inc." ], "product_ndc": [ "50458-585", "50458-588", "50458-586", "50458-587" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091157", "1091170", "1091172", "1091185", "1091187", "1091210", "1091212" ], "spl_id": [ "64d7c1e1-e7ed-4d74-a44d-13b4da64af9a" ], "spl_set_id": [ "1a88218c-5b18-4220-8f56-526de1a276cd" ], "package_ndc": [ "50458-585-01", "50458-588-01", "50458-586-01", "50458-587-01" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/19/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01)", "company_name": "Janssen Pharmaceuticals", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "0409-1209-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA088571" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1209", "0409-3177", "0409-3178", "0409-3181", "0409-3182", "0409-3183", "0409-0007", "0409-0147" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE", "EPINEPHRINE" ], "rxcui": [ "1010688", "1010745", "1010751", "1010759", "1867996", "1867998" ], "spl_id": [ "68a37af1-d237-4836-af13-1eec28245f8b" ], "spl_set_id": [ "2f94f711-14c4-48ec-c5a3-c5ec4b8e8729" ], "package_ndc": [ "0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10" ], "nui": [ "N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647" ], "pharm_class_moa": [ "Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]" ], "pharm_class_epc": [ "alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]" ], "pharm_class_cs": [ "Catecholamines [CS]" ], "unii": [ "YKH834O4BH", "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 75 mg/5 mL (1.5%; 1:200,000) (NDC 0409-1209-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "05/05/2026", "update_type": "New", "initial_posting_date": "05/05/2026", "package_ndc": "71288-722-32", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-824-8426", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/05/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-095-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": { "application_number": [ "NDA216117" ], "brand_name": [ "RELEXXII" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Vertical Pharmaceuticals, LLC" ], "product_ndc": [ "68025-095", "68025-088", "68025-089", "68025-096", "68025-097", "68025-084", "68025-098" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505" ], "spl_id": [ "86f477e9-07fc-466b-913e-1a4434c91df4" ], "spl_set_id": [ "22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d" ], "package_ndc": [ "68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current" }, { "discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0832-6003-11", "generic_name": "Fluphenazine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": { "application_number": [ "ANDA213784" ], "brand_name": [ "FLUPHENAZINE HYDROCHLORIDE" ], "generic_name": [ "FLUPHENAZINE HYDROCHLORIDE" ], "manufacturer_name": [ "Upsher-Smith Laboratories,LLC" ], "product_ndc": [ "0832-6003", "0832-6004", "0832-6005", "0832-6006" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "FLUPHENAZINE HYDROCHLORIDE" ], "rxcui": [ "859841", "860918", "865117", "865123" ], "spl_id": [ "3bb74f82-8872-9829-e063-6294a90aeace" ], "spl_set_id": [ "f07bb3f1-c68c-441b-9de4-99a219f2500a" ], "package_ndc": [ "0832-6004-11", "0832-6003-11", "0832-6005-11", "0832-6006-11" ], "unii": [ "ZOU145W1XL" ] }, "update_date": "09/18/2025", "therapeutic_category": [ "Neurology", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Fluphenazine Hydrochloride, Tablet, 1 mg (NDC 0832-6003-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "71357-002-10", "generic_name": "Sodium Acetate Injection", "contact_info": "833-251-8463", "availability": "Available", "openfda": { "application_number": [ "ANDA214805" ], "brand_name": [ "SODIUM ACETATE" ], "generic_name": [ "SODIUM ACETATE" ], "manufacturer_name": [ "MILLA PHARMACEUTICALS INC." ], "product_ndc": [ "71357-002" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM ACETATE" ], "rxcui": [ "1859490" ], "spl_id": [ "2bdf8f55-9a63-bff7-e063-6394a90aafd0" ], "spl_set_id": [ "1ea04916-78e5-4651-e063-6394a90ac4be" ], "package_ndc": [ "71357-002-01", "71357-002-10" ], "unii": [ "4550K0SC9B" ] }, "update_date": "08/15/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition" ], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 40 mEq/20mL (2 mEq/mL) (NDC 71357-002-10)", "company_name": "Milla Pharmaceuticals", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6002-10", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA018140" ], "brand_name": [ "ATIVAN" ], "generic_name": [ "LORAZEPAM" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6002", "0641-6003", "0641-6001", "0641-6000" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "LORAZEPAM" ], "rxcui": [ "206819", "206820", "238100", "238101", "1665188", "1665190", "1665326", "1665327" ], "spl_id": [ "209b0091-c890-4f69-a693-d0594c2606fe" ], "spl_set_id": [ "5fc0e987-61c9-40c4-b0d5-fcea07c8733e" ], "package_ndc": [ "0641-6003-01", "0641-6003-25", "0641-6002-01", "0641-6002-10", "0641-6001-01", "0641-6001-25", "0641-6000-01", "0641-6000-10" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "O26FZP769L" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Injection", "presentation": "Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0264-7510-10", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "NDA019626" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-7510", "0264-7520" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE, UNSPECIFIED FORM" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795610", "1795612" ], "spl_id": [ "c9f87749-8dd5-41fd-b393-f63d45fd00ef" ], "spl_set_id": [ "085614c7-ada4-4e2c-87c0-c9bc2f18365a" ], "package_ndc": [ "0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20" ], "unii": [ "IY9XDZ35W2" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-10)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "76329-3352-1", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "800-423-4136", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": { "application_number": [ "ANDA203449" ], "brand_name": [ "SODIUM BICARBONATE" ], "generic_name": [ "SODIUM BICARBONATE" ], "manufacturer_name": [ "International Medication Systems, Limited" ], "product_ndc": [ "76329-3352" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM BICARBONATE" ], "rxcui": [ "792582" ], "spl_id": [ "74a86dc7-0929-40d0-9661-9f9063a8fd7d" ], "spl_set_id": [ "77698221-a01d-4568-a7bc-d3d4e982875d" ], "package_ndc": [ "76329-3352-1" ], "unii": [ "8MDF5V39QO" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 76329-3352-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "13107-072-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 OR CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability: October 2026", "openfda": { "application_number": [ "ANDA202424" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Aurolife Pharma, LLC" ], "product_ndc": [ "13107-072", "13107-068", "13107-069", "13107-070", "13107-071", "13107-073", "13107-074" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "5962d880-9f18-4a57-8c95-ca0ec1e86f44" ], "spl_set_id": [ "a582d57f-d191-4ca5-b105-585b2d8a0e3e" ], "package_ndc": [ "13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "07/21/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 13107-072-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1007-03", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA019615" ], "brand_name": [ "DOPAMINE HYDROCHLORIDE AND DEXTROSE" ], "generic_name": [ "DOPAMINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-1007", "0338-1005", "0338-1009" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOPAMINE HYDROCHLORIDE" ], "rxcui": [ "1292887", "1743869", "1743871", "1743877", "1743879" ], "spl_id": [ "edc9a091-4cb5-4ec7-b6f9-44d2d588bab9" ], "spl_set_id": [ "cb97d4a0-89ed-407c-a763-209386b6f75c" ], "package_ndc": [ "0338-1005-02", "0338-1005-03", "0338-1007-02", "0338-1007-03", "0338-1009-02" ], "unii": [ "7L3E358N9L" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-03)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/24/2017", "package_ndc": "51754-5012-4", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "828-758-5474 ext. 154", "availability": "Available", "openfda": { "application_number": [ "ANDA211091" ], "brand_name": [ "SODIUM BICARBONATE" ], "generic_name": [ "SODIUM BICARBONATE" ], "manufacturer_name": [ "Exela Pharma Sciences, LLC" ], "product_ndc": [ "51754-5012", "51754-5001", "51754-5011", "51754-5002" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM BICARBONATE" ], "rxcui": [ "807284", "1868486", "1923484", "2198792" ], "spl_id": [ "4da0ba66-756d-4b4d-8018-81ca16578ef1" ], "spl_set_id": [ "e9698a4f-1a95-4f28-a945-e8009d1d6dd4" ], "package_ndc": [ "51754-5001-5", "51754-5001-4", "51754-5011-4", "51754-5002-5", "51754-5012-4" ], "unii": [ "8MDF5V39QO" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 51754-5012-4)", "company_name": "Exela Pharma Sciences, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1362-01", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Demerol, Injection, 25 mg/1 mL (NDC 0409-1362-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-482-57", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release August 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-482", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428", "0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17", "4dd52202-8eef-4136-92dd-ada573b7cf74" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31", "63323-492-41", "63323-492-16", "63323-492-43", "63323-492-36", "63323-492-45", "63323-492-26", "63323-485-41", "63323-485-26", "63323-486-41", "63323-486-26", "63323-482-41", "63323-482-26", "63323-495-41", "63323-495-26" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-57)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "12/10/2025", "update_type": "New", "initial_posting_date": "12/10/2025", "package_ndc": "0025-1001-31", "generic_name": "Spironolactone Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": { "application_number": [ "NDA012151" ], "brand_name": [ "ALDACTONE" ], "generic_name": [ "SPIRONOLACTONE" ], "manufacturer_name": [ "Pfizer Laboratories Div Pfizer Inc" ], "product_ndc": [ "0025-1001", "0025-1041", "0025-1031" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "SPIRONOLACTONE" ], "rxcui": [ "198222", "198223", "200817", "200820", "200825", "313096" ], "spl_id": [ "22946678-dcad-4518-9bc6-cbdf51a38c16" ], "spl_set_id": [ "0fed2822-3a03-4b64-9857-c682fcd462bc" ], "package_ndc": [ "0025-1001-31", "0025-1041-31", "0025-1031-31" ], "nui": [ "N0000175557", "N0000011310" ], "pharm_class_epc": [ "Aldosterone Antagonist [EPC]" ], "pharm_class_moa": [ "Aldosterone Antagonists [MoA]" ], "unii": [ "27O7W4T232" ] }, "update_date": "12/10/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Aldactone, Tablet, 25 mg (NDC 0025-1001-31)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-555-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA218604" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Elite Laboratories, Inc." ], "product_ndc": [ "64850-555", "64850-550", "64850-551", "64850-552", "64850-553", "64850-554", "64850-556" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "2d33f701-8067-4a48-98cc-4e7dacaf3cc4" ], "spl_set_id": [ "0e024b69-567c-4b40-9c3e-a2daec34256c" ], "package_ndc": [ "64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 64850-555-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/14/2016", "package_ndc": "63323-489-27", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release September 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE MPF" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-489", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-27)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "0990-7139-09", "generic_name": "Sterile Water Irrigant", "related_info_link": "https://www.fda.gov/media/182619/download?attachment", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Unavailable", "related_info": "Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-7139-09)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "12/08/2025", "update_type": "New", "initial_posting_date": "12/08/2025", "package_ndc": "0781-9409-95", "generic_name": "Ampicillin Sodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of private label only", "openfda": { "application_number": [ "ANDA061395" ], "brand_name": [ "AMPICILLIN" ], "generic_name": [ "AMPICILLIN SODIUM" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-9409" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "AMPICILLIN SODIUM" ], "rxcui": [ "789980" ], "spl_id": [ "86e9a3cc-bc65-4d4f-916d-98c916588730" ], "spl_set_id": [ "5308ddfa-4a5b-4f7b-83ce-9d1b528e050d" ], "package_ndc": [ "0781-9409-46", "0781-9409-95" ], "unii": [ "JFN36L5S8K" ] }, "update_date": "12/08/2025", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Ampicillin Sodium, Injection, 10 g (NDC 0781-9409-95)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5114-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Available", "openfda": { "application_number": [ "ANDA211840" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "SpecGx LLC" ], "product_ndc": [ "0406-5114", "0406-5111", "0406-5112", "0406-5113", "0406-5115", "0406-5116", "0406-5117" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "b4be564a-404d-4ca1-bac0-ec9cf40fef93" ], "spl_set_id": [ "806a1c15-0842-4787-b2ad-09a21fd96b37" ], "package_ndc": [ "0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0406-5114-01)", "company_name": "SpecGx LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/31/2018", "package_ndc": "25021-321-04", "generic_name": "Bumetanide Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": { "application_number": [ "ANDA074441" ], "brand_name": [ "BUMETANIDE" ], "generic_name": [ "BUMETANIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-321" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "BUMETANIDE" ], "rxcui": [ "282486", "1727569" ], "spl_id": [ "88a191ea-bf0d-4c27-a33c-91a126ff1aba" ], "spl_set_id": [ "c38a404d-a919-4a2c-9fbb-d0655dee9516" ], "package_ndc": [ "25021-321-04", "25021-321-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "0Y2S3XUQ5H" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 25021-321-04)", "company_name": "Sagent Pharmaceuticals", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "72205-136-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA218306" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Novadoz Pharmaceuticals LLC" ], "product_ndc": [ "72205-136", "72205-132", "72205-133", "72205-134", "72205-135", "72205-137" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811" ], "spl_set_id": [ "a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811" ], "package_ndc": [ "72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 50 mg (NDC 72205-136-91)", "company_name": "Novadoz Pharmaceuticals LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9094-31", "generic_name": "Fentanyl Citrate Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA019115" ], "brand_name": [ "FENTANYL CITRATE" ], "generic_name": [ "FENTANYL CITRATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-9094", "0409-9093" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FENTANYL CITRATE" ], "rxcui": [ "1735003", "1735004", "1735006", "1735007", "1735008", "1735013" ], "spl_id": [ "e4eaad6d-c21e-42fd-8fd9-f0b769966d61" ], "spl_set_id": [ "bfa8018a-4cbc-434b-e09e-782872b0340a" ], "package_ndc": [ "0409-9093-41", "0409-9093-36", "0409-9093-31", "0409-9093-38", "0409-9094-12", "0409-9094-22", "0409-9094-18", "0409-9094-25", "0409-9094-17", "0409-9094-28", "0409-9094-16", "0409-9094-31", "0409-9094-41", "0409-9094-61" ], "unii": [ "MUN5LYG46H" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 1000 mcg/20 mL (50 ug/1 mL) (NDC 0409-9094-31)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-464-17", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA070552", "NDA018304" ], "brand_name": [ "SENSORCAINE MPF" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-464", "63323-466", "63323-462", "63323-465", "63323-467", "63323-460" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457" ], "spl_id": [ "b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715" ], "spl_set_id": [ "e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8" ], "package_ndc": [ "63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31" ], "unii": [ "7TQO7W3VT8", "30Q7KI53AK" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5167-21", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "PHENOBARBITAL" ], "generic_name": [ "PHENOBARBITAL" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "0603-5167", "0603-5165", "0603-5166", "0603-5168" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "PHENOBARBITAL" ], "rxcui": [ "198086", "199164", "199167", "199168" ], "spl_id": [ "f8c5136e-e35c-4425-8d49-b7f92c827b42" ], "spl_set_id": [ "069b92ce-0061-4724-8c25-08d8596770a2" ], "package_ndc": [ "0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32" ], "unii": [ "YQE403BP4D" ] }, "update_date": "10/31/2025", "therapeutic_category": [ "Analgesia/Addiction", "Neurology", "Other" ], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 64.8 mg (NDC 0603-5167-21)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "08/14/2026", "update_type": "New", "initial_posting_date": "08/14/2026", "package_ndc": "63323-715-05", "generic_name": "Fulvestrant Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA210326" ], "brand_name": [ "FULVESTRANT" ], "generic_name": [ "FULVESTRANT" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-715" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "FULVESTRANT" ], "rxcui": [ "727762" ], "spl_id": [ "c584c51e-3ce0-4682-a4dd-d0ac149201a8" ], "spl_set_id": [ "fabe9bd8-ac23-4df1-a89a-223d5cd38914" ], "package_ndc": [ "63323-715-01", "63323-715-05" ], "nui": [ "N0000175582", "N0000000145", "N0000000168" ], "pharm_class_epc": [ "Estrogen Receptor Antagonist [EPC]" ], "pharm_class_moa": [ "Estrogen Receptor Antagonists [MoA]", "Selective Estrogen Receptor Modulators [MoA]" ], "unii": [ "22X328QOC4" ] }, "update_date": "08/14/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Fulvestrant, Injection, 250 mg per 5mL (NDC 63323-715-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "discontinued_date": "06/01/2026", "update_type": "New", "initial_posting_date": "06/01/2026", "package_ndc": "0009-0870-26", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA050441" ], "brand_name": [ "CLEOCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0870", "0009-0775", "0009-0902", "0009-0728", "0009-3124", "0009-3447", "0009-3381", "0009-3375", "0009-3382", "0009-6582" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "205964", "309335", "309336", "309339", "685574", "685576", "685578", "706461", "1737244", "1737245", "1737578", "1737579", "1737581", "1737582" ], "spl_id": [ "fa11e62e-4625-4e9c-8676-f318b1cb890f" ], "spl_set_id": [ "05a75685-0af5-407c-ac57-e380c882b49d" ], "package_ndc": [ "0009-0870-21", "0009-0870-26", "0009-0775-20", "0009-0775-26", "0009-0902-11", "0009-0902-18", "0009-0728-05", "0009-0728-09", "0009-3124-01", "0009-3124-03", "0009-3447-01", "0009-3447-03", "0009-3381-01", "0009-3381-02", "0009-3375-01", "0009-3375-02", "0009-3382-01", "0009-3382-02", "0009-6582-02", "0009-6582-01" ], "unii": [ "EH6D7113I8" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial (NDC 0009-0870-26)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2859-10", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA075757" ], "brand_name": [ "OMEPRAZOLE" ], "generic_name": [ "OMEPRAZOLE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-2859", "0781-2868" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OMEPRAZOLE" ], "rxcui": [ "198051", "199119" ], "spl_id": [ "b182f298-e28f-434b-b6f1-ecfac29d495e" ], "spl_set_id": [ "516170d4-4913-4577-a2d2-f5c52d1e79c6" ], "package_ndc": [ "0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31" ], "nui": [ "N0000175525", "N0000000147", "N0000182140" ], "pharm_class_epc": [ "Proton Pump Inhibitor [EPC]" ], "pharm_class_moa": [ "Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]" ], "unii": [ "KG60484QX9" ] }, "update_date": "10/09/2025", "therapeutic_category": [ "Gastroenterology" ], "presentation": "Omeprazole, Delayed Release Capsule, 10 mg (NDC 0781-2859-10)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "57844-120-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA040422" ], "brand_name": [ "ADDERALL" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "57844-120", "57844-105", "57844-117", "57844-110", "57844-112", "57844-115", "57844-130" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147" ], "spl_id": [ "79af1dc6-c7cf-41b1-a750-e9b47c2187ff" ], "spl_set_id": [ "f22635fe-821d-4cde-aa12-419f8b53db81" ], "package_ndc": [ "57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 57844-120-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "07/17/2026", "update_type": "New", "initial_posting_date": "07/17/2026", "package_ndc": "0409-3578-01", "generic_name": "Tobramycin Sulfate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA063111" ], "brand_name": [ "TOBRAMYCIN" ], "generic_name": [ "TOBRAMYCIN" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3578" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "TOBRAMYCIN SULFATE" ], "rxcui": [ "597823" ], "spl_id": [ "d69232fd-aeae-44b9-9e43-2f2e5bd843be" ], "spl_set_id": [ "c5a005b0-7b6f-4e30-df92-9a20b1ca66a1" ], "package_ndc": [ "0409-3578-11", "0409-3578-01" ], "unii": [ "HJT0RXD7JK" ] }, "update_date": "07/17/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Tobramycin Sulfate, Injection, 80 mg/2 mL (40 mg/mL); 2 mL Multiple Dose Glass Fliptop Vial (NDC 0409-3578-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3073-23", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Next Delivery: October 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA011757" ], "brand_name": [ "DEPO-MEDROL" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-3073", "0009-3475" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE", "INTRA-ARTICULAR" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1743779", "1743781", "1743855", "1743856" ], "spl_id": [ "e4917f75-3e1c-4f3c-803d-d9ec65df06c7", "742fcec7-8db3-4cc6-b276-42587a993810" ], "spl_set_id": [ "bf1b104d-85cb-414d-a366-78068c82c883", "9a7b3837-e038-48bf-97e9-78ad463760dc" ], "package_ndc": [ "0009-3073-22", "0009-3073-23", "0009-3475-22", "0009-3475-23", "0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4741-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Available", "openfda": { "application_number": [ "ANDA216944" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Apotex Corp." ], "product_ndc": [ "60505-4741", "60505-4739", "60505-4740", "60505-4742", "60505-4743", "60505-4744", "60505-4745" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "2eec36cd-6063-fea0-d6dd-b7a5c8df186b" ], "spl_set_id": [ "ecad4442-a644-18e3-6ff2-fdbac45eec47" ], "package_ndc": [ "60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 60505-4741-1)", "company_name": "Apotex Corp.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1162-02", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA070584" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1162", "0409-1159", "0409-1160", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9045", "0409-9042" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596" ], "spl_id": [ "6e442bfd-d3da-4913-8585-ce3485644364" ], "spl_set_id": [ "02a845c3-4521-4926-e397-25ab536e7cf6" ], "package_ndc": [ "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-1162-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "62175-313-37", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "844-834-0530", "availability": "Available", "openfda": { "application_number": [ "ANDA091695" ], "brand_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Lannett Company, Inc." ], "product_ndc": [ "62175-313", "62175-310", "62175-311", "62175-312" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "2001564", "2001565", "2001566", "2001568" ], "spl_id": [ "8b133cd2-e3c6-4742-b402-2393b56ffc93" ], "spl_set_id": [ "3d1f5aff-5d39-496c-b5ed-7f3c70ec641c" ], "package_ndc": [ "62175-310-37", "62175-311-37", "62175-312-37", "62175-313-37" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62175-313-37)", "company_name": "Lannett Company, Inc.", "status": "Current" }, { "discontinued_date": "01/27/2026", "update_type": "New", "initial_posting_date": "01/27/2026", "package_ndc": "0781-8017-31", "generic_name": "Fluvastatin Sodium Tablet, Extended Release", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA021192" ], "brand_name": [ "FLUVASTATIN SODIUM ER" ], "generic_name": [ "FLUVASTATIN SODIUM" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-8017" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "FLUVASTATIN SODIUM" ], "rxcui": [ "360507" ], "spl_id": [ "37375ca6-3a81-4d10-9b39-9aee948e51a4" ], "spl_set_id": [ "5ab4296c-87c2-4c64-b218-d620eef51310" ], "package_ndc": [ "0781-8017-31", "0781-8017-01" ], "unii": [ "PYF7O1FV7F" ] }, "update_date": "01/27/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-31)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "11/14/2025", "update_type": "New", "initial_posting_date": "11/14/2025", "package_ndc": "0409-5017-01", "generic_name": "Vancomycin Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/14/2025", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Vancomycin Hydrochloride, Injection, 10 g Vial NovaPlus (NDC 0409-5017-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-1893-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA202515" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1893", "0409-1890", "0409-1891", "0409-1892", "0409-1894" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "894912", "998212", "998213", "1729197", "1731995", "1732014" ], "spl_id": [ "56671cfe-7548-442e-a2b5-ffebebf65ade" ], "spl_set_id": [ "be420e8b-bcb0-49b5-bb4d-1df8b9959809" ], "package_ndc": [ "0409-1890-03", "0409-1890-01", "0409-1890-13", "0409-1890-23", "0409-1891-03", "0409-1891-01", "0409-1891-13", "0409-1891-23", "0409-1892-03", "0409-1892-01", "0409-1892-13", "0409-1892-23", "0409-1893-03", "0409-1893-01", "0409-1893-13", "0409-1893-23", "0409-1894-03", "0409-1894-01" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "63323-806-20", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA210762" ], "brand_name": [ "FENTANYL CITRATE" ], "generic_name": [ "FENTANYL CITRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-806" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FENTANYL CITRATE" ], "rxcui": [ "1735003", "1735007", "1735008", "1735013", "2168270" ], "spl_id": [ "341b092a-1f6f-40f1-98f2-9346bf2e1242" ], "spl_set_id": [ "38d0c14a-a0c1-44cc-a939-0304eb8037d6" ], "package_ndc": [ "63323-806-11", "63323-806-01", "63323-806-12", "63323-806-02", "63323-806-13", "63323-806-05", "63323-806-14", "63323-806-20", "63323-806-50" ], "unii": [ "MUN5LYG46H" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1749-10", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA016964" ], "brand_name": [ "MARCAINE WITH EPINEPHRINE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1749", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1746", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614" ], "spl_id": [ "7040888c-2cde-4408-af99-d249985f8444" ], "spl_set_id": [ "67578b56-7540-487e-1fba-481255620e78" ], "package_ndc": [ "0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2596-05", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA075293" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-2596", "0409-2587" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "311700", "311702" ], "spl_id": [ "6c075a2d-b68b-41a7-aa0c-bcf9894e3f76" ], "spl_set_id": [ "affecd4d-1f78-4bbe-5a8d-86849bbdc520" ], "package_ndc": [ "0409-2587-04", "0409-2587-05", "0409-2596-13", "0409-2596-03", "0409-2596-15", "0409-2596-05" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-2596-05)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "discontinued_date": "05/21/2026", "update_type": "New", "initial_posting_date": "05/21/2026", "package_ndc": "65219-084-15", "generic_name": "Gadoterate Meglumine Injection", "contact_info": "Marketed by Fresenius Kabi, USA; Customer service: 888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA215304" ], "brand_name": [ "GADOTERATE MEGLUMINE" ], "generic_name": [ "GADOTERATE MEGLUMINE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-084", "65219-080", "65219-082", "65219-086" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GADOTERATE MEGLUMINE" ], "spl_id": [ "f05922b7-99d4-48c7-972a-7966bbbbc3b4" ], "spl_set_id": [ "e0655aac-9508-4141-94f5-fcca6af1c41d" ], "package_ndc": [ "65219-080-01", "65219-080-05", "65219-082-01", "65219-082-10", "65219-084-01", "65219-084-15", "65219-086-01", "65219-086-20" ], "unii": [ "L0ND3981AG" ] }, "update_date": "05/21/2026", "therapeutic_category": [ "Medical Imaging" ], "dosage_form": "Injection", "presentation": "Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-084-15)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/25/2022", "package_ndc": "64980-642-03", "generic_name": "Albuterol Sulfate Solution", "contact_info": "201-961-9000", "availability": "Available", "openfda": { "application_number": [ "ANDA075664" ], "brand_name": [ "ALBUTEROL SULFATE" ], "generic_name": [ "ALBUTEROL SULFATE" ], "manufacturer_name": [ "Rising Pharma Holdings, Inc." ], "product_ndc": [ "64980-642" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RESPIRATORY (INHALATION)" ], "substance_name": [ "ALBUTEROL SULFATE" ], "rxcui": [ "245314" ], "spl_id": [ "56c00cc1-5ed0-8ff5-e063-6394a90a132b" ], "spl_set_id": [ "3236f82c-14e9-dfd4-e063-6294a90ac43d" ], "package_ndc": [ "64980-642-03" ], "unii": [ "021SEF3731" ] }, "update_date": "06/03/2026", "therapeutic_category": [ "Pediatric", "Pulmonary/Allergy" ], "dosage_form": "Solution", "presentation": "Albuterol Sulfate, Solution, 2.5 mg/.5 mL (NDC 64980-642-03)", "company_name": "Rising Pharma Holdings, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-1630-10", "generic_name": "Atropine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: August 2026; Estimated Recovery: September 2026. Shortage per Manufacturer: Manufacturing Delay.", "openfda": { "application_number": [ "NDA021146" ], "brand_name": [ "ATROPINE SULFATE" ], "generic_name": [ "ATROPINE SULFATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1630", "0409-9630", "0409-4910", "0409-4911" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ATROPINE SULFATE" ], "rxcui": [ "1190546", "1190551", "1190552" ], "spl_id": [ "3f33c683-46fb-40db-af0d-9211bc29d2a7" ], "spl_set_id": [ "ad8916e7-206e-409e-2582-30d072845dd4" ], "package_ndc": [ "0409-1630-15", "0409-1630-10", "0409-9630-15", "0409-9630-05", "0409-4910-11", "0409-4910-34", "0409-4911-11", "0409-4911-34" ], "unii": [ "03J5ZE7KA5" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 1 mg/10 mL (0.1 mg/mL) Syringes (NDC 0409-1630-10)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0480-3567-01)", "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3567-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "company_name": "Teva Pharmaceuticals USA, Inc.", "contact_info": "800-545-8800", "availability": "Available", "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "status": "Current", "dosage_form": "Capsule" }, { "discontinued_date": "12/04/2025", "update_type": "New", "initial_posting_date": "12/04/2025", "package_ndc": "0093-7353-01", "generic_name": "Calcitriol Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug", "openfda": { "application_number": [ "ANDA075765" ], "brand_name": [ "CALCITRIOL" ], "generic_name": [ "CALCITRIOL" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0093-7353", "0093-7352" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CALCITRIOL" ], "rxcui": [ "308867", "308868" ], "spl_id": [ "9e6df585-e3d1-4a89-bc02-8e4b223578c4" ], "spl_set_id": [ "ec93b667-aad2-4e3a-adc6-952f070a0c0a" ], "package_ndc": [ "0093-7352-01", "0093-7353-01" ], "nui": [ "M0004229", "N0000175908" ], "pharm_class_cs": [ "Cholecalciferol [CS]" ], "pharm_class_epc": [ "Vitamin D3 Analog [EPC]" ], "unii": [ "FXC9231JVH" ] }, "update_date": "12/04/2025", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Capsule", "presentation": "Calcitriol, Capsule, .5 ug (NDC 0093-7353-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6040-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "NDA018565" ], "brand_name": [ "INFUMORPH 500" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6040", "0641-6039" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRATHECAL" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "892652", "1731522", "1731998", "1731999" ], "spl_id": [ "b1c060cb-5c5b-495f-90b5-044e04f2a3f2" ], "spl_set_id": [ "db9ac9e3-d761-4a99-9f34-4946ebe8f255" ], "package_ndc": [ "0641-6039-01", "0641-6040-01" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "0228-2850-11", "generic_name": "Guanfacine Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA200881" ], "brand_name": [ "GUANFACINE" ], "generic_name": [ "GUANFACINE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0228-2850", "0228-2851", "0228-2853", "0228-2855" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "GUANFACINE HYDROCHLORIDE" ], "rxcui": [ "862006", "862013", "862019", "862025" ], "spl_id": [ "00143252-2b74-4b11-86ed-9b864635f129" ], "spl_set_id": [ "3a171942-37af-430d-8b9d-bb678ca2be4b" ], "package_ndc": [ "0228-2850-11", "0228-2851-11", "0228-2853-11", "0228-2855-11" ], "unii": [ "PML56A160O" ] }, "update_date": "11/13/2025", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Guanfacine Hydrochloride, Tablet, Extended Release, 1 mg (NDC 0228-2850-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "60505-6282-1", "generic_name": "Carboplatin Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Carboplatin%20Injection&st=d", "contact_info": "Apotex Inc.: 800-706-5575", "availability": "Unavailable", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA077861" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Apotex Corp." ], "product_ndc": [ "60505-6282" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "0e68e276-b0df-4f03-e063-6394a90a22b9" ], "spl_set_id": [ "1c275825-0275-4c73-b650-e4c1519f13b8" ], "package_ndc": [ "60505-6282-1", "60505-6282-3", "60505-6282-6", "60505-6282-7" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)", "company_name": "Teyro Labs", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "12/22/2021", "package_ndc": "68180-658-06", "generic_name": "Rifampin Capsule", "contact_info": "866-587-4617", "availability": "Available", "openfda": { "application_number": [ "ANDA090034" ], "brand_name": [ "RIFAMPIN" ], "generic_name": [ "RIFAMPIN" ], "manufacturer_name": [ "Lupin Pharmaceuticals, Inc." ], "product_ndc": [ "68180-658", "68180-659" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RIFAMPIN" ], "rxcui": [ "198201", "198202" ], "spl_id": [ "5ed1edac-e11e-4f87-b390-e770a69a9b37" ], "spl_set_id": [ "b56004f0-f23d-47f6-80c7-39884fccbccc" ], "package_ndc": [ "68180-658-06", "68180-658-01", "68180-659-06", "68180-659-07", "68180-659-01" ], "nui": [ "N0000175500", "M0019113" ], "pharm_class_epc": [ "Rifamycin Antibacterial [EPC]" ], "pharm_class_cs": [ "Rifamycins [CS]" ], "unii": [ "VJT6J7R4TR" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 150 mg (NDC 68180-658-06)", "company_name": "Lupin Pharmaceuticals, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "63323-412-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA075154" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-412", "63323-411" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "311700", "311702" ], "spl_id": [ "9814447b-a93e-42ad-b57e-5db0a5b7f552" ], "spl_set_id": [ "a91ce254-14a3-4cbf-8ab8-5da252aa3fdc" ], "package_ndc": [ "63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 63323-412-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "43598-976-58", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "Distributed by DRL", "availability": "Available", "related_info": "Distributed by DRL", "openfda": { "application_number": [ "ANDA209307" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Dr.Reddy's Laboratories Inc" ], "product_ndc": [ "43598-976", "43598-975" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909" ], "spl_id": [ "5785a11f-7784-4ae0-8029-f50b782eaf4a" ], "spl_set_id": [ "d174c19d-56f1-4ef4-087c-23c26db8e40b" ], "package_ndc": [ "43598-976-11", "43598-976-58", "43598-975-11", "43598-975-58" ], "unii": [ "1018WH7F9I" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 43598-976-58)", "company_name": "Gland Pharma Limited", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0220-23", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Accuretic, Tablet, 20 mg/12.5 mg (NDC 0071-0220-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-114-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Unavailable", "related_info": "Estimated recovery: October 2026", "openfda": { "application_number": [ "ANDA215771" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Granules Pharmaceuticals Inc." ], "product_ndc": [ "70010-114", "70010-111", "70010-112", "70010-113", "70010-115", "70010-116", "70010-117" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "56c7c921-e560-c5ad-e063-6294a90a4c81" ], "spl_set_id": [ "b0b4eccc-34c7-483d-966f-82d588358e1b" ], "package_ndc": [ "70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 70010-114-01)", "company_name": "Granules Pharmaceuticals Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "55150-171-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA203895" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-171", "55150-167", "55150-168", "55150-169", "55150-170", "55150-172", "55150-249", "55150-250" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "RETROBULBAR" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082" ], "spl_id": [ "39649703-e633-4a20-ba71-0c04dbf8ff2a" ], "spl_set_id": [ "ffecf450-1f01-4721-8e10-251385852612" ], "package_ndc": [ "55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 55150-171-10)", "company_name": "Eugia US LLC", "status": "Current" }, { "discontinued_date": "01/30/2026", "update_type": "New", "initial_posting_date": "01/30/2026", "package_ndc": "57664-655-88", "generic_name": "Pindolol Tablet", "contact_info": "800-818-4555", "related_info": "Discontinuation of the manufacture of the drug; Expiry date of last distributed batch January 2027", "openfda": { "application_number": [ "ANDA074063" ], "brand_name": [ "PINDOLOL" ], "generic_name": [ "PINDOLOL" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "57664-655", "57664-656" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "PINDOLOL" ], "rxcui": [ "198104", "198105" ], "spl_id": [ "4d3c89dd-e947-5f23-e063-6294a90aeb1f" ], "spl_set_id": [ "b331a73f-bf7b-4442-8901-36d016530279" ], "package_ndc": [ "57664-656-88", "57664-655-88" ], "nui": [ "N0000000161", "N0000175556" ], "pharm_class_moa": [ "Adrenergic beta-Antagonists [MoA]" ], "pharm_class_epc": [ "beta-Adrenergic Blocker [EPC]" ], "unii": [ "BJ4HF6IU1D" ] }, "update_date": "01/30/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Pindolol, Tablet, 5 mg (NDC 57664-655-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "61703-408-25", "generic_name": "Methotrexate Sodium Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA011719" ], "brand_name": [ "METHOTREXATE" ], "generic_name": [ "METHOTREXATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "61703-408", "61703-350" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "METHOTREXATE SODIUM" ], "rxcui": [ "1655956", "1946772" ], "spl_id": [ "95b8b8da-da4e-4bba-9038-3cf65f3d5c1a", "37b3e76b-ac3d-4f93-adf1-91f52f676b8a" ], "spl_set_id": [ "0d63ba29-b692-41b4-87e8-351265c8273f", "0e30eaef-5a09-4104-8a11-c32933eadeab" ], "package_ndc": [ "61703-350-37", "61703-350-38", "61703-408-41", "61703-350-09", "61703-350-10", "61703-408-25" ], "unii": [ "3IG1E710ZN" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology", "Oncology" ], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-153-05", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": { "application_number": [ "ANDA075468" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Advagen Pharma Ltd" ], "product_ndc": [ "72888-153", "72888-497", "72888-152", "72888-154" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529", "204892" ], "spl_id": [ "5510f17b-a980-f412-e063-6394a90ae1c4" ], "spl_set_id": [ "30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec" ], "package_ndc": [ "72888-497-01", "72888-497-02", "72888-497-03", "72888-497-04", "72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 72888-153-05)", "company_name": "Rubicon Research Private Limited", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/26/2023", "package_ndc": "60793-702-10", "generic_name": "Penicillin G Benzathine Injection", "related_info_link": "https://www.fda.gov/media/190713/download", "contact_info": "800-533-4535", "availability": "Limited Availability", "related_info": "Next Delivery: Fourth Quarter 2026 Estimated Recovery: 4Q 2027; Manufacturing delay", "openfda": { "application_number": [ "NDA050141" ], "brand_name": [ "BICILLIN L-A" ], "generic_name": [ "PENICILLIN G BENZATHINE" ], "manufacturer_name": [ "Pfizer Laboratories Div Pfizer Inc" ], "product_ndc": [ "60793-702", "60793-700", "60793-701" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "PENICILLIN G BENZATHINE" ], "rxcui": [ "731564", "731566", "731567", "731568", "731570", "731571" ], "spl_id": [ "526e051e-d0fc-4f5d-886a-d61947aa8a7f" ], "spl_set_id": [ "012d46f1-d0a0-4676-a879-cd320297ab16" ], "package_ndc": [ "60793-700-01", "60793-700-10", "60793-701-02", "60793-701-10", "60793-702-04", "60793-702-10" ], "unii": [ "RIT82F58GK" ] }, "update_date": "08/12/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Bicillin L-A, Injection, 2400000 [iU]/4 mL (NDC 60793-702-10)", "company_name": "Pfizer Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0016-12", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": { "application_number": [ "NDA009866" ], "brand_name": [ "SOLU-CORTEF" ], "generic_name": [ "HYDROCORTISONE SODIUM SUCCINATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0016", "0009-0825", "0009-0011", "0009-0013", "0009-0005" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "HYDROCORTISONE SODIUM SUCCINATE" ], "rxcui": [ "105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596" ], "spl_id": [ "8512044a-4a54-4634-bb97-9e20126adc61" ], "spl_set_id": [ "65eefd58-b166-4d71-ade6-45c8fdf86922" ], "package_ndc": [ "0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01" ], "unii": [ "50LQB69S1Z" ] }, "update_date": "02/24/2026", "therapeutic_category": [ "Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 500 mg/vial (NDC 0009-0016-12)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1761-62", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA018692" ], "brand_name": [ "MARCAINE SPINAL" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE IN DEXTROSE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1761" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBARACHNOID" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1724784", "1724792" ], "spl_id": [ "ef77810e-d05c-4501-9512-10dbe0bc7f00" ], "spl_set_id": [ "9679cc05-2f8a-4e88-53b5-6e9122c8b8c0" ], "package_ndc": [ "0409-1761-19", "0409-1761-02", "0409-1761-18", "0409-1761-62", "0409-1761-05", "0409-1761-10" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Marcaine, Injection, 0.75% 15 mg/2 mL (NDC 0409-1761-62)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "43547-411-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-931-9829", "availability": "Unavailable", "related_info": "Not available. Long-term backorder for all NDCs. No estimated release date at this time.", "openfda": { "application_number": [ "ANDA205823" ], "brand_name": [ "QUINAPRIL" ], "generic_name": [ "QUINAPRIL" ], "manufacturer_name": [ "Solco Healthcare US, LLC" ], "product_ndc": [ "43547-411", "43547-410", "43547-412", "43547-413" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE" ], "rxcui": [ "312748", "312749", "312750", "314203" ], "spl_id": [ "b8f1731a-cbac-4f64-a8d4-320b80b335e1" ], "spl_set_id": [ "cd46691d-5593-4a9f-a937-999c6803e312" ], "package_ndc": [ "43547-410-09", "43547-411-09", "43547-412-09", "43547-413-09" ], "unii": [ "33067B3N2M" ] }, "update_date": "06/29/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 10 mg (NDC 43547-411-09)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-095-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": { "application_number": [ "NDA216117" ], "brand_name": [ "RELEXXII" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Vertical Pharmaceuticals, LLC" ], "product_ndc": [ "68025-095", "68025-088", "68025-089", "68025-096", "68025-097", "68025-084", "68025-098" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505" ], "spl_id": [ "86f477e9-07fc-466b-913e-1a4434c91df4" ], "spl_set_id": [ "22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d" ], "package_ndc": [ "68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current" }, { "discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "68001-573-41", "generic_name": "Decitabine Injection", "contact_info": "866-321-5031", "related_info": "Labeler: BluePoint Laboratories; Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA210984" ], "brand_name": [ "DECITABINE" ], "generic_name": [ "DECITABINE" ], "manufacturer_name": [ "BluePoint Laboratories" ], "product_ndc": [ "68001-573" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DECITABINE" ], "rxcui": [ "636631" ], "spl_id": [ "fc96fe77-06cc-dc04-e053-6394a90a99da" ], "spl_set_id": [ "6c6ab831-6234-4803-8a01-5c51ec3b0716" ], "package_ndc": [ "68001-573-41" ], "nui": [ "N0000000233", "N0000175595" ], "pharm_class_moa": [ "Nucleic Acid Synthesis Inhibitors [MoA]" ], "pharm_class_epc": [ "Nucleoside Metabolic Inhibitor [EPC]" ], "unii": [ "776B62CQ27" ] }, "update_date": "02/20/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Decitabine, Injection, 50 mg (NDC 68001-573-41)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "11/21/2023", "package_ndc": "0641-6083-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "This presentation is temporarily on backorder. Expected in October 2026 timeframe", "openfda": { "application_number": [ "ANDA083312" ], "brand_name": [ "PHENERGAN" ], "generic_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6083", "0641-6082" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "rxcui": [ "992460", "992462", "992858", "992876" ], "spl_id": [ "a64f0625-8d56-4994-8908-13614ca7b09f" ], "spl_set_id": [ "6f7e47cc-f823-4336-8107-f980e3049617" ], "package_ndc": [ "0641-6082-01", "0641-6082-25", "0641-6083-01", "0641-6083-25" ], "unii": [ "R61ZEH7I1I" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy" ], "dosage_form": "Injection", "presentation": "Phenergan, Injection, 50 mg/1 mL (NDC 0641-6083-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "06/12/2026", "package_ndc": "0338-3991-01", "generic_name": "Ifosfamide Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: October 2026", "openfda": { "application_number": [ "NDA019763" ], "brand_name": [ "IFEX" ], "generic_name": [ "IFOSFAMIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-3991", "0338-3993" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "IFOSFAMIDE" ], "rxcui": [ "1791588", "1791591", "1791593", "1791595" ], "spl_id": [ "56f50d8e-7c87-4119-a7dc-bfd77fa3dcec" ], "spl_set_id": [ "b7241707-7538-4d1a-91e7-3a25a91e0b9a" ], "package_ndc": [ "0338-3991-01", "0338-3993-01" ], "nui": [ "N0000000236", "N0000175558" ], "pharm_class_moa": [ "Alkylating Activity [MoA]" ], "pharm_class_epc": [ "Alkylating Drug [EPC]" ], "unii": [ "UM20QQM95Y" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Oncology", "Pediatric" ], "dosage_form": "Injection", "presentation": "IFEX, Injection, 1 g/20 mL (NDC 0338-3991-01)", "company_name": "Baxter Healthcare", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0430-51", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA020183" ], "brand_name": [ "DIANEAL LOW CALCIUM WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0430", "0941-0411", "0941-0413", "0941-0415", "0941-0409", "0941-0457", "0941-0459", "0941-0426", "0941-0427", "0941-0429", "0941-0424", "0941-0433", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0430-51)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "72078-036-05", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "NDA020630" ], "brand_name": [ "ULTIVA" ], "generic_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "manufacturer_name": [ "Mylan Institutional LLC" ], "product_ndc": [ "72078-036", "72078-034", "72078-035" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "rxcui": [ "1729578", "1729581", "1729584", "1729586", "1729710", "1729712" ], "spl_id": [ "f41b6542-9305-43e7-bbbc-52c7ee2cb0dc" ], "spl_set_id": [ "8b4c8696-e23e-4c51-a4d2-babab5bd945a" ], "package_ndc": [ "72078-034-00", "72078-034-01", "72078-035-00", "72078-035-02", "72078-036-00", "72078-036-05" ], "unii": [ "5V444H5WIC" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ultiva, Injection, 5 mg (NDC 72078-036-05)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current" }, { "discontinued_date": "08/10/2026", "update_type": "New", "initial_posting_date": "08/10/2026", "package_ndc": "0093-9477-53", "generic_name": "Glyburide Tablet", "contact_info": "800-633-1610", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA017532" ], "brand_name": [ "GLYBURIDE" ], "generic_name": [ "GLYBURIDE" ], "manufacturer_name": [ "TEVA Pharmaceuticals USA Inc" ], "product_ndc": [ "0093-9477", "0093-9433", "0093-9364" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "GLYBURIDE" ], "rxcui": [ "197737", "310534", "310537" ], "spl_id": [ "84b83205-8813-494e-933e-a70697393744" ], "spl_set_id": [ "50d16f1d-c814-4411-8749-62561321ecce" ], "package_ndc": [ "0093-9477-53", "0093-9433-01", "0093-9433-05", "0093-9364-01", "0093-9364-05", "0093-9364-10" ], "nui": [ "N0000175608", "M0020795" ], "pharm_class_epc": [ "Sulfonylurea [EPC]" ], "pharm_class_cs": [ "Sulfonylurea Compounds [CS]" ], "unii": [ "SX6K58TVWC" ] }, "update_date": "08/10/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Tablet", "presentation": "Diabeta, Tablet, 1.25 mg (NDC 0093-9477-53)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1660-20", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA021038" ], "brand_name": [ "PRECEDEX" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1660", "0409-1638", "0409-1434", "0409-1596", "0409-7838", "0409-7853", "0409-7875" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892" ], "spl_id": [ "3c5274fd-6597-4b88-babc-92e4e16c6329" ], "spl_set_id": [ "548a88c0-afda-427e-75ac-5af0cfa2224c" ], "package_ndc": [ "0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Precedex, Injection, 80 mcg/20 mL (4 mcg/mL) (NDC 0409-1660-20)", "company_name": "Pfizer Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "43547-413-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-931-9829", "availability": "Unavailable", "related_info": "Not available. Long-term backorder for all NDCs. No estimated release date at this time.", "openfda": { "application_number": [ "ANDA205823" ], "brand_name": [ "QUINAPRIL" ], "generic_name": [ "QUINAPRIL" ], "manufacturer_name": [ "Solco Healthcare US, LLC" ], "product_ndc": [ "43547-413", "43547-410", "43547-411", "43547-412" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE" ], "rxcui": [ "312748", "312749", "312750", "314203" ], "spl_id": [ "b8f1731a-cbac-4f64-a8d4-320b80b335e1" ], "spl_set_id": [ "cd46691d-5593-4a9f-a937-999c6803e312" ], "package_ndc": [ "43547-410-09", "43547-411-09", "43547-412-09", "43547-413-09" ], "unii": [ "33067B3N2M" ] }, "update_date": "06/29/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 40 mg (NDC 43547-413-09)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "discontinued_date": "05/21/2026", "update_type": "New", "initial_posting_date": "05/21/2026", "package_ndc": "67457-957-99", "generic_name": "Iron Sucrose Injection", "contact_info": "800-796-9526", "related_info": "A business decision has been made to discontinue of 2.5mL presentation only. Continuity of supply is forecasted across all other presentations of Iron Sucrose: 67457-639-10 Iron Sucrose 20mg/mL 10mL SDV 5PK 67457-638-10 Iron Sucrose 20mg/mL 5mL SDV 10PK 67457-638-25 Iron Sucrose 20mg/mL 5mL SDV 25PK.", "openfda": { "application_number": [ "ANDA212559" ], "brand_name": [ "IRON SUCROSE" ], "generic_name": [ "IRON SUCROSE" ], "manufacturer_name": [ "Mylan Institutional LLC" ], "product_ndc": [ "67457-957", "67457-638", "67457-639" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "IRON SUCROSE" ], "rxcui": [ "1741261", "1741267", "1741270" ], "spl_id": [ "3f109bdb-a412-43b2-84c7-9dad05e85a71" ], "spl_set_id": [ "3f109bdb-a412-43b2-84c7-9dad05e85a71" ], "package_ndc": [ "67457-957-00", "67457-957-99", "67457-957-25", "67457-638-00", "67457-638-10", "67457-638-25", "67457-639-00", "67457-639-10", "67457-639-99" ], "nui": [ "M0011718", "N0000177913" ], "pharm_class_cs": [ "Iron [CS]" ], "pharm_class_epc": [ "Parenteral Iron Replacement [EPC]" ], "unii": [ "FZ7NYF5N8L" ] }, "update_date": "05/21/2026", "therapeutic_category": [ "Hematology" ], "dosage_form": "Injection", "presentation": "Iron Sucrose, Injection, 50 mg/2.5 mL (NDC 67457-957-99)", "company_name": "Mylan Institutional, a Viatris Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "16729-138-16", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": { "application_number": [ "ANDA077147" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Accord Healthcare Inc." ], "product_ndc": [ "16729-138", "16729-136", "16729-137" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "0e1e7f41-f78b-27cf-e063-6394a90a1ae0" ], "spl_set_id": [ "ebc11109-e7bf-452d-b675-4b3236d54164" ], "package_ndc": [ "16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 16729-138-16)", "company_name": "Accord Healthcare Inc.", "status": "Current" }, { "discontinued_date": "05/05/2026", "update_type": "New", "initial_posting_date": "05/05/2026", "package_ndc": "71288-728-32", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-824-8426", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "05/05/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0372-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": { "application_number": [ "ANDA202827" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0054-0372", "0054-0660", "0054-0370", "0054-0371", "0054-0373", "0054-0374", "0054-0375" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "ccd9e87c-bd03-4fe0-8129-41c1ced49c8d" ], "spl_set_id": [ "6740a621-9bec-4178-a4fc-a3fc89f34e0a" ], "package_ndc": [ "0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0054-0372-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "discontinued_date": "10/07/2025", "update_type": "New", "initial_posting_date": "10/07/2025", "package_ndc": "0074-9037-30", "generic_name": "Paricalcitol Capsule", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA021606" ], "brand_name": [ "ZEMPLAR" ], "generic_name": [ "PARICALCITOL" ], "manufacturer_name": [ "AbbVie Inc." ], "product_ndc": [ "0074-9037", "0074-4314", "0074-4317", "0074-9036" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "PARICALCITOL" ], "rxcui": [ "577315", "577317", "606854", "606859" ], "spl_id": [ "61ef39c0-0c32-4b82-962e-8ebdd55ce427" ], "spl_set_id": [ "1b27c026-2d60-47b4-2a9c-ded1818f21b5" ], "package_ndc": [ "0074-4314-30", "0074-4317-30", "0074-4317-73", "0074-9036-30", "0074-9037-30" ], "nui": [ "M0007651", "N0000175907", "N0000175849" ], "pharm_class_cs": [ "Ergocalciferols [CS]" ], "pharm_class_epc": [ "Vitamin D2 Analog [EPC]", "Vitamin D Analog [EPC]" ], "unii": [ "6702D36OG5" ] }, "update_date": "10/07/2025", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Capsule", "presentation": "Zemplar, Capsule, 2 ug (NDC 0074-9037-30)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "42806-341-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(718) 276-8600 ext. 3", "availability": "Available", "openfda": { "application_number": [ "ANDA040444" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Epic Pharma, LLC" ], "product_ndc": [ "42806-341", "42806-339", "42806-343", "42806-344", "42806-345" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961" ], "spl_id": [ "f11301e2-3b5d-468d-b44c-45839e7e5dfb" ], "spl_set_id": [ "1757e132-061d-4773-89ed-fdc77f69008f" ], "package_ndc": [ "42806-339-01", "42806-341-01", "42806-343-01", "42806-344-01", "42806-345-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 42806-341-01)", "company_name": "Epic Pharma, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/24/2017", "package_ndc": "51754-5011-4", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "828-758-5474 ext. 154", "availability": "Available", "openfda": { "application_number": [ "ANDA211091" ], "brand_name": [ "SODIUM BICARBONATE" ], "generic_name": [ "SODIUM BICARBONATE" ], "manufacturer_name": [ "Exela Pharma Sciences, LLC" ], "product_ndc": [ "51754-5011", "51754-5001", "51754-5002", "51754-5012" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM BICARBONATE" ], "rxcui": [ "807284", "1868486", "1923484", "2198792" ], "spl_id": [ "4da0ba66-756d-4b4d-8018-81ca16578ef1" ], "spl_set_id": [ "e9698a4f-1a95-4f28-a945-e8009d1d6dd4" ], "package_ndc": [ "51754-5001-5", "51754-5001-4", "51754-5011-4", "51754-5002-5", "51754-5012-4" ], "unii": [ "8MDF5V39QO" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 51754-5011-4)", "company_name": "Exela Pharma Sciences, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "61703-262-05", "generic_name": "Carboplatin Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA076517" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "61703-262", "61703-360", "61703-150", "61703-600" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "5aa72c15-8033-4559-b257-373371b18958" ], "spl_set_id": [ "47677091-fd20-49af-933c-c9dd2be21de9" ], "package_ndc": [ "61703-360-18", "61703-150-05", "61703-262-05", "61703-600-05" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) (NDC 61703-262-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-652-82", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Available", "related_info": "Marketed by Sagent Pharmaceuticals", "openfda": { "application_number": [ "ANDA206166" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-652", "25021-671" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734347", "1734355", "1734479", "1734481" ], "spl_id": [ "41f4446a-ca6e-465e-9a79-8c4f99eb1ac3" ], "spl_set_id": [ "8c5c762f-d266-4b1a-809e-f11bfc89bc2d" ], "package_ndc": [ "25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87" ], "unii": [ "V910P86109" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-652-82)", "company_name": "InfoRLife SA", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "25021-655-02", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "Avet Pharmaceuticals, Inc.: 855-228-9470; Sagent Pharmaceuticals: 866-625-1618", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals", "openfda": { "application_number": [ "ANDA090696" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-655" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "1666798" ], "spl_id": [ "943346c0-d98e-4ac2-a1a2-75427decf2fc" ], "spl_set_id": [ "e22611dd-1830-40af-9139-7cdb07f5a426" ], "package_ndc": [ "25021-655-02" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 25021-655-02)", "company_name": "Gland Pharma Limited", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-0155-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA021038" ], "brand_name": [ "PRECEDEX" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-0155", "0409-4596" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718907", "1718909", "1718910" ], "spl_id": [ "b62d8928-1ce3-488e-a89f-d7085c5510a7" ], "spl_set_id": [ "92b7ddaa-e45a-4b64-a802-bb5df8771dd6" ], "package_ndc": [ "0409-4596-01", "0409-4596-20", "0409-0155-01", "0409-0155-02" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-0155-02)", "company_name": "Pfizer Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "55150-225-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA206206" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-225", "55150-226" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "1bb59a7e-d219-466c-abae-8a0680af9b8c" ], "spl_set_id": [ "116385ea-69fc-4f44-b463-6210291032df" ], "package_ndc": [ "55150-225-05", "55150-226-10" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 55150-225-05)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-485-57", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-485", "63323-492", "63323-491", "63323-495", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428", "0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17", "4dd52202-8eef-4136-92dd-ada573b7cf74" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31", "63323-492-41", "63323-492-16", "63323-492-43", "63323-492-36", "63323-492-45", "63323-492-26", "63323-485-41", "63323-485-26", "63323-486-41", "63323-486-26", "63323-482-41", "63323-482-26", "63323-495-41", "63323-495-26" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "06/30/2026", "update_type": "New", "initial_posting_date": "06/30/2026", "package_ndc": "0781-3421-94", "generic_name": "Caspofungin Acetate Injection", "contact_info": "Sandoz: 800-525-8747", "related_info": "Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA200833" ], "brand_name": [ "CASPOFUNGIN ACETATE" ], "generic_name": [ "CASPOFUNGIN ACETATE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-3421", "0781-3423" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CASPOFUNGIN ACETATE" ], "rxcui": [ "828539", "828755" ], "spl_id": [ "d70d52c0-6601-f632-e053-2995a90a9291" ], "spl_set_id": [ "722facc6-d4ea-4975-b83e-3ae63df69ed2" ], "package_ndc": [ "0781-3421-01", "0781-3421-94", "0781-3423-01", "0781-3423-94" ], "unii": [ "VUW370O5QE" ] }, "update_date": "06/30/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Caspofungin Acetate, Injection, 5 mg/1 mL (NDC 0781-3421-94)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-288-11", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-288", "63323-286", "63323-287", "63323-285" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484" ], "spl_id": [ "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c", "75465ceb-e894-487d-aa80-671fa0841fce" ], "spl_set_id": [ "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6", "56dfabf7-f7a8-4601-b17a-cb16fb995b0f" ], "package_ndc": [ "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95", "63323-288-25", "63323-288-27" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 10 mg/1 mL (NDC 63323-288-11)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/14/2017", "package_ndc": "0264-9872-10", "generic_name": "Heparin Sodium Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "NDA019953" ], "brand_name": [ "HEPARIN SODIUM IN SODIUM CHLORIDE" ], "generic_name": [ "HEPARIN SODIUM IN SODIUM CHLORIDE" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-9872" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "HEPARIN SODIUM" ], "rxcui": [ "1658690", "1658692" ], "spl_id": [ "48e17807-e73d-4ea2-81bc-901355903aa7" ], "spl_set_id": [ "a3041c04-0ea8-4d36-81ce-c5091c906316" ], "package_ndc": [ "0264-9872-10", "0264-9872-00" ], "unii": [ "ZZ45AB24CA" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Hematology" ], "dosage_form": "Injection", "presentation": "Heparin Sodium 1,000 Units In Sodium Chloride 0.9% In Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-10)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "63323-824-75", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA209448" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-824" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481" ], "spl_id": [ "0591ab74-99a6-40ee-af96-80bc2ef423dc" ], "spl_set_id": [ "3b8f2692-4371-4f1a-95af-b41842131fdd" ], "package_ndc": [ "63323-824-24", "63323-824-74", "63323-824-25", "63323-824-75", "63323-824-26", "63323-824-76" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 mg/1 mL (NDC 63323-824-75)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-061-25", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": { "application_number": [ "ANDA207636" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-061", "70069-062", "70069-063", "70069-064", "70069-065", "70069-066", "70069-067" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483" ], "spl_id": [ "79b226f0-c08a-4f84-bf2b-ae5c60e01d67" ], "spl_set_id": [ "ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64" ], "package_ndc": [ "70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10" ], "unii": [ "V910P86109" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-061-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6854-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA202835" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE" ], "manufacturer_name": [ "Mylan Pharmaceuticals Inc." ], "product_ndc": [ "0378-6854", "0378-6855", "0378-6856", "0378-6857", "0378-6858", "0378-6859", "0378-6860" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "6e77cd71-95ae-4fa8-830b-ab62b714e4b9" ], "spl_set_id": [ "efbde0f6-b848-4664-b741-c6c630e66108" ], "package_ndc": [ "0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0378-6854-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0644-06", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA018931" ], "brand_name": [ "TRAVASOL" ], "generic_name": [ "LEUCINE, PHENYLALANINE, LYSINE HYDROCHLORIDE, METHIONINE, ISOLEUCINE, VALINE, HISTIDINE, THREONINE, TRYPTOPHAN, ALANINE, GLYCINE, ARGININE, PROLINE, TYROSINE, SERINE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0644" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LEUCINE", "PHENYLALANINE", "LYSINE HYDROCHLORIDE", "METHIONINE", "ISOLEUCINE", "VALINE", "HISTIDINE", "THREONINE", "TRYPTOPHAN", "ALANINE", "GLYCINE", "ARGININE", "PROLINE", "TYROSINE", "SERINE" ], "rxcui": [ "801644", "801648" ], "spl_id": [ "e0279078-016d-48fd-8de1-c894422b33ff" ], "spl_set_id": [ "8543b5be-0f43-4891-9e56-d7c39fe839b5" ], "package_ndc": [ "0338-0644-03", "0338-0644-04", "0338-0644-06" ], "nui": [ "N0000175780", "M0000922" ], "pharm_class_epc": [ "Amino Acid [EPC]" ], "pharm_class_cs": [ "Amino Acids [CS]" ], "unii": [ "GMW67QNF9C", "47E5O17Y3R", "JNJ23Q2COM", "AE28F7PNPL", "04Y7590D77", "HG18B9YRS7", "4QD397987E", "2ZD004190S", "8DUH1N11BX", "OF5P57N2ZX", "TE7660XO1C", "94ZLA3W45F", "9DLQ4CIU6V", "42HK56048U", "452VLY9402" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "Travasol, Injection, 2.07 g/100 mL; 1.15 g/100 mL; 1.03 g/100 mL; 480 mg/100 mL; 600 mg/100 mL; 730 mg/100 mL; 580 mg/100 mL; 400 mg/100 mL; 560 mg/100 mL; 680 mg/100 mL; 500 mg/100 mL; 420 mg/100 mL; 180 mg/100 mL; 40 mg/100 mL; 580 mg/100 mL (NDC 0338-0644-06)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0641-6147-10", "generic_name": "Sterile Water Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be scheduled for manufacturing. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA206369" ], "brand_name": [ "STERILE WATER" ], "generic_name": [ "WATER" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6147" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "WATER" ], "spl_id": [ "081540ac-58cf-437f-ba1b-86d5264ec3dc" ], "spl_set_id": [ "78ef7ad3-451d-43d0-a9b6-5cf0aadca003" ], "package_ndc": [ "0641-6147-01", "0641-6147-10", "0641-6147-25" ], "unii": [ "059QF0KO0R" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0641-6147-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "72516-011-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "855-257-0292", "availability": "Unavailable", "related_info": "Estimated availability April 2027", "openfda": { "application_number": [ "ANDA210293" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Oryza Pharmaceuticals Inc." ], "product_ndc": [ "72516-011", "72516-016", "72516-015", "72516-014", "72516-013", "72516-012" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "1009145" ], "spl_id": [ "5734011d-5044-b490-e063-6394a90a3174" ], "spl_set_id": [ "acd27181-a3f3-4c38-85d8-029a4a82e7c2" ], "package_ndc": [ "72516-016-01", "72516-015-01", "72516-014-01", "72516-013-01", "72516-012-01", "72516-011-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 72516-011-01)", "company_name": "Oryza Pharmaceuticals Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "discontinued_date": "12/01/2025", "update_type": "New", "initial_posting_date": "12/01/2025", "package_ndc": "59212-111-14", "generic_name": "Nilutamide Tablet", "contact_info": "847-283-7921", "related_info": "Product to expire in March 2026; Discontinuation of the manufacture of the drug", "update_date": "12/01/2025", "therapeutic_category": [ "Oncology" ], "dosage_form": "Tablet", "presentation": "Nilandron, Tablet, 150 mg (NDC 59212-111-14)", "company_name": "Advanz Pharma (US) Corp.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7922-09", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Available", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA016367" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "ICU Medical, Inc." ], "product_ndc": [ "0990-7922", "0990-7923", "0990-7930" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621" ], "spl_id": [ "06e4d957-1a56-4adb-a42b-fe0773b2fa97" ], "spl_set_id": [ "8b25b7e0-703e-4b43-a4eb-52863511602d" ], "package_ndc": [ "0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7922-09)", "company_name": "Otsuka ICU Medical LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-288-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-288", "63323-286", "63323-287", "63323-285" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484" ], "spl_id": [ "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c", "75465ceb-e894-487d-aa80-671fa0841fce" ], "spl_set_id": [ "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6", "56dfabf7-f7a8-4601-b17a-cb16fb995b0f" ], "package_ndc": [ "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95", "63323-288-25", "63323-288-27" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 10 mg/1 mL (NDC 63323-288-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-02", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA016673" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0017", "0338-0023" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618" ], "spl_id": [ "9c644eb4-5844-415a-8c01-4459d98af222" ], "spl_set_id": [ "3bb406a9-f5cb-403a-b1bb-5c4facbea3d5" ], "package_ndc": [ "0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-02)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0338-9553-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA208083" ], "brand_name": [ "CLINDAMYCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "0338-9553", "0338-9545", "0338-9549" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "309335", "309336", "309339" ], "spl_id": [ "b0a47c5e-911b-4b12-a0d1-a4425f173eec" ], "spl_set_id": [ "44fa506b-90ac-42de-831b-5f3f1a500fc0" ], "package_ndc": [ "0338-9545-50", "0338-9545-24", "0338-9549-50", "0338-9549-24", "0338-9553-50", "0338-9553-24" ], "unii": [ "EH6D7113I8" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0306-02", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA011757" ], "brand_name": [ "DEPO-MEDROL" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0306", "0009-0274", "0009-0280" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1358510", "1358512", "1358610", "1358612", "1358617", "1358619" ], "spl_id": [ "267dd735-f800-4735-ba1c-d39d00f0cee5" ], "spl_set_id": [ "823b0010-2b57-4e76-b5ac-4a8c2963438f" ], "package_ndc": [ "0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-02)", "company_name": "Pfizer Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "25021-701-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "833-291-9645", "availability": "Available", "openfda": { "application_number": [ "ANDA204216" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-701", "25021-700" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "cb23332a-48fa-458b-93ab-c4eef189a051" ], "spl_set_id": [ "62591551-a644-4b2c-a0de-982e906fabc3" ], "package_ndc": [ "25021-700-01", "25021-701-01", "25021-701-02" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-01)", "company_name": "Gland Pharma Limited", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-195-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": { "application_number": [ "ANDA209799" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "SUNRISE PHARMACEUTICAL, INC." ], "product_ndc": [ "11534-195", "11534-190", "11534-191", "11534-192", "11534-193", "11534-194", "11534-196" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "60dcfbf6-d07a-4010-ae77-8a9ae4529828" ], "spl_set_id": [ "ac102599-3a5b-4154-899e-6ff262be7ff7" ], "package_ndc": [ "11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/16/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 11534-195-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current" }, { "discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "60951-700-70", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA040330" ], "brand_name": [ "ENDOCET" ], "generic_name": [ "OXYCODONE AND ACETAMINOPHEN" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "60951-700", "60951-602", "60951-712", "60951-701" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OXYCODONE HYDROCHLORIDE", "ACETAMINOPHEN" ], "rxcui": [ "1049214", "1049216", "1049221", "1049223", "1049225", "1049227", "1049635", "1487288" ], "spl_id": [ "a8475489-982f-4080-9565-7948155d9abb" ], "spl_set_id": [ "944d3e60-7eee-11de-a413-0002a5d5c51b" ], "package_ndc": [ "60951-602-70", "60951-602-85", "60951-700-70", "60951-712-70", "60951-701-70" ], "unii": [ "C1ENJ2TE6C", "362O9ITL9D" ] }, "update_date": "11/03/2025", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 7.5 mg (NDC 60951-700-70)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-153-00", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": { "application_number": [ "ANDA075468" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Advagen Pharma Ltd" ], "product_ndc": [ "72888-153", "72888-497", "72888-152", "72888-154" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529", "204892" ], "spl_id": [ "5510f17b-a980-f412-e063-6394a90ae1c4" ], "spl_set_id": [ "30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec" ], "package_ndc": [ "72888-497-01", "72888-497-02", "72888-497-03", "72888-497-04", "72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 72888-153-00)", "company_name": "Rubicon Research Private Limited", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1165-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA070585" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1165", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-9043", "0409-9046", "0409-9045", "0409-9042" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "RETROBULBAR" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596" ], "spl_id": [ "6e442bfd-d3da-4913-8585-ce3485644364" ], "spl_set_id": [ "02a845c3-4521-4926-e397-25ab536e7cf6" ], "package_ndc": [ "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 0409-1165-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-102-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": { "application_number": [ "NDA021977" ], "brand_name": [ "VYVANSE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "59417-102", "59417-101", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469" ], "spl_id": [ "81d087b6-4cb4-466a-9693-679edeb062e2" ], "spl_set_id": [ "704e4378-ca83-445c-8b45-3cfa51c1ecad" ], "package_ndc": [ "59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 20 mg (NDC 59417-102-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current" }, { "discontinued_date": "10/24/2025", "update_type": "New", "initial_posting_date": "10/24/2025", "package_ndc": "0002-8235-99", "generic_name": "Insulin Lispro-aabc Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "BLA761109" ], "brand_name": [ "LYUMJEV TEMPO PEN" ], "generic_name": [ "INSULIN LISPRO-AABC" ], "manufacturer_name": [ "Eli Lilly and Company" ], "product_ndc": [ "0002-8235", "0002-7728", "0002-7726", "0002-8207", "0002-8351", "0002-8228" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "INSULIN LISPRO" ], "rxcui": [ "2380231", "2380236", "2380248", "2380250", "2380254", "2380256", "2380259", "2380260", "2380265", "2380266", "2380267", "2380268" ], "spl_id": [ "965b6bd6-37d4-451e-8c41-4df16df442d1" ], "spl_set_id": [ "c5a056e2-b568-4ca6-9ed8-79c010942d00" ], "package_ndc": [ "0002-7728-01", "0002-7728-99", "0002-7726-01", "0002-7726-05", "0002-8207-01", "0002-8207-05", "0002-8207-61", "0002-8351-01", "0002-8351-05", "0002-8235-01", "0002-8235-05", "0002-8235-99", "0002-8228-01", "0002-8228-27" ], "nui": [ "N0000004931", "N0000175453" ], "pharm_class_cs": [ "Insulin [Chemical/Ingredient]" ], "pharm_class_epc": [ "Insulin Analog [EPC]" ], "unii": [ "GFX7QIS1II" ] }, "update_date": "10/24/2025", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Lyumjev, Injection, U-100 Tempo Pen Sample (NDC 0002-8235-99)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued" }, { "discontinued_date": "08/13/2026", "update_type": "New", "initial_posting_date": "08/13/2026", "package_ndc": "0228-2550-96", "generic_name": "Diclofenac Sodium Tablet, Delayed Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA074514" ], "brand_name": [ "DICLOFENAC SODIUM" ], "generic_name": [ "DICLOFENAC SODIUM" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0228-2550", "0228-2551" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DICLOFENAC SODIUM" ], "rxcui": [ "855906", "855926" ], "spl_id": [ "a1fbc994-b8a6-4759-be76-1cfd98275ca6" ], "spl_set_id": [ "a57b897e-0cbe-4ac3-969f-b00357a0cfa8" ], "package_ndc": [ "0228-2550-06", "0228-2550-11", "0228-2550-96", "0228-2551-06", "0228-2551-11", "0228-2551-96" ], "unii": [ "QTG126297Q" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Musculoskeletal", "Rheumatology" ], "dosage_form": "Tablet", "presentation": "Diclofenac Sodium, Tablet, Delayed Release, 50 mg (NDC 0228-2550-96)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4900-14", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 0409-4900-14)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "New", "initial_posting_date": "04/10/2020", "package_ndc": "70069-759-04", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": { "application_number": [ "ANDA218112" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-759", "70069-758" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1788947" ], "spl_id": [ "6a1a2c33-1467-4eb0-adc6-6e21771fbf6b" ], "spl_set_id": [ "649e777b-9b30-4f1e-9fb9-6bba57580976" ], "package_ndc": [ "70069-758-04", "70069-759-04" ], "unii": [ "1018WH7F9I" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 70069-759-04)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0426-52", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA020163" ], "brand_name": [ "DIANEAL PD-2 WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0426", "0941-0411", "0941-0413", "0941-0415", "0941-0409", "0941-0457", "0941-0459", "0941-0427", "0941-0429", "0941-0424", "0941-0430", "0941-0433", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0426-52)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-551-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA218604" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Elite Laboratories, Inc." ], "product_ndc": [ "64850-551", "64850-550", "64850-552", "64850-553", "64850-554", "64850-555", "64850-556" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "2d33f701-8067-4a48-98cc-4e7dacaf3cc4" ], "spl_set_id": [ "0e024b69-567c-4b40-9c3e-a2daec34256c" ], "package_ndc": [ "64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 64850-551-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "discontinued_date": "03/27/2026", "update_type": "New", "initial_posting_date": "03/27/2026", "package_ndc": "0023-6150-04", "generic_name": "Progesterone Vaginal Gel", "contact_info": "800-678-1605", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA020701" ], "brand_name": [ "CRINONE" ], "generic_name": [ "PROGESTERONE" ], "manufacturer_name": [ "Allergan, Inc." ], "product_ndc": [ "0023-6150", "0023-6151" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "VAGINAL" ], "substance_name": [ "PROGESTERONE" ], "rxcui": [ "153579", "153580", "312643", "312645" ], "spl_id": [ "ab1523af-0bbb-4231-a12c-ac52e3ec91cd" ], "spl_set_id": [ "75e97aa1-daa4-45f9-b2e2-1a371302914e" ], "package_ndc": [ "0023-6150-04", "0023-6151-08" ], "nui": [ "M0017672", "N0000175601" ], "pharm_class_cs": [ "Progesterone [CS]" ], "pharm_class_epc": [ "Progesterone [EPC]" ], "unii": [ "4G7DS2Q64Y" ] }, "update_date": "03/27/2026", "therapeutic_category": [ "Urology" ], "dosage_form": "Vaginal Gel", "presentation": "Crinone, Vaginal Gel, 4% (NDC 0023-6150-04)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-9104-20", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA018132" ], "brand_name": [ "DOPAMINE HYDROCHLORIDE" ], "generic_name": [ "DOPAMINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-9104", "0409-5820" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOPAMINE HYDROCHLORIDE" ], "rxcui": [ "1743938", "1743941" ], "spl_id": [ "7a125e39-1ecb-4c76-931a-efc9b5921d1c" ], "spl_set_id": [ "1f306ad2-3606-4525-5a8a-ce78f426c1a2" ], "package_ndc": [ "0409-5820-11", "0409-5820-01", "0409-9104-21", "0409-9104-20" ], "unii": [ "7L3E358N9L" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride, Injection, 400 mg/10mL (40 mg/1 mL) (NDC 0409-9104-20)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "discontinued_date": "01/20/2026", "update_type": "New", "initial_posting_date": "01/20/2026", "package_ndc": "0069-3150-83", "generic_name": "Azithromycin Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": { "application_number": [ "NDA050733" ], "brand_name": [ "ZITHROMAX" ], "generic_name": [ "AZITHROMYCIN DIHYDRATE" ], "manufacturer_name": [ "Pfizer Laboratories Div Pfizer Inc" ], "product_ndc": [ "0069-3150" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "AZITHROMYCIN DIHYDRATE" ], "rxcui": [ "1668238", "1668240" ], "spl_id": [ "73a19258-3cc4-49b1-8f18-e17fd418fe36" ], "spl_set_id": [ "3b631aa1-2d46-40bc-a614-d698301ea4f9" ], "package_ndc": [ "0069-3150-84", "0069-3150-83" ], "unii": [ "5FD1131I7S" ] }, "update_date": "01/20/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Zithromax IV, Injection, 500 mg/5 mL (NDC 0069-3150-83)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0990-7923-36", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Available", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA016367" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "ICU Medical, Inc." ], "product_ndc": [ "0990-7923", "0990-7922", "0990-7930" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621" ], "spl_id": [ "06e4d957-1a56-4adb-a42b-fe0773b2fa97" ], "spl_set_id": [ "8b25b7e0-703e-4b43-a4eb-52863511602d" ], "package_ndc": [ "0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0990-7923-36)", "company_name": "Otsuka ICU Medical LLC", "status": "Current" }, { "discontinued_date": "06/01/2026", "update_type": "New", "initial_posting_date": "06/01/2026", "package_ndc": "0009-3051-02", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA050441" ], "brand_name": [ "CLEOCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-3051", "0009-4073", "0009-5095" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "1737244", "1737245", "1737578", "1737579", "1737581", "1737582" ], "spl_id": [ "8d0dac99-6ec9-4648-8ae1-0cc2894d56cf" ], "spl_set_id": [ "a0a2eff7-b7de-42fe-8e5a-0cfbed38bb4b" ], "package_ndc": [ "0009-3051-01", "0009-3051-02", "0009-4073-03", "0009-4073-04", "0009-5095-05", "0009-5095-06" ], "unii": [ "EH6D7113I8" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, 300 mg/2 mL (150 mg/mL); 2 mL Vial NovaPlus (NDC 0009-3051-02)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/28/2025", "package_ndc": "0574-2410-65", "generic_name": "Methylphenidate Film, Extended Release", "contact_info": "800-455-8070", "availability": "Available", "related_info": "Available. Distributed by Padagis US LLC", "openfda": { "application_number": [ "NDA021514" ], "brand_name": [ "METHYLPHENIDATE TRANSDERMAL SYSTEM" ], "generic_name": [ "METHYLPHENIDATE" ], "manufacturer_name": [ "PADAGIS US LLC" ], "product_ndc": [ "0574-2410", "0574-2415", "0574-2420", "0574-2430" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "TRANSDERMAL" ], "substance_name": [ "METHYLPHENIDATE" ], "rxcui": [ "753436", "753438", "753440", "753441" ], "spl_id": [ "b743ef45-2fc0-4086-8a02-6078e6a09eaa" ], "spl_set_id": [ "7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb" ], "package_ndc": [ "0574-2410-65", "0574-2415-65", "0574-2420-65", "0574-2430-65" ], "nui": [ "N0000175739", "N0000175729" ], "pharm_class_epc": [ "Central Nervous System Stimulant [EPC]" ], "pharm_class_pe": [ "Central Nervous System Stimulation [PE]" ], "unii": [ "207ZZ9QZ49" ] }, "update_date": "08/15/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Film, Extended Release", "presentation": "Methylphenidate, Film, Extended Release, 10 mg (NDC 0574-2410-65)", "company_name": "Noven Pharmaceuticals, Inc.", "status": "Current" }, { "discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-0530-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 10 mg (NDC 0071-0530-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "10/05/2022", "package_ndc": "0409-6695-02", "generic_name": "Etomidate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: November 2026; Estimated Recovery: December 2026. Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA018227" ], "brand_name": [ "AMIDATE" ], "generic_name": [ "ETOMIDATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-6695" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008", "1654009", "1654011" ], "spl_id": [ "3f83ed21-1b60-486c-8c70-1d5aa7553404" ], "spl_set_id": [ "b7ed5bf8-ba75-44dc-8f81-96b4ad5766be" ], "package_ndc": [ "0409-6695-11", "0409-6695-01", "0409-6695-12", "0409-6695-02" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Amidate, Injection, 2 mg/mL (NDC 0409-6695-02)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "12/13/2017", "package_ndc": "72205-101-01", "generic_name": "Bumetanide Injection", "contact_info": "855-668-2369; customerservice@novadozpharma.com", "availability": "Available", "related_info": "Distributed by: Novadoz Pharmaceuticals LLC", "openfda": { "application_number": [ "ANDA215364" ], "brand_name": [ "BUMETANIDE" ], "generic_name": [ "BUMETANIDE" ], "manufacturer_name": [ "Novadoz Pharmaceuticals LLC" ], "product_ndc": [ "72205-101", "72205-102" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "BUMETANIDE" ], "rxcui": [ "282486", "1727569" ], "spl_id": [ "387edfd4-be85-41cd-8a6d-14e6a022b5a9" ], "spl_set_id": [ "387edfd4-be85-41cd-8a6d-14e6a022b5a9" ], "package_ndc": [ "72205-101-01", "72205-101-07", "72205-102-01", "72205-102-07" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "0Y2S3XUQ5H" ] }, "update_date": "08/21/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, 0.25 mg/mL, 4mL (NDC 72205-101-01)", "company_name": "MSN Laboratories Private Limited", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-711-30", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": { "application_number": [ "NDA216117" ], "brand_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Trigen Laboratories, LLC" ], "product_ndc": [ "13811-711", "13811-700" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "2605796", "2605798" ], "spl_id": [ "ba649db4-df0d-4587-8370-3f866e66e54b" ], "spl_set_id": [ "dd8d7b6e-c23d-4e16-bb53-959e9127ebc6" ], "package_ndc": [ "13811-711-30", "13811-700-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "06/30/2026", "update_type": "New", "initial_posting_date": "06/30/2026", "package_ndc": "65219-281-02", "generic_name": "Gadobutrol Injection", "contact_info": "888-386-1300", "related_info": "Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA", "openfda": { "application_number": [ "ANDA215061" ], "brand_name": [ "GADOBUTROL" ], "generic_name": [ "GADOBUTROL" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-281" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GADOBUTROL" ], "spl_id": [ "490c8c3e-3195-40af-8f34-40d8df2719c3" ], "spl_set_id": [ "007696d0-4b62-4937-9640-4ad619504df4" ], "package_ndc": [ "65219-281-00", "65219-281-02", "65219-281-03", "65219-281-07", "65219-281-08", "65219-281-10", "65219-281-05", "65219-281-15" ], "nui": [ "N0000183362", "N0000175862" ], "pharm_class_epc": [ "Gadolinium-based Contrast Agent [EPC]" ], "pharm_class_moa": [ "Magnetic Resonance Contrast Activity [MoA]" ], "unii": [ "1BJ477IO2L" ] }, "update_date": "06/30/2026", "therapeutic_category": [ "Medical Imaging" ], "dosage_form": "Injection", "presentation": "Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-02)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "To Be Discontinued" }, { "discontinued_date": "12/10/2025", "update_type": "New", "initial_posting_date": "12/10/2025", "package_ndc": "0025-1031-31", "generic_name": "Spironolactone Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": { "application_number": [ "NDA012151" ], "brand_name": [ "ALDACTONE" ], "generic_name": [ "SPIRONOLACTONE" ], "manufacturer_name": [ "Pfizer Laboratories Div Pfizer Inc" ], "product_ndc": [ "0025-1031", "0025-1001", "0025-1041" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "SPIRONOLACTONE" ], "rxcui": [ "198222", "198223", "200817", "200820", "200825", "313096" ], "spl_id": [ "22946678-dcad-4518-9bc6-cbdf51a38c16" ], "spl_set_id": [ "0fed2822-3a03-4b64-9857-c682fcd462bc" ], "package_ndc": [ "0025-1001-31", "0025-1041-31", "0025-1031-31" ], "nui": [ "N0000175557", "N0000011310" ], "pharm_class_epc": [ "Aldosterone Antagonist [EPC]" ], "pharm_class_moa": [ "Aldosterone Antagonists [MoA]" ], "unii": [ "27O7W4T232" ] }, "update_date": "12/10/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Aldactone, Tablet, 100 mg (NDC 0025-1031-31)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "11/01/2017", "package_ndc": "63323-854-10", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA019034" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-854", "63323-851", "63323-852", "63323-853" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897653", "897753", "1724276", "1724338", "1724340", "1724341" ], "spl_id": [ "9e8522c6-595c-46f9-bb25-272aa4683e0f" ], "spl_set_id": [ "e034eb96-03e0-46e1-8b92-5e1f94555e7b" ], "package_ndc": [ "63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 4 mg/1 mL (NDC 63323-854-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "0703-4244-01", "generic_name": "Carboplatin Injection", "contact_info": "800-545-8800", "availability": "Unavailable", "related_info": "Estimated recovery: October 2026", "openfda": { "application_number": [ "ANDA077269" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Teva Parenteral Medicines, Inc." ], "product_ndc": [ "0703-4244", "0703-4246", "0703-4248", "0703-4239" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "bed4c1cf-f3ef-4faa-b2a4-24ee9a9879df", "b943761e-6a46-45a0-bdb4-1fec1e101f8c" ], "spl_set_id": [ "f330f5a2-2cad-402f-bcbb-26245a753276", "e176b6ef-2ff6-498b-a9d8-7a634d147f37" ], "package_ndc": [ "0703-4244-01", "0703-4246-01", "0703-4248-01", "0703-4239-01", "0703-4244-81", "0703-4246-81", "0703-4248-81", "0703-4239-81" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 0703-4244-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "03/24/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "0074-7098-05", "generic_name": "Pilocarpine Hydrochloride Ophthalmic Solution", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA214028" ], "brand_name": [ "VUITY" ], "generic_name": [ "PILOCARPINE HYDROCHLORIDE" ], "manufacturer_name": [ "AbbVie Inc." ], "product_ndc": [ "0074-7098" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "OPHTHALMIC" ], "substance_name": [ "PILOCARPINE HYDROCHLORIDE" ], "rxcui": [ "2584552", "2584557" ], "spl_id": [ "ed4cf150-c4b6-4d26-9326-e3a3490de489" ], "spl_set_id": [ "8d806897-8a2a-4518-8c68-0ec3b778de50" ], "package_ndc": [ "0074-7098-02", "0074-7098-01", "0074-7098-03", "0074-7098-04", "0074-7098-05", "0074-7098-06" ], "unii": [ "0WW6D218XJ" ] }, "update_date": "03/24/2026", "therapeutic_category": [ "Ophthalmology" ], "dosage_form": "Ophthalmic Solution", "presentation": "Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-05)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "11/14/2017", "package_ndc": "63323-519-10", "generic_name": "Heparin Sodium Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA212441" ], "brand_name": [ "HEPARIN SODIUM" ], "generic_name": [ "HEPARIN SODIUM" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-519" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "HEPARIN SODIUM" ], "rxcui": [ "1658690", "1658692" ], "spl_id": [ "3bbbe74a-1246-41a6-9fc3-ca0230529b40" ], "spl_set_id": [ "25b0ba06-3274-4a3f-8c39-42d13764ecdf" ], "package_ndc": [ "63323-519-02", "63323-519-77", "63323-519-01", "63323-519-10" ], "unii": [ "ZZ45AB24CA" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Hematology" ], "dosage_form": "Injection", "presentation": "Heparin Sodium, Injection, 200 [USP'U]/100 mL (NDC 63323-519-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "05/03/2018", "package_ndc": "76329-8261-1", "generic_name": "Lorazepam Injection", "contact_info": "800-423-4136", "availability": "Available", "openfda": { "application_number": [ "ANDA076150" ], "brand_name": [ "LORAZEPAM" ], "generic_name": [ "LORAZEPAM" ], "manufacturer_name": [ "International Medication Systems, Limited" ], "product_ndc": [ "76329-8261" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "LORAZEPAM" ], "rxcui": [ "238100" ], "spl_id": [ "b85a6695-55b9-4780-a803-33f8f2464138" ], "spl_set_id": [ "7dda070d-7809-46c4-8592-eb4e4c509707" ], "package_ndc": [ "76329-8261-1" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "O26FZP769L" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)", "company_name": "Amphastar Pharmaceuticals, Inc.", "status": "Current" }, { "discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0378-0007-85", "generic_name": "Everolimus Tablet", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/03/2025", "therapeutic_category": [ "Transplant" ], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 5 mg (NDC 0378-0007-85)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "0409-7037-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA205656" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-7037", "0409-3189" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "c96726ef-f1fa-4ebb-ba33-3479c3902a8e" ], "spl_set_id": [ "c96726ef-f1fa-4ebb-ba33-3479c3902a8e" ], "package_ndc": [ "0409-3189-05", "0409-3189-10", "0409-7037-01", "0409-7037-10" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-7037-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "63323-280-02", "generic_name": "Furosemide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA018902" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-280" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "9804efac-5457-417a-8de7-a688467759c0", "64b3fb5f-3516-4e39-b74e-e0e402ed9c4d" ], "spl_set_id": [ "3747bbcd-783d-4baa-bb5b-b6827bf390e3", "c794c95a-654e-48fe-9596-201fc122ff75" ], "package_ndc": [ "63323-280-41", "63323-280-16", "63323-280-43", "63323-280-26", "63323-280-45", "63323-280-36", "63323-280-01", "63323-280-02", "63323-280-03", "63323-280-04", "63323-280-05", "63323-280-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "02/19/2026", "update_type": "New", "initial_posting_date": "02/19/2026", "package_ndc": "0591-5543-10", "generic_name": "Allopurinol Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA018832" ], "brand_name": [ "ALLOPURINOL" ], "generic_name": [ "ALLOPURINOL" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0591-5543", "0591-5544" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ALLOPURINOL" ], "rxcui": [ "197319", "197320" ], "spl_id": [ "f7e04d88-1d9b-47e6-a9ad-deb08af3c098" ], "spl_set_id": [ "a80fe56f-8d03-423f-8e2a-7ec8c9e5045b" ], "package_ndc": [ "0591-5543-01", "0591-5543-10", "0591-5544-01", "0591-5544-05" ], "nui": [ "N0000175698", "N0000000206" ], "pharm_class_epc": [ "Xanthine Oxidase Inhibitor [EPC]" ], "pharm_class_moa": [ "Xanthine Oxidase Inhibitors [MoA]" ], "unii": [ "63CZ7GJN5I" ] }, "update_date": "02/19/2026", "therapeutic_category": [ "Oncology", "Renal", "Rheumatology" ], "dosage_form": "Tablet", "presentation": "Allopurinol, Tablet, 100 mg (NDC 0591-5543-10)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "23155-601-41", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "855-228-9470", "availability": "Available", "openfda": { "application_number": [ "ANDA090850" ], "brand_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc." ], "product_ndc": [ "23155-601" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "311702" ], "spl_id": [ "e20feff9-3aca-4bc1-a5c3-44fff8a9459c" ], "spl_set_id": [ "843cc25e-45ea-4372-ae34-843f805fa869" ], "package_ndc": [ "23155-601-31", "23155-601-41", "23155-601-32", "23155-601-42" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-41)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6030-01", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Additional lots will be available September 2026 timeframe. Product will be made available as it is released.", "openfda": { "application_number": [ "NDA019101" ], "brand_name": [ "FENTANYL CITRATE" ], "generic_name": [ "FENTANYL CITRATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6030", "0641-6024", "0641-6027", "0641-6025", "0641-6028", "0641-6026", "0641-6029", "0641-6247", "0641-6248", "0641-6249" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "FENTANYL CITRATE" ], "rxcui": [ "1735003", "1735007", "1735008", "1735013", "2168270", "2474269", "2629337" ], "spl_id": [ "546a047c-1faf-4751-9e48-079e4c35b6fa" ], "spl_set_id": [ "ce5db1c2-feb1-4ad2-847a-d02e865bd47e" ], "package_ndc": [ "0641-6024-01", "0641-6024-10", "0641-6027-01", "0641-6027-25", "0641-6025-01", "0641-6025-10", "0641-6028-01", "0641-6028-10", "0641-6028-25", "0641-6026-01", "0641-6026-05", "0641-6029-01", "0641-6029-25", "0641-6030-01", "0641-6247-01", "0641-6247-25", "0641-6248-01", "0641-6248-10", "0641-6249-01", "0641-6249-10" ], "unii": [ "MUN5LYG46H" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6030-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "64850-505-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": { "application_number": [ "ANDA211352" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Elite Laboratories, Inc." ], "product_ndc": [ "64850-505", "64850-500", "64850-501", "64850-502", "64850-503", "64850-504", "64850-506" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "a41cf8e5-cb1b-488c-96b3-3bef8283d6c4" ], "spl_set_id": [ "e677690f-790f-4626-ad78-097cdb6ea540" ], "package_ndc": [ "64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 64850-505-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6026-05", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Inventory available in vial presentations.", "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6026-05)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/22/2020", "package_ndc": "43066-027-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Baxter", "openfda": { "application_number": [ "ANDA212808" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "43066-027", "43066-015", "43066-019", "43066-023" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734084", "1734207", "1734475", "1734483" ], "spl_id": [ "a8d08579-825f-40d9-b1e3-e47b73765ae6" ], "spl_set_id": [ "781d4b7f-7556-4695-8d48-7772d7a0d8e9" ], "package_ndc": [ "43066-015-01", "43066-015-10", "43066-019-01", "43066-019-10", "43066-023-01", "43066-023-10", "43066-027-01", "43066-027-10" ], "unii": [ "V910P86109" ] }, "update_date": "06/10/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 43066-027-10)", "company_name": "Caplin Steriles, Ltd.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-10", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA018667" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-6102" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "e598e8a6-c854-48f5-a412-fb6a6783774a", "981d5143-60cd-4987-9b47-dec24c10de42" ], "spl_set_id": [ "aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7" ], "package_ndc": [ "0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0427-53", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA020163" ], "brand_name": [ "DIANEAL PD-2 WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0427", "0941-0411", "0941-0413", "0941-0415", "0941-0409", "0941-0457", "0941-0459", "0941-0426", "0941-0429", "0941-0424", "0941-0430", "0941-0433", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0427-53)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "discontinued_date": "07/23/2026", "update_type": "New", "initial_posting_date": "07/23/2026", "package_ndc": "0574-7116-12", "generic_name": "Morphine Sulfate Suppository", "contact_info": "(800) 775-2054", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-7116", "0574-7110", "0574-7112", "0574-7114" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RECTAL" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "892516", "892603", "892678", "894807" ], "spl_id": [ "fa18ac09-a625-47aa-8cde-7051dc4d0c49" ], "spl_set_id": [ "649d731b-962a-45df-b043-7e0781e8a530" ], "package_ndc": [ "0574-7110-12", "0574-7112-12", "0574-7114-12", "0574-7116-12" ], "unii": [ "X3P646A2J0" ] }, "update_date": "07/23/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Suppository", "presentation": "Morphine Sulfate, Suppository, 30 mg (NDC 0574-7116-12)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "discontinued_date": "11/12/2025", "update_type": "New", "initial_posting_date": "11/12/2025", "package_ndc": "0603-3718-34", "generic_name": "Frovatriptan Succinate Tablet", "contact_info": "800-828-9393", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "11/12/2025", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Frova, Tablet, 2.5 mg (NDC 0603-3718-34)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-098-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": { "application_number": [ "NDA216117" ], "brand_name": [ "RELEXXII" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Vertical Pharmaceuticals, LLC" ], "product_ndc": [ "68025-098", "68025-088", "68025-089", "68025-095", "68025-096", "68025-097", "68025-084" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505" ], "spl_id": [ "86f477e9-07fc-466b-913e-1a4434c91df4" ], "spl_set_id": [ "22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d" ], "package_ndc": [ "68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-194-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": { "application_number": [ "ANDA209799" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "SUNRISE PHARMACEUTICAL, INC." ], "product_ndc": [ "11534-194", "11534-190", "11534-191", "11534-192", "11534-193", "11534-195", "11534-196" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "60dcfbf6-d07a-4010-ae77-8a9ae4529828" ], "spl_set_id": [ "ac102599-3a5b-4154-899e-6ff262be7ff7" ], "package_ndc": [ "11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/16/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 11534-194-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-287-21", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-287", "63323-286", "63323-288", "63323-285" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "905191", "1734084", "1734086", "1734090", "1734091", "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484" ], "spl_id": [ "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9" ], "spl_set_id": [ "23d2d448-a744-4877-9f2d-7e57c198da89" ], "package_ndc": [ "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 7.5 mg/1 mL (NDC 63323-287-21)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0825-01", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": { "application_number": [ "NDA009866" ], "brand_name": [ "SOLU-CORTEF" ], "generic_name": [ "HYDROCORTISONE SODIUM SUCCINATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0825", "0009-0011", "0009-0013", "0009-0016", "0009-0005" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "HYDROCORTISONE SODIUM SUCCINATE" ], "rxcui": [ "105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596" ], "spl_id": [ "8512044a-4a54-4634-bb97-9e20126adc61" ], "spl_set_id": [ "65eefd58-b166-4d71-ade6-45c8fdf86922" ], "package_ndc": [ "0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01" ], "unii": [ "50LQB69S1Z" ] }, "update_date": "02/24/2026", "therapeutic_category": [ "Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 100 mg/vial (NDC 0009-0825-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0457-05", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA017512" ], "brand_name": [ "DIANEAL LOW CALCIUM WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0457", "0941-0411", "0941-0413", "0941-0415", "0941-0409", "0941-0459", "0941-0426", "0941-0427", "0941-0429", "0941-0424", "0941-0430", "0941-0433", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0457-05)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4911-34", "generic_name": "Atropine Sulfate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, (Adult)1 mg/10 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4911-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "discontinued_date": "08/10/2026", "update_type": "New", "initial_posting_date": "08/10/2026", "package_ndc": "0093-9433-01", "generic_name": "Glyburide Tablet", "contact_info": "800-633-1610", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA017532" ], "brand_name": [ "GLYBURIDE" ], "generic_name": [ "GLYBURIDE" ], "manufacturer_name": [ "TEVA Pharmaceuticals USA Inc" ], "product_ndc": [ "0093-9433", "0093-9477", "0093-9364" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "GLYBURIDE" ], "rxcui": [ "197737", "310534", "310537" ], "spl_id": [ "84b83205-8813-494e-933e-a70697393744" ], "spl_set_id": [ "50d16f1d-c814-4411-8749-62561321ecce" ], "package_ndc": [ "0093-9477-53", "0093-9433-01", "0093-9433-05", "0093-9364-01", "0093-9364-05", "0093-9364-10" ], "nui": [ "N0000175608", "M0020795" ], "pharm_class_epc": [ "Sulfonylurea [EPC]" ], "pharm_class_cs": [ "Sulfonylurea Compounds [CS]" ], "unii": [ "SX6K58TVWC" ] }, "update_date": "08/10/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Tablet", "presentation": "Diabeta, Tablet, 2.5 mg (NDC 0093-9433-01)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6029-25", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.", "openfda": { "application_number": [ "NDA019101" ], "brand_name": [ "FENTANYL CITRATE" ], "generic_name": [ "FENTANYL CITRATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6029", "0641-6024", "0641-6027", "0641-6025", "0641-6028", "0641-6026", "0641-6030", "0641-6247", "0641-6248", "0641-6249" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "FENTANYL CITRATE" ], "rxcui": [ "1735003", "1735007", "1735008", "1735013", "2168270", "2474269", "2629337" ], "spl_id": [ "546a047c-1faf-4751-9e48-079e4c35b6fa" ], "spl_set_id": [ "ce5db1c2-feb1-4ad2-847a-d02e865bd47e" ], "package_ndc": [ "0641-6024-01", "0641-6024-10", "0641-6027-01", "0641-6027-25", "0641-6025-01", "0641-6025-10", "0641-6028-01", "0641-6028-10", "0641-6028-25", "0641-6026-01", "0641-6026-05", "0641-6029-01", "0641-6029-25", "0641-6030-01", "0641-6247-01", "0641-6247-25", "0641-6248-01", "0641-6248-10", "0641-6249-01", "0641-6249-10" ], "unii": [ "MUN5LYG46H" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6029-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0143-9532-25", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Product temporarily on backorder. Additional lots will be available in the September 2026 timeframe.", "openfda": { "application_number": [ "ANDA205046" ], "brand_name": [ "DEXMEDETOMIDINE HCL" ], "generic_name": [ "DEXMEDETOMIDINE HCL" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9532" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "309710" ], "spl_id": [ "8cb1c4c8-48b4-471f-b443-5f03896a3fb7" ], "spl_set_id": [ "de6f01a2-9f2d-4c68-9c02-06643704acb1" ], "package_ndc": [ "0143-9532-01", "0143-9532-25" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 0143-9532-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "63323-750-20", "generic_name": "Oxaliplatin Injection", "contact_info": "847-550-2300", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "02/25/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-484-57", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-484", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 5 mg/1 mL (NDC 63323-484-57)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "01/05/2026", "update_type": "New", "initial_posting_date": "01/05/2026", "package_ndc": "0093-2401-01", "generic_name": "Hydroxychloroquine Sulfate Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA040081" ], "brand_name": [ "HYDROXYCHLOROQUINE SULFATE" ], "generic_name": [ "HYDROXYCHLOROQUINE SULFATE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0093-2401" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "HYDROXYCHLOROQUINE SULFATE" ], "rxcui": [ "979092" ], "spl_id": [ "0c6c28a5-e86f-4643-bb22-f7eb5b1f440d" ], "spl_set_id": [ "5f3e49b2-dc11-40a9-b366-c88e36a471e5" ], "package_ndc": [ "0093-2401-01" ], "unii": [ "8Q2869CNVH" ] }, "update_date": "01/05/2026", "therapeutic_category": [ "Anti-Infective", "Other", "Rheumatology" ], "dosage_form": "Tablet", "presentation": "Hydroxychloroquine Sulfate, Tablet, 200 mg (NDC 0093-2401-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "0480-5795-08", "generic_name": "Cetrorelix Acetate Injection", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/13/2025", "therapeutic_category": [ "Reproductive" ], "dosage_form": "Injection", "presentation": "Cetrorelix Acetate, Injection, Kit (NDC 0480-5795-08)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "02/20/2026", "update_type": "New", "initial_posting_date": "02/20/2026", "package_ndc": "50742-431-08", "generic_name": "Docetaxel Injection", "contact_info": "866-321-5031", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "02/20/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Docetaxel, Injection, 10 mg/1 mL (NDC 50742-431-08)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-154-01", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": { "application_number": [ "ANDA075468" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Advagen Pharma Ltd" ], "product_ndc": [ "72888-154", "72888-497", "72888-152", "72888-153" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529", "204892" ], "spl_id": [ "5510f17b-a980-f412-e063-6394a90ae1c4" ], "spl_set_id": [ "30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec" ], "package_ndc": [ "72888-497-01", "72888-497-02", "72888-497-03", "72888-497-04", "72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 72888-154-01)", "company_name": "Rubicon Research Private Limited", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0641-6060-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA075243" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6060", "0641-6057", "0641-6059", "0641-6056", "0641-6061", "0641-6063" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "311700", "311702" ], "spl_id": [ "559c03fb-24ea-4b7b-8afd-e33cb3a2340a" ], "spl_set_id": [ "575d8bf0-7af7-427c-a231-966e2a5e070d" ], "package_ndc": [ "0641-6057-01", "0641-6057-10", "0641-6057-25", "0641-6059-01", "0641-6059-10", "0641-6056-01", "0641-6056-10", "0641-6061-01", "0641-6061-10", "0641-6061-25", "0641-6063-01", "0641-6063-10", "0641-6063-25", "0641-6060-01", "0641-6060-10" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6060-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "71288-700-06", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-824-8426", "availability": "Available", "openfda": { "application_number": [ "ANDA213453" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Meitheal Pharmaceuticals Inc." ], "product_ndc": [ "71288-700", "71288-718" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "aad39c88-2e2c-49a6-aa13-de852483661f", "37295b13-65a4-40fa-8d6c-53aeb45e2939" ], "spl_set_id": [ "b23aa80e-2af2-4a66-92ed-b1c8863be704", "b9abaf64-760d-43e0-8669-a9ca70feab11" ], "package_ndc": [ "71288-700-91", "71288-700-92", "71288-718-91", "71288-718-92", "71288-700-05", "71288-700-06", "71288-718-10", "71288-718-11" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-700-06)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "36000-282-25", "generic_name": "Furosemide Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "ANDA202747" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "36000-282", "36000-063", "36000-064", "36000-065", "36000-283", "36000-284" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "b4c1ae97-0f6c-4ae1-858a-4e0ab8f1ce53" ], "spl_set_id": [ "c71371a7-75c5-45b8-b762-8d782d4c71bc" ], "package_ndc": [ "36000-063-05", "36000-064-05", "36000-065-05", "36000-282-25", "36000-283-25", "36000-284-25" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 36000-282-25)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-464-31", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA070552", "NDA018304" ], "brand_name": [ "SENSORCAINE MPF" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-464", "63323-466", "63323-462", "63323-465", "63323-467", "63323-460" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457" ], "spl_id": [ "b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715" ], "spl_set_id": [ "e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8" ], "package_ndc": [ "63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31" ], "unii": [ "7TQO7W3VT8", "30Q7KI53AK" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-464-31)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-481-57", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-481", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-483", "63323-482", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 5 mg/1 mL (NDC 63323-481-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "05/27/2026", "update_type": "New", "initial_posting_date": "05/27/2026", "package_ndc": "16729-710-45", "generic_name": "Dehydrated Alcohol Injection, Solution", "contact_info": "866-941-7875", "related_info": "Accord is transitioning to the 5-pack configuration (NDC 16729-710-53).", "openfda": { "application_number": [ "ANDA217845" ], "brand_name": [ "DEHYDRATED ALCOHOL" ], "generic_name": [ "ALCOHOL" ], "manufacturer_name": [ "Accord Healthcare, Inc." ], "product_ndc": [ "16729-710" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "PERCUTANEOUS" ], "substance_name": [ "ALCOHOL" ], "rxcui": [ "2048982" ], "spl_id": [ "52566f68-6e40-af49-e063-6394a90a01ad" ], "spl_set_id": [ "07fa92f7-d752-42e3-a572-b552461c4389" ], "package_ndc": [ "16729-710-31", "16729-710-53", "16729-710-45" ], "unii": [ "3K9958V90M" ] }, "update_date": "05/27/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Dehydrated Alcohol, Injection, Solution, 1 mL/1 mL (10 pack) (NDC 16729-710-45)", "company_name": "Accord Healthcare Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-355-05", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-05)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0974-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA040422" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0555-0974", "0555-0971", "0555-0775", "0555-0972", "0555-0776", "0555-0777", "0555-0973" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "88468f3d-7d03-4cee-aabf-3abc8c9b5e38" ], "spl_set_id": [ "cffbbb15-d776-41ae-a8a6-687f2c07bfa4" ], "package_ndc": [ "0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0555-0974-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0591-0347-05", "generic_name": "Hydrochlorothiazide Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA020504" ], "brand_name": [ "HYDROCHLOROTHIAZIDE" ], "generic_name": [ "HYDROCHLOROTHIAZIDE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0591-0347" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "HYDROCHLOROTHIAZIDE" ], "rxcui": [ "199903" ], "spl_id": [ "b062bc7e-af92-4648-aed1-e02568313e21" ], "spl_set_id": [ "a3eb7294-f913-434b-896c-da028bfebc73" ], "package_ndc": [ "0591-0347-01", "0591-0347-05" ], "nui": [ "N0000175359", "N0000175419", "M0471776" ], "pharm_class_pe": [ "Increased Diuresis [PE]" ], "pharm_class_epc": [ "Thiazide Diuretic [EPC]" ], "pharm_class_cs": [ "Thiazides [CS]" ], "unii": [ "0J48LPH2TH" ] }, "update_date": "11/19/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Capsule", "presentation": "Microzide, Capsule, 12.5 mg (NDC 0591-0347-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1761-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: September 2026", "openfda": { "application_number": [ "NDA018692" ], "brand_name": [ "MARCAINE SPINAL" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE IN DEXTROSE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1761" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBARACHNOID" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1724784", "1724792" ], "spl_id": [ "ef77810e-d05c-4501-9512-10dbe0bc7f00" ], "spl_set_id": [ "9679cc05-2f8a-4e88-53b5-6e9122c8b8c0" ], "package_ndc": [ "0409-1761-19", "0409-1761-02", "0409-1761-18", "0409-1761-62", "0409-1761-05", "0409-1761-10" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Marcaine, Injection, 0.75% 15 mg/2 mL (7.5 mg/mL) in Dextrose 8.25% (NDC 0409-1761-10)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3178-02", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: November 2026; Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA089644" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3178", "0409-1209", "0409-3177", "0409-3181", "0409-3182", "0409-3183", "0409-0007", "0409-0147" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE", "EPINEPHRINE" ], "rxcui": [ "1010688", "1010745", "1010751", "1010759", "1867996", "1867998" ], "spl_id": [ "68a37af1-d237-4836-af13-1eec28245f8b" ], "spl_set_id": [ "2f94f711-14c4-48ec-c5a3-c5ec4b8e8729" ], "package_ndc": [ "0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10" ], "nui": [ "N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647" ], "pharm_class_moa": [ "Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]" ], "pharm_class_epc": [ "alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]" ], "pharm_class_cs": [ "Catecholamines [CS]" ], "unii": [ "YKH834O4BH", "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 300 mg/30 mL (1%; 1:100,000) (NDC 0409-3178-02)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "67457-420-10", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA040802" ], "brand_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "generic_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "manufacturer_name": [ "Mylan Institutional LLC" ], "product_ndc": [ "67457-420", "67457-423", "67457-422", "67457-421" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "rxcui": [ "309696", "1116927", "1812194" ], "spl_id": [ "dd5c82b6-a194-462c-9626-34a9b410cfea" ], "spl_set_id": [ "dff598e8-e662-411f-978d-4ba3fb8ef7db" ], "package_ndc": [ "67457-423-00", "67457-423-12", "67457-422-00", "67457-422-54", "67457-421-00", "67457-421-30", "67457-420-00", "67457-420-10" ], "unii": [ "AI9376Y64P" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current" }, { "discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2234-01", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA076515" ], "brand_name": [ "OMEPRAZOLE" ], "generic_name": [ "OMEPRAZOLE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-2234" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OMEPRAZOLE" ], "rxcui": [ "200329" ], "spl_id": [ "fe6aa833-89e6-4679-a7b8-6600e92c1bed" ], "spl_set_id": [ "5a09ce48-7139-4fc7-9b6e-439459c8e866" ], "package_ndc": [ "0781-2234-10", "0781-2234-01", "0781-2234-31" ], "nui": [ "N0000175525", "N0000000147", "N0000182140" ], "pharm_class_epc": [ "Proton Pump Inhibitor [EPC]" ], "pharm_class_moa": [ "Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]" ], "unii": [ "KG60484QX9" ] }, "update_date": "10/09/2025", "therapeutic_category": [ "Gastroenterology" ], "presentation": "Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-01)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "39822-4200-6", "generic_name": "Rocuronium Bromide Injection", "contact_info": "866-390-4411", "availability": "Available", "related_info": "Tamarang is the application holder and X-Gen is the distributor/labeler", "openfda": { "application_number": [ "ANDA091115" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "XGen Pharmaceuticals DJB, Inc." ], "product_ndc": [ "39822-4200" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "eedcfb07-4e23-3152-e053-2995a90a6e6a" ], "spl_set_id": [ "b73f192c-2912-4ec3-9b4f-05a58d9b35ba" ], "package_ndc": [ "39822-4200-1", "39822-4200-2", "39822-4200-5", "39822-4200-6" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (NDC 39822-4200-6)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-2634-01", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA078591" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-2634" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "1724338", "1724340", "1724341" ], "spl_id": [ "50886ad5-eeca-4fe7-beb0-01305f92c65d" ], "spl_set_id": [ "3832ede8-d3fc-455d-ecab-3b77be5869f5" ], "package_ndc": [ "0409-2634-10", "0409-2634-01", "0409-2634-25", "0409-2634-05", "0409-2634-50" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0409-2634-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-461-57", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesaler for inventory", "openfda": { "application_number": [ "ANDA070967" ], "brand_name": [ "SENSORCAINE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-461", "63323-472", "63323-463", "63323-468" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810", "1867594", "1867596", "1867618", "1867620" ], "spl_id": [ "cc1f6507-eb3e-4398-a1d3-0c56a2099e6b" ], "spl_set_id": [ "bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb" ], "package_ndc": [ "63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0972-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA040422" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0555-0972", "0555-0971", "0555-0775", "0555-0776", "0555-0777", "0555-0973", "0555-0974" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "88468f3d-7d03-4cee-aabf-3abc8c9b5e38" ], "spl_set_id": [ "cffbbb15-d776-41ae-a8a6-687f2c07bfa4" ], "package_ndc": [ "0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0555-0972-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "42806-345-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(718) 276-8600 ext. 3", "availability": "Available", "openfda": { "application_number": [ "ANDA040444" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Epic Pharma, LLC" ], "product_ndc": [ "42806-345", "42806-339", "42806-341", "42806-343", "42806-344" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961" ], "spl_id": [ "f11301e2-3b5d-468d-b44c-45839e7e5dfb" ], "spl_set_id": [ "1757e132-061d-4773-89ed-fdc77f69008f" ], "package_ndc": [ "42806-339-01", "42806-341-01", "42806-343-01", "42806-344-01", "42806-345-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 42806-345-01)", "company_name": "Epic Pharma, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0530-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 10 mg (NDC 0071-0530-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-4916-14", "generic_name": "Sodium Bicarbonate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Sodium%20Bicarbonate%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 44.6 mEq/50 mL (7.5%, 0.9 mEq/mL) Syringes (NDC 0409-4916-14)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4278-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA088328" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4278", "0409-4713", "0409-4279", "0409-4776", "0409-4282", "0409-4277", "0409-4276", "0409-4275" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "INTRAVENOUS" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763" ], "spl_id": [ "05d1a200-9d75-4e48-b14a-5069d4ab816f" ], "spl_set_id": [ "3b2dd84e-cee8-4e58-d494-395a65a353a0" ], "package_ndc": [ "0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 250 mg/50 mL (0.5%; 5 mg/mL) (NDC 0409-4278-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "63323-671-20", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Expected recovery: TBD", "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 63323-671-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "02/24/2026", "update_type": "New", "initial_posting_date": "02/24/2026", "package_ndc": "63481-025-09", "generic_name": "Frovatriptan Succinate Tablet", "contact_info": "800-828-9393", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "02/24/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Frova, Tablet, 2.5 mg (NDC 63481-025-09)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1434-01", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA021038" ], "brand_name": [ "PRECEDEX" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1434", "0409-1660", "0409-1638", "0409-1596", "0409-7838", "0409-7853", "0409-7875" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892" ], "spl_id": [ "3c5274fd-6597-4b88-babc-92e4e16c6329" ], "spl_set_id": [ "548a88c0-afda-427e-75ac-5af0cfa2224c" ], "package_ndc": [ "0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Precedex, Injection, 1000 mcg/250 mL Single Dose Glass Bottle (NDC 0409-1434-01)", "company_name": "Pfizer Inc.", "status": "Current" }, { "discontinued_date": "10/16/2025", "update_type": "New", "initial_posting_date": "10/16/2025", "package_ndc": "0002-7640-01", "generic_name": "Pemetrexed Disodium Injection", "contact_info": "800-545-5979", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA021462" ], "brand_name": [ "ALIMTA" ], "generic_name": [ "PEMETREXED DISODIUM" ], "manufacturer_name": [ "Eli Lilly and Company" ], "product_ndc": [ "0002-7640", "0002-7623" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "PEMETREXED DISODIUM HEPTAHYDRATE" ], "rxcui": [ "1728072", "1728075", "1728077", "1728079" ], "spl_id": [ "3af0bc84-13d6-46aa-a4c0-c62410b73bc6" ], "spl_set_id": [ "f5a860f3-37ec-429c-ae04-9c88d7c55c08" ], "package_ndc": [ "0002-7640-01", "0002-7623-01" ], "unii": [ "9T47E4OM16" ] }, "update_date": "10/16/2025", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Alimta, Injection, 100 mg/4 mL (NDC 0002-7640-01)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "12/22/2020", "package_ndc": "68001-313-56", "generic_name": "Azacitidine Injection", "contact_info": "800-545-8800", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA208216" ], "brand_name": [ "AZACITIDINE" ], "generic_name": [ "AZACITIDINE" ], "manufacturer_name": [ "BluePoint Laboratories" ], "product_ndc": [ "68001-313" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "AZACITIDINE" ], "rxcui": [ "485246" ], "spl_id": [ "36080e4e-a0fe-ba15-e063-6394a90aed5c" ], "spl_set_id": [ "5f0f9ee3-a5b1-4a25-a34c-7f38c8433f4a" ], "package_ndc": [ "68001-313-56" ], "nui": [ "N0000000233", "N0000175595" ], "pharm_class_moa": [ "Nucleic Acid Synthesis Inhibitors [MoA]" ], "pharm_class_epc": [ "Nucleoside Metabolic Inhibitor [EPC]" ], "unii": [ "M801H13NRU" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg (NDC 68001-313-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-161-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA075784" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-161", "63323-162" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "2b1c6066-d9e0-40a0-ade5-776fc35a3626", "55ed7afb-db66-4b28-939b-db45b55bf058", "ab476c4c-2c72-47b1-bf42-7a89703b0dd4" ], "spl_set_id": [ "ccf905ca-e164-4779-9485-2d139c821bad", "950b7295-3f68-4027-ac2b-2f7d0f5f8ef9", "d1920335-8e45-4960-b6e9-e6f1f9e6820c" ], "package_ndc": [ "63323-161-41", "63323-161-16", "63323-162-43", "63323-162-16", "63323-162-45", "63323-162-26", "63323-161-21", "63323-161-12", "63323-162-23", "63323-162-12", "63323-162-25", "63323-162-14", "63323-161-00", "63323-161-01", "63323-162-11", "63323-162-51", "63323-162-00", "63323-162-01", "63323-162-03", "63323-162-02" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 63323-161-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/10/2023", "package_ndc": "0093-0832-05", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA074569" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0093-0832", "0093-3212", "0093-3213" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "d6abe4e3-7699-4ead-95f4-739a961b23ad" ], "spl_set_id": [ "8069b1a0-7c06-4252-b44e-e2eef065d9b8" ], "package_ndc": [ "0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 0093-0832-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "08/10/2026", "update_type": "New", "initial_posting_date": "08/10/2026", "package_ndc": "0093-9364-10", "generic_name": "Glyburide Tablet", "contact_info": "800-633-1610", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA017532" ], "brand_name": [ "GLYBURIDE" ], "generic_name": [ "GLYBURIDE" ], "manufacturer_name": [ "TEVA Pharmaceuticals USA Inc" ], "product_ndc": [ "0093-9364", "0093-9477", "0093-9433" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "GLYBURIDE" ], "rxcui": [ "197737", "310534", "310537" ], "spl_id": [ "84b83205-8813-494e-933e-a70697393744" ], "spl_set_id": [ "50d16f1d-c814-4411-8749-62561321ecce" ], "package_ndc": [ "0093-9477-53", "0093-9433-01", "0093-9433-05", "0093-9364-01", "0093-9364-05", "0093-9364-10" ], "nui": [ "N0000175608", "M0020795" ], "pharm_class_epc": [ "Sulfonylurea [EPC]" ], "pharm_class_cs": [ "Sulfonylurea Compounds [CS]" ], "unii": [ "SX6K58TVWC" ] }, "update_date": "08/10/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Tablet", "presentation": "Diabeta, Tablet, 5 mg (NDC 0093-9364-10)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0990-7930-02", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Available", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA018080" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "ICU Medical, Inc." ], "product_ndc": [ "0990-7930", "0990-7923", "0990-7922" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621" ], "spl_id": [ "06e4d957-1a56-4adb-a42b-fe0773b2fa97" ], "spl_set_id": [ "8b25b7e0-703e-4b43-a4eb-52863511602d" ], "package_ndc": [ "0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-02)", "company_name": "Otsuka ICU Medical LLC", "status": "Current" }, { "discontinued_date": "11/21/2025", "update_type": "New", "initial_posting_date": "11/21/2025", "package_ndc": "62037-720-01", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA075604" ], "brand_name": [ "POTASSIUM CHLORIDE" ], "generic_name": [ "POTASSIUM CHLORIDE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "62037-720", "62037-710" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "POTASSIUM CHLORIDE" ], "rxcui": [ "1801294", "1801298" ], "spl_id": [ "01fbdb24-0987-40f6-a920-f36349f6ba61" ], "spl_set_id": [ "db002ae3-f54c-40a4-9cb4-e5681bf426e3" ], "package_ndc": [ "62037-710-01", "62037-720-01", "62037-720-05", "62037-720-10" ], "unii": [ "660YQ98I10" ] }, "update_date": "11/21/2025", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology" ], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 20 meq (NDC 62037-720-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "71357-009-10", "generic_name": "Sodium Acetate Injection", "contact_info": "833-251-8463", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA214805" ], "brand_name": [ "SODIUM ACETATE" ], "generic_name": [ "SODIUM ACETATE INJECTION, USP, 400 MEQ/100 ML" ], "manufacturer_name": [ "MILLA PHARMACEUTICALS INC." ], "product_ndc": [ "71357-009", "71357-007", "71357-008" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM ACETATE" ], "rxcui": [ "237371", "312965" ], "spl_id": [ "47d8d0e7-6db5-950d-e063-6294a90ab1bf" ], "spl_set_id": [ "1ea1466d-a492-4056-e063-6394a90a80bf" ], "package_ndc": [ "71357-007-01", "71357-007-10", "71357-008-01", "71357-008-10", "71357-009-01", "71357-009-10" ], "unii": [ "4550K0SC9B" ] }, "update_date": "08/15/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition" ], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 400 mEq/100mL (4 mEq/mL) (NDC 71357-009-10)", "company_name": "Milla Pharmaceuticals", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "06/06/2018", "package_ndc": "0641-6042-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA075772" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6042", "0641-6043", "0641-6041" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "25d6c438-45d2-4162-91c2-b5caa0f86bf3" ], "spl_set_id": [ "0c2c75c9-ed7b-46a8-9543-429bf2d8f090" ], "package_ndc": [ "0641-6043-01", "0641-6043-25", "0641-6042-01", "0641-6042-25", "0641-6041-01", "0641-6041-25" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0641-6042-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/03/2023", "package_ndc": "16571-600-96", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "(201) 961-9000 or contact@risingpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA202583" ], "brand_name": [ "CROMOLYN SODIUM" ], "generic_name": [ "CROMOLYN SODIUM" ], "manufacturer_name": [ "Rising Pharma Holdings, Inc." ], "product_ndc": [ "16571-600" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CROMOLYN SODIUM" ], "rxcui": [ "831261" ], "spl_id": [ "ca2c72ae-db00-4694-9fd0-d4b6b45f8108" ], "spl_set_id": [ "61c9cb85-129e-4490-b5f7-357307fcecbf" ], "package_ndc": [ "16571-600-96" ], "unii": [ "Q2WXR1I0PK" ] }, "update_date": "07/01/2026", "therapeutic_category": [ "Pulmonary/Allergy" ], "dosage_form": "Concentrate", "presentation": "Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 16571-600-96)", "company_name": "Rising Pharma Holdings, Inc.", "status": "Current" }, { "discontinued_date": "10/24/2025", "update_type": "New", "initial_posting_date": "10/24/2025", "package_ndc": "0002-8213-05", "generic_name": "Insulin Lispro Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "BLA020563" ], "brand_name": [ "HUMALOG TEMPO PEN" ], "generic_name": [ "INSULIN LISPRO" ], "manufacturer_name": [ "Eli Lilly and Company" ], "product_ndc": [ "0002-8213", "0002-7510", "0002-7533", "0002-8799", "0002-7516", "0002-7714", "0002-0800", "0002-7712" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "INSULIN LISPRO" ], "rxcui": [ "242120", "865098", "1652239", "1652242", "1652639", "1652640", "1652644", "1652646", "1926331", "1926332", "2621571", "2621572" ], "spl_id": [ "03be5386-187a-420f-9021-55778a73eba0" ], "spl_set_id": [ "c8ecbd7a-0e22-4fc7-a503-faa58c1b6f3f" ], "package_ndc": [ "0002-7510-01", "0002-7510-17", "0002-7533-01", "0002-8799-01", "0002-8799-59", "0002-7516-01", "0002-7516-59", "0002-7516-99", "0002-7714-01", "0002-7714-59", "0002-7714-61", "0002-8213-01", "0002-8213-05", "0002-0800-01", "0002-7712-01", "0002-7712-27", "0002-7712-61" ], "nui": [ "N0000004931", "N0000175453" ], "pharm_class_cs": [ "Insulin [Chemical/Ingredient]" ], "pharm_class_epc": [ "Insulin Analog [EPC]" ], "unii": [ "GFX7QIS1II", "059QF0KO0R" ] }, "update_date": "10/24/2025", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Humalog, Injection, U-100 Tempo Pen (NDC 0002-8213-05)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued" }, { "discontinued_date": "08/13/2026", "update_type": "New", "initial_posting_date": "08/13/2026", "package_ndc": "0228-2551-11", "generic_name": "Diclofenac Sodium Tablet, Delayed Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA074514" ], "brand_name": [ "DICLOFENAC SODIUM" ], "generic_name": [ "DICLOFENAC SODIUM" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0228-2551", "0228-2550" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DICLOFENAC SODIUM" ], "rxcui": [ "855906", "855926" ], "spl_id": [ "a1fbc994-b8a6-4759-be76-1cfd98275ca6" ], "spl_set_id": [ "a57b897e-0cbe-4ac3-969f-b00357a0cfa8" ], "package_ndc": [ "0228-2550-06", "0228-2550-11", "0228-2550-96", "0228-2551-06", "0228-2551-11", "0228-2551-96" ], "unii": [ "QTG126297Q" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Musculoskeletal", "Rheumatology" ], "dosage_form": "Tablet", "presentation": "Diclofenac Sodium, Tablet, Delayed Release, 75 mg (NDC 0228-2551-11)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "11/21/2023", "package_ndc": "0641-1496-35", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA083312" ], "brand_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "generic_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-1496", "0641-1495" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "rxcui": [ "992460", "992858" ], "spl_id": [ "80a400d2-d293-4180-bfa7-7a8ce0734bc5" ], "spl_set_id": [ "13d9e59d-eadb-41d5-9f47-9c11a6efb31c" ], "package_ndc": [ "0641-1495-31", "0641-1495-35", "0641-1496-31", "0641-1496-35" ], "unii": [ "R61ZEH7I1I" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy" ], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-1496-35)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4282-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA088294" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4282", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4277", "0409-4276", "0409-4275" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763" ], "spl_id": [ "05d1a200-9d75-4e48-b14a-5069d4ab816f" ], "spl_set_id": [ "3b2dd84e-cee8-4e58-d494-395a65a353a0" ], "package_ndc": [ "0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 40 mg/2 mL (2%; 20 mg/mL) (NDC 0409-4282-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4903-34", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 2%, USP (For Cardiac Use Only) 100 mg/5 mL (20 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4903-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0527-0764-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-834-0530", "availability": "Available", "openfda": { "application_number": [ "ANDA215565" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Lannett Company, LLC" ], "product_ndc": [ "0527-0764", "0527-0760", "0527-0761", "0527-0762", "0527-0763", "0527-0765", "0527-0766" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "391d7c4a-47df-41ce-b1ba-3c4758adf87f" ], "spl_set_id": [ "f92497b5-baea-4760-b615-45a0b6184402" ], "package_ndc": [ "0527-0760-37", "0527-0761-37", "0527-0762-37", "0527-0763-37", "0527-0764-37", "0527-0765-37", "0527-0766-37" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0527-0764-37)", "company_name": "Lannett Company, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4279-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA088329" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4279", "0409-4713", "0409-4278", "0409-4776", "0409-4282", "0409-4277", "0409-4276", "0409-4275" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763" ], "spl_id": [ "05d1a200-9d75-4e48-b14a-5069d4ab816f" ], "spl_set_id": [ "3b2dd84e-cee8-4e58-d494-395a65a353a0" ], "package_ndc": [ "0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 300 mg/30 mL (1%; 10 mg/mL) (NDC 0409-4279-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0185-2099-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-525-8747", "availability": "Available", "openfda": { "application_number": [ "ANDA040439" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0185-2099", "0185-0831", "0185-0842", "0185-0853", "0185-0864", "0185-2098" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577961" ], "spl_id": [ "9a21fb59-a99c-4c63-91e8-4b5d72fbd9cd" ], "spl_set_id": [ "288dafc4-fe6e-4891-832f-511022c87445" ], "package_ndc": [ "0185-0831-01", "0185-0842-01", "0185-0853-01", "0185-0864-01", "0185-2099-01", "0185-2098-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0185-2099-01)", "company_name": "Sandoz Inc.", "status": "Current" }, { "discontinued_date": "07/23/2026", "update_type": "New", "initial_posting_date": "07/23/2026", "package_ndc": "63323-943-10", "generic_name": "Succinylcholine Chloride Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA211346" ], "brand_name": [ "SUCCINYLCHOLINE CHLORIDE" ], "generic_name": [ "SUCCINYLCHOLINE CHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-943" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "SUCCINYLCHOLINE CHLORIDE" ], "rxcui": [ "1594589" ], "spl_id": [ "28aa281f-6312-44cc-ab8e-480a5c8d1ffb" ], "spl_set_id": [ "4e2d3394-c9e0-4191-ba0d-da21034c22b5" ], "package_ndc": [ "63323-943-21", "63323-943-10" ], "unii": [ "I9L0DDD30I" ] }, "update_date": "07/23/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Succinylcholine Chloride, Injection, 20 mg/1 mL (NDC 63323-943-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "discontinued_date": "09/08/2025", "update_type": "New", "initial_posting_date": "09/08/2025", "package_ndc": "47335-932-44", "generic_name": "Vecuronium Bromide Injection", "contact_info": "800-818-4555", "related_info": "The 10 mg presentation remains available.", "update_date": "09/08/2025", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Vecuronium Bromide, Injection, 20 mg (NDC 47335-932-44)", "company_name": "Sun Pharmaceutical Industries Limited", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "09/05/2018", "package_ndc": "0641-6046-10", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA018140" ], "brand_name": [ "LORAZEPAM" ], "generic_name": [ "LORAZEPAM" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6046", "0641-6044", "0641-6045", "0641-6047" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "LORAZEPAM" ], "rxcui": [ "238100", "238101", "1665188", "1665326" ], "spl_id": [ "7c73dbc6-2623-4443-9b05-97dec7a0be2e" ], "spl_set_id": [ "e9b54e42-04cf-4c62-90e1-36f7b31a4e81" ], "package_ndc": [ "0641-6044-01", "0641-6044-25", "0641-6046-01", "0641-6046-10", "0641-6045-01", "0641-6045-25", "0641-6047-01", "0641-6047-10" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "O26FZP769L" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "01/13/2022", "package_ndc": "0409-7517-16", "generic_name": "Dextrose Monohydrate 50% Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA019445" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-7517", "0409-6648" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "727517", "1795514" ], "spl_id": [ "34b869af-c42d-457c-8b21-6215a4e07aff" ], "spl_set_id": [ "4ed365da-4e62-4329-c1b9-c197ab4fb6e1" ], "package_ndc": [ "0409-7517-66", "0409-7517-16", "0409-6648-16", "0409-6648-02" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-7517-16)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "discontinued_date": "01/01/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "55513-813-28", "generic_name": "Ivabradine Solution", "contact_info": "1-800-772-6436", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": { "application_number": [ "NDA209964" ], "brand_name": [ "CORLANOR" ], "generic_name": [ "IVABRADINE" ], "manufacturer_name": [ "Amgen Inc" ], "product_ndc": [ "55513-813", "55513-800", "55513-810" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "IVABRADINE HYDROCHLORIDE" ], "rxcui": [ "1649485", "1649491", "1649493", "1649495", "2168592", "2168596" ], "spl_id": [ "8ab000cd-0258-489a-b1bb-4cc1ca359d6c" ], "spl_set_id": [ "92018a65-38f6-45f7-91d4-a34921b81d0d" ], "package_ndc": [ "55513-800-60", "55513-800-99", "55513-810-60", "55513-813-01", "55513-813-28" ], "unii": [ "TP19837BZK" ] }, "update_date": "03/24/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Solution", "presentation": "Corlanor, Solution, 5 mg/5 mL (NDC 55513-813-28)", "company_name": "Amgen Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "11/06/2017", "package_ndc": "0143-9252-25", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Product temporarily on backorder. Additional lots will be available in the February 2027 timeframe.", "openfda": { "application_number": [ "ANDA207707" ], "brand_name": [ "DOPAMINE HYDROCHLORIDE" ], "generic_name": [ "DOPAMINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9252", "0143-9253", "0143-9254", "0143-9255" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOPAMINE HYDROCHLORIDE" ], "rxcui": [ "1743938", "1743941", "1743950", "1743953" ], "spl_id": [ "67349236-e8e3-45ec-a76d-2a0a150d8d59" ], "spl_set_id": [ "0e499952-46c7-4172-8c70-186312e240a3" ], "package_ndc": [ "0143-9252-01", "0143-9252-25", "0143-9253-01", "0143-9253-25", "0143-9254-01", "0143-9254-25", "0143-9255-01", "0143-9255-25" ], "unii": [ "7L3E358N9L" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride, Injection, 40 mg/1 mL (NDC 0143-9252-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "0143-9251-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA204679" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9251", "0143-9250" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "51fc5473-b651-4c85-83ff-7edc65a6cef2" ], "spl_set_id": [ "d3a172a5-01ab-47d8-92ac-a8539b1d4dc4" ], "package_ndc": [ "0143-9250-01", "0143-9250-10", "0143-9251-01", "0143-9251-10" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9251-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "09/08/2025", "update_type": "New", "initial_posting_date": "09/08/2025", "package_ndc": "66993-081-69", "generic_name": "Sumatriptan Nasal Spray", "contact_info": "866-525-0688", "related_info": "This product discontinuation is a business-related decision. The anticipated date that Prasco will cease distribution of the product is approximately February 28, 2026.", "openfda": { "application_number": [ "NDA020626" ], "brand_name": [ "SUMATRIPTAN" ], "generic_name": [ "SUMATRIPTAN" ], "manufacturer_name": [ "Prasco Laboratories" ], "product_ndc": [ "66993-081", "66993-082" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "NASAL" ], "substance_name": [ "SUMATRIPTAN" ], "rxcui": [ "313159", "314227" ], "spl_id": [ "c3c253a9-c0e5-4aa2-927e-8777ee89aa48" ], "spl_set_id": [ "f63e616b-ae0c-432b-badc-8c45023aa725" ], "package_ndc": [ "66993-081-69", "66993-082-69" ], "nui": [ "N0000175763", "N0000175764", "N0000175765" ], "pharm_class_moa": [ "Serotonin 1b Receptor Agonists [MoA]", "Serotonin 1d Receptor Agonists [MoA]" ], "pharm_class_epc": [ "Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]" ], "unii": [ "8R78F6L9VO" ] }, "update_date": "09/08/2025", "therapeutic_category": [ "Neurology" ], "dosage_form": "Nasal Spray", "presentation": "Imitrex, Nasal Spray, 5 mg/100 uL (NDC 66993-081-69)", "company_name": "Prasco Laboratories", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-603-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": { "application_number": [ "ANDA216266" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE CAPSULES" ], "manufacturer_name": [ "Solco Healthcare US,LLC" ], "product_ndc": [ "43547-603", "43547-602", "43547-604", "43547-605", "43547-606", "43547-607", "43547-608" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "d6435613-e052-4b4f-8bf7-4acb7458d8df" ], "spl_set_id": [ "68b10d9f-ca3e-493d-a309-45f1d7e08061" ], "package_ndc": [ "43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/29/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 43547-603-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "52536-125-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "877-495-6856", "availability": "Available", "related_info": "Distributed by Wilshire Pharmaceuticals, Inc.", "openfda": { "application_number": [ "ANDA212791" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Wilshire Pharmaceuticals, Inc." ], "product_ndc": [ "52536-125", "52536-126" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909" ], "spl_id": [ "f550d2ba-49ac-4a3b-95db-692b468af479" ], "spl_set_id": [ "f550d2ba-49ac-4a3b-95db-692b468af479" ], "package_ndc": [ "52536-125-01", "52536-125-10", "52536-126-01", "52536-126-08" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 52536-125-10)", "company_name": "Azurity Pharmaceuticals, Inc", "status": "Current" }, { "discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "0002-4491-62", "generic_name": "Lasmiditan Succinate Tablet", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026.", "openfda": { "application_number": [ "NDA211280" ], "brand_name": [ "REYVOW" ], "generic_name": [ "LASMIDITAN" ], "manufacturer_name": [ "Eli Lilly and Company" ], "product_ndc": [ "0002-4491", "0002-4312" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LASMIDITAN" ], "rxcui": [ "2256937", "2256943", "2256945", "2256947" ], "spl_id": [ "29f467c6-0365-4831-b4ce-9a0eefaf5896" ], "spl_set_id": [ "aea3358c-ff41-4490-9e6d-c7bf7b3de13f" ], "package_ndc": [ "0002-4312-08", "0002-4312-61", "0002-4312-62", "0002-4491-08", "0002-4491-61", "0002-4491-62" ], "unii": [ "760I9WM792" ] }, "update_date": "11/03/2025", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Reyvow, Tablet, 100 mg (NDC 0002-4491-62)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "10/05/2022", "package_ndc": "65219-447-20", "generic_name": "Etomidate Injection", "contact_info": "800-551-7176", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Fresenius Kabi", "openfda": { "application_number": [ "ANDA215028" ], "brand_name": [ "ETOMIDATE" ], "generic_name": [ "ETOMIDATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-447", "65219-445" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008" ], "spl_id": [ "30488a7e-ea9e-4a27-95a9-a07149c50282" ], "spl_set_id": [ "d07efb9e-5264-461d-96d8-e11fa71c5751" ], "package_ndc": [ "65219-445-01", "65219-445-10", "65219-447-02", "65219-447-20" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "06/16/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2mg/mL (NDC 65219-447-20)", "company_name": "Caplin Steriles, Ltd.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2016", "package_ndc": "71357-008-10", "generic_name": "Sodium Acetate Injection", "contact_info": "833-251-8463", "availability": "Available", "openfda": { "application_number": [ "ANDA214805" ], "brand_name": [ "SODIUM ACETATE" ], "generic_name": [ "SODIUM ACETATE INJECTION, USP, 200 MEQ/100 ML" ], "manufacturer_name": [ "MILLA PHARMACEUTICALS INC." ], "product_ndc": [ "71357-008", "71357-007", "71357-009" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM ACETATE" ], "rxcui": [ "237371", "312965" ], "spl_id": [ "47d8d0e7-6db5-950d-e063-6294a90ab1bf" ], "spl_set_id": [ "1ea1466d-a492-4056-e063-6394a90a80bf" ], "package_ndc": [ "71357-007-01", "71357-007-10", "71357-008-01", "71357-008-10", "71357-009-01", "71357-009-10" ], "unii": [ "4550K0SC9B" ] }, "update_date": "08/15/2026", "therapeutic_category": [ "Total Parenteral Nutrition" ], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 200 mEq/100mL (2 mEq/mL) (NDC 71357-008-10)", "company_name": "Milla Pharmaceuticals", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-048-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA214484" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "57664-048", "57664-047", "57664-046", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "560b4c9e-9cce-4717-e063-6294a90a58c9" ], "spl_set_id": [ "da3148af-f9b6-4725-adae-3595b4c7dc4b" ], "package_ndc": [ "57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 57664-048-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "47781-563-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": { "application_number": [ "ANDA214547" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Alvogen Inc." ], "product_ndc": [ "47781-563", "47781-562", "47781-564", "47781-565", "47781-566", "47781-567", "47781-568" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "db02ec6b-f17f-ab22-b671-e1ddb90e017c" ], "spl_set_id": [ "7f2dd6ee-3363-c87c-9693-ed838942556c" ], "package_ndc": [ "47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 47781-563-01)", "company_name": "Alvogen", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1454-20", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA021038" ], "brand_name": [ "PRECEDEX" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1454", "0409-3301", "0409-1174", "0409-2815" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892" ], "spl_id": [ "e1705533-5a85-441f-a95b-3cb88c47e482" ], "spl_set_id": [ "4419162d-81d4-49bd-96de-1729440bdb74" ], "package_ndc": [ "0409-1454-01", "0409-1454-20", "0409-3301-01", "0409-3301-10", "0409-1174-01", "0409-1174-10", "0409-2815-01" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Precedex, Injection, 200 mcg/50 mL (4 mcg/mL) (NDC 0409-1454-20)", "company_name": "Pfizer Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/25/2017", "package_ndc": "0264-9594-20", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "NDA019830" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE AND DEXTROSE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS AND DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-9594", "0264-9598" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS", "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1737723", "1737742", "1737744" ], "spl_id": [ "9e352802-107c-4f90-babe-4f69c7dc892e" ], "spl_set_id": [ "7dff29d9-522d-40eb-a9d9-42377912d640" ], "package_ndc": [ "0264-9598-20", "0264-9594-20", "0264-9594-10" ], "unii": [ "EC2CNF7XFP", "LX22YL083G" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Dextrose, Injection, 5 g/100 mL; .4 g/100 mL (NDC 0264-9594-20)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "discontinued_date": "01/06/2026", "update_type": "New", "initial_posting_date": "01/06/2026", "package_ndc": "49884-127-91", "generic_name": "Everolimus Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "01/06/2026", "therapeutic_category": [ "Transplant" ], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 7.5 mg (NDC 49884-127-91)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "12/21/2020", "package_ndc": "16729-306-10", "generic_name": "Azacitidine Injection", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": { "application_number": [ "ANDA207475" ], "brand_name": [ "AZACITIDINE" ], "generic_name": [ "AZACITIDINE" ], "manufacturer_name": [ "Accord Healthcare Inc." ], "product_ndc": [ "16729-306" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "AZACITIDINE" ], "rxcui": [ "485246" ], "spl_id": [ "28604daf-46a3-ef6c-e063-6394a90a4b27" ], "spl_set_id": [ "70140e11-33f1-2240-e053-2991aa0a0480" ], "package_ndc": [ "16729-306-10" ], "nui": [ "N0000000233", "N0000175595" ], "pharm_class_moa": [ "Nucleic Acid Synthesis Inhibitors [MoA]" ], "pharm_class_epc": [ "Nucleoside Metabolic Inhibitor [EPC]" ], "unii": [ "M801H13NRU" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg (NDC 16729-306-10)", "company_name": "Accord Healthcare Inc.", "status": "Current" }, { "discontinued_date": "07/23/2026", "update_type": "New", "initial_posting_date": "07/23/2026", "package_ndc": "0574-7040-04", "generic_name": "Belladonna and Opium Suppository", "contact_info": "(800) 775-2054", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "BELLADONNA AND OPIUM" ], "generic_name": [ "ATROPA BELLADONNA AND OPIUM" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-7040", "0574-7045" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RECTAL" ], "substance_name": [ "ATROPA BELLADONNA", "OPIUM" ], "rxcui": [ "312104", "312107" ], "spl_id": [ "7b45a1d7-c3a5-4434-a848-45638cedd6e1" ], "spl_set_id": [ "8301e76b-134a-43d2-a7dc-c600ccf2695c" ], "package_ndc": [ "0574-7040-12", "0574-7040-04", "0574-7045-12", "0574-7045-04" ], "unii": [ "37M3MZ001L", "WQZ3G9PF0H" ] }, "update_date": "07/23/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Suppository", "presentation": "Belladonna and Opium, Suppository, 16.2 mg; 60 mg (NDC 0574-7040-04)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "discontinued_date": "07/24/2026", "update_type": "New", "initial_posting_date": "07/24/2026", "package_ndc": "0074-3956-46", "generic_name": "Lopinavir and Ritonavir Oral Solution", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA021251" ], "brand_name": [ "KALETRA" ], "generic_name": [ "LOPINAVIR AND RITONAVIR" ], "manufacturer_name": [ "AbbVie Inc." ], "product_ndc": [ "0074-3956", "0074-4014", "0074-3008" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LOPINAVIR", "RITONAVIR" ], "rxcui": [ "311369", "597730", "746645", "847741", "847745", "847749" ], "spl_id": [ "36abdfba-ddc2-43ae-9173-903d66a23b23" ], "spl_set_id": [ "8290add3-4449-4e58-6c97-8fe1eec972e3" ], "package_ndc": [ "0074-3956-46", "0074-4014-12", "0074-3008-60" ], "nui": [ "N0000000246", "N0000175889", "N0000185503", "N0000190114", "N0000190107", "N0000191001", "N0000182137", "N0000185607", "N0000190118", "N0000190113", "N0000182141", "N0000191266", "N0000185507", "N0000187064", "N0000190117" ], "pharm_class_moa": [ "HIV Protease Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 2C19 Inducers [MoA]", "Cytochrome P450 3A Inducers [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "UDP Glucuronosyltransferases Inducers [MoA]" ], "pharm_class_epc": [ "Protease Inhibitor [EPC]", "Cytochrome P450 3A Inhibitor [EPC]" ], "unii": [ "2494G1JF75", "O3J8G9O825" ] }, "update_date": "07/24/2026", "therapeutic_category": [ "Antiviral" ], "dosage_form": "Oral Solution", "presentation": "Kaletra, Oral Solution, 80 mg/1 mL; 20 mg/1 mL (NDC 0074-3956-46)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0070-10", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA016673" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0070", "0338-9651", "0338-9649", "0338-9655", "0338-9653", "0338-0078", "0338-0062", "0338-0074", "0338-0066", "0338-0082" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795607", "1795609", "1795610", "1795612", "1795616" ], "spl_id": [ "b28d6bb9-8496-48bd-b6aa-f67996d0829c" ], "spl_set_id": [ "36e9478c-5df0-4b47-b97d-de3626d7cb29" ], "package_ndc": [ "0338-9651-75", "0338-9649-75", "0338-9655-60", "0338-9653-60", "0338-0078-20", "0338-0062-30", "0338-0074-30", "0338-0066-20", "0338-0070-10", "0338-0070-12", "0338-0082-10", "0338-0082-12" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0070-10)", "company_name": "Baxter Healthcare", "status": "Current" }, { "discontinued_date": "07/24/2026", "update_type": "New", "initial_posting_date": "07/24/2026", "package_ndc": "0074-4014-12", "generic_name": "Lopinavir and Ritonavir Tablet", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA021906" ], "brand_name": [ "KALETRA" ], "generic_name": [ "LOPINAVIR AND RITONAVIR" ], "manufacturer_name": [ "AbbVie Inc." ], "product_ndc": [ "0074-4014", "0074-3956", "0074-3008" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LOPINAVIR", "RITONAVIR" ], "rxcui": [ "311369", "597730", "746645", "847741", "847745", "847749" ], "spl_id": [ "36abdfba-ddc2-43ae-9173-903d66a23b23" ], "spl_set_id": [ "8290add3-4449-4e58-6c97-8fe1eec972e3" ], "package_ndc": [ "0074-3956-46", "0074-4014-12", "0074-3008-60" ], "nui": [ "N0000000246", "N0000175889", "N0000185503", "N0000190114", "N0000190107", "N0000191001", "N0000182137", "N0000185607", "N0000190118", "N0000190113", "N0000182141", "N0000191266", "N0000185507", "N0000187064", "N0000190117" ], "pharm_class_moa": [ "HIV Protease Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 2C19 Inducers [MoA]", "Cytochrome P450 3A Inducers [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "UDP Glucuronosyltransferases Inducers [MoA]" ], "pharm_class_epc": [ "Protease Inhibitor [EPC]", "Cytochrome P450 3A Inhibitor [EPC]" ], "unii": [ "2494G1JF75", "O3J8G9O825" ] }, "update_date": "07/24/2026", "therapeutic_category": [ "Antiviral" ], "dosage_form": "Tablet", "presentation": "Kaletra, Tablet, 200 mg; 50 mg (NDC 0074-4014-12)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "05/07/2026", "update_type": "New", "initial_posting_date": "05/07/2026", "package_ndc": "63323-574-93", "generic_name": "Icatibant Acetate Injection", "contact_info": "847-550-2300", "related_info": "Discontinuation of the manufacturer of the drug", "openfda": { "application_number": [ "ANDA208317" ], "brand_name": [ "ICATIBANT" ], "generic_name": [ "ICATIBANT" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-574" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "ICATIBANT ACETATE" ], "rxcui": [ "1148141" ], "spl_id": [ "d1c9afa7-c4ac-4739-85f1-2ae82440210c" ], "spl_set_id": [ "52c12c15-c00b-4efc-952d-1425c907706a" ], "package_ndc": [ "63323-574-01", "63323-574-86", "63323-574-93" ], "unii": [ "325O8467XK" ] }, "update_date": "05/07/2026", "therapeutic_category": [ "Hematology" ], "dosage_form": "Injection", "presentation": "Icatibant Acetate, Injection, 10 mg/1 mL (NDC 63323-574-93)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "16729-295-31", "generic_name": "Carboplatin Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA206775" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Accord Healthcare, Inc." ], "product_ndc": [ "16729-295" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "35cf6068-f31a-211b-e063-6294a90a6b53" ], "spl_set_id": [ "48aa7ef3-9f44-2a08-e054-00144ff88e88" ], "package_ndc": [ "16729-295-31", "16729-295-33", "16729-295-34", "16729-295-12", "16729-295-38" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-31)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "02/10/2026", "update_type": "New", "initial_posting_date": "02/10/2026", "package_ndc": "63323-326-20", "generic_name": "Cefepime Hydrochloride Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": { "application_number": [ "ANDA065441" ], "brand_name": [ "CEFEPIME" ], "generic_name": [ "CEFEPIME" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-326", "63323-340" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CEFEPIME HYDROCHLORIDE" ], "rxcui": [ "1665088", "1665093" ], "spl_id": [ "8c2fbf43-34bd-49d1-bda8-a2191c8bc54b" ], "spl_set_id": [ "5e1695e0-1310-4cd8-a5da-ad1a7dcd1792" ], "package_ndc": [ "63323-326-21", "63323-326-20", "63323-340-21", "63323-340-20" ], "unii": [ "I8X1O0607P" ] }, "update_date": "02/10/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Cefepime Hydrochloride, Injection, 1 g (NDC 63323-326-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "70121-1574-1", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-525-7270", "availability": "Available", "openfda": { "application_number": [ "ANDA210043" ], "brand_name": [ "METHYLPREDNISOLONE ACETATE" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Amneal Pharmaceuticals LLC" ], "product_ndc": [ "70121-1574", "70121-1573" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1743779", "1743855" ], "spl_id": [ "af4215ff-94ca-44f8-8506-3024e738cd13" ], "spl_set_id": [ "d944240d-2c19-46ba-ad4f-3fbee7b8629c" ], "package_ndc": [ "70121-1573-1", "70121-1573-5", "70121-1574-1", "70121-1574-5" ], "unii": [ "43502P7F0P" ] }, "update_date": "06/17/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 70121-1574-1)", "company_name": "Amneal Pharmaceuticals", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "25021-311-02", "generic_name": "Furosemide Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Furosemide%20Injection&st=d", "contact_info": "866-625-1618", "availability": "Unavailable", "related_info": "Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product", "openfda": { "application_number": [ "ANDA213902" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-311" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "222ce48f-2856-4be2-b16f-6fca38c0dceb" ], "spl_set_id": [ "d63c1277-dd7e-4d21-9e80-68143f55e2dc" ], "package_ndc": [ "25021-311-02", "25021-311-04", "25021-311-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)", "company_name": "Gland Pharma Limited", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-046-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA214484" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "57664-046", "57664-047", "57664-048", "57664-049", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "560b4c9e-9cce-4717-e063-6294a90a58c9" ], "spl_set_id": [ "da3148af-f9b6-4725-adae-3595b4c7dc4b" ], "package_ndc": [ "57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 57664-046-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "23155-473-41", "generic_name": "Furosemide Injection", "contact_info": "855-228-9470", "availability": "Available", "openfda": { "application_number": [ "ANDA203428" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc." ], "product_ndc": [ "23155-473" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "c14acada-333e-43bb-b1cf-81d569e3e918" ], "spl_set_id": [ "1b9117d5-0dd9-4577-a1fd-bb0aaf7e68ec" ], "package_ndc": [ "23155-473-31", "23155-473-41", "23155-473-32", "23155-473-42", "23155-473-43", "23155-473-33", "23155-473-44", "23155-473-45" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-41)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/30/2020", "package_ndc": "63323-494-05", "generic_name": "Valproate Sodium Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Checkwholesalers for inventory", "openfda": { "application_number": [ "ANDA076539" ], "brand_name": [ "VALPROATE SODIUM" ], "generic_name": [ "VALPROATE SODIUM" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-494" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "VALPROATE SODIUM" ], "rxcui": [ "1099648" ], "spl_id": [ "f09a2148-edd9-4918-8359-7554ed263d3a", "fff889dc-6006-43c2-be57-01b2a5724b26" ], "spl_set_id": [ "3dfb6da1-f66a-4618-9f74-d2d6c16c0b58", "c572ece7-03d3-4c2a-aeb5-61f2023b28ea" ], "package_ndc": [ "63323-494-41", "63323-494-16", "63323-494-01", "63323-494-05" ], "unii": [ "5VOM6GYJ0D" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Injection", "presentation": "Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "55150-250-50", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA207183" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-250", "55150-167", "55150-168", "55150-169", "55150-170", "55150-171", "55150-172", "55150-249" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082" ], "spl_id": [ "39649703-e633-4a20-ba71-0c04dbf8ff2a" ], "spl_set_id": [ "ffecf450-1f01-4721-8e10-251385852612" ], "package_ndc": [ "55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-250-50)", "company_name": "Eugia US LLC", "status": "Current" }, { "discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-010-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 10 mg/.4 mL (NDC 82497-010-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "47781-174-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": { "application_number": [ "ANDA207388" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 5 MG,CLL" ], "manufacturer_name": [ "Alvogen Inc." ], "product_ndc": [ "47781-174", "47781-175", "47781-176", "47781-177", "47781-178", "47781-179", "47781-180" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "0374f0f7-9297-810c-38b3-623a72709a7d" ], "spl_set_id": [ "c907301d-e24d-9609-5529-fed14f94549f" ], "package_ndc": [ "47781-174-30", "47781-174-05", "47781-174-01", "47781-175-30", "47781-175-05", "47781-175-01", "47781-176-30", "47781-176-05", "47781-176-01", "47781-177-30", "47781-177-05", "47781-177-01", "47781-178-30", "47781-178-05", "47781-178-01", "47781-179-30", "47781-179-05", "47781-179-01", "47781-180-30", "47781-180-05", "47781-180-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5mg (NDC 47781-174-01)", "company_name": "Alvogen", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "47781-567-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": { "application_number": [ "ANDA214547" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Alvogen Inc." ], "product_ndc": [ "47781-567", "47781-562", "47781-563", "47781-564", "47781-565", "47781-566", "47781-568" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "db02ec6b-f17f-ab22-b671-e1ddb90e017c" ], "spl_set_id": [ "7f2dd6ee-3363-c87c-9693-ed838942556c" ], "package_ndc": [ "47781-562-01", "47781-563-01", "47781-564-01", "47781-565-01", "47781-566-01", "47781-567-01", "47781-568-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 47781-567-01)", "company_name": "Alvogen", "status": "Current" }, { "discontinued_date": "06/30/2026", "update_type": "New", "initial_posting_date": "06/30/2026", "package_ndc": "65219-281-15", "generic_name": "Gadobutrol Injection", "contact_info": "888-386-1300", "related_info": "Discontinuance of single dose vials, the other two Imaging Bulk Package(IBP) strengths are to remain in supply: the IBP strengths (18.1416 g/30 mL and 39.3068 g/65 mL); Marketed by Fresenius Kabi, USA", "openfda": { "application_number": [ "ANDA215061" ], "brand_name": [ "GADOBUTROL" ], "generic_name": [ "GADOBUTROL" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-281" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GADOBUTROL" ], "spl_id": [ "490c8c3e-3195-40af-8f34-40d8df2719c3" ], "spl_set_id": [ "007696d0-4b62-4937-9640-4ad619504df4" ], "package_ndc": [ "65219-281-00", "65219-281-02", "65219-281-03", "65219-281-07", "65219-281-08", "65219-281-10", "65219-281-05", "65219-281-15" ], "nui": [ "N0000183362", "N0000175862" ], "pharm_class_epc": [ "Gadolinium-based Contrast Agent [EPC]" ], "pharm_class_moa": [ "Magnetic Resonance Contrast Activity [MoA]" ], "unii": [ "1BJ477IO2L" ] }, "update_date": "06/30/2026", "therapeutic_category": [ "Medical Imaging" ], "dosage_form": "Injection", "presentation": "Gadobutrol, Injection, 604.72 mg/mL (NDC 65219-281-15)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "71288-722-32", "generic_name": "Bupivacaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-824-8426", "availability": "Limited Availability", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "update_date": "05/05/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 71288-722-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9043-01", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA071167" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-9043", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9046", "0409-9045", "0409-9042" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596" ], "spl_id": [ "6e442bfd-d3da-4913-8585-ce3485644364" ], "spl_set_id": [ "02a845c3-4521-4926-e397-25ab536e7cf6" ], "package_ndc": [ "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "50458-586-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET", "availability": "Available", "openfda": { "application_number": [ "NDA021121" ], "brand_name": [ "CONCERTA" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Janssen Pharmaceuticals, Inc." ], "product_ndc": [ "50458-586", "50458-585", "50458-588", "50458-587" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091157", "1091170", "1091172", "1091185", "1091187", "1091210", "1091212" ], "spl_id": [ "64d7c1e1-e7ed-4d74-a44d-13b4da64af9a" ], "spl_set_id": [ "1a88218c-5b18-4220-8f56-526de1a276cd" ], "package_ndc": [ "50458-585-01", "50458-588-01", "50458-586-01", "50458-587-01" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/19/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01)", "company_name": "Janssen Pharmaceuticals", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "55150-222-20", "generic_name": "Etomidate Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA206126" ], "brand_name": [ "ETOMIDATE" ], "generic_name": [ "ETOMIDATE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-222", "55150-221" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008" ], "spl_id": [ "278b160e-cdc4-451e-9405-cb001f443680" ], "spl_set_id": [ "0820f15a-046b-4185-a2b3-2e4051ee3d82" ], "package_ndc": [ "55150-221-10", "55150-222-20" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 40 mg/20 mL (NDC 55150-222-20)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4744-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Available", "openfda": { "application_number": [ "ANDA216944" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Apotex Corp." ], "product_ndc": [ "60505-4744", "60505-4739", "60505-4740", "60505-4741", "60505-4742", "60505-4743", "60505-4745" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "2eec36cd-6063-fea0-d6dd-b7a5c8df186b" ], "spl_set_id": [ "ecad4442-a644-18e3-6ff2-fdbac45eec47" ], "package_ndc": [ "60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 60505-4744-1)", "company_name": "Apotex Corp.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-2634-50", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA078591" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-2634" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "1724338", "1724340", "1724341" ], "spl_id": [ "50886ad5-eeca-4fe7-beb0-01305f92c65d" ], "spl_set_id": [ "3832ede8-d3fc-455d-ecab-3b77be5869f5" ], "package_ndc": [ "0409-2634-10", "0409-2634-01", "0409-2634-25", "0409-2634-05", "0409-2634-50" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 500 mg/50 mL (10 mg/mL) (NDC 0409-2634-50)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-1130-06", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "ANDA075880" ], "brand_name": [ "PREMASOL - SULFITE-FREE (AMINO ACID)" ], "generic_name": [ "LEUCINE, LYSINE, ISOLEUCINE, VALINE, HISTIDINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, TYROSINE, N-ACETYL-TYROSINE, ARGININE, PROLINE, ALANINE, GLUTAMIC ACIDE, SERINE, GLYCINE, ASPARTIC ACID, TAURINE, CYSTEINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "0338-1130", "0338-1131" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LEUCINE", "LYSINE ACETATE", "ISOLEUCINE", "VALINE", "HISTIDINE", "PHENYLALANINE", "THREONINE", "METHIONINE", "TRYPTOPHAN", "TYROSINE", "ARGININE", "PROLINE", "ALANINE", "GLUTAMIC ACID", "SERINE", "GLYCINE", "ASPARTIC ACID", "TAURINE", "CYSTEINE HYDROCHLORIDE" ], "rxcui": [ "801395", "801398", "801403", "801405" ], "spl_id": [ "c874a813-b145-4f7f-833e-97d6c4dd727c" ], "spl_set_id": [ "9afdcc3e-0d06-47f4-86ca-40da48b2b02b" ], "package_ndc": [ "0338-1130-03", "0338-1130-04", "0338-1130-06", "0338-1131-03" ], "nui": [ "N0000175780", "M0000922" ], "pharm_class_epc": [ "Amino Acid [EPC]" ], "pharm_class_cs": [ "Amino Acids [CS]" ], "unii": [ "GMW67QNF9C", "TTL6G7LIWZ", "04Y7590D77", "HG18B9YRS7", "4QD397987E", "47E5O17Y3R", "2ZD004190S", "AE28F7PNPL", "8DUH1N11BX", "42HK56048U", "94ZLA3W45F", "9DLQ4CIU6V", "OF5P57N2ZX", "3KX376GY7L", "452VLY9402", "TE7660XO1C", "30KYC7MIAI", "1EQV5MLY3D", "ZT934N0X4W" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-06)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "55150-335-01", "generic_name": "Carboplatin Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA205487" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-335", "55150-333", "55150-334", "55150-386" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "6029d051-ee8d-44cc-8dae-b91c3385d4c3", "5abfcb87-bb02-4384-9c9d-7d0e3e809311" ], "spl_set_id": [ "f5fe9a20-47a5-45b9-ab06-c6158d9b6aca", "5abfcb87-bb02-4384-9c9d-7d0e3e809311" ], "package_ndc": [ "55150-333-01", "55150-334-01", "55150-335-01", "55150-386-01", "55150-335-00", "55150-386-00" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450 mg/45 mL (NDC 55150-335-01)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "12/08/2025", "update_type": "New", "initial_posting_date": "12/08/2025", "package_ndc": "0781-9413-92", "generic_name": "Ampicillin Sodium Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of private label only", "openfda": { "application_number": [ "ANDA062738" ], "brand_name": [ "AMPICILLIN" ], "generic_name": [ "AMPICILLIN SODIUM" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-9413", "0781-9412" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "AMPICILLIN SODIUM" ], "rxcui": [ "1721475", "1721476" ], "spl_id": [ "f1afd007-8e8c-40e2-b353-8def35a0ce8b" ], "spl_set_id": [ "f77db491-31c4-4a7c-a114-0f3244c97090" ], "package_ndc": [ "0781-9412-15", "0781-9412-92", "0781-9413-15", "0781-9413-92" ], "unii": [ "JFN36L5S8K" ] }, "update_date": "12/08/2025", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Ampicillin Sodium, Injection, 2 g (NDC 0781-9413-92)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "62135-736-90", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "845-268-5000 Ext. 510", "availability": "Available", "openfda": { "application_number": [ "ANDA072368" ], "brand_name": [ "FLURAZEPAM HYDROCHLORIDE" ], "generic_name": [ "FLURAZEPAM HYDROCHLORIDE" ], "manufacturer_name": [ "Chartwell RX, LLC" ], "product_ndc": [ "62135-736", "62135-737" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "FLURAZEPAM HYDROCHLORIDE" ], "rxcui": [ "1298088", "1298091" ], "spl_id": [ "25893c92-c8f1-567a-e063-6294a90a00d4" ], "spl_set_id": [ "8f476891-1346-4e8c-ac1b-f8cbdc64f5a1" ], "package_ndc": [ "62135-736-30", "62135-736-90", "62135-737-30", "62135-737-90" ], "unii": [ "756RDM536M" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Oncology", "Other" ], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "01/13/2022", "package_ndc": "25021-131-82", "generic_name": "Metronidazole Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Limited Availability", "related_info": "Estimated recovery: August 2026; Marketed by Sagent Pharmaceuticals", "openfda": { "application_number": [ "ANDA206191" ], "brand_name": [ "METRONIDAZOLE" ], "generic_name": [ "METRONIDAZOLE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-131" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "METRONIDAZOLE" ], "rxcui": [ "311683" ], "spl_id": [ "416d01ed-8a1e-4626-bee0-eb1409c2465c" ], "spl_set_id": [ "d46870f5-e2b1-46bd-8413-4a0a8bcf3175" ], "package_ndc": [ "25021-131-82" ], "nui": [ "N0000175435", "M0014907" ], "pharm_class_epc": [ "Nitroimidazole Antimicrobial [EPC]" ], "pharm_class_cs": [ "Nitroimidazoles [CS]" ], "unii": [ "140QMO216E" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Metronidazole, Injection, 500 mg/100 mL (NDC 25021-131-82)", "company_name": "InfoRLife SA", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "71288-563-84", "generic_name": "Liraglutide Injection", "contact_info": "844-824-8426", "availability": "Available", "openfda": { "application_number": [ "ANDA218115" ], "brand_name": [ "LIRAGLUTIDE" ], "generic_name": [ "LIRAGLUTIDE" ], "manufacturer_name": [ "Meitheal Pharmaceuticals Inc." ], "product_ndc": [ "71288-563" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "LIRAGLUTIDE" ], "rxcui": [ "897122" ], "spl_id": [ "a0bb0116-f90a-490b-9ca9-5bcd6210c763" ], "spl_set_id": [ "0efc3a89-211a-4496-baab-e8265e07de2b" ], "package_ndc": [ "71288-563-84", "71288-563-85" ], "nui": [ "N0000178480", "M0160181", "N0000020058" ], "pharm_class_epc": [ "GLP-1 Receptor Agonist [EPC]" ], "pharm_class_cs": [ "Glucagon-Like Peptide 1 [CS]" ], "pharm_class_moa": [ "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]" ], "unii": [ "839I73S42A" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 71288-563-84)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-407-50", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": { "application_number": [ "ANDA077856" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Solco Healthcare LLC" ], "product_ndc": [ "43547-407", "43547-406", "43547-408" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "dc17b9d4-2890-4f6c-8476-daa39d0cbc9c" ], "spl_set_id": [ "4acbb7a9-4db5-4497-b8db-9f358b3f6fb4" ], "package_ndc": [ "43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "07/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 43547-407-50)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "59651-723-01", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": { "application_number": [ "ANDA075150" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Aurobindo Pharma Limited" ], "product_ndc": [ "59651-723", "59651-722", "59651-724" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "b1582eb7-af35-45d5-a52e-0e380d08527d" ], "spl_set_id": [ "b1582eb7-af35-45d5-a52e-0e380d08527d" ], "package_ndc": [ "59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "06/02/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 59651-723-01)", "company_name": "Aurobindo Pharma USA", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-4910-34", "generic_name": "Atropine Sulfate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Atropine+Sulfate+Injection&st=d&tab=tabs-2", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/01/2017", "package_ndc": "0703-0113-03", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA078591" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Teva Parenteral Medicines, Inc." ], "product_ndc": [ "0703-0113", "0703-0110", "0703-0018" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "1724338", "1724340", "1724341" ], "spl_id": [ "540b835a-db66-417c-8507-0c1ed05c95bf" ], "spl_set_id": [ "f0b78db9-a38c-41bb-8233-5e93f7f18c5c" ], "package_ndc": [ "0703-0110-01", "0703-0110-03", "0703-0113-01", "0703-0113-03", "0703-0018-01" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 0703-0113-03)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-020-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 20 mg/.4 mL (NDC 82497-020-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "06/06/2018", "package_ndc": "72266-118-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.", "openfda": { "application_number": [ "ANDA204216" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "FOSUN PHARMA USA INC" ], "product_ndc": [ "72266-118", "72266-234", "72266-119" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "4dc7a413-f46f-2537-e063-6294a90a9b8c" ], "spl_set_id": [ "1aae6a4d-0909-4672-aa26-e3f2d8c4d413" ], "package_ndc": [ "72266-234-01", "72266-234-25", "72266-118-01", "72266-118-25", "72266-119-01", "72266-119-25" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 72266-118-25)", "company_name": "Gland Pharma Limited", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "06/01/2026", "update_type": "New", "initial_posting_date": "06/01/2026", "package_ndc": "60505-6282-3", "generic_name": "Carboplatin Injection", "contact_info": "Apotex Inc.: 800-706-5575", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA077861" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Apotex Corp." ], "product_ndc": [ "60505-6282" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "0e68e276-b0df-4f03-e063-6394a90a22b9" ], "spl_set_id": [ "1c275825-0275-4c73-b650-e4c1519f13b8" ], "package_ndc": [ "60505-6282-1", "60505-6282-3", "60505-6282-6", "60505-6282-7" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 150 mg/15 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-3)", "company_name": "Teyro Labs", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0264-4500-00", "generic_name": "Amino Acid Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "ANDA091112" ], "brand_name": [ "PLENAMINE" ], "generic_name": [ "LYSINE ACETATE, LEUCINE, PHENYLALANINE, VALINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, HISTIDINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, AND TYROSINE" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-4500" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LYSINE ACETATE", "LEUCINE", "PHENYLALANINE", "VALINE", "ISOLEUCINE", "METHIONINE", "THREONINE", "TRYPTOPHAN", "ALANINE", "ARGININE", "GLYCINE", "HISTIDINE", "PROLINE", "GLUTAMIC ACID", "SERINE", "ASPARTIC ACID", "TYROSINE" ], "rxcui": [ "800584", "1601982" ], "spl_id": [ "905f7c55-bf0d-4150-90ef-e8f1a5455bc1" ], "spl_set_id": [ "a3244d1a-45b0-4e4c-bd96-f0632d761a1f" ], "package_ndc": [ "0264-4500-00", "0264-4500-05" ], "nui": [ "N0000175780", "M0000922" ], "pharm_class_epc": [ "Amino Acid [EPC]" ], "pharm_class_cs": [ "Amino Acids [CS]" ], "unii": [ "TTL6G7LIWZ", "GMW67QNF9C", "47E5O17Y3R", "HG18B9YRS7", "04Y7590D77", "AE28F7PNPL", "2ZD004190S", "8DUH1N11BX", "OF5P57N2ZX", "94ZLA3W45F", "TE7660XO1C", "4QD397987E", "9DLQ4CIU6V", "3KX376GY7L", "452VLY9402", "30KYC7MIAI", "42HK56048U" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "Plenamine, Injection, 0.15 (NDC 0264-4500-00)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3475-03", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA011757" ], "brand_name": [ "DEPO-MEDROL" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-3475", "0009-3073" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1743779", "1743781", "1743855", "1743856" ], "spl_id": [ "742fcec7-8db3-4cc6-b276-42587a993810" ], "spl_set_id": [ "9a7b3837-e038-48bf-97e9-78ad463760dc" ], "package_ndc": [ "0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-3475-03)", "company_name": "Pfizer Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "11/14/2017", "package_ndc": "0264-9872-00", "generic_name": "Heparin Sodium Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "NDA019953" ], "brand_name": [ "HEPARIN SODIUM IN SODIUM CHLORIDE" ], "generic_name": [ "HEPARIN SODIUM IN SODIUM CHLORIDE" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-9872" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "HEPARIN SODIUM" ], "rxcui": [ "1658690", "1658692" ], "spl_id": [ "48e17807-e73d-4ea2-81bc-901355903aa7" ], "spl_set_id": [ "a3041c04-0ea8-4d36-81ce-c5091c906316" ], "package_ndc": [ "0264-9872-10", "0264-9872-00" ], "unii": [ "ZZ45AB24CA" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Hematology" ], "dosage_form": "Injection", "presentation": "Heparin Sodium 2,000 Units in Sodium Chloride 0.9% in Plastic Container, Injection, 200 [USP'U]/100 mL (NDC 0264-9872-00)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "63323-123-10", "generic_name": "Methotrexate Sodium Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesaler for inventory", "openfda": { "application_number": [ "ANDA040263" ], "brand_name": [ "METHOTREXATE" ], "generic_name": [ "METHOTREXATE SODIUM" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-123" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "METHOTREXATE SODIUM" ], "rxcui": [ "1946772" ], "spl_id": [ "880c2caa-1b11-45ce-a54e-a3733da367f0" ], "spl_set_id": [ "b585f621-f6c9-4735-ab61-bd1b401f3df0" ], "package_ndc": [ "63323-123-10" ], "unii": [ "3IG1E710ZN" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Rheumatology", "Oncology" ], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 25 mg/1 mL (NDC 63323-123-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4776-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA080408" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4776", "0409-4713", "0409-4278", "0409-4279", "0409-4282", "0409-4277", "0409-4276", "0409-4275" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763" ], "spl_id": [ "05d1a200-9d75-4e48-b14a-5069d4ab816f" ], "spl_set_id": [ "3b2dd84e-cee8-4e58-d494-395a65a353a0" ], "package_ndc": [ "0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free, Injection, 300 mg/20 mL (1.5%; 15 mg/mL) (NDC 0409-4776-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/17/2015", "package_ndc": "21586-012-02", "generic_name": "Cefotaxime Sodium Powder, for Solution", "related_info_link": "https://www.fda.gov/media/193116/download?attachment", "contact_info": "800-881-3550", "availability": "Available", "openfda": { "brand_name": [ "CEFOTAXIME" ], "generic_name": [ "CEFOTAXIME INJECTION" ], "manufacturer_name": [ "SteriMax Inc." ], "product_ndc": [ "21586-012", "21586-011" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CEFOTAXIME SODIUM" ], "rxcui": [ "1656313", "1656318" ], "spl_id": [ "7a77a18a-3d8c-4bac-8d21-54a88db396f6" ], "spl_set_id": [ "8efe3bd0-c43a-2bd6-e053-2a95a90a92fa" ], "package_ndc": [ "21586-011-01", "21586-011-02", "21586-012-01", "21586-012-02" ], "unii": [ "258J72S7TZ" ] }, "update_date": "06/15/2026", "therapeutic_category": [ "Anti-Infective", "Pediatric" ], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 2 g (NDC 21586-012-02)", "company_name": "SteriMax, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "61269-620-10", "generic_name": "Clonazepam Tablet", "contact_info": "orders@h2-pharma.com", "availability": "Available", "related_info": "Marketed by H2-Pharma", "openfda": { "application_number": [ "NDA017533" ], "brand_name": [ "KLONOPIN" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "H2-Pharma, LLC" ], "product_ndc": [ "61269-620", "61269-605", "61269-610" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529", "206157", "206159", "206160" ], "spl_id": [ "63cfdab9-fb3d-4c2b-bf88-8ba841dba839" ], "spl_set_id": [ "cfa0d79a-843c-4b88-95a1-e9511d649ca1" ], "package_ndc": [ "61269-605-10", "61269-610-10", "61269-620-10" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Klonopin, Tablet, 2 mg (NDC 61269-620-10)", "company_name": "Cheplapharm Arzneimittel GmbH", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "0409-3815-12", "generic_name": "Morphine Sulfate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA073510" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3815", "0409-3814" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRATHECAL", "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "1728783", "1728800" ], "spl_id": [ "0a2ba20b-448f-4412-9899-b82040ebfa7d" ], "spl_set_id": [ "1d181906-f3ec-4222-1883-e61577a3122e" ], "package_ndc": [ "0409-3814-11", "0409-3814-12", "0409-3815-11", "0409-3815-12" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "discontinued_date": "07/23/2026", "update_type": "New", "initial_posting_date": "07/23/2026", "package_ndc": "0574-7093-12", "generic_name": "Hydrocortisone Acetate Suppository", "contact_info": "(800) 775-2054", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "HYDROCORTISONE ACETATE" ], "generic_name": [ "HYDROCORTISONE ACETATE" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-7093", "0574-7090" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RECTAL" ], "substance_name": [ "HYDROCORTISONE ACETATE" ], "rxcui": [ "1291082", "1291085" ], "spl_id": [ "5ae35aec-6ba9-48b8-8b5f-c1b5accb9e1c" ], "spl_set_id": [ "2fdb9940-6da8-49b0-a236-9817943f7a4b" ], "package_ndc": [ "0574-7090-12", "0574-7093-12" ], "unii": [ "3X7931PO74" ] }, "update_date": "07/23/2026", "therapeutic_category": [ "Analgesia/Addiction", "Other" ], "dosage_form": "Suppository", "presentation": "Hydrocortisone Acetate, Suppository, 30 mg (NDC 0574-7093-12)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0280-03", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA011757" ], "brand_name": [ "DEPO-MEDROL" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0280", "0009-0274", "0009-0306" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1358510", "1358512", "1358610", "1358612", "1358617", "1358619" ], "spl_id": [ "267dd735-f800-4735-ba1c-d39d00f0cee5" ], "spl_set_id": [ "823b0010-2b57-4e76-b5ac-4a8c2963438f" ], "package_ndc": [ "0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-03)", "company_name": "Pfizer Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "55150-159-74", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA203040" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-159", "55150-158", "55150-160" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1737566", "1737568", "1737757" ], "spl_id": [ "cc439f66-fdd6-41f9-8a08-3f623898f20c" ], "spl_set_id": [ "5524cbfd-d6e6-42eb-aaa5-22495e0a86b6" ], "package_ndc": [ "55150-158-72", "55150-159-74", "55150-160-72" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-159-74)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "16729-136-00", "generic_name": "Clonazepam Tablet", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": { "application_number": [ "ANDA077147" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Accord Healthcare Inc." ], "product_ndc": [ "16729-136", "16729-137", "16729-138" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "0e1e7f41-f78b-27cf-e063-6394a90a1ae0" ], "spl_set_id": [ "ebc11109-e7bf-452d-b675-4b3236d54164" ], "package_ndc": [ "16729-136-00", "16729-136-16", "16729-137-00", "16729-137-16", "16729-138-00", "16729-138-16" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 16729-136-00)", "company_name": "Accord Healthcare Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "0093-3213-05", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA074569" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0093-3213", "0093-0832", "0093-3212" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "d6abe4e3-7699-4ead-95f4-739a961b23ad" ], "spl_set_id": [ "8069b1a0-7c06-4252-b44e-e2eef065d9b8" ], "package_ndc": [ "0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 0093-3213-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-353-30", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 2.5 mg (NDC 13668-353-30)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "11/01/2017", "package_ndc": "0409-1805-01", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA200403" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1805", "0409-1283", "0409-1312", "0409-4264" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897756", "897757", "1433251", "1724383", "1724644", "2675350" ], "spl_id": [ "766e302a-2d03-4d93-b237-2348b57ee517" ], "spl_set_id": [ "f9ca2ef5-46d8-475a-a26e-f7c8becd6db7" ], "package_ndc": [ "0409-1283-17", "0409-1283-37", "0409-1312-16", "0409-1312-36", "0409-4264-11", "0409-4264-01", "0409-1805-10", "0409-1805-01" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 0.25 mg/ 0.5 mL NexJect™ Single-dose Syringe Luer Lock (no needle) (NDC 0409-1805-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "08/13/2026", "update_type": "New", "initial_posting_date": "08/13/2026", "package_ndc": "65649-400-01", "generic_name": "Polyethylene glycol 3350, Sodium Ascorbate, Sodium Sulfate Anhydrous, Ascorbic Acid, Sodium Chloride, and Potassium Chloride Oral Solution", "contact_info": "800-321-4576", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA209381" ], "brand_name": [ "PLENVU" ], "generic_name": [ "POLYETHYLENE GLYCOL 3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, ASCORBIC ACID, SODIUM ASCORBATE" ], "manufacturer_name": [ "Salix Pharmaceuticals, Inc" ], "product_ndc": [ "65649-400" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "rxcui": [ "2045233", "2045243", "2045244", "2045245" ], "spl_id": [ "4919e150-c34f-4ad3-8137-42f8cf91b997" ], "spl_set_id": [ "79f930fa-5674-4f30-8ae8-9448d6243797" ], "package_ndc": [ "65649-400-02", "65649-400-01" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Oral Solution", "presentation": "Plenvu, Oral Solution, KIT (NDC 65649-400-01)", "company_name": "Salix Pharmaceuticals, a division of Bausch Health US, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "64850-501-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": { "application_number": [ "ANDA211352" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Elite Laboratories, Inc." ], "product_ndc": [ "64850-501", "64850-500", "64850-502", "64850-503", "64850-504", "64850-505", "64850-506" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "a41cf8e5-cb1b-488c-96b3-3bef8283d6c4" ], "spl_set_id": [ "e677690f-790f-4626-ad78-097cdb6ea540" ], "package_ndc": [ "64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 64850-501-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0551-11", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA020179" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "0338-0551" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795609", "1795616" ], "spl_id": [ "1abb6ba4-fa29-4807-8623-3bd98ac11440" ], "spl_set_id": [ "7de48bdb-9a05-4f2a-bbff-dcfeb284ca6e" ], "package_ndc": [ "0338-0551-11", "0338-0551-18" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0551-11)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "66794-230-42", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "855-273-0154", "availability": "Available", "related_info": "Marketed by Piramal Critical Care Inc.: 800-414-1901", "openfda": { "application_number": [ "ANDA202126" ], "brand_name": [ "DEXMEDETOMIDINE" ], "generic_name": [ "DEXMEDETOMIDINE" ], "manufacturer_name": [ "Piramal Critical Care Inc" ], "product_ndc": [ "66794-230" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "309710" ], "spl_id": [ "5354326c-c6e7-cc50-e063-6294a90a7833" ], "spl_set_id": [ "b93a71ed-0f9e-1ff9-e053-2995a90a789d" ], "package_ndc": [ "66794-230-02", "66794-230-42" ], "unii": [ "1018WH7F9I" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 ug/2 mL (NDC 66794-230-42)", "company_name": "Gland Pharma Limited", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "12/22/2021", "package_ndc": "68180-659-07", "generic_name": "Rifampin Capsule", "contact_info": "866-587-4617", "availability": "Available", "openfda": { "application_number": [ "ANDA090034" ], "brand_name": [ "RIFAMPIN" ], "generic_name": [ "RIFAMPIN" ], "manufacturer_name": [ "Lupin Pharmaceuticals, Inc." ], "product_ndc": [ "68180-659", "68180-658" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RIFAMPIN" ], "rxcui": [ "198201", "198202" ], "spl_id": [ "5ed1edac-e11e-4f87-b390-e770a69a9b37" ], "spl_set_id": [ "b56004f0-f23d-47f6-80c7-39884fccbccc" ], "package_ndc": [ "68180-658-06", "68180-658-01", "68180-659-06", "68180-659-07", "68180-659-01" ], "nui": [ "N0000175500", "M0019113" ], "pharm_class_epc": [ "Rifamycin Antibacterial [EPC]" ], "pharm_class_cs": [ "Rifamycins [CS]" ], "unii": [ "VJT6J7R4TR" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 68180-659-07)", "company_name": "Lupin Pharmaceuticals, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-493-91", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE MPF" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-493", "63323-492", "63323-496" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "rxcui": [ "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737636", "1737637", "1737640", "1737641", "1737763", "1737764" ], "spl_id": [ "fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df" ], "spl_set_id": [ "d5e0d06f-ba1e-44d4-aa89-39d6c146dc23" ], "package_ndc": [ "63323-492-08", "63323-492-97", "63323-493-03", "63323-493-97", "63323-493-01", "63323-493-91", "63323-496-03", "63323-496-97" ], "unii": [ "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 15 mg/1 mL (NDC 63323-493-91)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0641-6057-25", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA075243" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6057", "0641-6059", "0641-6056", "0641-6061", "0641-6063", "0641-6060" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "311700", "311702" ], "spl_id": [ "559c03fb-24ea-4b7b-8afd-e33cb3a2340a" ], "spl_set_id": [ "575d8bf0-7af7-427c-a231-966e2a5e070d" ], "package_ndc": [ "0641-6057-01", "0641-6057-10", "0641-6057-25", "0641-6059-01", "0641-6059-10", "0641-6056-01", "0641-6056-10", "0641-6061-01", "0641-6061-10", "0641-6061-25", "0641-6063-01", "0641-6063-10", "0641-6063-25", "0641-6060-01", "0641-6060-10" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 0641-6057-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4665-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": { "application_number": [ "ANDA215802" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Lannett Company, Inc." ], "product_ndc": [ "0527-4665", "0527-4661", "0527-4662", "0527-4663", "0527-4664", "0527-4666", "0527-4667" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "cb49954d-0f9d-4471-bc86-0c926473c00b" ], "spl_set_id": [ "2cedb4c2-1e40-4bc4-b9f4-127150c4afbd" ], "package_ndc": [ "0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0527-4665-37)", "company_name": "Lannett Company, Inc.", "status": "Current" }, { "discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "70370-5025-1", "generic_name": "Crinecerfont Capsule", "contact_info": "858-617-7600", "related_info": "Neurocrine is discontinuing only the 25 mg soft gel capsule dose strength (NDC 70370-5025-01). The 50mg and 100mg soft gel capsule dose strength (NDC 70370-5050-1 and 70370-5100-1), and 50 mg/mL oral solution will continue to be marketed (NDC 70370-5250-1).", "update_date": "04/28/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Capsule", "presentation": "Crenessity, Capsule, 25 mg (NDC 70370-5025-1)", "company_name": "Neurocrine Biosciences, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "72572-127-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "877-495-6856", "availability": "Available", "related_info": "Distributed by Civica", "openfda": { "application_number": [ "ANDA212791" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "CIVICA, INC." ], "product_ndc": [ "72572-127", "72572-128" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909" ], "spl_id": [ "8906e391-411f-456b-8263-17e0e05bbb35" ], "spl_set_id": [ "1faf1ac8-ff9b-4ed9-b562-06dab971173a" ], "package_ndc": [ "72572-127-01", "72572-127-10", "72572-128-01", "72572-128-08" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 mcg/50 mL (4 ug/1 mL) (NDC 72572-127-10)", "company_name": "Azurity Pharmaceuticals, Inc", "status": "Current" }, { "discontinued_date": "10/31/2025", "update_type": "New", "initial_posting_date": "10/31/2025", "package_ndc": "0603-5168-21", "generic_name": "Phenobarbital Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "PHENOBARBITAL" ], "generic_name": [ "PHENOBARBITAL" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "0603-5168", "0603-5165", "0603-5166", "0603-5167" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "PHENOBARBITAL" ], "rxcui": [ "198086", "199164", "199167", "199168" ], "spl_id": [ "f8c5136e-e35c-4425-8d49-b7f92c827b42" ], "spl_set_id": [ "069b92ce-0061-4724-8c25-08d8596770a2" ], "package_ndc": [ "0603-5165-21", "0603-5165-32", "0603-5166-16", "0603-5166-20", "0603-5166-02", "0603-5166-21", "0603-5166-22", "0603-5166-32", "0603-5167-21", "0603-5167-32", "0603-5168-21", "0603-5168-32" ], "unii": [ "YQE403BP4D" ] }, "update_date": "10/31/2025", "therapeutic_category": [ "Analgesia/Addiction", "Neurology", "Other" ], "dosage_form": "Tablet", "presentation": "Phenobarbital, Tablet, 97.2 mg (NDC 0603-5168-21)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "01/01/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "55513-810-60", "generic_name": "Ivabradine Hydrochloride Tablet", "contact_info": "1-800-772-6436", "related_info": "Discontinuation of the manufacture of the drug product", "openfda": { "application_number": [ "NDA206143" ], "brand_name": [ "CORLANOR" ], "generic_name": [ "IVABRADINE" ], "manufacturer_name": [ "Amgen Inc" ], "product_ndc": [ "55513-810", "55513-800", "55513-813" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "IVABRADINE HYDROCHLORIDE" ], "rxcui": [ "1649485", "1649491", "1649493", "1649495", "2168592", "2168596" ], "spl_id": [ "8ab000cd-0258-489a-b1bb-4cc1ca359d6c" ], "spl_set_id": [ "92018a65-38f6-45f7-91d4-a34921b81d0d" ], "package_ndc": [ "55513-800-60", "55513-800-99", "55513-810-60", "55513-813-01", "55513-813-28" ], "unii": [ "TP19837BZK" ] }, "update_date": "03/24/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Corlanor, Tablet, eq. 7.5 mg base (NDC 55513-810-60)", "company_name": "Amgen Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-354-30", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 5 mg (NDC 13668-354-30)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-607-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": { "application_number": [ "ANDA216266" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE CAPSULES" ], "manufacturer_name": [ "Solco Healthcare US,LLC" ], "product_ndc": [ "43547-607", "43547-602", "43547-603", "43547-604", "43547-605", "43547-606", "43547-608" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "d6435613-e052-4b4f-8bf7-4acb7458d8df" ], "spl_set_id": [ "68b10d9f-ca3e-493d-a309-45f1d7e08061" ], "package_ndc": [ "43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/29/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 43547-607-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0527-0760-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-834-0530", "availability": "Available", "openfda": { "application_number": [ "ANDA215565" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Lannett Company, LLC" ], "product_ndc": [ "0527-0760", "0527-0761", "0527-0762", "0527-0763", "0527-0764", "0527-0765", "0527-0766" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "391d7c4a-47df-41ce-b1ba-3c4758adf87f" ], "spl_set_id": [ "f92497b5-baea-4760-b615-45a0b6184402" ], "package_ndc": [ "0527-0760-37", "0527-0761-37", "0527-0762-37", "0527-0763-37", "0527-0764-37", "0527-0765-37", "0527-0766-37" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0527-0760-37)", "company_name": "Lannett Company, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "44567-600-04", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "WG Critical Care 888-493-0861", "availability": "Available", "related_info": "Marketed by WG Critical Care", "openfda": { "application_number": [ "NDA206628" ], "brand_name": [ "DEXMEDETOMIDINE" ], "generic_name": [ "DEXMEDETOMIDINE" ], "manufacturer_name": [ "WG Critical Care, LLC" ], "product_ndc": [ "44567-600", "44567-601", "44567-602", "44567-603" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909", "1788947" ], "spl_id": [ "42a0bb50-be84-4c46-abfd-fd44c6f10087" ], "spl_set_id": [ "0d2710f2-ee47-4114-ab5c-8dca74cdcb8d" ], "package_ndc": [ "44567-600-04", "44567-601-04", "44567-602-24", "44567-603-24" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-600-04)", "company_name": "HQ Specialty Pharma", "status": "Current" }, { "discontinued_date": "01/20/2026", "update_type": "New", "initial_posting_date": "01/20/2026", "package_ndc": "65219-434-20", "generic_name": "Piperacillin and Tazobactam Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA203719" ], "brand_name": [ "PIPERACILLIN AND TAZOBACTAM" ], "generic_name": [ "PIPERACILLIN AND TAZOBACTAM" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-434", "65219-436", "65219-259" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "PIPERACILLIN SODIUM", "TAZOBACTAM SODIUM" ], "rxcui": [ "1659131", "1659137", "1659149" ], "spl_id": [ "76af03be-bc73-40f9-bde0-31fe9c359ca2" ], "spl_set_id": [ "a798faf5-cd97-4e35-a700-94c372978c46" ], "package_ndc": [ "65219-434-02", "65219-434-20", "65219-436-02", "65219-436-20", "65219-259-05", "65219-259-45" ], "unii": [ "UXA545ABTT", "M98T69Q7HP" ] }, "update_date": "01/20/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Piperacillin and Tazobactam, Injection, 2.25 g vial (NDC 65219-434-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/26/2018", "package_ndc": "25021-701-02", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": { "application_number": [ "ANDA204216" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-701", "25021-700" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "cb23332a-48fa-458b-93ab-c4eef189a051" ], "spl_set_id": [ "62591551-a644-4b2c-a0de-982e906fabc3" ], "package_ndc": [ "25021-700-01", "25021-701-01", "25021-701-02" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)", "company_name": "Sagent Pharmaceuticals", "status": "Current" }, { "discontinued_date": "10/20/2025", "update_type": "New", "initial_posting_date": "10/20/2025", "package_ndc": "0781-3315-70", "generic_name": "Oxaliplatin Injection", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA078817" ], "brand_name": [ "OXALIPLATIN" ], "generic_name": [ "OXALIPLATIN" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-3315", "0781-3317" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "OXALIPLATIN" ], "rxcui": [ "1736776", "1736781" ], "spl_id": [ "f3766495-fce3-461c-8c95-e890f5e3383f" ], "spl_set_id": [ "ab162009-6f84-4d56-ab56-5e84409ec814" ], "package_ndc": [ "0781-3315-70", "0781-3317-80" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "04ZR38536J" ] }, "update_date": "10/20/2025", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Oxaliplatin, Injection, 5 mg/1 mL (NDC 0781-3315-70)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-117-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": { "application_number": [ "NDA208510" ], "brand_name": [ "VYVANSE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "59417-117", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-118", "59417-119", "59417-120" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469" ], "spl_id": [ "81d087b6-4cb4-466a-9693-679edeb062e2" ], "spl_set_id": [ "704e4378-ca83-445c-8b45-3cfa51c1ecad" ], "package_ndc": [ "59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 30 mg (NDC 59417-117-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/10/2020", "package_ndc": "0338-9555-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: September 2026", "openfda": { "application_number": [ "ANDA208532" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "0338-9555", "0338-9557" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909" ], "spl_id": [ "594e9faa-bc32-42e0-9c0a-8fa9460b1e24" ], "spl_set_id": [ "8ccb45a7-8290-469c-9644-a4dca967d88f" ], "package_ndc": [ "0338-9555-24", "0338-9557-12" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 0338-9555-24)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8885-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Available", "openfda": { "application_number": [ "ANDA040440" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "SpecGx LLC" ], "product_ndc": [ "0406-8885", "0406-8891", "0406-8884", "0406-8892", "0406-8893", "0406-8894" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "1009145" ], "spl_id": [ "0d3fb5ba-ff79-4862-bc1d-45b8343e115b" ], "spl_set_id": [ "72ddd1c9-ddbd-4c95-acd9-003189a353a3" ], "package_ndc": [ "0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 0406-8885-01)", "company_name": "SpecGx LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "06/28/2022", "package_ndc": "0143-9392-10", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA210594" ], "brand_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "generic_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9392", "0143-9391", "0143-9393" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "rxcui": [ "1729578", "1729584", "1729710" ], "spl_id": [ "5c5e498b-d829-4f78-bcca-466631014767" ], "spl_set_id": [ "9d289052-1eb6-4ba2-a3ca-d2e542a052ae" ], "package_ndc": [ "0143-9391-01", "0143-9391-10", "0143-9392-01", "0143-9392-10", "0143-9393-01", "0143-9393-10" ], "unii": [ "5V444H5WIC" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 2 mg per vial (NDC 0143-9392-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "06/08/2026", "update_type": "New", "initial_posting_date": "06/08/2026", "package_ndc": "0088-2161-30", "generic_name": "Leflunomide Tablet", "contact_info": "800-981-2491", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA020905" ], "brand_name": [ "ARAVA" ], "generic_name": [ "LEFLUNOMIDE" ], "manufacturer_name": [ "sanofi-aventis U.S. LLC" ], "product_ndc": [ "0088-2161", "0088-2160", "0088-2162" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LEFLUNOMIDE" ], "rxcui": [ "205284", "205285", "205286", "213377", "213379", "213380" ], "spl_id": [ "765327c7-cb5b-4637-84da-4fd9a024ad96" ], "spl_set_id": [ "320f63f2-fac3-4aee-aff8-85724e00ef52" ], "package_ndc": [ "0088-2160-30", "0088-2161-30", "0088-2162-33" ], "nui": [ "N0000175713" ], "pharm_class_epc": [ "Antirheumatic Agent [EPC]" ], "unii": [ "G162GK9U4W" ] }, "update_date": "06/08/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Tablet", "presentation": "Arava, Tablet, 20 mg (NDC 0088-2161-30)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "43066-007-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "ANDA091115" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "43066-007", "43066-013" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "9e0317de-2d78-4fd8-8926-4c7b476f3ed4" ], "spl_set_id": [ "31e15c3f-aefa-4379-b684-7707744fe40d" ], "package_ndc": [ "43066-007-10", "43066-013-10" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 50 mg/5 mL (NDC 43066-007-10)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "57664-608-88", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "Currently not marketed", "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6024-10", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Inventory available in vial presentations.", "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 ug/1 mL (NDC 0641-6024-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "63323-806-50", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release September 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "ANDA210762" ], "brand_name": [ "FENTANYL CITRATE" ], "generic_name": [ "FENTANYL CITRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-806" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FENTANYL CITRATE" ], "rxcui": [ "1735003", "1735007", "1735008", "1735013", "2168270" ], "spl_id": [ "341b092a-1f6f-40f1-98f2-9346bf2e1242" ], "spl_set_id": [ "38d0c14a-a0c1-44cc-a939-0304eb8037d6" ], "package_ndc": [ "63323-806-11", "63323-806-01", "63323-806-12", "63323-806-02", "63323-806-13", "63323-806-05", "63323-806-14", "63323-806-20", "63323-806-50" ], "unii": [ "MUN5LYG46H" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-50)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "0338-0004-02", "generic_name": "Sterile Water Irrigant", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA017428" ], "brand_name": [ "STERILE WATER" ], "generic_name": [ "WATER" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0004", "0338-0003" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "IRRIGATION" ], "substance_name": [ "WATER" ], "rxcui": [ "150985" ], "spl_id": [ "97390588-b679-4caa-b7f3-3d2e11074d0e" ], "spl_set_id": [ "ef3e79c5-3f58-4b36-a296-64b7d9a651c1" ], "package_ndc": [ "0338-0003-44", "0338-0003-46", "0338-0003-47", "0338-0004-02", "0338-0004-03", "0338-0004-04", "0338-0004-05" ], "unii": [ "059QF0KO0R" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Irrigant", "presentation": "Sterile Water, Irrigant, 100 mL/100 mL (NDC 0338-0004-02)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-550-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA218604" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Elite Laboratories, Inc." ], "product_ndc": [ "64850-550", "64850-551", "64850-552", "64850-553", "64850-554", "64850-555", "64850-556" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "2d33f701-8067-4a48-98cc-4e7dacaf3cc4" ], "spl_set_id": [ "0e024b69-567c-4b40-9c3e-a2daec34256c" ], "package_ndc": [ "64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 64850-550-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0517-1004-25", "generic_name": "Atropine Sulfate Injection", "contact_info": "800-645-1706", "availability": "Available", "openfda": { "application_number": [ "ANDA216120" ], "brand_name": [ "ATROPINE SULFATE" ], "generic_name": [ "ATROPINE SULFATE" ], "manufacturer_name": [ "American Regent, Inc." ], "product_ndc": [ "0517-1004", "0517-1001" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ATROPINE SULFATE" ], "rxcui": [ "1190795", "1666781" ], "spl_id": [ "1c500ed9-94a9-472c-bfb7-50e1fcfc31fb" ], "spl_set_id": [ "6fee1727-52b7-4f73-ab45-ef47d6a1c5bb" ], "package_ndc": [ "0517-1004-01", "0517-1004-25", "0517-1001-01", "0517-1001-25" ], "unii": [ "03J5ZE7KA5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .4 mg/1 mL (NDC 0517-1004-25)", "company_name": "American Regent, Inc.", "status": "Current" }, { "discontinued_date": "01/13/2026", "update_type": "New", "initial_posting_date": "01/13/2026", "package_ndc": "61314-531-64", "generic_name": "Adalimumab-adaz Injection", "contact_info": "800-525-8747", "related_info": "Equivalent Sandoz format is available.", "update_date": "01/13/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Hyrimoz, Injection, Kit (NDC 61314-531-64)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "11/06/2017", "package_ndc": "0409-7809-24", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA018826" ], "brand_name": [ "DOPAMINE HYDROCHLORIDE IN DEXTROSE" ], "generic_name": [ "DOPAMINE HYDROCHLORIDE IN DEXTROSE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-7809", "0409-7810", "0409-0042", "0409-1858" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOPAMINE HYDROCHLORIDE" ], "rxcui": [ "1292887", "1743877", "1743879" ], "spl_id": [ "188ce800-ff3a-4b22-9a95-2273c3bc99ae" ], "spl_set_id": [ "08f23f6e-150d-45ea-098e-f2edf64c21a1" ], "package_ndc": [ "0409-7809-11", "0409-7809-22", "0409-7809-31", "0409-7809-24", "0409-7810-11", "0409-7810-22", "0409-0042-01", "0409-0042-12", "0409-1858-01", "0409-1858-12" ], "unii": [ "7L3E358N9L" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/500 mL (1.6 mg/1 mL) (NDC 0409-7809-24)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-41", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA016673" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0017", "0338-0023" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618" ], "spl_id": [ "9c644eb4-5844-415a-8c01-4459d98af222" ], "spl_set_id": [ "3bb406a9-f5cb-403a-b1bb-5c4facbea3d5" ], "package_ndc": [ "0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-41)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-671-82", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Available", "related_info": "Marketed by Sagent Pharmaceuticals", "openfda": { "application_number": [ "ANDA206166" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-671", "25021-652" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734347", "1734355", "1734479", "1734481" ], "spl_id": [ "41f4446a-ca6e-465e-9a79-8c4f99eb1ac3", "22d83514-0f7b-4671-ae6a-7ca47449c184" ], "spl_set_id": [ "8c5c762f-d266-4b1a-809e-f11bfc89bc2d", "9572b3de-684c-4028-a577-5aa69ba6b02d" ], "package_ndc": [ "25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87", "25021-671-66", "25021-671-67" ], "unii": [ "V910P86109" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-82)", "company_name": "InfoRLife SA", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "72516-013-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "855-257-0292", "availability": "Unavailable", "related_info": "Estimated availability April 2027", "openfda": { "application_number": [ "ANDA210293" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Oryza Pharmaceuticals Inc." ], "product_ndc": [ "72516-013", "72516-016", "72516-015", "72516-014", "72516-012", "72516-011" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "1009145" ], "spl_id": [ "5734011d-5044-b490-e063-6394a90a3174" ], "spl_set_id": [ "acd27181-a3f3-4c38-85d8-029a4a82e7c2" ], "package_ndc": [ "72516-016-01", "72516-015-01", "72516-014-01", "72516-013-01", "72516-012-01", "72516-011-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 72516-013-01)", "company_name": "Oryza Pharmaceuticals Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "11/21/2023", "package_ndc": "0641-0928-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA083312" ], "brand_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "generic_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-0928", "0641-0929" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "rxcui": [ "992460", "992858" ], "spl_id": [ "9f14d3f5-ad01-44b5-a2b7-16ed5f501f87" ], "spl_set_id": [ "4bf3912c-8339-401e-9711-dad6acf15f11" ], "package_ndc": [ "0641-0928-21", "0641-0928-25", "0641-0929-21", "0641-0929-25" ], "unii": [ "R61ZEH7I1I" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy" ], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-0928-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0641-6052-25", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA080445" ], "brand_name": [ "MEPERIDINE HYDROCHLORIDE" ], "generic_name": [ "MEPERIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6052", "0641-6053", "0641-6054" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "MEPERIDINE HYDROCHLORIDE" ], "rxcui": [ "861476", "1665685", "1665697" ], "spl_id": [ "9566d54d-7343-4695-94ff-8b5f2d384c81" ], "spl_set_id": [ "e0e998da-f056-4fce-be8e-ed60cf3b461b" ], "package_ndc": [ "0641-6053-01", "0641-6053-25", "0641-6054-01", "0641-6054-25", "0641-6052-01", "0641-6052-25" ], "unii": [ "N8E7F7Q170" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Meperidine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-6052-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-487-17", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE MPF" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-487", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 10 mg/1 mL (NDC 63323-487-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0264-7510-00", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "NDA019626" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-7510", "0264-7520" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE, UNSPECIFIED FORM" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795610", "1795612" ], "spl_id": [ "c9f87749-8dd5-41fd-b393-f63d45fd00ef" ], "spl_set_id": [ "085614c7-ada4-4e2c-87c0-c9bc2f18365a" ], "package_ndc": [ "0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20" ], "unii": [ "IY9XDZ35W2" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-00)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-31", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-286", "63323-285", "63323-287", "63323-288" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091" ], "spl_id": [ "324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cb6583ff-cde4-4280-aa5b-0bea2b844792", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c" ], "spl_set_id": [ "dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "cb6583ff-cde4-4280-aa5b-0bea2b844792", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6" ], "package_ndc": [ "63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-51", "63323-286-55", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-31)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "72516-012-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "855-257-0292", "availability": "Unavailable", "related_info": "Estimated availability April 2027", "openfda": { "application_number": [ "ANDA210293" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Oryza Pharmaceuticals Inc." ], "product_ndc": [ "72516-012", "72516-016", "72516-015", "72516-014", "72516-013", "72516-011" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "1009145" ], "spl_id": [ "5734011d-5044-b490-e063-6394a90a3174" ], "spl_set_id": [ "acd27181-a3f3-4c38-85d8-029a4a82e7c2" ], "package_ndc": [ "72516-016-01", "72516-015-01", "72516-014-01", "72516-013-01", "72516-012-01", "72516-011-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 72516-012-01)", "company_name": "Oryza Pharmaceuticals Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "discontinued_date": "04/20/2026", "update_type": "New", "initial_posting_date": "04/20/2026", "package_ndc": "0068-0597-01", "generic_name": "Rifampin Injection", "contact_info": "800-633-1610", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA050627" ], "brand_name": [ "RIFADIN IV" ], "generic_name": [ "RIFAMPIN" ], "manufacturer_name": [ "Sanofi-Aventis U.S. LLC" ], "product_ndc": [ "0068-0597" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "RIFAMPIN" ], "rxcui": [ "207436", "312821" ], "spl_id": [ "82e2bbb1-cc73-4fbd-8d85-610634876355" ], "spl_set_id": [ "036ab68e-5085-4edc-bd83-784b43d64eab" ], "package_ndc": [ "0068-0597-01" ], "nui": [ "N0000175500", "M0019113" ], "pharm_class_epc": [ "Rifamycin Antibacterial [EPC]" ], "pharm_class_cs": [ "Rifamycins [CS]" ], "unii": [ "VJT6J7R4TR" ] }, "update_date": "04/20/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Rifadin, Injection, 600 mg/10 mL (NDC 0068-0597-01)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "62037-727-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA076655" ], "brand_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "62037-727", "62037-725", "62037-734", "62037-726" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210" ], "spl_id": [ "24aa9277-3773-489d-8459-f9215140c53f" ], "spl_set_id": [ "85ef422d-af27-4126-9841-6892af1871d6" ], "package_ndc": [ "62037-725-01", "62037-734-01", "62037-726-01", "62037-727-01" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 62037-727-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4933-10", "generic_name": "Epinephrine Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": [ "Cardiovascular", "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Epinephrine, Injection, .1 mg/1 mL (NDC 0409-4933-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3181-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA089645" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3181", "0409-1209", "0409-3177", "0409-3178", "0409-3182", "0409-3183", "0409-0007", "0409-0147" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE", "EPINEPHRINE" ], "rxcui": [ "1010688", "1010745", "1010751", "1010759", "1867996", "1867998" ], "spl_id": [ "68a37af1-d237-4836-af13-1eec28245f8b" ], "spl_set_id": [ "2f94f711-14c4-48ec-c5a3-c5ec4b8e8729" ], "package_ndc": [ "0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10" ], "nui": [ "N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647" ], "pharm_class_moa": [ "Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]" ], "pharm_class_epc": [ "alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]" ], "pharm_class_cs": [ "Catecholamines [CS]" ], "unii": [ "YKH834O4BH", "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 450 mg/30 mL (1.5%; 1:200,000) (NDC 0409-3181-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "0409-4887-20", "generic_name": "Sterile Water Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA018801" ], "brand_name": [ "STERILE WATER" ], "generic_name": [ "WATER" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4887" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "WATER" ], "spl_id": [ "055437a7-5be5-414a-a97a-946e2730fe12" ], "spl_set_id": [ "2b9ea23a-f9e9-48a8-25b7-519e3bbd6828" ], "package_ndc": [ "0409-4887-25", "0409-4887-99", "0409-4887-31", "0409-4887-05", "0409-4887-17", "0409-4887-10", "0409-4887-32", "0409-4887-34", "0409-4887-23", "0409-4887-20", "0409-4887-24", "0409-4887-50" ], "unii": [ "059QF0KO0R" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Injection", "presentation": "Sterile Water, Injection, 1 mL/1 mL (NDC 0409-4887-20)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-101-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": { "application_number": [ "NDA021977" ], "brand_name": [ "VYVANSE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469" ], "spl_id": [ "81d087b6-4cb4-466a-9693-679edeb062e2" ], "spl_set_id": [ "704e4378-ca83-445c-8b45-3cfa51c1ecad" ], "package_ndc": [ "59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 10 mg (NDC 59417-101-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "0264-2101-00", "generic_name": "Sterile Water Irrigant", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "NDA016734" ], "brand_name": [ "STERILE WATER" ], "generic_name": [ "WATER" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-2101" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "IRRIGATION" ], "substance_name": [ "WATER" ], "rxcui": [ "150985" ], "spl_id": [ "969bdf41-6565-42fb-8ac1-8661a928cc22" ], "spl_set_id": [ "f4284eb6-e553-46d4-90d8-efc80a90a480" ], "package_ndc": [ "0264-2101-00", "0264-2101-10", "0264-2101-50", "0264-2101-70" ], "unii": [ "059QF0KO0R" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0264-2101-00)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "46163-212-94", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "openfda": { "application_number": [ "NDA020171" ], "brand_name": [ "DELFLEX" ], "generic_name": [ "DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE" ], "manufacturer_name": [ "Fresenius Medical Care de Mexico, S.A. de C.V." ], "product_ndc": [ "46163-212", "46163-209", "46163-206" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "spl_id": [ "579dba0f-f820-8f9a-e063-6294a90a76b0" ], "spl_set_id": [ "a98facd6-9daa-4d37-8209-63a0599dbfaa" ], "package_ndc": [ "46163-209-92", "46163-209-94", "46163-209-95", "46163-212-95", "46163-212-92", "46163-212-94", "46163-206-92", "46163-206-94", "46163-206-95" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "03/10/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 4.25% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 46163-212-94)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued" }, { "discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "0228-2853-11", "generic_name": "Guanfacine Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA200881" ], "brand_name": [ "GUANFACINE" ], "generic_name": [ "GUANFACINE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0228-2853", "0228-2850", "0228-2851", "0228-2855" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "GUANFACINE HYDROCHLORIDE" ], "rxcui": [ "862006", "862013", "862019", "862025" ], "spl_id": [ "00143252-2b74-4b11-86ed-9b864635f129" ], "spl_set_id": [ "3a171942-37af-430d-8b9d-bb678ca2be4b" ], "package_ndc": [ "0228-2850-11", "0228-2851-11", "0228-2853-11", "0228-2855-11" ], "unii": [ "PML56A160O" ] }, "update_date": "11/13/2025", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Guanfacine Hydrochloride, Tablet, Extended Release, 3 mg (NDC 0228-2853-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-851-10", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA019034" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-851", "63323-852", "63323-853", "63323-854" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897653", "897753", "1724276", "1724338", "1724340", "1724341" ], "spl_id": [ "9e8522c6-595c-46f9-bb25-272aa4683e0f" ], "spl_set_id": [ "e034eb96-03e0-46e1-8b92-5e1f94555e7b" ], "package_ndc": [ "63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0427-52", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA020163" ], "brand_name": [ "DIANEAL PD-2 WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0427", "0941-0411", "0941-0413", "0941-0415", "0941-0409", "0941-0457", "0941-0459", "0941-0426", "0941-0429", "0941-0424", "0941-0430", "0941-0433", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 2.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0427-52)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0641-6061-25", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA075243" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6061", "0641-6057", "0641-6059", "0641-6056", "0641-6063", "0641-6060" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "311700", "311702" ], "spl_id": [ "559c03fb-24ea-4b7b-8afd-e33cb3a2340a" ], "spl_set_id": [ "575d8bf0-7af7-427c-a231-966e2a5e070d" ], "package_ndc": [ "0641-6057-01", "0641-6057-10", "0641-6057-25", "0641-6059-01", "0641-6059-10", "0641-6056-01", "0641-6056-10", "0641-6061-01", "0641-6061-10", "0641-6061-25", "0641-6063-01", "0641-6063-10", "0641-6063-25", "0641-6060-01", "0641-6060-10" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 0641-6061-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/18/2020", "package_ndc": "0143-9606-01", "generic_name": "Azacitidine Injection", "contact_info": "1-800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA209337" ], "brand_name": [ "AZACITIDINE" ], "generic_name": [ "AZACITIDINE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9606" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "AZACITIDINE" ], "rxcui": [ "485246" ], "spl_id": [ "592a688f-2e42-4e91-a3ea-34befe2a4e07" ], "spl_set_id": [ "ff73515d-bd55-4eb5-992b-d2138c80887e" ], "package_ndc": [ "0143-9606-01" ], "nui": [ "N0000000233", "N0000175595" ], "pharm_class_moa": [ "Nucleic Acid Synthesis Inhibitors [MoA]" ], "pharm_class_epc": [ "Nucleoside Metabolic Inhibitor [EPC]" ], "unii": [ "M801H13NRU" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg/ Vial (NDC 0143-9606-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "02/24/2026", "update_type": "New", "initial_posting_date": "02/24/2026", "package_ndc": "50742-438-10", "generic_name": "Arsenic Trioxide Injection", "contact_info": "866-321-5031", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA209315" ], "brand_name": [ "ARSENIC TRIOXIDE" ], "generic_name": [ "ARSENIC TRIOXIDE" ], "manufacturer_name": [ "Ingenus Pharmaceuticals, LLC" ], "product_ndc": [ "50742-438" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ARSENIC TRIOXIDE" ], "rxcui": [ "829926" ], "spl_id": [ "c5fa4ad7-39fa-472e-be5f-cf39164bd49d" ], "spl_set_id": [ "c99b01b4-67ff-4793-8375-fe3a21c6c9be" ], "package_ndc": [ "50742-438-10" ], "unii": [ "S7V92P67HO" ] }, "update_date": "02/24/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Arsenic Trioxide, Injection, 1 mg/1 mL (NDC 50742-438-10)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued" }, { "discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0832-6005-11", "generic_name": "Fluphenazine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": { "application_number": [ "ANDA213784" ], "brand_name": [ "FLUPHENAZINE HYDROCHLORIDE" ], "generic_name": [ "FLUPHENAZINE HYDROCHLORIDE" ], "manufacturer_name": [ "Upsher-Smith Laboratories,LLC" ], "product_ndc": [ "0832-6005", "0832-6004", "0832-6003", "0832-6006" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "FLUPHENAZINE HYDROCHLORIDE" ], "rxcui": [ "859841", "860918", "865117", "865123" ], "spl_id": [ "3bb74f82-8872-9829-e063-6294a90aeace" ], "spl_set_id": [ "f07bb3f1-c68c-441b-9de4-99a219f2500a" ], "package_ndc": [ "0832-6004-11", "0832-6003-11", "0832-6005-11", "0832-6006-11" ], "unii": [ "ZOU145W1XL" ] }, "update_date": "09/18/2025", "therapeutic_category": [ "Neurology", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Fluphenazine Hydrochloride, Tablet, 5 mg (NDC 0832-6005-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued" }, { "discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "25021-311-02", "generic_name": "Furosemide Injection", "contact_info": "Sagent Pharmaceuticals: 866-625-1618", "related_info": "Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA213902" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-311" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "222ce48f-2856-4be2-b16f-6fca38c0dceb" ], "spl_set_id": [ "d63c1277-dd7e-4d21-9e80-68143f55e2dc" ], "package_ndc": [ "25021-311-02", "25021-311-04", "25021-311-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "04/28/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-02)", "company_name": "Gland Pharma Limited", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "70069-752-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": { "application_number": [ "ANDA217792" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-752", "70069-753" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404" ], "spl_id": [ "2b24af95-6f20-4945-bf8c-742f1d6f2721" ], "spl_set_id": [ "bcaab86f-20f0-4482-8d73-e29b36dced58" ], "package_ndc": [ "70069-752-25", "70069-752-10", "70069-752-01", "70069-753-25", "70069-753-01", "70069-753-10" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 70069-752-10)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "discontinued_date": "08/29/2025", "update_type": "New", "initial_posting_date": "08/29/2025", "package_ndc": "82497-025-04", "generic_name": "Methotrexate Injection", "contact_info": "224-441-6390", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/29/2025", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Otrexup, Injection, 25 mg/.4 mL (NDC 82497-025-04)", "company_name": "Assertio Specialty Pharmaceuticals, LLC", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-067-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": { "application_number": [ "ANDA207636" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-067", "70069-061", "70069-062", "70069-063", "70069-064", "70069-065", "70069-066" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483" ], "spl_id": [ "79b226f0-c08a-4f84-bf2b-ae5c60e01d67" ], "spl_set_id": [ "ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64" ], "package_ndc": [ "70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10" ], "unii": [ "V910P86109" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 70069-067-10)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-455-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA204223" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-455", "63323-452", "63323-454", "63323-458", "63323-451" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "1731993", "1732006", "1732011", "1732136", "2003714" ], "spl_id": [ "dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc" ], "spl_set_id": [ "582f42e5-444e-4246-af8c-e7e28097c69a" ], "package_ndc": [ "63323-452-00", "63323-452-01", "63323-454-00", "63323-454-01", "63323-455-00", "63323-455-01", "63323-458-00", "63323-458-01", "63323-451-00", "63323-451-01" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0781-3476-95", "generic_name": "Fondaparinux Sodium Injection", "contact_info": "609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.", "openfda": { "application_number": [ "ANDA206812" ], "brand_name": [ "FONDAPARINUX SODIUM" ], "generic_name": [ "FONDAPARINUX SODIUM" ], "manufacturer_name": [ "Sandoz Inc." ], "product_ndc": [ "0781-3476", "0781-3443", "0781-3454", "0781-3465" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "FONDAPARINUX SODIUM" ], "rxcui": [ "861356", "861360", "861363", "861365" ], "spl_id": [ "3d5a4b69-462b-7e51-e063-6294a90a0721" ], "spl_set_id": [ "baa50757-a927-4d56-a933-5d7798fe6ab0" ], "package_ndc": [ "0781-3443-94", "0781-3443-12", "0781-3443-95", "0781-3454-94", "0781-3454-12", "0781-3454-95", "0781-3465-94", "0781-3465-12", "0781-3465-95", "0781-3476-94", "0781-3476-12", "0781-3476-95" ], "unii": [ "X0Q6N9USOZ" ] }, "update_date": "09/29/2025", "therapeutic_category": [ "Hematology" ], "dosage_form": "Injection", "presentation": "Fondaparinux Sodium, Injection, 10 mg/.8 mL (NDC 0781-3476-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued" }, { "discontinued_date": "07/30/2026", "update_type": "New", "initial_posting_date": "07/30/2026", "package_ndc": "63323-578-01", "generic_name": "Glycopyrrolate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA209328" ], "brand_name": [ "GLYCOPYRROLATE" ], "generic_name": [ "GLYCOPYRROLATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-578" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "GLYCOPYRROLATE" ], "rxcui": [ "238212", "1731582", "1731590" ], "spl_id": [ "779dc924-ecc3-41cc-8cf9-a7354db4f763", "d528572e-598b-4c0e-b280-b083c73c017f" ], "spl_set_id": [ "54458620-d888-4df6-ae4b-78c3dfed3423", "ccafb5c2-86dd-4bb2-883a-c13e3171227c" ], "package_ndc": [ "63323-578-03", "63323-578-01", "63323-578-04", "63323-578-02", "63323-578-07", "63323-578-05", "63323-578-18", "63323-578-20", "63323-578-41", "63323-578-11", "63323-578-42", "63323-578-12" ], "unii": [ "V92SO9WP2I" ] }, "update_date": "07/30/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Glycopyrrolate, Injection, .2 mg/1 mL (NDC 63323-578-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "discontinued_date": "02/19/2026", "update_type": "New", "initial_posting_date": "02/19/2026", "package_ndc": "0591-5543-01", "generic_name": "Allopurinol Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA018832" ], "brand_name": [ "ALLOPURINOL" ], "generic_name": [ "ALLOPURINOL" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0591-5543", "0591-5544" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ALLOPURINOL" ], "rxcui": [ "197319", "197320" ], "spl_id": [ "f7e04d88-1d9b-47e6-a9ad-deb08af3c098" ], "spl_set_id": [ "a80fe56f-8d03-423f-8e2a-7ec8c9e5045b" ], "package_ndc": [ "0591-5543-01", "0591-5543-10", "0591-5544-01", "0591-5544-05" ], "nui": [ "N0000175698", "N0000000206" ], "pharm_class_epc": [ "Xanthine Oxidase Inhibitor [EPC]" ], "pharm_class_moa": [ "Xanthine Oxidase Inhibitors [MoA]" ], "unii": [ "63CZ7GJN5I" ] }, "update_date": "02/19/2026", "therapeutic_category": [ "Oncology", "Renal", "Rheumatology" ], "dosage_form": "Tablet", "presentation": "Allopurinol, Tablet, 100 mg (NDC 0591-5543-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "16729-277-35", "generic_name": "Methotrexate Sodium Injection", "contact_info": "866-941-7875, option 2", "availability": "Available", "openfda": { "application_number": [ "ANDA040716" ], "brand_name": [ "METHOTREXATE" ], "generic_name": [ "METHOTREXATE" ], "manufacturer_name": [ "Accord Healthcare, Inc." ], "product_ndc": [ "16729-277" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS" ], "substance_name": [ "METHOTREXATE" ], "rxcui": [ "1655956", "1655959", "1655960" ], "spl_id": [ "2bae3cfe-7aa0-c14c-e063-6294a90a19f4" ], "spl_set_id": [ "dd035a9f-cd40-4314-b9d8-2294b8a924e2" ], "package_ndc": [ "16729-277-30", "16729-277-03", "16729-277-35" ], "nui": [ "N0000175584", "N0000000111" ], "pharm_class_epc": [ "Folate Analog Metabolic Inhibitor [EPC]" ], "pharm_class_moa": [ "Folic Acid Metabolism Inhibitors [MoA]" ], "unii": [ "YL5FZ2Y5U1" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Rheumatology", "Oncology" ], "dosage_form": "Injection", "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35)", "company_name": "Accord Healthcare Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-3299-06", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Next Delivery and Estimated Recovery: September 2026. Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA018893" ], "brand_name": [ "SODIUM ACETATE" ], "generic_name": [ "SODIUM ACETATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3299" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM ACETATE ANHYDROUS" ], "rxcui": [ "237371" ], "spl_id": [ "4e6137c2-6b7c-4882-985c-03b591b6c046", "b7a713f4-3c97-484b-b182-2824e1e944bb" ], "spl_set_id": [ "abc41ed1-9512-4bea-9295-1a9ca134b6c2", "c3be2468-45e8-4ecc-a30b-e966743a563f" ], "package_ndc": [ "0409-3299-15", "0409-3299-05", "0409-3299-16", "0409-3299-06", "0409-3299-45", "0409-3299-25", "0409-3299-46", "0409-3299-26" ], "unii": [ "NVG71ZZ7P0" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition" ], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-06)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "76045-005-11", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release date not available at this time. Check wholesalers for inventory.", "openfda": { "application_number": [ "NDA204223" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Fresenius Kabi, USA LLC" ], "product_ndc": [ "76045-005", "76045-004", "76045-006", "76045-007", "76045-008" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "894912", "894914", "998212", "998213", "1442790" ], "spl_id": [ "286bce70-23cd-4d5b-989b-230d6cdd5a91" ], "spl_set_id": [ "1f53de80-efc8-4930-b3e3-fba0d026af05" ], "package_ndc": [ "76045-004-01", "76045-004-11", "76045-005-01", "76045-005-11", "76045-006-01", "76045-006-11", "76045-007-01", "76045-007-11", "76045-008-01", "76045-008-11" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-27", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Next Delivery and Estimated Recovery: December 2028", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA018667" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-6102" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "e598e8a6-c854-48f5-a412-fb6a6783774a", "981d5143-60cd-4987-9b47-dec24c10de42" ], "spl_set_id": [ "aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7" ], "package_ndc": [ "0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) (NDC 0409-6102-27)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/14/2017", "package_ndc": "0338-0433-04", "generic_name": "Heparin Sodium Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA018609" ], "brand_name": [ "HEPARIN SODIUM IN SODIUM CHLORIDE" ], "generic_name": [ "HEPARIN SODIUM" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0433", "0338-0431", "0338-0424", "0338-0428" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "HEPARIN SODIUM" ], "rxcui": [ "1658690", "1658692" ], "spl_id": [ "d28ff87a-c535-49db-ba0c-48080149936b" ], "spl_set_id": [ "0d929726-76c3-48fc-b4e7-fd06409f9fb3" ], "package_ndc": [ "0338-0431-03", "0338-0433-04", "0338-0424-18", "0338-0428-12" ], "unii": [ "ZZ45AB24CA" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Hematology" ], "dosage_form": "Injection", "presentation": "Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0433-04)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "0409-3613-01", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026", "openfda": { "application_number": [ "ANDA071810" ], "brand_name": [ "BUPIVACAINE SPINAL" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE IN DEXTROSE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3613" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBARACHNOID" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1724784" ], "spl_id": [ "7a09a90d-26da-42bd-bb54-2d2102eb8c1c" ], "spl_set_id": [ "7a8d2539-4422-4312-0298-207ef1a2948e" ], "package_ndc": [ "0409-3613-11", "0409-3613-01" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, Bupivacaine Spinal 15 mg/2 mL (7.5 mg/mL in 8.25% dextrose) (NDC 0409-3613-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0280-52", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA011757" ], "brand_name": [ "DEPO-MEDROL" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0280", "0009-0274", "0009-0306" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1358510", "1358512", "1358610", "1358612", "1358617", "1358619" ], "spl_id": [ "267dd735-f800-4735-ba1c-d39d00f0cee5" ], "spl_set_id": [ "823b0010-2b57-4e76-b5ac-4a8c2963438f" ], "package_ndc": [ "0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-0280-52)", "company_name": "Pfizer Inc.", "status": "Current" }, { "discontinued_date": "05/21/2026", "update_type": "New", "initial_posting_date": "05/21/2026", "package_ndc": "50242-085-27", "generic_name": "Alteplase Injection", "contact_info": "800-551-2231", "related_info": "Discontinuation of the 100mg vial configuration", "openfda": { "application_number": [ "BLA103172" ], "brand_name": [ "ACTIVASE" ], "generic_name": [ "ALTEPLASE" ], "manufacturer_name": [ "Genentech, Inc." ], "product_ndc": [ "50242-085", "50242-044" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "rxcui": [ "1804799", "1804802", "1804804", "1804806" ], "spl_id": [ "48ed2eb6-728a-41d8-b024-6b34e75dc4dc" ], "spl_set_id": [ "c669f77c-fa48-478b-a14b-80b20a0139c2" ], "package_ndc": [ "50242-044-13", "50242-085-27" ] }, "update_date": "05/21/2026", "therapeutic_category": [ "Cardiovascular", "Hematology", "Neurology" ], "dosage_form": "Injection", "presentation": "Activase, Injection, 1 KIT in 1 CARTON (50242-085-27) * 100 mL in 1 VIAL, SINGLE-USE * 100 mL in 1 VIAL, SINGLE USE (NDC 50242-085-27)", "company_name": "Genentech, Inc", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "63323-725-10", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA206223" ], "brand_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "generic_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-725", "63323-723", "63323-724" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "rxcui": [ "1729578", "1729584", "1729710" ], "spl_id": [ "2f27e51f-2b55-47ee-bd4a-001b71c60622" ], "spl_set_id": [ "d2374b84-81c9-44f9-a4a9-1071281b2531" ], "package_ndc": [ "63323-723-01", "63323-723-03", "63323-724-01", "63323-724-05", "63323-725-01", "63323-725-10" ], "unii": [ "5V444H5WIC" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-725-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-116-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Unavailable", "related_info": "Estimated recovery: October 2026", "openfda": { "application_number": [ "ANDA215771" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Granules Pharmaceuticals Inc." ], "product_ndc": [ "70010-116", "70010-111", "70010-112", "70010-113", "70010-114", "70010-115", "70010-117" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "56c7c921-e560-c5ad-e063-6294a90a4c81" ], "spl_set_id": [ "b0b4eccc-34c7-483d-966f-82d588358e1b" ], "package_ndc": [ "70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 5 mg; 5 mg; 5 mg; 5 mg (NDC 70010-116-01)", "company_name": "Granules Pharmaceuticals Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4282-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA088294" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4282", "0409-4713", "0409-4278", "0409-4279", "0409-4776", "0409-4277", "0409-4276", "0409-4275" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671", "1010900", "1737343", "1737562", "1737566", "1737568", "1737636", "1737757", "1737763" ], "spl_id": [ "05d1a200-9d75-4e48-b14a-5069d4ab816f" ], "spl_set_id": [ "3b2dd84e-cee8-4e58-d494-395a65a353a0" ], "package_ndc": [ "0409-4713-12", "0409-4713-26", "0409-4713-02", "0409-4713-72", "0409-4713-62", "0409-4713-75", "0409-4713-65", "0409-4713-42", "0409-4713-25", "0409-4713-32", "0409-4278-16", "0409-4278-01", "0409-4279-16", "0409-4279-02", "0409-4776-10", "0409-4776-01", "0409-4282-11", "0409-4282-25", "0409-4282-01", "0409-4282-12", "0409-4282-02", "0409-4277-16", "0409-4277-01", "0409-4277-17", "0409-4277-02", "0409-4276-16", "0409-4276-01", "0409-4276-17", "0409-4276-02", "0409-4275-16", "0409-4275-01" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 200 mg/10 mL (2%; 20 mg/mL) (NDC 0409-4282-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/12/2021", "package_ndc": "69918-501-05", "generic_name": "Desmopressin Acetate Spray", "contact_info": "888-337-7464", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "05/01/2026", "therapeutic_category": [ "Hematology" ], "dosage_form": "Spray", "presentation": "Desmopressin Acetate, Spray, 10 ug/.1 mL (NDC 69918-501-05)", "company_name": "Ferring", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "discontinued_date": "11/21/2025", "update_type": "New", "initial_posting_date": "11/21/2025", "package_ndc": "62037-710-01", "generic_name": "Potassium Chloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/21/2025", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology" ], "dosage_form": "Tablet", "presentation": "Potassium Chloride, Tablet, Extended Release, 10 meq (NDC 62037-710-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0009-0017-58", "generic_name": "Triazolam Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug.", "update_date": "09/29/2025", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Halcion, Tablet, .25 mg (NDC 0009-0017-58)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "12/01/2025", "update_type": "New", "initial_posting_date": "12/01/2025", "package_ndc": "66993-066-02", "generic_name": "Phenoxybenzamine Hydrochloride Capsule", "contact_info": "847-283-7921", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/01/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Capsule", "presentation": "Dibenzyline, Capsule, 10 mg (NDC 66993-066-02)", "company_name": "Advanz Pharma (US) Corp.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "0409-3365-10", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA200403" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3365", "0409-2552", "0409-3356", "0409-2540", "0409-1283", "0409-1312", "0409-1304" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897653", "897753", "897756", "897757", "897758", "1724276", "1724383", "1724644" ], "spl_id": [ "a3ebafac-648e-47b1-a6f5-1e3bff1e3e08" ], "spl_set_id": [ "e9c9ef18-7dfc-4322-b2fc-29b934c30f8b" ], "package_ndc": [ "0409-2552-11", "0409-2552-01", "0409-3356-11", "0409-3356-01", "0409-2540-11", "0409-2540-01", "0409-3365-11", "0409-3365-01", "0409-3365-10", "0409-1283-03", "0409-1283-31", "0409-1312-03", "0409-1312-30", "0409-1304-03", "0409-1304-31" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0409-3365-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "discontinued_date": "09/26/2025", "update_type": "New", "initial_posting_date": "09/26/2025", "package_ndc": "25021-230-02", "generic_name": "Irinotecan Hydrochloride Injection", "contact_info": "Company Contact: 609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sagent Pharmaceuticals", "openfda": { "application_number": [ "ANDA090675" ], "brand_name": [ "IRINOTECAN HYDROCHLORIDE" ], "generic_name": [ "IRINOTECAN HYDROCHLORIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-230" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "IRINOTECAN HYDROCHLORIDE" ], "rxcui": [ "1726319", "1726324" ], "spl_id": [ "beff4b0b-e884-4134-ba9e-290020a94add" ], "spl_set_id": [ "caab50e6-0dad-4ddd-9a6c-96cc2b87aee7" ], "package_ndc": [ "25021-230-02", "25021-230-05" ], "unii": [ "042LAQ1IIS" ] }, "update_date": "09/26/2025", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Irinotecan Hydrochloride, Injection, 40 mg/2 mL (NDC 25021-230-02)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0459-05", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA017512" ], "brand_name": [ "DIANEAL LOW CALCIUM WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0459", "0941-0411", "0941-0413", "0941-0415", "0941-0409", "0941-0457", "0941-0426", "0941-0427", "0941-0429", "0941-0424", "0941-0430", "0941-0433", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 4.25 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0459-05)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-355-01", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-01)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued" }, { "presentation": "Marcaine, Injection, Marcaine 50 mg/10 mL (5 mg/mL) (NDC 0409-1560-10)", "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1560-10", "generic_name": "Bupivacaine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "status": "Current", "dosage_form": "Injection" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "68180-554-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-587-4617", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA077690" ], "brand_name": [ "QUINAPRIL" ], "generic_name": [ "QUINAPRIL" ], "manufacturer_name": [ "Lupin Pharmaceuticals, Inc." ], "product_ndc": [ "68180-554", "68180-556", "68180-557", "68180-558", "68180-559" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE" ], "rxcui": [ "312748", "312749", "312750", "314203" ], "spl_id": [ "a9598a21-6f99-4c86-ace6-b5638da2bec8" ], "spl_set_id": [ "8ded0773-3aec-4e89-9836-d22a5a84abf0" ], "package_ndc": [ "68180-556-09", "68180-557-09", "68180-557-03", "68180-558-09", "68180-558-03", "68180-554-09", "68180-554-03", "68180-559-03", "68180-559-09" ], "unii": [ "33067B3N2M" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 40 mg (NDC 68180-554-09)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "discontinued_date": "02/27/2026", "update_type": "New", "initial_posting_date": "02/27/2026", "package_ndc": "10147-1700-3", "generic_name": "Itraconazole Capsule", "contact_info": "800-JANSSEN (1-800-526-7736)", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA020083" ], "brand_name": [ "ITRACONAZOLE" ], "generic_name": [ "ITRACONAZOLE" ], "manufacturer_name": [ "Patriot Pharmaceuticals" ], "product_ndc": [ "10147-1700" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ITRACONAZOLE" ], "rxcui": [ "311204" ], "spl_id": [ "2cca3625-96e8-34cf-e063-6294a90ac975" ], "spl_set_id": [ "6242b7ad-eaa0-a524-b6e0-ec33e63407db" ], "package_ndc": [ "10147-1700-3", "10147-1700-7" ], "nui": [ "N0000175487", "M0002083", "N0000182141", "N0000185503", "N0000190113" ], "pharm_class_epc": [ "Azole Antifungal [EPC]" ], "pharm_class_cs": [ "Azoles [CS]" ], "pharm_class_moa": [ "Cytochrome P450 3A4 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]" ], "unii": [ "304NUG5GF4" ] }, "update_date": "02/27/2026", "therapeutic_category": [ "Anti-Infective", "Other" ], "dosage_form": "Capsule", "presentation": "Sporanox, Capsule, 100 mg (NDC 10147-1700-3)", "company_name": "Janssen Pharmaceuticals", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "25021-700-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "833-291-9645", "availability": "Available", "openfda": { "application_number": [ "ANDA204216" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-700", "25021-701" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "cb23332a-48fa-458b-93ab-c4eef189a051" ], "spl_set_id": [ "62591551-a644-4b2c-a0de-982e906fabc3" ], "package_ndc": [ "25021-700-01", "25021-701-01", "25021-701-02" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 25021-700-01)", "company_name": "Gland Pharma Limited", "status": "Current" }, { "discontinued_date": "06/01/2026", "update_type": "New", "initial_posting_date": "06/01/2026", "package_ndc": "0009-5095-06", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA050441" ], "brand_name": [ "CLEOCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-5095", "0009-3051", "0009-4073" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "1737244", "1737245", "1737578", "1737579", "1737581", "1737582" ], "spl_id": [ "8d0dac99-6ec9-4648-8ae1-0cc2894d56cf" ], "spl_set_id": [ "a0a2eff7-b7de-42fe-8e5a-0cfbed38bb4b" ], "package_ndc": [ "0009-3051-01", "0009-3051-02", "0009-4073-03", "0009-4073-04", "0009-5095-05", "0009-5095-06" ], "unii": [ "EH6D7113I8" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL); 6 mL Vial NovaPlus (NDC 0009-5095-06)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "09/19/2025", "update_type": "New", "initial_posting_date": "09/19/2025", "package_ndc": "69516-010-30", "generic_name": "Obeticholic Acid Tablet", "contact_info": "1-844-782-4278", "related_info": "Business decision. Products will not be available after November 14, 2025.", "update_date": "09/19/2025", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Tablet", "presentation": "Ocaliva, Tablet, 10 mg (NDC 69516-010-30)", "company_name": "Intercept Pharmaceuticals", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "71288-726-52", "generic_name": "Bupivacaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-824-8426", "availability": "Limited Availability", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "openfda": { "application_number": [ "ANDA216039" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Meitheal Pharmaceuticals Inc" ], "product_ndc": [ "71288-726", "71288-723" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404" ], "spl_id": [ "0949c302-51ce-4fc9-8b99-1df94e693718" ], "spl_set_id": [ "fe340f98-a0f3-446e-b281-47fd91c1e537" ], "package_ndc": [ "71288-723-52", "71288-726-52" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "05/05/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-726-52)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-163-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA078450" ], "brand_name": [ "QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE" ], "generic_name": [ "QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE" ], "manufacturer_name": [ "Aurobindo Pharma Limited" ], "product_ndc": [ "65862-163", "65862-161", "65862-162" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE", "HYDROCHLOROTHIAZIDE" ], "rxcui": [ "310796", "310797", "310809" ], "spl_id": [ "5842ecc2-874a-481b-8997-afa9d862dc5d" ], "spl_set_id": [ "50a58159-9572-4445-9859-b392632597da" ], "package_ndc": [ "65862-161-90", "65862-162-30", "65862-162-90", "65862-163-90" ], "nui": [ "N0000175359", "N0000175419", "M0471776" ], "pharm_class_pe": [ "Increased Diuresis [PE]" ], "pharm_class_epc": [ "Thiazide Diuretic [EPC]" ], "pharm_class_cs": [ "Thiazides [CS]" ], "unii": [ "0J48LPH2TH", "33067B3N2M" ] }, "update_date": "06/02/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 65862-163-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-492-57", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE MPF" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487", "63323-493", "63323-496" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029", "1737636", "1737637", "1737640", "1737641", "1737763", "1737764" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428", "0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33", "fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17", "4dd52202-8eef-4136-92dd-ada573b7cf74", "d5e0d06f-ba1e-44d4-aa89-39d6c146dc23" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31", "63323-492-41", "63323-492-16", "63323-492-43", "63323-492-36", "63323-492-45", "63323-492-26", "63323-485-41", "63323-485-26", "63323-486-41", "63323-486-26", "63323-482-41", "63323-482-26", "63323-495-41", "63323-495-26", "63323-492-08", "63323-492-97", "63323-493-03", "63323-493-97", "63323-493-01", "63323-493-91", "63323-496-03", "63323-496-97" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0555-0971-02", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA040422" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0555-0971", "0555-0775", "0555-0972", "0555-0776", "0555-0777", "0555-0973", "0555-0974" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "88468f3d-7d03-4cee-aabf-3abc8c9b5e38" ], "spl_set_id": [ "cffbbb15-d776-41ae-a8a6-687f2c07bfa4" ], "package_ndc": [ "0555-0971-02", "0555-0775-02", "0555-0972-02", "0555-0776-02", "0555-0777-02", "0555-0973-02", "0555-0974-02" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0555-0971-02)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/21/2023", "package_ndc": "0338-3612-50", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: October 2026", "openfda": { "application_number": [ "ANDA208084" ], "brand_name": [ "CLINDAMYCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "0338-3612", "0338-3410", "0338-3814" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "309335", "309336", "309339" ], "spl_id": [ "c8906ab2-37d2-4fde-9784-0442bf7b9565" ], "spl_set_id": [ "78832ac6-04c5-45e0-ae4d-f56d7920dda9" ], "package_ndc": [ "0338-3410-50", "0338-3410-24", "0338-3612-50", "0338-3612-24", "0338-3814-50", "0338-3814-24" ], "unii": [ "EH6D7113I8" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50)", "company_name": "Baxter Healthcare", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "63323-750-10", "generic_name": "Oxaliplatin Injection", "contact_info": "847-550-2300", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "02/25/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Oxaliplatin, Injection, 5 mg/mL (NDC 63323-750-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-406-50", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": { "application_number": [ "ANDA077856" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Solco Healthcare LLC" ], "product_ndc": [ "43547-406", "43547-407", "43547-408" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "dc17b9d4-2890-4f6c-8476-daa39d0cbc9c" ], "spl_set_id": [ "4acbb7a9-4db5-4497-b8db-9f358b3f6fb4" ], "package_ndc": [ "43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "07/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 43547-406-50)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "81298-7620-3", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "833-268-5559", "availability": "Available", "openfda": { "application_number": [ "ANDA216042" ], "brand_name": [ "SODIUM BICARBONATE" ], "generic_name": [ "SODIUM BICARBONATE INJECTION," ], "manufacturer_name": [ "Long Grove Pharmaceuticals, LLC" ], "product_ndc": [ "81298-7620" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM BICARBONATE" ], "rxcui": [ "1868486" ], "spl_id": [ "1a255946-a137-4e13-8203-65dd80b34872" ], "spl_set_id": [ "a26d709b-b294-4b02-9a88-7e840f099a33" ], "package_ndc": [ "81298-7620-1", "81298-7620-3" ], "unii": [ "8MDF5V39QO" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 81298-7620-3)", "company_name": "Long Grove Pharmaceuticals LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-608-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": { "application_number": [ "ANDA216266" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE CAPSULES" ], "manufacturer_name": [ "Solco Healthcare US,LLC" ], "product_ndc": [ "43547-608", "43547-602", "43547-603", "43547-604", "43547-605", "43547-606", "43547-607" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "d6435613-e052-4b4f-8bf7-4acb7458d8df" ], "spl_set_id": [ "68b10d9f-ca3e-493d-a309-45f1d7e08061" ], "package_ndc": [ "43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/29/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 43547-608-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "presentation": "Lisdexamfetamine Dimesylate, Capsule, 10 mg (NDC 0480-3565-01)", "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3565-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "company_name": "Teva Pharmaceuticals USA, Inc.", "contact_info": "800-545-8800", "availability": "Available", "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "status": "Current", "dosage_form": "Capsule" }, { "discontinued_date": "01/05/2026", "update_type": "New", "initial_posting_date": "01/05/2026", "package_ndc": "0409-4350-03", "generic_name": "Diltiazem Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA075853" ], "brand_name": [ "DILTIAZEM HYDROCHLORIDE" ], "generic_name": [ "DILTIAZEM HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4350", "0409-1171" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DILTIAZEM HYDROCHLORIDE" ], "rxcui": [ "1791230", "1791240" ], "spl_id": [ "9e518c0c-b7a9-457c-9ca5-6b6c132f985e" ], "spl_set_id": [ "bba03666-ff4f-4bf6-fa92-78e1ec2d9073" ], "package_ndc": [ "0409-1171-11", "0409-1171-01", "0409-1171-12", "0409-1171-02", "0409-4350-13", "0409-4350-03" ], "unii": [ "OLH94387TE" ] }, "update_date": "01/05/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Diltiazem Hydrochloride, Injection, 100 mg Single Dose ADD-Vantage® Glass Vial (NDC 0409-4350-03)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "01/26/2024", "package_ndc": "70726-0305-1", "generic_name": "Riluzole Oral Suspension", "related_info_link": "https://www.fda.gov/media/177206/download", "contact_info": "610-937-6172", "availability": "Available", "openfda": { "brand_name": [ "TEGLUTIK" ], "generic_name": [ "RILUZOLE" ], "manufacturer_name": [ "EDW PHARMA" ], "product_ndc": [ "70726-0305" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RILUZOLE" ], "rxcui": [ "2058147", "2675565" ], "spl_id": [ "4746c4d8-402a-0390-e063-6294a90a7fc2" ], "spl_set_id": [ "125fdd37-02f7-a610-e063-6294a90a009d" ], "package_ndc": [ "70726-0305-1" ], "nui": [ "N0000175740", "M0483511" ], "pharm_class_epc": [ "Benzothiazole [EPC]" ], "pharm_class_cs": [ "Benzothiazoles [CS]" ], "unii": [ "7LJ087RS6F" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Oral Suspension", "presentation": "Teglutik, Oral Suspension, 5 mg/1 mL (NDC 70726-0305-1)", "company_name": "EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)", "status": "Current" }, { "discontinued_date": "12/19/2025", "update_type": "New", "initial_posting_date": "12/19/2025", "package_ndc": "54092-173-12", "generic_name": "Carbamazepine Capsule, Extended Release", "contact_info": "855-268-1825", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA020712" ], "brand_name": [ "CARBATROL" ], "generic_name": [ "CARBAMAZEPINE" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "54092-173", "54092-171", "54092-172" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CARBAMAZEPINE" ], "rxcui": [ "200131", "200133", "308977", "313931", "388311", "404742" ], "spl_id": [ "39171a32-c78d-4130-be53-638e19cf2261" ], "spl_set_id": [ "bc03e499-5bac-4293-bff4-6864153a624d" ], "package_ndc": [ "54092-171-12", "54092-172-12", "54092-173-12" ], "nui": [ "N0000008486", "N0000175751", "N0000185506", "N0000191266", "N0000187064", "N0000185507", "N0000185607" ], "pharm_class_pe": [ "Decreased Central Nervous System Disorganized Electrical Activity [PE]" ], "pharm_class_epc": [ "Mood Stabilizer [EPC]" ], "pharm_class_moa": [ "Cytochrome P450 3A4 Inducers [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2C19 Inducers [MoA]" ], "unii": [ "33CM23913M" ] }, "update_date": "12/19/2025", "therapeutic_category": [ "Neurology" ], "dosage_form": "Capsule, Extended Release", "presentation": "Carbatrol, Capsule, Extended Release, 300 mg (NDC 54092-173-12)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/27/2018", "package_ndc": "25021-671-67", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "Sagent: 866-625-1618", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; Marketed by Sagent Pharmaceuticals", "openfda": { "application_number": [ "ANDA206166" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-671", "25021-652" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734347", "1734355", "1734479", "1734481" ], "spl_id": [ "41f4446a-ca6e-465e-9a79-8c4f99eb1ac3", "22d83514-0f7b-4671-ae6a-7ca47449c184" ], "spl_set_id": [ "8c5c762f-d266-4b1a-809e-f11bfc89bc2d", "9572b3de-684c-4028-a577-5aa69ba6b02d" ], "package_ndc": [ "25021-671-82", "25021-671-87", "25021-652-82", "25021-652-87", "25021-671-66", "25021-671-67" ], "unii": [ "V910P86109" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 25021-671-67)", "company_name": "InfoRLife SA", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4283-01", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA088295" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-4283" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RETROBULBAR", "TOPICAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010844" ], "spl_id": [ "3681d241-f269-4d2d-b614-f87fc30aeecb" ], "spl_set_id": [ "89a4bd73-89f4-4fd7-2c9f-921e1da8f96b" ], "package_ndc": [ "0409-4283-11", "0409-4283-25", "0409-4283-01" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free, Injection, 200 mg/5 mL (4%; 40 mg/mL) (NDC 0409-4283-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-049-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA214484" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "57664-049", "57664-047", "57664-046", "57664-048", "57664-050", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "560b4c9e-9cce-4717-e063-6294a90a58c9" ], "spl_set_id": [ "da3148af-f9b6-4725-adae-3595b4c7dc4b" ], "package_ndc": [ "57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 57664-049-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "63323-165-05", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA084916" ], "brand_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "generic_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-165" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "rxcui": [ "1116927", "1812194" ], "spl_id": [ "1815f54a-5637-45bc-a582-3e62350935ba", "9dd90418-e564-4bc5-9077-506a1c2c1bce" ], "spl_set_id": [ "2b626a48-c7aa-4443-9164-a08ff069ccd1", "4fedef4f-ec96-4f36-b2f0-01e243e3b89e" ], "package_ndc": [ "63323-165-11", "63323-165-51", "63323-165-13", "63323-165-53", "63323-165-02", "63323-165-01", "63323-165-03", "63323-165-05", "63323-165-30", "63323-165-16", "63323-165-26" ], "unii": [ "AI9376Y64P" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 63323-165-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-1495-35", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA083312" ], "brand_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "generic_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-1495", "0641-1496" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "rxcui": [ "992460", "992858" ], "spl_id": [ "80a400d2-d293-4180-bfa7-7a8ce0734bc5" ], "spl_set_id": [ "13d9e59d-eadb-41d5-9f47-9c11a6efb31c" ], "package_ndc": [ "0641-1495-31", "0641-1495-35", "0641-1496-31", "0641-1496-35" ], "unii": [ "R61ZEH7I1I" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy" ], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 0641-1495-35)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "83831-141-08", "generic_name": "Carboplatin Injection", "contact_info": "877-595-7337; customerservice@avyxa.com", "availability": "Available", "openfda": { "application_number": [ "NDA219921" ], "brand_name": [ "KYXATA" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Avyxa Pharma, LLC" ], "product_ndc": [ "83831-141", "83831-140", "83831-142" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195", "2721602" ], "spl_id": [ "5c711945-70be-42f4-b153-e1459dd9929c" ], "spl_set_id": [ "f91c48da-68d1-4aa7-89b8-d84a3e8b629b" ], "package_ndc": [ "83831-140-02", "83831-141-08", "83831-142-50" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Kyxata, Injection, 80 mg/8 mL (10 mg/mL) (NDC 83831-141-08)", "company_name": "Avyxa Pharma, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "55150-197-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA205612" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-197", "55150-195", "55150-196", "55150-198", "55150-199", "55150-200", "55150-201" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483" ], "spl_id": [ "1e5f1368-058a-492c-b4b7-d9329a7745e2" ], "spl_set_id": [ "3763b7b6-da49-4658-b93d-28f5da24d09e" ], "package_ndc": [ "55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20" ], "unii": [ "V910P86109" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-197-20)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6856-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA202835" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE" ], "manufacturer_name": [ "Mylan Pharmaceuticals Inc." ], "product_ndc": [ "0378-6856", "0378-6854", "0378-6855", "0378-6857", "0378-6858", "0378-6859", "0378-6860" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "6e77cd71-95ae-4fa8-830b-ab62b714e4b9" ], "spl_set_id": [ "efbde0f6-b848-4664-b741-c6c630e66108" ], "package_ndc": [ "0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0378-6856-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4663-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": { "application_number": [ "ANDA215802" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Lannett Company, Inc." ], "product_ndc": [ "0527-4663", "0527-4661", "0527-4662", "0527-4664", "0527-4665", "0527-4666", "0527-4667" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "cb49954d-0f9d-4471-bc86-0c926473c00b" ], "spl_set_id": [ "2cedb4c2-1e40-4bc4-b9f4-127150c4afbd" ], "package_ndc": [ "0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 0527-4663-37)", "company_name": "Lannett Company, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "83634-600-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "See Related Information section below for customer service information", "availability": "Available", "related_info": "Distributed by Avenacy; Contact information: 877-283-6229", "openfda": { "application_number": [ "ANDA209065" ], "brand_name": [ "DEXMEDETOMIDINE" ], "generic_name": [ "DEXMEDETOMIDINE" ], "manufacturer_name": [ "Avenacy Inc." ], "product_ndc": [ "83634-600" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "309710" ], "spl_id": [ "f036291f-40af-44b9-8a7f-d4475788ea63" ], "spl_set_id": [ "eee6145b-d83f-4596-92d3-733934d8a3a4" ], "package_ndc": [ "83634-600-41", "83634-600-02" ], "unii": [ "1018WH7F9I" ] }, "update_date": "07/30/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 mcg/2 mL (NDC 83634-600-02)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "16729-512-43", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA213424" ], "brand_name": [ "ATROPINE SULFATE" ], "generic_name": [ "ATROPINE SULFATE" ], "manufacturer_name": [ "Accord Healthcare Inc." ], "product_ndc": [ "16729-512" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ENDOTRACHEAL", "INTRAMEDULLARY", "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "ATROPINE SULFATE" ], "rxcui": [ "1190776" ], "spl_id": [ "275def6c-5b2d-918b-e063-6294a90aa71f" ], "spl_set_id": [ "f3cb74e9-b4ac-4efe-bd8e-8a71970ee7c7" ], "package_ndc": [ "16729-512-05", "16729-512-43" ], "unii": [ "03J5ZE7KA5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .4 mg/1 mL (NDC 16729-512-43)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0781-3290-09", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-525-8747", "availability": "Available", "openfda": { "application_number": [ "ANDA201692" ], "brand_name": [ "CLINDAMYCIN IN 5 PERCENT DEXTROSE" ], "generic_name": [ "CLINDAMYCIN IN 5 PERCENT DEXTROSE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-3290", "0781-3288", "0781-3289" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN" ], "rxcui": [ "309335", "309336", "309339" ], "spl_id": [ "b553b8ab-ef4d-40ae-a5fb-a6242f2ad30a" ], "spl_set_id": [ "231d95a6-5e5f-4a45-a92b-d3d16ef0a7ca" ], "package_ndc": [ "0781-3288-91", "0781-3288-09", "0781-3289-91", "0781-3289-09", "0781-3290-91", "0781-3290-09" ], "nui": [ "N0000009982", "N0000175443", "M0515779", "N0000175731" ], "pharm_class_pe": [ "Decreased Sebaceous Gland Activity [PE]", "Neuromuscular Blockade [PE]" ], "pharm_class_epc": [ "Lincosamide Antibacterial [EPC]" ], "pharm_class_cs": [ "Lincosamides [CS]" ], "unii": [ "3U02EL437C" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09)", "company_name": "Sandoz Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-64", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-285", "63323-286", "63323-287", "63323-288" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091" ], "spl_id": [ "324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c" ], "spl_set_id": [ "dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6" ], "package_ndc": [ "63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-64)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "09/20/2023", "package_ndc": "0527-4666-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": { "application_number": [ "ANDA215802" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Lannett Company, Inc." ], "product_ndc": [ "0527-4666", "0527-4661", "0527-4662", "0527-4663", "0527-4664", "0527-4665", "0527-4667" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "cb49954d-0f9d-4471-bc86-0c926473c00b" ], "spl_set_id": [ "2cedb4c2-1e40-4bc4-b9f4-127150c4afbd" ], "package_ndc": [ "0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0527-4666-37)", "company_name": "Lannett Company, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "43547-605-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-931-9829", "availability": "Limited Availability", "related_info": "On allocation", "openfda": { "application_number": [ "ANDA216266" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE CAPSULES" ], "manufacturer_name": [ "Solco Healthcare US,LLC" ], "product_ndc": [ "43547-605", "43547-602", "43547-603", "43547-604", "43547-606", "43547-607", "43547-608" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "d6435613-e052-4b4f-8bf7-4acb7458d8df" ], "spl_set_id": [ "68b10d9f-ca3e-493d-a309-45f1d7e08061" ], "package_ndc": [ "43547-602-10", "43547-603-10", "43547-604-10", "43547-605-10", "43547-606-10", "43547-607-10", "43547-608-10" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/29/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 43547-605-10)", "company_name": "Solco Healthcare US, LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0990-7930-09", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Available", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA018080" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "ICU Medical, Inc." ], "product_ndc": [ "0990-7930", "0990-7923", "0990-7922" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618", "1795621" ], "spl_id": [ "06e4d957-1a56-4adb-a42b-fe0773b2fa97" ], "spl_set_id": [ "8b25b7e0-703e-4b43-a4eb-52863511602d" ], "package_ndc": [ "0990-7923-20", "0990-7923-23", "0990-7923-36", "0990-7923-37", "0990-7923-13", "0990-7922-02", "0990-7922-03", "0990-7922-09", "0990-7922-53", "0990-7922-55", "0990-7922-61", "0990-7930-02", "0990-7930-03", "0990-7930-09" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 10 g/100 mL (NDC 0990-7930-09)", "company_name": "Otsuka ICU Medical LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0535-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 40 mg (NDC 0071-0535-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-48", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA016673" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0017", "0338-0023" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618" ], "spl_id": [ "9c644eb4-5844-415a-8c01-4459d98af222" ], "spl_set_id": [ "3bb406a9-f5cb-403a-b1bb-5c4facbea3d5" ], "package_ndc": [ "0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-48)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-472-17", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA070554" ], "brand_name": [ "SENSORCAINE MPF" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-472", "63323-463", "63323-461", "63323-468" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "RETROBULBAR" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810", "1867594", "1867596", "1867618", "1867620" ], "spl_id": [ "cc1f6507-eb3e-4398-a1d3-0c56a2099e6b" ], "spl_set_id": [ "bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb" ], "package_ndc": [ "63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/26/2023", "package_ndc": "57664-609-88", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-818-4555", "availability": "Unavailable", "related_info": "Currently not marketed", "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "62037-734-01", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA076772" ], "brand_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "62037-734", "62037-725", "62037-726", "62037-727" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210" ], "spl_id": [ "24aa9277-3773-489d-8459-f9215140c53f" ], "spl_set_id": [ "85ef422d-af27-4126-9841-6892af1871d6" ], "package_ndc": [ "62037-725-01", "62037-734-01", "62037-726-01", "62037-727-01" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62037-734-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/20/2023", "package_ndc": "0641-6247-25", "generic_name": "Fentanyl Citrate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be scheduled for manufacturing to meet demand. Product will be made available as it is released.", "openfda": { "application_number": [ "NDA019101" ], "brand_name": [ "FENTANYL CITRATE" ], "generic_name": [ "FENTANYL CITRATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6247", "0641-6024", "0641-6027", "0641-6025", "0641-6028", "0641-6026", "0641-6029", "0641-6030", "0641-6248", "0641-6249" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FENTANYL CITRATE" ], "rxcui": [ "1735003", "1735007", "1735008", "1735013", "2168270", "2474269", "2629337" ], "spl_id": [ "546a047c-1faf-4751-9e48-079e4c35b6fa" ], "spl_set_id": [ "ce5db1c2-feb1-4ad2-847a-d02e865bd47e" ], "package_ndc": [ "0641-6024-01", "0641-6024-10", "0641-6027-01", "0641-6027-25", "0641-6025-01", "0641-6025-10", "0641-6028-01", "0641-6028-10", "0641-6028-25", "0641-6026-01", "0641-6026-05", "0641-6029-01", "0641-6029-25", "0641-6030-01", "0641-6247-01", "0641-6247-25", "0641-6248-01", "0641-6248-10", "0641-6249-01", "0641-6249-10" ], "unii": [ "MUN5LYG46H" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 50 mcg/1 mL (NDC 0641-6247-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/12/2022", "package_ndc": "68118-100-01", "generic_name": "Streptozocin Powder, For Solution", "related_info_link": "https://www.fda.gov/media/187353/download?attachment", "contact_info": "USSZTOrders@esteve.com", "availability": "Available", "openfda": { "application_number": [ "NDA211415" ], "brand_name": [ "QUZYTTIR" ], "generic_name": [ "CETIRIZINE HYDROCHLORIDE" ], "manufacturer_name": [ "ESTEVE PHARMACEUTICALS, S.A." ], "product_ndc": [ "68118-100" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CETIRIZINE HYDROCHLORIDE" ], "rxcui": [ "2261746", "2261754" ], "spl_id": [ "57e97eb8-9e05-8888-e063-6394a90a68de" ], "spl_set_id": [ "573770f6-b76e-f6ba-e063-6294a90aa54d" ], "package_ndc": [ "68118-100-02", "68118-100-25", "68118-100-10" ], "unii": [ "64O047KTOA" ] }, "update_date": "05/06/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Powder, For Solution", "presentation": "Zanosar, Powder, For Solution, 1 g/10 mL (NDC 68118-100-01)", "company_name": "ESTEVE PHARMACEUTICALS, S.A.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "63323-506-01", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA040491" ], "brand_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "generic_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-506", "63323-516" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "rxcui": [ "309696", "1812079" ], "spl_id": [ "2ce90eb7-067d-4f1c-9184-c250e387e533", "756dda45-ea6d-4c90-a14a-18a78bf186a6" ], "spl_set_id": [ "cca2c160-9188-48e8-9505-49a52388dcb7", "7cbd9005-7df2-47ee-adb3-7244c1c69bc3" ], "package_ndc": [ "63323-506-00", "63323-506-01", "63323-506-03", "63323-506-13", "63323-516-01", "63323-516-10", "63323-506-41", "63323-506-16" ], "unii": [ "AI9376Y64P" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate Preservative Free, Injection, 10 mg/1 mL (NDC 63323-506-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "63323-185-20", "generic_name": "Sterile Water Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA088400" ], "brand_name": [ "STERILE WATER" ], "generic_name": [ "WATER" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-185" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "WATER" ], "spl_id": [ "42c6c812-706a-425b-b8cb-931006e40484" ], "spl_set_id": [ "e71c6c83-d518-496c-b2ab-efd5987e4783" ], "package_ndc": [ "63323-185-07", "63323-185-10", "63323-185-09", "63323-185-50", "63323-185-08", "63323-185-20", "63323-185-04", "63323-185-05" ], "unii": [ "059QF0KO0R" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Injection", "presentation": "Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-118-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": { "application_number": [ "NDA208510" ], "brand_name": [ "VYVANSE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "59417-118", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-119", "59417-120" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469" ], "spl_id": [ "81d087b6-4cb4-466a-9693-679edeb062e2" ], "spl_set_id": [ "704e4378-ca83-445c-8b45-3cfa51c1ecad" ], "package_ndc": [ "59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 40 mg (NDC 59417-118-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "13107-074-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 OR CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability: October 2026", "openfda": { "application_number": [ "ANDA202424" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Aurolife Pharma, LLC" ], "product_ndc": [ "13107-074", "13107-068", "13107-069", "13107-070", "13107-071", "13107-072", "13107-073" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "5962d880-9f18-4a57-8c95-ca0ec1e86f44" ], "spl_set_id": [ "a582d57f-d191-4ca5-b105-585b2d8a0e3e" ], "package_ndc": [ "13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "07/21/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 13107-074-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "discontinued_date": "06/15/2026", "update_type": "New", "initial_posting_date": "06/15/2026", "package_ndc": "69238-1247-3", "generic_name": "Donepezil Hydrochloride; Memantine Hydrochloride Capsule, Extended Release", "contact_info": "866-525-7270", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA208328" ], "brand_name": [ "MEMANTINE AND DONEPEZIL HYDROCHLORIDES EXTENDED-RELEASE" ], "generic_name": [ "MEMANTINE AND DONEPEZIL" ], "manufacturer_name": [ "Amneal Pharmaceuticals NY LLC" ], "product_ndc": [ "69238-1247", "69238-1248", "69238-1552", "69238-1553" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "MEMANTINE HYDROCHLORIDE", "DONEPEZIL HYDROCHLORIDE" ], "rxcui": [ "1599803", "1599805", "1805420", "1805425" ], "spl_id": [ "acd577e1-312c-4d5a-85b5-bc50ef9de545" ], "spl_set_id": [ "2335950c-be3b-4248-ad04-e9763aee47d2" ], "package_ndc": [ "69238-1248-3", "69238-1248-9", "69238-1247-3", "69238-1247-9", "69238-1552-3", "69238-1552-9", "69238-1553-3", "69238-1553-9" ], "unii": [ "3O2T2PJ89D", "JY0WD0UA60" ] }, "update_date": "06/15/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Capsule, Extended Release", "presentation": "Donepezil Hydrochloride; Memantine Hydrochloride, Capsule, Extended Release, 10 mg; 28 mg (NDC 69238-1247-3)", "company_name": "Amneal Pharmaceuticals", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "0143-9250-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA204679" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9250", "0143-9251" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "51fc5473-b651-4c85-83ff-7edc65a6cef2" ], "spl_set_id": [ "d3a172a5-01ab-47d8-92ac-a8539b1d4dc4" ], "package_ndc": [ "0143-9250-01", "0143-9250-10", "0143-9251-01", "0143-9251-10" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 0143-9250-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "16729-239-93", "generic_name": "Dexmedetomidine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Dexmedetomidine%20Hydrochloride%20Injection&st=d", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA204023" ], "brand_name": [ "DEXMEDETOMIDINE" ], "generic_name": [ "DEXMEDETOMIDINE" ], "manufacturer_name": [ "Accord Healthcare Inc." ], "product_ndc": [ "16729-239" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "309710" ], "spl_id": [ "2de0daf8-b7a3-1dca-e063-6394a90a4d0a" ], "spl_set_id": [ "2b9881f0-4a66-660f-e054-00144ff88e88" ], "package_ndc": [ "16729-239-30", "16729-239-93" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 16729-239-93)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/31/2018", "package_ndc": "0641-6008-10", "generic_name": "Bumetanide Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA079196" ], "brand_name": [ "BUMETANIDE" ], "generic_name": [ "BUMETANIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6008", "0641-6007" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "BUMETANIDE" ], "rxcui": [ "282486", "1727569" ], "spl_id": [ "fd0b9cd7-b786-44b0-8dc7-02ffd38576a4" ], "spl_set_id": [ "681b5e9d-e2c7-4f29-aaad-e06d4a528c11" ], "package_ndc": [ "0641-6007-01", "0641-6007-10", "0641-6008-01", "0641-6008-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "0Y2S3XUQ5H" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6008-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0641-6053-25", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA080445" ], "brand_name": [ "MEPERIDINE HYDROCHLORIDE" ], "generic_name": [ "MEPERIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6053", "0641-6054", "0641-6052" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "MEPERIDINE HYDROCHLORIDE" ], "rxcui": [ "861476", "1665685", "1665697" ], "spl_id": [ "9566d54d-7343-4695-94ff-8b5f2d384c81" ], "spl_set_id": [ "e0e998da-f056-4fce-be8e-ed60cf3b461b" ], "package_ndc": [ "0641-6053-01", "0641-6053-25", "0641-6054-01", "0641-6054-25", "0641-6052-01", "0641-6052-25" ], "unii": [ "N8E7F7Q170" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Meperidine Hydrochloride, Injection, 50 mg/1 mL (NDC 0641-6053-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-115-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": { "application_number": [ "NDA208510" ], "brand_name": [ "VYVANSE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "59417-115", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469" ], "spl_id": [ "81d087b6-4cb4-466a-9693-679edeb062e2" ], "spl_set_id": [ "704e4378-ca83-445c-8b45-3cfa51c1ecad" ], "package_ndc": [ "59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 10 mg (NDC 59417-115-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current" }, { "discontinued_date": "12/10/2025", "update_type": "New", "initial_posting_date": "12/10/2025", "package_ndc": "58468-0123-1", "generic_name": "Doxercalciferol Injection", "contact_info": "800-633-1610", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/10/2025", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Hectorol, Injection, 4 mcg/2 mL injection 50 single-dose vials (NDC 58468-0123-1)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "12/18/2020", "package_ndc": "72485-201-01", "generic_name": "Azacitidine Injection", "contact_info": "732-637-1971", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA207518" ], "brand_name": [ "AZACITIDINE" ], "generic_name": [ "AZACITIDINE" ], "manufacturer_name": [ "Armas Pharmaceuticals Inc." ], "product_ndc": [ "72485-201" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "AZACITIDINE" ], "rxcui": [ "485246" ], "spl_id": [ "ca345575-17a6-43a3-aa02-3d4bb9d136c5" ], "spl_set_id": [ "5c0a2d5f-8c34-4c04-8425-7543965cedd4" ], "package_ndc": [ "72485-201-01" ], "nui": [ "N0000000233", "N0000175595" ], "pharm_class_moa": [ "Nucleic Acid Synthesis Inhibitors [MoA]" ], "pharm_class_epc": [ "Nucleoside Metabolic Inhibitor [EPC]" ], "unii": [ "M801H13NRU" ] }, "update_date": "06/08/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg (NDC 72485-201-01)", "company_name": "Armas Pharmaceuticals Inc", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/14/2022", "package_ndc": "65219-460-20", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA207449" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "FRESENIUS KABI USA, LLC" ], "product_ndc": [ "65219-460", "65219-456", "65219-464", "65219-458", "65219-462" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795607", "1795609", "1795610", "1795612", "1795616" ], "spl_id": [ "efc3b0c9-518a-47db-bb3e-ebdfd4646e9b" ], "spl_set_id": [ "576a22d8-5f2f-497e-80ad-1842ca74bb53" ], "package_ndc": [ "65219-456-05", "65219-456-60", "65219-464-05", "65219-464-50", "65219-458-05", "65219-458-30", "65219-460-05", "65219-460-20", "65219-462-05", "65219-462-10" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 65219-460-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "New", "initial_posting_date": "02/20/2018", "package_ndc": "31722-275-32", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "732-529-0430, customerservice@camberpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA217821" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Camber Pharmaceuticals, Inc." ], "product_ndc": [ "31722-275", "31722-276", "31722-277" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1724786", "1724787", "1724880", "1724884", "1725078", "1725082" ], "spl_id": [ "4ea16f8e-77de-3ba7-e063-6394a90a5667" ], "spl_set_id": [ "0e552e3a-cf52-4d74-9381-6cc1b29b4c90" ], "package_ndc": [ "31722-275-10", "31722-275-31", "31722-275-32", "31722-275-30", "31722-275-33", "31722-275-34", "31722-275-35", "31722-276-10", "31722-276-31", "31722-276-32", "31722-276-30", "31722-276-33", "31722-276-34", "31722-277-10", "31722-277-31", "31722-277-32", "31722-277-30", "31722-277-33", "31722-277-34" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "07/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 2.5 mg/1 mL (NDC 31722-275-32)", "company_name": "Aspiro Pharma Limited", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-706-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": { "application_number": [ "ANDA205327" ], "brand_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Trigen Laboratories, LLC" ], "product_ndc": [ "13811-706", "13811-709", "13811-707", "13811-708", "13811-710" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210", "1995461" ], "spl_id": [ "0944cf70-d59a-483b-9698-e96ef955a65a" ], "spl_set_id": [ "c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f" ], "package_ndc": [ "13811-709-10", "13811-706-10", "13811-707-10", "13811-708-10", "13811-710-10", "13811-710-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "06/15/2026", "update_type": "New", "initial_posting_date": "06/15/2026", "package_ndc": "0069-0227-03", "generic_name": "Lorlatinib Tablet", "contact_info": "800-533-4535", "related_info": "Supply expected to exhaust 6/30/2026; NDC 0069-0227-01 25 mg; 30 tablets bottle with a child-resistant closure will continue to be manufactured; Discontinuation of the manufacture of this presentation", "openfda": { "application_number": [ "NDA210868" ], "brand_name": [ "LORBRENA" ], "generic_name": [ "LORLATINIB" ], "manufacturer_name": [ "Pfizer Laboratories Div Pfizer Inc" ], "product_ndc": [ "0069-0227", "0069-0231" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LORLATINIB" ], "rxcui": [ "2103169", "2103175", "2103177", "2103179" ], "spl_id": [ "46cb56ce-da15-49af-b72b-f9e377cae4a6" ], "spl_set_id": [ "2b34d62d-e02a-4af3-bc0d-1571dd4ee76d" ], "package_ndc": [ "0069-0227-01", "0069-0227-03", "0069-0231-01" ], "nui": [ "N0000175605", "N0000175082", "N0000190118", "N0000191264", "N0000187064", "N0000191265", "N0000190111", "N0000191423", "N0000190113" ], "pharm_class_epc": [ "Kinase Inhibitor [EPC]" ], "pharm_class_moa": [ "Kinase Inhibitors [MoA]", "Cytochrome P450 3A Inducers [MoA]", "P-Glycoprotein Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Organic Cation Transporter 1 Inhibitors [MoA]", "Organic Anion Transporter 3 Inhibitors [MoA]", "Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]" ], "unii": [ "OSP71S83EU" ] }, "update_date": "06/15/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Tablet", "presentation": "Lorbrena, Tablet, 25 mg; 120 tablets bottle with a child-resistant closure (NDC 0069-0227-03)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "72572-161-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Distributed by Civica", "openfda": { "application_number": [ "ANDA202354" ], "brand_name": [ "ETOMIDATE" ], "generic_name": [ "ETOMIDATE" ], "manufacturer_name": [ "Civica, Inc." ], "product_ndc": [ "72572-161", "72572-160" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008" ], "spl_id": [ "380f0c88-03f8-4cfa-8823-4766c2f7700c" ], "spl_set_id": [ "98002094-f065-4b5f-963f-2c34b5241316" ], "package_ndc": [ "72572-160-01", "72572-160-10", "72572-161-01", "72572-161-10" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 72572-161-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2016", "package_ndc": "71357-007-10", "generic_name": "Sodium Acetate Injection", "contact_info": "833-251-8463", "availability": "Available", "openfda": { "application_number": [ "ANDA214805" ], "brand_name": [ "SODIUM ACETATE" ], "generic_name": [ "SODIUM ACETATE" ], "manufacturer_name": [ "MILLA PHARMACEUTICALS INC." ], "product_ndc": [ "71357-007", "71357-008", "71357-009" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM ACETATE" ], "rxcui": [ "237371", "312965" ], "spl_id": [ "47d8d0e7-6db5-950d-e063-6294a90ab1bf" ], "spl_set_id": [ "1ea1466d-a492-4056-e063-6394a90a80bf" ], "package_ndc": [ "71357-007-01", "71357-007-10", "71357-008-01", "71357-008-10", "71357-009-01", "71357-009-10" ], "unii": [ "4550K0SC9B" ] }, "update_date": "08/15/2026", "therapeutic_category": [ "Total Parenteral Nutrition" ], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 100 mEq/50mL (2 mEq/mL) (NDC 71357-007-10)", "company_name": "Milla Pharmaceuticals", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9094-28", "generic_name": "Fentanyl Citrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA019115" ], "brand_name": [ "FENTANYL CITRATE" ], "generic_name": [ "FENTANYL CITRATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-9094", "0409-9093" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FENTANYL CITRATE" ], "rxcui": [ "1735003", "1735004", "1735006", "1735007", "1735008", "1735013" ], "spl_id": [ "e4eaad6d-c21e-42fd-8fd9-f0b769966d61" ], "spl_set_id": [ "bfa8018a-4cbc-434b-e09e-782872b0340a" ], "package_ndc": [ "0409-9093-41", "0409-9093-36", "0409-9093-31", "0409-9093-38", "0409-9094-12", "0409-9094-22", "0409-9094-18", "0409-9094-25", "0409-9094-17", "0409-9094-28", "0409-9094-16", "0409-9094-31", "0409-9094-41", "0409-9094-61" ], "unii": [ "MUN5LYG46H" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 500 mcg/10 mL (50 ug/1 mL) (NDC 0409-9094-28)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/21/2023", "package_ndc": "0009-0870-26", "generic_name": "Clindamycin Phosphate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028", "openfda": { "application_number": [ "NDA050441" ], "brand_name": [ "CLEOCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0870", "0009-0775", "0009-0902", "0009-0728", "0009-3124", "0009-3447", "0009-3381", "0009-3375", "0009-3382", "0009-6582" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "205964", "309335", "309336", "309339", "685574", "685576", "685578", "706461", "1737244", "1737245", "1737578", "1737579", "1737581", "1737582" ], "spl_id": [ "fa11e62e-4625-4e9c-8676-f318b1cb890f" ], "spl_set_id": [ "05a75685-0af5-407c-ac57-e380c882b49d" ], "package_ndc": [ "0009-0870-21", "0009-0870-26", "0009-0775-20", "0009-0775-26", "0009-0902-11", "0009-0902-18", "0009-0728-05", "0009-0728-09", "0009-3124-01", "0009-3124-03", "0009-3447-01", "0009-3447-03", "0009-3381-01", "0009-3381-02", "0009-3375-01", "0009-3375-02", "0009-3382-01", "0009-3382-02", "0009-6582-02", "0009-6582-01" ], "unii": [ "EH6D7113I8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26)", "company_name": "Pfizer Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "07/23/2026", "update_type": "New", "initial_posting_date": "07/23/2026", "package_ndc": "0574-7110-12", "generic_name": "Morphine Sulfate Suppository", "contact_info": "(800) 775-2054", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-7110", "0574-7112", "0574-7114", "0574-7116" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RECTAL" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "892516", "892603", "892678", "894807" ], "spl_id": [ "fa18ac09-a625-47aa-8cde-7051dc4d0c49" ], "spl_set_id": [ "649d731b-962a-45df-b043-7e0781e8a530" ], "package_ndc": [ "0574-7110-12", "0574-7112-12", "0574-7114-12", "0574-7116-12" ], "unii": [ "X3P646A2J0" ] }, "update_date": "07/23/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Suppository", "presentation": "Morphine Sulfate, Suppository, 5 mg (NDC 0574-7110-12)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "46163-206-92", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "openfda": { "application_number": [ "NDA020171" ], "brand_name": [ "DELFLEX" ], "generic_name": [ "DEXTROSE MONOHYDRATE, SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE" ], "manufacturer_name": [ "Fresenius Medical Care de Mexico, S.A. de C.V." ], "product_ndc": [ "46163-206", "46163-209", "46163-212" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "spl_id": [ "579dba0f-f820-8f9a-e063-6294a90a76b0" ], "spl_set_id": [ "a98facd6-9daa-4d37-8209-63a0599dbfaa" ], "package_ndc": [ "46163-209-92", "46163-209-94", "46163-209-95", "46163-212-95", "46163-212-92", "46163-212-94", "46163-206-92", "46163-206-94", "46163-206-95" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "03/10/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 1.5% Low Mg/Low Ca 2L, 5/cs (NDC 46163-206-92)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued" }, { "discontinued_date": "06/30/2026", "update_type": "New", "initial_posting_date": "06/30/2026", "package_ndc": "65219-082-10", "generic_name": "Gadoterate Meglumine Injection", "contact_info": "888-386-1800", "related_info": "Marketed by Fresenius Kabi, USA; Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA215304" ], "brand_name": [ "GADOTERATE MEGLUMINE" ], "generic_name": [ "GADOTERATE MEGLUMINE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-082", "65219-080", "65219-084", "65219-086" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GADOTERATE MEGLUMINE" ], "spl_id": [ "f05922b7-99d4-48c7-972a-7966bbbbc3b4" ], "spl_set_id": [ "e0655aac-9508-4141-94f5-fcca6af1c41d" ], "package_ndc": [ "65219-080-01", "65219-080-05", "65219-082-01", "65219-082-10", "65219-084-01", "65219-084-15", "65219-086-01", "65219-086-20" ], "unii": [ "L0ND3981AG" ] }, "update_date": "06/30/2026", "therapeutic_category": [ "Medical Imaging" ], "dosage_form": "Injection", "presentation": "Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-082-10)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "16729-295-33", "generic_name": "Carboplatin Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; NDC is non-exempt", "openfda": { "application_number": [ "ANDA206775" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Accord Healthcare, Inc." ], "product_ndc": [ "16729-295" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "35cf6068-f31a-211b-e063-6294a90a6b53" ], "spl_set_id": [ "48aa7ef3-9f44-2a08-e054-00144ff88e88" ], "package_ndc": [ "16729-295-31", "16729-295-33", "16729-295-34", "16729-295-12", "16729-295-38" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-33)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0338-1007-02", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA019615" ], "brand_name": [ "DOPAMINE HYDROCHLORIDE AND DEXTROSE" ], "generic_name": [ "DOPAMINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-1007", "0338-1005", "0338-1009" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOPAMINE HYDROCHLORIDE" ], "rxcui": [ "1292887", "1743869", "1743871", "1743877", "1743879" ], "spl_id": [ "edc9a091-4cb5-4ec7-b6f9-44d2d588bab9" ], "spl_set_id": [ "cb97d4a0-89ed-407c-a763-209386b6f75c" ], "package_ndc": [ "0338-1005-02", "0338-1005-03", "0338-1007-02", "0338-1007-03", "0338-1009-02" ], "unii": [ "7L3E358N9L" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 160 mg/100 mL (NDC 0338-1007-02)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-462-17", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "7 month dating available on request. Check wholesalers for inventory.", "openfda": { "application_number": [ "NDA018304" ], "brand_name": [ "SENSORCAINE MPF" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-462", "63323-464", "63323-466", "63323-465", "63323-467", "63323-460" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457" ], "spl_id": [ "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715" ], "spl_set_id": [ "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8" ], "package_ndc": [ "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "01/13/2026", "update_type": "New", "initial_posting_date": "01/13/2026", "package_ndc": "61314-517-36", "generic_name": "Adalimumab-adaz Injection", "contact_info": "800-525-8747", "related_info": "Equivalent Sandoz format is available.", "update_date": "01/13/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Hyrimoz, Injection, Kit (NDC 61314-517-36)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0172-5241-60", "generic_name": "Anagrelide Hydrochloride Capsule", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "update_date": "11/19/2025", "therapeutic_category": [ "Hematology" ], "dosage_form": "Capsule", "presentation": "Anagrelide Hydrochloride, Capsule, 0.5 mg (NDC 0172-5241-60)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "0378-4430-01", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "1-844-874-7464", "availability": "Unavailable", "related_info": "Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility.", "update_date": "06/03/2026", "therapeutic_category": [ "Neurology", "Other" ], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 30 mg (NDC 0378-4430-01)", "company_name": "Rising Pharma Holdings, Inc.", "shortage_reason": "Regulatory delay", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/30/2020", "package_ndc": "0143-9785-10", "generic_name": "Valproate Sodium Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots will be available. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA078523" ], "brand_name": [ "VALPROATE SODIUM" ], "generic_name": [ "VALPROATE SODIUM" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9785" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "VALPROATE SODIUM" ], "rxcui": [ "1099648" ], "spl_id": [ "0610e50d-6447-4a0e-bc36-dc0bffa95c7d" ], "spl_set_id": [ "bcf57b31-4811-4104-82b3-46fb91a53ee0" ], "package_ndc": [ "0143-9785-01", "0143-9785-10" ], "unii": [ "5VOM6GYJ0D" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Injection", "presentation": "Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "01/12/2026", "update_type": "New", "initial_posting_date": "01/12/2026", "package_ndc": "0378-0167-13", "generic_name": "Doxycycline Hyclate Tablet", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "01/12/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Tablet", "presentation": "Doxycycline Hyclate, Tablet, 100 mg (NDC 0378-0167-13)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0409-07", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA017512" ], "brand_name": [ "DIANEAL LOW CALCIUM WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0409", "0941-0411", "0941-0413", "0941-0415", "0941-0457", "0941-0459", "0941-0426", "0941-0427", "0941-0429", "0941-0424", "0941-0430", "0941-0433", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL Low Calcium with Dextrose, Intraperitoneal Injection, Solution, 18.3 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0409-07)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "discontinued_date": "07/23/2026", "update_type": "New", "initial_posting_date": "07/23/2026", "package_ndc": "0574-7034-12", "generic_name": "Aspirin Suppository", "contact_info": "(800) 775-2054", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "ASPIRIN" ], "generic_name": [ "ASPIRIN" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-7034" ], "product_type": [ "HUMAN OTC DRUG" ], "route": [ "RECTAL" ], "substance_name": [ "ASPIRIN" ], "rxcui": [ "198464" ], "spl_id": [ "a6ca751c-7438-4a0f-adae-d176f73f4915" ], "spl_set_id": [ "cce244aa-cd79-49c8-b68e-267f2bd0ef67" ], "package_ndc": [ "0574-7034-12" ], "nui": [ "N0000000160", "N0000008836", "M0001335", "N0000175722", "N0000175578", "N0000008832" ], "pharm_class_moa": [ "Cyclooxygenase Inhibitors [MoA]" ], "pharm_class_pe": [ "Decreased Prostaglandin Production [PE]", "Decreased Platelet Aggregation [PE]" ], "pharm_class_cs": [ "Anti-Inflammatory Agents, Non-Steroidal [CS]" ], "pharm_class_epc": [ "Nonsteroidal Anti-inflammatory Drug [EPC]", "Platelet Aggregation Inhibitor [EPC]" ], "unii": [ "R16CO5Y76E" ] }, "update_date": "07/23/2026", "therapeutic_category": [ "Analgesia/Addiction", "Cardiovascular" ], "dosage_form": "Suppository", "presentation": "Aspirin, Suppository, 300 mg (NDC 0574-7034-12)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "63323-452-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA204223" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-452", "63323-454", "63323-455", "63323-458", "63323-451" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "1731993", "1732006", "1732011", "1732136", "2003714" ], "spl_id": [ "dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc" ], "spl_set_id": [ "582f42e5-444e-4246-af8c-e7e28097c69a" ], "package_ndc": [ "63323-452-00", "63323-452-01", "63323-454-00", "63323-454-01", "63323-455-00", "63323-455-01", "63323-458-00", "63323-458-01", "63323-451-00", "63323-451-01" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "23155-473-44", "generic_name": "Furosemide Injection", "contact_info": "855-228-9470", "availability": "Unavailable", "related_info": "Estimated recovery: late October 2026; Manufacturing delay", "openfda": { "application_number": [ "ANDA203428" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc." ], "product_ndc": [ "23155-473" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "c14acada-333e-43bb-b1cf-81d569e3e918" ], "spl_set_id": [ "1b9117d5-0dd9-4577-a1fd-bb0aaf7e68ec" ], "package_ndc": [ "23155-473-31", "23155-473-41", "23155-473-32", "23155-473-42", "23155-473-43", "23155-473-33", "23155-473-44", "23155-473-45" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 23155-473-44)", "company_name": "Avet Pharmaceuticals, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "70069-753-25", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": { "application_number": [ "ANDA217792" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-753", "70069-752" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404" ], "spl_id": [ "2b24af95-6f20-4945-bf8c-742f1d6f2721" ], "spl_set_id": [ "bcaab86f-20f0-4482-8d73-e29b36dced58" ], "package_ndc": [ "70069-752-25", "70069-752-10", "70069-752-01", "70069-753-25", "70069-753-01", "70069-753-10" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-753-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-488-37", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE MPF" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-488", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-481", "63323-483", "63323-482", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "0009-0225-02", "generic_name": "Clindamycin Hydrochloride Capsule", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA050162" ], "brand_name": [ "CLEOCIN HYDROCHLORIDE" ], "generic_name": [ "CLINDAMYCIN HYDROCHLORIDE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0225", "0009-0331", "0009-0395" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLINDAMYCIN HYDROCHLORIDE" ], "rxcui": [ "197518", "284215", "309329", "748746", "748748", "748750" ], "spl_id": [ "51cea3cd-28cf-455e-ba27-5a0d8e052858" ], "spl_set_id": [ "df9a2a41-b132-4f43-8940-b2d773b1369a" ], "package_ndc": [ "0009-0331-02", "0009-0225-02", "0009-0395-14" ], "unii": [ "T20OQ1YN1W" ] }, "update_date": "02/25/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Capsule", "presentation": "Cleocin Hydrochloride, Capsule, 150 mg (NDC 0009-0225-02)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "63323-451-01", "generic_name": "Morphine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA204223" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-451", "63323-452", "63323-454", "63323-455", "63323-458" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "1731993", "1732006", "1732011", "1732136", "2003714" ], "spl_id": [ "dbf870e7-7bfe-48f0-ba6a-9cc476dfe5cc" ], "spl_set_id": [ "582f42e5-444e-4246-af8c-e7e28097c69a" ], "package_ndc": [ "63323-452-00", "63323-452-01", "63323-454-00", "63323-454-01", "63323-455-00", "63323-455-01", "63323-458-00", "63323-458-01", "63323-451-00", "63323-451-01" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2868-01", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA075757" ], "brand_name": [ "OMEPRAZOLE" ], "generic_name": [ "OMEPRAZOLE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-2868", "0781-2859" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OMEPRAZOLE" ], "rxcui": [ "198051", "199119" ], "spl_id": [ "b182f298-e28f-434b-b6f1-ecfac29d495e" ], "spl_set_id": [ "516170d4-4913-4577-a2d2-f5c52d1e79c6" ], "package_ndc": [ "0781-2859-10", "0781-2859-01", "0781-2859-92", "0781-2859-31", "0781-2868-10", "0781-2868-01", "0781-2868-92", "0781-2868-31" ], "nui": [ "N0000175525", "N0000000147", "N0000182140" ], "pharm_class_epc": [ "Proton Pump Inhibitor [EPC]" ], "pharm_class_moa": [ "Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]" ], "unii": [ "KG60484QX9" ] }, "update_date": "10/09/2025", "therapeutic_category": [ "Gastroenterology" ], "presentation": "Omeprazole, Delayed Release Capsule, 20 mg (NDC 0781-2868-01)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0185-0842-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-525-8747", "availability": "Available", "openfda": { "application_number": [ "ANDA040439" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0185-0842", "0185-0831", "0185-0853", "0185-0864", "0185-2099", "0185-2098" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577961" ], "spl_id": [ "9a21fb59-a99c-4c63-91e8-4b5d72fbd9cd" ], "spl_set_id": [ "288dafc4-fe6e-4891-832f-511022c87445" ], "package_ndc": [ "0185-0831-01", "0185-0842-01", "0185-0853-01", "0185-0864-01", "0185-2099-01", "0185-2098-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0185-0842-01)", "company_name": "Sandoz Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-1130-04", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "ANDA075880" ], "brand_name": [ "PREMASOL - SULFITE-FREE (AMINO ACID)" ], "generic_name": [ "LEUCINE, LYSINE, ISOLEUCINE, VALINE, HISTIDINE, PHENYLALANINE, THREONINE, METHIONINE, TRYPTOPHAN, TYROSINE, N-ACETYL-TYROSINE, ARGININE, PROLINE, ALANINE, GLUTAMIC ACIDE, SERINE, GLYCINE, ASPARTIC ACID, TAURINE, CYSTEINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "0338-1130", "0338-1131" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LEUCINE", "LYSINE ACETATE", "ISOLEUCINE", "VALINE", "HISTIDINE", "PHENYLALANINE", "THREONINE", "METHIONINE", "TRYPTOPHAN", "TYROSINE", "ARGININE", "PROLINE", "ALANINE", "GLUTAMIC ACID", "SERINE", "GLYCINE", "ASPARTIC ACID", "TAURINE", "CYSTEINE HYDROCHLORIDE" ], "rxcui": [ "801395", "801398", "801403", "801405" ], "spl_id": [ "c874a813-b145-4f7f-833e-97d6c4dd727c" ], "spl_set_id": [ "9afdcc3e-0d06-47f4-86ca-40da48b2b02b" ], "package_ndc": [ "0338-1130-03", "0338-1130-04", "0338-1130-06", "0338-1131-03" ], "nui": [ "N0000175780", "M0000922" ], "pharm_class_epc": [ "Amino Acid [EPC]" ], "pharm_class_cs": [ "Amino Acids [CS]" ], "unii": [ "GMW67QNF9C", "TTL6G7LIWZ", "04Y7590D77", "HG18B9YRS7", "4QD397987E", "47E5O17Y3R", "2ZD004190S", "AE28F7PNPL", "8DUH1N11BX", "42HK56048U", "94ZLA3W45F", "9DLQ4CIU6V", "OF5P57N2ZX", "3KX376GY7L", "452VLY9402", "TE7660XO1C", "30KYC7MIAI", "1EQV5MLY3D", "ZT934N0X4W" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "Premasol 10% Sulfite Free in VIAFLEX Plastic Container, Injection, 0.1 (NDC 0338-1130-04)", "company_name": "Baxter Healthcare", "status": "Current" }, { "discontinued_date": "07/30/2026", "update_type": "New", "initial_posting_date": "07/30/2026", "package_ndc": "65219-801-01", "generic_name": "Glycopyrrolate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA209328" ], "brand_name": [ "GLYCOPYRROLATE" ], "generic_name": [ "GLYCOPYRROLATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-801" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "GLYCOPYRROLATE" ], "rxcui": [ "1731582" ], "spl_id": [ "516b2ac1-7eab-4d63-a0d0-97245858a1d0" ], "spl_set_id": [ "250eeef7-b1a9-45e7-a927-7807232e10be" ], "package_ndc": [ "65219-801-00", "65219-801-01" ], "unii": [ "V92SO9WP2I" ] }, "update_date": "07/30/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Glycopyrrolate, Injection, 0.2 mg per 1 mL (NDC 65219-801-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0338-0023-03", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA016694" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0023", "0338-0017" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618" ], "spl_id": [ "9c644eb4-5844-415a-8c01-4459d98af222" ], "spl_set_id": [ "3bb406a9-f5cb-403a-b1bb-5c4facbea3d5" ], "package_ndc": [ "0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-03)", "company_name": "Baxter Healthcare", "status": "Current" }, { "discontinued_date": "01/20/2026", "update_type": "New", "initial_posting_date": "01/20/2026", "package_ndc": "25357-025-03", "generic_name": "Riboflavin 5-phosphate Ophthalmic Solution", "contact_info": "949-367-9600", "related_info": "Discontinuing manufacture of the product as of July 2026.", "openfda": { "application_number": [ "NDA203324" ], "brand_name": [ "PHOTREXA CROSS-LINKING KIT" ], "generic_name": [ "RIBOFLAVIN 5-PHOSPHATE OPHTHALMIC" ], "manufacturer_name": [ "Glaukos Corporation" ], "product_ndc": [ "25357-025" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "rxcui": [ "1925825", "1925830" ], "spl_id": [ "c945d9a7-2e14-41c7-a209-e537aba21749" ], "spl_set_id": [ "f82cfe92-1a24-11e3-8ffd-0800200c9a66" ], "package_ndc": [ "25357-025-03" ] }, "update_date": "01/20/2026", "therapeutic_category": [ "Ophthalmology" ], "dosage_form": "Ophthalmic Solution", "presentation": "Photrexa Cross-linking Kit, Ophthalmic Solution, Kit (NDC 25357-025-03)", "company_name": "Glaukos Corporation", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-161-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA078450" ], "brand_name": [ "QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE" ], "generic_name": [ "QUINAPRIL HYDROCHLORIDE/HYDROCHLOROTHIAZIDE" ], "manufacturer_name": [ "Aurobindo Pharma Limited" ], "product_ndc": [ "65862-161", "65862-162", "65862-163" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE", "HYDROCHLOROTHIAZIDE" ], "rxcui": [ "310796", "310797", "310809" ], "spl_id": [ "5842ecc2-874a-481b-8997-afa9d862dc5d" ], "spl_set_id": [ "50a58159-9572-4445-9859-b392632597da" ], "package_ndc": [ "65862-161-90", "65862-162-30", "65862-162-90", "65862-163-90" ], "nui": [ "N0000175359", "N0000175419", "M0471776" ], "pharm_class_pe": [ "Increased Diuresis [PE]" ], "pharm_class_epc": [ "Thiazide Diuretic [EPC]" ], "pharm_class_cs": [ "Thiazides [CS]" ], "unii": [ "0J48LPH2TH", "33067B3N2M" ] }, "update_date": "06/02/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride And Hydrochlorothiazide, Tablet, 12.5 mg; 10 mg (NDC 65862-161-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "55150-162-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA203082" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-162", "55150-161", "55150-163", "55150-164", "55150-165" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1737562", "1737566", "1737568", "1737757", "1737761" ], "spl_id": [ "bab2ea79-0aed-4f48-8b4e-f864f8b82fb8", "d95a0a28-804f-44d2-aa31-01df376a3154" ], "spl_set_id": [ "9916b09d-a116-469d-92d5-60e50ea9782b", "89701fac-7536-4f16-87fb-f4cc121e74ee" ], "package_ndc": [ "55150-161-09", "55150-162-09", "55150-163-00", "55150-163-24", "55150-164-09", "55150-165-09", "55150-161-02", "55150-162-05", "55150-163-30", "55150-163-25", "55150-164-02", "55150-165-05" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-162-05)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0338-0502-06", "generic_name": "Amino Acid Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "ANDA020512" ], "brand_name": [ "CLINISOL" ], "generic_name": [ "LYSINE, LEUCINE, PHENYLALANINE, VALINE, HISTIDINE, ISOLEUCINE, METHIONINE, THREONINE, TRYPTOPHAN, ALANINE, ARGININE, GLYCINE, PROLINE, GLUTAMIC ACID, SERINE, ASPARTIC ACID, TYROSINE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0502" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LYSINE ACETATE", "LEUCINE", "PHENYLALANINE", "VALINE", "HISTIDINE", "ISOLEUCINE", "METHIONINE", "THREONINE", "TRYPTOPHAN", "ALANINE", "ARGININE", "GLYCINE", "PROLINE", "GLUTAMIC ACID", "SERINE", "ASPARTIC ACID", "TYROSINE" ], "rxcui": [ "800584", "800588" ], "spl_id": [ "85da84a9-36a7-4d9b-bc6b-d0a58941b5c9" ], "spl_set_id": [ "65ffc962-7538-41ea-9afb-4af5fbce4c5b" ], "package_ndc": [ "0338-0502-03", "0338-0502-06" ], "nui": [ "N0000175780", "M0000922" ], "pharm_class_epc": [ "Amino Acid [EPC]" ], "pharm_class_cs": [ "Amino Acids [CS]" ], "unii": [ "TTL6G7LIWZ", "GMW67QNF9C", "47E5O17Y3R", "HG18B9YRS7", "4QD397987E", "04Y7590D77", "AE28F7PNPL", "2ZD004190S", "8DUH1N11BX", "OF5P57N2ZX", "94ZLA3W45F", "TE7660XO1C", "9DLQ4CIU6V", "3KX376GY7L", "452VLY9402", "30KYC7MIAI", "42HK56048U" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "Clinisol 15% Sulfite Free In Plastic Container, Injection, 0.15 (NDC 0338-0502-06)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "63323-806-05", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA210762" ], "brand_name": [ "FENTANYL CITRATE" ], "generic_name": [ "FENTANYL CITRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-806" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FENTANYL CITRATE" ], "rxcui": [ "1735003", "1735007", "1735008", "1735013", "2168270" ], "spl_id": [ "341b092a-1f6f-40f1-98f2-9346bf2e1242" ], "spl_set_id": [ "38d0c14a-a0c1-44cc-a939-0304eb8037d6" ], "package_ndc": [ "63323-806-11", "63323-806-01", "63323-806-12", "63323-806-02", "63323-806-13", "63323-806-05", "63323-806-14", "63323-806-20", "63323-806-50" ], "unii": [ "MUN5LYG46H" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "06/08/2026", "update_type": "New", "initial_posting_date": "06/08/2026", "package_ndc": "0069-1198-30", "generic_name": "Dacomitinib Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA211288" ], "brand_name": [ "VIZIMPRO" ], "generic_name": [ "DACOMITINIB" ], "manufacturer_name": [ "Pfizer Laboratories Div Pfizer Inc" ], "product_ndc": [ "0069-1198", "0069-0197", "0069-2299" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DACOMITINIB" ], "rxcui": [ "2058915", "2058922", "2058924", "2058926", "2058930", "2058932" ], "spl_id": [ "3ffd0da1-5601-4ecc-a8fb-f484693cb4c5" ], "spl_set_id": [ "4ab27d2f-e385-4e9c-b324-fa69c10b855a" ], "package_ndc": [ "0069-0197-30", "0069-1198-30", "0069-2299-30" ], "unii": [ "5092U85G58" ] }, "update_date": "06/08/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Tablet", "presentation": "Vizimpro, Tablet, 30 mg (NDC 0069-1198-30)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "49230-206-94", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "update_date": "03/10/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 1.5% Low Mg/Low Ca 2.5L/3L, 5/cs (NDC 49230-206-94)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued" }, { "discontinued_date": "12/01/2025", "update_type": "New", "initial_posting_date": "12/01/2025", "package_ndc": "59212-001-01", "generic_name": "Phenoxybenzamine Hydrochloride Capsule", "contact_info": "847-283-7921", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "12/01/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Capsule", "presentation": "Dibenzyline, Capsule, 10 mg (NDC 59212-001-01)", "company_name": "Advanz Pharma (US) Corp.", "status": "To Be Discontinued" }, { "discontinued_date": "04/01/2026", "update_type": "New", "initial_posting_date": "04/01/2026", "package_ndc": "61474-9711-1", "generic_name": "Icosapent Ethyl Capsule", "contact_info": "800-706-5575", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "04/01/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Capsule", "presentation": "Icosapent Ethyl, Capsule, 1 g (NDC 61474-9711-1)", "company_name": "Apotex Corp.", "status": "To Be Discontinued" }, { "discontinued_date": "06/01/2026", "update_type": "New", "initial_posting_date": "06/01/2026", "package_ndc": "60505-6282-1", "generic_name": "Carboplatin Injection", "contact_info": "Apotex Inc.: 800-706-5575", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA077861" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Apotex Corp." ], "product_ndc": [ "60505-6282" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "0e68e276-b0df-4f03-e063-6394a90a22b9" ], "spl_set_id": [ "1c275825-0275-4c73-b650-e4c1519f13b8" ], "package_ndc": [ "60505-6282-1", "60505-6282-3", "60505-6282-6", "60505-6282-7" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 50 mg/5 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-1)", "company_name": "Teyro Labs", "status": "To Be Discontinued" }, { "discontinued_date": "01/27/2026", "update_type": "New", "initial_posting_date": "01/27/2026", "package_ndc": "0781-8017-01", "generic_name": "Fluvastatin Sodium Tablet, Extended Release", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA021192" ], "brand_name": [ "FLUVASTATIN SODIUM ER" ], "generic_name": [ "FLUVASTATIN SODIUM" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-8017" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "FLUVASTATIN SODIUM" ], "rxcui": [ "360507" ], "spl_id": [ "37375ca6-3a81-4d10-9b39-9aee948e51a4" ], "spl_set_id": [ "5ab4296c-87c2-4c64-b218-d620eef51310" ], "package_ndc": [ "0781-8017-31", "0781-8017-01" ], "unii": [ "PYF7O1FV7F" ] }, "update_date": "01/27/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-01)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0472-0803-02", "generic_name": "Desonide Lotion", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": { "application_number": [ "ANDA072354" ], "brand_name": [ "DESONIDE" ], "generic_name": [ "DESONIDE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0472-0803", "0472-0804" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "TOPICAL" ], "substance_name": [ "DESONIDE" ], "rxcui": [ "197572", "349351" ], "spl_id": [ "f3953b9e-138f-4d86-8eea-0fc03c3c2747" ], "spl_set_id": [ "ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99" ], "package_ndc": [ "0472-0804-15", "0472-0804-60", "0472-0803-02", "0472-0803-04" ], "nui": [ "N0000175576", "N0000175450" ], "pharm_class_epc": [ "Corticosteroid [EPC]" ], "pharm_class_moa": [ "Corticosteroid Hormone Receptor Agonists [MoA]" ], "unii": [ "J280872D1O" ] }, "update_date": "09/18/2025", "therapeutic_category": [ "Dermatology" ], "dosage_form": "Lotion", "presentation": "Desowen, Lotion, .5 mg/1 mL (NDC 0472-0803-02)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "03/24/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "0074-7098-01", "generic_name": "Pilocarpine Hydrochloride Ophthalmic Solution", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA214028" ], "brand_name": [ "VUITY" ], "generic_name": [ "PILOCARPINE HYDROCHLORIDE" ], "manufacturer_name": [ "AbbVie Inc." ], "product_ndc": [ "0074-7098" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "OPHTHALMIC" ], "substance_name": [ "PILOCARPINE HYDROCHLORIDE" ], "rxcui": [ "2584552", "2584557" ], "spl_id": [ "ed4cf150-c4b6-4d26-9326-e3a3490de489" ], "spl_set_id": [ "8d806897-8a2a-4518-8c68-0ec3b778de50" ], "package_ndc": [ "0074-7098-02", "0074-7098-01", "0074-7098-03", "0074-7098-04", "0074-7098-05", "0074-7098-06" ], "unii": [ "0WW6D218XJ" ] }, "update_date": "03/24/2026", "therapeutic_category": [ "Ophthalmology" ], "dosage_form": "Ophthalmic Solution", "presentation": "Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-01)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2023", "package_ndc": "0143-9872-10", "generic_name": "Propranolol Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA077760" ], "brand_name": [ "PROPRANOLOL HYDROCHLORIDE" ], "generic_name": [ "PROPRANOLOL HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9872" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "PROPRANOLOL HYDROCHLORIDE" ], "rxcui": [ "856443" ], "spl_id": [ "4432e36f-bed0-4e42-87aa-1330d1725963" ], "spl_set_id": [ "91f2ff1d-68d8-4e83-a2db-618f0410ead7" ], "package_ndc": [ "0143-9872-01", "0143-9872-10" ], "unii": [ "F8A3652H1V" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Propranolol Hydrochloride, Injection, 1 mg/1 mL (NDC 0143-9872-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "discontinued_date": "04/20/2026", "update_type": "New", "initial_posting_date": "04/20/2026", "package_ndc": "0378-1134-01", "generic_name": "Ketorolac Tromethamine Tablet", "contact_info": "877-446-3679", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA074761" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Mylan Pharmaceuticals Inc." ], "product_ndc": [ "0378-1134" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "834022" ], "spl_id": [ "fa08c7fb-128c-4b41-acac-de47c51a36c7" ], "spl_set_id": [ "2837a082-3a34-6f81-5e43-45a70295686b" ], "package_ndc": [ "0378-1134-01" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "04/20/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Tablet", "presentation": "Ketorolac Tromethamine, Tablet, 10 mg (NDC 0378-1134-01)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "72572-076-24", "generic_name": "Clindamycin Phosphate Injection", "contact_info": "800-525-8747", "availability": "Available", "related_info": "Civica Label", "openfda": { "application_number": [ "ANDA201692" ], "brand_name": [ "CLINDAMYCIN IN 5 PERCENT DEXTROSE" ], "generic_name": [ "CLINDAMYCIN IN 5 PERCENT DEXTROSE" ], "manufacturer_name": [ "Civica, Inc." ], "product_ndc": [ "72572-076", "72572-074" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN" ], "rxcui": [ "309335", "309336" ], "spl_id": [ "4711c157-19a5-4886-b468-8739876e67be" ], "spl_set_id": [ "80217bd6-2bc4-401c-9345-22532b36a24f" ], "package_ndc": [ "72572-074-01", "72572-074-24", "72572-076-01", "72572-076-24" ], "nui": [ "N0000009982", "N0000175443", "M0515779", "N0000175731" ], "pharm_class_pe": [ "Decreased Sebaceous Gland Activity [PE]", "Neuromuscular Blockade [PE]" ], "pharm_class_epc": [ "Lincosamide Antibacterial [EPC]" ], "pharm_class_cs": [ "Lincosamides [CS]" ], "unii": [ "3U02EL437C" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24)", "company_name": "Sandoz Inc.", "status": "Current" }, { "discontinued_date": "05/21/2026", "update_type": "New", "initial_posting_date": "05/21/2026", "package_ndc": "65219-082-10", "generic_name": "Gadoterate Meglumine Injection", "contact_info": "Marketed by Fresenius Kabi, USA; Customer service: 888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA215304" ], "brand_name": [ "GADOTERATE MEGLUMINE" ], "generic_name": [ "GADOTERATE MEGLUMINE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-082", "65219-080", "65219-084", "65219-086" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GADOTERATE MEGLUMINE" ], "spl_id": [ "f05922b7-99d4-48c7-972a-7966bbbbc3b4" ], "spl_set_id": [ "e0655aac-9508-4141-94f5-fcca6af1c41d" ], "package_ndc": [ "65219-080-01", "65219-080-05", "65219-082-01", "65219-082-10", "65219-084-01", "65219-084-15", "65219-086-01", "65219-086-20" ], "unii": [ "L0ND3981AG" ] }, "update_date": "05/21/2026", "therapeutic_category": [ "Medical Imaging" ], "dosage_form": "Injection", "presentation": "Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-082-10)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "67457-924-50", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA212571" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Mylan Institutional LLC" ], "product_ndc": [ "67457-924", "67457-925" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909" ], "spl_id": [ "e4cda7fa-dac8-4de7-abc1-d1fd622795d8" ], "spl_set_id": [ "f140de5a-f13d-46b4-a742-049c63e474f5" ], "package_ndc": [ "67457-924-00", "67457-924-50", "67457-925-00", "67457-925-10" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 67457-924-50)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-617-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA202725" ], "brand_name": [ "QUINAPRIL" ], "generic_name": [ "QUINAPRIL HYDROCHLORIDE" ], "manufacturer_name": [ "Aurobindo Pharma Limited" ], "product_ndc": [ "65862-617", "65862-618", "65862-619", "65862-620" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE" ], "rxcui": [ "312748", "312749", "312750", "314203" ], "spl_id": [ "5263abd5-ce46-4918-9bb0-9632861bcbc9" ], "spl_set_id": [ "93e6e668-5306-4f26-81d8-cbc3a7a5e787" ], "package_ndc": [ "65862-617-30", "65862-617-90", "65862-617-99", "65862-617-55", "65862-617-10", "65862-617-78", "65862-618-30", "65862-618-90", "65862-618-99", "65862-618-55", "65862-618-10", "65862-618-78", "65862-619-30", "65862-619-90", "65862-619-99", "65862-619-19", "65862-619-10", "65862-619-78", "65862-620-30", "65862-620-90", "65862-620-99", "65862-620-39", "65862-620-10", "65862-620-78" ], "unii": [ "33067B3N2M" ] }, "update_date": "06/02/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 5 mg (NDC 65862-617-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "68180-557-09", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "Lupin Pharmaceuticals, Inc.", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA077690" ], "brand_name": [ "QUINAPRIL" ], "generic_name": [ "QUINAPRIL" ], "manufacturer_name": [ "Lupin Pharmaceuticals, Inc." ], "product_ndc": [ "68180-557", "68180-556", "68180-558", "68180-554", "68180-559" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE" ], "rxcui": [ "312748", "312749", "312750", "314203" ], "spl_id": [ "a9598a21-6f99-4c86-ace6-b5638da2bec8" ], "spl_set_id": [ "8ded0773-3aec-4e89-9836-d22a5a84abf0" ], "package_ndc": [ "68180-556-09", "68180-557-09", "68180-557-03", "68180-558-09", "68180-558-03", "68180-554-09", "68180-554-03", "68180-559-03", "68180-559-09" ], "unii": [ "33067B3N2M" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 10 mg (NDC 68180-557-09)", "company_name": "Lupin Pharmaceuticals, Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "06/13/2018", "package_ndc": "55150-252-20", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA207182" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-252", "55150-251", "55150-254", "55150-255", "55150-253", "55150-256" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671" ], "spl_id": [ "ccc38d8a-43fd-44c0-985e-32af9ed956ab", "0b1f03c2-db2f-4f90-acc0-d73abd731bf6" ], "spl_set_id": [ "ccc38d8a-43fd-44c0-985e-32af9ed956ab", "ef782e5e-e2d7-465a-99c6-b12611f3158c" ], "package_ndc": [ "55150-251-24", "55150-252-24", "55150-254-24", "55150-255-24", "55150-251-10", "55150-252-20", "55150-253-50", "55150-254-10", "55150-255-20", "55150-256-50" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/mL (NDC 55150-252-20)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-407-11", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": { "application_number": [ "ANDA077856" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Solco Healthcare LLC" ], "product_ndc": [ "43547-407", "43547-406", "43547-408" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "dc17b9d4-2890-4f6c-8476-daa39d0cbc9c" ], "spl_set_id": [ "4acbb7a9-4db5-4497-b8db-9f358b3f6fb4" ], "package_ndc": [ "43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "07/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 43547-407-11)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "06/13/2018", "package_ndc": "0143-9594-25", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA084625" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9594", "0143-9595" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1737566", "1737761" ], "spl_id": [ "a7da0a25-5efb-48fa-9063-f7c0423f820f" ], "spl_set_id": [ "1631e5ca-03d0-4d3b-91e3-2dc14f4eb0e1" ], "package_ndc": [ "0143-9595-01", "0143-9595-25", "0143-9594-01", "0143-9594-25" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Preservative Free, Injection, 20 mg/1 mL (NDC 0143-9594-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "47781-180-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": { "application_number": [ "ANDA207388" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 30 MG,CLL" ], "manufacturer_name": [ "Alvogen Inc." ], "product_ndc": [ "47781-180", "47781-174", "47781-175", "47781-176", "47781-177", "47781-178", "47781-179" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "0374f0f7-9297-810c-38b3-623a72709a7d" ], "spl_set_id": [ "c907301d-e24d-9609-5529-fed14f94549f" ], "package_ndc": [ "47781-174-30", "47781-174-05", "47781-174-01", "47781-175-30", "47781-175-05", "47781-175-01", "47781-176-30", "47781-176-05", "47781-176-01", "47781-177-30", "47781-177-05", "47781-177-01", "47781-178-30", "47781-178-05", "47781-178-01", "47781-179-30", "47781-179-05", "47781-179-01", "47781-180-30", "47781-180-05", "47781-180-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 30mg (NDC 47781-180-01)", "company_name": "Alvogen", "status": "Current" }, { "discontinued_date": "12/03/2025", "update_type": "New", "initial_posting_date": "12/03/2025", "package_ndc": "0409-7101-02", "generic_name": "Sodium Chloride 0.9% Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA019465" ], "brand_name": [ "SODIUM CHLORIDE" ], "generic_name": [ "SODIUM CHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-7101", "0409-7132" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM CHLORIDE" ], "rxcui": [ "1807547", "1807631", "1807632", "1807633" ], "spl_id": [ "147cbba6-2ead-49c4-bce7-4e9c65b303c9" ], "spl_set_id": [ "a2a964f7-c3ec-4dfb-e3a0-6d8136a80397" ], "package_ndc": [ "0409-7101-68", "0409-7101-66", "0409-7101-69", "0409-7101-67", "0409-7101-04", "0409-7101-02", "0409-7132-68", "0409-7132-66", "0409-7132-69", "0409-7132-67", "0409-7132-04", "0409-7132-02" ], "unii": [ "451W47IQ8X" ] }, "update_date": "12/03/2025", "therapeutic_category": [ "Gastroenterology", "Other", "Renal" ], "dosage_form": "Injection", "presentation": "Sodium Chloride 0.9%, Injection, 250 mL ADD-Vantage® Flexible Container (NDC 0409-7101-02)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-5534-14", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 0409-5534-14)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4743-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Unavailable", "related_info": "Estimated recovery: Mid September 2026", "openfda": { "application_number": [ "ANDA216944" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Apotex Corp." ], "product_ndc": [ "60505-4743", "60505-4739", "60505-4740", "60505-4741", "60505-4742", "60505-4744", "60505-4745" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "2eec36cd-6063-fea0-d6dd-b7a5c8df186b" ], "spl_set_id": [ "ecad4442-a644-18e3-6ff2-fdbac45eec47" ], "package_ndc": [ "60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 60505-4743-1)", "company_name": "Apotex Corp.", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0017-38", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA016673" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0017", "0338-0023" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618" ], "spl_id": [ "9c644eb4-5844-415a-8c01-4459d98af222" ], "spl_set_id": [ "3bb406a9-f5cb-403a-b1bb-5c4facbea3d5" ], "package_ndc": [ "0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 g/1000 mL (NDC 0338-0017-38)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "57844-115-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA040422" ], "brand_name": [ "ADDERALL" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "57844-115", "57844-105", "57844-117", "57844-110", "57844-112", "57844-120", "57844-130" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541365", "541878", "541879", "541892", "541894", "577957", "577960", "577961", "577962", "687043", "687045", "1009145", "1009147" ], "spl_id": [ "79af1dc6-c7cf-41b1-a750-e9b47c2187ff" ], "spl_set_id": [ "f22635fe-821d-4cde-aa12-419f8b53db81" ], "package_ndc": [ "57844-105-01", "57844-117-01", "57844-110-01", "57844-112-01", "57844-115-01", "57844-120-01", "57844-130-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Adderall, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 57844-115-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/11/2024", "package_ndc": "0264-7387-50", "generic_name": "Dextrose Monohydrate 70% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "NDA019626" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-7387" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE" ], "rxcui": [ "237656" ], "spl_id": [ "200c4b9e-283a-4dea-b33a-9bb4936b2b99" ], "spl_set_id": [ "8ccb10fe-75a5-440b-8cd4-b11f4e98f7b0" ], "package_ndc": [ "0264-7387-50" ], "unii": [ "IY9XDZ35W2" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 70%, Injection, 70 g/100 mL (NDC 0264-7387-50)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-064-01", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": { "application_number": [ "ANDA207636" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-064", "70069-061", "70069-062", "70069-063", "70069-065", "70069-066", "70069-067" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483" ], "spl_id": [ "79b226f0-c08a-4f84-bf2b-ae5c60e01d67" ], "spl_set_id": [ "ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64" ], "package_ndc": [ "70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10" ], "unii": [ "V910P86109" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-01)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "06/28/2022", "package_ndc": "63323-723-03", "generic_name": "Remifentanil Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA206223" ], "brand_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "generic_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-723", "63323-724", "63323-725" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "REMIFENTANIL HYDROCHLORIDE" ], "rxcui": [ "1729578", "1729584", "1729710" ], "spl_id": [ "406a07e3-a3f8-4fef-901e-021d00743c40", "2f27e51f-2b55-47ee-bd4a-001b71c60622" ], "spl_set_id": [ "5b8025d2-3424-477b-9cff-3990a98c2a65", "d2374b84-81c9-44f9-a4a9-1071281b2531" ], "package_ndc": [ "63323-723-04", "63323-723-06", "63323-723-01", "63323-723-03", "63323-724-01", "63323-724-05", "63323-725-01", "63323-725-10" ], "unii": [ "5V444H5WIC" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Remifentanil Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-723-03)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0480-3667-20", "generic_name": "Liraglutide Injection", "contact_info": "833-493-4689", "availability": "Available", "related_info": "Distributed by Teva", "openfda": { "application_number": [ "NDA022341" ], "brand_name": [ "LIRAGLUTIDE" ], "generic_name": [ "LIRAGLUTIDE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0480-3667" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "LIRAGLUTIDE" ], "rxcui": [ "897122" ], "spl_id": [ "57c9f463-a1b8-4efa-8982-40175cf6cf4f" ], "spl_set_id": [ "14bf9812-14ee-46ce-93b1-686e4906cbbc" ], "package_ndc": [ "0480-3667-19", "0480-3667-22", "0480-3667-20" ], "nui": [ "N0000178480", "M0160181", "N0000020058" ], "pharm_class_epc": [ "GLP-1 Receptor Agonist [EPC]" ], "pharm_class_cs": [ "Glucagon-Like Peptide 1 [CS]" ], "pharm_class_moa": [ "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]" ], "unii": [ "839I73S42A" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Liraglutide, Injection, 6 mg/1 mL (NDC 0480-3667-20)", "company_name": "Novo Nordisk, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/14/2022", "package_ndc": "66220-160-10", "generic_name": "Conivaptan Hydrochloride Injection", "contact_info": "800-706-5575", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "08/18/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10)", "company_name": "Cumberland Pharmaceuticals Inc.", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "06/12/2026", "package_ndc": "10019-926-02", "generic_name": "Ifosfamide Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: September 2026", "openfda": { "application_number": [ "NDA019763" ], "brand_name": [ "IFOSFAMIDE" ], "generic_name": [ "IFOSFAMIDE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "10019-926", "10019-925" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "IFOSFAMIDE" ], "rxcui": [ "1791588", "1791593" ], "spl_id": [ "d505027a-76e6-49f1-8ed1-3eeffe9a958b" ], "spl_set_id": [ "91e433a9-6800-43a6-ac13-a49a04a5aecd" ], "package_ndc": [ "10019-925-82", "10019-925-01", "10019-926-16", "10019-926-02" ], "nui": [ "N0000000236", "N0000175558" ], "pharm_class_moa": [ "Alkylating Activity [MoA]" ], "pharm_class_epc": [ "Alkylating Drug [EPC]" ], "unii": [ "UM20QQM95Y" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Oncology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Ifosfamide, Injection, 3 g/60 mL (NDC 10019-926-02)", "company_name": "Baxter Healthcare", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "11/06/2017", "package_ndc": "0409-2344-88", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA074086" ], "brand_name": [ "DOBUTAMINE" ], "generic_name": [ "DOBUTAMINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-2344" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOBUTAMINE HYDROCHLORIDE" ], "rxcui": [ "1812168" ], "spl_id": [ "e71e9520-871b-479d-9652-1857fceca863", "f6a67673-07a7-44e4-b05c-1f7e63326f79" ], "spl_set_id": [ "dc537761-d5f4-488d-24ab-b2bcd2b17b7a", "89becb0c-da60-4f43-0a98-29ff7a9eca58" ], "package_ndc": [ "0409-2344-01", "0409-2344-62", "0409-2344-02", "0409-2344-68", "0409-2344-88" ], "unii": [ "0WR771DJXV" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular", "Pediatric", "Renal" ], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride, Injection, 250 mg/20mL (12.5 mg/1 mL) (NDC 0409-2344-88)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "55150-198-30", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA205612" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-198", "55150-195", "55150-196", "55150-197", "55150-199", "55150-200", "55150-201" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483" ], "spl_id": [ "1e5f1368-058a-492c-b4b7-d9329a7745e2" ], "spl_set_id": [ "3763b7b6-da49-4658-b93d-28f5da24d09e" ], "package_ndc": [ "55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20" ], "unii": [ "V910P86109" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-198-30)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-062-25", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": { "application_number": [ "ANDA207636" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-062", "70069-061", "70069-063", "70069-064", "70069-065", "70069-066", "70069-067" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483" ], "spl_id": [ "79b226f0-c08a-4f84-bf2b-ae5c60e01d67" ], "spl_set_id": [ "ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64" ], "package_ndc": [ "70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10" ], "unii": [ "V910P86109" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 2 mg/1 mL (NDC 70069-062-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5116-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Available", "openfda": { "application_number": [ "ANDA211840" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "SpecGx LLC" ], "product_ndc": [ "0406-5116", "0406-5111", "0406-5112", "0406-5113", "0406-5114", "0406-5115", "0406-5117" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "b4be564a-404d-4ca1-bac0-ec9cf40fef93" ], "spl_set_id": [ "806a1c15-0842-4787-b2ad-09a21fd96b37" ], "package_ndc": [ "0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0406-5116-01)", "company_name": "SpecGx LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/08/2019", "package_ndc": "0641-6146-25", "generic_name": "Dexamethasone Sodium Phosphate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional product will be made available as it is released.", "openfda": { "application_number": [ "ANDA084282" ], "brand_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "generic_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6146", "0641-0367", "0641-6145" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRAVENOUS", "SOFT TISSUE" ], "substance_name": [ "DEXAMETHASONE SODIUM PHOSPHATE" ], "rxcui": [ "309696", "1116927", "1812194" ], "spl_id": [ "02bf3273-f0c8-448c-9f74-eb009fee9299" ], "spl_set_id": [ "0277cc0a-2fd4-4605-a310-b613be84ee26" ], "package_ndc": [ "0641-0367-21", "0641-0367-25", "0641-6145-01", "0641-6145-25", "0641-6146-01", "0641-6146-10", "0641-6146-25" ], "unii": [ "AI9376Y64P" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Other", "Pulmonary/Allergy", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Dexamethasone Sodium Phosphate, Injection, 4 mg/1 mL (NDC 0641-6146-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "02/24/2026", "update_type": "New", "initial_posting_date": "02/24/2026", "package_ndc": "50742-402-05", "generic_name": "Irinotecan Hydrochloride Injection", "contact_info": "866-321-5031", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA206935" ], "brand_name": [ "IRINOTECAN HYDROCHLORIDE" ], "generic_name": [ "IRINOTECAN HYDROCHLORIDE" ], "manufacturer_name": [ "Ingenus Pharmaceuticals, LLC" ], "product_ndc": [ "50742-402", "50742-401" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "IRINOTECAN HYDROCHLORIDE" ], "rxcui": [ "1726319", "1726324" ], "spl_id": [ "b3cfa0f6-fbdc-4f19-9dac-beaf398603d8" ], "spl_set_id": [ "d04f2471-3085-4fc8-a657-bb3918d48e6e" ], "package_ndc": [ "50742-401-02", "50742-402-05" ], "unii": [ "042LAQ1IIS" ] }, "update_date": "02/24/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Irinotecan Hydrochloride, Injection, 100 mg/5 mL (NDC 50742-402-05)", "company_name": "Ingenus Pharmaceuticals LLC", "status": "To Be Discontinued" }, { "discontinued_date": "05/15/2026", "update_type": "New", "initial_posting_date": "05/15/2026", "package_ndc": "0574-0520-74", "generic_name": "Activated Charcoal Oral Suspension", "contact_info": "866-634-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "M023" ], "brand_name": [ "ACTIDOSE" ], "generic_name": [ "ACTIVATED CHARCOAL" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-0520" ], "product_type": [ "HUMAN OTC DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ACTIVATED CHARCOAL" ], "rxcui": [ "309150", "1251411" ], "spl_id": [ "cf3da077-fe7d-4685-8c5c-f773bc88c88d" ], "spl_set_id": [ "76e4fe6a-afd4-4f68-b12d-0b094f750615" ], "package_ndc": [ "0574-0520-74", "0574-0520-76" ], "unii": [ "2P3VWU3H10" ] }, "update_date": "05/15/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Oral Suspension", "presentation": "Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-74)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-286-00", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-286", "63323-285", "63323-287", "63323-288" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091" ], "spl_id": [ "324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cb6583ff-cde4-4280-aa5b-0bea2b844792", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c" ], "spl_set_id": [ "dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "cb6583ff-cde4-4280-aa5b-0bea2b844792", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6" ], "package_ndc": [ "63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-51", "63323-286-55", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 5 mg/1 mL (NDC 63323-286-00)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-63", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-285", "63323-286", "63323-287", "63323-288" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091" ], "spl_id": [ "324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c" ], "spl_set_id": [ "dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6" ], "package_ndc": [ "63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-63)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0527-4667-37", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "844-834-0530", "availability": "Available", "openfda": { "application_number": [ "ANDA215802" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Lannett Company, Inc." ], "product_ndc": [ "0527-4667", "0527-4661", "0527-4662", "0527-4663", "0527-4664", "0527-4665", "0527-4666" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "cb49954d-0f9d-4471-bc86-0c926473c00b" ], "spl_set_id": [ "2cedb4c2-1e40-4bc4-b9f4-127150c4afbd" ], "package_ndc": [ "0527-4661-37", "0527-4662-37", "0527-4663-37", "0527-4664-37", "0527-4665-37", "0527-4666-37", "0527-4667-37" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0527-4667-37)", "company_name": "Lannett Company, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "55150-209-02", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA205867" ], "brand_name": [ "DEXMEDETOMIDINE" ], "generic_name": [ "DEXMEDETOMIDINE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-209", "55150-296", "55150-297" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "309710", "1718906", "1718909" ], "spl_id": [ "a1eab62d-fcef-4b83-9266-3c5f7a05927b" ], "spl_set_id": [ "8c162541-986b-4b30-866c-b2631ba2c975" ], "package_ndc": [ "55150-209-02", "55150-296-10", "55150-297-10" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 55150-209-02)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5115-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Available", "openfda": { "application_number": [ "ANDA211840" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "SpecGx LLC" ], "product_ndc": [ "0406-5115", "0406-5111", "0406-5112", "0406-5113", "0406-5114", "0406-5116", "0406-5117" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "b4be564a-404d-4ca1-bac0-ec9cf40fef93" ], "spl_set_id": [ "806a1c15-0842-4787-b2ad-09a21fd96b37" ], "package_ndc": [ "0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0406-5115-01)", "company_name": "SpecGx LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-25", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA018667" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-6102" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "e598e8a6-c854-48f5-a412-fb6a6783774a", "981d5143-60cd-4987-9b47-dec24c10de42" ], "spl_set_id": [ "aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7" ], "package_ndc": [ "0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) (NDC 0409-6102-25)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "New", "initial_posting_date": "02/20/2018", "package_ndc": "31722-276-32", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "732-529-0430, customerservice@camberpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA217821" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Camber Pharmaceuticals, Inc." ], "product_ndc": [ "31722-276", "31722-275", "31722-277" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1724786", "1724787", "1724880", "1724884", "1725078", "1725082" ], "spl_id": [ "4ea16f8e-77de-3ba7-e063-6394a90a5667" ], "spl_set_id": [ "0e552e3a-cf52-4d74-9381-6cc1b29b4c90" ], "package_ndc": [ "31722-275-10", "31722-275-31", "31722-275-32", "31722-275-30", "31722-275-33", "31722-275-34", "31722-275-35", "31722-276-10", "31722-276-31", "31722-276-32", "31722-276-30", "31722-276-33", "31722-276-34", "31722-277-10", "31722-277-31", "31722-277-32", "31722-277-30", "31722-277-33", "31722-277-34" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "07/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 31722-276-32)", "company_name": "Aspiro Pharma Limited", "status": "Current" }, { "discontinued_date": "05/06/2026", "update_type": "New", "initial_posting_date": "05/06/2026", "package_ndc": "0409-1208-01", "generic_name": "Cisatracurium Besylate Injection", "contact_info": "844-646-4398", "related_info": "Supply expected to exhaust late June 2026; Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA203238" ], "brand_name": [ "CISATRACURIUM BESYLATE" ], "generic_name": [ "CISATRACURIUM BESYLATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1208", "0409-1098", "0409-1103" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CISATRACURIUM BESYLATE" ], "rxcui": [ "199211", "199212", "1730194" ], "spl_id": [ "7b64e51a-1a55-4949-ac7c-b0a21cbd6ec9" ], "spl_set_id": [ "67908e20-044d-454d-9c51-bf106e817bd0" ], "package_ndc": [ "0409-1098-12", "0409-1098-02", "0409-1103-11", "0409-1103-01", "0409-1208-11", "0409-1208-01" ], "unii": [ "80YS8O1MBS" ] }, "update_date": "05/06/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Cisatracurium Besylate, Injection, 20 mg/10 mL (2 mg/mL) Multidose Vial (NDC 0409-1208-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-097-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": { "application_number": [ "NDA216117" ], "brand_name": [ "RELEXXII" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Vertical Pharmaceuticals, LLC" ], "product_ndc": [ "68025-097", "68025-088", "68025-089", "68025-095", "68025-096", "68025-084", "68025-098" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505" ], "spl_id": [ "86f477e9-07fc-466b-913e-1a4434c91df4" ], "spl_set_id": [ "22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d" ], "package_ndc": [ "68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current" }, { "discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0832-6004-11", "generic_name": "Fluphenazine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": { "application_number": [ "ANDA213784" ], "brand_name": [ "FLUPHENAZINE HYDROCHLORIDE" ], "generic_name": [ "FLUPHENAZINE HYDROCHLORIDE" ], "manufacturer_name": [ "Upsher-Smith Laboratories,LLC" ], "product_ndc": [ "0832-6004", "0832-6003", "0832-6005", "0832-6006" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "FLUPHENAZINE HYDROCHLORIDE" ], "rxcui": [ "859841", "860918", "865117", "865123" ], "spl_id": [ "3bb74f82-8872-9829-e063-6294a90aeace" ], "spl_set_id": [ "f07bb3f1-c68c-441b-9de4-99a219f2500a" ], "package_ndc": [ "0832-6004-11", "0832-6003-11", "0832-6005-11", "0832-6006-11" ], "unii": [ "ZOU145W1XL" ] }, "update_date": "09/18/2025", "therapeutic_category": [ "Neurology", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Fluphenazine Hydrochloride, Tablet, 2.5 mg (NDC 0832-6004-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-113-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Unavailable", "related_info": "Estimated recovery: October 2026", "openfda": { "application_number": [ "ANDA215771" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Granules Pharmaceuticals Inc." ], "product_ndc": [ "70010-113", "70010-111", "70010-112", "70010-114", "70010-115", "70010-116", "70010-117" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "56c7c921-e560-c5ad-e063-6294a90a4c81" ], "spl_set_id": [ "b0b4eccc-34c7-483d-966f-82d588358e1b" ], "package_ndc": [ "70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 70010-113-01)", "company_name": "Granules Pharmaceuticals Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "0143-9507-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional product will be made available as it is released.", "openfda": { "application_number": [ "ANDA202354" ], "brand_name": [ "ETOMIDATE" ], "generic_name": [ "ETOMIDATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9507", "0143-9506" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008" ], "spl_id": [ "98560882-bfdf-404e-ab8b-3ee2a6875830" ], "spl_set_id": [ "75bf0494-7cb9-4e8a-8edd-af62f035d236" ], "package_ndc": [ "0143-9506-01", "0143-9506-10", "0143-9507-01", "0143-9507-10" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 0143-9507-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/23/2021", "package_ndc": "63323-185-50", "generic_name": "Sterile Water Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA088400" ], "brand_name": [ "STERILE WATER" ], "generic_name": [ "WATER" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-185" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "WATER" ], "spl_id": [ "42c6c812-706a-425b-b8cb-931006e40484" ], "spl_set_id": [ "e71c6c83-d518-496c-b2ab-efd5987e4783" ], "package_ndc": [ "63323-185-07", "63323-185-10", "63323-185-09", "63323-185-50", "63323-185-08", "63323-185-20", "63323-185-04", "63323-185-05" ], "unii": [ "059QF0KO0R" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Injection", "presentation": "Sterile Water For Injection In Plastic Container, Injection, 1 mL/1 mL (NDC 63323-185-50)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "12/13/2017", "package_ndc": "72205-102-01", "generic_name": "Bumetanide Injection", "contact_info": "855-668-2369; customerservice@novadozpharma.com", "availability": "Available", "related_info": "Distributed by: Novadoz Pharmaceuticals LLC", "openfda": { "application_number": [ "ANDA215364" ], "brand_name": [ "BUMETANIDE" ], "generic_name": [ "BUMETANIDE" ], "manufacturer_name": [ "Novadoz Pharmaceuticals LLC" ], "product_ndc": [ "72205-102", "72205-101" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "BUMETANIDE" ], "rxcui": [ "282486", "1727569" ], "spl_id": [ "387edfd4-be85-41cd-8a6d-14e6a022b5a9" ], "spl_set_id": [ "387edfd4-be85-41cd-8a6d-14e6a022b5a9" ], "package_ndc": [ "72205-101-01", "72205-101-07", "72205-102-01", "72205-102-07" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "0Y2S3XUQ5H" ] }, "update_date": "08/21/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, 0.25 mg/mL, 10 mL (NDC 72205-102-01)", "company_name": "MSN Laboratories Private Limited", "status": "Current" }, { "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0480-3569-01)", "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3569-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "company_name": "Teva Pharmaceuticals USA, Inc.", "contact_info": "800-545-8800", "availability": "Available", "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "status": "Current", "dosage_form": "Capsule" }, { "update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-7809-22", "generic_name": "Dopamine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA018826" ], "brand_name": [ "DOPAMINE HYDROCHLORIDE IN DEXTROSE" ], "generic_name": [ "DOPAMINE HYDROCHLORIDE IN DEXTROSE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-7809", "0409-7810", "0409-0042", "0409-1858" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOPAMINE HYDROCHLORIDE" ], "rxcui": [ "1292887", "1743877", "1743879" ], "spl_id": [ "188ce800-ff3a-4b22-9a95-2273c3bc99ae" ], "spl_set_id": [ "08f23f6e-150d-45ea-098e-f2edf64c21a1" ], "package_ndc": [ "0409-7809-11", "0409-7809-22", "0409-7809-31", "0409-7809-24", "0409-7810-11", "0409-7810-22", "0409-0042-01", "0409-0042-12", "0409-1858-01", "0409-1858-12" ], "unii": [ "7L3E358N9L" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 400 mg/250 mL (1.6 mg/1 mL) (NDC 0409-7809-22)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-485-27", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-485", "63323-492", "63323-491", "63323-495", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428", "0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17", "4dd52202-8eef-4136-92dd-ada573b7cf74" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31", "63323-492-41", "63323-492-16", "63323-492-43", "63323-492-36", "63323-492-45", "63323-492-26", "63323-485-41", "63323-485-26", "63323-486-41", "63323-486-26", "63323-482-41", "63323-482-26", "63323-495-41", "63323-495-26" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-485-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "03/02/2026", "update_type": "New", "initial_posting_date": "03/02/2026", "package_ndc": "0093-7767-24", "generic_name": "Everolimus Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA210050" ], "brand_name": [ "EVEROLIMUS" ], "generic_name": [ "EVEROLIMUS" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0093-7767", "0093-7766", "0093-7768", "0093-7769" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "EVEROLIMUS" ], "rxcui": [ "845507", "845515", "998189", "1119400" ], "spl_id": [ "0f7ea770-928b-43b2-8971-849d1d12bbc8" ], "spl_set_id": [ "e3bca36b-29ed-4a2b-a1be-a57b6af805f6" ], "package_ndc": [ "0093-7766-19", "0093-7766-24", "0093-7767-19", "0093-7767-24", "0093-7768-19", "0093-7768-24", "0093-7769-19", "0093-7769-24" ], "nui": [ "N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550" ], "pharm_class_epc": [ "Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]" ], "pharm_class_moa": [ "Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]" ], "pharm_class_pe": [ "Decreased Immunologic Activity [PE]" ], "unii": [ "9HW64Q8G6G" ] }, "update_date": "03/02/2026", "therapeutic_category": [ "Transplant" ], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 5 mg (NDC 0093-7767-24)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "12/27/2023", "package_ndc": "69945-094-20", "generic_name": "Technetium TC-99M Pyrophosphate Kit Injection", "contact_info": "888-744-1414", "availability": "Limited Availability", "related_info": "Available via allocation", "openfda": { "application_number": [ "NDA017538" ], "brand_name": [ "TECHNESCAN PYP" ], "generic_name": [ "TECHNETIUM TC 99M PYROPHOSPHATE" ], "manufacturer_name": [ "Curium US LLC" ], "product_ndc": [ "69945-094" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM PYROPHOSPHATE", "STANNOUS CHLORIDE" ], "spl_id": [ "45358120-83e7-a04b-e063-6394a90af91e" ], "spl_set_id": [ "304b63f4-a32e-4700-805d-5bc9f27e7d6a" ], "package_ndc": [ "69945-094-01", "69945-094-20" ], "unii": [ "O352864B8Z", "1BQV3749L5" ] }, "update_date": "08/19/2026", "therapeutic_category": [ "Medical Imaging" ], "dosage_form": "Injection", "presentation": "Technescan PYP, Injection, 11.9 mg/10 mL; 3.2 mg/10 mL (NDC 69945-094-20)", "company_name": "Curium US LLC", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-466-37", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA070553", "NDA018304" ], "brand_name": [ "SENSORCAINE MPF" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-466", "63323-464", "63323-462", "63323-465", "63323-467", "63323-460" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRACAUDAL", "PERINEURAL", "INFILTRATION" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1724880", "1724881", "1725078", "1725175", "1724884", "1724885", "1725082", "1725177", "1672917", "1672919", "1673296", "1673298", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457" ], "spl_id": [ "b41b5dbd-7aff-4d97-ac97-f4355393ee4e", "d3ba9fb9-63c8-4597-bb0a-cd01d31a24b6", "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715" ], "spl_set_id": [ "e700eb7b-8b14-49c9-96b2-331f18776e45", "b6bfc04a-1868-4630-9ca1-8c027af97ce3", "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8" ], "package_ndc": [ "63323-464-01", "63323-464-17", "63323-466-03", "63323-466-17", "63323-464-08", "63323-464-38", "63323-466-08", "63323-466-38", "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31" ], "unii": [ "7TQO7W3VT8", "30Q7KI53AK" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL (NDC 63323-466-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "05/03/2018", "package_ndc": "65219-368-02", "generic_name": "Lorazepam Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA217598" ], "brand_name": [ "LORAZEPAM" ], "generic_name": [ "LORAZEPAM" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-368" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "LORAZEPAM" ], "rxcui": [ "1665188" ], "spl_id": [ "5cd2d0d8-9639-4e96-aafd-4991ad35fabc", "462a13da-259a-40e7-bd5b-f7f42ae025b7" ], "spl_set_id": [ "b2487467-a63f-48b5-b0de-3a6ce6672d50", "462a13da-259a-40e7-bd5b-f7f42ae025b7" ], "package_ndc": [ "65219-368-01", "65219-368-02", "65219-368-14", "65219-368-24" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "O26FZP769L" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-482-17", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-482", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428", "0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17", "4dd52202-8eef-4136-92dd-ada573b7cf74" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31", "63323-492-41", "63323-492-16", "63323-492-43", "63323-492-36", "63323-492-45", "63323-492-26", "63323-485-41", "63323-485-26", "63323-486-41", "63323-486-26", "63323-482-41", "63323-482-26", "63323-495-41", "63323-495-26" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .01 mg/1 mL; 10 mg/1 mL (NDC 63323-482-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/18/2023", "package_ndc": "0169-2800-15", "generic_name": "Liraglutide Injection", "contact_info": "833-493-4689", "availability": "Available", "openfda": { "application_number": [ "NDA206321" ], "brand_name": [ "SAXENDA" ], "generic_name": [ "LIRAGLUTIDE" ], "manufacturer_name": [ "Novo Nordisk Pharmaceutical Industries, LP" ], "product_ndc": [ "0169-2800" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "LIRAGLUTIDE" ], "rxcui": [ "1598268", "2735350" ], "spl_id": [ "7e183945-550d-4b6a-bf4e-300193517cac" ], "spl_set_id": [ "3946d389-0926-4f77-a708-0acb8153b143" ], "package_ndc": [ "0169-2800-15", "0169-2800-90", "0169-2800-97" ], "nui": [ "N0000178480", "M0160181", "N0000020058" ], "pharm_class_epc": [ "GLP-1 Receptor Agonist [EPC]" ], "pharm_class_cs": [ "Glucagon-Like Peptide 1 [CS]" ], "pharm_class_moa": [ "Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]" ], "unii": [ "839I73S42A" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "Saxenda, Injection, 6 mg/1 mL (NDC 0169-2800-15)", "company_name": "Novo Nordisk, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "63323-280-04", "generic_name": "Furosemide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA018902" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-280" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "9804efac-5457-417a-8de7-a688467759c0", "64b3fb5f-3516-4e39-b74e-e0e402ed9c4d" ], "spl_set_id": [ "3747bbcd-783d-4baa-bb5b-b6827bf390e3", "c794c95a-654e-48fe-9596-201fc122ff75" ], "package_ndc": [ "63323-280-41", "63323-280-16", "63323-280-43", "63323-280-26", "63323-280-45", "63323-280-36", "63323-280-01", "63323-280-02", "63323-280-03", "63323-280-04", "63323-280-05", "63323-280-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-04)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "01/31/2018", "package_ndc": "0641-6007-10", "generic_name": "Bumetanide Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA079196" ], "brand_name": [ "BUMETANIDE" ], "generic_name": [ "BUMETANIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6007", "0641-6008" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "BUMETANIDE" ], "rxcui": [ "282486", "1727569" ], "spl_id": [ "fd0b9cd7-b786-44b0-8dc7-02ffd38576a4" ], "spl_set_id": [ "681b5e9d-e2c7-4f29-aaad-e06d4a528c11" ], "package_ndc": [ "0641-6007-01", "0641-6007-10", "0641-6008-01", "0641-6008-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "0Y2S3XUQ5H" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 0641-6007-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-468-17", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA070966" ], "brand_name": [ "SENSORCAINE MPF" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-468", "63323-472", "63323-463", "63323-461" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1867594", "1867596", "1867618", "1867620", "1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810" ], "spl_id": [ "b671015d-f620-4930-a890-5e27a40ae42f", "cc1f6507-eb3e-4398-a1d3-0c56a2099e6b" ], "spl_set_id": [ "b671015d-f620-4930-a890-5e27a40ae42f", "bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb" ], "package_ndc": [ "63323-468-08", "63323-468-38", "63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17" ], "unii": [ "7TQO7W3VT8", "30Q7KI53AK" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "64850-503-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": { "application_number": [ "ANDA211352" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Elite Laboratories, Inc." ], "product_ndc": [ "64850-503", "64850-500", "64850-501", "64850-502", "64850-504", "64850-505", "64850-506" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "a41cf8e5-cb1b-488c-96b3-3bef8283d6c4" ], "spl_set_id": [ "e677690f-790f-4626-ad78-097cdb6ea540" ], "package_ndc": [ "64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.125 mg; 3.125 mg; 3.125 mg; 3.125 mg (NDC 64850-503-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "0409-9094-61", "generic_name": "Fentanyl Citrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA019115" ], "brand_name": [ "FENTANYL CITRATE" ], "generic_name": [ "FENTANYL CITRATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-9094", "0409-9093" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FENTANYL CITRATE" ], "rxcui": [ "1735003", "1735004", "1735006", "1735007", "1735008", "1735013" ], "spl_id": [ "e4eaad6d-c21e-42fd-8fd9-f0b769966d61" ], "spl_set_id": [ "bfa8018a-4cbc-434b-e09e-782872b0340a" ], "package_ndc": [ "0409-9093-41", "0409-9093-36", "0409-9093-31", "0409-9093-38", "0409-9094-12", "0409-9094-22", "0409-9094-18", "0409-9094-25", "0409-9094-17", "0409-9094-28", "0409-9094-16", "0409-9094-31", "0409-9094-41", "0409-9094-61" ], "unii": [ "MUN5LYG46H" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate, Injection, 2500 mcg/50 mL (50 ug/1 mL) (NDC 0409-9094-61)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "05/03/2018", "package_ndc": "0641-6047-10", "generic_name": "Lorazepam Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA018140" ], "brand_name": [ "LORAZEPAM" ], "generic_name": [ "LORAZEPAM" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6047", "0641-6044", "0641-6046", "0641-6045" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "LORAZEPAM" ], "rxcui": [ "238100", "238101", "1665188", "1665326" ], "spl_id": [ "7c73dbc6-2623-4443-9b05-97dec7a0be2e" ], "spl_set_id": [ "e9b54e42-04cf-4c62-90e1-36f7b31a4e81" ], "package_ndc": [ "0641-6044-01", "0641-6044-25", "0641-6046-01", "0641-6046-10", "0641-6045-01", "0641-6045-25", "0641-6047-01", "0641-6047-10" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "O26FZP769L" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Injection", "presentation": "Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-564-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "04/29/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 200 mg (NDC 49884-564-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "63323-172-60", "generic_name": "Carboplatin Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release November 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "ANDA077266" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-172" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "3a1dd588-13b0-4d58-8d46-3a25a4fc6b40" ], "spl_set_id": [ "b4fa7aac-c9d2-4af4-a281-3e6cfc502ff6" ], "package_ndc": [ "63323-172-60" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 63323-172-60)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/03/2023", "package_ndc": "0037-0678-96", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "(800) 796-9526", "availability": "Available", "openfda": { "application_number": [ "NDA020479" ], "brand_name": [ "GASTROCROM" ], "generic_name": [ "CROMOLYN SODIUM" ], "manufacturer_name": [ "Viatris Specialty LLC" ], "product_ndc": [ "0037-0678" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CROMOLYN SODIUM" ], "rxcui": [ "831261", "831269" ], "spl_id": [ "15aec235-80e7-4d95-b48c-bbca69b4b04d" ], "spl_set_id": [ "00623958-a8fe-47d1-a0d2-0aa4e2f7966e" ], "package_ndc": [ "0037-0678-08", "0037-0678-96" ], "unii": [ "Q2WXR1I0PK" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Pulmonary/Allergy" ], "dosage_form": "Concentrate", "presentation": "Gastrocrom, Concentrate, 20 mg/1 mL (NDC 0037-0678-96)", "company_name": "Mylan Specialty, a Viatris Company", "status": "Current" }, { "discontinued_date": "03/10/2026", "update_type": "New", "initial_posting_date": "03/10/2026", "package_ndc": "49230-209-92", "generic_name": "Peritoneal Dialysis Solution", "contact_info": "800-323-5188", "related_info": "The NDC codes are being discontinued, to be replaced with NDC labeler code #46163.", "update_date": "03/10/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DELFLEX® w/Dextrose, Solution, 2.5% Low Mg/Low Ca 2L, 5/cs (NDC 49230-209-92)", "company_name": "Fresenius Medical Care North America", "status": "To Be Discontinued" }, { "discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "0228-2851-11", "generic_name": "Guanfacine Hydrochloride Tablet, Extended Release", "contact_info": "800-545-8800", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA200881" ], "brand_name": [ "GUANFACINE" ], "generic_name": [ "GUANFACINE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0228-2851", "0228-2850", "0228-2853", "0228-2855" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "GUANFACINE HYDROCHLORIDE" ], "rxcui": [ "862006", "862013", "862019", "862025" ], "spl_id": [ "00143252-2b74-4b11-86ed-9b864635f129" ], "spl_set_id": [ "3a171942-37af-430d-8b9d-bb678ca2be4b" ], "package_ndc": [ "0228-2850-11", "0228-2851-11", "0228-2853-11", "0228-2855-11" ], "unii": [ "PML56A160O" ] }, "update_date": "11/13/2025", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Guanfacine Hydrochloride, Tablet, Extended Release, 2 mg (NDC 0228-2851-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "11/01/2023", "package_ndc": "60505-4742-1", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-706-5575", "availability": "Unavailable", "related_info": "Estimated recovery: Late August 2026", "openfda": { "application_number": [ "ANDA216944" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Apotex Corp." ], "product_ndc": [ "60505-4742", "60505-4739", "60505-4740", "60505-4741", "60505-4743", "60505-4744", "60505-4745" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "2eec36cd-6063-fea0-d6dd-b7a5c8df186b" ], "spl_set_id": [ "ecad4442-a644-18e3-6ff2-fdbac45eec47" ], "package_ndc": [ "60505-4739-1", "60505-4740-1", "60505-4741-1", "60505-4742-1", "60505-4743-1", "60505-4744-1", "60505-4745-1" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 60505-4742-1)", "company_name": "Apotex Corp.", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0011-04", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": { "application_number": [ "NDA009866" ], "brand_name": [ "SOLU-CORTEF" ], "generic_name": [ "HYDROCORTISONE SODIUM SUCCINATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0011", "0009-0825", "0009-0013", "0009-0016", "0009-0005" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "HYDROCORTISONE SODIUM SUCCINATE" ], "rxcui": [ "105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596" ], "spl_id": [ "8512044a-4a54-4634-bb97-9e20126adc61" ], "spl_set_id": [ "65eefd58-b166-4d71-ade6-45c8fdf86922" ], "package_ndc": [ "0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01" ], "unii": [ "50LQB69S1Z" ] }, "update_date": "02/24/2026", "therapeutic_category": [ "Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 100 mg/vial (NDC 0009-0011-04)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-472-37", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA070554" ], "brand_name": [ "SENSORCAINE MPF" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-472", "63323-463", "63323-461", "63323-468" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "RETROBULBAR" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012377", "1012384", "1012413", "1012417", "1724786", "1724787", "1724809", "1724810", "1867594", "1867596", "1867618", "1867620" ], "spl_id": [ "cc1f6507-eb3e-4398-a1d3-0c56a2099e6b" ], "spl_set_id": [ "bc61a9a6-0a4e-48a9-b908-e5e66b9f23eb" ], "package_ndc": [ "63323-472-03", "63323-472-17", "63323-472-01", "63323-472-37", "63323-463-01", "63323-463-57", "63323-461-01", "63323-461-57", "63323-468-02", "63323-468-37", "63323-468-01", "63323-468-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 7.5 mg/1 mL (NDC 63323-472-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/21/2023", "package_ndc": "0009-5095-06", "generic_name": "Clindamycin Phosphate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA050441" ], "brand_name": [ "CLEOCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-5095", "0009-3051", "0009-4073" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "1737244", "1737245", "1737578", "1737579", "1737581", "1737582" ], "spl_id": [ "8d0dac99-6ec9-4648-8ae1-0cc2894d56cf" ], "spl_set_id": [ "a0a2eff7-b7de-42fe-8e5a-0cfbed38bb4b" ], "package_ndc": [ "0009-3051-01", "0009-3051-02", "0009-4073-03", "0009-4073-04", "0009-5095-05", "0009-5095-06" ], "unii": [ "EH6D7113I8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, 900 mg/6 mL (150 mg/mL) (NDC 0009-5095-06)", "company_name": "Pfizer Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "12/22/2025", "update_type": "New", "initial_posting_date": "12/22/2025", "package_ndc": "0002-8011-27", "generic_name": "Mirikizumab-mrkz Injection", "contact_info": "800-545-5979", "related_info": "A business decision was made to discontinue. Distribution will end April 2026. The 200 mg/2 mL injection presentation (NDC 0002-3116-11) will remain.", "openfda": { "application_number": [ "BLA761279" ], "brand_name": [ "OMVOH" ], "generic_name": [ "MIRIKIZUMAB-MRKZ" ], "manufacturer_name": [ "Eli Lilly and Company" ], "product_ndc": [ "0002-8011", "0002-7575", "0002-8870", "0002-7717", "0002-7722", "0002-3116", "0002-1442" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "MIRIKIZUMAB" ], "rxcui": [ "2668391", "2668398", "2668405", "2668410", "2680728", "2680732", "2703047", "2703048", "2703049", "2703050", "2703051", "2703052", "2703053", "2703054" ], "spl_id": [ "3553ca93-cbe0-4286-b806-a423598eb42a" ], "spl_set_id": [ "472cbe04-263e-433d-9a0f-58c1b50b715a" ], "package_ndc": [ "0002-7575-01", "0002-8011-01", "0002-8011-27", "0002-8011-61", "0002-8870-01", "0002-8870-27", "0002-7717-11", "0002-7717-61", "0002-3116-01", "0002-7722-11", "0002-1442-01", "0002-3116-11", "0002-3116-61", "0002-1442-11" ], "nui": [ "N0000192799", "N0000192798" ], "pharm_class_epc": [ "Interleukin-23 Antagonist [EPC]" ], "pharm_class_moa": [ "Interleukin-23 Antagonists [MoA]" ], "unii": [ "Z7HVY03PHP" ] }, "update_date": "12/22/2025", "therapeutic_category": [ "Gastroenterology", "Other" ], "dosage_form": "Injection", "presentation": "Omvoh, Injection, 100 mg/1 mL (NDC 0002-8011-27)", "company_name": "Eli Lilly and Co.", "status": "To Be Discontinued" }, { "discontinued_date": "01/27/2026", "update_type": "New", "initial_posting_date": "01/27/2026", "package_ndc": "66758-211-31", "generic_name": "Fluvastatin Sodium Tablet, Extended Release", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA021192" ], "brand_name": [ "LESCOL XL" ], "generic_name": [ "FLUVASTATIN SODIUM" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "66758-211" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "FLUVASTATIN SODIUM" ], "rxcui": [ "360507", "687048" ], "spl_id": [ "726ea2db-f1b0-4b73-a515-02157db88a42" ], "spl_set_id": [ "726ea2db-f1b0-4b73-a515-02157db88a42" ], "package_ndc": [ "66758-211-01", "66758-211-31" ], "unii": [ "PYF7O1FV7F" ] }, "update_date": "01/27/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Lescol XL, Tablet, Extended Release, 80 mg (NDC 66758-211-31)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 0480-3568-01)", "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0480-3568-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "company_name": "Teva Pharmaceuticals USA, Inc.", "contact_info": "800-545-8800", "availability": "Available", "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "status": "Current", "dosage_form": "Capsule" }, { "update_type": "Reverified", "initial_posting_date": "11/01/2017", "package_ndc": "76045-121-11", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA019034" ], "brand_name": [ "DILAUDID" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "76045-121", "76045-009", "76045-010" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897756", "897757", "1433251", "1872265", "1872269", "1872752", "2277368", "2277370" ], "spl_id": [ "97bfcafb-2037-47dc-a0ae-f7b8007c47df" ], "spl_set_id": [ "9eebd88a-5632-460f-b7b6-26c8a180540d" ], "package_ndc": [ "76045-009-96", "76045-009-06", "76045-009-01", "76045-009-11", "76045-010-01", "76045-010-11", "76045-121-01", "76045-121-11" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Dilaudid, Injection, .2 mg/1 mL (NDC 76045-121-11)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "63323-462-37", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA018304" ], "brand_name": [ "SENSORCAINE MPF" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-462", "63323-464", "63323-466", "63323-465", "63323-467", "63323-460" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177", "1012391", "1012396", "1012404", "1012421", "1012455", "1012457" ], "spl_id": [ "13a48007-3784-46f2-bd4d-da1004186b81", "2b1a1f80-cb29-4ac1-9e72-20225ed45715" ], "spl_set_id": [ "dcf3c0ad-9eb8-4ee7-96df-d0db7ff23175", "eb6d8fee-def4-4c96-9972-695e8cea8ea8" ], "package_ndc": [ "63323-462-03", "63323-462-38", "63323-464-09", "63323-464-39", "63323-466-09", "63323-466-39", "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "0093-3212-05", "generic_name": "Clonazepam Tablet", "contact_info": "800-545-8800", "availability": "Available", "openfda": { "application_number": [ "ANDA074569" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0093-3212", "0093-0832", "0093-3213" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "d6abe4e3-7699-4ead-95f4-739a961b23ad" ], "spl_set_id": [ "8069b1a0-7c06-4252-b44e-e2eef065d9b8" ], "package_ndc": [ "0093-0832-01", "0093-0832-05", "0093-3212-01", "0093-3212-05", "0093-3213-01", "0093-3213-05" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 0093-3212-05)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "04/10/2026", "update_type": "New", "initial_posting_date": "04/10/2026", "package_ndc": "69238-2512-9", "generic_name": "Nitrofurantoin Oral Suspension", "contact_info": "866-525-7270", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA201679" ], "brand_name": [ "NITROFURANTOIN" ], "generic_name": [ "NITROFURANTOIN" ], "manufacturer_name": [ "Amneal Pharmaceuticals NY LLC" ], "product_ndc": [ "69238-2512" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "NITROFURANTOIN" ], "rxcui": [ "311989" ], "spl_id": [ "87af7ed1-6ae7-4eaf-ab35-d46d07549450" ], "spl_set_id": [ "80129dba-5939-4292-bfd0-8d53ba165941" ], "package_ndc": [ "69238-2512-9" ], "nui": [ "N0000175494", "M0014892" ], "pharm_class_epc": [ "Nitrofuran Antibacterial [EPC]" ], "pharm_class_cs": [ "Nitrofurans [CS]" ], "unii": [ "927AH8112L" ] }, "update_date": "04/10/2026", "therapeutic_category": [ "Anti-Infective", "Other" ], "dosage_form": "Oral Suspension", "presentation": "Nitrofurantoin, Oral Suspension, 25 mg/5 mL (NDC 69238-2512-9)", "company_name": "Amneal Pharmaceuticals", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "16729-502-43", "generic_name": "Furosemide Injection", "contact_info": "866-941-7875", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; NDC is non-exempt", "openfda": { "application_number": [ "ANDA070017" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Accord Healthcare, Inc." ], "product_ndc": [ "16729-502", "16729-500", "16729-501" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "1cfab300-d796-6a68-e063-6394a90a73f9" ], "spl_set_id": [ "f6f64972-714c-4ee9-8a5e-9ffcab41a73b" ], "package_ndc": [ "16729-500-30", "16729-500-08", "16729-501-64", "16729-501-43", "16729-502-03", "16729-502-43" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 16729-502-43)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "64850-502-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "888-852-6657", "availability": "Available", "openfda": { "application_number": [ "ANDA211352" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Elite Laboratories, Inc." ], "product_ndc": [ "64850-502", "64850-500", "64850-501", "64850-503", "64850-504", "64850-505", "64850-506" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "a41cf8e5-cb1b-488c-96b3-3bef8283d6c4" ], "spl_set_id": [ "e677690f-790f-4626-ad78-097cdb6ea540" ], "package_ndc": [ "64850-500-01", "64850-500-05", "64850-500-30", "64850-501-01", "64850-501-05", "64850-501-30", "64850-502-01", "64850-502-05", "64850-502-30", "64850-503-01", "64850-503-05", "64850-503-30", "64850-504-01", "64850-504-05", "64850-504-30", "64850-505-01", "64850-505-05", "64850-505-30", "64850-506-01", "64850-506-05", "64850-506-30" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 64850-502-01)", "company_name": "Elite Laboratories, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/26/2018", "package_ndc": "0409-3796-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: June 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA074802" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3796", "0409-3793", "0409-3795" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "4beb8ebd-934e-4181-8374-01be0bb80680" ], "spl_set_id": [ "8accbb78-fc64-45d5-69b0-35c23a1d2a2e" ], "package_ndc": [ "0409-3793-19", "0409-3793-01", "0409-3793-25", "0409-3795-19", "0409-3795-01", "0409-3795-25", "0409-3796-19", "0409-3796-01", "0409-3796-25" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 60 mg/2 mL (30 mg/mL) (NDC 0409-3796-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "08/03/2026", "update_type": "New", "initial_posting_date": "08/03/2026", "package_ndc": "0941-0411-06", "generic_name": "Calcium Chloride; Dextrose; Magnesium Chloride; Sodium Chloride; Sodium Lactate Intraperitoneal Injection, Solution", "contact_info": "800-284-4060", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "NDA017512" ], "brand_name": [ "DIANEAL PD-2 WITH DEXTROSE" ], "generic_name": [ "SODIUM CHLORIDE, SODIUM LACTATE, CALCIUM CHLORIDE, MAGNESIUM CHLORIDE AND DEXTROSE" ], "manufacturer_name": [ "Vantive US Healthcare LLC" ], "product_ndc": [ "0941-0411", "0941-0413", "0941-0415", "0941-0409", "0941-0457", "0941-0459", "0941-0426", "0941-0427", "0941-0429", "0941-0424", "0941-0430", "0941-0433", "0941-0484", "0941-0487", "0941-0490" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAPERITONEAL" ], "substance_name": [ "DEXTROSE MONOHYDRATE", "SODIUM CHLORIDE", "SODIUM LACTATE", "CALCIUM CHLORIDE", "MAGNESIUM CHLORIDE" ], "rxcui": [ "799999", "800003", "800057", "800061", "800062", "800064", "800066", "800074", "800111", "800115", "800472", "800474" ], "spl_id": [ "194f41a6-655b-456a-955f-7566eb429b7b" ], "spl_set_id": [ "aa268d3f-7389-4f25-801f-5d4825495f08" ], "package_ndc": [ "0941-0411-05", "0941-0411-06", "0941-0411-07", "0941-0411-04", "0941-0411-11", "0941-0413-05", "0941-0413-06", "0941-0413-07", "0941-0413-01", "0941-0413-04", "0941-0415-05", "0941-0415-06", "0941-0415-04", "0941-0415-07", "0941-0415-01", "0941-0409-06", "0941-0409-05", "0941-0409-07", "0941-0409-01", "0941-0457-08", "0941-0457-02", "0941-0457-05", "0941-0457-01", "0941-0459-08", "0941-0459-02", "0941-0459-05", "0941-0459-01", "0941-0426-52", "0941-0426-53", "0941-0427-52", "0941-0427-53", "0941-0429-52", "0941-0429-53", "0941-0424-51", "0941-0424-52", "0941-0424-53", "0941-0430-51", "0941-0430-52", "0941-0430-53", "0941-0433-51", "0941-0433-52", "0941-0433-53", "0941-0484-01", "0941-0487-01", "0941-0490-01" ], "unii": [ "02F3473H9O", "TU7HW0W0QT", "451W47IQ8X", "M4I0D6VV5M", "LX22YL083G" ] }, "update_date": "08/03/2026", "therapeutic_category": [ "Renal" ], "dosage_form": "Solution", "presentation": "DIANEAL PD-2 with Dextrose, Intraperitoneal Injection, Solution, 25.7 mg/100 mL; 1.5 g/100 mL; 5.08 mg/100 mL; 538 mg/100 mL; 448 mg/100 mL (NDC 0941-0411-06)", "company_name": "Vantive US Healthcare LLC", "status": "To Be Discontinued" }, { "discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "60951-712-70", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA040330" ], "brand_name": [ "ENDOCET" ], "generic_name": [ "OXYCODONE AND ACETAMINOPHEN" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "60951-712", "60951-602", "60951-700", "60951-701" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OXYCODONE HYDROCHLORIDE", "ACETAMINOPHEN" ], "rxcui": [ "1049214", "1049216", "1049221", "1049223", "1049225", "1049227", "1049635", "1487288" ], "spl_id": [ "a8475489-982f-4080-9565-7948155d9abb" ], "spl_set_id": [ "944d3e60-7eee-11de-a413-0002a5d5c51b" ], "package_ndc": [ "60951-602-70", "60951-602-85", "60951-700-70", "60951-712-70", "60951-701-70" ], "unii": [ "C1ENJ2TE6C", "362O9ITL9D" ] }, "update_date": "11/03/2025", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 10 mg (NDC 60951-712-70)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "01/24/2025", "package_ndc": "82154-0451-4", "generic_name": "Peginterferon alfa-2a Injection", "contact_info": "800-506-8501, email: medinfo.us@pharmaand.com", "availability": "Available", "openfda": { "application_number": [ "BLA103964" ], "brand_name": [ "PEGASYS" ], "generic_name": [ "PEGINTERFERON ALFA-2A" ], "manufacturer_name": [ "pharmaand GmbH" ], "product_ndc": [ "82154-0451", "82154-0449" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "PEGINTERFERON ALFA-2A" ], "rxcui": [ "351270", "352297", "731326", "731328" ], "spl_id": [ "560699fb-9630-ebaa-e063-6394a90ad0ab" ], "spl_set_id": [ "d9290e5b-6d40-2318-e053-2995a90a9916" ], "package_ndc": [ "82154-0449-1", "82154-0451-4" ], "nui": [ "N0000175521", "M0025711" ], "pharm_class_epc": [ "Interferon alpha [EPC]" ], "pharm_class_cs": [ "Interferon-alpha [CS]" ], "unii": [ "Q46947FE7K" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Antiviral" ], "dosage_form": "Injection", "presentation": "Pegasys, Injection, 180 ug/.5 mL (NDC 82154-0451-4)", "company_name": "pharmaand GmbH (pharma&)", "status": "Current" }, { "discontinued_date": "05/21/2026", "update_type": "New", "initial_posting_date": "05/21/2026", "package_ndc": "65219-086-20", "generic_name": "Gadoterate Meglumine Injection", "contact_info": "Marketed by Fresenius Kabi, USA; Customer service: 888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA215304" ], "brand_name": [ "GADOTERATE MEGLUMINE" ], "generic_name": [ "GADOTERATE MEGLUMINE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-086", "65219-080", "65219-082", "65219-084" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "GADOTERATE MEGLUMINE" ], "spl_id": [ "f05922b7-99d4-48c7-972a-7966bbbbc3b4" ], "spl_set_id": [ "e0655aac-9508-4141-94f5-fcca6af1c41d" ], "package_ndc": [ "65219-080-01", "65219-080-05", "65219-082-01", "65219-082-10", "65219-084-01", "65219-084-15", "65219-086-01", "65219-086-20" ], "unii": [ "L0ND3981AG" ] }, "update_date": "05/21/2026", "therapeutic_category": [ "Medical Imaging" ], "dosage_form": "Injection", "presentation": "Gadoterate Meglumine, Injection, 376.9 mg/1 mL (NDC 65219-086-20)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "To Be Discontinued" }, { "discontinued_date": "12/01/2025", "update_type": "New", "initial_posting_date": "12/01/2025", "package_ndc": "66993-212-38", "generic_name": "Nilutamide Tablet", "contact_info": "847-283-7921", "related_info": "Product to expire in March 2026; Discontinuation of the manufacture of the drug", "update_date": "12/01/2025", "therapeutic_category": [ "Oncology" ], "dosage_form": "Tablet", "presentation": "Nilandron, Tablet, 150 mg (NDC 66993-212-38)", "company_name": "Advanz Pharma (US) Corp.", "status": "To Be Discontinued" }, { "discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "60951-602-70", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA040330" ], "brand_name": [ "ENDOCET" ], "generic_name": [ "OXYCODONE AND ACETAMINOPHEN" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "60951-602", "60951-700", "60951-712", "60951-701" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OXYCODONE HYDROCHLORIDE", "ACETAMINOPHEN" ], "rxcui": [ "1049214", "1049216", "1049221", "1049223", "1049225", "1049227", "1049635", "1487288" ], "spl_id": [ "a8475489-982f-4080-9565-7948155d9abb" ], "spl_set_id": [ "944d3e60-7eee-11de-a413-0002a5d5c51b" ], "package_ndc": [ "60951-602-70", "60951-602-85", "60951-700-70", "60951-712-70", "60951-701-70" ], "unii": [ "C1ENJ2TE6C", "362O9ITL9D" ] }, "update_date": "11/03/2025", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-70)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "67457-925-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA212571" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Mylan Institutional LLC" ], "product_ndc": [ "67457-925", "67457-924" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909" ], "spl_id": [ "e4cda7fa-dac8-4de7-abc1-d1fd622795d8" ], "spl_set_id": [ "f140de5a-f13d-46b4-a742-049c63e474f5" ], "package_ndc": [ "67457-924-00", "67457-924-50", "67457-925-00", "67457-925-10" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 67457-925-10)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "70121-1389-1", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "866-525-7270", "availability": "Available", "openfda": { "application_number": [ "ANDA207551" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Amneal Pharmaceuticals LLC" ], "product_ndc": [ "70121-1389", "70121-1388" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909" ], "spl_id": [ "af193b53-1488-401f-8f06-cc193297c4a8" ], "spl_set_id": [ "eb1ba463-ab42-4f49-9ebe-3ad5af108326" ], "package_ndc": [ "70121-1388-1", "70121-1388-8", "70121-1389-1", "70121-1389-7" ], "unii": [ "1018WH7F9I" ] }, "update_date": "06/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 mcg/mL, 100 mL (NDC 70121-1389-1)", "company_name": "Amneal Pharmaceuticals", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "67457-228-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA079199" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Mylan Institutional LLC" ], "product_ndc": [ "67457-228" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "b65fbcab-781e-4706-a60b-a8eb4aeae0c1" ], "spl_set_id": [ "f58803b0-f173-4997-b2f8-0f415b94dacf" ], "package_ndc": [ "67457-228-00", "67457-228-05", "67457-228-99", "67457-228-10" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 67457-228-05)", "company_name": "Mylan Institutional, a Viatris Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "70010-115-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "877-770-3183", "availability": "Unavailable", "related_info": "Estimated recovery: October 2026", "openfda": { "application_number": [ "ANDA215771" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Granules Pharmaceuticals Inc." ], "product_ndc": [ "70010-115", "70010-111", "70010-112", "70010-113", "70010-114", "70010-116", "70010-117" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "56c7c921-e560-c5ad-e063-6294a90a4c81" ], "spl_set_id": [ "b0b4eccc-34c7-483d-966f-82d588358e1b" ], "package_ndc": [ "70010-111-01", "70010-111-03", "70010-112-01", "70010-112-03", "70010-113-01", "70010-113-03", "70010-114-01", "70010-114-03", "70010-115-01", "70010-115-03", "70010-116-01", "70010-116-03", "70010-117-01", "70010-117-03" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 3.75 mg; 3.75 mg; 3.75 mg; 3.75 mg (NDC 70010-115-01)", "company_name": "Granules Pharmaceuticals Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/13/2023", "package_ndc": "61703-124-40", "generic_name": "Methotrexate Sodium Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA011719" ], "brand_name": [ "METHOTREXATE" ], "generic_name": [ "METHOTREXATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "61703-124", "61703-161" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "METHOTREXATE SODIUM" ], "rxcui": [ "1655956", "1946772" ], "spl_id": [ "6bb8643f-6ab4-4e1c-bcf9-b82e8cf18910" ], "spl_set_id": [ "bd287e89-32f9-4396-95fa-4b562869f476" ], "package_ndc": [ "61703-124-40", "61703-161-02", "61703-161-05" ], "unii": [ "3IG1E710ZN" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology", "Oncology" ], "dosage_form": "Injection", "presentation": "Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "83634-651-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "Avenacy, LLC: 877-283-6229", "availability": "Available", "related_info": "Distributed by Avenacy, LLC", "openfda": { "application_number": [ "ANDA219535" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Avenacy, LLC" ], "product_ndc": [ "83634-651", "83634-653" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1737562", "1737566", "1737568" ], "spl_id": [ "8fb1dd7b-f349-4a64-96c1-bd72bf748f3b" ], "spl_set_id": [ "46480253-29b9-4d7f-98ed-10377929026b" ], "package_ndc": [ "83634-653-41", "83634-653-02", "83634-653-42", "83634-653-05", "83634-653-43", "83634-653-30", "83634-651-41", "83634-651-10", "83634-651-42", "83634-651-20", "83634-651-43", "83634-651-50" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 100 mg/10 mL (NDC 83634-651-10)", "company_name": "Anthea Pharma", "status": "Current" }, { "discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "0009-0331-02", "generic_name": "Clindamycin Hydrochloride Capsule", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA050162" ], "brand_name": [ "CLEOCIN HYDROCHLORIDE" ], "generic_name": [ "CLINDAMYCIN HYDROCHLORIDE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0331", "0009-0225", "0009-0395" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLINDAMYCIN HYDROCHLORIDE" ], "rxcui": [ "197518", "284215", "309329", "748746", "748748", "748750" ], "spl_id": [ "51cea3cd-28cf-455e-ba27-5a0d8e052858" ], "spl_set_id": [ "df9a2a41-b132-4f43-8940-b2d773b1369a" ], "package_ndc": [ "0009-0331-02", "0009-0225-02", "0009-0395-14" ], "unii": [ "T20OQ1YN1W" ] }, "update_date": "02/25/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Capsule", "presentation": "Cleocin Hydrochloride, Capsule, 75 mg (NDC 0009-0331-02)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "03/12/2021", "package_ndc": "60505-0815-0", "generic_name": "Desmopressin Acetate Spray", "contact_info": "800-706-5575", "availability": "Limited Availability", "related_info": "Estimated recovery: 8/31/26", "openfda": { "application_number": [ "ANDA076703" ], "brand_name": [ "DESMOPRESSIN ACETATE" ], "generic_name": [ "DESMOPRESSIN ACETATE" ], "manufacturer_name": [ "Apotex Corp." ], "product_ndc": [ "60505-0815" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "NASAL" ], "substance_name": [ "DESMOPRESSIN ACETATE" ], "rxcui": [ "849506" ], "spl_id": [ "f90935bd-bb23-2f9c-3271-8508e92d45c4" ], "spl_set_id": [ "1ac423b8-27a6-4cef-4a82-c50bf81b4f49" ], "package_ndc": [ "60505-0815-0" ], "unii": [ "XB13HYU18U" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Hematology" ], "dosage_form": "Spray", "presentation": "Desmopressin Acetate (needs No Refrigeration), Spray, 10 ug (NDC 60505-0815-0)", "company_name": "Apotex Corp.", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "11/21/2023", "package_ndc": "39822-5550-6", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "866-390-4411", "availability": "Unvailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA040737" ], "brand_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "generic_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "manufacturer_name": [ "XGen Pharmaceuticals DJB, Inc." ], "product_ndc": [ "39822-5550" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "rxcui": [ "992858" ], "spl_id": [ "0e860109-725f-1c28-e063-6394a90a50ef" ], "spl_set_id": [ "b6f6698f-f23c-452a-9b38-bbb96ab88ae4" ], "package_ndc": [ "39822-5550-5", "39822-5550-6" ], "unii": [ "R61ZEH7I1I" ] }, "update_date": "06/23/2026", "therapeutic_category": [ "Analgesia/Addiction", "Gastroenterology", "Other", "Pulmonary/Allergy" ], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 50 mg/1 mL (NDC 39822-5550-6)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/31/2017", "package_ndc": "76045-009-06", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release August 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "NDA019034" ], "brand_name": [ "DILAUDID" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "76045-009", "76045-010", "76045-121" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897756", "897757", "1433251", "1872265", "1872269", "1872752", "2277368", "2277370" ], "spl_id": [ "97bfcafb-2037-47dc-a0ae-f7b8007c47df" ], "spl_set_id": [ "9eebd88a-5632-460f-b7b6-26c8a180540d" ], "package_ndc": [ "76045-009-96", "76045-009-06", "76045-009-01", "76045-009-11", "76045-010-01", "76045-010-11", "76045-121-01", "76045-121-11" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Dilaudid, Injection, 1 mg/1 mL (NDC 76045-009-06)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "68025-096-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Available", "openfda": { "application_number": [ "NDA216117" ], "brand_name": [ "RELEXXII" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Vertical Pharmaceuticals, LLC" ], "product_ndc": [ "68025-096", "68025-088", "68025-089", "68025-095", "68025-097", "68025-084", "68025-098" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210", "1995461", "2052826", "2605796", "2605798", "2605943", "2605946", "2668496", "2668499", "2668502", "2668505" ], "spl_id": [ "86f477e9-07fc-466b-913e-1a4434c91df4" ], "spl_set_id": [ "22d5fa47-b5b9-4fd9-980c-4eb88e95ae5d" ], "package_ndc": [ "68025-088-30", "68025-089-30", "68025-095-10", "68025-095-30", "68025-096-10", "68025-096-30", "68025-097-10", "68025-097-30", "68025-084-30", "68025-098-10", "68025-098-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10)", "company_name": "Vertical Pharmaceuticals, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-486-27", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-486", "63323-492", "63323-491", "63323-495", "63323-485", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428", "0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17", "4dd52202-8eef-4136-92dd-ada573b7cf74" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31", "63323-492-41", "63323-492-16", "63323-492-43", "63323-492-36", "63323-492-45", "63323-492-26", "63323-485-41", "63323-485-26", "63323-486-41", "63323-486-26", "63323-482-41", "63323-482-26", "63323-495-41", "63323-495-26" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/21/2023", "package_ndc": "0009-0775-26", "generic_name": "Clindamycin Phosphate Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Clindamycin%20Phosphate%20Injection&st=d", "contact_info": "800-533-4535", "availability": "Available", "openfda": { "application_number": [ "NDA050441" ], "brand_name": [ "CLEOCIN PHOSPHATE" ], "generic_name": [ "CLINDAMYCIN PHOSPHATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0775", "0009-0870", "0009-0902", "0009-0728", "0009-3124", "0009-3447", "0009-3381", "0009-3375", "0009-3382", "0009-6582" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CLINDAMYCIN PHOSPHATE" ], "rxcui": [ "205964", "309335", "309336", "309339", "685574", "685576", "685578", "706461", "1737244", "1737245", "1737578", "1737579", "1737581", "1737582" ], "spl_id": [ "fa11e62e-4625-4e9c-8676-f318b1cb890f" ], "spl_set_id": [ "05a75685-0af5-407c-ac57-e380c882b49d" ], "package_ndc": [ "0009-0870-21", "0009-0870-26", "0009-0775-20", "0009-0775-26", "0009-0902-11", "0009-0902-18", "0009-0728-05", "0009-0728-09", "0009-3124-01", "0009-3124-03", "0009-3447-01", "0009-3447-03", "0009-3381-01", "0009-3381-02", "0009-3375-01", "0009-3375-02", "0009-3382-01", "0009-3382-02", "0009-6582-02", "0009-6582-01" ], "unii": [ "EH6D7113I8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26)", "company_name": "Pfizer Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0527-0766-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-834-0530", "availability": "Available", "openfda": { "application_number": [ "ANDA215565" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Lannett Company, LLC" ], "product_ndc": [ "0527-0766", "0527-0760", "0527-0761", "0527-0762", "0527-0763", "0527-0764", "0527-0765" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "391d7c4a-47df-41ce-b1ba-3c4758adf87f" ], "spl_set_id": [ "f92497b5-baea-4760-b615-45a0b6184402" ], "package_ndc": [ "0527-0760-37", "0527-0761-37", "0527-0762-37", "0527-0763-37", "0527-0764-37", "0527-0765-37", "0527-0766-37" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 7.5 mg; 7.5 mg; 7.5 mg; 7.5 mg (NDC 0527-0766-37)", "company_name": "Lannett Company, Inc.", "status": "Current" }, { "discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-0535-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 40 mg (NDC 0071-0535-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "04/16/2026", "package_ndc": "72336-032-01", "generic_name": "Isocarboxazid Tablet", "contact_info": "833.627.0070", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA011961" ], "brand_name": [ "MARPLAN" ], "generic_name": [ "ISOCARBOXAZID" ], "manufacturer_name": [ "Lifsa Drugs LLC" ], "product_ndc": [ "72336-032" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ISOCARBOXAZID" ], "rxcui": [ "104837", "201708" ], "spl_id": [ "97745d9b-c2a6-45e3-9e1e-7fabec4681fb" ], "spl_set_id": [ "95fde749-44ad-4668-86c4-0ff17bca0074" ], "package_ndc": [ "72336-032-01" ], "nui": [ "N0000175744", "N0000000184" ], "pharm_class_epc": [ "Monoamine Oxidase Inhibitor [EPC]" ], "pharm_class_moa": [ "Monoamine Oxidase Inhibitors [MoA]" ], "unii": [ "34237V843T" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Marplan, Tablet, 10 mg, 100 count bottle (NDC 72336-032-01)", "company_name": "Lifsa Drugs LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "25021-661-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "Avet Pharmaceuticals, Inc.: 855-228-9470; Sagent Pharmaceuticals: 866-625-1618", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; Distributed by Sagent Pharmaceuticals", "openfda": { "application_number": [ "ANDA090850" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-661" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "311702" ], "spl_id": [ "002ea282-09ba-4d79-8bd1-94c9859f442b" ], "spl_set_id": [ "880cac48-5c0f-49a9-8aef-3c9770bf5d84" ], "package_ndc": [ "25021-661-10" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 25021-661-10)", "company_name": "Gland Pharma Limited", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "06/13/2018", "package_ndc": "55150-256-50", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA207182" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-256", "55150-251", "55150-252", "55150-253", "55150-254", "55150-255" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671" ], "spl_id": [ "0b1f03c2-db2f-4f90-acc0-d73abd731bf6" ], "spl_set_id": [ "ef782e5e-e2d7-465a-99c6-b12611f3158c" ], "package_ndc": [ "55150-251-10", "55150-252-20", "55150-253-50", "55150-254-10", "55150-255-20", "55150-256-50" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-256-50)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0472-0803-04", "generic_name": "Desonide Lotion", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": { "application_number": [ "ANDA072354" ], "brand_name": [ "DESONIDE" ], "generic_name": [ "DESONIDE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0472-0803", "0472-0804" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "TOPICAL" ], "substance_name": [ "DESONIDE" ], "rxcui": [ "197572", "349351" ], "spl_id": [ "f3953b9e-138f-4d86-8eea-0fc03c3c2747" ], "spl_set_id": [ "ff5d4cd8-ab4d-4a9e-b84b-445c81eeea99" ], "package_ndc": [ "0472-0804-15", "0472-0804-60", "0472-0803-02", "0472-0803-04" ], "nui": [ "N0000175576", "N0000175450" ], "pharm_class_epc": [ "Corticosteroid [EPC]" ], "pharm_class_moa": [ "Corticosteroid Hormone Receptor Agonists [MoA]" ], "unii": [ "J280872D1O" ] }, "update_date": "09/18/2025", "therapeutic_category": [ "Dermatology" ], "dosage_form": "Lotion", "presentation": "Desowen, Lotion, .5 mg/1 mL (NDC 0472-0803-04)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "42023-186-20", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "800-828-9393", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; Please check wholesalers for inventory", "openfda": { "application_number": [ "ANDA208266" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "42023-186", "42023-146", "42023-187" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "309710", "1718906", "1718909" ], "spl_id": [ "54174211-6684-4fb9-a605-be12b94e2948" ], "spl_set_id": [ "1ee59985-4c1d-48f7-b8f9-5584c2d55e08" ], "package_ndc": [ "42023-146-25", "42023-186-20", "42023-187-10" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 42023-186-20)", "company_name": "Par Health, USA LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-668-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA076374" ], "brand_name": [ "QUINAPRIL AND HYDROCHLOROTHIAZIDE" ], "generic_name": [ "QUINAPRIL AND HYDROCHLOROTHIAZIDE" ], "manufacturer_name": [ "Chartwell RX, LLC" ], "product_ndc": [ "62135-668", "62135-667", "62135-669" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE", "HYDROCHLOROTHIAZIDE" ], "rxcui": [ "310796", "310797", "310809" ], "spl_id": [ "0c3f4504-d57e-aa79-e063-6294a90ad5b8" ], "spl_set_id": [ "2eae533f-d0af-47e8-a1f2-94bc8cc89b5a" ], "package_ndc": [ "62135-667-90", "62135-668-90", "62135-669-90" ], "nui": [ "N0000175359", "N0000175419", "M0471776" ], "pharm_class_pe": [ "Increased Diuresis [PE]" ], "pharm_class_epc": [ "Thiazide Diuretic [EPC]" ], "pharm_class_cs": [ "Thiazides [CS]" ], "unii": [ "0J48LPH2TH", "33067B3N2M" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril/Hydrochlorothiazide, Tablet, 12.5 mg; 20 mg (NDC 62135-668-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-492-27", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release August 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE MPF" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487", "63323-493", "63323-496" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029", "1737636", "1737637", "1737640", "1737641", "1737763", "1737764" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428", "0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33", "fa12a8e8-09fd-496f-8cc6-ffe0eb02e2df" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17", "4dd52202-8eef-4136-92dd-ada573b7cf74", "d5e0d06f-ba1e-44d4-aa89-39d6c146dc23" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31", "63323-492-41", "63323-492-16", "63323-492-43", "63323-492-36", "63323-492-45", "63323-492-26", "63323-485-41", "63323-485-26", "63323-486-41", "63323-486-26", "63323-482-41", "63323-482-26", "63323-495-41", "63323-495-26", "63323-492-08", "63323-492-97", "63323-493-03", "63323-493-97", "63323-493-01", "63323-493-91", "63323-496-03", "63323-496-97" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 10 mg/1 mL (NDC 63323-492-27)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "62135-669-90", "generic_name": "Quinapril/Hydrochlorothiazide Tablet", "contact_info": "845-268-5000 x 510 or Chartwell Customer service at cs@chartwellpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA076374" ], "brand_name": [ "QUINAPRIL AND HYDROCHLOROTHIAZIDE" ], "generic_name": [ "QUINAPRIL AND HYDROCHLOROTHIAZIDE" ], "manufacturer_name": [ "Chartwell RX, LLC" ], "product_ndc": [ "62135-669", "62135-667", "62135-668" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE", "HYDROCHLOROTHIAZIDE" ], "rxcui": [ "310796", "310797", "310809" ], "spl_id": [ "0c3f4504-d57e-aa79-e063-6294a90ad5b8" ], "spl_set_id": [ "2eae533f-d0af-47e8-a1f2-94bc8cc89b5a" ], "package_ndc": [ "62135-667-90", "62135-668-90", "62135-669-90" ], "nui": [ "N0000175359", "N0000175419", "M0471776" ], "pharm_class_pe": [ "Increased Diuresis [PE]" ], "pharm_class_epc": [ "Thiazide Diuretic [EPC]" ], "pharm_class_cs": [ "Thiazides [CS]" ], "unii": [ "0J48LPH2TH", "33067B3N2M" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril/Hydrochlorothiazide, Tablet, 25 mg; 20 mg (NDC 62135-669-90)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/28/2025", "package_ndc": "0574-2420-65", "generic_name": "Methylphenidate Film, Extended Release", "contact_info": "800-455-8070", "availability": "Available", "related_info": "Available. Distributed by Padagis US LLC", "openfda": { "application_number": [ "NDA021514" ], "brand_name": [ "METHYLPHENIDATE TRANSDERMAL SYSTEM" ], "generic_name": [ "METHYLPHENIDATE" ], "manufacturer_name": [ "PADAGIS US LLC" ], "product_ndc": [ "0574-2420", "0574-2410", "0574-2415", "0574-2430" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "TRANSDERMAL" ], "substance_name": [ "METHYLPHENIDATE" ], "rxcui": [ "753436", "753438", "753440", "753441" ], "spl_id": [ "b743ef45-2fc0-4086-8a02-6078e6a09eaa" ], "spl_set_id": [ "7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb" ], "package_ndc": [ "0574-2410-65", "0574-2415-65", "0574-2420-65", "0574-2430-65" ], "nui": [ "N0000175739", "N0000175729" ], "pharm_class_epc": [ "Central Nervous System Stimulant [EPC]" ], "pharm_class_pe": [ "Central Nervous System Stimulation [PE]" ], "unii": [ "207ZZ9QZ49" ] }, "update_date": "08/15/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Film, Extended Release", "presentation": "Methylphenidate, Film, Extended Release, 20 mg (NDC 0574-2420-65)", "company_name": "Noven Pharmaceuticals, Inc.", "status": "Current" }, { "discontinued_date": "07/30/2026", "update_type": "New", "initial_posting_date": "07/30/2026", "package_ndc": "0591-4550-22", "generic_name": "Doxycycline Hyclate Tablet, Delayed Release", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA090134" ], "brand_name": [ "DOXYCYCLINE HYCLATE" ], "generic_name": [ "DOXYCYCLINE HYCLATE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0591-4550", "0591-4575" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DOXYCYCLINE HYCLATE" ], "rxcui": [ "1423080", "1653433" ], "spl_id": [ "304ae0bb-5f05-4389-8952-5a99391b8047" ], "spl_set_id": [ "c2b08332-3256-4658-965a-ede3d973a388" ], "package_ndc": [ "0591-4550-22", "0591-4575-60" ], "unii": [ "19XTS3T51U" ] }, "update_date": "07/30/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Tablet", "presentation": "Doxycycline Hyclate, Tablet, Delayed Release, 50 mg (NDC 0591-4550-22)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "59676-570-01", "generic_name": "Etravirine Tablet", "contact_info": "800-526-7736", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA022187" ], "brand_name": [ "INTELENCE" ], "generic_name": [ "ETRAVIRINE" ], "manufacturer_name": [ "Janssen Products LP" ], "product_ndc": [ "59676-570", "59676-571", "59676-572" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ETRAVIRINE" ], "rxcui": [ "754761", "758555", "1052658", "1052660", "1250721", "1250723" ], "spl_id": [ "02fc6f4f-330d-b32e-e063-6294a90a028a" ], "spl_set_id": [ "6a9cbc29-9f15-4b24-8d86-206b82887f3d" ], "package_ndc": [ "59676-570-01", "59676-571-01", "59676-572-01" ], "nui": [ "N0000175463", "N0000175460", "N0000009948", "N0000190118", "N0000185504", "N0000182140", "N0000185503" ], "pharm_class_epc": [ "Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]" ], "pharm_class_moa": [ "Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]", "Cytochrome P450 3A Inducers [MoA]", "Cytochrome P450 2C9 Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]" ], "unii": [ "0C50HW4FO1" ] }, "update_date": "04/28/2026", "therapeutic_category": [ "Antiviral" ], "dosage_form": "Tablet", "presentation": "Intelence, Tablet, 100 mg (NDC 59676-570-01)", "company_name": "Janssen Research and Development", "status": "To Be Discontinued" }, { "discontinued_date": "07/23/2026", "update_type": "New", "initial_posting_date": "07/23/2026", "package_ndc": "0574-7045-04", "generic_name": "Belladonna and Opium Suppository", "contact_info": "(800) 775-2054", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "BELLADONNA AND OPIUM" ], "generic_name": [ "ATROPA BELLADONNA AND OPIUM" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-7045", "0574-7040" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RECTAL" ], "substance_name": [ "ATROPA BELLADONNA", "OPIUM" ], "rxcui": [ "312104", "312107" ], "spl_id": [ "7b45a1d7-c3a5-4434-a848-45638cedd6e1" ], "spl_set_id": [ "8301e76b-134a-43d2-a7dc-c600ccf2695c" ], "package_ndc": [ "0574-7040-12", "0574-7040-04", "0574-7045-12", "0574-7045-04" ], "unii": [ "37M3MZ001L", "WQZ3G9PF0H" ] }, "update_date": "07/23/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Suppository", "presentation": "Belladonna and Opium, Suppository, 16.2 mg; 30 mg (NDC 0574-7045-04)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-552-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA218604" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Elite Laboratories, Inc." ], "product_ndc": [ "64850-552", "64850-550", "64850-551", "64850-553", "64850-554", "64850-555", "64850-556" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "2d33f701-8067-4a48-98cc-4e7dacaf3cc4" ], "spl_set_id": [ "0e024b69-567c-4b40-9c3e-a2daec34256c" ], "package_ndc": [ "64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 30 mg (NDC 64850-552-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/24/2025", "package_ndc": "82154-0449-1", "generic_name": "Peginterferon alfa-2a Injection", "contact_info": "800-506-8501, email: medinfo.us@pharmaand.com", "availability": "Unavailable", "related_info": "Product replenishment timeline to be confirmed sometime in Q1 2027 or earlier.", "openfda": { "application_number": [ "BLA103964" ], "brand_name": [ "PEGASYS" ], "generic_name": [ "PEGINTERFERON ALFA-2A" ], "manufacturer_name": [ "pharmaand GmbH" ], "product_ndc": [ "82154-0449", "82154-0451" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "PEGINTERFERON ALFA-2A" ], "rxcui": [ "351270", "352297", "731326", "731328" ], "spl_id": [ "560699fb-9630-ebaa-e063-6394a90ad0ab" ], "spl_set_id": [ "d9290e5b-6d40-2318-e053-2995a90a9916" ], "package_ndc": [ "82154-0449-1", "82154-0451-4" ], "nui": [ "N0000175521", "M0025711" ], "pharm_class_epc": [ "Interferon alpha [EPC]" ], "pharm_class_cs": [ "Interferon-alpha [CS]" ], "unii": [ "Q46947FE7K" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Antiviral" ], "dosage_form": "Injection", "presentation": "Pegasys, Injection, 180 ug/1 mL (NDC 82154-0449-1)", "company_name": "pharmaand GmbH (pharma&)", "shortage_reason": "Regulatory delay", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0374-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": { "application_number": [ "ANDA202827" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0054-0374", "0054-0660", "0054-0370", "0054-0371", "0054-0372", "0054-0373", "0054-0375" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "ccd9e87c-bd03-4fe0-8129-41c1ced49c8d" ], "spl_set_id": [ "6740a621-9bec-4178-a4fc-a3fc89f34e0a" ], "package_ndc": [ "0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 0054-0374-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2022", "package_ndc": "0338-0023-04", "generic_name": "Dextrose Monohydrate 10% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA016694" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0023", "0338-0017" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795609", "1795610", "1795612", "1795616", "1795618" ], "spl_id": [ "9c644eb4-5844-415a-8c01-4459d98af222" ], "spl_set_id": [ "3bb406a9-f5cb-403a-b1bb-5c4facbea3d5" ], "package_ndc": [ "0338-0017-10", "0338-0017-41", "0338-0017-11", "0338-0017-31", "0338-0017-48", "0338-0017-18", "0338-0017-38", "0338-0017-02", "0338-0017-03", "0338-0017-04", "0338-0023-02", "0338-0023-03", "0338-0023-04" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 10% In Plastic Container, Injection, 100 g/1000 mL (NDC 0338-0023-04)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "01/13/2022", "package_ndc": "0409-6648-02", "generic_name": "Dextrose Monohydrate 50% Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Next Delivery: October 2026; Estimated Recovery: December 2026. Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA019445" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-6648", "0409-7517" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "727517", "1795514" ], "spl_id": [ "34b869af-c42d-457c-8b21-6215a4e07aff" ], "spl_set_id": [ "4ed365da-4e62-4329-c1b9-c197ab4fb6e1" ], "package_ndc": [ "0409-7517-66", "0409-7517-16", "0409-6648-16", "0409-6648-02" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/01/2017", "package_ndc": "0409-6625-35", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA202432" ], "brand_name": [ "SODIUM BICARBONATE" ], "generic_name": [ "SODIUM BICARBONATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-6625" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM BICARBONATE" ], "rxcui": [ "1868486" ], "spl_id": [ "dcc55d90-d55e-4e1a-9e48-5703cbc74a52", "c39c0ef6-4140-4c6c-91c4-e43d67872b05" ], "spl_set_id": [ "8664c7ce-707b-4c6c-9ce4-7160b5f877f8", "084f5572-8c1f-4802-b179-ca0cc838fc68" ], "package_ndc": [ "0409-6625-30", "0409-6625-35", "0409-6625-22", "0409-6625-14" ], "unii": [ "8MDF5V39QO" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-35)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0378-6855-77", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-796-9526", "availability": "Available", "openfda": { "application_number": [ "ANDA202835" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE" ], "manufacturer_name": [ "Mylan Pharmaceuticals Inc." ], "product_ndc": [ "0378-6855", "0378-6854", "0378-6856", "0378-6857", "0378-6858", "0378-6859", "0378-6860" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "6e77cd71-95ae-4fa8-830b-ab62b714e4b9" ], "spl_set_id": [ "efbde0f6-b848-4664-b741-c6c630e66108" ], "package_ndc": [ "0378-6854-77", "0378-6855-77", "0378-6856-77", "0378-6857-77", "0378-6858-77", "0378-6859-77", "0378-6860-77" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 0378-6855-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "39822-5525-3", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "866-390-4411", "availability": "Available", "openfda": { "application_number": [ "ANDA040737" ], "brand_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "generic_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "manufacturer_name": [ "XGen Pharmaceuticals DJB, Inc." ], "product_ndc": [ "39822-5525" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "rxcui": [ "992460" ], "spl_id": [ "0e3526e1-38be-1d89-e063-6294a90a775d" ], "spl_set_id": [ "1d02d52b-84bb-4e81-b352-125029eb39f6" ], "package_ndc": [ "39822-5525-2", "39822-5525-3" ], "unii": [ "R61ZEH7I1I" ] }, "update_date": "06/23/2026", "therapeutic_category": [ "Analgesia/Addiction", "Gastroenterology", "Other", "Pulmonary/Allergy" ], "dosage_form": "Injection", "presentation": "Promethazine Hydrochloride, Injection, 25 mg/1 mL (NDC 39822-5525-3)", "company_name": "XGen Pharmaceuticals DJB, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "13107-069-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 or CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability: October 2026", "openfda": { "application_number": [ "ANDA202424" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Aurolife Pharma, LLC" ], "product_ndc": [ "13107-069", "13107-068", "13107-070", "13107-071", "13107-072", "13107-073", "13107-074" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "5962d880-9f18-4a57-8c95-ca0ec1e86f44" ], "spl_set_id": [ "a582d57f-d191-4ca5-b105-585b2d8a0e3e" ], "package_ndc": [ "13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "07/21/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 13107-069-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/11/2024", "package_ndc": "0990-7918-19", "generic_name": "Dextrose Monohydrate 70% Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Available", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA018561" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE" ], "manufacturer_name": [ "ICU Medical Inc." ], "product_ndc": [ "0990-7918", "0990-7935", "0990-7936", "0990-7937", "0990-8004" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "237649", "237650", "237656", "242694", "1795518" ], "spl_id": [ "98e136db-75df-429c-8d33-03bfae8f511e" ], "spl_set_id": [ "b5cb7a5a-bbe8-4217-a82e-da818f7771c9" ], "package_ndc": [ "0990-7918-19", "0990-7935-19", "0990-7936-19", "0990-7937-19", "0990-8004-15" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "DEXTROSE 70% IN PLASTIC CONTAINER, Injection, 70 g/100 mL (NDC 0990-7918-19)", "company_name": "Otsuka ICU Medical LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "47781-178-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-842-8672 and email: CustomerService-US@alvogen.com", "availability": "Available", "openfda": { "application_number": [ "ANDA207388" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS,CII" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AMPHETAMINE SULFATE TABLETS, 15 MG,CLL" ], "manufacturer_name": [ "Alvogen Inc." ], "product_ndc": [ "47781-178", "47781-174", "47781-175", "47781-176", "47781-177", "47781-179", "47781-180" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "AMPHETAMINE ASPARTATE MONOHYDRATE", "AMPHETAMINE SULFATE", "DEXTROAMPHETAMINE SACCHARATE", "DEXTROAMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "0374f0f7-9297-810c-38b3-623a72709a7d" ], "spl_set_id": [ "c907301d-e24d-9609-5529-fed14f94549f" ], "package_ndc": [ "47781-174-30", "47781-174-05", "47781-174-01", "47781-175-30", "47781-175-05", "47781-175-01", "47781-176-30", "47781-176-05", "47781-176-01", "47781-177-30", "47781-177-05", "47781-177-01", "47781-178-30", "47781-178-05", "47781-178-01", "47781-179-30", "47781-179-05", "47781-179-01", "47781-180-30", "47781-180-05", "47781-180-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 15mg (NDC 47781-178-01)", "company_name": "Alvogen", "status": "Current" }, { "discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0069-1975-40", "generic_name": "Tafamidis Meglumine Capsule", "contact_info": "800-879-3477", "related_info": "Discontinuation of the manufacture of the drug upon exhausted supply/stop sale in December 2025.", "openfda": { "application_number": [ "NDA211996" ], "brand_name": [ "VYNDAQEL" ], "generic_name": [ "TAFAMIDIS MEGLUMINE" ], "manufacturer_name": [ "Pfizer Laboratories Div Pfizer Inc" ], "product_ndc": [ "0069-1975", "0069-8730" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "TAFAMIDIS MEGLUMINE" ], "rxcui": [ "2168534", "2168540", "2168542", "2168548" ], "spl_id": [ "67f1031d-c298-4cf9-9051-bb8f99e56442" ], "spl_set_id": [ "1b4121ee-a733-4456-a917-be2603477839" ], "package_ndc": [ "0069-1975-12", "0069-1975-40", "0069-8730-01", "0069-8730-30" ], "unii": [ "ZU7CF08A1A", "8FG9H9D31J" ] }, "update_date": "09/29/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Capsule", "presentation": "Vyndaqel, Capsule, 20 mg soft gelatin capsules; blister card (120 total capsules) (NDC 0069-1975-40)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0373-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": { "application_number": [ "ANDA202827" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0054-0373", "0054-0660", "0054-0370", "0054-0371", "0054-0372", "0054-0374", "0054-0375" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "ccd9e87c-bd03-4fe0-8129-41c1ced49c8d" ], "spl_set_id": [ "6740a621-9bec-4178-a4fc-a3fc89f34e0a" ], "package_ndc": [ "0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 0054-0373-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "discontinued_date": "10/01/2025", "update_type": "New", "initial_posting_date": "10/01/2025", "package_ndc": "0071-0532-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/01/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 20 mg (NDC 0071-0532-23)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-553-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA218604" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Elite Laboratories, Inc." ], "product_ndc": [ "64850-553", "64850-550", "64850-551", "64850-552", "64850-554", "64850-555", "64850-556" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "2d33f701-8067-4a48-98cc-4e7dacaf3cc4" ], "spl_set_id": [ "0e024b69-567c-4b40-9c3e-a2daec34256c" ], "package_ndc": [ "64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 40 mg (NDC 64850-553-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "70436-203-80", "generic_name": "Dobutamine Hydrochloride Injection", "contact_info": "Slate Run Pharmaceuticals, LLC: 844-529-8988", "availability": "Available", "related_info": "Distributed by Slate Run Pharmaceuticals, LLC, 1-844-529-8988", "openfda": { "application_number": [ "ANDA216131" ], "brand_name": [ "DOBUTAMINE" ], "generic_name": [ "DOBUTAMINE" ], "manufacturer_name": [ "Slate Run Pharmaceuticals" ], "product_ndc": [ "70436-203" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DOBUTAMINE HYDROCHLORIDE" ], "rxcui": [ "1812168" ], "spl_id": [ "49562559-8e19-fb8a-e063-6394a90a0966" ], "spl_set_id": [ "ee09a55f-9992-48bb-b8d6-1184bd548536" ], "package_ndc": [ "70436-203-80", "70436-203-82" ], "unii": [ "0WR771DJXV" ] }, "update_date": "05/08/2026", "therapeutic_category": [ "Cardiovascular", "Pediatric", "Renal" ], "dosage_form": "Injection", "presentation": "Dobutamine Hydrochloride, Injection, 250 mg/20 mL (NDC 70436-203-80)", "company_name": "Hainan Poly Pharm. Co., Ltd.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "72266-147-10", "generic_name": "Etomidate Injection", "contact_info": "833-291-9645", "availability": "Available", "related_info": "Distributed by Fosun Pharma USA, Inc.. To order, contact: 833-291-9645.", "openfda": { "application_number": [ "ANDA209058" ], "brand_name": [ "ETOMIDATE" ], "generic_name": [ "ETOMIDATE INJECTION" ], "manufacturer_name": [ "Fosun Pharma USA Inc" ], "product_ndc": [ "72266-147", "72266-146" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008" ], "spl_id": [ "2b365133-b609-3285-e063-6394a90a69a6" ], "spl_set_id": [ "8b6c54d8-3f3f-4290-841c-976bea01086f" ], "package_ndc": [ "72266-146-01", "72266-146-10", "72266-147-01", "72266-147-10" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 72266-147-10)", "company_name": "Gland Pharma Limited", "status": "Current" }, { "discontinued_date": "10/16/2025", "update_type": "New", "initial_posting_date": "10/16/2025", "package_ndc": "80789-117-50", "generic_name": "Vigabatrin Oral Solution", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "10/16/2025", "therapeutic_category": [ "Neurology" ], "dosage_form": "Oral Solution", "presentation": "Vigpoder, Oral Solution, 50 mg/1 mL (NDC 80789-117-50)", "company_name": "Pyros Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "13107-068-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 or CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability: October 2026", "openfda": { "application_number": [ "ANDA202424" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Aurolife Pharma, LLC" ], "product_ndc": [ "13107-068", "13107-069", "13107-070", "13107-071", "13107-072", "13107-073", "13107-074" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "5962d880-9f18-4a57-8c95-ca0ec1e86f44" ], "spl_set_id": [ "a582d57f-d191-4ca5-b105-585b2d8a0e3e" ], "package_ndc": [ "13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "07/21/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 13107-068-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/01/2017", "package_ndc": "0409-6625-14", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA202432" ], "brand_name": [ "SODIUM BICARBONATE" ], "generic_name": [ "SODIUM BICARBONATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-6625" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM BICARBONATE" ], "rxcui": [ "1868486" ], "spl_id": [ "dcc55d90-d55e-4e1a-9e48-5703cbc74a52", "c39c0ef6-4140-4c6c-91c4-e43d67872b05" ], "spl_set_id": [ "8664c7ce-707b-4c6c-9ce4-7160b5f877f8", "084f5572-8c1f-4802-b179-ca0cc838fc68" ], "package_ndc": [ "0409-6625-30", "0409-6625-35", "0409-6625-22", "0409-6625-14" ], "unii": [ "8MDF5V39QO" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 50 mEq/50 mL (8.4%, 1 mEq/mL) (NDC 0409-6625-14)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6020-10", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "NDA018565" ], "brand_name": [ "DURAMORPH" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6020", "0641-6019" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRATHECAL", "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "892473", "892489", "1728783", "1728800" ], "spl_id": [ "aa74af85-7068-4254-9a79-c7f3792044a6" ], "spl_set_id": [ "ebb18761-e5c4-4238-bb84-f9549f500210" ], "package_ndc": [ "0641-6020-01", "0641-6020-10", "0641-6019-01", "0641-6019-10" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "discontinued_date": "05/15/2026", "update_type": "New", "initial_posting_date": "05/15/2026", "package_ndc": "0574-0520-76", "generic_name": "Activated Charcoal Oral Suspension", "contact_info": "866-634-9120", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "M023" ], "brand_name": [ "ACTIDOSE" ], "generic_name": [ "ACTIVATED CHARCOAL" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-0520" ], "product_type": [ "HUMAN OTC DRUG" ], "route": [ "ORAL" ], "substance_name": [ "ACTIVATED CHARCOAL" ], "rxcui": [ "309150", "1251411" ], "spl_id": [ "cf3da077-fe7d-4685-8c5c-f773bc88c88d" ], "spl_set_id": [ "76e4fe6a-afd4-4f68-b12d-0b094f750615" ], "package_ndc": [ "0574-0520-74", "0574-0520-76" ], "unii": [ "2P3VWU3H10" ] }, "update_date": "05/15/2026", "therapeutic_category": [ "Other" ], "dosage_form": "Oral Suspension", "presentation": "Actidose, Oral Suspension, 208 mg/1 mL (NDC 0574-0520-76)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0005-01", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": { "application_number": [ "NDA009866" ], "brand_name": [ "SOLU-CORTEF" ], "generic_name": [ "HYDROCORTISONE SODIUM SUCCINATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0005", "0009-0825", "0009-0011", "0009-0013", "0009-0016" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "HYDROCORTISONE SODIUM SUCCINATE" ], "rxcui": [ "105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596" ], "spl_id": [ "8512044a-4a54-4634-bb97-9e20126adc61" ], "spl_set_id": [ "65eefd58-b166-4d71-ade6-45c8fdf86922" ], "package_ndc": [ "0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01" ], "unii": [ "50LQB69S1Z" ] }, "update_date": "02/24/2026", "therapeutic_category": [ "Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Solu-cortef, Injection, 1000 mg/vial (NDC 0009-0005-01)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved" }, { "discontinued_date": "02/25/2026", "update_type": "New", "initial_posting_date": "02/25/2026", "package_ndc": "0009-0395-14", "generic_name": "Clindamycin Hydrochloride Capsule", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA050162" ], "brand_name": [ "CLEOCIN HYDROCHLORIDE" ], "generic_name": [ "CLINDAMYCIN HYDROCHLORIDE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0395", "0009-0331", "0009-0225" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLINDAMYCIN HYDROCHLORIDE" ], "rxcui": [ "197518", "284215", "309329", "748746", "748748", "748750" ], "spl_id": [ "51cea3cd-28cf-455e-ba27-5a0d8e052858" ], "spl_set_id": [ "df9a2a41-b132-4f43-8940-b2d773b1369a" ], "package_ndc": [ "0009-0331-02", "0009-0225-02", "0009-0395-14" ], "unii": [ "T20OQ1YN1W" ] }, "update_date": "02/25/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Capsule", "presentation": "Cleocin Hydrochloride, Capsule, 300 mg (NDC 0009-0395-14)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "11/03/2017", "package_ndc": "0641-6019-10", "generic_name": "Morphine Sulfate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "NDA018565" ], "brand_name": [ "DURAMORPH" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6019", "0641-6020" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRATHECAL", "INTRAVENOUS" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "892473", "892489", "1728783", "1728800" ], "spl_id": [ "aa74af85-7068-4254-9a79-c7f3792044a6" ], "spl_set_id": [ "ebb18761-e5c4-4238-bb84-f9549f500210" ], "package_ndc": [ "0641-6020-01", "0641-6020-10", "0641-6019-01", "0641-6019-10" ], "unii": [ "X3P646A2J0" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "71288-718-11", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-824-8426", "availability": "Available", "openfda": { "application_number": [ "ANDA213453" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Meitheal Pharmaceuticals Inc." ], "product_ndc": [ "71288-718", "71288-700" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "aad39c88-2e2c-49a6-aa13-de852483661f", "37295b13-65a4-40fa-8d6c-53aeb45e2939" ], "spl_set_id": [ "b23aa80e-2af2-4a66-92ed-b1c8863be704", "b9abaf64-760d-43e0-8669-a9ca70feab11" ], "package_ndc": [ "71288-700-91", "71288-700-92", "71288-718-91", "71288-718-92", "71288-700-05", "71288-700-06", "71288-718-10", "71288-718-11" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 71288-718-11)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "62175-311-37", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "844-834-0530", "availability": "Available", "openfda": { "application_number": [ "ANDA091695" ], "brand_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Lannett Company, Inc." ], "product_ndc": [ "62175-311", "62175-310", "62175-312", "62175-313" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "2001564", "2001565", "2001566", "2001568" ], "spl_id": [ "8b133cd2-e3c6-4742-b402-2393b56ffc93" ], "spl_set_id": [ "3d1f5aff-5d39-496c-b5ed-7f3c70ec641c" ], "package_ndc": [ "62175-310-37", "62175-311-37", "62175-312-37", "62175-313-37" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 62175-311-37)", "company_name": "Lannett Company, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "0143-9310-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Novaplus label", "openfda": { "application_number": [ "ANDA202354" ], "brand_name": [ "ETOMIDATE" ], "generic_name": [ "ETOMIDATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9310", "0143-9311" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008" ], "spl_id": [ "c15bd8c1-34e3-40f2-b31a-634136fe197c" ], "spl_set_id": [ "4312e3c3-34de-4cb3-8abd-c24d24a4bea1" ], "package_ndc": [ "0143-9310-01", "0143-9310-10", "0143-9311-01", "0143-9311-10" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 0143-9310-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "0378-4415-01", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "1-844-874-7464", "availability": "Unavailable", "related_info": "Anticipated availability: Q4 2026; Delay is due to manufacturing delays at the contract manufacturing facility.", "update_date": "06/03/2026", "therapeutic_category": [ "Neurology", "Other" ], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 15 mg (NDC 0378-4415-01)", "company_name": "Rising Pharma Holdings, Inc.", "shortage_reason": "Regulatory delay", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9045-17", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA071168" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-9045", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9042" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596" ], "spl_id": [ "6e442bfd-d3da-4913-8585-ce3485644364" ], "spl_set_id": [ "02a845c3-4521-4926-e397-25ab536e7cf6" ], "package_ndc": [ "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/28/2025", "package_ndc": "0574-2415-65", "generic_name": "Methylphenidate Film, Extended Release", "contact_info": "800-455-8070", "availability": "Available", "related_info": "Available. Distributed by Padagis US LLC", "openfda": { "application_number": [ "NDA021514" ], "brand_name": [ "METHYLPHENIDATE TRANSDERMAL SYSTEM" ], "generic_name": [ "METHYLPHENIDATE" ], "manufacturer_name": [ "PADAGIS US LLC" ], "product_ndc": [ "0574-2415", "0574-2410", "0574-2420", "0574-2430" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "TRANSDERMAL" ], "substance_name": [ "METHYLPHENIDATE" ], "rxcui": [ "753436", "753438", "753440", "753441" ], "spl_id": [ "b743ef45-2fc0-4086-8a02-6078e6a09eaa" ], "spl_set_id": [ "7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb" ], "package_ndc": [ "0574-2410-65", "0574-2415-65", "0574-2420-65", "0574-2430-65" ], "nui": [ "N0000175739", "N0000175729" ], "pharm_class_epc": [ "Central Nervous System Stimulant [EPC]" ], "pharm_class_pe": [ "Central Nervous System Stimulation [PE]" ], "unii": [ "207ZZ9QZ49" ] }, "update_date": "08/15/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Film, Extended Release", "presentation": "Methylphenidate, Film, Extended Release, 15 mg (NDC 0574-2415-65)", "company_name": "Noven Pharmaceuticals, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "25021-687-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "866-625-1618", "availability": "Available", "openfda": { "application_number": [ "ANDA205656" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-687" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "1d066c67-eac2-494a-ad10-ba7e9c60b0e9" ], "spl_set_id": [ "01825411-be08-4402-b101-cb546291c972" ], "package_ndc": [ "25021-687-05", "25021-687-10" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 25021-687-05)", "company_name": "Sagent Pharmaceuticals", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "12/15/2021", "package_ndc": "0009-3073-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: August 2026; Estimated Recovery: September 2026", "openfda": { "application_number": [ "NDA011757" ], "brand_name": [ "DEPO-MEDROL" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-3073", "0009-3475" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE", "INTRA-ARTICULAR" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1743779", "1743781", "1743855", "1743856" ], "spl_id": [ "e4917f75-3e1c-4f3c-803d-d9ec65df06c7", "742fcec7-8db3-4cc6-b276-42587a993810" ], "spl_set_id": [ "bf1b104d-85cb-414d-a366-78068c82c883", "9a7b3837-e038-48bf-97e9-78ad463760dc" ], "package_ndc": [ "0009-3073-22", "0009-3073-23", "0009-3475-22", "0009-3475-23", "0009-3073-01", "0009-3073-03", "0009-3475-01", "0009-3475-03" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 40 mg/1 mL (NDC 0009-3073-01)", "company_name": "Pfizer Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "11534-190-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "732-382-6085 Monday to Friday 9 am to 3:45 pm", "availability": "Available", "openfda": { "application_number": [ "ANDA209799" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "SUNRISE PHARMACEUTICAL, INC." ], "product_ndc": [ "11534-190", "11534-191", "11534-192", "11534-193", "11534-194", "11534-195", "11534-196" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "60dcfbf6-d07a-4010-ae77-8a9ae4529828" ], "spl_set_id": [ "ac102599-3a5b-4154-899e-6ff262be7ff7" ], "package_ndc": [ "11534-190-01", "11534-190-03", "11534-191-01", "11534-191-03", "11534-192-01", "11534-192-03", "11534-193-01", "11534-193-03", "11534-194-01", "11534-194-03", "11534-195-01", "11534-195-03", "11534-196-01", "11534-196-03" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/16/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 11534-190-01)", "company_name": "Sunrise Pharmaceutical, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "25021-311-10", "generic_name": "Furosemide Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Furosemide%20Injection&st=d", "contact_info": "866-625-1918", "availability": "Unavailable", "related_info": "Distributed by Sagent Pharmaceuticals: 1-866-625-1618, Discontinued product", "openfda": { "application_number": [ "ANDA213902" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-311" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "222ce48f-2856-4be2-b16f-6fca38c0dceb" ], "spl_set_id": [ "d63c1277-dd7e-4d21-9e80-68143f55e2dc" ], "package_ndc": [ "25021-311-02", "25021-311-04", "25021-311-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)", "company_name": "Gland Pharma Limited", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "16729-295-34", "generic_name": "Carboplatin Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: TBD; NDC is non-exempt", "openfda": { "application_number": [ "ANDA206775" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Accord Healthcare, Inc." ], "product_ndc": [ "16729-295" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "35cf6068-f31a-211b-e063-6294a90a6b53" ], "spl_set_id": [ "48aa7ef3-9f44-2a08-e054-00144ff88e88" ], "package_ndc": [ "16729-295-31", "16729-295-33", "16729-295-34", "16729-295-12", "16729-295-38" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 10 mg/1 mL (NDC 16729-295-34)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "0009-0306-12", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA011757" ], "brand_name": [ "DEPO-MEDROL" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0306", "0009-0274", "0009-0280" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1358510", "1358512", "1358610", "1358612", "1358617", "1358619" ], "spl_id": [ "267dd735-f800-4735-ba1c-d39d00f0cee5" ], "spl_set_id": [ "823b0010-2b57-4e76-b5ac-4a8c2963438f" ], "package_ndc": [ "0009-0274-01", "0009-0280-02", "0009-0280-51", "0009-0280-03", "0009-0280-52", "0009-0306-02", "0009-0306-12" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Depo-medrol, Injection, 80 mg/1 mL (NDC 0009-0306-12)", "company_name": "Pfizer Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/18/2020", "package_ndc": "59572-102-01", "generic_name": "Azacitidine Injection", "contact_info": "1-888-423-5436", "availability": "Available", "openfda": { "application_number": [ "NDA050794" ], "brand_name": [ "VIDAZA" ], "generic_name": [ "AZACITIDINE" ], "manufacturer_name": [ "Celgene Corporation" ], "product_ndc": [ "59572-102" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "AZACITIDINE" ], "rxcui": [ "485246", "545206" ], "spl_id": [ "8cba79e2-11fa-4eb9-87e7-827ca781fbf3" ], "spl_set_id": [ "3495a71a-cc04-4776-851f-f185956f32af" ], "package_ndc": [ "59572-102-01" ], "nui": [ "N0000000233", "N0000175595" ], "pharm_class_moa": [ "Nucleic Acid Synthesis Inhibitors [MoA]" ], "pharm_class_epc": [ "Nucleoside Metabolic Inhibitor [EPC]" ], "unii": [ "M801H13NRU" ] }, "update_date": "08/16/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Vidaza, Injection, 100 mg (NDC 59572-102-01)", "company_name": "Bristol Myers Squibb Co.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2305-05", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: October 2026; Estimated Recovery: December 2026", "openfda": { "application_number": [ "ANDA075857" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-2305", "0409-2308", "0409-0001" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "1666800", "1666814", "1666823", "1666798" ], "spl_id": [ "2f69c5b1-6505-42dc-8bb3-edbd9b6c0781", "8954486a-8512-4831-8178-0b49f1efb73e" ], "spl_set_id": [ "b95415fa-17c2-42ab-a6b0-e628d01c94ed", "1abda8b8-48a8-4995-af86-39220d1aa240" ], "package_ndc": [ "0409-2305-55", "0409-2305-50", "0409-2308-69", "0409-2308-49", "0409-2308-70", "0409-2308-50", "0409-2305-16", "0409-2305-17", "0409-2305-04", "0409-2305-05", "0409-2308-21", "0409-2308-01", "0409-2308-22", "0409-2308-02", "0409-0001-01", "0409-0001-25" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride Preservative Free, Injection, 5 mg/5 mL (1 mg/mL) (NDC 0409-2305-05)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "03/02/2026", "update_type": "New", "initial_posting_date": "03/02/2026", "package_ndc": "0093-7768-24", "generic_name": "Everolimus Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA210050" ], "brand_name": [ "EVEROLIMUS" ], "generic_name": [ "EVEROLIMUS" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0093-7768", "0093-7766", "0093-7767", "0093-7769" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "EVEROLIMUS" ], "rxcui": [ "845507", "845515", "998189", "1119400" ], "spl_id": [ "0f7ea770-928b-43b2-8971-849d1d12bbc8" ], "spl_set_id": [ "e3bca36b-29ed-4a2b-a1be-a57b6af805f6" ], "package_ndc": [ "0093-7766-19", "0093-7766-24", "0093-7767-19", "0093-7767-24", "0093-7768-19", "0093-7768-24", "0093-7769-19", "0093-7769-24" ], "nui": [ "N0000175605", "N0000175076", "N0000182141", "N0000182137", "N0000175625", "N0000175624", "N0000175550" ], "pharm_class_epc": [ "Kinase Inhibitor [EPC]", "mTOR Inhibitor Immunosuppressant [EPC]" ], "pharm_class_moa": [ "Protein Kinase Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "mTOR Inhibitors [MoA]" ], "pharm_class_pe": [ "Decreased Immunologic Activity [PE]" ], "unii": [ "9HW64Q8G6G" ] }, "update_date": "03/02/2026", "therapeutic_category": [ "Transplant" ], "dosage_form": "Tablet", "presentation": "Everolimus, Tablet, 7.5 mg (NDC 0093-7768-24)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-04", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA018667" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-6102" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "e598e8a6-c854-48f5-a412-fb6a6783774a", "981d5143-60cd-4987-9b47-dec24c10de42" ], "spl_set_id": [ "aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7" ], "package_ndc": [ "0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-04)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/17/2015", "package_ndc": "0143-9930-10", "generic_name": "Cefotaxime Sodium Powder, for Solution", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA065072" ], "brand_name": [ "CEFOTAXIME" ], "generic_name": [ "CEFOTAXIME" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9930", "0143-9931", "0143-9933" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CEFOTAXIME SODIUM" ], "rxcui": [ "309068", "1656313", "1656318" ], "spl_id": [ "7e0897ec-2275-4438-9cc5-4c951e52ad97" ], "spl_set_id": [ "ed23b6bc-32c7-4c50-a53d-313ae78e5623" ], "package_ndc": [ "0143-9931-01", "0143-9931-25", "0143-9933-01", "0143-9933-25", "0143-9930-01", "0143-9930-10" ], "unii": [ "258J72S7TZ" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anti-Infective", "Pediatric" ], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 500 mg (NDC 0143-9930-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2305-17", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA075857" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-2305", "0409-2308", "0409-0001" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "1666800", "1666814", "1666823", "1666798" ], "spl_id": [ "2f69c5b1-6505-42dc-8bb3-edbd9b6c0781", "8954486a-8512-4831-8178-0b49f1efb73e" ], "spl_set_id": [ "b95415fa-17c2-42ab-a6b0-e628d01c94ed", "1abda8b8-48a8-4995-af86-39220d1aa240" ], "package_ndc": [ "0409-2305-55", "0409-2305-50", "0409-2308-69", "0409-2308-49", "0409-2308-70", "0409-2308-50", "0409-2305-16", "0409-2305-17", "0409-2305-04", "0409-2305-05", "0409-2308-21", "0409-2308-01", "0409-2308-22", "0409-2308-02", "0409-0001-01", "0409-0001-25" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride Preservative Free, Injection, 2 mg/2mL (1 mg/mL) (NDC 0409-2305-17)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "0409-9045-01", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA071168" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-9045", "0409-1159", "0409-1160", "0409-1162", "0409-1163", "0409-1165", "0409-9043", "0409-9046", "0409-9042" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1012377", "1012384", "1012396", "1012404", "1672917", "1672919", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082", "1867594", "1867596" ], "spl_id": [ "6e442bfd-d3da-4913-8585-ce3485644364" ], "spl_set_id": [ "02a845c3-4521-4926-e397-25ab536e7cf6" ], "package_ndc": [ "0409-1159-18", "0409-1159-01", "0409-1159-19", "0409-1159-02", "0409-1160-18", "0409-1160-01", "0409-1162-18", "0409-1162-01", "0409-1162-19", "0409-1162-02", "0409-1163-18", "0409-1163-01", "0409-1165-18", "0409-1165-01", "0409-1165-19", "0409-1165-02", "0409-9043-11", "0409-9043-01", "0409-9046-11", "0409-9046-01", "0409-9045-11", "0409-9045-01", "0409-9045-16", "0409-9045-17", "0409-9042-11", "0409-9042-01", "0409-9042-16", "0409-9042-17" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/21/2023", "package_ndc": "0641-6085-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled to be manufactured. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA083312" ], "brand_name": [ "PHENERGAN" ], "generic_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6085", "0641-6084" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "rxcui": [ "992460", "992462", "992858", "992876" ], "spl_id": [ "7d6e64fc-bbf2-4ea9-b866-8115c448e687" ], "spl_set_id": [ "481866da-a712-48a5-853f-8e84aacaab6d" ], "package_ndc": [ "0641-6084-01", "0641-6084-25", "0641-6085-01", "0641-6085-25" ], "unii": [ "R61ZEH7I1I" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy" ], "dosage_form": "Injection", "presentation": "Phenergan, Injection, 50 mg/1 mL (NDC 0641-6085-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "06/06/2018", "package_ndc": "0338-0072-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "888-229-0001", "availability": "Unavailable", "related_info": "Estimated recovery: October 2026", "openfda": { "application_number": [ "ANDA209900" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0072", "0338-0069", "0338-0076" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "2da4dd8a-1b18-481d-b733-9c031d9ea7e3" ], "spl_set_id": [ "4b58836d-9d58-4539-9691-9e11c505ef2a" ], "package_ndc": [ "0338-0069-10", "0338-0072-25", "0338-0076-10" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 0338-0072-25)", "company_name": "Baxter Healthcare", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "06/08/2026", "update_type": "New", "initial_posting_date": "06/08/2026", "package_ndc": "0955-1735-30", "generic_name": "Leflunomide Tablet", "contact_info": "800-981-2491", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "06/08/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Tablet", "presentation": "Leflunomide, Tablet, 10 mg (NDC 0955-1735-30)", "company_name": "Sanofi-Aventis U.S. LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "59651-724-01", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": { "application_number": [ "ANDA075150" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Aurobindo Pharma Limited" ], "product_ndc": [ "59651-724", "59651-722", "59651-723" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "b1582eb7-af35-45d5-a52e-0e380d08527d" ], "spl_set_id": [ "b1582eb7-af35-45d5-a52e-0e380d08527d" ], "package_ndc": [ "59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "06/02/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 59651-724-01)", "company_name": "Aurobindo Pharma USA", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/26/2023", "package_ndc": "84383-110-01", "generic_name": "Penicillin G Benzathine Injection", "related_info_link": "https://www.fda.gov/media/193578/download", "contact_info": "Mark Cuban Cost Plus Drug Company: 682-428-8081", "availability": "Available", "openfda": { "brand_name": [ "LENTOCILIN" ], "generic_name": [ "PENICILLIN G BENZATHIN" ], "manufacturer_name": [ "LABORATRIOS ATRAL, S.A." ], "product_ndc": [ "84383-110" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "PENICILLIN G BENZATHINE" ], "rxcui": [ "2671687", "2684991" ], "spl_id": [ "1a4e5124-618c-ce44-e063-6394a90a43e3" ], "spl_set_id": [ "1a4e5124-618b-ce44-e063-6394a90a43e3" ], "package_ndc": [ "84383-110-01" ], "unii": [ "RIT82F58GK" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Lentocilin, Injection, 1200000 U/4 mL (NDC 84383-110-01)", "company_name": "Laboratorios Atral", "status": "Current" }, { "discontinued_date": "09/08/2025", "update_type": "New", "initial_posting_date": "09/08/2025", "package_ndc": "66993-082-69", "generic_name": "Sumatriptan Nasal Spray", "contact_info": "866-525-0688", "related_info": "This product discontinuation is a business-related decision. The anticipated date that Prasco will cease distribution of the product is approximately March 16, 2026.", "openfda": { "application_number": [ "NDA020626" ], "brand_name": [ "SUMATRIPTAN" ], "generic_name": [ "SUMATRIPTAN" ], "manufacturer_name": [ "Prasco Laboratories" ], "product_ndc": [ "66993-082", "66993-081" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "NASAL" ], "substance_name": [ "SUMATRIPTAN" ], "rxcui": [ "313159", "314227" ], "spl_id": [ "c3c253a9-c0e5-4aa2-927e-8777ee89aa48" ], "spl_set_id": [ "f63e616b-ae0c-432b-badc-8c45023aa725" ], "package_ndc": [ "66993-081-69", "66993-082-69" ], "nui": [ "N0000175763", "N0000175764", "N0000175765" ], "pharm_class_moa": [ "Serotonin 1b Receptor Agonists [MoA]", "Serotonin 1d Receptor Agonists [MoA]" ], "pharm_class_epc": [ "Serotonin-1b and Serotonin-1d Receptor Agonist [EPC]" ], "unii": [ "8R78F6L9VO" ] }, "update_date": "09/08/2025", "therapeutic_category": [ "Neurology" ], "dosage_form": "Nasal Spray", "presentation": "Imitrex, Nasal Spray, 20 mg/100 uL (NDC 66993-082-69)", "company_name": "Prasco Laboratories", "status": "To Be Discontinued" }, { "discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2234-31", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA076515" ], "brand_name": [ "OMEPRAZOLE" ], "generic_name": [ "OMEPRAZOLE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-2234" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OMEPRAZOLE" ], "rxcui": [ "200329" ], "spl_id": [ "fe6aa833-89e6-4679-a7b8-6600e92c1bed" ], "spl_set_id": [ "5a09ce48-7139-4fc7-9b6e-439459c8e866" ], "package_ndc": [ "0781-2234-10", "0781-2234-01", "0781-2234-31" ], "nui": [ "N0000175525", "N0000000147", "N0000182140" ], "pharm_class_epc": [ "Proton Pump Inhibitor [EPC]" ], "pharm_class_moa": [ "Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]" ], "unii": [ "KG60484QX9" ] }, "update_date": "10/09/2025", "therapeutic_category": [ "Gastroenterology" ], "presentation": "Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-31)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "0409-6102-26", "generic_name": "Furosemide Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA018667" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-6102" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "e598e8a6-c854-48f5-a412-fb6a6783774a", "981d5143-60cd-4987-9b47-dec24c10de42" ], "spl_set_id": [ "aaced7a8-c3d7-4d66-8c07-aa407b8b3f35", "39fd32f2-6bb7-4a65-d298-e48d26bc80c7" ], "package_ndc": [ "0409-6102-35", "0409-6102-25", "0409-6102-36", "0409-6102-26", "0409-6102-37", "0409-6102-27", "0409-6102-19", "0409-6102-02", "0409-6102-18", "0409-6102-04", "0409-6102-20", "0409-6102-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) (NDC 0409-6102-26)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-853-25", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA019034" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-853", "63323-851", "63323-852", "63323-854" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897653", "897753", "1724276", "1724338", "1724340", "1724341" ], "spl_id": [ "9e8522c6-595c-46f9-bb25-272aa4683e0f" ], "spl_set_id": [ "e034eb96-03e0-46e1-8b92-5e1f94555e7b" ], "package_ndc": [ "63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 63323-853-25)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-406-11", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": { "application_number": [ "ANDA077856" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Solco Healthcare LLC" ], "product_ndc": [ "43547-406", "43547-407", "43547-408" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "dc17b9d4-2890-4f6c-8476-daa39d0cbc9c" ], "spl_set_id": [ "4acbb7a9-4db5-4497-b8db-9f358b3f6fb4" ], "package_ndc": [ "43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "07/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 43547-406-11)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current" }, { "discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-355-30", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 10 mg (NDC 13668-355-30)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued" }, { "discontinued_date": "11/21/2025", "update_type": "New", "initial_posting_date": "11/21/2025", "package_ndc": "0409-9633-05", "generic_name": "Verapamil Hydrochloride Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/21/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Verapamil Hydrochloride, Injection, 2.5 mg/1 mL (NDC 0409-9633-05)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "06/29/2026", "update_type": "New", "initial_posting_date": "06/29/2026", "package_ndc": "25021-233-20", "generic_name": "Oxaliplatin Injection", "contact_info": "Sagent Pharmaceuticals: 866-625-1618", "related_info": "Marketed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA203869" ], "brand_name": [ "OXALIPLATIN" ], "generic_name": [ "OXALIPLATIN" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-233" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "OXALIPLATIN" ], "rxcui": [ "1736776", "1736781" ], "spl_id": [ "c159050a-e588-4091-b9ee-ea502e1b9529" ], "spl_set_id": [ "29a5d098-bfa7-4a65-bb4f-5daa1fef1c2f" ], "package_ndc": [ "25021-233-10", "25021-233-20" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "04ZR38536J" ] }, "update_date": "06/29/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Oxaliplatin, Injection, 5 mg/1 mL (NDC 25021-233-20)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "03/24/2023", "change_date": "02/24/2026", "package_ndc": "0009-0011-03", "generic_name": "Hydrocortisone Sodium Succinate Injection", "contact_info": "844-646-4398", "resolved_note": "Available", "openfda": { "application_number": [ "NDA009866" ], "brand_name": [ "SOLU-CORTEF" ], "generic_name": [ "HYDROCORTISONE SODIUM SUCCINATE" ], "manufacturer_name": [ "Pharmacia & Upjohn Company LLC" ], "product_ndc": [ "0009-0011", "0009-0825", "0009-0013", "0009-0016", "0009-0005" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "HYDROCORTISONE SODIUM SUCCINATE" ], "rxcui": [ "105398", "238755", "1738586", "1738589", "1738590", "1738592", "1738594", "1738596" ], "spl_id": [ "8512044a-4a54-4634-bb97-9e20126adc61" ], "spl_set_id": [ "65eefd58-b166-4d71-ade6-45c8fdf86922" ], "package_ndc": [ "0009-0825-01", "0009-0011-03", "0009-0011-04", "0009-0013-05", "0009-0013-06", "0009-0016-12", "0009-0005-01" ], "unii": [ "50LQB69S1Z" ] }, "update_date": "02/24/2026", "therapeutic_category": [ "Pulmonary/Allergy", "Dermatology", "Endocrinology/Metabolism", "Gastroenterology", "Hematology", "Neurology", "Oncology", "Ophthalmology", "Pediatric", "Renal", "Rheumatology" ], "dosage_form": "Injection", "presentation": "Solu-Cortef, Injection, 100 mg/vial (NDC 0009-0011-03)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Resolved" }, { "update_type": "Reverified", "initial_posting_date": "11/03/2017", "change_date": "01/03/2025", "package_ndc": "0641-0121-25", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.", "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 2 mg/1 mL (NDC 0641-0121-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0990-7172-17", "generic_name": "Amino Acid Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Available", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA020015" ], "brand_name": [ "AMINOSYN II" ], "generic_name": [ "ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, HISTIDINE, PROLINE, SERINE, N-ACETYLTYROSINE, AND GLYCINE" ], "manufacturer_name": [ "ICU Medical Inc." ], "product_ndc": [ "0990-7172", "0990-7171" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "THREONINE", "TRYPTOPHAN", "VALINE", "ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "HISTIDINE", "PROLINE", "SERINE", "ACETYL L-TYROSINE", "GLYCINE" ], "rxcui": [ "800188", "800192", "800237", "800241" ], "spl_id": [ "0c99ec81-2c27-4352-8dbe-d7ec9e0e80e4" ], "spl_set_id": [ "5b426208-f090-4650-86c3-89040ba45c2d" ], "package_ndc": [ "0990-7172-17", "0990-7171-17" ], "nui": [ "N0000175780", "M0000922" ], "pharm_class_epc": [ "Amino Acid [EPC]" ], "pharm_class_cs": [ "Amino Acids [CS]" ], "unii": [ "HG18B9YRS7", "94ZLA3W45F", "452VLY9402", "GMW67QNF9C", "04Y7590D77", "8DUH1N11BX", "2ZD004190S", "AE28F7PNPL", "9DLQ4CIU6V", "TE7660XO1C", "47E5O17Y3R", "OF5P57N2ZX", "DA8G610ZO5", "30KYC7MIAI", "4QD397987E", "TTL6G7LIWZ", "3KX376GY7L" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "Aminosyn II 10% In Plastic Container, Injection, 0.1 (NDC 0990-7172-17)", "company_name": "Otsuka ICU Medical LLC", "status": "Current" }, { "discontinued_date": "10/09/2025", "update_type": "New", "initial_posting_date": "10/09/2025", "package_ndc": "0781-2234-10", "generic_name": "Omeprazole Delayed Release Capsule", "contact_info": "800-525-8747", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA076515" ], "brand_name": [ "OMEPRAZOLE" ], "generic_name": [ "OMEPRAZOLE" ], "manufacturer_name": [ "Sandoz Inc" ], "product_ndc": [ "0781-2234" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OMEPRAZOLE" ], "rxcui": [ "200329" ], "spl_id": [ "fe6aa833-89e6-4679-a7b8-6600e92c1bed" ], "spl_set_id": [ "5a09ce48-7139-4fc7-9b6e-439459c8e866" ], "package_ndc": [ "0781-2234-10", "0781-2234-01", "0781-2234-31" ], "nui": [ "N0000175525", "N0000000147", "N0000182140" ], "pharm_class_epc": [ "Proton Pump Inhibitor [EPC]" ], "pharm_class_moa": [ "Proton Pump Inhibitors [MoA]", "Cytochrome P450 2C19 Inhibitors [MoA]" ], "unii": [ "KG60484QX9" ] }, "update_date": "10/09/2025", "therapeutic_category": [ "Gastroenterology" ], "presentation": "Omeprazole, Delayed Release Capsule, 40 mg (NDC 0781-2234-10)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "07/23/2026", "update_type": "New", "initial_posting_date": "07/23/2026", "package_ndc": "0574-7040-12", "generic_name": "Belladonna and Opium Suppository", "contact_info": "(800) 775-2054", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "BELLADONNA AND OPIUM" ], "generic_name": [ "ATROPA BELLADONNA AND OPIUM" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-7040", "0574-7045" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RECTAL" ], "substance_name": [ "ATROPA BELLADONNA", "OPIUM" ], "rxcui": [ "312104", "312107" ], "spl_id": [ "7b45a1d7-c3a5-4434-a848-45638cedd6e1" ], "spl_set_id": [ "8301e76b-134a-43d2-a7dc-c600ccf2695c" ], "package_ndc": [ "0574-7040-12", "0574-7040-04", "0574-7045-12", "0574-7045-04" ], "unii": [ "37M3MZ001L", "WQZ3G9PF0H" ] }, "update_date": "07/23/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Suppository", "presentation": "Belladonna and Opium, Suppository, 16.2 mg; 60 mg (NDC 0574-7040-12)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "04/26/2023", "package_ndc": "60793-700-10", "generic_name": "Penicillin G Benzathine Injection", "related_info_link": "https://www.fda.gov/media/190713/download", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: 4Q 2027; Manufacturing delay", "openfda": { "application_number": [ "NDA050141" ], "brand_name": [ "BICILLIN L-A" ], "generic_name": [ "PENICILLIN G BENZATHINE" ], "manufacturer_name": [ "Pfizer Laboratories Div Pfizer Inc" ], "product_ndc": [ "60793-700", "60793-701", "60793-702" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR" ], "substance_name": [ "PENICILLIN G BENZATHINE" ], "rxcui": [ "731564", "731566", "731567", "731568", "731570", "731571" ], "spl_id": [ "526e051e-d0fc-4f5d-886a-d61947aa8a7f" ], "spl_set_id": [ "012d46f1-d0a0-4676-a879-cd320297ab16" ], "package_ndc": [ "60793-700-01", "60793-700-10", "60793-701-02", "60793-701-10", "60793-702-04", "60793-702-10" ], "unii": [ "RIT82F58GK" ] }, "update_date": "08/12/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Bicillin L-A, Injection, 600000 [iU]/1 mL (NDC 60793-700-10)", "company_name": "Pfizer Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/01/2017", "package_ndc": "76045-010-11", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release not available at this time. Check wholesalers for inventory.", "openfda": { "application_number": [ "NDA019034" ], "brand_name": [ "DILAUDID" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "76045-010", "76045-009", "76045-121" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897756", "897757", "1433251", "1872265", "1872269", "1872752", "2277368", "2277370" ], "spl_id": [ "97bfcafb-2037-47dc-a0ae-f7b8007c47df" ], "spl_set_id": [ "9eebd88a-5632-460f-b7b6-26c8a180540d" ], "package_ndc": [ "76045-009-96", "76045-009-06", "76045-009-01", "76045-009-11", "76045-010-01", "76045-010-11", "76045-121-01", "76045-121-11" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Dilaudid, Injection, 2 mg/1 mL (NDC 76045-010-11)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/26/2018", "package_ndc": "0409-3793-01", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2027", "openfda": { "application_number": [ "ANDA074802" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3793", "0409-3795", "0409-3796" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "4beb8ebd-934e-4181-8374-01be0bb80680" ], "spl_set_id": [ "8accbb78-fc64-45d5-69b0-35c23a1d2a2e" ], "package_ndc": [ "0409-3793-19", "0409-3793-01", "0409-3793-25", "0409-3795-19", "0409-3795-01", "0409-3795-25", "0409-3796-19", "0409-3796-01", "0409-3796-25" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 0409-3793-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-152-01", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": { "application_number": [ "ANDA075468" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Advagen Pharma Ltd" ], "product_ndc": [ "72888-152", "72888-497", "72888-153", "72888-154" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529", "204892" ], "spl_id": [ "5510f17b-a980-f412-e063-6394a90ae1c4" ], "spl_set_id": [ "30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec" ], "package_ndc": [ "72888-497-01", "72888-497-02", "72888-497-03", "72888-497-04", "72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 72888-152-01)", "company_name": "Rubicon Research Private Limited", "status": "Current" }, { "discontinued_date": "06/29/2026", "update_type": "New", "initial_posting_date": "06/29/2026", "package_ndc": "25021-233-10", "generic_name": "Oxaliplatin Injection", "contact_info": "Sagent Pharmaceuticals: 866-625-1618", "related_info": "Marketed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA203869" ], "brand_name": [ "OXALIPLATIN" ], "generic_name": [ "OXALIPLATIN" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-233" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "OXALIPLATIN" ], "rxcui": [ "1736776", "1736781" ], "spl_id": [ "c159050a-e588-4091-b9ee-ea502e1b9529" ], "spl_set_id": [ "29a5d098-bfa7-4a65-bb4f-5daa1fef1c2f" ], "package_ndc": [ "25021-233-10", "25021-233-20" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "04ZR38536J" ] }, "update_date": "06/29/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Oxaliplatin, Injection, 5 mg/1 mL (NDC 25021-233-10)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co., Ltd.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-406-10", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": { "application_number": [ "ANDA077856" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Solco Healthcare LLC" ], "product_ndc": [ "43547-406", "43547-407", "43547-408" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "dc17b9d4-2890-4f6c-8476-daa39d0cbc9c" ], "spl_set_id": [ "4acbb7a9-4db5-4497-b8db-9f358b3f6fb4" ], "package_ndc": [ "43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "07/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 43547-406-10)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-3299-26", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA018893" ], "brand_name": [ "SODIUM ACETATE" ], "generic_name": [ "SODIUM ACETATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3299" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM ACETATE ANHYDROUS" ], "rxcui": [ "237371" ], "spl_id": [ "4e6137c2-6b7c-4882-985c-03b591b6c046", "b7a713f4-3c97-484b-b182-2824e1e944bb" ], "spl_set_id": [ "abc41ed1-9512-4bea-9295-1a9ca134b6c2", "c3be2468-45e8-4ecc-a30b-e966743a563f" ], "package_ndc": [ "0409-3299-15", "0409-3299-05", "0409-3299-16", "0409-3299-06", "0409-3299-45", "0409-3299-25", "0409-3299-46", "0409-3299-26" ], "unii": [ "NVG71ZZ7P0" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition" ], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 100 mEq/50 mL (2 mEq/mL) (NDC 0409-3299-26)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-486-57", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-486", "63323-492", "63323-491", "63323-495", "63323-485", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428", "0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17", "4dd52202-8eef-4136-92dd-ada573b7cf74" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31", "63323-492-41", "63323-492-16", "63323-492-43", "63323-492-36", "63323-492-45", "63323-492-26", "63323-485-41", "63323-485-26", "63323-486-41", "63323-486-26", "63323-482-41", "63323-482-26", "63323-495-41", "63323-495-26" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-486-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-105-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": { "application_number": [ "NDA021977" ], "brand_name": [ "VYVANSE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "59417-105", "59417-101", "59417-102", "59417-103", "59417-104", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119", "59417-120" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469" ], "spl_id": [ "81d087b6-4cb4-466a-9693-679edeb062e2" ], "spl_set_id": [ "704e4378-ca83-445c-8b45-3cfa51c1ecad" ], "package_ndc": [ "59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 50 mg (NDC 59417-105-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8892-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA040440" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "SpecGx LLC" ], "product_ndc": [ "0406-8892", "0406-8891", "0406-8884", "0406-8885", "0406-8893", "0406-8894" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "1009145" ], "spl_id": [ "0d3fb5ba-ff79-4862-bc1d-45b8343e115b" ], "spl_set_id": [ "72ddd1c9-ddbd-4c95-acd9-003189a353a3" ], "package_ndc": [ "0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0406-8892-01)", "company_name": "SpecGx LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/03/2016", "package_ndc": "0409-3299-25", "generic_name": "Sodium Acetate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA018893" ], "brand_name": [ "SODIUM ACETATE" ], "generic_name": [ "SODIUM ACETATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3299" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM ACETATE ANHYDROUS" ], "rxcui": [ "237371" ], "spl_id": [ "4e6137c2-6b7c-4882-985c-03b591b6c046", "b7a713f4-3c97-484b-b182-2824e1e944bb" ], "spl_set_id": [ "abc41ed1-9512-4bea-9295-1a9ca134b6c2", "c3be2468-45e8-4ecc-a30b-e966743a563f" ], "package_ndc": [ "0409-3299-15", "0409-3299-05", "0409-3299-16", "0409-3299-06", "0409-3299-45", "0409-3299-25", "0409-3299-46", "0409-3299-26" ], "unii": [ "NVG71ZZ7P0" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition" ], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 200 mEq/100 mL (2 mEq/mL) (NDC 0409-3299-25)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/28/2023", "package_ndc": "55150-386-01", "generic_name": "Carboplatin Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA205487" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-386", "55150-333", "55150-334", "55150-335" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "6029d051-ee8d-44cc-8dae-b91c3385d4c3", "5abfcb87-bb02-4384-9c9d-7d0e3e809311" ], "spl_set_id": [ "f5fe9a20-47a5-45b9-ab06-c6158d9b6aca", "5abfcb87-bb02-4384-9c9d-7d0e3e809311" ], "package_ndc": [ "55150-333-01", "55150-334-01", "55150-335-01", "55150-386-01", "55150-335-00", "55150-386-00" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/60 mL (NDC 55150-386-01)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0527-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 5 mg (NDC 0071-0527-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "04/29/2026", "update_type": "New", "initial_posting_date": "04/29/2026", "package_ndc": "49884-604-11", "generic_name": "Lamotrigine Tablet, Extended Release", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA201791" ], "brand_name": [ "LAMOTRIGINE EXTENDED RELEASE" ], "generic_name": [ "LAMOTRIGINE EXTENDED RELEASE" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "49884-604", "49884-561", "49884-562", "49884-563", "49884-564", "49884-605" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LAMOTRIGINE" ], "rxcui": [ "850087", "850091", "900156", "900164", "1098608", "1146690" ], "spl_id": [ "9c5e0c2a-800e-47e9-a26b-582b98a05957" ], "spl_set_id": [ "fb59c76a-9b6f-40ea-ac3a-58c3195c4377" ], "package_ndc": [ "49884-561-11", "49884-561-01", "49884-561-05", "49884-562-11", "49884-562-01", "49884-562-05", "49884-563-11", "49884-563-01", "49884-563-05", "49884-564-11", "49884-564-01", "49884-564-05", "49884-604-11", "49884-604-01", "49884-604-05", "49884-605-11", "49884-605-01", "49884-605-05" ], "nui": [ "N0000175753", "N0000008486", "N0000175751", "N0000187061", "N0000000191" ], "pharm_class_epc": [ "Anti-epileptic Agent [EPC]", "Mood Stabilizer [EPC]" ], "pharm_class_pe": [ "Decreased Central Nervous System Disorganized Electrical Activity [PE]" ], "pharm_class_moa": [ "Organic Cation Transporter 2 Inhibitors [MoA]", "Dihydrofolate Reductase Inhibitors [MoA]" ], "unii": [ "U3H27498KS" ] }, "update_date": "04/29/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Lamotrigine, Tablet, Extended Release, 250 mg (NDC 49884-604-11)", "company_name": "Par Health, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-208-05", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA017584" ], "brand_name": [ "LIDOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-208" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1737761" ], "spl_id": [ "289524c2-d0be-443d-aedf-39d621f217a5" ], "spl_set_id": [ "f1b26274-a55e-4321-b96c-ce0df830f205" ], "package_ndc": [ "63323-208-01", "63323-208-05" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride Preservative Free, Injection, 20 mg/1 mL (NDC 63323-208-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "03/27/2026", "update_type": "New", "initial_posting_date": "03/27/2026", "package_ndc": "69238-1627-6", "generic_name": "Dapsone Gel", "contact_info": "866-525-7270", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA212701" ], "brand_name": [ "DAPSONE" ], "generic_name": [ "DASPONE" ], "manufacturer_name": [ "Amneal Pharmaceuticals NY LLC" ], "product_ndc": [ "69238-1627" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "TOPICAL" ], "substance_name": [ "DAPSONE" ], "rxcui": [ "1741905" ], "spl_id": [ "0622cdcc-1196-4a2f-8c85-6f34f0f97f9d" ], "spl_set_id": [ "fba0b181-077a-4667-bde1-cf9592f120c2" ], "package_ndc": [ "69238-1627-6", "69238-1627-9" ], "nui": [ "N0000175881", "M0020791" ], "pharm_class_epc": [ "Sulfone [EPC]" ], "pharm_class_cs": [ "Sulfones [CS]" ], "unii": [ "8W5C518302" ] }, "update_date": "03/27/2026", "therapeutic_category": [ "Dermatology" ], "dosage_form": "Gel", "presentation": "Dapsone, Gel, 7.5% (NDC 69238-1627-6)", "company_name": "Amneal Pharmaceuticals", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "11/21/2023", "package_ndc": "0641-6084-25", "generic_name": "Promethazine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA083312" ], "brand_name": [ "PHENERGAN" ], "generic_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0641-6084", "0641-6085" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "PROMETHAZINE HYDROCHLORIDE" ], "rxcui": [ "992460", "992462", "992858", "992876" ], "spl_id": [ "7d6e64fc-bbf2-4ea9-b866-8115c448e687" ], "spl_set_id": [ "481866da-a712-48a5-853f-8e84aacaab6d" ], "package_ndc": [ "0641-6084-01", "0641-6084-25", "0641-6085-01", "0641-6085-25" ], "unii": [ "R61ZEH7I1I" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Gastroenterology", "Pediatric", "Pulmonary/Allergy" ], "dosage_form": "Injection", "presentation": "Phenergan, Injection, 25 mg/1 mL (NDC 0641-6084-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "02/10/2026", "update_type": "New", "initial_posting_date": "02/10/2026", "package_ndc": "63323-340-20", "generic_name": "Cefepime Hydrochloride Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": { "application_number": [ "ANDA065441" ], "brand_name": [ "CEFEPIME" ], "generic_name": [ "CEFEPIME" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-340", "63323-326" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CEFEPIME HYDROCHLORIDE" ], "rxcui": [ "1665088", "1665093" ], "spl_id": [ "8c2fbf43-34bd-49d1-bda8-a2191c8bc54b" ], "spl_set_id": [ "5e1695e0-1310-4cd8-a5da-ad1a7dcd1792" ], "package_ndc": [ "63323-326-21", "63323-326-20", "63323-340-21", "63323-340-20" ], "unii": [ "I8X1O0607P" ] }, "update_date": "02/10/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Cefepime Hydrochloride, Injection, 2 g (NDC 63323-340-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "65219-442-05", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA217472" ], "brand_name": [ "ROCURONIUM" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-442", "65219-444", "65219-695", "65219-697" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "2720024", "2720026" ], "spl_id": [ "31c4c874-3d24-4c86-a301-ee9faf0b5c00" ], "spl_set_id": [ "9a622308-7bda-4ca0-9de5-d6b3b4be3384" ], "package_ndc": [ "65219-442-02", "65219-442-05", "65219-444-04", "65219-444-10", "65219-695-01", "65219-695-05", "65219-697-01", "65219-697-10" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-442-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "83634-651-20", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "Avenacy, LLC: 877-283-6229", "availability": "Available", "related_info": "Distributed by Avenacy, LLC", "openfda": { "application_number": [ "ANDA219535" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Avenacy, LLC" ], "product_ndc": [ "83634-651", "83634-653" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1737562", "1737566", "1737568" ], "spl_id": [ "8fb1dd7b-f349-4a64-96c1-bd72bf748f3b" ], "spl_set_id": [ "46480253-29b9-4d7f-98ed-10377929026b" ], "package_ndc": [ "83634-653-41", "83634-653-02", "83634-653-42", "83634-653-05", "83634-653-43", "83634-653-30", "83634-651-41", "83634-651-10", "83634-651-42", "83634-651-20", "83634-651-43", "83634-651-50" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 200 mg/20 mL (NDC 83634-651-20)", "company_name": "Anthea Pharma", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "55150-164-02", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA203082" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-164", "55150-161", "55150-162", "55150-163", "55150-165" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1737562", "1737566", "1737568", "1737757", "1737761" ], "spl_id": [ "bab2ea79-0aed-4f48-8b4e-f864f8b82fb8", "d95a0a28-804f-44d2-aa31-01df376a3154" ], "spl_set_id": [ "9916b09d-a116-469d-92d5-60e50ea9782b", "89701fac-7536-4f16-87fb-f4cc121e74ee" ], "package_ndc": [ "55150-161-09", "55150-162-09", "55150-163-00", "55150-163-24", "55150-164-09", "55150-165-09", "55150-161-02", "55150-162-05", "55150-163-30", "55150-163-25", "55150-164-02", "55150-165-05" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 20 mg/mL (NDC 55150-164-02)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "44567-602-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "WG Critical Care 888-493-0861", "availability": "Available", "related_info": "Marketed by WG Critical Care", "openfda": { "application_number": [ "NDA206628" ], "brand_name": [ "DEXMEDETOMIDINE IN DEXTROSE" ], "generic_name": [ "DEXMEDETOMIDINE" ], "manufacturer_name": [ "WG Critical Care, LLC" ], "product_ndc": [ "44567-602", "44567-600", "44567-601", "44567-603" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909", "1788947" ], "spl_id": [ "42a0bb50-be84-4c46-abfd-fd44c6f10087" ], "spl_set_id": [ "0d2710f2-ee47-4114-ab5c-8dca74cdcb8d" ], "package_ndc": [ "44567-600-04", "44567-601-04", "44567-602-24", "44567-603-24" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 4 ug/1 mL (NDC 44567-602-24)", "company_name": "HQ Specialty Pharma", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "0071-0532-23", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "800-533-4535", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Accupril, Tablet, 20 mg (NDC 0071-0532-23)", "company_name": "Pfizer Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0990-7171-17", "generic_name": "Amino Acid Injection", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Available", "related_info": "This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "openfda": { "application_number": [ "NDA020041" ], "brand_name": [ "AMINOSYN II" ], "generic_name": [ "ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, ALANINE, ARGININE, ASPARTIC ACID, GLUTAMIC ACID, HISTIDINE, PROLINE, SERINE, N-ACETYLTYROSINE, AND GLYCINE" ], "manufacturer_name": [ "ICU Medical Inc." ], "product_ndc": [ "0990-7171", "0990-7172" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "THREONINE", "TRYPTOPHAN", "VALINE", "ALANINE", "ARGININE", "ASPARTIC ACID", "GLUTAMIC ACID", "HISTIDINE", "PROLINE", "SERINE", "ACETYL L-TYROSINE", "GLYCINE" ], "rxcui": [ "800188", "800192", "800237", "800241" ], "spl_id": [ "0c99ec81-2c27-4352-8dbe-d7ec9e0e80e4" ], "spl_set_id": [ "5b426208-f090-4650-86c3-89040ba45c2d" ], "package_ndc": [ "0990-7172-17", "0990-7171-17" ], "nui": [ "N0000175780", "M0000922" ], "pharm_class_epc": [ "Amino Acid [EPC]" ], "pharm_class_cs": [ "Amino Acids [CS]" ], "unii": [ "HG18B9YRS7", "94ZLA3W45F", "452VLY9402", "GMW67QNF9C", "04Y7590D77", "8DUH1N11BX", "2ZD004190S", "AE28F7PNPL", "9DLQ4CIU6V", "TE7660XO1C", "47E5O17Y3R", "OF5P57N2ZX", "DA8G610ZO5", "30KYC7MIAI", "4QD397987E", "TTL6G7LIWZ", "3KX376GY7L" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "Aminosyn II 15% In Plastic Container, Injection, 0.15 (NDC 0990-7171-17)", "company_name": "Otsuka ICU Medical LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "0409-5160-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "ANDA205656" ], "brand_name": [ "ROCURONIUM BROMIDE" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-5160", "0409-1403" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "1234995" ], "spl_id": [ "f01f9986-43f9-40e8-9506-11bfe78f9242" ], "spl_set_id": [ "f01f9986-43f9-40e8-9506-11bfe78f9242" ], "package_ndc": [ "0409-1403-05", "0409-1403-10", "0409-5160-01", "0409-5160-10" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 100 mg/10 mL (10 mg/mL) (NDC 0409-5160-10)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "06/13/2018", "package_ndc": "0143-9577-10", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Additional lots are scheduled for manufacturing to meet demand. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA080407" ], "brand_name": [ "LIDOCAINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9577", "0143-9579", "0143-9578", "0143-9576", "0143-9575", "0143-9172", "0143-9173" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671" ], "spl_id": [ "e9b92d4d-8944-4235-8d77-3218f82f00a9" ], "spl_set_id": [ "5523fdfe-69fd-49a5-b51f-73e2223d49a9" ], "package_ndc": [ "0143-9579-01", "0143-9579-25", "0143-9578-01", "0143-9578-10", "0143-9577-01", "0143-9577-10", "0143-9576-01", "0143-9576-25", "0143-9575-01", "0143-9575-10", "0143-9172-01", "0143-9172-10", "0143-9173-01", "0143-9173-10" ], "unii": [ "V13007Z41A" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 0143-9577-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-166-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Available", "openfda": { "application_number": [ "ANDA215330" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Rhodes Pharmaceuticals LLC" ], "product_ndc": [ "42858-166", "42858-161", "42858-162", "42858-163", "42858-164", "42858-165", "42858-167" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "0002e227-1109-4ecc-a8c5-4b4f11fac3cc" ], "spl_set_id": [ "d918b40d-a461-41bc-b6c0-83dc76c28e32" ], "package_ndc": [ "42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/24/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 42858-166-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-7853-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA021038" ], "brand_name": [ "PRECEDEX" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-7853", "0409-1660", "0409-1638", "0409-1434", "0409-1596", "0409-7838", "0409-7875" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892" ], "spl_id": [ "3c5274fd-6597-4b88-babc-92e4e16c6329" ], "spl_set_id": [ "548a88c0-afda-427e-75ac-5af0cfa2224c" ], "package_ndc": [ "0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Precedex, Injection, 400 mcg/100 mL (NDC 0409-7853-24)", "company_name": "Pfizer Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/15/2023", "package_ndc": "65219-444-10", "generic_name": "Rocuronium Bromide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA217472" ], "brand_name": [ "ROCURONIUM" ], "generic_name": [ "ROCURONIUM BROMIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-444", "65219-442", "65219-695", "65219-697" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ROCURONIUM BROMIDE" ], "rxcui": [ "2720024", "2720026" ], "spl_id": [ "31c4c874-3d24-4c86-a301-ee9faf0b5c00" ], "spl_set_id": [ "9a622308-7bda-4ca0-9de5-d6b3b4be3384" ], "package_ndc": [ "65219-442-02", "65219-442-05", "65219-444-04", "65219-444-10", "65219-695-01", "65219-695-05", "65219-697-01", "65219-697-10" ], "unii": [ "I65MW4OFHZ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Rocuronium Bromide, Injection, 10 mg/1 mL (NDC 65219-444-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "72572-128-08", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "877-495-6856", "availability": "Available", "related_info": "Distributed by Civica", "openfda": { "application_number": [ "ANDA212791" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "CIVICA, INC." ], "product_ndc": [ "72572-128", "72572-127" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909" ], "spl_id": [ "8906e391-411f-456b-8263-17e0e05bbb35" ], "spl_set_id": [ "1faf1ac8-ff9b-4ed9-b562-06dab971173a" ], "package_ndc": [ "72572-127-01", "72572-127-10", "72572-128-01", "72572-128-08" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 400 mcg/100 mL (4 ug/1 mL) (NDC 72572-128-08)", "company_name": "Azurity Pharmaceuticals, Inc", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/31/2018", "package_ndc": "65219-570-04", "generic_name": "Bumetanide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA216434" ], "brand_name": [ "BUMETANIDE" ], "generic_name": [ "BUMETANIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "65219-570", "65219-572" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "BUMETANIDE" ], "rxcui": [ "282486", "1727569" ], "spl_id": [ "aaff61c4-203b-4905-9138-0f98959ad013" ], "spl_set_id": [ "a007f3aa-3977-4be3-a9a2-db3d458bca58" ], "package_ndc": [ "65219-570-01", "65219-570-04", "65219-572-01", "65219-572-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "0Y2S3XUQ5H" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Bumetanide, Injection, .25 mg/1 mL (NDC 65219-570-04)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1176-30", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "NDA021171" ], "brand_name": [ "DEMEROL" ], "generic_name": [ "MEPERIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1176", "0409-1181", "0409-1178", "0409-1179", "0409-1180", "0409-1362", "0409-1418" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "MEPERIDINE HYDROCHLORIDE" ], "rxcui": [ "860792", "861463", "861473", "861493", "861494", "861522", "861529", "861617", "1242106", "1242503", "2539186", "2539188", "2539191", "2539192" ], "spl_id": [ "b6935f73-7b93-496d-871b-de6f9b379649" ], "spl_set_id": [ "b31d1308-28c3-43f4-e0a6-2f3ed76b8975" ], "package_ndc": [ "0409-1181-30", "0409-1176-03", "0409-1176-30", "0409-1178-03", "0409-1178-30", "0409-1179-03", "0409-1179-30", "0409-1180-59", "0409-1180-69", "0409-1362-11", "0409-1362-01", "0409-1418-11", "0409-1418-01" ], "unii": [ "N8E7F7Q170" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Demerol, Injection, 25 mg/1 mL (NDC 0409-1176-30)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "63323-411-10", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA075154" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-411", "63323-412" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "311700", "311702" ], "spl_id": [ "9814447b-a93e-42ad-b57e-5db0a5b7f552" ], "spl_set_id": [ "a91ce254-14a3-4cbf-8ab8-5da252aa3fdc" ], "package_ndc": [ "63323-411-22", "63323-411-27", "63323-411-15", "63323-411-12", "63323-411-18", "63323-411-25", "63323-411-13", "63323-411-10", "63323-412-18", "63323-412-25", "63323-412-03", "63323-412-02", "63323-412-06", "63323-412-05", "63323-412-13", "63323-412-10" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 1 mg/1 mL (NDC 63323-411-10)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Delay in shipping of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "63323-806-02", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA210762" ], "brand_name": [ "FENTANYL CITRATE" ], "generic_name": [ "FENTANYL CITRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-806" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FENTANYL CITRATE" ], "rxcui": [ "1735003", "1735007", "1735008", "1735013", "2168270" ], "spl_id": [ "341b092a-1f6f-40f1-98f2-9346bf2e1242" ], "spl_set_id": [ "38d0c14a-a0c1-44cc-a939-0304eb8037d6" ], "package_ndc": [ "63323-806-11", "63323-806-01", "63323-806-12", "63323-806-02", "63323-806-13", "63323-806-05", "63323-806-14", "63323-806-20", "63323-806-50" ], "unii": [ "MUN5LYG46H" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0378-5807-93", "generic_name": "Valsartan Tablet", "contact_info": "800-796-9526", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA090866" ], "brand_name": [ "VALSARTAN" ], "generic_name": [ "VALSARTAN" ], "manufacturer_name": [ "Mylan Pharmaceuticals Inc." ], "product_ndc": [ "0378-5807", "0378-5813", "0378-5814", "0378-5815" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "VALSARTAN" ], "rxcui": [ "349199", "349200", "349201", "349483" ], "spl_id": [ "a5384d58-48c7-494a-a8a8-c296b316bd91" ], "spl_set_id": [ "73e01dc6-7dd4-421a-a4f6-137e75f69f9a" ], "package_ndc": [ "0378-5807-93", "0378-5813-77", "0378-5814-77", "0378-5815-77" ], "nui": [ "N0000000070", "N0000175561" ], "pharm_class_moa": [ "Angiotensin 2 Receptor Antagonists [MoA]" ], "pharm_class_epc": [ "Angiotensin 2 Receptor Blocker [EPC]" ], "unii": [ "80M03YXJ7I" ] }, "update_date": "11/19/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Valsartan, Tablet, 40 mg (NDC 0378-5807-93)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "72888-152-30", "generic_name": "Clonazepam Tablet", "contact_info": "sales@advagenpharma.com", "availability": "Available", "related_info": "Marketed by Advagen Pharma Ltd.", "openfda": { "application_number": [ "ANDA075468" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Advagen Pharma Ltd" ], "product_ndc": [ "72888-152", "72888-497", "72888-153", "72888-154" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529", "204892" ], "spl_id": [ "5510f17b-a980-f412-e063-6394a90ae1c4" ], "spl_set_id": [ "30d674f9-f1b3-4c2d-a8e9-3bc8e476f1ec" ], "package_ndc": [ "72888-497-01", "72888-497-02", "72888-497-03", "72888-497-04", "72888-152-30", "72888-152-01", "72888-152-05", "72888-152-00", "72888-153-30", "72888-153-01", "72888-153-05", "72888-153-00", "72888-154-30", "72888-154-01", "72888-154-05", "72888-154-00" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, .5 mg (NDC 72888-152-30)", "company_name": "Rubicon Research Private Limited", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/24/2017", "package_ndc": "63323-089-50", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA206688" ], "brand_name": [ "SODIUM BICARBONATE" ], "generic_name": [ "SODIUM BICARBONATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-089", "63323-083" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM BICARBONATE" ], "rxcui": [ "1868469", "1868486" ], "spl_id": [ "9def795c-abcf-483c-8b1d-e4374666efb2" ], "spl_set_id": [ "0ab55004-bb63-436d-ad77-cd3796905370" ], "package_ndc": [ "63323-083-03", "63323-083-05", "63323-089-25", "63323-089-50" ], "unii": [ "8MDF5V39QO" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 84 mg/1 mL (NDC 63323-089-50)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2018", "package_ndc": "73293-0001-2", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "intbiz@huons.com", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA212821" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Huons Co., Ltd." ], "product_ndc": [ "73293-0001", "73293-0004", "73293-0005", "73293-0003" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE" ], "rxcui": [ "1010033", "1010671", "1737566", "1737761" ], "spl_id": [ "4711fd53-dad3-f117-e063-6394a90a8d3d" ], "spl_set_id": [ "8ec2d256-fc4f-44f6-bee2-eef2bf3bf580" ], "package_ndc": [ "73293-0004-1", "73293-0004-2", "73293-0005-1", "73293-0005-2", "73293-0001-1", "73293-0001-2", "73293-0003-1", "73293-0003-2" ], "unii": [ "V13007Z41A" ] }, "update_date": "07/30/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 10 mg/1 mL (NDC 73293-0001-2)", "company_name": "Huons Co., Ltd. (South Korea)", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "05/30/2025", "package_ndc": "0409-1179-30", "generic_name": "Meperidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2027; Shortage per Manufacturer: Manufacturing Delay", "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Demerol, Injection, 75 mg/1 mL (NDC 0409-1179-30)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0264-1510-32", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "NDA016730" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-1510" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795609", "1795616", "1795618" ], "spl_id": [ "638a41c3-0f07-4d1a-bb4e-1bab16e61266" ], "spl_set_id": [ "60b6d7c3-0164-46c9-aa38-b5aa1c31a5d5" ], "package_ndc": [ "0264-1510-36", "0264-1510-31", "0264-1510-32" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 50 mg/1 mL (NDC 0264-1510-32)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/22/2020", "package_ndc": "55150-393-01", "generic_name": "Azacitidine Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA215066" ], "brand_name": [ "AZACITIDINE" ], "generic_name": [ "AZACITIDINE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-393" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "AZACITIDINE" ], "rxcui": [ "485246" ], "spl_id": [ "e89b9510-86df-4095-b6d3-4eb05b613c4f" ], "spl_set_id": [ "ecd108bd-bb5f-4b2e-ad91-210fca452e9b" ], "package_ndc": [ "55150-393-01" ], "nui": [ "N0000000233", "N0000175595" ], "pharm_class_moa": [ "Nucleic Acid Synthesis Inhibitors [MoA]" ], "pharm_class_epc": [ "Nucleoside Metabolic Inhibitor [EPC]" ], "unii": [ "M801H13NRU" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Azacitidine, Injection, 100 mg/4 mL (NDC 55150-393-01)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "59651-723-99", "generic_name": "Clonazepam Tablet", "contact_info": "866-850-2876", "availability": "Available", "openfda": { "application_number": [ "ANDA075150" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Aurobindo Pharma Limited" ], "product_ndc": [ "59651-723", "59651-722", "59651-724" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "b1582eb7-af35-45d5-a52e-0e380d08527d" ], "spl_set_id": [ "b1582eb7-af35-45d5-a52e-0e380d08527d" ], "package_ndc": [ "59651-722-01", "59651-722-99", "59651-723-01", "59651-723-99", "59651-724-01", "59651-724-05" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "06/02/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 1 mg (NDC 59651-723-99)", "company_name": "Aurobindo Pharma USA", "status": "Current" }, { "discontinued_date": "09/04/2025", "update_type": "New", "initial_posting_date": "09/04/2025", "package_ndc": "0378-3458-23", "generic_name": "Azelastine Hydrochloride; Fluticasone Propionate Nasal Spray", "contact_info": "800-796-9526", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA202236" ], "brand_name": [ "AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE" ], "generic_name": [ "AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE" ], "manufacturer_name": [ "Mylan Pharmaceuticals Inc." ], "product_ndc": [ "0378-3458" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "NASAL" ], "substance_name": [ "AZELASTINE HYDROCHLORIDE", "FLUTICASONE PROPIONATE" ], "rxcui": [ "1797847" ], "spl_id": [ "6e1e173a-2d01-4e67-8361-dd30604bc8aa" ], "spl_set_id": [ "7b5cc5a0-0d47-46b5-b5fb-eb9cc248ae9e" ], "package_ndc": [ "0378-3458-23" ], "unii": [ "0L591QR10I", "O2GMZ0LF5W" ] }, "update_date": "09/04/2025", "therapeutic_category": [ "Pulmonary/Allergy" ], "dosage_form": "Nasal Spray", "presentation": "Azelastine Hydrochloride; Fluticasone Propionate, Nasal Spray, 137 ug; 50 ug (NDC 0378-3458-23)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "42858-162-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-827-0616", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA215330" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Rhodes Pharmaceuticals LLC" ], "product_ndc": [ "42858-162", "42858-161", "42858-163", "42858-164", "42858-165", "42858-166", "42858-167" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "0002e227-1109-4ecc-a8c5-4b4f11fac3cc" ], "spl_set_id": [ "d918b40d-a461-41bc-b6c0-83dc76c28e32" ], "package_ndc": [ "42858-161-01", "42858-162-01", "42858-163-01", "42858-164-01", "42858-165-01", "42858-166-01", "42858-167-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/24/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 42858-162-01)", "company_name": "Rhodes Pharmaceuticals L.P.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/13/2023", "package_ndc": "0703-3675-01", "generic_name": "Methotrexate Sodium Injection", "contact_info": "800-545-8800", "availability": "Unavailable", "related_info": "Estimated recovery: December 2026", "openfda": { "application_number": [ "ANDA040843" ], "brand_name": [ "METHOTREXATE" ], "generic_name": [ "METHOTREXATE" ], "manufacturer_name": [ "Teva Parenteral Medicines, Inc." ], "product_ndc": [ "0703-3675", "0703-3671", "0703-3678" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS" ], "substance_name": [ "METHOTREXATE SODIUM" ], "rxcui": [ "1655956", "1655959", "1655960" ], "spl_id": [ "e81074cc-12b4-4ac9-a5bb-749188989b2c" ], "spl_set_id": [ "346ec9ce-dc98-4a55-b55e-d3af11f2d703" ], "package_ndc": [ "0703-3671-01", "0703-3675-01", "0703-3678-01" ], "unii": [ "3IG1E710ZN" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Rheumatology", "Oncology" ], "dosage_form": "Injection", "presentation": "Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)", "company_name": "Teva Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3182-02", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Limited Availability", "related_info": "Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA089646" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3182", "0409-1209", "0409-3177", "0409-3178", "0409-3181", "0409-3183", "0409-0007", "0409-0147" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE", "EPINEPHRINE" ], "rxcui": [ "1010688", "1010745", "1010751", "1010759", "1867996", "1867998" ], "spl_id": [ "68a37af1-d237-4836-af13-1eec28245f8b" ], "spl_set_id": [ "2f94f711-14c4-48ec-c5a3-c5ec4b8e8729" ], "package_ndc": [ "0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10" ], "nui": [ "N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647" ], "pharm_class_moa": [ "Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]" ], "pharm_class_epc": [ "alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]" ], "pharm_class_cs": [ "Catecholamines [CS]" ], "unii": [ "YKH834O4BH", "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride and Epinephrine, Injection, 600 mg/30 mL (2%; 1:100,000) (NDC 0409-3182-02)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/24/2017", "package_ndc": "63323-083-05", "generic_name": "Sodium Bicarbonate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory.", "openfda": { "application_number": [ "ANDA206688" ], "brand_name": [ "SODIUM BICARBONATE" ], "generic_name": [ "SODIUM BICARBONATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-083", "63323-089" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM BICARBONATE" ], "rxcui": [ "1868469", "1868486" ], "spl_id": [ "9def795c-abcf-483c-8b1d-e4374666efb2" ], "spl_set_id": [ "0ab55004-bb63-436d-ad77-cd3796905370" ], "package_ndc": [ "63323-083-03", "63323-083-05", "63323-089-25", "63323-089-50" ], "unii": [ "8MDF5V39QO" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sodium Bicarbonate, Injection, 42 mg/1 mL (NDC 63323-083-05)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "discontinued_date": "06/08/2026", "update_type": "New", "initial_posting_date": "06/08/2026", "package_ndc": "0069-2299-30", "generic_name": "Dacomitinib Tablet", "contact_info": "800-533-4535", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA211288" ], "brand_name": [ "VIZIMPRO" ], "generic_name": [ "DACOMITINIB" ], "manufacturer_name": [ "Pfizer Laboratories Div Pfizer Inc" ], "product_ndc": [ "0069-2299", "0069-0197", "0069-1198" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DACOMITINIB" ], "rxcui": [ "2058915", "2058922", "2058924", "2058926", "2058930", "2058932" ], "spl_id": [ "3ffd0da1-5601-4ecc-a8fb-f484693cb4c5" ], "spl_set_id": [ "4ab27d2f-e385-4e9c-b324-fa69c10b855a" ], "package_ndc": [ "0069-0197-30", "0069-1198-30", "0069-2299-30" ], "unii": [ "5092U85G58" ] }, "update_date": "06/08/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Tablet", "presentation": "Vizimpro, Tablet, 45 mg (NDC 0069-2299-30)", "company_name": "Pfizer Inc.", "status": "To Be Discontinued" }, { "discontinued_date": "11/19/2025", "update_type": "New", "initial_posting_date": "11/19/2025", "package_ndc": "0378-5813-77", "generic_name": "Valsartan Tablet", "contact_info": "800-796-9526", "related_info": "A business decision was made to discontinue manufacture of the drug.", "openfda": { "application_number": [ "ANDA090866" ], "brand_name": [ "VALSARTAN" ], "generic_name": [ "VALSARTAN" ], "manufacturer_name": [ "Mylan Pharmaceuticals Inc." ], "product_ndc": [ "0378-5813", "0378-5807", "0378-5814", "0378-5815" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "VALSARTAN" ], "rxcui": [ "349199", "349200", "349201", "349483" ], "spl_id": [ "a5384d58-48c7-494a-a8a8-c296b316bd91" ], "spl_set_id": [ "73e01dc6-7dd4-421a-a4f6-137e75f69f9a" ], "package_ndc": [ "0378-5807-93", "0378-5813-77", "0378-5814-77", "0378-5815-77" ], "nui": [ "N0000000070", "N0000175561" ], "pharm_class_moa": [ "Angiotensin 2 Receptor Antagonists [MoA]" ], "pharm_class_epc": [ "Angiotensin 2 Receptor Blocker [EPC]" ], "unii": [ "80M03YXJ7I" ] }, "update_date": "11/19/2025", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Valsartan, Tablet, 80 mg (NDC 0378-5813-77)", "company_name": "Mylan Pharmaceuticals Inc., a Viatris Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "59417-120-01", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available", "openfda": { "application_number": [ "NDA208510" ], "brand_name": [ "VYVANSE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Takeda Pharmaceuticals America, Inc." ], "product_ndc": [ "59417-120", "59417-101", "59417-102", "59417-103", "59417-104", "59417-105", "59417-106", "59417-107", "59417-115", "59417-116", "59417-117", "59417-118", "59417-119" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854832", "854834", "854836", "854838", "854840", "854842", "854844", "854846", "854848", "854850", "854852", "1593856", "1593858", "1871456", "1871459", "1871460", "1871461", "1871462", "1871463", "1871464", "1871465", "1871466", "1871467", "1871468", "1871469" ], "spl_id": [ "81d087b6-4cb4-466a-9693-679edeb062e2" ], "spl_set_id": [ "704e4378-ca83-445c-8b45-3cfa51c1ecad" ], "package_ndc": [ "59417-101-10", "59417-102-10", "59417-103-10", "59417-104-10", "59417-105-10", "59417-106-10", "59417-107-10", "59417-115-01", "59417-116-01", "59417-117-01", "59417-118-01", "59417-119-01", "59417-120-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Vyvanse, Tablet, Chewable, 60 mg (NDC 59417-120-01)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "25021-821-05", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "866-625-1618", "availability": "Limited Availability", "related_info": "Estimated recovery: November 2026, Product on hand is 8-12 months of dating prior to expiry", "openfda": { "application_number": [ "ANDA201835" ], "brand_name": [ "METHYLPREDNISOLONE ACETATE" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-821", "25021-820" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "INTRASYNOVIAL", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1358610", "1358617" ], "spl_id": [ "f73618f0-0723-4d8b-8a8d-b9081acb44f9" ], "spl_set_id": [ "f98314ea-a4e4-4f78-987b-3e9b45a08bb4" ], "package_ndc": [ "25021-820-05", "25021-820-10", "25021-821-05" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 25021-821-05)", "company_name": "Sagent Pharmaceuticals", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/05/2022", "package_ndc": "0143-9311-10", "generic_name": "Etomidate Injection", "contact_info": "800-631-2174", "availability": "Available", "related_info": "Novaplus label", "openfda": { "application_number": [ "ANDA202354" ], "brand_name": [ "ETOMIDATE" ], "generic_name": [ "ETOMIDATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9311", "0143-9310" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008" ], "spl_id": [ "c15bd8c1-34e3-40f2-b31a-634136fe197c" ], "spl_set_id": [ "4312e3c3-34de-4cb3-8abd-c24d24a4bea1" ], "package_ndc": [ "0143-9310-01", "0143-9310-10", "0143-9311-01", "0143-9311-10" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/1 mL (NDC 0143-9311-10)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "05/03/2022", "package_ndc": "0409-3382-21", "generic_name": "Sufentanil Citrate Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: August 2026; Estimated Recovery: September 2026; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA074534" ], "brand_name": [ "SUFENTANIL CITRATE" ], "generic_name": [ "SUFENTANIL CITRATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3382" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRAVENOUS" ], "substance_name": [ "SUFENTANIL CITRATE" ], "rxcui": [ "1809097" ], "spl_id": [ "2f400934-519c-4d94-a8d5-bad870eaa1a6" ], "spl_set_id": [ "20293943-46ff-4345-1aa4-929b4e017a25" ], "package_ndc": [ "0409-3382-11", "0409-3382-21" ], "unii": [ "S9ZFX8403R" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sufentanil Citrate, Injection, 50 ug/1 mL (NDC 0409-3382-21)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0264-7510-20", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "NDA019626" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-7510", "0264-7520" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE, UNSPECIFIED FORM" ], "rxcui": [ "1795477", "1795480", "1795481", "1795607", "1795610", "1795612" ], "spl_id": [ "c9f87749-8dd5-41fd-b393-f63d45fd00ef" ], "spl_set_id": [ "085614c7-ada4-4e2c-87c0-c9bc2f18365a" ], "package_ndc": [ "0264-7510-00", "0264-7510-10", "0264-7510-20", "0264-7520-00", "0264-7520-10", "0264-7520-20" ], "unii": [ "IY9XDZ35W2" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose Monohydrate 5%, Injection, 5 g/100 mL (NDC 0264-7510-20)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "discontinued_date": "11/14/2025", "update_type": "New", "initial_posting_date": "11/14/2025", "package_ndc": "0409-5092-16", "generic_name": "Ceftazidime Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/14/2025", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Injection", "presentation": "Tazicef, Injection, 1 g (NDC 0409-5092-16)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/02/2020", "package_ndc": "23155-601-42", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "855-228-9470", "availability": "Available", "openfda": { "application_number": [ "ANDA090850" ], "brand_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc." ], "product_ndc": [ "23155-601" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "311702" ], "spl_id": [ "e20feff9-3aca-4bc1-a5c3-44fff8a9459c" ], "spl_set_id": [ "843cc25e-45ea-4372-ae34-843f805fa869" ], "package_ndc": [ "23155-601-31", "23155-601-41", "23155-601-32", "23155-601-42" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride, Injection, 5 mg/1 mL (NDC 23155-601-42)", "company_name": "Avet Pharmaceuticals, Inc.", "status": "Current" }, { "discontinued_date": "09/19/2025", "update_type": "New", "initial_posting_date": "09/19/2025", "package_ndc": "0228-2801-11", "generic_name": "Pilocarpine Hydrochloride Tablet", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": { "application_number": [ "NDA020237" ], "brand_name": [ "PILOCARPINE HYDROCHLORIDE" ], "generic_name": [ "PILOCARPINE HYDROCHLORIDE" ], "manufacturer_name": [ "Actavis Pharma, Inc." ], "product_ndc": [ "0228-2801", "0228-2837" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "PILOCARPINE HYDROCHLORIDE" ], "rxcui": [ "1000913", "1001004" ], "spl_id": [ "7db72b88-d664-4f26-901c-46c901b20d80" ], "spl_set_id": [ "610022b7-7dc9-405a-a580-104657f43bdf" ], "package_ndc": [ "0228-2801-11", "0228-2837-11" ], "unii": [ "0WW6D218XJ" ] }, "update_date": "09/19/2025", "therapeutic_category": [ "Other" ], "dosage_form": "Tablet", "presentation": "Salagen, Tablet, 5 mg (NDC 0228-2801-11)", "company_name": "Actavis Pharma, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-851-50", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA019034" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-851", "63323-852", "63323-853", "63323-854" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897653", "897753", "1724276", "1724338", "1724340", "1724341" ], "spl_id": [ "9e8522c6-595c-46f9-bb25-272aa4683e0f" ], "spl_set_id": [ "e034eb96-03e0-46e1-8b92-5e1f94555e7b" ], "package_ndc": [ "63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-50)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/08/2020", "package_ndc": "0264-1933-10", "generic_name": "Amino Acid Injection", "contact_info": "800-227-2862", "availability": "Available", "openfda": { "application_number": [ "NDA019018" ], "brand_name": [ "TROPHAMINE" ], "generic_name": [ "ISOLEUCINE, LEUCINE, LYSINE ACETATE, METHIONINE, PHENYLALANINE, THREONINE, TRYPTOPHAN, VALINE, CYSTEINE HYDROCHLORIDE, HISTIDINE, TYROSINE, N-ACETYL-TYROSINE, ALANINE, ARGININE, PROLINE, SERINE, GLYCINE, ASPARTIC ACID, GLUTAMIC ACID, AND TAURINE" ], "manufacturer_name": [ "B. Braun Medical Inc." ], "product_ndc": [ "0264-1933" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ISOLEUCINE", "LEUCINE", "LYSINE ACETATE", "METHIONINE", "PHENYLALANINE", "THREONINE", "TRYPTOPHAN", "VALINE", "CYSTEINE HYDROCHLORIDE", "HISTIDINE", "TYROSINE", "ACETYL L-TYROSINE", "ALANINE", "ARGININE", "PROLINE", "SERINE", "GLYCINE", "ASPARTIC ACID", "GLUTAMIC ACID", "TAURINE" ], "rxcui": [ "800611", "1189640" ], "spl_id": [ "07f53291-419d-4d14-ad81-26f00dc0c474" ], "spl_set_id": [ "cb6d23ff-3ec5-445a-acbe-f88fd57949bf" ], "package_ndc": [ "0264-1933-10" ], "nui": [ "N0000175780", "M0000922" ], "pharm_class_epc": [ "Amino Acid [EPC]" ], "pharm_class_cs": [ "Amino Acids [CS]" ], "unii": [ "04Y7590D77", "GMW67QNF9C", "TTL6G7LIWZ", "AE28F7PNPL", "47E5O17Y3R", "2ZD004190S", "8DUH1N11BX", "HG18B9YRS7", "ZT934N0X4W", "4QD397987E", "42HK56048U", "DA8G610ZO5", "OF5P57N2ZX", "94ZLA3W45F", "9DLQ4CIU6V", "452VLY9402", "TE7660XO1C", "30KYC7MIAI", "3KX376GY7L", "1EQV5MLY3D" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Gastroenterology" ], "dosage_form": "Injection", "presentation": "TrophAmine 10%, Injection, 0.1 (NDC 0264-1933-10)", "company_name": "B. Braun Medical Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "44567-601-04", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "WG Critical Care 888-493-0861", "availability": "Available", "related_info": "Marketed by WG Critical Care", "openfda": { "application_number": [ "NDA206628" ], "brand_name": [ "DEXMEDETOMIDINE" ], "generic_name": [ "DEXMEDETOMIDINE" ], "manufacturer_name": [ "WG Critical Care, LLC" ], "product_ndc": [ "44567-601", "44567-600", "44567-602", "44567-603" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909", "1788947" ], "spl_id": [ "42a0bb50-be84-4c46-abfd-fd44c6f10087" ], "spl_set_id": [ "0d2710f2-ee47-4114-ab5c-8dca74cdcb8d" ], "package_ndc": [ "44567-600-04", "44567-601-04", "44567-602-24", "44567-603-24" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 100 ug/1 mL (NDC 44567-601-04)", "company_name": "HQ Specialty Pharma", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "71288-728-32", "generic_name": "Bupivacaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-824-8426", "availability": "Limited Availability", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "update_date": "05/05/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 7.5 mg/1 mL (NDC 71288-728-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/13/2023", "package_ndc": "0143-9830-01", "generic_name": "Methotrexate Sodium Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Additional lots will be available in the September 2026 timeframe. Product will be made available as it is released.", "openfda": { "application_number": [ "ANDA040632" ], "brand_name": [ "METHOTREXATE" ], "generic_name": [ "METHOTREXATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0143-9830" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTERIAL", "INTRAMUSCULAR", "INTRATHECAL", "INTRAVENOUS" ], "substance_name": [ "METHOTREXATE" ], "rxcui": [ "311625" ], "spl_id": [ "49eb25b2-c59c-4374-a216-076767fe1126" ], "spl_set_id": [ "b080eb92-fc72-4ce6-a7ab-3f9ce2415526" ], "package_ndc": [ "0143-9830-01" ], "nui": [ "N0000175584", "N0000000111" ], "pharm_class_epc": [ "Folate Analog Metabolic Inhibitor [EPC]" ], "pharm_class_moa": [ "Folic Acid Metabolism Inhibitors [MoA]" ], "unii": [ "YL5FZ2Y5U1" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Rheumatology", "Oncology" ], "dosage_form": "Injection", "presentation": "Methotrexate, Preservative Free, Injection, 1 g (NDC 0143-9830-01)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "12/22/2025", "update_type": "New", "initial_posting_date": "12/22/2025", "package_ndc": "0832-0274-11", "generic_name": "Morphine Sulfate Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA210610" ], "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Upsher-Smith Laboratories, LLC" ], "product_ndc": [ "0832-0274", "0832-0273" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "892582", "892672" ], "spl_id": [ "46a682fc-0430-5a66-e063-6294a90a6179" ], "spl_set_id": [ "5ceb3205-2f8d-4ba3-9f27-dc328bab4fa1" ], "package_ndc": [ "0832-0273-11", "0832-0274-11" ], "unii": [ "X3P646A2J0" ] }, "update_date": "12/22/2025", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Tablet", "presentation": "Morphine Sulfate, Tablet, 30 mg (NDC 0832-0274-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued" }, { "discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "25021-311-10", "generic_name": "Furosemide Injection", "contact_info": "866-625-1618", "related_info": "Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA213902" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-311" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "222ce48f-2856-4be2-b16f-6fca38c0dceb" ], "spl_set_id": [ "d63c1277-dd7e-4d21-9e80-68143f55e2dc" ], "package_ndc": [ "25021-311-02", "25021-311-04", "25021-311-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "04/28/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-10)", "company_name": "Gland Pharma Limited", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "71288-725-32", "generic_name": "Bupivacaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Bupivacaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-824-8426", "availability": "Limited Availability", "related_info": "Meitheal Pharmaceuticals is distributor/labeler", "update_date": "05/05/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 71288-725-32)", "company_name": "Kindos Pharmaceuticals Co. Ltd.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-7838-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA021038" ], "brand_name": [ "PRECEDEX" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-7838", "0409-1660", "0409-1638", "0409-1434", "0409-1596", "0409-7853", "0409-7875" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892" ], "spl_id": [ "3c5274fd-6597-4b88-babc-92e4e16c6329" ], "spl_set_id": [ "548a88c0-afda-427e-75ac-5af0cfa2224c" ], "package_ndc": [ "0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Precedex, Injection, 200 mcg/50 mL (NDC 0409-7838-24)", "company_name": "Pfizer Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1752-50", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA016964" ], "brand_name": [ "MARCAINE WITH EPINEPHRINE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1752", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1746", "0409-1749", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614" ], "spl_id": [ "7040888c-2cde-4408-af99-d249985f8444" ], "spl_set_id": [ "67578b56-7540-487e-1fba-481255620e78" ], "package_ndc": [ "0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "13811-708-10", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "800-541-4802", "availability": "Limited Availability", "related_info": "Allocation to current contracted customers", "openfda": { "application_number": [ "ANDA205327" ], "brand_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Trigen Laboratories, LLC" ], "product_ndc": [ "13811-708", "13811-709", "13811-706", "13811-707", "13811-710" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "1091155", "1091170", "1091185", "1091210", "1995461" ], "spl_id": [ "0944cf70-d59a-483b-9698-e96ef955a65a" ], "spl_set_id": [ "c45dc1de-adfa-4b3c-a7dc-cffbc8eac74f" ], "package_ndc": [ "13811-709-10", "13811-706-10", "13811-707-10", "13811-708-10", "13811-710-10", "13811-710-30" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10)", "company_name": "Trigen Laboratories, LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "03/25/2026", "update_type": "New", "initial_posting_date": "03/25/2026", "package_ndc": "13668-356-01", "generic_name": "Nebivolol Hydrochloride Tablet", "contact_info": "908-280-3333", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "03/25/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Nebivolol Hydrochloride, Tablet, 20 mg (NDC 13668-356-01)", "company_name": "Torrent Pharmaceuticals Limited", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "55150-322-25", "generic_name": "Furosemide Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA212174" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-322", "55150-323", "55150-324" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "9bb2ffa4-0891-4197-a970-90b178bbfad9" ], "spl_set_id": [ "421aa6d5-623b-4dc2-abd5-bb9e7765bf37" ], "package_ndc": [ "55150-322-01", "55150-322-25", "55150-323-01", "55150-323-25", "55150-324-01", "55150-324-25" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 20 mg/2 mL (NDC 55150-322-25)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/20/2018", "package_ndc": "0409-1749-29", "generic_name": "Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA016964" ], "brand_name": [ "MARCAINE WITH EPINEPHRINE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1749", "0409-1559", "0409-1560", "0409-1582", "0409-1587", "0409-1610", "0409-1746", "0409-1752", "0409-1755", "0409-2510", "0409-7535", "0409-1250", "0409-5010", "0409-1530", "0409-0525", "0409-7510", "0409-2253" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1012377", "1012381", "1012384", "1012388", "1012396", "1012400", "1012404", "1012406", "1672917", "1672919", "1673242", "1673243", "1724786", "1724787", "1724794", "1724796", "1724880", "1724884", "1725044", "1725046", "1725078", "1725079", "1725082", "1725083", "1867594", "1867596", "1867612", "1867614" ], "spl_id": [ "7040888c-2cde-4408-af99-d249985f8444" ], "spl_set_id": [ "67578b56-7540-487e-1fba-481255620e78" ], "package_ndc": [ "0409-1559-18", "0409-1559-10", "0409-1559-19", "0409-1559-30", "0409-1560-18", "0409-1560-10", "0409-1560-19", "0409-1560-29", "0409-1582-18", "0409-1582-10", "0409-1582-19", "0409-1582-29", "0409-1587-50", "0409-1610-50", "0409-1746-70", "0409-1746-10", "0409-1746-71", "0409-1746-30", "0409-1749-70", "0409-1749-10", "0409-1749-71", "0409-1749-29", "0409-1752-50", "0409-1755-50", "0409-2510-01", "0409-2510-25", "0409-7535-01", "0409-7535-25", "0409-1250-01", "0409-1250-25", "0409-5010-01", "0409-5010-25", "0409-1530-01", "0409-1530-25", "0409-0525-01", "0409-0525-25", "0409-7510-01", "0409-7510-25", "0409-2253-01", "0409-2253-25" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29)", "company_name": "Hospira, Inc., a Pfizer Company", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0406-8891-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "800-325-8888", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA040440" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE AND AMPHETAMINE ASPARTATE AND DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "SpecGx LLC" ], "product_ndc": [ "0406-8891", "0406-8884", "0406-8892", "0406-8885", "0406-8893", "0406-8894" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "1009145" ], "spl_id": [ "0d3fb5ba-ff79-4862-bc1d-45b8343e115b" ], "spl_set_id": [ "72ddd1c9-ddbd-4c95-acd9-003189a353a3" ], "package_ndc": [ "0406-8891-01", "0406-8884-01", "0406-8892-01", "0406-8885-01", "0406-8893-01", "0406-8894-01" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.25 mg; 1.25 mg; 1.25 mg; 1.25 mg (NDC 0406-8891-01)", "company_name": "SpecGx LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "06/01/2026", "update_type": "New", "initial_posting_date": "06/01/2026", "package_ndc": "60505-6282-7", "generic_name": "Carboplatin Injection", "contact_info": "Apotex Inc.: 800-706-5575", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA077861" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Apotex Corp." ], "product_ndc": [ "60505-6282" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "0e68e276-b0df-4f03-e063-6394a90a22b9" ], "spl_set_id": [ "1c275825-0275-4c73-b650-e4c1519f13b8" ], "package_ndc": [ "60505-6282-1", "60505-6282-3", "60505-6282-6", "60505-6282-7" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 600 mg/60 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-7)", "company_name": "Teyro Labs", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "12/15/2021", "package_ndc": "55150-314-01", "generic_name": "Methylprednisolone Acetate Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: TBD. Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA211930" ], "brand_name": [ "METHYLPREDNISOLONE ACETATE" ], "generic_name": [ "METHYLPREDNISOLONE ACETATE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-314", "55150-313" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRA-ARTICULAR", "INTRALESIONAL", "INTRAMUSCULAR", "SOFT TISSUE" ], "substance_name": [ "METHYLPREDNISOLONE ACETATE" ], "rxcui": [ "1358610", "1358617" ], "spl_id": [ "25c5133c-ee17-4be0-88a3-d0231e38f5a0" ], "spl_set_id": [ "a0cbcdb5-f657-49f7-8f86-cc5959d69db0" ], "package_ndc": [ "55150-313-25", "55150-313-01", "55150-314-25", "55150-314-01" ], "unii": [ "43502P7F0P" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Methylprednisolone Acetate, Injection, 80 mg/1 mL (NDC 55150-314-01)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "63323-580-20", "generic_name": "Atropine Sulfate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA209260" ], "brand_name": [ "ATROPINE SULFATE" ], "generic_name": [ "ATROPINE SULFATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-580" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ENDOTRACHEAL", "INTRAMEDULLARY", "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "ATROPINE SULFATE" ], "rxcui": [ "1190776" ], "spl_id": [ "8039a2a4-4c0a-4062-9ca5-78137ba74082" ], "spl_set_id": [ "310c8a74-ea24-4357-8099-81e394b1634e" ], "package_ndc": [ "63323-580-20" ], "unii": [ "03J5ZE7KA5" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .4 mg/1 mL (NDC 63323-580-20)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "presentation": "Heparin Sodium, Injection, 1,000 Units/500 mL (2 Units/mL) (NDC 0409-7620-03)", "update_type": "Reverified", "initial_posting_date": "11/14/2017", "package_ndc": "0409-7620-03", "generic_name": "Heparin Sodium Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "08/07/2026", "therapeutic_category": [ "Hematology" ], "status": "Current", "dosage_form": "Injection" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "54288-164-01", "generic_name": "Carboplatin Injection", "contact_info": "Distributed by BPI Labs, LLC; Customer service number: (727) 471-0850 Ext 270", "availability": "Unavailable", "related_info": "Discontinued; Distributed by BPI Labs, LLC", "openfda": { "application_number": [ "ANDA207324" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "BPI Labs LLC" ], "product_ndc": [ "54288-164", "54288-165", "54288-166", "54288-167" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "c0a7463c-d90f-4060-a54e-6a4888e8af0e" ], "spl_set_id": [ "5484d2f0-0cc2-4bba-8f26-c7f6539a9606" ], "package_ndc": [ "54288-165-01", "54288-166-01", "54288-167-01", "54288-164-01" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 50mg/5mL (NDC 54288-164-01)", "company_name": "Gland Pharma Limited", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/07/2020", "package_ndc": "63323-280-10", "generic_name": "Furosemide Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA018902" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-280" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "9804efac-5457-417a-8de7-a688467759c0", "64b3fb5f-3516-4e39-b74e-e0e402ed9c4d" ], "spl_set_id": [ "3747bbcd-783d-4baa-bb5b-b6827bf390e3", "c794c95a-654e-48fe-9596-201fc122ff75" ], "package_ndc": [ "63323-280-41", "63323-280-16", "63323-280-43", "63323-280-26", "63323-280-45", "63323-280-36", "63323-280-01", "63323-280-02", "63323-280-03", "63323-280-04", "63323-280-05", "63323-280-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 63323-280-10)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "43066-555-24", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "ANDA208532" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "43066-555", "43066-557" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909" ], "spl_id": [ "d0910ea1-c3e1-44f8-b8b5-1f39ffd43290" ], "spl_set_id": [ "aea9a3ad-c244-42be-9cd3-5df83fe2b522" ], "package_ndc": [ "43066-555-24", "43066-557-12" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 200 ug/50 mL (NDC 43066-555-24)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/19/2023", "package_ndc": "65862-618-90", "generic_name": "Quinapril Hydrochloride Tablet", "contact_info": "866-850-2876", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA202725" ], "brand_name": [ "QUINAPRIL" ], "generic_name": [ "QUINAPRIL HYDROCHLORIDE" ], "manufacturer_name": [ "Aurobindo Pharma Limited" ], "product_ndc": [ "65862-618", "65862-617", "65862-619", "65862-620" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "QUINAPRIL HYDROCHLORIDE" ], "rxcui": [ "312748", "312749", "312750", "314203" ], "spl_id": [ "5263abd5-ce46-4918-9bb0-9632861bcbc9" ], "spl_set_id": [ "93e6e668-5306-4f26-81d8-cbc3a7a5e787" ], "package_ndc": [ "65862-617-30", "65862-617-90", "65862-617-99", "65862-617-55", "65862-617-10", "65862-617-78", "65862-618-30", "65862-618-90", "65862-618-99", "65862-618-55", "65862-618-10", "65862-618-78", "65862-619-30", "65862-619-90", "65862-619-99", "65862-619-19", "65862-619-10", "65862-619-78", "65862-620-30", "65862-620-90", "65862-620-99", "65862-620-39", "65862-620-10", "65862-620-78" ], "unii": [ "33067B3N2M" ] }, "update_date": "06/02/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Tablet", "presentation": "Quinapril Hydrochloride, Tablet, 10 mg (NDC 65862-618-90)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "discontinued_date": "07/24/2026", "update_type": "New", "initial_posting_date": "07/24/2026", "package_ndc": "0074-3399-30", "generic_name": "Ritonavir Oral Powder", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA209512" ], "brand_name": [ "NORVIR" ], "generic_name": [ "RITONAVIR" ], "manufacturer_name": [ "AbbVie Inc." ], "product_ndc": [ "0074-3399", "0074-3333", "0074-1940", "0074-2340" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RITONAVIR" ], "rxcui": [ "152971", "199249", "900575", "900577", "1926066", "1926069" ], "spl_id": [ "08f28b14-eabc-4a9a-b066-d8eda837e9e4" ], "spl_set_id": [ "2849298e-de6e-47bb-8194-56e075b33fc3" ], "package_ndc": [ "0074-3333-30", "0074-1940-63", "0074-3399-30", "0074-2340-30" ], "nui": [ "N0000000246", "N0000191001", "N0000175889", "N0000190114", "N0000182137", "N0000185607", "N0000190118", "N0000185503", "N0000190113", "N0000182141", "N0000191266", "N0000185507", "N0000187064", "N0000190117" ], "pharm_class_moa": [ "HIV Protease Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 2C19 Inducers [MoA]", "Cytochrome P450 3A Inducers [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Breast Cancer Resistance Protein Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "Cytochrome P450 1A2 Inducers [MoA]", "Cytochrome P450 2C9 Inducers [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "UDP Glucuronosyltransferases Inducers [MoA]" ], "pharm_class_epc": [ "Cytochrome P450 3A Inhibitor [EPC]", "Protease Inhibitor [EPC]" ], "unii": [ "O3J8G9O825" ] }, "update_date": "07/24/2026", "therapeutic_category": [ "Antiviral" ], "dosage_form": "Oral Powder", "presentation": "Norvir, Oral Powder, 100 mg (NDC 0074-3399-30)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-051-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA214484" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "57664-051", "57664-047", "57664-046", "57664-048", "57664-049", "57664-050", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "560b4c9e-9cce-4717-e063-6294a90a58c9" ], "spl_set_id": [ "da3148af-f9b6-4725-adae-3595b4c7dc4b" ], "package_ndc": [ "57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 60 mg (NDC 57664-051-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/03/2023", "package_ndc": "81665-104-96", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or customerservice@omniviumpharma.com", "availability": "Available", "related_info": "Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195", "openfda": { "application_number": [ "ANDA209264" ], "brand_name": [ "CROMOLYN SODIUM" ], "generic_name": [ "CROMOLYN SODIUM" ], "manufacturer_name": [ "Omnivium Pharmaceuticals LLC" ], "product_ndc": [ "81665-104" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CROMOLYN SODIUM" ], "rxcui": [ "831261" ], "spl_id": [ "fd09b0f1-907c-4d4d-a693-9756efd60f20" ], "spl_set_id": [ "a742664b-265e-49f9-9744-d04e1fb620ae" ], "package_ndc": [ "81665-104-96" ], "unii": [ "Q2WXR1I0PK" ] }, "update_date": "07/17/2026", "therapeutic_category": [ "Pulmonary/Allergy" ], "dosage_form": "Concentrate", "presentation": "Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 81665-104-96)", "company_name": "Ailex Pharmaceuticals", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/22/2012", "package_ndc": "0409-3182-01", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay", "openfda": { "application_number": [ "ANDA089646" ], "brand_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-3182", "0409-1209", "0409-3177", "0409-3178", "0409-3181", "0409-3183", "0409-0007", "0409-0147" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE", "EPINEPHRINE" ], "rxcui": [ "1010688", "1010745", "1010751", "1010759", "1867996", "1867998" ], "spl_id": [ "68a37af1-d237-4836-af13-1eec28245f8b" ], "spl_set_id": [ "2f94f711-14c4-48ec-c5a3-c5ec4b8e8729" ], "package_ndc": [ "0409-1209-10", "0409-1209-01", "0409-1209-05", "0409-1209-70", "0409-1209-65", "0409-3177-16", "0409-3177-01", "0409-3178-16", "0409-3178-01", "0409-3178-17", "0409-3178-02", "0409-3178-18", "0409-3178-03", "0409-3181-11", "0409-3181-01", "0409-3182-11", "0409-3182-01", "0409-3182-21", "0409-3182-02", "0409-3182-31", "0409-3182-03", "0409-3183-11", "0409-3183-01", "0409-0007-01", "0409-0007-10", "0409-0147-01", "0409-0147-10" ], "nui": [ "N0000000209", "N0000000245", "N0000175552", "N0000175555", "N0000175570", "M0003647" ], "pharm_class_moa": [ "Adrenergic alpha-Agonists [MoA]", "Adrenergic beta-Agonists [MoA]" ], "pharm_class_epc": [ "alpha-Adrenergic Agonist [EPC]", "beta-Adrenergic Agonist [EPC]", "Catecholamine [EPC]" ], "pharm_class_cs": [ "Catecholamines [CS]" ], "unii": [ "YKH834O4BH", "V13007Z41A" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride And Epinephrine, Injection, 400 mg/20 mL (2%; 1:100,000) (NDC 0409-3182-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-408-50", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": { "application_number": [ "ANDA077856" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Solco Healthcare LLC" ], "product_ndc": [ "43547-408", "43547-406", "43547-407" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "dc17b9d4-2890-4f6c-8476-daa39d0cbc9c" ], "spl_set_id": [ "4acbb7a9-4db5-4497-b8db-9f358b3f6fb4" ], "package_ndc": [ "43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "07/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 43547-408-50)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current" }, { "discontinued_date": "11/07/2025", "update_type": "New", "initial_posting_date": "11/07/2025", "package_ndc": "0409-4910-34", "generic_name": "Atropine Sulfate Injection", "contact_info": "844-646-4398", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "11/07/2025", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, (Adult) 0.5 mg/5 mL (0.1 mg/mL) LifeShield® ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4910-34)\"", "company_name": "Hospira, Inc., a Pfizer Company", "status": "To Be Discontinued" }, { "discontinued_date": "10/27/2025", "update_type": "New", "initial_posting_date": "10/27/2025", "package_ndc": "0310-6615-02", "generic_name": "Pramlintide Acetate Injection", "contact_info": "800-236-9933", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": { "application_number": [ "NDA021332" ], "brand_name": [ "SYMLINPEN" ], "generic_name": [ "PRAMLINTIDE ACETATE" ], "manufacturer_name": [ "AstraZeneca Pharmaceuticals LP" ], "product_ndc": [ "0310-6615", "0310-6627" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "PRAMLINTIDE ACETATE" ], "rxcui": [ "861042", "861043", "861044", "861045" ], "spl_id": [ "a84753f1-6ac5-4a47-a382-29972938ccaa" ], "spl_set_id": [ "4aea30ff-eb0d-45c1-b114-3127966328ff" ], "package_ndc": [ "0310-6615-02", "0310-6627-02" ], "unii": [ "726I6TE06G" ] }, "update_date": "10/27/2025", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Injection", "presentation": "SymlinPen® 60 , Injection, 1000 ug/1 mL (NDC 0310-6615-02)", "company_name": "AstraZeneca AB", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "62332-599-25", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "908-393-9604", "availability": "Available", "openfda": { "application_number": [ "ANDA214456" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Alembic Pharmaceuticals Inc." ], "product_ndc": [ "62332-599", "62332-600", "62332-601" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "9030f496-5021-4454-ac16-dbb376315608" ], "spl_set_id": [ "419cf756-3c96-4bb8-ae96-6aea5a5f3afd" ], "package_ndc": [ "62332-599-01", "62332-599-25", "62332-600-01", "62332-600-25", "62332-601-02", "62332-601-25" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "05/15/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 15 mg/1 mL (NDC 62332-599-25)", "company_name": "Alembic Pharmaceuticals", "status": "Current" }, { "discontinued_date": "06/01/2026", "update_type": "New", "initial_posting_date": "06/01/2026", "package_ndc": "60505-6282-6", "generic_name": "Carboplatin Injection", "contact_info": "Apotex Inc.: 800-706-5575", "related_info": "Wholesaler & Distributor through Marketing partner (Apotex Inc.); Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA077861" ], "brand_name": [ "CARBOPLATIN" ], "generic_name": [ "CARBOPLATIN" ], "manufacturer_name": [ "Apotex Corp." ], "product_ndc": [ "60505-6282" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "CARBOPLATIN" ], "rxcui": [ "597195" ], "spl_id": [ "0e68e276-b0df-4f03-e063-6394a90a22b9" ], "spl_set_id": [ "1c275825-0275-4c73-b650-e4c1519f13b8" ], "package_ndc": [ "60505-6282-1", "60505-6282-3", "60505-6282-6", "60505-6282-7" ], "nui": [ "N0000175413", "N0000175073" ], "pharm_class_epc": [ "Platinum-based Drug [EPC]" ], "unii": [ "BG3F62OND5" ] }, "update_date": "06/01/2026", "therapeutic_category": [ "Oncology" ], "dosage_form": "Injection", "presentation": "Carboplatin, Injection, 450 mg/45 mL (10 mg/mL) Multiple Dose Vial (NDC 60505-6282-6)", "company_name": "Teyro Labs", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "63323-806-01", "generic_name": "Fentanyl Citrate Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA210762" ], "brand_name": [ "FENTANYL CITRATE" ], "generic_name": [ "FENTANYL CITRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-806" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FENTANYL CITRATE" ], "rxcui": [ "1735003", "1735007", "1735008", "1735013", "2168270" ], "spl_id": [ "341b092a-1f6f-40f1-98f2-9346bf2e1242" ], "spl_set_id": [ "38d0c14a-a0c1-44cc-a939-0304eb8037d6" ], "package_ndc": [ "63323-806-11", "63323-806-01", "63323-806-12", "63323-806-02", "63323-806-13", "63323-806-05", "63323-806-14", "63323-806-20", "63323-806-50" ], "unii": [ "MUN5LYG46H" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Fentanyl Citrate Preservative Free, Injection, .05 mg/1 mL (NDC 63323-806-01)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/03/2023", "package_ndc": "69784-200-96", "generic_name": "Cromolyn Sodium Concentrate", "contact_info": "Distributed by Omnivium Pharmaceuticals LLC (888) 807-9195 or customerservice@omniviumpharma.com", "availability": "Limited Availability", "related_info": "No longer manufactured, some supplies still available in supply chain. Distributed by Woodward Pharma Services LLC (248) 308-1120 Ext 2", "update_date": "07/17/2026", "therapeutic_category": [ "Pulmonary/Allergy" ], "dosage_form": "Concentrate", "presentation": "Cromolyn Sodium, Concentrate, 100 mg/5 mL (NDC 69784-200-96)", "company_name": "Ailex Pharmaceuticals", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "07/23/2026", "update_type": "New", "initial_posting_date": "07/23/2026", "package_ndc": "0574-7114-12", "generic_name": "Morphine Sulfate Suppository", "contact_info": "(800) 775-2054", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "brand_name": [ "MORPHINE SULFATE" ], "generic_name": [ "MORPHINE SULFATE" ], "manufacturer_name": [ "Padagis US LLC" ], "product_ndc": [ "0574-7114", "0574-7110", "0574-7112", "0574-7116" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "RECTAL" ], "substance_name": [ "MORPHINE SULFATE" ], "rxcui": [ "892516", "892603", "892678", "894807" ], "spl_id": [ "fa18ac09-a625-47aa-8cde-7051dc4d0c49" ], "spl_set_id": [ "649d731b-962a-45df-b043-7e0781e8a530" ], "package_ndc": [ "0574-7110-12", "0574-7112-12", "0574-7114-12", "0574-7116-12" ], "unii": [ "X3P646A2J0" ] }, "update_date": "07/23/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Suppository", "presentation": "Morphine Sulfate, Suppository, 20 mg (NDC 0574-7114-12)", "company_name": "Padagis US LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-799-01", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA064150" ], "brand_name": [ "RIFAMPIN" ], "generic_name": [ "RIFAMPIN" ], "manufacturer_name": [ "EPIC PHARMA, LLC" ], "product_ndc": [ "42806-799", "42806-801" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RIFAMPIN" ], "rxcui": [ "198201", "198202" ], "spl_id": [ "a4ac02e8-68ac-4e79-8ca5-0939dd002c87" ], "spl_set_id": [ "0391f1e1-70d4-4b15-8b58-055bb6a385b8" ], "package_ndc": [ "42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05" ], "nui": [ "N0000175500", "M0019113" ], "pharm_class_epc": [ "Rifamycin Antibacterial [EPC]" ], "pharm_class_cs": [ "Rifamycins [CS]" ], "unii": [ "VJT6J7R4TR" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 300 mg (NDC 42806-799-01)", "company_name": "Epic Pharma, LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4903-34", "generic_name": "Lidocaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lidocaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 100 mg/5mL (2%, 20 mg/1 mL) Syringes (NDC 0409-4903-34)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "02/17/2015", "package_ndc": "21586-011-02", "generic_name": "Cefotaxime Sodium Powder, for Solution", "related_info_link": "https://www.fda.gov/media/193116/download?attachment", "contact_info": "800-881-3550", "availability": "Available", "openfda": { "brand_name": [ "CEFOTAXIME" ], "generic_name": [ "CEFOTAXIME INJECTION" ], "manufacturer_name": [ "SteriMax Inc." ], "product_ndc": [ "21586-011", "21586-012" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "CEFOTAXIME SODIUM" ], "rxcui": [ "1656313", "1656318" ], "spl_id": [ "7a77a18a-3d8c-4bac-8d21-54a88db396f6" ], "spl_set_id": [ "8efe3bd0-c43a-2bd6-e053-2a95a90a92fa" ], "package_ndc": [ "21586-011-01", "21586-011-02", "21586-012-01", "21586-012-02" ], "unii": [ "258J72S7TZ" ] }, "update_date": "06/15/2026", "therapeutic_category": [ "Anti-Infective", "Pediatric" ], "dosage_form": "Powder, For Solution", "presentation": "Cefotaxime Sodium, Powder, for Solution, 1 g (NDC 21586-011-02)", "company_name": "SteriMax, Inc.", "status": "Current" }, { "discontinued_date": "04/28/2026", "update_type": "New", "initial_posting_date": "04/28/2026", "package_ndc": "25021-311-04", "generic_name": "Furosemide Injection", "contact_info": "Sagent Pharmaceuticals: 866-625-1618", "related_info": "Distributed by Sagent Pharmaceuticals; Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA213902" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-311" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "222ce48f-2856-4be2-b16f-6fca38c0dceb" ], "spl_set_id": [ "d63c1277-dd7e-4d21-9e80-68143f55e2dc" ], "package_ndc": [ "25021-311-02", "25021-311-04", "25021-311-10" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "04/28/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 25021-311-04)", "company_name": "Gland Pharma Limited", "status": "To Be Discontinued" }, { "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 0527-1502-37)", "update_type": "Revised", "initial_posting_date": "10/12/2022", "package_ndc": "0527-1502-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "company_name": "Lannett Company, Inc.", "contact_info": "844-834-0530", "availability": "Available", "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "status": "Current", "dosage_form": "Tablet" }, { "discontinued_date": "03/24/2026", "update_type": "New", "initial_posting_date": "03/24/2026", "package_ndc": "0074-7098-04", "generic_name": "Pilocarpine Hydrochloride Ophthalmic Solution", "contact_info": "800-633-9110", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA214028" ], "brand_name": [ "VUITY" ], "generic_name": [ "PILOCARPINE HYDROCHLORIDE" ], "manufacturer_name": [ "AbbVie Inc." ], "product_ndc": [ "0074-7098" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "OPHTHALMIC" ], "substance_name": [ "PILOCARPINE HYDROCHLORIDE" ], "rxcui": [ "2584552", "2584557" ], "spl_id": [ "ed4cf150-c4b6-4d26-9326-e3a3490de489" ], "spl_set_id": [ "8d806897-8a2a-4518-8c68-0ec3b778de50" ], "package_ndc": [ "0074-7098-02", "0074-7098-01", "0074-7098-03", "0074-7098-04", "0074-7098-05", "0074-7098-06" ], "unii": [ "0WW6D218XJ" ] }, "update_date": "03/24/2026", "therapeutic_category": [ "Ophthalmology" ], "dosage_form": "Ophthalmic Solution", "presentation": "Vuity, Ophthalmic Solution, 12.5 mg/1 mL (NDC 0074-7098-04)", "company_name": "AbbVie Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2020", "package_ndc": "16729-484-90", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA212868" ], "brand_name": [ "ATROPINE SULFATE" ], "generic_name": [ "ATROPINE SULFATE" ], "manufacturer_name": [ "Accord Healthcare, Inc.," ], "product_ndc": [ "16729-484", "16729-483" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ATROPINE SULFATE" ], "rxcui": [ "1190546", "1190551", "1190552" ], "spl_id": [ "4082a1cf-1e1b-6f40-e063-6294a90aec06" ], "spl_set_id": [ "c82cb295-ffce-47d6-97ad-a8aa723f4e4f" ], "package_ndc": [ "16729-483-03", "16729-483-31", "16729-484-90", "16729-484-31", "16729-484-45", "16729-484-03" ], "unii": [ "03J5ZE7KA5" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, .1 mg/1 mL (NDC 16729-484-90)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "63323-495-27", "generic_name": "Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE MPF" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-495", "63323-492", "63323-491", "63323-485", "63323-486", "63323-484", "63323-489", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428", "0ff12fe1-0ad7-4ae0-83bf-30f11e3adb33" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17", "4dd52202-8eef-4136-92dd-ada573b7cf74" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31", "63323-492-41", "63323-492-16", "63323-492-43", "63323-492-36", "63323-492-45", "63323-492-26", "63323-485-41", "63323-485-26", "63323-486-41", "63323-486-26", "63323-482-41", "63323-482-26", "63323-495-41", "63323-495-26" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, 20 mg/1 mL (NDC 63323-495-27)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/10/2023", "package_ndc": "43547-408-10", "generic_name": "Clonazepam Tablet", "contact_info": "For orders, Solco Healthcare 866-931-9829", "availability": "Available", "related_info": "Marketed by Solco Healthcare", "openfda": { "application_number": [ "ANDA077856" ], "brand_name": [ "CLONAZEPAM" ], "generic_name": [ "CLONAZEPAM" ], "manufacturer_name": [ "Solco Healthcare LLC" ], "product_ndc": [ "43547-408", "43547-406", "43547-407" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CLONAZEPAM" ], "rxcui": [ "197527", "197528", "197529" ], "spl_id": [ "dc17b9d4-2890-4f6c-8476-daa39d0cbc9c" ], "spl_set_id": [ "4acbb7a9-4db5-4497-b8db-9f358b3f6fb4" ], "package_ndc": [ "43547-406-10", "43547-406-50", "43547-406-11", "43547-407-10", "43547-407-50", "43547-407-11", "43547-408-10", "43547-408-50" ], "nui": [ "N0000175694", "M0002356" ], "pharm_class_epc": [ "Benzodiazepine [EPC]" ], "pharm_class_cs": [ "Benzodiazepines [CS]" ], "unii": [ "5PE9FDE8GB" ] }, "update_date": "07/01/2026", "therapeutic_category": [ "Neurology", "Pediatric", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Clonazepam, Tablet, 2 mg (NDC 43547-408-10)", "company_name": "Prinston Pharmaceutical, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "25021-701-02", "generic_name": "Ketorolac Tromethamine Injection", "contact_info": "833-291-9645", "availability": "Available", "openfda": { "application_number": [ "ANDA204216" ], "brand_name": [ "KETOROLAC TROMETHAMINE" ], "generic_name": [ "KETOROLAC TROMETHAMINE" ], "manufacturer_name": [ "Sagent Pharmaceuticals" ], "product_ndc": [ "25021-701", "25021-700" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "KETOROLAC TROMETHAMINE" ], "rxcui": [ "860092", "1665459", "1665461" ], "spl_id": [ "cb23332a-48fa-458b-93ab-c4eef189a051" ], "spl_set_id": [ "62591551-a644-4b2c-a0de-982e906fabc3" ], "package_ndc": [ "25021-700-01", "25021-701-01", "25021-701-02" ], "unii": [ "4EVE5946BQ" ] }, "update_date": "07/22/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Ketorolac Tromethamine, Injection, 30 mg/1 mL (NDC 25021-701-02)", "company_name": "Gland Pharma Limited", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-489-17", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE MPF" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-489", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-488", "63323-481", "63323-483", "63323-482", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 20 mg/1 mL (NDC 63323-489-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/26/2024", "package_ndc": "70726-0303-1", "generic_name": "Riluzole Oral Suspension", "contact_info": "610-937-6172", "availability": "Unavailable", "related_info": "Next release not available at this time; Shortage per Manufacturer: Product manufacturing interrupted due to testing", "openfda": { "application_number": [ "NDA209080" ], "brand_name": [ "TIGLUTIK" ], "generic_name": [ "RILUZOLE" ], "manufacturer_name": [ "EDW PHARMA, INC" ], "product_ndc": [ "70726-0303" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RILUZOLE" ], "rxcui": [ "2058147", "2059266" ], "spl_id": [ "57997dd0-4d88-c2e5-e063-6394a90ae8ae" ], "spl_set_id": [ "75d68f19-4208-109e-e053-2991aa0ac857" ], "package_ndc": [ "70726-0303-2", "70726-0303-1" ], "nui": [ "N0000175740", "M0483511" ], "pharm_class_epc": [ "Benzothiazole [EPC]" ], "pharm_class_cs": [ "Benzothiazoles [CS]" ], "unii": [ "7LJ087RS6F" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Oral Suspension", "presentation": "Tiglutik, Oral Suspension, 50 mg/10 mL (NDC 70726-0303-1)", "company_name": "EDW Pharma, Inc. (formerly Italfarmaco Pharma, Inc.)", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "05/03/2022", "package_ndc": "17478-050-02", "generic_name": "Sufentanil Citrate Injection", "contact_info": "800-631-2174", "availability": "Unavailable", "related_info": "Not currently manufactured", "update_date": "08/13/2026", "therapeutic_category": [ "Analgesia/Addiction", "Pediatric" ], "dosage_form": "Injection", "presentation": "Sufentanil Citrate, Injection, 50 mcg/1 mL (NDC 17478-050-02)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "64850-554-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "888-852-6657", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA218604" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Elite Laboratories, Inc." ], "product_ndc": [ "64850-554", "64850-550", "64850-551", "64850-552", "64850-553", "64850-555", "64850-556" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "2d33f701-8067-4a48-98cc-4e7dacaf3cc4" ], "spl_set_id": [ "0e024b69-567c-4b40-9c3e-a2daec34256c" ], "package_ndc": [ "64850-550-01", "64850-551-01", "64850-552-01", "64850-553-01", "64850-554-01", "64850-555-01", "64850-556-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 64850-554-01)", "company_name": "Elite Laboratories, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0338-0078-20", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA016673" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0078", "0338-9651", "0338-9649", "0338-9655", "0338-9653", "0338-0062", "0338-0074", "0338-0066", "0338-0070", "0338-0082" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795607", "1795609", "1795610", "1795612", "1795616" ], "spl_id": [ "b28d6bb9-8496-48bd-b6aa-f67996d0829c" ], "spl_set_id": [ "36e9478c-5df0-4b47-b97d-de3626d7cb29" ], "package_ndc": [ "0338-9651-75", "0338-9649-75", "0338-9655-60", "0338-9653-60", "0338-0078-20", "0338-0062-30", "0338-0074-30", "0338-0066-20", "0338-0070-10", "0338-0070-12", "0338-0082-10", "0338-0082-12" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0078-20)", "company_name": "Baxter Healthcare", "status": "Current" }, { "discontinued_date": "07/30/2026", "update_type": "New", "initial_posting_date": "07/30/2026", "package_ndc": "63323-578-02", "generic_name": "Glycopyrrolate Injection", "contact_info": "888-386-1300", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA209328" ], "brand_name": [ "GLYCOPYRROLATE" ], "generic_name": [ "GLYCOPYRROLATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-578" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "GLYCOPYRROLATE" ], "rxcui": [ "238212", "1731582", "1731590" ], "spl_id": [ "779dc924-ecc3-41cc-8cf9-a7354db4f763", "d528572e-598b-4c0e-b280-b083c73c017f" ], "spl_set_id": [ "54458620-d888-4df6-ae4b-78c3dfed3423", "ccafb5c2-86dd-4bb2-883a-c13e3171227c" ], "package_ndc": [ "63323-578-03", "63323-578-01", "63323-578-04", "63323-578-02", "63323-578-07", "63323-578-05", "63323-578-18", "63323-578-20", "63323-578-41", "63323-578-11", "63323-578-42", "63323-578-12" ], "unii": [ "V92SO9WP2I" ] }, "update_date": "07/30/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Glycopyrrolate, Injection, 0.4 mg per 2 mL (NDC 63323-578-02)", "company_name": "Fresenius Kabi USA, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0409-1596-10", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Available", "openfda": { "application_number": [ "NDA021038" ], "brand_name": [ "PRECEDEX" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-1596", "0409-1660", "0409-1638", "0409-1434", "0409-7838", "0409-7853", "0409-7875" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "284397", "309710", "1718900", "1718902", "1718906", "1718907", "1718909", "1718910", "2396891", "2396892" ], "spl_id": [ "3c5274fd-6597-4b88-babc-92e4e16c6329" ], "spl_set_id": [ "548a88c0-afda-427e-75ac-5af0cfa2224c" ], "package_ndc": [ "0409-1660-55", "0409-1660-50", "0409-1660-35", "0409-1660-10", "0409-1660-22", "0409-1660-20", "0409-1638-32", "0409-1638-02", "0409-1434-01", "0409-1596-01", "0409-1596-10", "0409-7838-01", "0409-7838-24", "0409-7853-01", "0409-7853-24", "0409-7875-01", "0409-7875-12" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Precedex, Injection, 400 mcg/100 mL (4 mcg/mL) (NDC 0409-1596-10)", "company_name": "Pfizer Inc.", "status": "Current" }, { "discontinued_date": "01/13/2026", "update_type": "New", "initial_posting_date": "01/13/2026", "package_ndc": "61314-454-68", "generic_name": "Adalimumab-adaz Injection", "contact_info": "800-525-8747", "related_info": "Equivalent Sandoz format is available.", "update_date": "01/13/2026", "therapeutic_category": [ "Rheumatology" ], "dosage_form": "Injection", "presentation": "Hyrimoz, Injection, 80 mg/.8 mL (NDC 61314-454-68)", "company_name": "Sandoz Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-20", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-285", "63323-286", "63323-287", "63323-288" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091" ], "spl_id": [ "324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c" ], "spl_set_id": [ "dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6" ], "package_ndc": [ "63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-20)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "discontinued_date": "11/03/2025", "update_type": "New", "initial_posting_date": "11/03/2025", "package_ndc": "60951-602-85", "generic_name": "Acetaminophen; Oxycodone Hydrochloride Tablet", "contact_info": "800-828-9393", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA040330" ], "brand_name": [ "ENDOCET" ], "generic_name": [ "OXYCODONE AND ACETAMINOPHEN" ], "manufacturer_name": [ "Par Health USA, LLC" ], "product_ndc": [ "60951-602", "60951-700", "60951-712", "60951-701" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "OXYCODONE HYDROCHLORIDE", "ACETAMINOPHEN" ], "rxcui": [ "1049214", "1049216", "1049221", "1049223", "1049225", "1049227", "1049635", "1487288" ], "spl_id": [ "a8475489-982f-4080-9565-7948155d9abb" ], "spl_set_id": [ "944d3e60-7eee-11de-a413-0002a5d5c51b" ], "package_ndc": [ "60951-602-70", "60951-602-85", "60951-700-70", "60951-712-70", "60951-701-70" ], "unii": [ "C1ENJ2TE6C", "362O9ITL9D" ] }, "update_date": "11/03/2025", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Tablet", "presentation": "Acetaminophen; Oxycodone Hydrochloride, Tablet, 325 mg; 5 mg (NDC 60951-602-85)", "company_name": "Endo Pharmaceuticals, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "0527-0761-37", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "844-834-0530", "availability": "Available", "openfda": { "application_number": [ "ANDA215565" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Lannett Company, LLC" ], "product_ndc": [ "0527-0761", "0527-0760", "0527-0762", "0527-0763", "0527-0764", "0527-0765", "0527-0766" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "391d7c4a-47df-41ce-b1ba-3c4758adf87f" ], "spl_set_id": [ "f92497b5-baea-4760-b615-45a0b6184402" ], "package_ndc": [ "0527-0760-37", "0527-0761-37", "0527-0762-37", "0527-0763-37", "0527-0764-37", "0527-0765-37", "0527-0766-37" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 1.875 mg; 1.875 mg; 1.875 mg; 1.875 mg (NDC 0527-0761-37)", "company_name": "Lannett Company, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "11/14/2017", "package_ndc": "0338-0431-03", "generic_name": "Heparin Sodium Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA018609" ], "brand_name": [ "HEPARIN SODIUM IN SODIUM CHLORIDE" ], "generic_name": [ "HEPARIN SODIUM" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0431", "0338-0433", "0338-0424", "0338-0428" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "HEPARIN SODIUM" ], "rxcui": [ "1658690", "1658692" ], "spl_id": [ "d28ff87a-c535-49db-ba0c-48080149936b" ], "spl_set_id": [ "0d929726-76c3-48fc-b4e7-fd06409f9fb3" ], "package_ndc": [ "0338-0431-03", "0338-0433-04", "0338-0424-18", "0338-0428-12" ], "unii": [ "ZZ45AB24CA" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Hematology" ], "dosage_form": "Injection", "presentation": "Heparin Sodium In Sodium Chloride, Injection, 200 [USP'U]/100 mL (NDC 0338-0431-03)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0338-9666-35", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA020179" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "0338-9666", "0338-9664" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795609", "1795616" ], "spl_id": [ "a6356cbf-8553-405f-9c27-57a301e43fc9" ], "spl_set_id": [ "bfc4224a-2fc9-4137-b4c6-9d2d6d948413" ], "package_ndc": [ "0338-9664-40", "0338-9666-35" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-9666-35)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "01/01/2012", "package_ndc": "16729-526-08", "generic_name": "Atropine Sulfate Injection", "contact_info": "866-941-7875, option 2", "availability": "Unavailable", "related_info": "Estimated recovery: TBD", "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia", "Neurology", "Pediatric" ], "dosage_form": "Injection", "presentation": "Atropine Sulfate, Injection, 1 mg/1 mL (NDC 16729-526-08)", "company_name": "Accord Healthcare Inc.", "shortage_reason": "Requirements related to complying with good manufacturing practices", "status": "Current" }, { "update_type": "New", "initial_posting_date": "02/03/2016", "package_ndc": "70069-047-25", "generic_name": "Sodium Acetate Injection", "contact_info": "732-554-1037", "availability": "Available", "openfda": { "application_number": [ "ANDA219826" ], "brand_name": [ "SODIUM ACETATE ANHYDROUS" ], "generic_name": [ "SODIUM ACETATE ANHYDROUS" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-047", "70069-048" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "SODIUM ACETATE ANHYDROUS" ], "rxcui": [ "237371" ], "spl_id": [ "1aae3237-9555-442b-b962-619d23f7e00a" ], "spl_set_id": [ "93edebd6-ef7f-483a-80b6-bfaf34ea5ded" ], "package_ndc": [ "70069-047-25", "70069-048-20" ], "unii": [ "NVG71ZZ7P0" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Pediatric", "Total Parenteral Nutrition" ], "dosage_form": "Injection", "presentation": "Sodium Acetate, Injection, 164 mg/1 mL (NDC 70069-047-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0054-0375-25", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-631-2174", "availability": "Limited Availability", "related_info": "Available on allocation", "openfda": { "application_number": [ "ANDA202827" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Hikma Pharmaceuticals USA Inc." ], "product_ndc": [ "0054-0375", "0054-0660", "0054-0370", "0054-0371", "0054-0372", "0054-0373", "0054-0374" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "ccd9e87c-bd03-4fe0-8129-41c1ced49c8d" ], "spl_set_id": [ "6740a621-9bec-4178-a4fc-a3fc89f34e0a" ], "package_ndc": [ "0054-0660-25", "0054-0370-25", "0054-0371-25", "0054-0372-25", "0054-0373-25", "0054-0374-25", "0054-0375-25" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/13/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0054-0375-25)", "company_name": "Hikma Pharmaceuticals USA, Inc.", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/10/2020", "package_ndc": "0338-9557-12", "generic_name": "Dexmedetomidine Hydrochloride Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "ANDA208532" ], "brand_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "generic_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "0338-9557", "0338-9555" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXMEDETOMIDINE HYDROCHLORIDE" ], "rxcui": [ "1718906", "1718909" ], "spl_id": [ "594e9faa-bc32-42e0-9c0a-8fa9460b1e24" ], "spl_set_id": [ "8ccb45a7-8290-469c-9644-a4dca967d88f" ], "package_ndc": [ "0338-9555-24", "0338-9557-12" ], "unii": [ "1018WH7F9I" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Dexmedetomidine Hydrochloride, Injection, 400 ug/100 mL (NDC 0338-9557-12)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/31/2017", "package_ndc": "63323-851-15", "generic_name": "Hydromorphone Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Unavailable", "related_info": "Next release August 2026. Check wholesalers for inventory.", "openfda": { "application_number": [ "NDA019034" ], "brand_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "generic_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-851", "63323-852", "63323-853", "63323-854" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS", "SUBCUTANEOUS" ], "substance_name": [ "HYDROMORPHONE HYDROCHLORIDE" ], "rxcui": [ "897653", "897753", "1724276", "1724338", "1724340", "1724341" ], "spl_id": [ "9e8522c6-595c-46f9-bb25-272aa4683e0f" ], "spl_set_id": [ "e034eb96-03e0-46e1-8b92-5e1f94555e7b" ], "package_ndc": [ "63323-851-03", "63323-851-10", "63323-851-07", "63323-851-15", "63323-851-50", "63323-852-03", "63323-852-25", "63323-853-03", "63323-853-25", "63323-854-03", "63323-854-10" ], "unii": [ "L960UP2KRW" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Analgesia/Addiction" ], "dosage_form": "Injection", "presentation": "Hydromorphone Hydrochloride, Injection, 10 mg/1 mL (NDC 63323-851-15)", "company_name": "Fresenius Kabi USA, LLC", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/20/2026", "package_ndc": "0338-0074-30", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA016673" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Corporation" ], "product_ndc": [ "0338-0074", "0338-9651", "0338-9649", "0338-9655", "0338-9653", "0338-0078", "0338-0062", "0338-0066", "0338-0070", "0338-0082" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795607", "1795609", "1795610", "1795612", "1795616" ], "spl_id": [ "b28d6bb9-8496-48bd-b6aa-f67996d0829c" ], "spl_set_id": [ "36e9478c-5df0-4b47-b97d-de3626d7cb29" ], "package_ndc": [ "0338-9651-75", "0338-9649-75", "0338-9655-60", "0338-9653-60", "0338-0078-20", "0338-0062-30", "0338-0074-30", "0338-0066-20", "0338-0070-10", "0338-0070-12", "0338-0082-10", "0338-0082-12" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 5 g/100 mL (NDC 0338-0074-30)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "12/22/2021", "package_ndc": "42806-801-01", "generic_name": "Rifampin Capsule", "contact_info": "(718) 276-8600 ext. 3", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "ANDA064150" ], "brand_name": [ "RIFAMPIN" ], "generic_name": [ "RIFAMPIN" ], "manufacturer_name": [ "EPIC PHARMA, LLC" ], "product_ndc": [ "42806-801", "42806-799" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "RIFAMPIN" ], "rxcui": [ "198201", "198202" ], "spl_id": [ "a4ac02e8-68ac-4e79-8ca5-0939dd002c87" ], "spl_set_id": [ "0391f1e1-70d4-4b15-8b58-055bb6a385b8" ], "package_ndc": [ "42806-801-30", "42806-801-01", "42806-799-30", "42806-799-60", "42806-799-01", "42806-799-05" ], "nui": [ "N0000175500", "M0019113" ], "pharm_class_epc": [ "Rifamycin Antibacterial [EPC]" ], "pharm_class_cs": [ "Rifamycins [CS]" ], "unii": [ "VJT6J7R4TR" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Anti-Infective" ], "dosage_form": "Capsule", "presentation": "Rifampin, Capsule, 150 mg (NDC 42806-801-01)", "company_name": "Epic Pharma, LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "04/28/2023", "package_ndc": "0990-6139-22", "generic_name": "Sterile Water Irrigant", "related_info_link": "https://www.fda.gov/media/182619/download?attachment", "contact_info": "1-866-829-9025 or ProductAvailability@icumed.com", "availability": "Unavailable", "related_info": "Product temporarily unavailable. Estimated recovery: TBD. This product is distributed by ICU Medical. For questions regarding this product, please contact ICU Medical.", "update_date": "08/17/2026", "therapeutic_category": [ "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Irrigant", "presentation": "Sterile Water In Plastic Container, Irrigant, 1 mL/1 mL (NDC 0990-6139-22)", "company_name": "Otsuka ICU Medical LLC", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/12/2022", "package_ndc": "13107-070-01", "generic_name": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet", "contact_info": "(866) 850-2876 or CustomerService@AurobindoUSA.com", "availability": "Unavailable", "related_info": "Estimated availability: October 2026", "openfda": { "application_number": [ "ANDA202424" ], "brand_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "generic_name": [ "DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE" ], "manufacturer_name": [ "Aurolife Pharma, LLC" ], "product_ndc": [ "13107-070", "13107-068", "13107-069", "13107-071", "13107-072", "13107-073", "13107-074" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "DEXTROAMPHETAMINE SACCHARATE", "AMPHETAMINE ASPARTATE MONOHYDRATE", "DEXTROAMPHETAMINE SULFATE", "AMPHETAMINE SULFATE" ], "rxcui": [ "541363", "541878", "541892", "577957", "577961", "687043", "1009145" ], "spl_id": [ "5962d880-9f18-4a57-8c95-ca0ec1e86f44" ], "spl_set_id": [ "a582d57f-d191-4ca5-b105-585b2d8a0e3e" ], "package_ndc": [ "13107-068-50", "13107-068-01", "13107-068-25", "13107-068-05", "13107-068-99", "13107-069-50", "13107-069-01", "13107-069-25", "13107-069-05", "13107-069-99", "13107-070-50", "13107-070-01", "13107-070-25", "13107-070-05", "13107-070-99", "13107-071-50", "13107-071-01", "13107-071-25", "13107-071-05", "13107-071-99", "13107-072-50", "13107-072-01", "13107-072-25", "13107-072-05", "13107-072-99", "13107-073-50", "13107-073-01", "13107-073-25", "13107-073-05", "13107-073-99", "13107-074-50", "13107-074-01", "13107-074-25", "13107-074-05", "13107-074-99" ], "unii": [ "O1ZPV620O4", "6DPV8NK46S", "JJ768O327N", "G83415V073" ] }, "update_date": "07/21/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate, Tablet, 2.5 mg; 2.5 mg; 2.5 mg; 2.5 mg (NDC 13107-070-01)", "company_name": "Aurobindo Pharma USA", "shortage_reason": "Shortage of an active ingredient", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/14/2022", "package_ndc": "0338-9664-40", "generic_name": "Dextrose Monohydrate 5% Injection", "contact_info": "888-229-0001", "availability": "Available", "openfda": { "application_number": [ "NDA020179" ], "brand_name": [ "DEXTROSE" ], "generic_name": [ "DEXTROSE MONOHYDRATE" ], "manufacturer_name": [ "Baxter Healthcare Company" ], "product_ndc": [ "0338-9664", "0338-9666" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "DEXTROSE MONOHYDRATE" ], "rxcui": [ "1795609", "1795616" ], "spl_id": [ "a6356cbf-8553-405f-9c27-57a301e43fc9" ], "spl_set_id": [ "bfc4224a-2fc9-4137-b4c6-9d2d6d948413" ], "package_ndc": [ "0338-9664-40", "0338-9666-35" ], "unii": [ "LX22YL083G" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Endocrinology/Metabolism", "Gastroenterology", "Other", "Pediatric" ], "dosage_form": "Injection", "presentation": "Dextrose 5% In Plastic Container, Injection, 2.5 g/50 mL (NDC 0338-9664-40)", "company_name": "Baxter Healthcare", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "65162-023-09", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "866-525-7270", "availability": "Available", "openfda": { "application_number": [ "ANDA202830" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE" ], "manufacturer_name": [ "Amneal Pharmaceuticals LLC" ], "product_ndc": [ "65162-023", "65162-024", "65162-025", "65162-026", "65162-027", "65162-028" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850" ], "spl_id": [ "ba9f3370-3096-4d8c-9571-e28faf54291f" ], "spl_set_id": [ "c11cb3b6-3dff-477b-a249-b4c3118edc5f" ], "package_ndc": [ "65162-023-09", "65162-024-09", "65162-025-09", "65162-026-09", "65162-027-09", "65162-028-09" ], "unii": [ "SJT761GEGS" ] }, "update_date": "06/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 20 mg (NDC 65162-023-09)", "company_name": "Amneal Pharmaceuticals", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/07/2020", "package_ndc": "71288-203-05", "generic_name": "Furosemide Injection", "contact_info": "844-824-8426", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA212803" ], "brand_name": [ "FUROSEMIDE" ], "generic_name": [ "FUROSEMIDE" ], "manufacturer_name": [ "Meitheal Pharmaceuticals Inc." ], "product_ndc": [ "71288-203" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FUROSEMIDE" ], "rxcui": [ "1719286", "1719290", "1719291" ], "spl_id": [ "b06d36f6-507c-4b04-b79d-d6370a30a551", "53a09c30-7295-4337-89a4-93d3748d6ea3" ], "spl_set_id": [ "a2e3c748-28ce-4c50-a182-721912919840", "3aadaca7-3661-4bfe-87f8-6368e4ab6536" ], "package_ndc": [ "71288-203-02", "71288-203-03", "71288-203-04", "71288-203-05", "71288-203-10", "71288-203-11", "71288-203-91", "71288-203-92", "71288-203-93", "71288-203-94" ], "nui": [ "N0000175366", "N0000175590" ], "pharm_class_pe": [ "Increased Diuresis at Loop of Henle [PE]" ], "pharm_class_epc": [ "Loop Diuretic [EPC]" ], "unii": [ "7LXU5N7ZO5" ] }, "update_date": "04/23/2026", "therapeutic_category": [ "Cardiovascular" ], "dosage_form": "Injection", "presentation": "Furosemide, Injection, 10 mg/1 mL (NDC 71288-203-05)", "company_name": "Meitheal Pharmaceuticals, Inc.", "status": "Current" }, { "discontinued_date": "06/04/2026", "update_type": "New", "initial_posting_date": "06/04/2026", "package_ndc": "0169-4303-30", "generic_name": "Semaglutide Tablet", "contact_info": "833-493-4689", "related_info": "Discontinuation of the manufacture of the drug. These products will be replaced by Ozempic (semaglutide) tablets.", "update_date": "06/04/2026", "therapeutic_category": [ "Endocrinology/Metabolism" ], "dosage_form": "Tablet", "presentation": "Rybelsus, Tablet, 3 mg (NDC 0169-4303-30)", "company_name": "Novo Nordisk, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "55150-169-10", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA203895" ], "brand_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-169", "55150-167", "55150-168", "55150-170", "55150-171", "55150-172", "55150-249", "55150-250" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INTRACAUDAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012396", "1012404", "1724786", "1724787", "1724880", "1724884", "1725078", "1725082" ], "spl_id": [ "39649703-e633-4a20-ba71-0c04dbf8ff2a" ], "spl_set_id": [ "ffecf450-1f01-4721-8e10-251385852612" ], "package_ndc": [ "55150-167-10", "55150-168-30", "55150-169-10", "55150-170-30", "55150-171-10", "55150-172-30", "55150-249-50", "55150-250-50" ], "unii": [ "7TQO7W3VT8" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Bupivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 55150-169-10)", "company_name": "Eugia US LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "04/02/2020", "package_ndc": "0409-2308-01", "generic_name": "Midazolam Hydrochloride Injection", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Next Delivery: September 2026; Estimated Recovery: December 2026", "openfda": { "application_number": [ "ANDA075857" ], "brand_name": [ "MIDAZOLAM" ], "generic_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "manufacturer_name": [ "Hospira, Inc." ], "product_ndc": [ "0409-2308", "0409-2305", "0409-0001" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "MIDAZOLAM HYDROCHLORIDE" ], "rxcui": [ "1666800", "1666814", "1666823", "1666798" ], "spl_id": [ "2f69c5b1-6505-42dc-8bb3-edbd9b6c0781", "8954486a-8512-4831-8178-0b49f1efb73e" ], "spl_set_id": [ "b95415fa-17c2-42ab-a6b0-e628d01c94ed", "1abda8b8-48a8-4995-af86-39220d1aa240" ], "package_ndc": [ "0409-2305-55", "0409-2305-50", "0409-2308-69", "0409-2308-49", "0409-2308-70", "0409-2308-50", "0409-2305-16", "0409-2305-17", "0409-2305-04", "0409-2305-05", "0409-2308-21", "0409-2308-01", "0409-2308-22", "0409-2308-02", "0409-0001-01", "0409-0001-25" ], "unii": [ "W7TTW573JJ" ] }, "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Neurology" ], "dosage_form": "Injection", "presentation": "Midazolam Hydrochloride Preservative Free, Injection, 5 mg/mL (5 mg/mL) (NDC 0409-2308-01)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "09/18/2025", "update_type": "New", "initial_posting_date": "09/18/2025", "package_ndc": "0832-6006-11", "generic_name": "Fluphenazine Hydrochloride Tablet", "contact_info": "763-315-2000", "related_info": "Discontinuation of the manufacture of the drug.", "openfda": { "application_number": [ "ANDA213784" ], "brand_name": [ "FLUPHENAZINE HYDROCHLORIDE" ], "generic_name": [ "FLUPHENAZINE HYDROCHLORIDE" ], "manufacturer_name": [ "Upsher-Smith Laboratories,LLC" ], "product_ndc": [ "0832-6006", "0832-6004", "0832-6003", "0832-6005" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "FLUPHENAZINE HYDROCHLORIDE" ], "rxcui": [ "859841", "860918", "865117", "865123" ], "spl_id": [ "3bb74f82-8872-9829-e063-6294a90aeace" ], "spl_set_id": [ "f07bb3f1-c68c-441b-9de4-99a219f2500a" ], "package_ndc": [ "0832-6004-11", "0832-6003-11", "0832-6005-11", "0832-6006-11" ], "unii": [ "ZOU145W1XL" ] }, "update_date": "09/18/2025", "therapeutic_category": [ "Neurology", "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Fluphenazine Hydrochloride, Tablet, 10 mg (NDC 0832-6006-11)", "company_name": "Upsher-Smith Laboratories, LLC", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/22/2012", "package_ndc": "0409-4904-34", "generic_name": "Lidocaine Hydrochloride Injection", "related_info_link": "https://www.accessdata.fda.gov/scripts/drugshortages/dsp_ActiveIngredientDetails.cfm?AI=Lidocaine%20Hydrochloride%20Injection&st=d", "contact_info": "844-646-4398", "availability": "Unavailable", "related_info": "Discontinuation of the manufacture of the drug", "update_date": "08/07/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Lidocaine Hydrochloride, Injection, 50 mg/5mL (1%,10 mg/1 mL) Syringes (NDC 0409-4904-34)", "company_name": "Hospira, Inc., a Pfizer Company", "shortage_reason": "Discontinuation of the manufacture of the drug", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/05/2022", "package_ndc": "72485-509-10", "generic_name": "Etomidate Injection", "contact_info": "908-803-2586", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586", "openfda": { "application_number": [ "ANDA215028" ], "brand_name": [ "ETOMIDATE" ], "generic_name": [ "ETOMIDATE" ], "manufacturer_name": [ "Armas Pharmaceuticals Inc." ], "product_ndc": [ "72485-509", "72485-508" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008" ], "spl_id": [ "7444860b-36c1-459d-94ba-d7301d9dc2ca" ], "spl_set_id": [ "75467058-da52-48fa-8d4e-e1025ec7d461" ], "package_ndc": [ "72485-508-01", "72485-508-10", "72485-509-01", "72485-509-10" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "06/16/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/mL (NDC 72485-509-10)", "company_name": "Caplin Steriles, Ltd.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "70069-064-25", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "732-554-1019", "availability": "Available", "openfda": { "application_number": [ "ANDA207636" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Somerset Therapeutics, LLC" ], "product_ndc": [ "70069-064", "70069-061", "70069-062", "70069-063", "70069-065", "70069-066", "70069-067" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "PERINEURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "1734084", "1734090", "1734203", "1734207", "1734475", "1734483" ], "spl_id": [ "79b226f0-c08a-4f84-bf2b-ae5c60e01d67" ], "spl_set_id": [ "ffeadbbf-4ca6-4ed8-94c1-6e0adf7fbe64" ], "package_ndc": [ "70069-061-01", "70069-061-25", "70069-061-10", "70069-062-01", "70069-062-25", "70069-062-10", "70069-063-01", "70069-063-25", "70069-064-01", "70069-064-10", "70069-064-25", "70069-065-01", "70069-065-25", "70069-066-01", "70069-066-25", "70069-066-10", "70069-067-01", "70069-067-25", "70069-067-10" ], "unii": [ "V910P86109" ] }, "update_date": "07/20/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 5 mg/1 mL (NDC 70069-064-25)", "company_name": "Somerset Therapeutics, LLC", "status": "Current" }, { "discontinued_date": "04/15/2026", "update_type": "New", "initial_posting_date": "04/15/2026", "package_ndc": "0093-8072-56", "generic_name": "Tiagabine Hydrochloride Tablet", "contact_info": "888-838-2872", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "NDA020646" ], "brand_name": [ "TIAGABINE HYDROCHLORIDE" ], "generic_name": [ "TIAGABINE HYDROCHLORIDE" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "0093-8072", "0093-5030", "0093-5031", "0093-8076" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "TIAGABINE HYDROCHLORIDE" ], "rxcui": [ "1299903", "1299909", "1299911", "1299917" ], "spl_id": [ "2a8d7987-54ae-45d7-8224-361dac37e0a4" ], "spl_set_id": [ "953ef3cc-e3cb-480f-b9ea-256520fd62b8" ], "package_ndc": [ "0093-5030-56", "0093-5031-56", "0093-8072-56", "0093-8076-56" ], "unii": [ "DQH6T6D8OY" ] }, "update_date": "04/15/2026", "therapeutic_category": [ "Neurology" ], "dosage_form": "Tablet", "presentation": "Tiagabine Hydrochloride, Tablet, 12mg 30 count (NDC 0093-8072-56)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "72205-135-91", "generic_name": "Lisdexamfetamine Dimesylate Tablet, Chewable", "contact_info": "(855) 668-2369; customerservice@novadozpharma.com", "availability": "Available", "openfda": { "application_number": [ "ANDA218306" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Novadoz Pharmaceuticals LLC" ], "product_ndc": [ "72205-135", "72205-132", "72205-133", "72205-134", "72205-136", "72205-137" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811" ], "spl_set_id": [ "a79cb70c-0bfa-4d68-9a21-a5ef4bc3c811" ], "package_ndc": [ "72205-132-91", "72205-133-91", "72205-134-91", "72205-135-91", "72205-136-91", "72205-137-91" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/17/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet, Chewable", "presentation": "Lisdexamfetamine Dimesylate, Tablet, Chewable, 40 mg (NDC 72205-135-91)", "company_name": "Novadoz Pharmaceuticals LLC", "status": "Current" }, { "presentation": "Dopamine Hydrochloride In Dextrose 5% In Plastic Container, Injection, 800 mg/250 mL (3.2 mg/1 mL) (NDC 0409-7810-22)", "update_type": "Reverified", "initial_posting_date": "11/06/2017", "package_ndc": "0409-7810-22", "generic_name": "Dopamine Hydrochloride Injection", "company_name": "Hospira, Inc., a Pfizer Company", "contact_info": "844-646-4398", "availability": "Available", "update_date": "08/07/2026", "therapeutic_category": [ "Cardiovascular" ], "status": "Current", "dosage_form": "Injection" }, { "update_type": "Revised", "initial_posting_date": "07/14/2023", "package_ndc": "57664-050-88", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-818-4555", "availability": "Limited Availability", "related_info": "Estimated recovery: TBD", "openfda": { "application_number": [ "ANDA214484" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "57664-050", "57664-047", "57664-046", "57664-048", "57664-049", "57664-051", "57664-052", "57664-083", "57664-084", "57664-085", "57664-086", "57664-087", "57664-088" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856", "1871456", "1871460", "1871462", "1871464", "1871466", "1871468" ], "spl_id": [ "560b4c9e-9cce-4717-e063-6294a90a58c9" ], "spl_set_id": [ "da3148af-f9b6-4725-adae-3595b4c7dc4b" ], "package_ndc": [ "57664-047-88", "57664-046-88", "57664-048-88", "57664-049-88", "57664-050-88", "57664-051-88", "57664-052-88", "57664-083-88", "57664-084-88", "57664-085-88", "57664-086-88", "57664-087-88", "57664-088-88" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/05/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 50 mg (NDC 57664-050-88)", "company_name": "Sun Pharmaceutical Industries, Inc.", "shortage_reason": "Other", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "08/03/2022", "package_ndc": "62135-736-30", "generic_name": "Flurazepam Hydrochloride Capsule", "contact_info": "845-268-5000 Ext. 510", "availability": "Available", "openfda": { "application_number": [ "ANDA072368" ], "brand_name": [ "FLURAZEPAM HYDROCHLORIDE" ], "generic_name": [ "FLURAZEPAM HYDROCHLORIDE" ], "manufacturer_name": [ "Chartwell RX, LLC" ], "product_ndc": [ "62135-736", "62135-737" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "FLURAZEPAM HYDROCHLORIDE" ], "rxcui": [ "1298088", "1298091" ], "spl_id": [ "25893c92-c8f1-567a-e063-6294a90a00d4" ], "spl_set_id": [ "8f476891-1346-4e8c-ac1b-f8cbdc64f5a1" ], "package_ndc": [ "62135-736-30", "62135-736-90", "62135-737-30", "62135-737-90" ], "unii": [ "756RDM536M" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Neurology", "Other" ], "dosage_form": "Capsule", "presentation": "Flurazepam Hydrochloride, Capsule, 15 mg (NDC 62135-736-30)", "company_name": "Chartwell Molecular Holdings LLC", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "03/23/2018", "package_ndc": "55150-200-10", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-238-7880", "availability": "Unavailable", "related_info": "On backorder. Recovery: end-August 2026. Check wholesalers for inventory", "openfda": { "application_number": [ "ANDA205612" ], "brand_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Eugia US LLC" ], "product_ndc": [ "55150-200", "55150-195", "55150-196", "55150-197", "55150-198", "55150-199", "55150-201" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "905189", "1734084", "1734090", "1734207", "1734347", "1734475", "1734483" ], "spl_id": [ "1e5f1368-058a-492c-b4b7-d9329a7745e2" ], "spl_set_id": [ "3763b7b6-da49-4658-b93d-28f5da24d09e" ], "package_ndc": [ "55150-195-20", "55150-196-99", "55150-197-20", "55150-198-30", "55150-199-20", "55150-200-10", "55150-201-20" ], "unii": [ "V910P86109" ] }, "update_date": "08/06/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Ropivacaine Hydrochloride, Injection, 10 mg/1 mL (NDC 55150-200-10)", "company_name": "Eugia US LLC", "shortage_reason": "Demand increase for the drug", "status": "Current" }, { "discontinued_date": "11/13/2025", "update_type": "New", "initial_posting_date": "11/13/2025", "package_ndc": "51759-523-21", "generic_name": "Adalimumab-ryvk Kit", "contact_info": "800-545-8800", "related_info": "Discontinuation of the manufacture of the drug", "openfda": { "application_number": [ "BLA761299" ], "brand_name": [ "SIMLANDI" ], "generic_name": [ "ADALIMUMAB-RYVK" ], "manufacturer_name": [ "Teva Pharmaceuticals USA, Inc." ], "product_ndc": [ "51759-523", "51759-402", "51759-386", "51759-412", "51759-274" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "rxcui": [ "797544", "2677780", "2677787", "2688819", "2688823", "2688826", "2688827", "2688828", "2688829", "2706644", "2706645" ], "spl_id": [ "021cc6a0-a2e6-4e30-95dc-065c64b7fe70" ], "spl_set_id": [ "12f609c9-2088-bb05-e063-6394a90a9ecc" ], "package_ndc": [ "51759-402-02", "51759-402-17", "51759-513-21", "65517-0002-1", "51759-386-22", "51759-497-31", "51759-412-22", "51759-624-31", "51759-523-21", "51759-634-31", "51759-274-17", "51759-384-21" ] }, "update_date": "11/13/2025", "therapeutic_category": [ "Rheumatology" ], "presentation": "Simlandi, Kit, Kit (NDC 51759-523-21)", "company_name": "Teva Pharmaceuticals USA, Inc.", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "02/28/2025", "package_ndc": "0574-2430-65", "generic_name": "Methylphenidate Film, Extended Release", "contact_info": "800-455-8070", "availability": "Available", "related_info": "Available. Distributed by Padagis US LLC", "openfda": { "application_number": [ "NDA021514" ], "brand_name": [ "METHYLPHENIDATE TRANSDERMAL SYSTEM" ], "generic_name": [ "METHYLPHENIDATE" ], "manufacturer_name": [ "PADAGIS US LLC" ], "product_ndc": [ "0574-2430", "0574-2410", "0574-2415", "0574-2420" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "TRANSDERMAL" ], "substance_name": [ "METHYLPHENIDATE" ], "rxcui": [ "753436", "753438", "753440", "753441" ], "spl_id": [ "b743ef45-2fc0-4086-8a02-6078e6a09eaa" ], "spl_set_id": [ "7bcff873-1fc2-45bc-a8e4-5db4edeb9bfb" ], "package_ndc": [ "0574-2410-65", "0574-2415-65", "0574-2420-65", "0574-2430-65" ], "nui": [ "N0000175739", "N0000175729" ], "pharm_class_epc": [ "Central Nervous System Stimulant [EPC]" ], "pharm_class_pe": [ "Central Nervous System Stimulation [PE]" ], "unii": [ "207ZZ9QZ49" ] }, "update_date": "08/15/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Film, Extended Release", "presentation": "Methylphenidate, Film, Extended Release, 30 mg (NDC 0574-2430-65)", "company_name": "Noven Pharmaceuticals, Inc.", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "10/14/2016", "package_ndc": "63323-488-17", "generic_name": "Epinephrine Bitartrate, Lidocaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA006488" ], "brand_name": [ "XYLOCAINE MPF" ], "generic_name": [ "LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-488", "63323-492", "63323-491", "63323-495", "63323-485", "63323-486", "63323-484", "63323-489", "63323-481", "63323-483", "63323-482", "63323-487" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION", "INTRACAUDAL", "PERINEURAL" ], "substance_name": [ "LIDOCAINE HYDROCHLORIDE ANHYDROUS", "EPINEPHRINE BITARTRATE" ], "rxcui": [ "1010033", "1010035", "1010671", "1010673", "1010688", "1010692", "1010745", "1010749", "1010751", "1010755", "1010759", "1010763", "1010900", "1010902", "1737343", "1737345", "1737562", "1737563", "1737566", "1737567", "1737568", "1737569", "1737570", "1737571", "1737757", "1737758", "1737761", "1737762", "1867938", "1867940", "1867943", "1867944", "1867992", "1867993", "1867996", "1867997", "1868028", "1868029" ], "spl_id": [ "ea480a68-5927-4278-9deb-2956961da428" ], "spl_set_id": [ "ba082c2f-64f4-419d-9c88-74f203316e17" ], "package_ndc": [ "63323-492-04", "63323-492-27", "63323-492-09", "63323-492-57", "63323-492-07", "63323-492-37", "63323-492-03", "63323-492-31", "63323-491-01", "63323-491-57", "63323-495-09", "63323-495-27", "63323-495-04", "63323-495-07", "63323-485-01", "63323-485-27", "63323-485-03", "63323-485-57", "63323-486-01", "63323-486-17", "63323-486-02", "63323-486-27", "63323-486-05", "63323-486-57", "63323-484-57", "63323-489-02", "63323-489-27", "63323-489-03", "63323-489-21", "63323-489-01", "63323-489-17", "63323-488-07", "63323-488-37", "63323-488-03", "63323-488-31", "63323-488-01", "63323-488-17", "63323-481-01", "63323-481-57", "63323-483-03", "63323-483-27", "63323-483-01", "63323-483-57", "63323-482-01", "63323-482-17", "63323-482-03", "63323-482-27", "63323-482-05", "63323-482-57", "63323-487-01", "63323-487-17", "63323-487-07", "63323-487-37", "63323-487-03", "63323-487-31" ], "unii": [ "30Q7KI53AK", "EC2CNF7XFP" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia", "Pediatric" ], "dosage_form": "Injection", "presentation": "Xylocaine, Injection, .005 mg/1 mL; 15 mg/1 mL (NDC 63323-488-17)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/14/2023", "package_ndc": "0406-5117-01", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "800-325-8888", "availability": "Available", "openfda": { "application_number": [ "ANDA211840" ], "brand_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "generic_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "manufacturer_name": [ "SpecGx LLC" ], "product_ndc": [ "0406-5117", "0406-5111", "0406-5112", "0406-5113", "0406-5114", "0406-5115", "0406-5116" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LISDEXAMFETAMINE DIMESYLATE" ], "rxcui": [ "854830", "854834", "854838", "854842", "854846", "854850", "1593856" ], "spl_id": [ "b4be564a-404d-4ca1-bac0-ec9cf40fef93" ], "spl_set_id": [ "806a1c15-0842-4787-b2ad-09a21fd96b37" ], "package_ndc": [ "0406-5111-01", "0406-5112-01", "0406-5113-01", "0406-5114-01", "0406-5115-01", "0406-5116-01", "0406-5117-01" ], "unii": [ "SJT761GEGS" ] }, "update_date": "08/20/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Lisdexamfetamine Dimesylate, Capsule, 70 mg (NDC 0406-5117-01)", "company_name": "SpecGx LLC", "status": "Current" }, { "discontinued_date": "09/29/2025", "update_type": "New", "initial_posting_date": "09/29/2025", "package_ndc": "0781-3454-95", "generic_name": "Fondaparinux Sodium Injection", "contact_info": "609-395-8625 ext. 203 (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "related_info": "Discontinuation of the manufacture of the drug; Distributed by Sandoz Inc.", "openfda": { "application_number": [ "ANDA206812" ], "brand_name": [ "FONDAPARINUX SODIUM" ], "generic_name": [ "FONDAPARINUX SODIUM" ], "manufacturer_name": [ "Sandoz Inc." ], "product_ndc": [ "0781-3454", "0781-3443", "0781-3465", "0781-3476" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "SUBCUTANEOUS" ], "substance_name": [ "FONDAPARINUX SODIUM" ], "rxcui": [ "861356", "861360", "861363", "861365" ], "spl_id": [ "3d5a4b69-462b-7e51-e063-6294a90a0721" ], "spl_set_id": [ "baa50757-a927-4d56-a933-5d7798fe6ab0" ], "package_ndc": [ "0781-3443-94", "0781-3443-12", "0781-3443-95", "0781-3454-94", "0781-3454-12", "0781-3454-95", "0781-3465-94", "0781-3465-12", "0781-3465-95", "0781-3476-94", "0781-3476-12", "0781-3476-95" ], "unii": [ "X0Q6N9USOZ" ] }, "update_date": "09/29/2025", "therapeutic_category": [ "Hematology" ], "dosage_form": "Injection", "presentation": "Fondaparinux Sodium, Injection, 5 mg/.4 mL (NDC 0781-3454-95)", "company_name": "Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)", "status": "To Be Discontinued" }, { "update_type": "Reverified", "initial_posting_date": "03/23/2018", "package_ndc": "63323-285-13", "generic_name": "Ropivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesaler for inventory", "openfda": { "application_number": [ "NDA020533" ], "brand_name": [ "NAROPIN" ], "generic_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-285", "63323-286", "63323-287", "63323-288" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "EPIDURAL", "INFILTRATION" ], "substance_name": [ "ROPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1734203", "1734204", "1734207", "1734208", "1734347", "1734348", "1734355", "1734356", "1734475", "1734476", "1734479", "1734480", "1734481", "1734482", "1734483", "1734484", "905189", "905191", "1734084", "1734086", "1734090", "1734091" ], "spl_id": [ "324532ac-4e54-4659-a1a2-9ade22a1ed3f", "cdcd6c58-85cf-4d7e-9d97-b7c282a4f6b9", "73218c89-8925-468c-84bf-9960b4b3dc3c" ], "spl_set_id": [ "dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7", "23d2d448-a744-4877-9f2d-7e57c198da89", "c6613708-c1f7-4f5c-91a3-ebbc1d7905c6" ], "package_ndc": [ "63323-286-41", "63323-286-27", "63323-286-43", "63323-286-38", "63323-285-41", "63323-285-28", "63323-285-53", "63323-285-68", "63323-285-59", "63323-285-73", "63323-286-01", "63323-286-20", "63323-286-05", "63323-286-23", "63323-286-09", "63323-286-31", "63323-286-11", "63323-286-35", "63323-286-03", "63323-286-00", "63323-286-33", "63323-286-63", "63323-286-30", "63323-287-01", "63323-287-20", "63323-287-03", "63323-287-21", "63323-288-01", "63323-288-10", "63323-288-06", "63323-288-20", "63323-288-03", "63323-288-11", "63323-288-07", "63323-288-21", "63323-285-01", "63323-285-10", "63323-285-06", "63323-285-20", "63323-285-03", "63323-285-13", "63323-285-07", "63323-285-23", "63323-285-57", "63323-285-64", "63323-285-51", "63323-285-65", "63323-285-02", "63323-285-61", "63323-285-04", "63323-285-63", "63323-285-55", "63323-285-67", "63323-288-23", "63323-288-29", "63323-286-93", "63323-286-95" ], "unii": [ "V910P86109" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Naropin, Injection, 2 mg/1 mL (NDC 63323-285-13)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "02/20/2018", "package_ndc": "63323-465-57", "generic_name": "Bupivacaine Hydrochloride Injection", "contact_info": "888-386-1300", "availability": "Available", "related_info": "Check wholesalers for inventory", "openfda": { "application_number": [ "NDA018304" ], "brand_name": [ "SENSORCAINE" ], "generic_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "manufacturer_name": [ "Fresenius Kabi USA, LLC" ], "product_ndc": [ "63323-465", "63323-467", "63323-460", "63323-464", "63323-466", "63323-462" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INFILTRATION", "PERINEURAL" ], "substance_name": [ "BUPIVACAINE HYDROCHLORIDE" ], "rxcui": [ "1012391", "1012396", "1012404", "1012421", "1012455", "1012457", "1672917", "1672919", "1673296", "1673298", "1724880", "1724881", "1724884", "1724885", "1725078", "1725082", "1725175", "1725177" ], "spl_id": [ "2b1a1f80-cb29-4ac1-9e72-20225ed45715" ], "spl_set_id": [ "eb6d8fee-def4-4c96-9972-695e8cea8ea8" ], "package_ndc": [ "63323-465-01", "63323-465-57", "63323-467-01", "63323-467-57", "63323-460-01", "63323-460-37", "63323-464-02", "63323-464-37", "63323-464-03", "63323-464-31", "63323-466-01", "63323-466-37", "63323-466-02", "63323-466-31", "63323-462-04", "63323-462-17", "63323-462-01", "63323-462-37", "63323-462-02", "63323-462-31" ], "unii": [ "30Q7KI53AK", "7TQO7W3VT8" ] }, "update_date": "08/04/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Sensorcaine, Injection, 2.5 mg/1 mL (NDC 63323-465-57)", "company_name": "Fresenius Kabi USA, LLC", "status": "Current" }, { "update_type": "Reverified", "initial_posting_date": "07/26/2023", "package_ndc": "62175-312-37", "generic_name": "Methylphenidate Hydrochloride Tablet, Extended Release", "contact_info": "844-834-0530", "availability": "Available", "openfda": { "application_number": [ "ANDA091695" ], "brand_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "generic_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "manufacturer_name": [ "Lannett Company, Inc." ], "product_ndc": [ "62175-312", "62175-310", "62175-311", "62175-313" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "METHYLPHENIDATE HYDROCHLORIDE" ], "rxcui": [ "2001564", "2001565", "2001566", "2001568" ], "spl_id": [ "8b133cd2-e3c6-4742-b402-2393b56ffc93" ], "spl_set_id": [ "3d1f5aff-5d39-496c-b5ed-7f3c70ec641c" ], "package_ndc": [ "62175-310-37", "62175-311-37", "62175-312-37", "62175-313-37" ], "unii": [ "4B3SC438HI" ] }, "update_date": "08/18/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Tablet", "presentation": "Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 62175-312-37)", "company_name": "Lannett Company, Inc.", "status": "Current" }, { "update_type": "Revised", "initial_posting_date": "10/05/2022", "package_ndc": "72485-508-10", "generic_name": "Etomidate Injection", "contact_info": "908-803-2586", "availability": "Available", "related_info": "Check wholesalers for inventory; Marketed by Armas Pharmaceuticals, Inc. 908-803-2586", "openfda": { "application_number": [ "ANDA215028" ], "brand_name": [ "ETOMIDATE" ], "generic_name": [ "ETOMIDATE" ], "manufacturer_name": [ "Armas Pharmaceuticals Inc." ], "product_ndc": [ "72485-508", "72485-509" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "ETOMIDATE" ], "rxcui": [ "1654006", "1654008" ], "spl_id": [ "7444860b-36c1-459d-94ba-d7301d9dc2ca" ], "spl_set_id": [ "75467058-da52-48fa-8d4e-e1025ec7d461" ], "package_ndc": [ "72485-508-01", "72485-508-10", "72485-509-01", "72485-509-10" ], "nui": [ "N0000175975", "N0000175681" ], "pharm_class_pe": [ "General Anesthesia [PE]" ], "pharm_class_epc": [ "General Anesthetic [EPC]" ], "unii": [ "Z22628B598" ] }, "update_date": "06/16/2026", "therapeutic_category": [ "Anesthesia" ], "dosage_form": "Injection", "presentation": "Etomidate, Injection, 2 mg/mL (NDC 72485-508-10)", "company_name": "Caplin Steriles, Ltd.", "status": "Current" } ] }